URL,HCVR,LCVR,HC_Description,LC_Description,Source
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser TyrAla Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Met Ile Asn Pro Gly Gly Gly Asn Thr Asn Tyr Ala Glu Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Glu Trp Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Tyr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Gly Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,334119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 334,394114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 394,"(334/394) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:334 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:394."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser TyrAla Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Ser Thr Thr Arg Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysTyr Ser Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Ser Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg GlnTyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,318119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 318,378114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 378,"(318/378) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:318 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:378."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly HisTyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Ser Glu Ala Arg Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr ThrSer Asn Asn Asn Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Gly Ser Thr Arg Gly Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg GlnTyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,322119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 322,382114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 382,"(322/382) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:322 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:382."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ile Thr TyrTrp Ile Gly Trp Val Arg GlnAla Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Asn Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Leu Phe Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Ser Thr Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,351119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 351,411114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 411,"(351/411) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:351 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:411."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser TyrAla Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Glu Trp Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Asn Ile Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,323119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 323,383114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 383,"(323/383) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:323 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:383."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Pro Phe Thr Asn TyrGly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Thr Leu Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Arg Ser Ser Gln Ser Val Leu Tyr SerSer Asn Asn Lys Asn Tyr Phe Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Ile Arg Gly Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys His GlnTyr Tyr Thr Thr Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,352119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 352,412114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 412,"(352/412) an antibody or an antigen-binding fragment that selectively binds to a sars-cov-2, that comprises a vh having an amino acid sequence of seq id no:352 and a vl having an amino acid sequence of seq id no:412."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser TyrAla Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gln Ile Asn Pro Ser Gly Asp Ser Thr Arg Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu His SerSer Asn Asn Leu Asn Tyr Phe Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Leu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg GlnTyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,366119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 366,426114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 426,"(366/426) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:366 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:426."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser TyrAla Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ser Val Ile Pro Val Phe Gly Arg Pro Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Glu Trp Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Leu Arg Glu Gly Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Tyr Ala Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,330119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 330,390114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 390,"(330/390) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:330 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:390."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Ser Asp TyrHis Val His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp ValGly Met Ile Ile Pro Arg His Gly Gly Thr Ala Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Asp Phe Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Ala Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,326119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 326,386114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 386,"(326/386) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:326 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:386."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Gly Phe Ile Thr TyrTrp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Ser Asp Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Phe Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Lys Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,341119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 341,401114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 401,"(341/401) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:341 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:401."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser TyrAla Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Val Leu His Thr Val Asp Tyr Ala Gln Arg LeuGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Glu Trp Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Phe Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Leu Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,374119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 374,434114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 434,"(374/434) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:374 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:434."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Gly Phe Ile Thr TyrTrp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Gly Glu Thr Arg Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Ser Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,358119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 358,418114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 418,"(358/418) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:358 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:418."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ile Thr TyrTrp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Thr Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Val Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,364119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 364,424114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 424,"(364/424) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:364 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:424."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn HisAla Ile Ser Trp Val Arg Gln Ala Tyr Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Gly Thr Thr Arg Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr ThrSer Asn Asn Asn Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Ser Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg GlnTyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,321119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 321,381114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 381,"(321/381) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:321 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:381."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ile Ser TyrTrp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Leu Glu Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Ser Ser Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,363119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 363,423114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 423,"(363/423) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:363 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:423."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ile Thr TyrTrp Ile Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Gly Glu Ala Arg Tyr Ser Gln Lys PheTyr Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Ser Gly Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Asn Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Thr Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,324119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 324,384114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 384,"(324/384) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:324 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:384."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Gly Phe Ile Thr TyrTrp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Gly Glu Ala Arg Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr His Ser Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,375119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 375,435114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 435,"(375/435) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:375 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:435."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser TyrAla Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Val Ile Asn Thr Gly Gly Gly Ser Val Thr Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly His Trp Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Phe Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Gly Thr Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,361119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 361,421114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 421,"(361/421) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:361 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:421."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Leu Ser Ser TyrAla Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Arg Ser Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Arg Ile Leu Ser Tyr SerPro Asp Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnSer Tyr Ile Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,371119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 371,431114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 431,"(371/431) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:371 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:431."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ile Thr TyrTrp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Gly Glu Ala Arg Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Ser Gly Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Asn Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Thr Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,327119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 327,387114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 387,"(327/387) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:327 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:387."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Gly Phe Ile Thr TyrTrp Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Gly Glu Ala Arg Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ile Gln Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Leu Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,377119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 377,437114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 437,"(377/437) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:377 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:437."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ile Ser TyrAla Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Thr Leu Gly Thr Tyr Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Ser Trp Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Leu Arg Glu Gly Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr His Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,365119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 365,425114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 425,"(365/425) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:365 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:425."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser TyrAla Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Ser Thr Ala Arg Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Leu Tyr Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Thr Ser Ser Gln Ser Val Leu His SerSer Asn Asn Leu Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Ser Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg GlnTyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,367119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 367,427114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 427,"(367/427) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:367 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:427."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ile Thr TyrTrp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Glu Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,370119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 370,430114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 430,"(370/430) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:370 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:430."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ile Thr TyrTrp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Leu Tyr Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr His Thr Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,339119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 339,399114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 399,"(339/399) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:339 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:399."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Asn Phe Thr Asp TyrHis Ile Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp ValGly Met Ile Ile Pro Arg His Gly Gly Thr Ala Tyr Ala Gln Arg PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Leu Thr Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln HisTyr Tyr Asn Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,372119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 372,432114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 432,"(372/432) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:372 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:432."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Thr TyrTrp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Ile Asp Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Asn Lys Asn Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Leu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg GlnTyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,331119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 331,391114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 391,"(331/391) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:331 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:391."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly HisTyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Ser Glu Ala Arg Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Asn Asn Leu Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Gly Ser Thr Arg Gly Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg GlnTyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,333119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 333,393114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 393,"(333/393) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:333 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:393."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Gly Phe Ile Thr TyrTrp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Val Leu Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Ala Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,340119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 340,400114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 400,"(340/400) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:340 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:400."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Gly Phe Ser Thr TyrTrp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp ValGly Trp Ile Asn Pro Asn Ser Gly Ala Thr Lys Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Phe His SerSer Asn Asn Lys Asn His Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg GlnTyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,343119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 343,403114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 403,"(343/403) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:343 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:403."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ile Thr TyrTrp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu His SerAla Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Ser Thr Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,348119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 348,408114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 408,"(348/408) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:348 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:408."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Ser Asp TyrTyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Ile Asp Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Asn Asn His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Ser Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg GlnTyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,347119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 347,407114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 407,"(347/407) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:347 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:407."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser TyrAla Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asp Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Gln PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Asn Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro ProLys Leu Leu Ile Ser Trp Ala Ser Thr Arg Glu Ser Gly Val Pro AspArg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile SerSer Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg Gln Tyr TyrSer Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,319119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 319,379112PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 379,"(319/379) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:319 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:379."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Gly Phe Ile Thr TyrTrp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Ile Asn Pro Asn Ser Gly Gly Thr Lys Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Ile Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Thr Arg Ala Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Ser Thr Val Ile Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,355119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 355,415114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 415,"(355/415) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:355 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:415."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser TyrAla Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Ser Thr Thr Arg Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysTyr Ser Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Ser Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg GlnTyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,320119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 320,380114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 380,"(320/380) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:320 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:380."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Thr TyrAla Phe Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Val Ile Asn Thr Gly Gly Gly Ser Val Thr Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Gly Ala Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Asn Asn Ile Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Ala Ala Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg GlnTyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,338119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 338,398114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 398,"(338/398) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:338 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:398."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser TyrAla Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Ser Thr Thr Asn Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly His Trp Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Tyr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr His Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,350119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 350,410114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 410,"(350/410) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:350 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:410."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ile Thr TyrTrp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Leu Leu Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,357119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 357,417114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 417,"(357/417) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:357 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:417."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ile Thr TyrTrp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Asn Asn His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Gly Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg GlnTyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,359119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 359,419114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 419,"(359/419) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:359 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:419."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Asn Ser HisAla Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Ile Asn Pro Asn Ser Gly Ala Thr Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Val Gly Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Ser Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg GlnTyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,328119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 328,388114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 388,"(328/388) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:328 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:388."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp TyrHis Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetAla Met Ile Val Pro Arg Gly Gly Ser Thr Thr Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Ser Thr Pro Val Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,346119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 346,406114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 406,"(346/406) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:346 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:406."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Gly Phe Ile Thr TyrTrp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Gly Glu Thr Arg Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Gly Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,373119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 373,433114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 433,"(373/433) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:373 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:433."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Arg Phe Thr Asp TyrHis Leu His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Val Pro Phe Ser Gly Thr Thr Asn Phe Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Glu Thr Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Ser Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Ser Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,345119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 345,405114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 405,"(345/405) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:345 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:405."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ile Thr TyrTrp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Tyr Val Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Lys Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,349119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 349,409114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 409,"(349/409) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:349 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:409."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser TyrGly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Gly Thr Thr Arg Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysLeu Pro Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Arg Val Leu Tyr SerSer Asn Asn Leu Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Gly Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg GlnTyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,337119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 337,397114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 397,"(337/397) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:337 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:397."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser TyrAla Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Ser Thr Thr Arg Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysTyr Ser Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Ser Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg GlnTyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,354119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 354,414114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 414,"(354/414) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:354 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:414."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn TyrGly Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Met Asn Pro Tyr Ser Gly Asn Thr Gly Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Val Leu Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Asn Asn Lys Asn Tyr LeuAla Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Thr Asn Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys His GlnTyr Tyr Asn Thr Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,369119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 369,429114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 429,"(369/429) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:369 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:429."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn SerSer Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Arg Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Asn Asn Ile Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Ala Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu GlnAla Glu Asp Val Ala Val Tyr Tyr Cys Arg GlnTyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,329119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 329,389114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 389,"(329/389) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:329 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:389."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ile Ser TyrTrp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Gly Glu Thr Arg Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Ser Asp Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,353119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 353,413114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 413,"(353/413) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:353 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:413."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ile Thr TyrTrp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Gly Glu Thr Arg Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Tyr Thr Arg Glu Pro Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,336119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 336,396114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 396,"(336/396) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:336 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:396."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ile Thr TyrTrp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Ser Asp Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,362119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 362,422114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 422,"(362/422) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:362 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:422."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser TyrAla Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Ile Phe Gly Ser Thr Ala Ser Tyr Ala Gln LysPhe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr AlaTyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr TyrCys Ala Gly Glu Trp Gly Ile Ser Thr Pro Met Asp Val Trp Gly GlnGly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ser Ser Leu Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Thr Ala Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,376120PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 376,436114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 436,"(376/436) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:376 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:436."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp TyrTyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Asn PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Ala Trp Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Arg Cys Thr Ser Ser Leu Ser Leu Gln Asp ArgSer Asn Asn Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnHis Tyr Ser Ala Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,325119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 325,385114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 385,"(325/385) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:325 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:385."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Gly Phe Ile Thr TyrTrp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Met Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Thr Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,342119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 342,402114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 402,"(342/402) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:342 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:402."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn AsnGly Leu Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysArg Met Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Thr Ile Ser Tyr SerSer Asp Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Leu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg GlnTyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,356119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 356,416114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 416,"(356/416) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:356 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:416."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ser Thr TyrTrp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr ArgSer Asn Asn Leu His Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Ser Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg GlnTyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,368119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 368,428114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 428,"(368/428) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:368 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:428."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ile Thr TyrTrp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Gly Glu Ala Arg Tyr Ser Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Pro Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr His Ser Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,360119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 360,420114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 420,"(360/420) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:360 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:420."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser TyrAla Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Thr Leu Gly Thr Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Ser Trp Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Leu Arg Glu Gly Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr His Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,344119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 344,404114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 404,"(344/404) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:344 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:404."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn TyrGly Ile Asn Trp Met Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Asn Arg Glu Pro Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Phe Cys His GlnTyr Tyr Ser Thr Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,335119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 335,395114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 395,"(335/395) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:335 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:395."
https://patents.google.com/patent/US11034762B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn TyrGly Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Ala Val Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln GlyThr Leu Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Arg Ser Ser Gln Thr Val Leu Tyr ArgSer Asn Asn Tyr Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Ser Thr Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg,332119PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 332,392114PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 392,"(332/392) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:332 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:392."
https://patents.google.com/patent/CN111647079B/en, Gln Val Gln Leu Leu Glu Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Thr Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Trp Ser Ser Ser Ala Gly Gly Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His His His His His His , Glu Ile Glu Leu Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Thr Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens,  Homo sapiens,"(4/3) the amino acid sequence of the light chain of the neutralizing antibody of the anti-novel coronavirus n protein is shown as seq id no:3, the amino acid sequence of the heavy chain is shown as seq id no:4, respectively"
https://patents.google.com/patent/CN111647079B/en, Gln Val Gln Leu Leu Glu Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Thr Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Trp Ser Ser Ser Ala Gly Gly Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Glu Leu Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Thr Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys ,  Homo sapiens,  Homo sapiens,"(2/1) the neutralizing antibody for resisting the novel coronavirus n protein consists of a light chain and a heavy chain, wherein the amino acid sequence of a variable region of the light chain is shown as seq id no:1, the amino acid sequence of the heavy chain variable region is shown as seq id no:2, respectively."
https://patents.google.com/patent/CN112239500B/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Asp Tyr Ala Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Leu Asn Thr Tyr Ser Gly Glu Pro Thr Tyr Ala Glu Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Thr Ala Ile Leu Arg Ser Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Cys Gly Cys Lys Pro Cys Ile Cys Thr Val Pro Glu Val Ser Ser Val Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu Thr Ile Thr Leu Thr Pro Lys Val Thr Cys Val Val Val Asp Ile Ser Lys Asp Asp Pro Glu Val Gln Phe Ser Trp Phe Val Asp Asp Val Glu Val His Thr Ala Gln Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser Val Ser Glu Leu Pro Ile Met His Gln Asp Trp Leu Asn Gly Lys Glu Phe Lys Cys Arg Val Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile Pro Pro Pro Lys Glu Gln Met Ala Lys Asp Lys Val Ser Leu Thr Cys Met Ile Thr Asp Phe Phe Pro Glu Asp Ile Thr Val Glu Trp Gln Trp Asn Gly Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met Asp Thr Asp Gly Ser Tyr Phe Val Tyr Ser Lys Leu Asn Val Gln Lys Ser Asn Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val Leu His Glu Gly Leu His Asn His His Thr Glu Lys Ser Leu Ser His Ser Pro Gly Lys , Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Glu Asp Leu Ser Thr Ala Leu Ala Trp Cys Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Gly Ser Thr Arg His Ser Gly Val Pro Asp Arg Phe Thr Gly Ile Arg Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Leu Tyr Tyr Cys Gln Gln His Trp Ser Thr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys , Artificial sequence, Artificial sequence,"(14/13) mu.g of an external control antibody was used as a control, and the electrophoretogram showed two bands, 1 of which mr was 50kd (heavy chain, seq id no:14) and the other mr was 28kd (light chain, seq id no:13), as shown in fig"
https://patents.google.com/patent/CN113429476A/en, Glu Val Gln Leu Val Gln Ser Gly Thr Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Ile Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys, Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial sequence (Artificial sequence), Artificial sequence (Artificial sequence),"(6/2) the coronavirus-binding bifunctional fusion protein of claim 1, which has the amino acid sequence of seq id no:6 and the amino acid sequence of the heavy chain shown in seq id no:2, or a light chain amino acid sequence set forth in seq id no."
https://patents.google.com/patent/CN107973856B/en, Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Ser Leu Ser Leu Thr Cys Ala Val Thr Gly Tyr Ser Ile Thr Ser Asp Tyr Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Arg Leu Glu Trp Met Gly Tyr Ile Arg Tyr Ser Gly His Thr Gly Tyr Asn Pro Ser Leu Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Phe Lys Asn Gln Phe Phe Leu Gln Phe Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Trp Val Asp Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val Tyr Asn Asn Arg Tyr Thr Tyr Leu Glu Trp Phe Val Gln Lys Pro Gly Gln Ser Leu Lys Leu Leu Ile Tyr Gly Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Met Gly Val Tyr Tyr Cys Tyr Gln Gly Thr His Ala Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , mice, mice,(68/72) the murine vl sequence of the anti-theophylline antibody is depicted in seq id no:72. the murine vh sequence of the anti-theophylline antibody is depicted in seq id no:68.
https://patents.google.com/patent/CN107973856B/en, Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ser Ser Gly Phe Asn Asn Lys Asp Thr Phe Phe Gln Trp Val Lys Gln Arg Pro Glu Glu Cys Leu Glu Trp Ile Gly Arg Ile Asp Pro Ala Asn Gly Phe Thr Lys Tyr Asp Pro Lys Phe Gln Gly Lys Ala Thr Ile Thr Val Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Asn Ser Leu Thr Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Thr Arg Trp Asp Thr Tyr Gly Ala Ala Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly Asn Ile His Asn Tyr Leu Ser Trp Phe Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val Tyr Ser Ala Lys Thr Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Pro Glu Asp Phe Gly Thr Tyr Tyr Cys Gln His Phe Trp Ser Ser Ile Tyr Thr Phe Gly Cys Gly Thr Lys Leu Glu Ile Lys , mice, mice,(36/40) the murine vl sequence of the anti-biotin antibody is depicted in seq id no:40. the murine vh sequence of the anti-biotin antibody is depicted in seq id no:36.
https://patents.google.com/patent/CN107973856B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Ala Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Cys Leu Glu Trp Val Ser Ser Ile Asn Ile Cys Ala Thr Tyr Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Gly Ser Pro Tyr Glu Tyr Asp Lys Ala Tyr Tyr Ser Met Ala Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Lys Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Tyr Ser Ser Thr Leu Leu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Ile Thr Leu Pro Pro Thr Phe Gly Cys Gly Thr Lys Val Glu Ile Lys , digoxigenin-resistant scdsFv VH, digoxigenin-resistant scdsFv VL,"(190/189) the sequences encoding the light chain variable region and the modified heavy chain variable region of this dig-binding scdsfv with the vh52bc mutant fv antibody derivative are listed under seq id no:190(vh), and the corresponding vl is listed under seq id no:189"
https://patents.google.com/patent/CN107973856B/en, Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gly Asn Ile His Asn Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile Tyr Ser Ala Lys Thr Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Val Ala Thr Tyr Tyr Cys Gln His Phe Trp Ser Ser Ile Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ser Ser Gly Phe Asn Asn Lys Asp Thr Phe Phe Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Asp Pro Ala Asn Gly Phe Thr Lys Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Trp Asp Thr Tyr Gly Ala Ala Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , humanized anti-biotin antibody VL, humanized anti-biotin antibody VH,"(48/44)  was generated based on the combination of human germline frameworks ighv1-69-02 and igkv 1-27-01. for vl, it is not necessary to integrate any back mutations in the framework of human igkv1-27-01 and in the human j-element of igkj2-01 germline. humanized vh's are based on human j elements of human ighv1-69-02 germline and ighj4-01-3 germline. two back mutations were introduced at position 24 in framework region 1 (a24s) and at position 73 in framework region 3 (k73t). the amino acid sequence of the humanized vh is depicted in seq id no:44 and the amino acid sequence of the humanized vl is depicted in seq id no:48. "
https://patents.google.com/patent/CN107973856B/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Asp Tyr Ala Trp Asn Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Arg Tyr Ser Gly His Thr Gly Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Trp Val Asp Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val Tyr Asn Asn Arg Tyr Thr Tyr Leu Glu Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Leu Leu Ile Tyr Gly Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Tyr Gln Gly Thr His Ala Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , humanized anti-theophylline antibody VH, humanized anti-theophylline antibody VL,(76/80) the amino acid sequence of the humanized vh is depicted in seq id no:76 and the amino acid sequence of the humanized vl is depicted in seq id no:80.
https://patents.google.com/patent/CN107973856B/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ser Ser Gly Phe Asn Asn Lys Asp Thr Phe Phe Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Asp Pro Ala Asn Gly Phe Thr Lys Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Trp Asp Thr Tyr Gly Ala Ala Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gly Asn Ile His Asn Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile Tyr Ser Ala Lys Thr Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Val Ala Thr Tyr Tyr Cys Gln His Phe Trp Ser Ser Ile Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , humanized anti-biotin antibody VH, humanized anti-biotin antibody VL,(44/48) the amino acid sequence of the humanized vh is depicted in seq id no:44 and the amino acid sequence of the humanized vl is depicted in seq id no:48
https://patents.google.com/patent/CN107973856B/en, Asp Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Ser Asp Tyr Tyr Met Tyr Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Tyr Ile Ser Asn Asp Asp Ser Ser Ala Ala Tyr Ser Asp Thr Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Thr Leu Tyr Leu Gln Met Ser Arg Leu Lys Ser Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Gly Leu Ala Trp Gly Ala Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Ala Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Cys Leu Glu Trp Val Ser Ser Ile Asn Ile Cys Ala Thr Tyr Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Gly Ser Pro Tyr Glu Tyr Asp Lys Ala Tyr Tyr Ser Met Ala Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Lys Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Tyr Ser Ser Thr Leu Leu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Ile Thr Leu Pro Pro Thr Phe Gly Cys Gly Thr Lys Val Glu Ile Lys, Asp Val Leu Met Thr Gln Ser Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ile Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly Ser His Val Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , anti-LeY antibody heavy chain _ ds44-100scFvDig-Cys53, anti-LeY antibody kappa light chain ,(192/191) the sequences encoding the light chain and modified heavy chain of such a ley-dig antibody derivative are set forth below seq id no:191 and seq id no:192
https://patents.google.com/patent/CN107973856B/en, Gly Val Lys Leu Asp Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Gly Ala Met Lys Leu Ser Cys Val Thr Ser Gly Phe Thr Phe Gly His Tyr Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Phe Arg Asn Cys Pro Tyr Asn Tyr Glu Thr Tyr Tyr Ser Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Asn Leu Arg Val Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Gly Ala Ser Tyr Gly Met Glu Tyr Leu Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu Arg Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Val Leu Ile Tyr Lys Val Ser Asn Arg Val Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Asn Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , murine anti-fluorescein antibody VH53C VH, mice,"(108/112) in one embodiment, the antibody comprises the vh and vl sequences in seq id no:108 or 116 and seq id no:112 or 120, respectively, including post-translational modifications of these sequences"
https://patents.google.com/patent/CN111690059A/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Trp Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser,Ala Ile Arg Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Leu Gly Met Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Artificial sequence, Artificial sequence,"(7/8) specifically, the sequences of the light chain variable region and the heavy chain variable region are respectively the same as seq id no:8 and seq id no:7."
https://patents.google.com/patent/WO2021245184A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Val Ser Leu Thr Gly Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Asn Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp Pro Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,"(142/147)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:142 and 147, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Leu Phe Trp Arg Arg Gly Ser Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Arg Ser Thr Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser Ser Tyr Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,"(82/87)   preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:82 and 87, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gln Glu Ser Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(92/97)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:92 and 97, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Asp Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Tyr Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Phe Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Thr Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Asn Ala Trp Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Glu Val Gln Leu Val Glu Ser Gly Gly Gly Met Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Thr His Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Thr Gly Ile Thr Tyr Asp Gly Ser Asp Glu Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ala Arg Asp Asn Ser Lys Asn Met Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys Ala Lys Asp Leu Glu Trp Leu Thr Asn Tyr Val Asp His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(17/12)  the vl comprises the amino acid sequence depicted in seq id no:17, or a variant thereof, wherein the variant comprises one or more amino acid substitutions;  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:12 and 17, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en, Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Asn Arg Ala Gly Trp Asp Gln Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(67/62)  the vl comprises the amino acid sequence depicted in seq id no:67, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:62 and 67, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gln Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asp Ser Tyr Pro Pro Arg Asp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(152/157)   preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:152 and 157, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Gly Gly Tyr Asp Val His Trp Tyr Gln Lys Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Phe Asp Asn Asp Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Asp Thr Ser Ala Ser Leu Thr Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Phe Gly Tyr Ile Phe Ser Asn Asp Trp Ile Gly Trp Val Arg Gln Lys Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Arg Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Val Ser Thr Ala Tyr Leu Gln Trp Asp Ser Leu Lys Ala Ser Asp Thr Ala Val Tyr Tyr Cys Thr Arg Pro Arg Tyr Thr Thr Met Ile Val Gly Ser Asn Pro Phe Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(237/232)  the vl comprises the amino acid sequence depicted in seq id no:237, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:232 and 237, respectively; or (xl"
https://patents.google.com/patent/WO2021245184A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Gly Thr Ala Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Ser Phe Leu Asp Tyr Ser Trp Leu Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Thr Gln Pro Glu Gly Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(42/47)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:42 and 47, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Ala Ile Arg Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Asn Ile Tyr Leu Asn Trp Tyr Gln Gln Arg Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys His Gln Tyr Asp Asn Leu Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys , Glu Val Gln Leu Val Glu Ser Gly Gly Asn Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys Ala Arg Asp Arg Val Val Arg Gly Val Arg Gly Asn Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(207/202)  the vl comprises the amino acid sequence depicted in seq id no:207, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:202 and 207, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en, Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Val Ser Ser Gly Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Val Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Ile Val Val Val Pro Ala Ala Arg Pro Leu Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Ser Val Asp Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Thr Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Val Arg Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,"(282/287)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:282 and 287, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Asp Ile Gln Leu Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys , Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gln Gly Gly Gly Gln Tyr Cys Ser Gly Gly Ser Cys Tyr Ser Gly Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(197/192)  the vl comprises the amino acid sequence depicted in seq id no:197, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:192 and 197, respectively; or (xl"
https://patents.google.com/patent/WO2021245184A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Phe Asp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Val Thr Trp Asn Ser Gly Ile Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Glu Phe Tyr Pro Arg Tyr Gly Ser Gly Ile Arg Ser His Tyr Phe Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Ser Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Val Gly Ser Asn Ala Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Arg Arg Pro Ser Gly Val Pro Asn Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Asp Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asp Gly Pro Thr Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,"(292/297)   preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:292 and 297, respectively. "
https://patents.google.com/patent/WO2021245184A1/en, Ala Ile Arg Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Ser Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Ile Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Val Arg Trp Gly Val Asp Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(247/242)  the vl comprises the amino acid sequence depicted in seq id no:247, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:242 and 247, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Phe Tyr Ser Met His Trp Val Arg Gln Val Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Phe Asp Gly Ser Thr Lys His Tyr Ala Glu Ser Leu Arg Gly Arg Phe Ala Val Ser Arg Asp Asn Ser Lys Ser Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Pro Pro Leu Ser Pro Ile Pro Ala Ala Gly Thr Pro Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Ile Phe Tyr Arg Ser Asp Asp Lys Asp Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Ser Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Phe Tyr Tyr Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(222/227)   preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:222 and 227, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Phe Cys Ala Arg Leu Leu Trp Leu Arg Gly Ser Tyr Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Tyr Glu Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,"(102/107)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:102 and 107, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gln Ile Ser Gly Tyr Asn Tyr Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(277/272)  the vl comprises the amino acid sequence depicted in seq id no:277, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:272 and 277, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Met Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Thr His Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Thr Gly Ile Thr Tyr Asp Gly Ser Asp Glu Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ala Arg Asp Asn Ser Lys Asn Met Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys Ala Lys Asp Leu Glu Trp Leu Thr Asn Tyr Val Asp His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Tyr Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Phe Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Thr Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Asn Ala Trp Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(12/17)   preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:12 and 17, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Asp Val Val Met Thr Gln Ser Pro Gly Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Asn Ile Asn Tyr Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Phe Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Thr Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Asn Ala Trp Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Gln Val Gln Leu Val Glu Ser Gly Gly Gly Arg Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr His Gly Met His Trp Val Arg Gln Val Pro Gly Lys Gly Leu Asp Trp Ile Thr Gly Ile Thr Tyr Asp Gly Ser Asp Gln Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Met Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys Ala Lys Asp Leu Glu Trp Leu Thr Asn Tyr Leu Asp His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(7/2)  the vl comprises the amino acid sequence depicted in seq id no:7, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:2 and 7, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Arg Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr His Phe Thr Asp Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Tyr Tyr Tyr Asp Ser Ser Ser Phe Ala Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Pro Ala Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(182/187)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:182 and 187, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Arg Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Val Asn His Arg Gly Val Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Ser Gln Phe Ser Leu Glu Leu Arg Ser Val Thr Asp Ala Asp Thr Ala Leu Tyr Phe Cys Ala Arg Ser Pro Phe Trp Thr Ile Ala Ala Arg Pro Phe Asp Tyr Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ile Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Phe Leu Ile Tyr Ala Ala Ser Thr Arg Ala Arg Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Ala Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Asn Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(262/267)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:262 and 267, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Asn Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys Ala Arg Asp Arg Val Val Arg Gly Val Arg Gly Asn Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Ala Ile Arg Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Asn Ile Tyr Leu Asn Trp Tyr Gln Gln Arg Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys His Gln Tyr Asp Asn Leu Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(202/207)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:202 and 207, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gln Gly Gly Gly Gln Tyr Cys Ser Gly Gly Ser Cys Tyr Ser Gly Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(192/197)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:192 and 197, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Gln Ser Val Leu Thr Gln Ser Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Val Gly Ser Asn Ala Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Arg Arg Pro Ser Gly Val Pro Asn Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Asp Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asp Gly Pro Thr Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Phe Asp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Val Thr Trp Asn Ser Gly Ile Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Glu Phe Tyr Pro Arg Tyr Gly Ser Gly Ile Arg Ser His Tyr Phe Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(297/292)  the vl comprises the amino acid sequence depicted in seq id no:297, or a variant thereof, wherein the variant comprises one or more amino acid substitutions;  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:292 and 297, respectively. "
https://patents.google.com/patent/WO2021245184A1/en, Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ile Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Phe Leu Ile Tyr Ala Ala Ser Thr Arg Ala Arg Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Ala Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Asn Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Arg Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Val Asn His Arg Gly Val Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Ser Gln Phe Ser Leu Glu Leu Arg Ser Val Thr Asp Ala Asp Thr Ala Leu Tyr Phe Cys Ala Arg Ser Pro Phe Trp Thr Ile Ala Ala Arg Pro Phe Asp Tyr Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(267/262)  the vl comprises the amino acid sequence depicted in seq id no:267, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:262 and 267, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en, Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Asp Arg Trp Tyr Tyr Asp Ser Ser Gly Tyr Pro Thr Pro Asp Glu Tyr Phe Gln His Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(217/212)  the vl comprises the amino acid sequence depicted in seq id no:217, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:212 and 217, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Asp Arg Trp Tyr Tyr Asp Ser Ser Gly Tyr Pro Thr Pro Asp Glu Tyr Phe Gln His Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,"(212/217)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:212 and 217, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Arg Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Asn Asn Lys Asn Tyr Glu Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Arg Arg Gly Gly Tyr Ser Tyr Gly Leu Phe Asp Tyr Trp Gly Gln Gly Ile Leu Val Thr Val Ser Ser , Ala Ile Arg Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Val Ala Thr Tyr Ser Cys Gln Gln Tyr Asp Asn Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(252/257)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:252 and 257, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Arg Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr His Phe Thr Asp Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Tyr Tyr Tyr Asp Ser Ser Ser Ser Ala Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Pro Ala Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(172/177)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:172 and 177, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Ile Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Val Arg Trp Gly Val Asp Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ala Ile Arg Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Ser Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(242/247)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:242 and 247, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Val Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Cys Ile Val Trp Glu Ile Ala Gly Ala Leu Cys Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(77/72)  the vl comprises the amino acid sequence depicted in seq id no:77, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:72 and 77, respectively; or (x"
https://patents.google.com/patent/WO2021245184A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Phe Gly Asp Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Gly Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Leu Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Arg Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(22/27)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:22 and 27, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Thr Gln Pro Glu Gly Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys , Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Gly Thr Ala Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Ser Phe Leu Asp Tyr Ser Trp Leu Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(47/42)  the vl comprises the amino acid sequence depicted in seq id no:47, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:42 and 47, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Ser Asp Ser Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Gly Ser Arg Ser Asp Trp Ser Asn Pro Ser Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp Pro Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,"(132/137)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:132 and 137, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Cys Ile Val Trp Glu Ile Ala Gly Ala Leu Cys Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Val Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(72/77)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:72 and 77, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Leu Val Gly Gln Trp Leu Gly Val Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,"(52/57)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:52 and 57, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asp Ser Tyr Pro Pro Arg Asp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gln Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(157/152)  the vl comprises the amino acid sequence depicted in seq id no:157, or a variant thereof, wherein the variant comprises one or more amino acid substitutions;  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:152 and 157, respectively; or (xxx"
https://patents.google.com/patent/WO2021245184A1/en, Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gln Glu Ser Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(97/92)  the vl comprises the amino acid sequence depicted in seq id no:97, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:92 and 97, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en, Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Pro Ala Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Arg Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr His Phe Thr Asp Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Tyr Tyr Tyr Asp Ser Ser Ser Phe Ala Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(187/182)  the vl comprises the amino acid sequence depicted in seq id no:187, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:182 and 187, respectively; or (xxx"
https://patents.google.com/patent/WO2021245184A1/en, Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Pro Ala Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Arg Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr His Phe Thr Asp Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Tyr Tyr Tyr Asp Ser Ser Ser Ser Ala Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(177/172)  the vl comprises the amino acid sequence depicted in seq id no:177, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:172 and 177, respectively; or (xxx"
https://patents.google.com/patent/WO2021245184A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Arg Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr His Gly Met His Trp Val Arg Gln Val Pro Gly Lys Gly Leu Asp Trp Ile Thr Gly Ile Thr Tyr Asp Gly Ser Asp Gln Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Met Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys Ala Lys Asp Leu Glu Trp Leu Thr Asn Tyr Leu Asp His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Val Val Met Thr Gln Ser Pro Gly Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Asn Ile Asn Tyr Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Phe Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Thr Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Asn Ala Trp Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(2/7)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:2 and 7, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Ser Leu Tyr Tyr Ser Asp Ser Ser Gly Tyr Ser His Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Pro Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Met Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,"(112/117)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:112 and 117, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Gly Asp Tyr Ala Met Ser Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Phe Ile Arg Ser Lys Ala Tyr Gly Gly Thr Thr Glu Tyr Ala Ala Ser Val Lys Gly Arg Phe Ser Ile Ser Arg Asp Asp Ser Lys Ser Ile Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Gly Trp Ile Val Val Val Ile Glu Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(167/162)  the vl comprises the amino acid sequence depicted in seq id no:167, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:162 and 167, respectively; or (xxx"
https://patents.google.com/patent/WO2021245184A1/en, Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Gly Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Leu Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Arg Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Phe Gly Asp Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(27/22)  the vl comprises the amino acid sequence depicted in seq id no:27, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:22 and 27, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en, Ser Tyr Glu Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Phe Cys Ala Arg Leu Leu Trp Leu Arg Gly Ser Tyr Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(107/102)  the vl comprises the amino acid sequence depicted in seq id no:107, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:102 and 107, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en, Gln Ser Val Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Arg Ser Thr Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser Ser Tyr Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Leu Phe Trp Arg Arg Gly Ser Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(87/82)  the vl comprises the amino acid sequence depicted in seq id no:87, or a variant thereof, wherein the variant comprises one or more amino acid substitutions;  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:82 and 87, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en, Gln Pro Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Met Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Ser Leu Tyr Tyr Ser Asp Ser Ser Gly Tyr Ser His Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(117/112)  the vl comprises the amino acid sequence depicted in seq id no:117, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:112 and 117, respectively; or (xx"
https://patents.google.com/patent/WO2021245184A1/en, Asp Ile Gln Leu Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Asn Ile Leu Tyr Ser Ser Ser Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Asp Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys His Gln Tyr Tyr Ser Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys , Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Phe Tyr Ser Val His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Thr Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asp Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Pro Pro Ile Ser Pro Ile Pro Ala Ala Gly Thr Pro Leu Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(127/122)  the vl comprises the amino acid sequence depicted in seq id no:127, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:122 and 127, respectively; or (xx"
https://patents.google.com/patent/WO2021245184A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Gly Asp Tyr Ala Met Ser Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Phe Ile Arg Ser Lys Ala Tyr Gly Gly Thr Thr Glu Tyr Ala Ala Ser Val Lys Gly Arg Phe Ser Ile Ser Arg Asp Asp Ser Lys Ser Ile Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Gly Trp Ile Val Val Val Ile Glu Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(162/167)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:162 and 167, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Asn Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp Pro Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Val Ser Leu Thr Gly Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(147/142)  the vl comprises the amino acid sequence depicted in seq id no:147, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:142 and 147, respectively; or (xxx"
https://patents.google.com/patent/WO2021245184A1/en, Gln Ser Val Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Leu Val Gly Gln Trp Leu Gly Val Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(57/52)  the vl comprises the amino acid sequence depicted in seq id no:57, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:52 and 57, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en, Glu Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Ile Phe Tyr Arg Ser Asp Asp Lys Asp Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Ser Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Phe Tyr Tyr Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys Leu Glu Ile Lys , Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Phe Tyr Ser Met His Trp Val Arg Gln Val Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Phe Asp Gly Ser Thr Lys His Tyr Ala Glu Ser Leu Arg Gly Arg Phe Ala Val Ser Arg Asp Asn Ser Lys Ser Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Pro Pro Leu Ser Pro Ile Pro Ala Ala Gly Thr Pro Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(227/222)  the vl comprises the amino acid sequence depicted in seq id no:227, or a variant thereof, wherein the variant comprises one or more amino acid substitutions;  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:222 and 227, respectively; or (xl"
https://patents.google.com/patent/WO2021245184A1/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Phe Gly Tyr Ile Phe Ser Asn Asp Trp Ile Gly Trp Val Arg Gln Lys Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Arg Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Val Ser Thr Ala Tyr Leu Gln Trp Asp Ser Leu Lys Ala Ser Asp Thr Ala Val Tyr Tyr Cys Thr Arg Pro Arg Tyr Thr Thr Met Ile Val Gly Ser Asn Pro Phe Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Gly Gly Tyr Asp Val His Trp Tyr Gln Lys Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Phe Asp Asn Asp Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Asp Thr Ser Ala Ser Leu Thr Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,"(232/237)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:232 and 237, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp Pro Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Ser Asp Ser Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Gly Ser Arg Ser Asp Trp Ser Asn Pro Ser Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(137/132)  the vl comprises the amino acid sequence depicted in seq id no:137, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:132 and 137, respectively; or (xx"
https://patents.google.com/patent/WO2021245184A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Phe Tyr Ser Val His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Thr Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asp Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Pro Pro Ile Ser Pro Ile Pro Ala Ala Gly Thr Pro Leu Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Asn Ile Leu Tyr Ser Ser Ser Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Asp Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys His Gln Tyr Tyr Ser Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(122/127)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:122 and 127, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Ala Ile Arg Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Val Ala Thr Tyr Ser Cys Gln Gln Tyr Asp Asn Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Arg Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Asn Asn Lys Asn Tyr Glu Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Arg Arg Gly Gly Tyr Ser Tyr Gly Leu Phe Asp Tyr Trp Gly Gln Gly Ile Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(257/252)  the vl comprises the amino acid sequence depicted in seq id no:257, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:252 and 257, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Asn Arg Ala Gly Trp Asp Gln Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(62/67)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:62 and 67, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Met Tyr Tyr Cys Ala Arg Glu Gly Cys Ile Val Trp Glu Ile Ala Gly Ala Leu Cys Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Val Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(32/37)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:32 and 37, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gln Ile Ser Gly Tyr Asn Tyr Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(272/277)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:272 and 277, respectively"
https://patents.google.com/patent/WO2021245184A1/en, Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Ser Val Asp Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Thr Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Val Arg Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Val Ser Ser Gly Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Val Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Ile Val Val Val Pro Ala Ala Arg Pro Leu Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(287/282)  the vl comprises the amino acid sequence depicted in seq id no:287, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:282 and 287, respectively; or (l"
https://patents.google.com/patent/WO2021245184A1/en, Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Val Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Met Tyr Tyr Cys Ala Arg Glu Gly Cys Ile Val Trp Glu Ile Ala Gly Ala Leu Cys Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(37/32)  the vl comprises the amino acid sequence depicted in seq id no:37, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:32 and 37, respectively; or "
https://patents.google.com/patent/KR20210128252A/en, Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Val Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Glu Asp Tyr Ala Met His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ser Gly Asp Gly Phe Phe Thr His Tyr Ala Asp Ser Val Glu Gly Arg Phe Thr Val Ser Arg Asp Asn Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Phe Gly Gly His Leu Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Arg Arg Leu Ala Trp Tyr Gln Arg Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Gly Val Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Thr Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Ser Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys Arg , JS_VH 4, JS 1_VL,"(78/67)  in one embodiment, the antibody or fragment having immunological activity specific for the corona-19 virus of the present invention comprises any one selected from seq id no:78 to 81, 66, 68, 70, 72, 74 and 76 vh, and/or a vl comprising any one selected from seq id no:67, 69, 71, 73, 75 and 77."
https://patents.google.com/patent/KR20210128252A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Ser Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Phe Ala Ile Gly Asp Asn Ala Leu Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Tyr Ile Arg Ser Asn Ser Tyr Gly Gly Thr Ala Glu Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Glu Ser Lys Asn Ile Ala Tyr Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Arg Ala His Tyr Tyr Gly Asp Ser Thr Tyr Asn Pro Ser Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Pro Val Thr Val Ser Ser , Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Val Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Glu Asp Tyr Ala Met His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ser Gly Asp Gly Phe Phe Thr His Tyr Ala Asp Ser Val Glu Gly Arg Phe Thr Val Ser Arg Asp Asn Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Phe Gly Gly His Leu Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , JS 1_VH, JS_VH 4,"(66/78)  in order to confirm the gene sequence of the scfv mutant clones obtained in example 2, the dna base sequence was analyzed using sanger sequencing. six scfv antibody variants with antibody sequences were selected through analysis. in this process, only the vh of scfv was additionally selected four vh antibody variants with increased binding affinity to the corona-19 virus-rbd region. in addition, the vh and vl amino acid sequences of six scfv variants (seq id no:66 to 77) (fig. 4) and the amino acid sequences of four vh variants (seq id no:78 to 81) (fig. 5) were identified."
https://patents.google.com/patent/CN112898415B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/CN112898415B/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Gly Pro Leu Met Val Arg Gly Val Ile Ile Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Asn Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) the antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain variable region has the amino acid sequence set forth in seq id no:4; the amino acid sequence of the light chain variable region is shown in seq id no:8."
https://patents.google.com/patent/CN113527471A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Val Ala Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Pro Val Asn Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Homo sapiens, Homo sapiens,(4/3) vh is seq id no:4 and vl is seq id no:3
https://patents.google.com/patent/CN113527471A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Cys Cys Ala Lys Gly Tyr Tyr Tyr Asp Ser Ser Gly Tyr Tyr Phe Arg Glu Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ala Met Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Val Pro Lys Arg Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Homo sapiens, Homo sapiens,(8/7) vh is seq id no:8 and vl is seq id no:7.
https://patents.google.com/patent/CN113527471A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Val Ser Arg Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ile Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Tyr Gly Asp Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Leu Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Homo sapiens, Homo sapiens,"(2/1) vh is seq id no:2, vl is seq id no:1"
https://patents.google.com/patent/CN113527471A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Phe Gly Ser Ser Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Glu Ser Pro Leu Gly Gly Gly Ser Gly Tyr Ser Val Ser Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Ser Asn Trp Pro Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Homo sapiens, Homo sapiens,(6/5) vh is seq id no:6 and vl is seq id no:5
https://patents.google.com/patent/WO2021247925A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Asp Ser Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ala Gly Phe Thr Phe Ser Ser Tyr Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Leu Ser Ser Gly Tyr Ser Gly Tyr Ala Gly Asn Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly His Tyr Pro Tyr Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Arg Thr Leu Ile Tyr Asp Thr Ser Asn Lys His Ser Trp Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Ala Arg Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Leu Leu Ser Tyr Ser Gly Ala Arg Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Synthetic sequence S2H13-v1 mAb VH  , Synthetic sequence S2H13-v1 mAb VL  ,"(31/35) an antibody, or an antigen-binding fragment thereof, that competes with an antibody or antigen-binding fragment comprising a vh amino acid sequence according to seq id no:31 and a vl amino acid sequence according to seq id no:35 for binding to a sars-cov-2 s glycoprotein of a s glycoprotein trimer"
https://patents.google.com/patent/WO2021247925A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Pro Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Thr Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Gly Tyr Met Glu Leu Arg Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Tyr Thr Arg Gly Ala Trp Phe Gly Glu Ser Leu Ile Gly Gly Phe Asp Asn Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Thr Val Ser Ser Thr Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Asp Thr Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic sequence S309 VH  , Synthetic sequence S309 VL  ,"(101/105)  comprises a vh comprising or consisting of an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96,%, 97%, 98%, or 99% identity to the amino acid sequence set forth in seq id no:101 and a vl comprising or consisting of an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96,%, 97%, 98%, or 99% identity to the amino acid sequence set forth in seq id no:105; and/or"
https://patents.google.com/patent/WO2021247925A1/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Ile Ser Ser Gly Thr Ser Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Ser Asp Thr Ser Ile Thr Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Ala Pro Phe Tyr Asp Phe Trp Ser Gly Tyr Ser Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Met Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Ala Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Synthetic sequence S2M11-v1 VH  , Synthetic sequence S2M11-v1 VL  ,(142/146)  a sars-cov-2 s polypeptide or multimer thereof capable of being bound by an antibody or antigen-binding fragment thereof comprising a vh comprising the sequence set forth in seq id no:142 and a vl comprising the sequence set forth in seq id no:146; 
https://patents.google.com/patent/WO2021247925A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Trp Trp Leu Arg Gly Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,, Synthetic sequence S2A4-v1 mAb VH  ,,"(64/58) in some embodiments, an antibody, or an antigen-binding fragment thereof, is provided that competes with an antibody or antigen-binding fragment comprising a vh amino acid sequence according to seq id no:64 and a vl amino acid sequence according to seq id no:58 for binding to a sars-cov-2 s glycoprotein of a s glycoprotein trimer"
https://patents.google.com/patent/WO2021247925A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Trp Trp Leu Arg Gly Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn His Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Synthetic sequence S2A4-v1 mAb VH  , Synthetic sequence S2A4-v1 mAb VL  ,"(64/68) an antibody, or an antigen-binding fragment thereof, that competes with an antibody or antigen-binding fragment comprising a vh amino acid sequence according to seq id no:64 and a vl amino acid sequence according to seq id no:68 for binding to a sars-cov-2 s glycoprotein of a s glycoprotein trimer"
https://patents.google.com/patent/WO2021247925A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Pro Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Thr Tyr Gln Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Gly Tyr Met Glu Leu Arg Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Tyr Thr Arg Gly Ala Trp Phe Gly Glu Ser Leu Ile Gly Gly Phe Asp Asn Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Thr Val Ser Ser Thr Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Asp Thr Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic sequence S309-v2 VH  , Synthetic sequence S309-v2 VL  ,"(93/97)  comprises a vh comprising or consisting of an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96,%, 97%, 98%, or 99% identity to the amino acid sequence set forth in seq id no:93 and a vl comprising or consisting of an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96,%, 97%, 98%, or 99% identity to the amino acid sequence set forth in seq id no:97.  embodiment 52. a composition comprising: "
https://patents.google.com/patent/WO2021247925A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Arg Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Thr Gly Ser Glu Thr Tyr Tyr Tyr Asp Ser Ser Gly Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Gln Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Synthetic sequence S2H14-v1 mAb VH  , Synthetic sequence S2H14-v1 mAb VL  ,"(47/51) an antibody, or an antigen-binding fragment thereof, that competes with an antibody or antigen-binding fragment comprising a vh amino acid sequence according to seq id no:47 and a vl amino acid sequence according to seq id no:51 for binding to a sars-cov-2 s glycoprotein of a s glycoprotein trimer"
https://patents.google.com/patent/WO2021247925A1/en, Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Thr Ser Val Arg Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Ser Ser Ala Val Gln Trp Val Arg Gln Ala Arg Gly Gln Arg Leu Glu Trp Val Gly Trp Ile Val Val Gly Ser Gly Asn Thr Asn Tyr Ala Gln Lys Phe His Glu Arg Val Thr Ile Thr Arg Asp Met Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Pro Tyr Cys Ser Gly Gly Ser Cys Ser Asp Gly Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Thr Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Val Gly Leu Thr Gly Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Synthetic sequence S2E12 VH  , Synthetic sequence S2E12 VL  ,(123/138) (b) a sars-cov-2 s polypeptide or multimer thereof capable of being bound by an antibody or antigen-binding fragment thereof comprising a vh comprising the sequence set forth in seq id no:123 and a vl comprising the sequence set forth in seq id no:138
https://patents.google.com/patent/WO2021247925A1/en, Asp Ile Val Leu Thr Gln Thr Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Val Gly Leu Thr Gly Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Thr Ser Val Arg Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Ser Ser Ala Val Gln Trp Val Arg Gln Ala Arg Gly Gln Arg Leu Glu Trp Val Gly Trp Ile Val Val Gly Ser Gly Asn Thr Asn Tyr Ala Gln Lys Phe His Glu Arg Val Thr Ile Thr Arg Asp Met Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Pro Tyr Cys Ser Gly Gly Ser Cys Ser Asp Gly Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Synthetic sequence S2E12 VL  , Synthetic sequence S2E12 VH  ,"(138/123) 90%, 91%, 92%, 93%, 94%, 95%, 96,%, 97%, 98%, or 99% identity to the amino acid sequence set forth in seq id no:123 and a vl comprising or consisting of an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96,%, 97%, 98%, or 99% identity to the sequence set forth in seq id no:138;  (3) the an antibody or antigen-binding fragment thereof of (c)(i) comprises a vh comprising or consisting of an amino acid sequence having at least 80%, 85%,"
https://patents.google.com/patent/WO2021247925A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ile Phe Asn Thr Tyr Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Leu Met Ser Gly Met Ala Asn Tyr Ala Gln Lys Ile Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Thr Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Phe Asn Gly Asn Tyr Tyr Gly Trp Gly Asp Asp Asp Ala Phe Asp Ile Ser Gly Gln Gly Thr Leu Val Thr Val Tyr Ser , Gln Thr Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Asn Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Cys Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Pro Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Synthetic S2X259 VH  , Synthetic sequence S2X259 VL  ,"(16/26) an antibody, or an antigen-binding fragment thereof, that competes with an antibody or antigen-binding fragment comprising a vh amino acid sequence according to seq id no:16 and a vl amino acid sequence according to seq id no:26 for binding to a sars-cov-2 s glycoprotein of a s glycoprotein trimer"
https://patents.google.com/patent/WO2021247925A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Asp Met His Trp Val Arg Gln Thr Thr Gly Lys Gly Leu Glu Trp Val Ser Thr Ile Gly Thr Ala Gly Asp Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Asp Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Ser Ser Gly Tyr Tyr Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Leu Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ala Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Ile Tyr Tyr Cys Gln Gln Ser Tyr Val Ser Pro Thr Tyr Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Synthetic sequence S304 VH  , Synthetic sequence S304 VL  ,"(150/154) an antibody, or an antigen-binding fragment thereof, that competes with an antibody or antigen-binding fragment comprising a vh amino acid sequence according to seq id no:150 and a vl amino acid sequence according to seq id no:154 for binding to a sars-cov-2 s glycoprotein of a s glycoprotein trimer"
https://patents.google.com/patent/WO2022022445A1/en, gaggtgcagc tggtggaatc tgggggaggc gtggtacagc cgggggggtc cctgagactc tcctgtgcag cctctggatt caggtttgat gatcatgcca tgcactgggt ccgtcaagct ccagggaagg gtctggagtg ggtctctgtt attagtgggg atggcggtag cacatactat gcagactctg tgaagggccg attcagcatc tccagagacg acagcaaaaa ctccctgtat ctgcaaatga acagtctgag aactgaggac accgccttgt attactgtgc aaaagatcgg agctatggtc ccccggacgt ttttaactac gaatacggta tggacgtctg gggccaaggg accacggtca ccgtctcctc a , cagtctgtgc tgactcagcc accctcagcg tctgggaccc ccgggcagag ggtcaccatc tcttgttctg gaagcagctc caacatcgga agtaatactg taaactggta ccagcagctc ccaggaacgg cccccaaact cctcatctat agtaataatc agcggccctc aggggtccct gaccgattct ctggctccaa gtctggcacc tcagcctccc tggccatcag tgggctccag tctgaggatg aggctgatta ttactgtgca gcatgggatg acagcctgaa ttgggtgttc ggcggaggga ccaagctgac cgtccta ,  Artificial Sequence  ,  Artificial Sequence  ,"(9/10)  after sequencing, the heavy chain variable region dna sequence is shown in seq id no:9; the light chain variable region dna sequence is shown in seq id no:10."
https://patents.google.com/patent/WO2022022445A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Arg Phe Asp Asp His Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Ser Gly Asp Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Ser Ile Ser Arg Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Arg Ser Tyr Gly Pro Pro Asp Val Phe Asn Tyr Glu Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Artificial Sequence  ,  Artificial Sequence  ,"(7/8)  according to the imgt numbering system scheme, the amino acid sequence of the heavy chain variable region of monoclonal antibody gw01 is shown in seq id no:7, and the amino acid sequence of the light chain variable region is shown in seq id no:8."
https://patents.google.com/patent/WO2022022445A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Arg Phe Asp Asp His Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Ser Gly Asp Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Ser Ile Ser Arg Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Arg Ser Tyr Gly Pro Pro Asp Val Phe Asn Tyr Glu Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Artificial Sequence  ,  Artificial Sequence  ,"(11/12)  similarly, the amino acid sequence of the heavy chain can be based on the sequence shown in seq id no:11 by deletion, insertion or amino acid mutation of a small number of amino acids; the amino acid sequence of the light chain can be based on the sequence shown in seq id no:12"
https://patents.google.com/patent/KR20210134300A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Thr Tyr Ser Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Thr Thr Met Val Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Thr Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic , Synthetic ,"(202/210) in some embodiments, the isolated antibody comprises an hcvr comprising the amino acid sequence set forth in seq id no:202 and an lcvr comprising the amino acid sequence set forth in seq id no:210"
https://patents.google.com/patent/KR20210134300A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Ala Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Gly Ser Asp Tyr Gly Asp Tyr Leu Leu Val Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Leu Thr Ser Ile Ser Thr Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Synthetic , Synthetic ,"(640/646) in some embodiments, the isolated antibody comprises an hcvr comprising the amino acid sequence set forth in seq id no:640 and an lcvr comprising the amino acid sequence set forth in seq id no:646"
https://patents.google.com/patent/KR20210134300A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Ala Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Gly Ser Asp Tyr Gly Asp Tyr Leu Leu Val Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Leu Thr Ser Ile Ser Thr Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser , Synthetic , Synthetic ,"(654/656) in some embodiments, the isolated antibody comprises a heavy chain comprising the amino acid sequence set forth in seq id no:654 and a light chain comprising the amino acid sequence set forth in seq id no:656"
https://patents.google.com/patent/KR20210134300A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Thr Tyr Ser Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Thr Thr Met Val Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Thr Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Synthetic , Synthetic ,"(216/218) in some embodiments, the isolated antibody comprises a heavy chain comprising the amino acid sequence set forth in seq id no:216 and a light chain comprising the amino acid sequence set forth in seq id no:218"
https://patents.google.com/patent/WO2021207433A2/en, Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Ile Thr Met Val Arg Gly Glu Asp Tyr Trp Gly Gln Gly Thr Leu , Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly His Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Asn Leu Pro Arg Thr Phe Gly Gly Gly Thr Lys ,  Synthetic heavy chain variable region amino acid sequence  ,  Synthetic light chain variable region amino acid sequence  ,"(7/8)   [00146] in some embodiments, the anti-sars-cov-2-spike antibodies in the present disclosure include a heavy chain variable region having an amino acid sequence at least 80% (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to seq id no:7 and a light chain variable region having an amino acid sequence at least 80% (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to seq id no:8"
https://patents.google.com/patent/CN113817052A/en, Met Glu Thr Gly Leu Arg Trp Leu Leu Leu Val Ala Val Leu Lys Gly Val Gln Cys Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Lys Pro Asp Glu Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Ile Ile Ala Tyr Tyr Gly Asp Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Ile Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Glu Ala Met Thr Met Val Thr Leu Asp Arg Leu Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Met Asp Thr Arg Ala Pro Thr Gln Leu Leu Gly Leu Leu Leu Leu Trp Leu Pro Gly Ala Arg Cys Ala Tyr Asp Met Thr Gln Thr Pro Ser Ser Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Asn Ile Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asp Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Gly Val Gln Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Tyr Ser Asn Leu Glu Tyr Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys , RN5502 heavy chain variable region amino acid sequence, RN5502 light chain variable region amino acid sequence,
https://patents.google.com/patent/CN113817052A/en, Met Glu Thr Gly Leu Arg Trp Leu Leu Leu Val Ala Val Leu Lys Gly Val Gln Cys Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr Thr Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Ile Ile Ile Ser Ser Ser Gly Ser Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Ile Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Val Glu Trp Asp Thr Tyr Asp Asp Tyr Gly Asp Tyr Ile Phe Gly Ile Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Met Asp Thr Arg Ala Pro Thr Gln Leu Leu Gly Leu Leu Leu Leu Trp Leu Pro Gly Ala Arg Cys Ala Asp Ile Val Met Thr Gln Thr Pro Ala Ser Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Glu Asp Ile Tyr Ser Leu Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asp Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Tyr Thr Leu Thr Ile Ser Asp Leu Glu Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Gly Tyr Tyr Ser Gly Ser Gly Thr Gly Gly Phe Gly Gly Gly Thr Glu Val Val Val Lys , RN8105 heavy chain variable region amino acid sequence, RN8105 light chain variable region amino acid sequence,
https://patents.google.com/patent/CN113817052A/en, Met Glu Thr Gly Leu Arg Trp Leu Leu Leu Val Ala Val Leu Lys Gly Val Gln Cys Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr Asp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Gly Ile Gly Gly Asn Ser Ile Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Val Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Asp Asp Asp Tyr Gly Asp Trp Phe Ala Phe Asp Pro Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Met Asp Thr Arg Ala Pro Thr Gln Leu Leu Gly Leu Leu Leu Leu Trp Leu Pro Gly Ala Thr Phe Ala Gln Val Leu Thr Gln Thr Ala Ser Pro Val Ser Ala Ala Val Gly Ser Thr Val Thr Ile Asn Cys Gln Ala Ser Gln Ser Val Tyr Asn Asn Asp Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Lys Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Glu Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Gly Val Gln Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Glu Phe Ser Cys Ser Ser Ala Asp Cys Thr Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys , RN0510 heavy chain variable region amino acid sequence, RN0510 light chain variable region amino acid sequence,
https://patents.google.com/patent/CN113817052A/en, Met Glu Thr Gly Leu Arg Trp Leu Leu Leu Val Ala Val Leu Lys Gly Val Gln Cys Gln Ser Leu Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Val Ser Gly Ile Asp Leu Asn Asn Tyr Ala Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Ile Gly Ile Ile Ser Phe Gly Gly Ser Thr Tyr Tyr Ala Ser Trp Val Asn Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Leu Thr Ser Pro Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala Arg Phe Ser Thr Tyr Asp Asp Tyr Gly Asp Tyr Phe Arg Ala Phe Asp Pro Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Met Asp Thr Arg Ala Pro Thr Gln Leu Leu Gly Leu Leu Leu Leu Trp Leu Pro Gly Ala Thr Phe Ala Leu Val Met Thr Gln Thr Pro Ser Ser Thr Ser Glu Pro Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Gly Ser Asp Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Tyr Ser Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Gly Val Gln Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Leu Gly Val Tyr Gly Phe Ser Ser Asp Asp Gly Ile Ala Phe Gly Gly Gly Thr Val Val Val Val Lys , RN2604 heavy chain variable region amino acid sequence, RN2604 light chain variable region amino acid sequence,
https://patents.google.com/patent/CN113817052A/en, Met Glu Thr Gly Leu Arg Trp Leu Leu Leu Val Ala Val Leu Lys Gly Val Gln Cys Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Ser Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr Asn Met Gln Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Ile Gly Tyr Ile Gly Pro Thr Gly Ser Ala Tyr Tyr Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Gln Met Thr Ser Leu Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Glu Asp Ala Thr Asp Trp Gly Leu Asp Ile Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Met Asp Thr Arg Ala Pro Thr Gln Leu Leu Gly Leu Leu Leu Leu Trp Leu Pro Gly Ala Arg Cys Ala Tyr Asp Met Thr Gln Thr Pro Ala Ser Val Glu Ala Ala Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Glu Ser Ile Gly Asn Ala Leu Ser Trp Tyr Gln Gln Lys Pro Arg Gln Arg Pro Arg Leu Leu Ile Tyr Arg Ala Ser Thr Leu Ala Ser Gly Val Ser Ser Arg Phe Arg Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ile Phe Ser Gly Ala Asn Ile Asp Asn Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys , RN1245 heavy chain variable region amino acid sequence, RN1245 light chain variable region amino acid sequence,
https://patents.google.com/patent/CN113817052A/en, Met Glu Thr Gly Leu Arg Trp Leu Leu Leu Val Ala Val Leu Lys Gly Val Gln Cys Gln Ser Leu Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Ser Tyr Asn Met Gly Trp Val Arg Gln Ala Pro Gly Glu Gly Leu Glu Trp Ile Gly Thr Thr Ser Asp Ser Gly Ile Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Ile Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Gly Arg Gly Trp Leu Tyr Phe Asn Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Met Asp Thr Arg Ala Pro Thr Gln Leu Leu Gly Leu Leu Leu Leu Trp Leu Pro Gly Ala Thr Phe Ala Gln Val Leu Thr Gln Thr Ala Ser Pro Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ser Ser Gln Ser Val Tyr Asp Asn Asn Ala Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Phe Leu Ile Tyr Asp Ala Ser Asp Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Ala Gly Gly Tyr Ser Asp Ala Ile Val Asn Phe Gly Gly Gly Thr Glu Val Val Val Lys , RN1279 heavy chain variable region amino acid sequence, 279 light chain variable region amino acid sequence,
https://patents.google.com/patent/CN113817052A/en, Met Glu Thr Gly Leu Arg Trp Leu Leu Leu Val Ala Val Leu Lys Gly Val Gln Cys Gln Gln Leu Glu Gln Ser Gly Gly Gly Ala Glu Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Glu Leu Cys Cys Lys Ala Ser Gly Phe Ser Leu Ser Asn Ser Tyr Trp Ile Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Cys Ile Tyr Pro Gly Ser Ser Gly Ser Ala Tyr Tyr Ala Ser Trp Val Asn Gly Arg Phe Thr Leu Ser Arg Asp Ile Asp Gln Ser Thr Gly Cys Leu Gln Leu Asn Ser Leu Thr Ala Ala Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Arg Ser Tyr Asp Asp Tyr Gly Asp Tyr Pro Asp Tyr Phe Asn Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser, Met Asp Thr Arg Ala Pro Thr Gln Leu Leu Gly Leu Leu Leu Leu Trp Leu Pro Gly Val Thr Phe Ala Ile Glu Met Thr Gln Thr Pro Phe Ser Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Asn Cys Gln Ala Ser Glu Ser Ile Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ala Ala Ser Tyr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Tyr Thr Leu Thr Ile Ser Gly Val Gln Cys Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Ser Ala Tyr Tyr Glu Ser Ser Val Val Tyr Thr Val Phe Gly Gly Gly Thr Glu Val Val Val Lys , RN1248 heavy chain variable region amino acid sequence, RN1248 light chain variable region amino acid sequence,
https://patents.google.com/patent/CN112010967B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Ala Ser Leu Arg Leu Phe Cys Val Ala Ser Gly Arg Thr Phe Ser Ser Thr Gly Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Gly Pro Gly Asp Thr Thr Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Ala Gly Phe Thr Trp Gly Leu Tyr Ser Asp Phe Val Asn Ser Tyr Glu Tyr Asn Tyr Trp Gly Gln Gly Thr Pro Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,"(4) according to some embodiments of the invention, the nanobody has an amino acid sequence as shown in seq id no:1, seq id no:2, seq id no:3 or seq id no:4."
https://patents.google.com/patent/CN112010967B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Ala Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Thr Gly Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Gly Asp Gly Asp Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Trp Asp Thr Ala Val Tyr Tyr Cys Ala Ser Thr Arg Phe Thr Trp Gly Leu Tyr Ser Asp Phe Val Asn Ser Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Pro Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,"(2) according to some embodiments of the invention, the nanobody has an amino acid sequence as shown in seq id no:1, seq id no:2, seq id no:3 or seq id no:4."
https://patents.google.com/patent/CN112010967B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Thr Gly Met Gly Trp Phe Arg Gln Gly Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Gly Asp Gly Asp Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Ala Arg Phe Thr Trp Gly Leu Tyr Ser Asp Phe Val Asn Ser Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Pro Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,"(3) according to some embodiments of the invention, the nanobody has an amino acid sequence as shown in seq id no:1, seq id no:2, seq id no:3 or seq id no:4."
https://patents.google.com/patent/CN112010967B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ala Cys Ala Ala Thr Gly Arg Thr Leu Ser Asn Tyr Ile Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Pro Leu Phe Val Ala Ala Ile Ser Arg Ser Gly Val Ile Thr Lys Tyr Ala Asp Ser Val Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Ala Tyr Leu Gln Met Thr Ser Leu Glu Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ser Ser Ser Lys Tyr Met Ala Thr Arg Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,"(1) according to some embodiments of the invention, the nanobody has an amino acid sequence as shown in seq id no:1, seq id no:2, seq id no:3 or seq id no:4."
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Val Ile Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asp Ser Ser Lys Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Lys Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Pro Asp Tyr Tyr Gly Ser Arg Tyr Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Leu Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Tyr Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Val Leu Ile Tyr Ser Ala Ala Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , A58 VH, A58 VH,"(11/29) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:11 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:29"
https://patents.google.com/patent/CN113980135A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Asp Leu Val Thr Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp His Tyr Ile His Trp Gly Lys Gln Ser His Gly Glu Asn Leu Glu Trp Ile Gly Arg Val Ser Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe Lys Gly Lys Ala Ile Phe Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Gly Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Trp Ile Tyr Tyr Asp Tyr Asp Gly Arg Ala Gly Phe Ala Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys , A5, A5、A57 VH,"(2/18) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:2 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:18"
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asp Ser Ser Thr Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Arg Gly Leu Leu Arg Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , A9 VH, A9、A74 VH,"(4/20) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:4 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:20"
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Val Ile Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile His Pro Asp Ser Ser Thr Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Pro Asp Tyr Tyr Gly Ser Arg Tyr Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Pro Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Arg Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , A77 VH, A77 VH,"(13/30) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:13 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:30"
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Val Ile Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ser Asn Pro Asp Ser Ser Lys Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Lys Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Pro Asp Tyr Tyr Gly Ser Arg Tyr Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys , A3、A20、A21 VH, A21 VH,"(1/23) or, the heavy chain variable region comprises an amino acid sequence as shown in seq id no:1, and the light chain variable region comprises an amino acid sequence as shown in seq id no:23"
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Val Ile Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Gln Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asp Ser Ser Thr Ile Ser Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Arg Gly Ile Thr Thr Trp Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Met Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , A8、A50、A81 VH, A50 VH,"(3/27) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:3 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:27"
https://patents.google.com/patent/CN113980135A/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Asp Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp His Tyr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Arg Ile Ser Pro Asn Asn Gly Ile Thr Ile Tyr Asn Gln Lys Phe Lys Asp Lys Ala Leu Leu Thr Val Asp Gln Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Leu Ile Tyr Tyr Asp Asn Asp Ser Phe Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Leu Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , A82 VH, A82 VH,"(14/32) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:14 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:32"
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Val Ile Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asp Ser Ser Lys Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Pro Asp Tyr Tyr Gly Ser Arg Tyr Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Phe Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , A14 VH, A14 VH,"(5/21) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:5 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:21"
https://patents.google.com/patent/CN113980135A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Val Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asp Ser Ser Thr Ile Ser Tyr Thr Pro Ser Leu Lys Asp Glu Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala His Tyr Tyr Cys Ala Arg Arg Gly Leu Leu Leu Leu Thr Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Gln Met Asn Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly Asp Thr Ile Thr Ile Thr Cys His Ala Ser Gln Asn Ile Asn Val Trp Leu Ser Trp Tyr Gln Gln Lys Pro Gly Asn Ile Pro Lys Leu Leu Ile Tyr Lys Ala Ser Lys Leu His Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Gly Gln Ser Tyr Pro Leu Ala Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , A55 VH, A55 VH,"(9/28) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:9 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:28"
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Leu Met Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asp Ser Ser Lys Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Pro Asp Tyr Tyr Gly Ser Arg Tyr Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Ile Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Asn Ile Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , A48 VH, A48 VH,"(8/26) or, the heavy chain variable region comprises the amino acid sequence shown as seq id no:8, and the light chain variable region comprises the amino acid sequence shown as seq id no:26"
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Val Ile Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Gln Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asp Ser Ser Thr Ile Ser Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Arg Gly Ile Thr Thr Trp Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Ile Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , A8、A50、A81 VH, A81 VH,"(3/31) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:3 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:31"
https://patents.google.com/patent/CN113980135A/en, Gln Met Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Gly Ala Phe Tyr Tyr Gly Ser Gly Ser Tyr Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asp Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ala Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , HC, LC,"(96/97) more preferably, the first binding epitope comprises a heavy chain having the sequence shown in seq id no:96 and a light chain having the sequence shown in seq id no:97."
https://patents.google.com/patent/CN113980135A/en, Gln Met Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Gly Ala Phe Tyr Tyr Gly Ser Gly Ser Tyr Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asp Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ala Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , VH, VL,"(94/95)  preferably, the first binding epitope comprises the heavy chain variable region of seq id no:94 and the light chain variable region of seq id no:95"
https://patents.google.com/patent/CN113980135A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Asp Leu Val Thr Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp His Tyr Ile His Trp Gly Lys Gln Ser His Gly Glu Ser Leu Glu Trp Ile Gly Arg Val Ser Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe Lys Gly Lys Ala Ile Phe Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Gly Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Trp Ile Tyr Phe Asp Tyr Asp Gly Arg Ala Gly Phe Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys , A57 VH, A5、A57 VH,"(10/18) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:10 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:18"
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Val Ile Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asp Ser Ser Lys Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Gly Arg Pro Asp Tyr Tyr Gly Ser Arg Tyr Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , A96 VH, A96 VH,"(15/33) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:15 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:33"
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Leu Met Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ser Asn Pro Asp Ser Ser Lys Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Lys Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Pro Asp Tyr Tyr Gly Ser Arg Tyr Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Leu Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Asp Ser Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , A105 VH, A105 VH,"(16/34) alternatively, the heavy chain variable region comprises the amino acid sequence shown as seq id no:16 and the light chain variable region comprises the amino acid sequence shown as seq id no:34."
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Leu Met Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Glu Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asp Ser Ser Thr Ile Ser Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Arg Gly Leu Leu Leu Leu Thr Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Lys Ser Leu Ser Met Ser Val Gly Glu Arg Val Thr Leu Ser Cys Lys Ala Ser Glu Asn Val Asp Thr Tyr Val Ser Trp Tyr Gln Gln Lys Pro Glu Gln Ser Pro Lys Leu Leu Ile Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Ala Thr Tyr Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Asp Tyr His Cys Gly Gln Thr Tyr Ser Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys , A24 VH, A24 VH,"(6/24) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:6 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:24"
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Val Ile Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ser Asn Pro Asp Ser Ser Lys Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Lys Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Pro Asp Tyr Tyr Gly Ser Arg Tyr Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , A3、A20、A21 VH, A3 VH,"(1/17) the anti-drug antibody of claim 4, wherein the heavy chain variable region comprises the amino acid sequence set forth in seq id no:1 and the light chain variable region comprises the amino acid sequence set forth in seq id no:17;"
https://patents.google.com/patent/CN113980135A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Asp Leu Val Thr Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp His Tyr Ile His Trp Gly Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Arg Val Ser Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe Lys Gly Lys Ala Ile Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Gly Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Trp Ile Tyr Tyr Asp Tyr Asp Gly Arg Ala Gly Phe Thr Tyr Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , A74 VH, A9、A74 VH,"(12/20) or, the heavy chain variable region comprises the amino acid sequence shown as seq id no:12 and the light chain variable region comprises the amino acid sequence shown as seq id no:20"
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Val Ile Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asp Ser Ser Thr Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Tyr Tyr Gly Tyr Gln Asp Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Lys Ser Met Ser Met Ser Val Gly Glu Arg Val Thr Leu Ser Cys Lys Ala Ser Glu Asn Val Gly Thr Tyr Val Ser Trp Tyr Gln Gln Lys Pro Glu Gln Ser Pro Lys Leu Leu Ile Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Asp Tyr His Cys Gly Gln Ser Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , A45 VH, A45 vh,"(7/25) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:7 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:25"
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Val Ile Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ser Asn Pro Asp Ser Ser Lys Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Lys Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Pro Asp Tyr Tyr Gly Ser Arg Tyr Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Pro Leu Ile Tyr Ser Thr Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Asn Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , A3、A20、A21 VH, A20 VH,"(1/22) or, the heavy chain variable region comprises an amino acid sequence as shown in seq id no:1, and the light chain variable region comprises an amino acid sequence as shown in seq id no:22"
https://patents.google.com/patent/KR20220012771A/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr His Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No.139 HC variable region , No.139 LC variable region ,"(2018/2017)  in one embodiment of the present invention, the binding molecule comprises a light chain variable region of the polypeptide sequence of seq id no:2017; and a heavy chain variable region of the polypeptide sequence of seq id no:2018."
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Asn Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Pro Thr Trp Phe Gly Glu Leu Pro Ser Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Pro Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Homo sapiens , Homo sapiens ,(5343/5344)  a heavy chain comprising seq id no:5343 and a light chain comprising seq id no:5344; or (
https://patents.google.com/patent/KR20210113936A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Gly Asp Gln Leu Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Homo sapiens , Homo sapiens ,(5353/5354)  a heavy chain comprising seq id no:5353 and a light chain comprising seq id no:5354; or (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Leu Ser Gly Ser Tyr Arg Ser Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Homo sapiens , Homo sapiens ,(1267/1268)  (vii) a vh set forth in seq id no:1267 and a vl set forth in seq id no:1268
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Pro Asp Tyr Tyr Asp Phe Trp Ser Gly Tyr Phe Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Homo sapiens , Homo sapiens ,(5325/5326)  a heavy chain comprising seq id no:5325 and a light chain comprising seq id no:5326; or (
https://patents.google.com/patent/KR20210113936A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Pro Tyr Gly Gly Asn Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , Homo sapiens , Homo sapiens ,(1121/1122)  a vh set forth in seq id no:1121 and a vl set forth in seq id no:1122; (
https://patents.google.com/patent/KR20210113936A/en, Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ser Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr His Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Gly Leu Arg Val Val Ile Thr Phe Gly Gly Val Ile Pro Lys Gly Gly Ala Phe Asp Ile Trp Gly Gly Gly Thr Met Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Homo sapiens , Homo sapiens ,(761/762)  a vh set forth in seq id no:761 and a vl set forth in seq id no:762; (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Tyr Tyr Glu Ala Arg His Tyr Tyr Tyr Tyr Tyr Ala Met Asp Val Trp Gly Gin Gly Thr Ala Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Homo sapiens , Homo sapiens ,(1255/1256)  a vh set forth in seq id no:1255 and a vl set forth in seq id no:1256.
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Tyr Ala Ala Thr Phe Gly Val Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ser Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Ala Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Homo sapiens , Homo sapiens ,(5361/5362)  a heavy chain comprising seq id no:5361 and a light chain comprising seq id no:5362; or (
https://patents.google.com/patent/KR20210113936A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gln Gly Gly Gly Gly Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Homo sapiens , Homo sapiens ,(5319/5320)  a heavy chain comprising seq id no:5319 and a light chain comprising seq id no:5320; or (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Pro Asp Tyr Tyr Asp Phe Trp Ser Gly Tyr Phe Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Homo sapiens , Homo sapiens ,(891/892)  a vh set forth in seq id no:891 and a vl set forth in seq id no:892; (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Ser Ser Gly Gly Tyr Gln Gly Pro Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Leu Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , Homo sapiens , Homo sapiens ,(1269/1270)  a vh set forth in seq id no:1269 and a vl set forth in seq id no:1270.
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Ser Gly Gly Ser Tyr Phe Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , Homo sapiens , Homo sapiens ,(727/728)  a vh set forth in seq id no:727 and a vl set forth in seq id no:728; (
https://patents.google.com/patent/KR20210113936A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly His Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Arg Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Homo sapiens , Homo sapiens ,(1225/1226)  a vh set forth in seq id no:1225 and a vl set forth in seq id no:1226; (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Ala Asp Thr Pro His Tyr Ser Gly Tyr Asp Phe Leu Ser Val Gly Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Phe Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ala Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Homo sapiens , Homo sapiens ,(5329/5330)  a heavy chain comprising seq id no:5329 and a light chain comprising seq id no:5330; or (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Val Gly Gly Tyr Ser Tyr Leu Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Homo sapiens , Homo sapiens ,(1071/1072)  a heavy chain variable region set forth in seq id no:1071 and a light chain variable region set forth in seq id no:1072; or (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Ser Ser Gly Gly Tyr Gln Gly Pro Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Leu Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser , Homo sapiens , Homo sapiens ,(5365/5366)  a heavy chain comprising seq id no:5365 and a light chain comprising seq id no:5366.
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Tyr Tyr Glu Ala Arg His Tyr Tyr Tyr Tyr Tyr Ala Met Asp Val Trp Gly Gin Gly Thr Ala Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Homo sapiens , Homo sapiens ,(5363/5364)  a heavy chain comprising seq id no:5363 and a light chain comprising seq id no:5364; or (
https://patents.google.com/patent/KR20210113936A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Lys Ser Ser Gly Ser Gly Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Homo sapiens , Homo sapiens ,(1039/1040)  a vh set forth in seq id no:1039 and a vl set forth in seq id no:1040; (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr Ala Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Arg Gly Gly Tyr Arg Ser Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Asn Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Homo sapiens , Homo sapiens ,(921/922)  a vh set forth in seq id no:921 and a vl set forth in seq id no:922; (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Pro Gly Arg Asp Phe Trp Ser Gly Tyr Tyr Phe Gly Ala Pro Asp Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Lys Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Homo sapiens , Homo sapiens ,(973/974)  a vh set forth in seq id no:973 and a vl set forth in seq id no:974; (
https://patents.google.com/patent/KR20210113936A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Pro Tyr Gly Gly Asn Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Homo sapiens , Homo sapiens ,(5351/5352)  a heavy chain comprising seq id no:5351 and a light chain comprising seq id no:5352; or (
https://patents.google.com/patent/KR20210113936A/en, Gln Val His Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Ala Ala Ser Gly Tyr Thr Phe Asn Asn Tyr Gly Val Ser Trp Val Arg Gln Ala Pro Gly Gly Gly Leu Glu Trp Met Gly Trp Ile Ser Ala Ser Asn Gly Asn Thr Lys Tyr Ala Gln Asn Leu Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Gly Pro Thr Ala Pro Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Ala Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Ser Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ala Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Leu Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , Homo sapiens , Homo sapiens ,(725/726)  a heavy chain variable region set forth in seq id no:725 and a light chain variable region set forth in seq id no:726; or (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Ser Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Lys Gly Gly Ser Tyr Ser Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Gln Ser Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Homo sapiens , Homo sapiens ,(5337/5338)  a heavy chain comprising seq id no:5337 and a light chain comprising seq id no:5338; or (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala Thr Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Leu Ile Ser His Asp Gly Ser Asn Lys His Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Gly Thr Ala Ile Tyr Tyr Cys Ala Arg Glu Ser Leu Glu Ala Ala Ala Pro Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Tyr Glu Leu Thr Gln Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Thr Ile Ile Cys Ser Gly Asp Lys Leu Gly Glu Lys Tyr Ala Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Ala Leu Val Ile Tyr Gln Asp Arg Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Asn Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Pro , Homo sapiens , Homo sapiens ,(1313/1314)  a vh set forth in seq id no:1313 and a vl set forth in seq id no:1314.
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Trp Thr Gln Ser Ser Gly Tyr Asp Tyr Tyr Tyr Gly Leu Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser , Ser Tyr Glu Leu Thr Gln Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Arg Ile Thr Cys Ser Gly Asp Ala Leu Pro Lys Gln Tyr Ala Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Val Val Val Ile Tyr Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Val Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Ala Asp Ser Ser Gly Thr Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Homo sapiens , Homo sapiens ,(983/984)  vh as set forth in seq id no:983 and vl as set forth in seq id no:984; (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr Ala Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Arg Gly Gly Tyr Arg Ser Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Asn Thr Phe Gly Gin Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Homo sapiens , Homo sapiens ,(5327/5328)  a heavy chain comprising seq id no:5327 and a light chain comprising seq id no:5328; or (
https://patents.google.com/patent/KR20210113936A/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Ser Pro Ser Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala His His Ser Leu Ser Ser Ile Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Asp Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser , Homo sapiens , Homo sapiens ,(5355/5356)  a heavy chain comprising seq id no:5355 and a light chain comprising seq id no:5356; or (
https://patents.google.com/patent/KR20210113936A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Gly Asp Gln Leu Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Homo sapiens , Homo sapiens ,(1133/1134)  a vh set forth in seq id no:1133 and a vl set forth in seq id no:1134; (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Thr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Ala Gly Tyr Gly Ser Ile Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Arg Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Homo sapiens , Homo sapiens ,(661/662)  a heavy chain variable region set forth in seq id no:661 and a light chain variable region set forth in seq id no:662; or (
https://patents.google.com/patent/KR20210113936A/en, Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Gly Asp Tyr Ala Met Ser Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Phe Ile Arg Ser Lys Ala Tyr Gly Gly Thr Thr Glu Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Phe Gly Ile Asp Tyr Asp Tyr Ile Trp Gly Ser Tyr Arg Tyr Thr Thr Leu Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Homo sapiens , Homo sapiens ,"(5322/5323) in some embodiments, provided herein is an antibody comprising a heavy chain comprising seq id no:5322 and a light chain comprising seq id no:5323"
https://patents.google.com/patent/KR20210113936A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Ser Ser Ser Ser Ser Ser Thr Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gly Ala Arg Thr Pro Trp Asp Ile Val Val Val Pro Ala Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Arg Ser Pro Asn Thr Phe Gly Gin Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Homo sapiens , Homo sapiens ,(5345/5346)  a heavy chain comprising seq id no:5345 and a light chain comprising seq id no:5346; or (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Ser Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Lys Gly Gly Ser Tyr Ser Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Gln Ser Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Homo sapiens , Homo sapiens ,(1029/1030)  a vh set forth in seq id no:1029 and a vl set forth in seq id no:1030; (
https://patents.google.com/patent/KR20210113936A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Ser Ser Ser Ser Ser Ser Thr Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gly Ala Arg Thr Pro Trp Asp Ile Val Val Val Pro Ala Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Arg Ser Pro Asn Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Homo sapiens , Homo sapiens ,(1103/1104)  a vh set forth in seq id no:1103 and a vl set forth in seq id no:1104; (
https://patents.google.com/patent/KR20210113936A/en, Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Ser Glu Lys Val Asp Phe Trp Ser Gly Gly Pro Tyr Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ile Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Homo sapiens , Homo sapiens ,(1167/1168)  a vh set forth in seq id no:1167 and a vl set forth in seq id no:1168; (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Gly Ser Gly Asn Tyr Tyr Asn Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Thr Val Ser Ser Asn Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Homo sapiens , Homo sapiens ,(1123/1124)  a vh set forth in seq id no:1123 and a vl set forth in seq id no:1124; (
https://patents.google.com/patent/KR20210113936A/en, Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Pro Ile Met Ile Thr Phe Gly Gly Val Thr Gly His Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Homo sapiens , Homo sapiens ,(979/980)  a vh set forth in seq id no:979 and a vl set forth in seq id no:980; (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly Gly Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Thr Thr Met Val Arg Gly Val Ile Arg Leu Asp His Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Leu Phe Gly Thr Gly Thr Lys Val Thr Val Leu , Homo sapiens , Homo sapiens ,(867/868)  a vh set forth in seq id no:867 and a vl set forth in seq id no:868; (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Trp Thr Gln Ser Ser Gly Tyr Asp Tyr Tyr Tyr Gly Leu Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ser Tyr Glu Leu Thr Gln Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Arg Ile Thr Cys Ser Gly Asp Ala Leu Pro Lys Gln Tyr Ala Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Val Val Val Ile Tyr Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Val Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Ala Asp Ser Ser Gly Thr Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser , Homo sapiens , Homo sapiens ,(5335/5336)  a heavy chain comprising seq id no:5335 and a light chain comprising seq id no:5336; or (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Tyr Ser Gly Ser Tyr Gln Ser Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Homo sapiens , Homo sapiens ,(5321/5322)  a heavy chain comprising seq id no:5321 and a light chain comprising seq id no:5322; or (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Pro Glu Glu Lys Ser Ser Glu Ile Gly Glu Leu Val Gly Trp Gly Trp Phe Asp Pro Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Ser Tyr Glu Leu Thr Gln Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Ser Ile Ile Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala Cys Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Homo sapiens , Homo sapiens ,(1111/1112)  a vh set forth in seq id no:1111 and a vl set forth in seq id no:1112; (
https://patents.google.com/patent/KR20210113936A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly His Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Arg Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Homo sapiens , Homo sapiens ,(5357/5358)  a heavy chain comprising seq id no:5357 and a light chain comprising seq id no:5358; or (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Thr Glu Val Gly Ala Thr Ser Glu Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ser Tyr Glu Leu Thr Gln Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Arg Ile Thr Cys Ser Gly Asp Ala Leu Pro Lys Gln Tyr Ala Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Val Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Ala Asp Ser Ser Gly Thr Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser , Homo sapiens , Homo sapiens ,(5339/5340)  a heavy chain comprising seq id no:5339 and a light chain comprising seq id no:5340; or (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Ser Pro Ala Ala Ala Gly Thr Ser Gln Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Thr Pro Leu Ser Ser Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Thr Gln Phe Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Homo sapiens , Homo sapiens ,(779/780)  a vh set forth in seq id no:779 and a vl set forth in seq id no:780; (
https://patents.google.com/patent/KR20210113936A/en, Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Pro Ile Met Ile Thr Phe Gly Gly Val Thr Gly His Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Homo sapiens , Homo sapiens ,(5333/5334)  a heavy chain comprising seq id no:5333 and a light chain comprising seq id no:5334; or (
https://patents.google.com/patent/KR20210113936A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Gly Asp Tyr Ala Met Ser Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Phe Ile Arg Ser Lys Ala Tyr Gly Gly Thr Thr Glu Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Phe Gly Ile Asp Tyr Asp Tyr Ile Trp Gly Ser Tyr Arg Tyr Thr Thr Leu Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Homo sapiens , Homo sapiens ,(873/874)  a vh set forth in seq id no:873 and a vl set forth in seq id no:874; (
https://patents.google.com/patent/KR20210113936A/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Ser Pro Ser Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala His His Ser Leu Ser Ser Ile Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Asp Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Homo sapiens , Homo sapiens ,(1157/1158)  a vh set forth in seq id no:1157 and a vl set forth in seq id no:1158; (
https://patents.google.com/patent/KR20210113936A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Pro Tyr Gly Gly Asn Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Gln Thr Ile Tyr Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Phe Leu Ile Tyr Ala Ala Ser Ser Phe Gln Asn Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Homo sapiens , Homo sapiens ,(5359/5360)  a heavy chain comprising seq id no:5359 and a light chain comprising seq id no:5360; or (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Thr Glu Val Gly Ala Thr Ser Glu Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser , Ser Tyr Glu Leu Thr Gln Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Arg Ile Thr Cys Ser Gly Asp Ala Leu Pro Lys Gln Tyr Ala Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Val Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Ala Asp Ser Ser Gly Thr Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Homo sapiens , Homo sapiens ,(1035/1036)  vh as set forth in seq id no:1035 and vl as set forth in seq id no:1036; (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Ala Asp Thr Pro His Tyr Ser Gly Tyr Asp Phe Leu Ser Val Gly Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Phe Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ala Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Homo sapiens , Homo sapiens ,(961/962)  a vh set forth in seq id no:961 and a vl set forth in seq id no:962; (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Tyr Ser Gly Ser Tyr Gln Ser Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Homo sapiens , Homo sapiens ,(763/764)  a vh set forth in seq id no:763 and a vl set forth in seq id no:764; (
https://patents.google.com/patent/KR20210113936A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Pro Ala Gly Ile Val Val Gly Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Phe Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr His Ser Ser Asn Pro His Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Homo sapiens , Homo sapiens ,(1143/1144)  a vh set forth in seq id no:1143 and a vl set forth in seq id no:1144; (x
https://patents.google.com/patent/KR20210113936A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Lys Ser Ser Gly Ser Gly Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Homo sapiens , Homo sapiens ,(5341/5342)  a heavy chain comprising seq id no:5341 and a light chain comprising seq id no:5342; or (
https://patents.google.com/patent/KR20210113936A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gln Gly Gly Gly Gly Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Homo sapiens , Homo sapiens ,(729/730)  a vh set forth in seq id no:729 and a vl set forth in seq id no:730; (
https://patents.google.com/patent/KR20210113936A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Val Ala Gly Thr Tyr Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Gly Gly Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Homo sapiens , Homo sapiens ,(1107/1108)  a vh set forth in seq id no:1107 and a vl set forth in seq id no:1108; (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Asn Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Pro Thr Trp Phe Gly Glu Leu Pro Ser Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Pro Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , Homo sapiens , Homo sapiens ,(1069/1070)  vh as set forth in seq id no:1069 and vl as set forth in seq id no:1070; (
https://patents.google.com/patent/KR20210113936A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Pro Tyr Gly Gly Asn Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Gln Thr Ile Tyr Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Phe Leu Ile Tyr Ala Ala Ser Ser Phe Gln Asn Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Homo sapiens , Homo sapiens ,(1243/1244)  a vh set forth in seq id no:1243 and a vl set forth in seq id no:1244; (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Pro Glu Glu Lys Ser Ser Glu Ile Gly Glu Leu Val Gly Trp Gly Trp Phe Asp Pro Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ser Tyr Glu Leu Thr Gln Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Ser Ile Ile Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala Cys Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser , Homo sapiens , Homo sapiens ,(5349/5350)  (q) a heavy chain comprising seq id no:5349 and a light chain comprising seq id no:5350
https://patents.google.com/patent/KR20210113936A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Gly Asp Tyr Ala Met Ser Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Phe Ile Arg Ser Lys Ala Tyr Gly Gly Thr Thr Glu Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Phe Gly Ile Asp Tyr Asp Tyr Ile Trp Gly Ser Tyr Arg Tyr Thr Thr Leu Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Homo sapiens , Homo sapiens ,(5323/5324)  a heavy chain comprising seq id no:5323 and a light chain comprising seq id no:5324; or (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Tyr Ala Ala Thr Phe Gly Val Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ser Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Ala Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Homo sapiens , Homo sapiens ,(1251/1252)  vh as set forth in seq id no:1251 and vl as set forth in seq id no:1252; (
https://patents.google.com/patent/KR20210113936A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Pro Gly Arg Asp Phe Trp Ser Gly Tyr Tyr Phe Gly Ala Pro Asp Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Lys Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Homo sapiens , Homo sapiens ,(5331/5332)  a heavy chain comprising seq id no:5331 and a light chain comprising seq id no:5332; or (
https://patents.google.com/patent/KR20210113936A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Val Ala Gly Thr Tyr Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Gly Gly Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Homo sapiens , Homo sapiens ,(5347/5348)  a heavy chain comprising seq id no:5347 and a light chain comprising seq id no:5348; (
https://patents.google.com/patent/WO2021227138A1/en, Glu Val Gln Leu Leu Glu Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Arg Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Pro Glu Val Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Thr Thr Pro Phe Ser Ser Ser Phe Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Ala Pro Ser Val Ser Gly Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  人工序列(Artificial Sequence)  ,  人工序列(Artificial Sequence)  ,"(4/8)  more preferably, the heavy chain variable region comprises the amino acid sequence shown in seq id no:4; the light chain variable region comprises the amino acid sequence shown in seq id no:8."
https://patents.google.com/patent/WO2021227138A1/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Tyr Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Thr Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Glu Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ala Met Phe Leu Gly Asp Ser Ser Gly Leu Thr Gly Leu Asp Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Glu Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Leu Tyr Tyr Cys Gln Gln Arg Gly Asn Trp Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  人工序列(Artificial Sequence)  ,  人工序列(Artificial Sequence)  ,"(20/24)  more preferably, the heavy chain variable region comprises the amino acid sequence shown in seq id no:20; the light chain variable region comprises the amino acid sequence shown in seq id no:24."
https://patents.google.com/patent/WO2021227138A1/en, Glu Val Gln Leu Leu Gln Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg Glu Arg Gly Tyr Ser Gly Tyr Gly Ala Ala Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  人工序列(Artificial Sequence)  ,  人工序列(Artificial Sequence)  ,"(12/16)  more preferably, the heavy chain variable region includes the amino acid sequence shown in seq id no:12; the light chain variable region includes the amino acid sequence shown in seq id no:16."
https://patents.google.com/patent/CN112430265A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Glu Ala Ser Glu Ile Ile Val Asn Arg Asn Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ile Ile Tyr Pro Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Met Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Tyr Gly Asp Phe Tyr Val Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(2/1) the amino acid sequences of the variable regions of the light and heavy chains of antibody ncov-61 are shown in seq id no:1 and 2, respectively."
https://patents.google.com/patent/WO2022010912A1/en, Glu Val Gln Leu Glu Glu Ser Gly Thr Val Leu Ala Arg Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr Arg Met His Trp Ile Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Ser Asp Thr Thr Tyr Asn Gln Lys Phe Lys Asp Lys Ala Lys Leu Thr Ala Val Thr Ser Thr Ser Ser Ala Tyr Met Glu Leu Ser Ser Leu Thr Asn Glu Asp Ser Ala Val Tyr Phe Cys Thr Arg Glu Gly Ile Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Leu Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly Glu Arg Val Ser Leu Thr Cys Arg Ala Ser Gln Glu Ile Ser Gly Tyr Leu Ser Trp Leu Gln Glu Lys Pro Asp Gly Thr Ile Lys Arg Leu Ile Tyr Ala Ala Ser Thr Leu Asp Ser Gly Val Pro Lys Arg Phe Ser Gly Ser Arg Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser Glu Asp Phe Ala Asp Tyr Tyr Cys Leu Gln Tyr Val Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  synthetic polypeptide  ,  synthetic polypeptide  ,"(3/12) in some embodiments, the reference antibody comprises a vh sequence of seq id no:3 and a vl sequence of seq id no:12"
https://patents.google.com/patent/WO2022010912A1/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr Trp Met His Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ala Ile Tyr Pro Gly Asn Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Leu Ser Val Asp Lys Ser Ile Thr Thr Ala Tyr Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Phe Cys Thr Arg Glu Gly Ile Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Gly Tyr Leu Ser Trp Leu Gln Gln Lys Pro Glu Lys Ala Pro Lys Arg Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Leu Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  synthetic polypeptide  ,  synthetic polypeptide  ,"(45/49) the polypeptide of any one of claims 2-22, wherein: a) the vh comprises seq id no:45; and  b) the vl comprises seq id no:49"
https://patents.google.com/patent/WO2022010912A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Ala Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Gly Ile Pro Gln Leu Leu Asn Thr Leu Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Glu Ile Ser Gly Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Leu Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  synthetic polypeptide  ,  synthetic polypeptide  ,"(43/47) the polypeptide of any one of claims 2-22, wherein: a) the vh comprises seq id no:43; and b) the vl comprises seq id no:47"
https://patents.google.com/patent/WO2022010912A1/en, Glu Val Gln Leu Glu Glu Ser Gly Thr Val Leu Ala Arg Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr Trp Met His Trp Ile Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Asn Tyr Asn Gln Lys Phe Lys Asp Lys Ala Lys Leu Thr Ala Val Lys Ser Thr Ser Ser Ala Tyr Met Glu Leu Ser Ser Leu Thr Asn Glu Asp Ser Ala Val Tyr Phe Cys Thr Arg Glu Gly Ile Pro Gln Leu Leu Arg Thr Phe Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Leu Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly Glu Arg Val Ser Leu Thr Cys Arg Ala Ser Gln Glu Ile Gly Gly Tyr Leu Ser Trp Leu Gln Glu Lys Pro Asp Gly Thr Ile Lys Arg Leu Ile Tyr Ala Ala Ser Thr Leu Asp Ser Gly Val Pro Lys Arg Phe Ser Gly Ser Arg Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser Glu Asp Phe Ala Asp Tyr Tyr Cys Leu Gln Tyr Leu Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  synthetic polypeptide  ,  synthetic polypeptide  ,"(7/14) the polypeptide of any one of claims 2-22, wherein: a) the vh comprises seq id no:7; and b) the vl comprises seq id no:14"
https://patents.google.com/patent/WO2022010912A1/en, Glu Val Gln Leu Glu Glu Ser Gly Thr Val Leu Ala Arg Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met His Trp Ile Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Asn Tyr Asn Gln Lys Phe Lys Asp Lys Ala Lys Leu Thr Ala Val Lys Ser Thr Ser Ser Ala Tyr Met Glu Leu Ser Ser Leu Thr Asn Glu Asp Ser Ala Val Tyr Phe Cys Thr Arg Glu Gly Ile Pro Gln Leu Leu Asn Thr Leu Asp Val Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Leu Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly Glu Arg Val Ser Leu Thr Cys Arg Ala Ser Gln Glu Ile Ser Gly Tyr Leu Ser Trp Leu Gln Glu Lys Pro Asp Gly Thr Ile Lys Arg Leu Ile Tyr Ala Ala Ser Thr Leu Asp Ser Gly Val Pro Lys Arg Phe Ser Gly Ser Arg Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser Glu Asp Phe Ala Asp Tyr Tyr Cys Gln Gln Tyr Leu Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  synthetic polypeptide  ,  synthetic polypeptide  ,"(8/15) the polypeptide of any one of claims 2-22, wherein: a) the vh comprises seq id no:8; and b) the vl comprises seq id no:15"
https://patents.google.com/patent/WO2022010912A1/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Ser Gly Glu Ser Leu Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr Trp Met His Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ala Ile Tyr Pro Gly Asn Ser Asp Thr Gln Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Leu Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Phe Cys Thr Arg Glu Gly Ile Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Glu Ile Ser Gly Tyr Leu Ala Trp Leu Gln Gln Lys Pro Gly Gln Ala Pro Arg Arg Leu Ile Tyr Ala Ala Ser Ser Leu Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Leu Gln Tyr Leu Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  synthetic polypeptide  ,  synthetic polypeptide  ,"(44/48) the polypeptide of any one of claims 2-22, wherein: a) the vh comprises seq id no:44; and b) the vl comprises seq id no:48"
https://patents.google.com/patent/WO2021231803A2/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Asn Val Asp Asp Tyr Gly Ile Gly Trp Phe Arg Gln Gly Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Asp Ser Ser Gly Gly Ser Ser Tyr Thr Ala Pro Phe Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Met Tyr Leu Gln Met Asn Ser Leu Lys Pro Asp Asp Thr Ala Val Tyr Tyr Cys Asn Ala Val Leu Tyr Leu Asn Ser Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Pro Gly Gly Gln His His His His His His ,, Description of Artificial Sequence: Synthetic       polypeptide  ,,"(8) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Gly Val Asn Asp Met Gly Trp Tyr Arg Gln Gly Pro Gly Lys Gln Arg Glu Leu Val Ala Ser Ile Ala Ser Gly Gly Tyr Thr Asn Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Cys Tyr Cys Asn Ala Glu Val Thr Asn Ile Gly Arg Leu Val Pro Val Thr Ser Gly Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Pro Gly Gly Gln His His His His His His ,, Description of Artificial Sequence: Synthetic       polypeptide  ,,"(3) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Arg Val Ala Ser Gly Gly Thr Leu Ser Ser Tyr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Thr Ala Ile Ser Trp Ile Gly Asn Thr Tyr Tyr Thr Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ser Val Val Arg Gly Thr Pro Asp Ser Leu Ala Leu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Pro Gly Gly Gln His His His His His His ,, Description of Artificial Sequence: Synthetic       polypeptide  ,,"(14) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Gly Ser Leu Arg Val Ser Cys Thr Ala Ser Gly Arg Thr Ala Arg Met Tyr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Arg Trp Asn Val Gly Ser Thr Phe Tyr Gly Asp Ser Val Lys Asp Arg Phe Ile Ile Thr Gly Asp Val Ala Ala Asn Thr Ile Tyr Leu Gln Met Asn Arg Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Phe Gly Thr Tyr Tyr Leu Val Gly Met Ser Asp Lys Gly Glu Tyr Asp Tyr Trp Gly Lys Gly Thr Leu Val Thr Val Ser Ser Gly Pro Gly Gly Gln His His His His His His ,, Description of Artificial Sequence: Synthetic       polypeptide  ,,"(2) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Leu Asp Asp Asp Asp Val Thr Val Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Ile Ser Cys Leu Asn Val Pro Asp Gly Gly Thr Tyr Tyr Ser Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Ile His Lys Asn Met Leu Tyr Leu His Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Gly Leu His Lys Gly Leu Ile Gly Glu Leu Val Cys His Tyr Gly Met Asp Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser Gly Pro Gly Gly Gln His His His His His His ,, Description of Artificial Sequence: Synthetic       polypeptide  ,,"(12) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Ser Ile Asn Val Met Ala Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Ala Ile Thr Ser Gly Gly Arg Ser Asn Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys His Thr Ile Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Leu Gly Ser Trp Tyr Thr Phe Gly Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Pro Gly Gly Gln His His His His His His ,, Description of Artificial Sequence: Synthetic       polypeptide  ,,"(6) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Leu Ser Trp Tyr Gly Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Arg Asn Ser Arg Ser Thr Phe Tyr Ala Val Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Val Gly Ala Arg Tyr Gly Ser Ser Ser Asp Val Ser Val Tyr Gln Tyr Asn Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Pro Gly Gly Gln His His His His His His ,, Description of Artificial Sequence: Synthetic       polypeptide  ,,"(4) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ile Leu Ser Ile Asn Ser Trp Gly Trp Tyr Arg Gln Pro Pro Gly Lys Gln Arg Glu Arg Val Ala Val Ile Thr Ser Gly Gly Ser Thr Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Thr Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn Ala Gly Thr Val Arg Arg Asn Tyr Ser Gly Ser Tyr Tyr Tyr Thr Ala Arg Gln Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Pro Gly Gly Gln His His His His His His ,, Description of Artificial Sequence: Synthetic       polypeptide  ,,"(15) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Val Gly Phe Glu Ser Val Phe Ser Phe Asn Pro Arg Leu Lys Asp Thr Met Asn Trp Tyr Arg Glu Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Ser Ile Asn Asp Asp Gly Ile Thr Asn Tyr Ala Asp Phe Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu Tyr Leu Gln Met Asn Phe Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn Gly Arg Arg Thr Asn Trp Pro Asp Val Arg Glu Thr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Pro Gly Gly Gln His His His His His His ,, Description of Artificial Sequence: Synthetic       polypeptide  ,,"(9) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Thr Leu Ser Cys Ala Ala Ser Gly Ser Phe Tyr Arg Ile Lys Thr Met Ala Trp His Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Gly Ile Ser Ala Asn Gly Val Ala Thr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ala Lys Asn Thr Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Gln Arg Leu Ser Trp Tyr Asn Ser Arg Trp Asn Leu Gln Ala Ala Gly Tyr Lys Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Pro Gly Gly Gln His His His His His His ,, Description of Artificial Sequence: Synthetic       polypeptide  ,,"(1) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Thr Leu Ser Cys Glu Ala Ser Gly Ser Ile Leu Ser Ile Tyr Val Leu Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu Leu Val Ala Ala Ile Thr Ser Gly Gly Asp Thr Ser Ile Ala His Ser Leu Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Thr Lys Ser Thr Val Thr Leu His Met Asp Ser Leu Glu Pro Glu Asp Thr Ala Val Tyr Phe Cys His Ala Gly Arg Tyr Arg Thr Gln Gly Arg Tyr Val Tyr Asn Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Pro Gly Gly Gln His His His His His His ,, Description of Artificial Sequence: Synthetic       polypeptide  ,,"(11) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en, Gln Val Gln Leu Val Glu Ser Gly Gly Val Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Leu Ser Arg Ser Gly Asp Tyr Thr Lys Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Gly Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ser Val Tyr Tyr Cys Ser Leu Arg Arg Leu Ser Gly Tyr Arg Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Pro Gly Gly Gln His His His His His His ,, Description of Artificial Sequence: Synthetic       polypeptide  ,,"(7) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Ser Ile Asn Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Arg Met Thr Ser Gly Gly Ala Thr Thr Tyr Ala Asp Ala Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Thr Met Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ser Leu Thr Lys Val Gly Leu Phe Thr Lys Arg Glu Ser Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Pro Gly Gly Gln His His His His His His ,, Description of Artificial Sequence: Synthetic       polypeptide  ,,"(5) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Arg Ala Ser Gly Met Thr Phe Ser Arg Phe Ala Met Ala Trp Tyr Arg Gln Ala Pro Gly Asn Gln Arg Ala Leu Ile Ala Phe Ile Thr Ser Glu Gly Thr Thr Lys Tyr Glu Pro Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asp Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn Ile Pro Pro Ala Tyr Tyr Gly Gln Arg Thr Leu Val Thr Val Ser Ser Gly Pro Gly Gly Gln His His His His His His ,, Description of Artificial Sequence: Synthetic       polypeptide  ,,"(13) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ile Ser Gly Pro Tyr Ser Met Gly Trp Phe Arg Gln Val Pro Gly Lys Glu Arg Gly Phe Val Ala Gly Leu Ser Trp Phe Asp Gly Ile Thr Thr Tyr Ile Asp Ala Val Lys Gly Arg Phe Thr Val Ser Arg Asp Ile Ala Lys Asn Thr Leu Ser Leu Val Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Thr Tyr Tyr Cys Ala Ala Arg Tyr His Asp Lys Val Tyr Tyr Ala Gly Asp Asn Asp Phe Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Pro Gly Gly Gln His His His His His His ,, Description of Artificial Sequence: Synthetic       polypeptide  ,,"(16) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Thr Arg Thr Asn Ser Asp Tyr Thr Met Gly Trp Phe Arg Arg Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ser Ile Thr Trp Ser Asp Asp Val Thr Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Arg Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Arg Phe Ser Asp Ser Tyr Leu Leu Tyr Val Ala Ser Gly Gln Tyr Asn Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Pro Gly Gly Gln His His His His His His ,, Description of Artificial Sequence: Synthetic       polypeptide  ,,"(10) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/CN113817050A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Ile Thr Val Ser Ser Asn Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Met Glu Val Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Val Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Val Ala Thr Tyr Tyr Cys Gln Asn Tyr Asn Ser Ala Pro Phe Ala Phe Gly Pro Gly Thr Lys Val Glu Ile Lys , Artificial sequence, Artificial sequence,"(7/8) specifically, the sequences of the light chain variable region and the heavy chain variable region are respectively the same as seq id no:8 and seq id no:7."
https://patents.google.com/patent/US11021532B1/en,Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly SerAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr ValSer Ala Ile Ser Arg Asn Gly Gly Thr Thr Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysAla Lys Asp Gly Thr Leu Ile Thr Thr Thr Leu Asp Tyr Trp Gly GlnGly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Tyr TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Thr Thr Pro LeuThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,343 <211> LENGTH: 120 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 343,367 <211> LENGTH: 108 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 367,"(343/367) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:343 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:367."
https://patents.google.com/patent/US11021532B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Asn TyrAsp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Val Ile Asn Pro Ser Ala Gly Ser Thr Ser Tyr Ala His Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Ser Ala His Ser Ser Ser Trp Tyr Ser Asp Trp Phe Asp Pro TrpGly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro LeuThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,348 <211> LENGTH: 122 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 348,372 <211> LENGTH: 108 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 372,"(348/372) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:348 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:372."
https://patents.google.com/patent/US11021532B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser TyrAsp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asp Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Thr Val Thr Pro Gly Tyr Gly Met Asp Val Trp Gly Gln Gly ThrThr Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Thr Ile Tyr Ser TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Ile Ser Phe Pro LeuThr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg,361 <211> LENGTH: 118 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 361,385 <211> LENGTH: 108 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 385,"(361/385) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:361 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:385."
https://patents.google.com/patent/US11021532B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Thr Ser TyrHis Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Leu Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Ser Phe Glu Arg Phe Gly Glu Leu Val Pro Glu Thr Phe Asp TyrTrp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn AspLeu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro ProThr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg,346 <211> LENGTH: 123 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 346,370 <211> LENGTH: 108 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 370,"(346/370) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:346 and an vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:370."
https://patents.google.com/patent/US11021532B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp TyrTyr Ile Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Ile Asn Pro Asn Ser Gly Gly Pro Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Val Asp Tyr Gly Asp Tyr Gly Arg Leu Glu Asp Tyr Trp GlyGln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Tyr Ser TrpLeu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro TyrThr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg,350 <211> LENGTH: 121 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 350,374 <211> LENGTH: 108 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:  Synthetic polypeptide <400> SEQUENCE: 374,"(350/374) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:350 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:374."
https://patents.google.com/patent/US11021532B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp TyrTyr Met Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Ile Asp Pro His Ser Gly Ala Thr Asn Tyr Ala His Ser PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Leu Glu Gly Gly Ser Tyr Trp Thr Gly Tyr Phe Asp Leu TrpGly Arg Gly Thr Leu Val Thr Val Ser Ser,Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro GlyGlu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser AsnTyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu LeuIle Tyr Ala Val Ser Ser Arg Ala Thr Gly Ile Pro Ala Arg Phe SerGly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu GlnSer Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser ProLeu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,351 <211> LENGTH: 122 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 351,375 <211> LENGTH: 109 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 375,"(351/375) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:351 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:375."
https://patents.google.com/patent/US11021532B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Arg TyrTyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asn Pro Ser Gly Gly Ser Thr Thr Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Lys Gly Ala Pro His Asp Tyr Ile Trp Gly Ser Tyr Arg Pro AspAla Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Asp Ser TrpLeu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Glu Ala Ser Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys His Gln Tyr Leu Ser Ser Pro GluThr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg,360 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 360,384 <211> LENGTH: 108 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 384,"(360/384) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:360 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:384."
https://patents.google.com/patent/US11021532B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn TyrGly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Ile Ser Ala Arg Asn Gly Asn Thr Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysThr Thr Asp Pro Val Leu Glu Trp Phe Gly Tyr Ser Ile Trp Gly GlnGly Thr Met Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Phe Ser SerSer Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg ,358 <211> LENGTH: 120 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 358,382 <211> LENGTH: 114 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 382,"(358/382) an antibody or an antigen-binding fragment that selectively binds to a sars-cov-2, that comprises a vh having an amino acid sequence of seq id no:358 and a vl having an amino acid sequence of seq id no:382."
https://patents.google.com/patent/US11021532B1/en,Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Asn TyrAsp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValAla Val Ile Ser Tyr Asp Gly Gly Phe Lys Leu Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu TyrLeu Arg Met Asn Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Gly Gln Val Arg Gly Ser Gly Pro Gln Val Val Val Met AspVal Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Gly Ile Arg Asn AspLeu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Asp Ala Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro ProLeu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg,342 <211> LENGTH: 124 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 342,366 <211> LENGTH: 109 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 366,"(342/366) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:342 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:366."
https://patents.google.com/patent/US11021532B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser TyrAla Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Val Asn Pro Ser Ser Gly Ser Thr Thr Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Val Arg Gly Ser Ala Ala Ile Ala Met Met Asp Val Trp GlyGln Gly Thr Thr Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Asn GluLeu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro ProTrp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg,345 <211> LENGTH: 121 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 345,369 <211> LENGTH: 109 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 369,"(345/369) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:345 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:369."
https://patents.google.com/patent/US11021532B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Ser TyrPro Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Arg Gly Ser Tyr Asp Thr Asp Ala Phe Asp Ile Trp GlyGln Gly Thr Met Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro SerThr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg,347 <211> LENGTH: 121 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 347,371 <211> LENGTH: 108 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 371,"(347/371) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:347 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:371."
https://patents.google.com/patent/US11021532B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly SerTyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu TrpMet Gly Trp Ile Asn Pro Lys Thr Gly Asp Thr Asn Tyr Ala Gln GluPhe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr ValTyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr TyrCys Ala Arg Gly Ser Ser Gly Tyr Tyr Phe Gly Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro LeuThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,357 <211> LENGTH: 118 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 357,381 <211> LENGTH: 108 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 381,"(357/381) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:357 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:381."
https://patents.google.com/patent/US11021532B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Tyr Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser TyrGly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Met Phe Gly Thr Thr Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Arg Gly Asp Thr Ile Asp Tyr Trp Gly Gln Gly Thr LeuVal Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn AsnLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Asn Gly Phe Pro LeuThr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg,364 <211> LENGTH: 117 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 364,388 <211> LENGTH: 108 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 388,"(364/388) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:364 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:388."
https://patents.google.com/patent/US11021532B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu AsnGlu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Ser Gly Val Asp Thr Ala Thr Leu Arg Tyr Tyr Tyr TyrGly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Lys TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Gly Ala Ser Thr Leu Ser Asp Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Thr Pro TyrSer Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg,354 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 354,378 <211> LENGTH: 108 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 378,"(354/378) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:354 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:378."
https://patents.google.com/patent/US11021532B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Ser TyrPro Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Arg Gly Ser Tyr Asp Thr Asp Ala Phe Asp Ile Trp GlyGln Gly Thr Met Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro SerThr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg,436 <211> LENGTH: 121 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 436,437 <211> LENGTH: 108 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 437,"(436/437) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:436 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:437."
https://patents.google.com/patent/US11021532B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu AsnGlu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Lys Thr Arg Tyr Gly Gly Asn Ser Arg Ser Arg Tyr Tyr Tyr TyrGly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln His Ile Ser Ser TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ala Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Gly Thr Pro TyrThr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg,352 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 352,376 <211> LENGTH: 108 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 376,"(352/376) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:352 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:376."
https://patents.google.com/patent/US11021532B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Arg Ser ThrAla Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Ala Gly Tyr Ser Ser Ser Ser Gly Tyr Tyr Tyr Tyr Gly MetAsp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn AsnLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Thr Phe Pro LeuThr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg,344 <211> LENGTH: 125 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 344,368 <211> LENGTH: 108 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 368,"(344/368) further provided herein is an sh antibody or antigen-binding fragment that comprises a vh having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to seq id no:344 and a vl having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to seq id no:368"
https://patents.google.com/patent/US11021532B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Asp Thr Phe Ser Asn TyrGly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Met Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Ile Gly Thr Thr Val Val Thr Pro Phe Gly Tyr Trp Gly Gln GlyThr Leu Val Asn Val Ser Ser,Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro GlyGlu Arg Ala Thr Leu Ser Cys Arg Ala Ser Glu Ser Val Ser Ser ArgTyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu LeuIle Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe SerGly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu GlnSer Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Gly Tyr Lys Asn ProPro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg,341 <211> LENGTH: 119 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 341,365 <211> LENGTH: 109 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 365,"(341/365) further provided herein is an sh antibody or antigen-binding fragment that comprises a vl having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to any one of seq id no:365-388 and 437, and a vh having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to any one of seq id no:341-364 and 436"
https://patents.google.com/patent/US11021532B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser TyrGlu Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asn Pro Ser Asp Gly Ser Ser Thr Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Arg Gly Tyr Ser Tyr Asp His Asp Gln Ile Tyr Tyr TyrTyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Val Ser Gln Gly Ile Ser Ser TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ile Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Thr Pro PheThr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg,363 <211> LENGTH: 128 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 363,387 <211> LENGTH: 108 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 387,"(363/387) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:363 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:387."
https://patents.google.com/patent/US11021532B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly AsnTyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Lys Asp Val Gln Asn Tyr Tyr Gly Ser Gly Ser Ser Phe Asp TyrTrp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn TyrLeu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Pro Pro LeuThr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg,356 <211> LENGTH: 123 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 356,380 <211> LENGTH: 108 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 380,"(356/380) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:356 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:380."
https://patents.google.com/patent/US11021532B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser TyrAsp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Met Asn Ser Asn Ser Gly Ser Thr Gly Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Gly Trp Met Ala Tyr Asp Ala Phe Asp Ile Trp Gly Gln GlyThr Met Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Tyr Asn TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Ile Ser Phe Pro LeuThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,362 <211> LENGTH: 119 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 362,386 <211> LENGTH: 108 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 386,"(362/386) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:362 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:386."
https://patents.google.com/patent/US11021532B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu AsnGlu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Leu Met Asp Ile Val Val Val Pro Trp Leu Gly Gly MetAsp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ala Ile Thr Asn TyrLeu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro ProThr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg,353 <211> LENGTH: 125 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 353,377 <211> LENGTH: 108 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 377,"(353/377) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:353 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:377."
https://patents.google.com/patent/US11021532B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp TyrHis Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Met Asn Pro Asn Ser Gly Asn Thr Ser Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Gly Met Gly Met Gly Arg Asp Gly Tyr Asn Ser Arg Ala Phe AspIle Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Thr TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Met Pro LeuThr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg,349 <211> LENGTH: 124 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 349,373 <211> LENGTH: 108 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 373,"(349/373) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:349 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:373."
https://patents.google.com/patent/US11021532B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu AsnGlu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Ser Gly Val Asp Thr Ala Thr Leu Arg Tyr Tyr Tyr TyrGly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Lys TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Gly Ala Ser Thr Leu Ser Asp Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Thr Pro TyrSer Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg,355 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 355,379 <211> LENGTH: 108 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 379,"(355/379) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:355 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:379."
https://patents.google.com/patent/US11021532B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Arg TyrTyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asn Pro Ser Gly Gly Ser Thr Thr Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Lys Gly Ala Pro His Asp Tyr Ile Trp Gly Ser Tyr Arg Pro AspAla Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Asp Ser TrpLeu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Glu Ala Ser Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys His Gln Tyr Leu Ser Ser Pro GluThr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg,359 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 359,383 <211> LENGTH: 108 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 383,"(359/383) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:359 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:383."
https://patents.google.com/patent/CN111978395A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Ile Asn Pro Tyr Asn Asp Asp Thr Asn Tyr Ile Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Asp Tyr Asp Tyr Ala Gly Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly Glu Lys Val Thr Val Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Ser Tyr Ser Met His Trp Val Lys Gln Thr Pro Gly Gln Gly Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Thr Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Thr Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp His Gly Asn Tyr Val Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Asp Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Asp Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Asp Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Arg Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ser Met His Trp Val Lys Gln Thr Pro Gly Gln Gly Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Tyr His Tyr Asp Gly Tyr Tyr Val Thr Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly Glu Arg Val Ser Leu Thr Cys Arg Ala Ser Gln Glu Ile Ser Gly Tyr Leu Ser Trp Leu Gln Gln Lys Pro Asp Gly Thr Ile Lys Arg Leu Ile Tyr Ala Ala Ser Thr Leu Asp Ser Gly Val Pro Lys Arg Phe Ser Gly Ser Arg Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser Glu Asp Phe Ala Asp Tyr Tyr Cys Leu Gln Tyr Ala Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Gln Val Gln Leu Gln Gln Pro Gly Thr Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ser Ile His Trp Val Lys Gln Thr Pro Gly Gln Gly Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Tyr His Tyr Asp Gly Tyr Tyr Val Thr Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly Glu Arg Val Ser Leu Thr Cys Arg Ala Ser Gln Glu Ile Ser Gly Tyr Leu Ser Trp Leu Gln Gln Lys Pro Asp Gly Thr Ile Lys Arg Leu Ile Tyr Ala Ala Ser Thr Leu Asp Ser Gly Val Pro Lys Arg Phe Ser Gly Ser Arg Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser Glu Asp Phe Ala Asp Tyr Tyr Cys Leu Gln Tyr Ala Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Glu Val Met Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg His Asp Gly Asn Tyr Val Asp Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Gln Leu Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Leu Leu Ile Tyr Thr Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser Cys Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Cys Cys Ala Arg Glu Asp Tyr Gly Ser Ser Tyr Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Asn Ser Asn Gln Lys Lys Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Ile Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ser Met His Trp Val Lys Gln Thr Pro Gly Gln Gly Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Thr Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Tyr His Tyr Asp Gly Tyr Tyr Val Thr Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly Glu Arg Val Ser Leu Thr Cys Arg Ala Ser Gln Glu Ile Ser Gly Tyr Leu Ser Trp Leu Gln Gln Lys Pro Asp Gly Thr Ile Lys Arg Leu Ile Tyr Ala Ala Ser Thr Leu Asp Ser Gly Val Pro Lys Arg Phe Ser Gly Ser Arg Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser Glu Asp Phe Ala Asp Tyr Tyr Cys Leu Gln Tyr Ala Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr Phe Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Arg Ile Asn Pro Tyr Asn Gly Asp Thr Phe Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala His Met Glu Leu Leu Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Gly Arg Gly Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser, Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Phe Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Glu His Tyr Ser Asn Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Glu Val Met Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Met Phe Ser Arg Tyr Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Met Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Asn Cys Ala Arg His Asp Gly Asn Tyr Val Asp Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Ser His Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Leu Leu Ile Tyr Ser Thr Phe Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser Ser Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Ala Ala Phe Ile Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Phe Lys Met Asn Ser Leu Gln Ala Asn Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Asn Arg Tyr Gly Ser Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Val Val Leu Thr Gln Thr Pro Leu Ser Leu Pro Val Asn Ile Gly Asp Gln Ala Ser Ile Ser Cys Lys Ser Thr Lys Arg Leu Leu Asn Ser Asp Gly Phe Thr Phe Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Ser His Tyr Leu Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Ser Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Glu Ile Asp Pro Ser Asp Ser Tyr Thr Asn Ser Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Ser Glu Leu Trp Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ala Ala Phe Ser Asn Pro Val Thr Leu Gly Thr Ser Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser His Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Ala Ser Gly Val Pro Asp Arg Phe Ser Ser Ser Gly Ser Gly Thr Asp Phe Thr Leu Arg Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn Leu Glu Leu Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Arg , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Phe Val Met Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Ala Ile Asp Thr Ser Asp Thr Tyr Thr Arg Tyr Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Val Asp Glu Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Phe Leu Tyr Tyr Tyr Gly Asn Pro Thr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Val Gln Ile Thr Gln Ser Pro Ser Tyr Leu Ala Ala Ser Pro Gly Glu Thr Ile Thr Ile Asn Cys Arg Ala Ser Lys Ser Ile Ser Lys Tyr Leu Ala Trp Tyr Gln Glu Lys Pro Gly Lys Thr Asn Lys Leu Leu Ile Tyr Ser Gly Ser Thr Leu Gln Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Met Tyr Tyr Cys Gln Gln His Asn Glu Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Asp Tyr Ser Ile Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Gly Gly Gly Ser Thr Tyr Tyr Asn Ser Ala Leu Lys Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala Lys His Pro Leu Tyr Tyr Gly Ser Asn Ser Asp Gly Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Ile Val Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Ser Tyr Trp Ile His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Glu Ile Asp Pro Ser Asp Ser Tyr Ser Asn Tyr Asn Gln Asn Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Ser Glu Leu Trp Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ala Ala Phe Ser Asn Pro Val Thr Leu Gly Thr Ser Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser His Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Ala Ser Gly Val Pro Asp Arg Phe Ser Ser Ser Gly Ser Gly Thr Asp Phe Thr Leu Arg Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn Leu Glu Leu Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN113583116A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met His Trp Val Lys Gln Ser Pro Gly Lys Ser Leu Glu Trp Ile Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ala Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Asp Tyr Tyr Val Ser Ser Tyr Gly Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Ser Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Phe Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys, h36H6-10/h36H6-12 VH, h36H6-10 VL,(17/18) (1) a vh comprising the sequence shown as seq id no:17 and a vl comprising the sequence shown as seq id no:18
https://patents.google.com/patent/CN113583116A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met His Trp Val Lys Gln Ser Pro Gly Lys Ser Leu Glu Trp Ile Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ala Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Asp Tyr Tyr Val Ser Ser Tyr Gly Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Ser Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Phe Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys, h36H6-10/h36H6-12 VH, h36H6-12 VL,(17/19)  a vh comprising the sequence shown as seq id no:17 and a vl comprising the sequence shown as seq id no:19.
https://patents.google.com/patent/CN113583116A/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met Asn Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Arg Ile Asp Pro Tyr Asp Ser Glu Thr His Tyr Asn Gln Lys Phe Lys Asp Lys Ala Ile Leu Thr Val Asp Lys Ser Ser Thr Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Trp Gly Thr Val Glu Trp Phe Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Gln , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ala Met Ser Val Gly Gln Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser Tyr Asn Gln Glu Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Val Tyr Phe Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ile Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln His Tyr Ser Thr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys, 2B4 VH, 2B4 VL,"(3/4) preferably, the antibody or antigen-binding fragment thereof comprises: a vh comprising the sequence shown as seq id no:3 and a vl comprising the sequence shown as seq id no:4."
https://patents.google.com/patent/CN113583116A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Asn Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Phe Tyr Cys Ala Arg Glu Gly Asp Tyr Tyr Val Ser Ser Tyr Gly Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Phe Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys, 36H6 VH, 36H6 VL,"(1/2) preferably, the antibody or antigen-binding fragment thereof comprises: a vh comprising the sequence shown as seq id no:1 and a vl comprising the sequence shown as seq id no:2."
https://patents.google.com/patent/CN113912710A/en, Val Lys Leu Gln Glu Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Arg Ile Ser Cys Lys Ala Ser Gly Tyr Thr Leu Thr Asp Tyr Ser Ile His Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Glu Thr Val Glu Pro Thr Tyr Thr Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ala Ser Thr Gly Thr Glu Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ile Thr Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(7/8) the amino acid sequence of the heavy chain variable region is shown as seq id no:7, and the amino acid sequence of the light chain variable region is shown as seq id no:8."
https://patents.google.com/patent/CN113480644A/en, Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Leu Val Lys Leu Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Trp Ile Asp Pro Glu Asn Gly Asn Ser Ile Tyr His Pro Asn Phe Gln Gly Lys Ala Ser Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Ala Ala Val Tyr Tyr Cys Ala Ser Pro Tyr Gly Phe Ile Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Ile Ser Cys Ser Ala Ser Ser Ser Val Ser Tyr Met Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Tyr His Ser Tyr Pro Tyr Met Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Synthetic, Synthetic,"(126/150) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:126, and the amino acid sequence of the light chain variable region is shown in seq id no:150"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ala Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr Ser Ala Ser His Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Leu Ala Thr Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhuv2, PR300928VLhuv1,"(177/182) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:177, and the amino acid sequence of the light chain variable region is shown as seq id no:182"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Val Thr Ile Thr Val Asp Lys Ser Ala Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr Ser Ala Ser Ser Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Pro Glu Asp Leu Ala Thr Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhuv1, PR300928VLhuv3,"(178/180) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:178, and the amino acid sequence of the light chain variable region is shown as seq id no:180"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Tyr Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Arg Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Asp Pro Pro Gly Leu Arg Phe Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic, Synthetic,"(130/154) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:130, and the amino acid sequence of the light chain variable region is shown as seq id no:154"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Asp Thr Tyr Glu Trp Tyr Phe Asp Val Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asn Asp Val Ala Asn Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300961VHhuv3, PR300961Vlhuv3,"(171/167) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:171, and the amino acid sequence of the light chain variable region is shown in seq id no:167"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Pro Val Ala Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr Gly Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Ala Gly Gly Asn Thr Asn Tyr Asn Ser Ala Leu Met Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys Leu Asn Ser Leu Gln Val Asp Asp Thr Ala Met Tyr Tyr Cys Ala Tyr Tyr Arg Tyr Asp Ala Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr Met Phe Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr His Cys Gln His Ser Arg Glu Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Synthetic, Synthetic,"(115/140) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:115, and the amino acid sequence of the light chain variable region is shown as seq id no:140"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Asp Gly Tyr Glu Trp Tyr Phe Asp Val Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asn Asp Val Ala Asn Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300961VHhuv2, PR300961Vlhuv1,"(172/169) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:172, and the amino acid sequence of the light chain variable region is shown as seq id no:169"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Asn Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser His Ser Gly Tyr Tyr Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Ser Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Thr Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic, Synthetic,"(127/151) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:127, and the amino acid sequence of the light chain variable region is shown as seq id no:151"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Tyr Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Arg Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Asp Pro Pro Gly Leu Arg Phe Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic, Synthetic,"(133/154) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:133, and the amino acid sequence of the light chain variable region is shown as seq id no:154"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Met Lys Ser Ser Gly Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Gly Ser Ile Arg Ser Ser Asn Trp Trp Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Phe Gln Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Lys Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Asp Tyr Tyr Gly Ser Gly Ser Ser Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Arg Gly Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic, Synthetic,"(128/152) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:128, and the amino acid sequence of the light chain variable region is shown as seq id no:152"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Phe Tyr Ala Asp Ser Val Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asn Tyr Tyr Gly Ser Gly Ile Tyr Leu Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Phe Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Synthetic, Synthetic,"(129/153) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:129, and the amino acid sequence of the light chain variable region is shown as seq id no:153"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Gln Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ala Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr Ser Ala Ser Ser Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Pro Glu Asp Leu Ala Thr Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhuv3, PR300928VLhuv3,"(176/180) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:176, and the amino acid sequence of the light chain variable region is shown as seq id no:180"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ala Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr Ser Ala Ser Ser Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Pro Glu Asp Leu Ala Thr Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhuv2, PR300928VLhuv3,"(177/180) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:177, and the amino acid sequence of the light chain variable region is shown as seq id no:180"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Asp Gly Tyr Glu Trp Tyr Phe Asp Val Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Ile Ser Cys Ser Ala Ser Ser Ser Val Ser Tyr Met Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Tyr His Ser Tyr Pro Tyr Met Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , PR300961VHhu, Synthetic,"(174/150) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:174, and the amino acid sequence of the light chain variable region is shown in seq id no:150"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Asp Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Tyr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Pro Gly Leu Arg Phe Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asp Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic, Synthetic,"(135/155) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:135, and the amino acid sequence of the light chain variable region is shown in seq id no:155"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Gln Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ala Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr Ser Ala Ser His Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Leu Ala Thr Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhuv3, PR300928VLhuv1,"(176/182) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:176, and the amino acid sequence of the light chain variable region is shown in seq id no:182"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Met Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Thr Tyr Trp Met Thr Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Arg Ala Thr Leu Thr Val Asp Lys Ser Ser Asn Thr Ala Tyr Met Gln Leu Ser Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Gly Gly Tyr Asp Trp Tyr Phe Asp Val Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Val Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Thr Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Thr Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Glu Gly Pro Trp Thr Phe Gly Gly Gly Thr Asn Leu Glu Ile Lys , Synthetic, Synthetic,"(117/142) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:117, and the amino acid sequence of the light chain variable region is shown as seq id no:142"
https://patents.google.com/patent/CN113480644A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Phe Thr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Leu Asn Pro Asn Asn Asp Asp Thr Thr Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Thr Arg Glu Asp Gly Asn Tyr Val Ser Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Gly Ala Ser Val Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Gly Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ile Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys, Synthetic, Synthetic,"(113/138) in a specific embodiment of the present invention, the amino acid sequence of the heavy chain variable region is represented by seq id no:113, and the amino acid sequence of the light chain variable region is represented by seq id no:138"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Arg Val Thr Met Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Asp Gly Tyr Glu Trp Tyr Phe Asp Val Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asn Asp Val Ala Asn Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300961VHhuv1, PR300961Vlhuv1,"(173/169) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:173, and the amino acid sequence of the light chain variable region is shown as seq id no:169"
https://patents.google.com/patent/CN113480644A/en, Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Ser Leu Glu Trp Val Ala Tyr Ile Ser Asn Gly Gly Ala Asn Thr Tyr Tyr Pro Asp Thr Val Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg His Arg Asp Trp Asp Asp Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Leu Leu Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser Thr Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Synthetic, Synthetic,"(116/141) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:116, and the amino acid sequence of the light chain variable region is shown as seq id no:141"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Val Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Ala Asp Gly Tyr Glu Trp Tyr Phe Asp Val Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Val Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Trp Thr Phe Ser Gly Gly Thr Lys Leu Glu Ile Lys , Synthetic, Synthetic,"(123/139) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:123, and the amino acid sequence of the light chain variable region is shown in seq id no:139"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Arg Val Thr Met Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Asp Gly Tyr Glu Trp Tyr Phe Asp Val Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asn Asp Val Ala Asn Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300961VHhuv1, PR300961Vlhuv3,"(173/167) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:173, and the amino acid sequence of the light chain variable region is shown as seq id no:167"
https://patents.google.com/patent/CN113480644A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Thr Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Phe Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Phe Phe Cys Ala Arg Glu Asp Gly Asn Tyr Val Ser Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Ser Val Ser Ala , Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys His Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys, Synthetic, Synthetic,"(125/149) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:125, and the amino acid sequence of the light chain variable region is shown in seq id no:149"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Val Thr Ile Thr Val Asp Lys Ser Ala Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr Ser Ala Ser His Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Pro Glu Asp Leu Ala Thr Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhuv1, PR300928VLhuv2,"(178/181) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:178, and the amino acid sequence of the light chain variable region is shown as seq id no:181"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Ile Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Ser Cys Ala Arg Glu Thr Ser Tyr Ser Gly Tyr Asp Trp Gly Tyr Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Thr Leu Gln Thr Pro Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys, Synthetic, Synthetic,"(137/97) or the amino acid sequence of the heavy chain variable region is shown as seq id no:137, and the amino acid sequence of the light chain variable region is shown as seq id no:97"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ala Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr Ser Ala Ser His Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Pro Glu Asp Leu Ala Thr Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhuv2, PR300928VLhuv2,"(177/181) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:177, and the amino acid sequence of the light chain variable region is shown as seq id no:181"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Ser Tyr Tyr Gly Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Pro Gly Leu Arg Phe Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Gln Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic, Synthetic,"(134/157) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:134, and the amino acid sequence of the light chain variable region is shown as seq id no:157"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Tyr Gln Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Asp Pro Pro Gly Leu Arg Phe Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Phe Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Phe Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Leu Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , Synthetic, Synthetic,"(136/91) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:136, and the amino acid sequence of the light chain variable region is shown as seq id no:91"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Gln Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ala Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr Ser Ala Ser His Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Pro Glu Asp Leu Ala Thr Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhuv4, PR300928VLhuv2,"(175/181) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:175, and the amino acid sequence of the light chain variable region is shown as seq id no:181"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile Tyr Ser Ala Ser His Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhu, PR300928VLhu,"(179/183) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:179, and the amino acid sequence of the light chain variable region is shown in seq id no:183"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Val Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Leu Gly Met Ile His Pro Ser Asp Ser Glu Ser Arg Leu Asn Gln Lys Phe Met Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Asn Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Ala Asp Gly Tyr Glu Trp Tyr Phe Asp Val Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Val Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Trp Thr Phe Ser Gly Gly Thr Lys Leu Glu Ile Lys , Synthetic, Synthetic,"(114/139) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:114, and the amino acid sequence of the light chain variable region is shown as seq id no:139"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Gln Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ala Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr Ser Ala Ser Ser Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Pro Glu Asp Leu Ala Thr Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhuv4, PR300928VLhuv3,"(175/180) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:175, and the amino acid sequence of the light chain variable region is shown as seq id no:180."
https://patents.google.com/patent/CN113480644A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Lys Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Arg Ile Arg Ser Lys Ser Asp Asn Tyr Ala Ala Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Gln Ser Met Leu Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Met Tyr Tyr Cys Val Arg Ala Asp Gly Tyr Ser Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Val Val Met Thr Gln Ile Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn Asn Gly Asn Thr Tyr Leu His Trp Phe Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Synthetic, Synthetic,"(118/143) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:118, and the amino acid sequence of the light chain variable region is shown as seq id no:143"
https://patents.google.com/patent/CN113480644A/en, Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Tyr Ile Ser Asn Gly Gly Val Asn Thr Tyr Tyr Pro Asp Thr Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg His Arg Asp Trp Asp Asp Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser Ala Thr Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Leu Leu Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser Ser Tyr Pro Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Synthetic, Synthetic,"(124/148) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:124, and the amino acid sequence of the light chain variable region is shown in seq id no:148"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Asp Thr Tyr Glu Trp Tyr Phe Asp Val Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asn Asp Val Ala Asn Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300961VHhuv3, PR300961Vlhuv1,"(171/169) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:171, and the amino acid sequence of the light chain variable region is shown in seq id no:169"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Asp Gly Tyr Glu Trp Tyr Phe Asp Val Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asn Asp Val Ala Asn Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300961VHhuv2, PR300961Vlhuv3,"(172/167) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:172, and the amino acid sequence of the light chain variable region is shown as seq id no:167"
https://patents.google.com/patent/CN113480644A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Leu Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Gly Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Asn Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Arg Asn Val Leu Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Asn Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Synthetic, Synthetic,"(120/145) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:120, and the amino acid sequence of the light chain variable region is shown as seq id no:145"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ala Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Arg Tyr Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Leu Gly Trp Asp Val Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Lys Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Synthetic, Synthetic,"(132/156) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:132, and the amino acid sequence of the light chain variable region is shown in seq id no:156"
https://patents.google.com/patent/CN113480644A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Ile Tyr Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Synthetic, Synthetic,"(121/146) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:121, and the amino acid sequence of the light chain variable region is shown as seq id no:146"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Gln Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ala Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr Ser Ala Ser His Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Pro Glu Asp Leu Ala Thr Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhuv3, PR300928VLhuv2,"(176/181) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:176, and the amino acid sequence of the light chain variable region is shown in seq id no:181"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Val Thr Ile Thr Val Asp Lys Ser Ala Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr Ser Ala Ser His Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Leu Ala Thr Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhuv1, PR300928VLhuv1,"(178/182) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:178, and the amino acid sequence of the light chain variable region is shown as seq id no:182"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Asp Gly Tyr Glu Trp Tyr Phe Asp Val Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asn Asp Val Ala Asn Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300961VHhuv2, PR300961Vlhuv2,"(172/168) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:172, and the amino acid sequence of the light chain variable region is shown as seq id no:168"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Arg Phe Thr Phe Ser Asn Tyr Asp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Tyr Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Pro Gly Leu Arg Phe Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asp Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic, Synthetic,"(131/155) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:131, and the amino acid sequence of the light chain variable region is shown as seq id no:155"
https://patents.google.com/patent/CN113480644A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Ile Asn Pro Asn Asn Gly Asp Asn Thr Tyr Asn Gln Lys Leu Lys Gly Lys Ala Thr Leu Thr Val His Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Tyr Ala Leu Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Pro Leu Ile Tyr Ser Ala Ser Ser Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Asn Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Synthetic, Synthetic,"(122/147) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:122, and the amino acid sequence of the light chain variable region is shown in seq id no:147"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Asp Thr Tyr Glu Trp Tyr Phe Asp Val Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asn Asp Val Ala Asn Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300961VHhuv3, PR300961Vlhuv2,"(171/168) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:171, and the amino acid sequence of the light chain variable region is shown in seq id no:168"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Arg Val Thr Met Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Asp Gly Tyr Glu Trp Tyr Phe Asp Val Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asn Asp Val Ala Asn Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300961VHhuv1, PR300961Vlhuv2,"(173/168) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:173, and the amino acid sequence of the light chain variable region is shown as seq id no:168"
https://patents.google.com/patent/CN113480644A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Phe Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Thr Thr Ala Tyr Met Asp Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Gly Leu Ile Tyr Ser Ala Ser His Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Synthetic, Synthetic,"(119/144) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:119, and the amino acid sequence of the light chain variable region is shown as seq id no:144"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Gln Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ala Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr Ser Ala Ser His Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Leu Ala Thr Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhuv4, PR300928VLhuv1,"(175/182) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:175, and the amino acid sequence of the light chain variable region is shown as seq id no:182"
https://patents.google.com/patent/CN113264998A/en, Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Asp Ser Ser Gly Arg Val Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Leu Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Asn Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Asn Gly Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Ala Tyr Tyr Cys Gln Gln Leu Ile Val Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Synthesis, Artificial Synthesis,"(12/16) the heavy chain variable region of the scfv-24 sequence of the single-chain antibody comprises an amino acid sequence which is at least 70% homologous to the amino acid sequence shown in seq id no:12, and the light chain variable region of the scfv-24 sequence of the single-chain antibody comprises an amino acid sequence which is at least 70% homologous to the amino acid sequence shown in seq id no:16."
https://patents.google.com/patent/CN113264998A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Thr Arg Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Arg Ile Asp Pro Ser Asp Ser Tyr Ser His Tyr Ser Pro Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Arg Ser Ile Thr Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Val Ser Gly Gly Asn Trp Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Glu Ala Pro Arg Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Pro Val Asn Trp Tyr Gln Gln Val Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Tyr Asn Asp Leu Leu Pro Ser Gly Val Ser Gly Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Synthesis, Artificial Synthesis,"(4/8) in certain preferred embodiments, the heavy chain variable region of the scfv-22 sequence of the single chain antibody comprises an amino acid sequence that is at least 70% homologous to the amino acid sequence set forth in seq id no:4, and the light chain variable region of the single chain antibody comprises an amino acid sequence that is at least 70% homologous to the amino acid sequence set forth in seq id no:8"
https://patents.google.com/patent/CN113484522A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Arg Met Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr Phe Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Arg Ile Asn Pro Tyr Thr Gly Asp Thr Phe Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Ala Val Asp Lys Ser Ser Asn Thr Ala His Met Glu Leu Leu Asn Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Gly Arg Arg Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Ile Thr Gln Thr Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Phe Cys Arg Ala Ser Gln Ser Val Asp Tyr Asn Gly Ile Ser Ser Val His Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro Lys Val Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Thr Ile Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Asn Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val Ser , artificial sequence, artificial sequence,"(9/10) in some embodiments, the heavy chain variable region amino acid sequence of the quality control antibody is represented by seq id no:9, and the light chain variable region amino acid sequence is represented by seq id no:10."
https://patents.google.com/patent/US7622112B2/en,Leu Val Gln Leu Glu Glu Ser Gly Thr Val Leu Pro Arg Pro Gly AlaSer Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser TyrTrp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp IleGly Ala Ile Tyr Pro Gly Asn Ser Asp Thr Asn Tyr Asn Gln Lys PheLys Gly Arg Ala Thr Leu Thr Ala Val Thr Ser Thr Ser Thr Ala SerMet Glu Leu Ser Ser Leu Thr Asn Glu Asp Ser Ala Val Tyr Tyr CysThr Arg Asp Gly Tyr Gly Ser Leu Tyr Tyr Tyr Ala Met Asp Phe TrpGly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Ala ProSer Val Lys ,Glu Leu Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu GlyAsp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn TyrLeu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu IleTyr Tyr Thr Ser Arg Leu His Ala Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu GlnGlu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Tyr Thr Leu Pro TyrThr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala AlaPro Thr Val Ser Lys Gly Glu Phe Gln His Thr Gly Gly Arg Tyr,5 190Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala 195 200 205Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Val Pro Thr Ser 210 215 220Gln Asn2255131PRTMus musculus 5,14127PRTMus musculus 14,(5/14)  monoclonal antibody f26g18 having a light chain amino acid sequence as set forth in seq id no:14 and a heavy chain amino acid sequence as set forth in seq id no:5.
https://patents.google.com/patent/WO2021242815A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Thr Tyr Ser Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Thr Thr Met Val Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Thr Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  Synthetic  ,  Synthetic  ,"(202/210) [00037] in some embodiments, a-hcvr comprises the amino acid sequence set forth in seq id no:202 and a-lcvr comprises the amino acid sequence set forth in seq id no:210"
https://patents.google.com/patent/WO2021242815A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Ala Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Gly Ser Asp Tyr Gly Asp Tyr Leu Leu Val Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Leu Thr Ser Ile Ser Thr Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Synthetic  ,  Synthetic  ,"(640/646) [00041] in some embodiments, b-hcvr comprises the amino acid sequence set forth in seq id no:640 and b-lcvr comprises the amino acid sequence set forth in seq id no:646"
https://patents.google.com/patent/WO2021242815A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Arg Gly Ser Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Gly Glu Arg Trp Asp Ser Val Val Val Pro Ser Ala Arg Asn Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu ,  Synthetic  ,  Synthetic  ,"(608/614) [00045] in some embodiments, c-hcvr comprises the amino acid sequence set forth in seq id no:608 and c-lcvr comprises the amino acid sequence set forth in seq id no:614"
https://patents.google.com/patent/WO2021194886A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Asn Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Gly Ile Pro Trp Trp Leu Arg Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Thr Thr Pro Glu Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(154/178) [0082] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:154 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:178"
https://patents.google.com/patent/WO2021194886A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Asn Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Val Ile Asn Pro Ser Gly Gly Tyr Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Gly Ile Pro Gln Leu Leu Arg His Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Gly Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Trp Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(161/185) [0089] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:161 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:185"
https://patents.google.com/patent/WO2021194886A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Asn Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Thr Ser Gly Gly Tyr Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Gly Ile Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Asn Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(160/184) [0088] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:160 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:184"
https://patents.google.com/patent/WO2021194886A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Gly Asn Tyr Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ala Ile Tyr Pro Gly Asn Ser Asp Thr Thr Tyr Asn Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Glu Ile Ser Gly Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Val Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(153/177) [0081] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:153 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:177"
https://patents.google.com/patent/WO2021194886A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Arg Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Ala Lys Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asp Thr Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(208/209) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:208 and a vl having an amino acid sequence of seq id no:209
https://patents.google.com/patent/WO2021194886A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Glu Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Tyr Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Gly Ile Pro Gln Val Leu Arg Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Asn Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(162/186) [0090] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:162 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:186"
https://patents.google.com/patent/WO2021194886A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Asn Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Met Ile Asn Pro Ser Gly Gly Tyr Thr Asn Tyr Ala Gln Glu Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Gly Ile Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Tyr Arg Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Gly Asn Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(159/183) [0087] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:159 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:183"
https://patents.google.com/patent/WO2021194886A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ser Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ala Ile Tyr Pro Gly Asn Ser Asp Thr Thr Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Leu Asp Gly Ile Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Gly Val Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr Val Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(155/179) [0009] the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:155 and a vl having an amino acid sequence of seq id no:179
https://patents.google.com/patent/WO2021194886A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Asp Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asp Pro Ser Gly Gly Ser Ala Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Gly Ile Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Val Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Leu Ala Val Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(163/187) [0091] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:163 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:187"
https://patents.google.com/patent/WO2021194886A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ala Ser Tyr Asp Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Arg Ser Gly Asp Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Arg His Pro Gln Leu Leu Met Pro Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Arg Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(156/180) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:156 and a vl having an amino acid sequence of seq id no:180
https://patents.google.com/patent/WO2021194886A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Asn Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Asp Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Gly Ile Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Arg Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Gln Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(158/182) [0086] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:158 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:182"
https://patents.google.com/patent/WO2021194886A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Arg Phe Thr Ser Tyr Glu Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Gly Ile Pro Gln Leu Leu Trp Ala Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(152/176) [0080] in one instance, an antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:152 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:176"
https://patents.google.com/patent/WO2021194886A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Asn Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Asn Gly Gly Gly Thr Tyr Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Gly Ile Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Ser Ala Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(168/192) [0096] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:168 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:192"
https://patents.google.com/patent/WO2021194886A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Asp Ile Trp Arg Leu His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Gly Ile Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Glu Ile Ser Ser Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Ser Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(149/173) [0077] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:149 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:173"
https://patents.google.com/patent/WO2021194886A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Asn Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ala Ile Tyr Pro Gly Gly Ser Asp Thr Ser Tyr Asn Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Gly Ile Pro Gln Leu Ala Trp Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Met Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Phe Gly Ser Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(148/172) [0076] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:148 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:172"
https://patents.google.com/patent/WO2021194886A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Asn Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Ala Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Gly Ile Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Ser Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(150/174) [0078] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:150 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:174"
https://patents.google.com/patent/WO2021194886A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Tyr Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Gly Ile Pro Gln Val Leu Arg Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Asn Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(165/189) [0093] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:165 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:189"
https://patents.google.com/patent/WO2021194886A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Asp Phe Ile Asn Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asp Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Gly Ile Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asp Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Arg Leu Ala Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(157/181) the antibody or the antigen- binding fragment can comprise a vh having an amino acid sequence of seq id no:157 and a vl having an amino acid sequence of seq id no:181
https://patents.google.com/patent/WO2021194886A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Glu Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Val Ile Asn Pro Ser Gly Gly His Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Gly Ile Pro Gln Leu Ala Gly Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Gly Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Thr Thr Pro Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(145/169) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:145 and a vl having an amino acid sequence of seq id no:169
https://patents.google.com/patent/WO2021194886A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Met Val Asp Pro Asn Ser Gly Asn Thr Tyr Tyr Ala Gln Lys Phe Gln Gly Arg Phe Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Gly Ile Pro Gln Leu Leu Gly Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Thr Thr Pro Arg Thr Phe Gly Gly Gly Thr Lys Gly Gly Asp Gln Thr , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(164/188) [0092] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:164 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:188"
https://patents.google.com/patent/WO2021194886A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Asn Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Gly Pro Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr His Thr Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Phe Pro Ala Thr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(166/190) [0094] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:166 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:190"
https://patents.google.com/patent/WO2021194886A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Asn Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Gly Ile Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Arg Thr Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Ser Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(151/175) [0079] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:151 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:175"
https://patents.google.com/patent/WO2021194886A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser His Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Met Ile Asn Pro Ser Gly Gly Tyr Thr Ser Tyr Ala Gln Asn Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Gly Ile Pro Ala Leu Leu Arg Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Thr Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(146/170) [0074] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:146 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:170"
https://patents.google.com/patent/WO2021194886A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Asn Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Val Val Asn Pro Ser Gly Gly Tyr Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Gly Ile Pro Gln Leu Leu Arg Ser Gln Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(147/171) [0075] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:147 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:171"
https://patents.google.com/patent/WO2021194886A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Asn Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Thr Ser Gly Gly Tyr Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Gly Ile Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Asn Pro Leu His Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(167/191) [0095] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:167 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:191"
https://patents.google.com/patent/CN113150135A/en, Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ile Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Phe Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Ser Gly Ser Tyr His Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Val Leu Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , Artificial sequence, Artificial sequence,"(17/18) preferably, the neutralizing antibody c2767p3s comprises the heavy chain variable region shown in seq id no:17 and the light chain variable region shown in seq id no:18"
https://patents.google.com/patent/CN113150135A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Phe Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Pro Leu His Met Ala Thr Glu Glu Gly Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Thr Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Artificial sequence, Artificial sequence,"(7/8) preferably, the neutralizing antibody c14646p3s comprises the heavy chain variable region of seq id no:7 and the light chain variable region of seq id no:8"
https://patents.google.com/patent/CN113861288A/en, caggtgcagc tggtggaatc gggtggggga ttggttcagg cggggggaag tttacgctta tcgtgtgcgg catctggtcg tattctggct gttttcgtta tgggttggta tcgccaggca ccaggtaaag aacgtgaatt cgttgcctct attactcatg gcggtactac caactacgcg gactcagtga aaggccgctt cactatctcc cgtgataatg ctaagaacac cgtttatctg cagatgaatt ctttgaaacc tgaagacact gccgtttatt attgcgcagc tcaggacctg gactacaacg tttacttcca tccgtactgg cagctgtacg actactgggg tcagggaacc caggttacgg tttcttct ,, Artificial sequence (Artificial sequence),,(4) the dna molecule shown in seq id no:4 encodes the single domain antibody i3a10 shown in seq id no:2.
https://patents.google.com/patent/CN113861288A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ile Leu Ala Val Phe Val Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ser Ile Thr His Gly Gly Thr Thr Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Gln Asp Leu Asp Tyr Asn Val Tyr Phe His Pro Tyr Trp Gln Leu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence (Artificial sequence),,(2) the dna molecule shown in seq id no:4 encodes the single domain antibody i3a10 shown in seq id no:2.
https://patents.google.com/patent/CN113861288A/en, caggtgcagc tggtggaatc gggtggggga ttggttcagg cggggggaag tttacgctta tcgtgtgcgg catctggtcg tattttcgaa gttacttgga tgggttggta tcgccaggca ccaggtaaag aacgtgaatt cgttgcctct atttctcgtg gcggtggtac caactacgcg gactcagtga aaggccgctt cactatctcc cgtgataatg ctaagaacac cgtttatctg cagatgaatt ctttgaaacc tgaagacact gccgtttatt attgcgcagc tctgcatcag actgttctga cttctgttga atgggaaggt tacgactact ggggtcaggg aacccaggtt acggtttctt ct ,, Artificial sequence (Artificial sequence),,(3) the nucleic acid molecule encoding the single domain antibody b3a3 is shown in seq id no:3.
https://patents.google.com/patent/CN113861288A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ile Phe Glu Val Thr Trp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ser Ile Ser Arg Gly Gly Gly Thr Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Leu His Gln Thr Val Leu Thr Ser Val Glu Trp Glu Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence (Artificial sequence),,"(1)  having the amino acid sequence of seq id no:1 is named b3a3, and the single domain antibody (heavy chain variable regio"
https://patents.google.com/patent/WO2021244601A1/en, Glu Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Val Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asn Thr Met Val Arg Gly Val Ile Ile Pro Phe Glu Tyr Trp Asp Lys Gly Thr Leu Val Thr Val Ser Ser , Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr Gln Trp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys ,  ˣHomo sapiens  ,  ˣHomo sapiens  ,"(2/20)  (4) the light chain variable region shown in seq id no:20, and/or the heavy chain variable region shown in seq id no:2"
https://patents.google.com/patent/WO2021244601A1/en, Glu Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Val Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asn Thr Met Val Arg Gly Val Ile Ile Pro Phe Glu Tyr Trp Asp Lys Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Thr Gln Ala Thr Gln Phe Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys ,  ˣHomo sapiens  ,  ˣHomo sapiens  ,(2/1)  (1) the light chain variable region shown in seq id no:1 and/or the heavy chain variable region shown in seq id no:2
https://patents.google.com/patent/WO2021244601A1/en, Glu Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Thr Arg Ala Ser Asn Asn Trp Gly Trp Arg Pro Phe Asp Tyr Trp Asp Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  ˣHomo sapiens  ,  ˣHomo sapiens  ,"(5/4)  (3) the light chain variable region shown in seq id no:4, and/or the heavy chain variable region shown in seq id no:5"
https://patents.google.com/patent/WO2021244601A1/en, Glu Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Val Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asn Thr Met Val Arg Gly Val Ile Ile Pro Phe Glu Tyr Trp Asp Lys Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  ˣHomo sapiens  ,  ˣHomo sapiens  ,"(2/3)  (2) the light chain variable region shown in seq id no:3, and/or the heavy chain variable region shown in seq id no:2"
https://patents.google.com/patent/WO2021183947A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala Val Ser Val Lys Ser Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Gln Gln Leu Val Pro His Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr Ser , Asp Val Val Met Thr Gln Ser Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Val Thr Ile Ser Cys Thr Gly Thr Thr Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln Arg Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Phe Gly Thr Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  heavy chain variable region of an antigen binder  ,  light chain variable region of an antigen binder  ,"(24/32) in some cases, a binder (e.g., an antibody, antigen binding fragment, and/or antibody domain) provided herein can include (a) a heavy chain variable domain that includes an amino acid sequence having 100 percent identity to the amino acid sequence set forth in seq id no:24 and/or (b) a light chain variable domain that includes an amino acid sequence having 100 percent identity to the amino acid sequence set forth in seq id no:32"
https://patents.google.com/patent/WO2021183947A1/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Val Ser Ala Ile Ser Thr Asp Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Thr Tyr Tyr Asp Phe Trp Arg Thr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Ala Thr Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Arg Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg ,  heavy chain variable region of an antigen binder  ,  light chain variable region of an antigen binder  ,"(40/48) in some cases, a binder (e.g., an antibody, antigen binding fragment, and/or antibody domain) provided herein can include (a) a heavy chain variable domain that includes an amino acid sequence having 100 percent identity to the amino acid sequence set forth in seq id no:40 and/or (b) a light chain variable domain that includes an amino acid sequence having 100 percent identity to the amino acid sequence set forth in seq id no:48"
https://patents.google.com/patent/WO2021183947A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg His Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Tyr Gly Asp Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys , Asp Val Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Lys Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  heavy chain variable region of an antigen binder  ,  light chain variable region of an antigen binder  ,"(8/16) in some cases, a binder (e.g., an antibody, antigen binding fragment, and/or antibody domain) provided herein can include (a) a heavy chain variable domain that includes an amino acid sequence having 100 percent identity to the amino acid sequence set forth in seq id no:8 and/or (b) a light chain variable domain that includes an amino acid sequence having 100 percent identity to the amino acid sequence set forth in seq id no:16"
https://patents.google.com/patent/WO2021183947A1/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Ala Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Thr Ile Ala Gly Ser Gly Asp Asn Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Asp Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Tyr Tyr Thr Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Val Thr Gln Pro Pro Ser Ala Ser Gly Ser Pro Gly Gln Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn His Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Glu Val Ser Glu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Asp Asn Lys Ala Ser Leu Thr Ile Ile Gly Leu Gln Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Leu Phe Gly Thr Gly Thr Lys Leu Thr Val Leu Arg ,  heavy chain variable region of an antigen binder  ,  light chain variable region of an antigen binder  ,"(56/64) in some cases, a binder (e.g., an antibody, antigen binding fragment, and/or antibody domain) provided herein can include (a) a heavy chain variable domain that includes an amino acid sequence having 100 percent identity to the amino acid sequence set forth in seq id no:56 and/or (b) a light chain variable domain that includes an amino acid sequence having 100 percent identity to the amino acid sequence set forth in seq id no:64"
https://patents.google.com/patent/WO2021237051A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Thr Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Asp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Lys Asn Gly Asn Ala Lys Phe Tyr Gly Asp Ser Val Lys Gly Gln Phe Thr Ile Ser Arg Asp Asn Phe Asn Asn Met Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Gln Ser Lys Val Tyr Phe Asp Ala Phe Asp Met Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly , Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Heavy Chain  ,  Light Chain  ,"(55/54)  a heavy chain of seq id no:55 and a light chain of seq id no:54, or ("
https://patents.google.com/patent/WO2021237051A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Leu His Thr Phe Gly Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Pro Val Leu Thr Gln Pro Pro Ser Ser Ser Ala Ser Pro Gly Glu Ser Ala Arg Leu Thr Cys Thr Leu Pro Ser Asp Ile Asn Val Asp Ser Tyr Asn Ile Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Pro Pro Arg Phe Leu Leu Tyr Tyr Tyr Ser Asp Ser Asn Lys Gly Gln Gly Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Lys Asp Ala Ser Ala Asn Thr Gly Ile Leu Leu Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Met Ile Trp Pro Ser Asn Ala Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu ,  VH  ,  VL  ,(65/69) a vh domain having the amino acid sequence of seq id no:65 and a vl domain having the amino acid sequence of seq id no:69
https://patents.google.com/patent/WO2021237051A1/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Thr Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Arg Tyr Pro Phe His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Asn Ile Gln Asp Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Gly Ile Tyr Tyr Cys Ala Arg Asp Pro Val Ile Gly Tyr Gly Asp Tyr Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Gly Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys ,  VH  ,  VL  ,"(74/78) [0087] in certain embodiments of such aspects, an antibody, or an antigen-binding fragment thereof, comprises a vh domain having the amino acid sequence of seq id no:74 and a vl domain having the amino acid sequence of seq id no:78"
https://patents.google.com/patent/WO2021237051A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Gln Leu Trp Leu Arg Gly Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly , Gln Pro Val Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Val Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Ala Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Gly Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Heavy Chain  ,  Light Chain  ,"(19/44)  a heavy chain of seq id no:19 and a light chain of seq id no:44, ("
https://patents.google.com/patent/WO2021237051A1/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Val Trp Val Ser Arg Ile Asn Ser Asp Gly Ser Ser Thr Ser Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Ser Gly Trp Tyr Arg Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly , Gln Pro Val Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Gly Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Heavy Chain  ,  Light Chain  ,"(37/49)  a heavy chain of seq id no:37 and a light chain of seq id no:49, ("
https://patents.google.com/patent/WO2021237051A1/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Phe Ile Tyr Pro Gly Gly Ser Thr Val Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Ser Glu Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Trp Ser Gly Thr Tyr Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asn Gly Trp Leu Ala Trp Tyr Gln Glu Arg Pro Gly Glu Ala Pro Lys Ser Leu Ile Phe Ala Thr Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Thr Asp Val Pro Ser Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys ,  VH  ,  VL  ,(29/33) a vh domain having the amino acid sequence of seq id no:29 and a vl domain having the amino acid sequence of seq id no:33; v
https://patents.google.com/patent/WO2021237051A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala Val Ser Val Arg Ser Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ala Gly Ala Gly Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly , Gln Pro Val Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Ala Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ala Ile Ala Ser Asn Tyr Val His Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Ala Val Ile Tyr Lys Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Arg Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Gly Ser Ser Arg Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Heavy Chain  ,  Light Chain  ,"(46/53)  a heavy chain of seq id no:46 and a light chain of seq id no:53, ("
https://patents.google.com/patent/WO2021237051A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Leu His Thr Phe Gly Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly , Gln Pro Val Leu Thr Gln Pro Pro Ser Ser Ser Ala Ser Pro Gly Glu Ser Ala Arg Leu Thr Cys Thr Leu Pro Ser Asp Ile Asn Val Asp Ser Tyr Asn Ile Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Pro Pro Arg Phe Leu Leu Tyr Tyr Tyr Ser Asp Ser Asn Lys Gly Gln Gly Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Lys Asp Ala Ser Ala Asn Thr Gly Ile Leu Leu Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Met Ile Trp Pro Ser Asn Ala Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Heavy Chain  ,  Light Chain  ,(64/82) an amino acid sequence having a heavy chain of seq id no:64 and a light chain of seq id no:82; d
https://patents.google.com/patent/WO2021237051A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala Val Ser Val Lys Ser Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Ile Ala Val Val Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Ala Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Gly Gly Tyr Leu Ala Ser Asn Tyr Val His Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Ala Val Ile Tyr Lys Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Arg Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Gly Ser Ser Arg Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Heavy Chain  ,  Light Chain  ,"(1/13)  a heavy chain of seq id no:1 and a light chain of seq id no:13, ("
https://patents.google.com/patent/WO2021237051A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Thr Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Asp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Lys Asn Gly Asn Ala Lys Phe Tyr Gly Asp Ser Val Lys Gly Gln Phe Thr Ile Ser Arg Asp Asn Phe Asn Asn Met Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Gln Ser Lys Val Tyr Phe Asp Ala Phe Asp Met Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys ,  VH  ,  VL  ,(56/60) a vh domain having the amino acid sequence of seq id no:56 and a vl domain having the amino acid sequence of seq id no:60; viii
https://patents.google.com/patent/WO2021237051A1/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Thr Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Arg Tyr Pro Phe His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Asn Ile Gln Asp Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Gly Ile Tyr Tyr Cys Ala Arg Asp Pro Val Ile Gly Tyr Gly Asp Tyr Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Gly Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Heavy Chain  ,  Light Chain  ,"(73/83) [0094] in some aspects, an antibody comprises a heavy chain comprising the amino acid sequence of seq id no:73 and a light chain comprising the amino acid sequence of seq id no:83"
https://patents.google.com/patent/WO2021237051A1/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Phe Ile Tyr Pro Gly Gly Ser Thr Val Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Ser Glu Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Trp Ser Gly Thr Tyr Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asn Gly Trp Leu Ala Trp Tyr Gln Glu Arg Pro Gly Glu Ala Pro Lys Ser Leu Ile Phe Ala Thr Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Thr Asp Val Pro Ser Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Heavy Chain  ,  Light Chain  ,"(28/48)  a  heavy chain of seq id no:28 and a light chain of seq id no:48, ("
https://patents.google.com/patent/WO2021237051A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala Val Ser Val Arg Ser Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ala Gly Ala Gly Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Pro Val Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Ala Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ala Ile Ala Ser Asn Tyr Val His Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Ala Val Ile Tyr Lys Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Arg Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Gly Ser Ser Arg Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu ,  VH  ,  VL  ,(47/51)  vi. a vh domain having the amino acid sequence of seq id no:47 and a vl domain having the amino acid sequence of seq id no:51
https://patents.google.com/patent/WO2021237051A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Glu Ser Thr Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala Ala Ser Val Asn Ser Arg Ile Thr Phe Asn Pro Asp Thr Ala Lys Asn Gln Ile Ser Leu Gln Leu Asn Ser Ala Thr Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ala Pro Gly Glu Arg Ala Ala Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Ala Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Gly Leu Glu Ser Asp Asp Ser Ala Val Tyr Tyr Cys Gln Gln Tyr Thr Asp Trp Leu Val Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys ,  VH  ,  VL  ,(11/15)  ii. a vh domain having the amino acid sequence of seq id no:11 and a vl domain having the amino acid sequence of seq id no:15
https://patents.google.com/patent/WO2021237051A1/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Val Trp Val Ser Arg Ile Asn Ser Asp Gly Ser Ser Thr Ser Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Ser Gly Trp Tyr Arg Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Gln Pro Val Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Gly Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  VH  ,  VL  ,(38/42)  v. a vh domain having the amino acid sequence of seq id no:38 and a vl domain having the amino acid sequence of seq id no:42
https://patents.google.com/patent/WO2021237051A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Glu Ser Thr Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala Ala Ser Val Asn Ser Arg Ile Thr Phe Asn Pro Asp Thr Ala Lys Asn Gln Ile Ser Leu Gln Leu Asn Ser Ala Thr Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ala Pro Gly Glu Arg Ala Ala Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Ala Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Gly Leu Glu Ser Asp Asp Ser Ala Val Tyr Tyr Cys Gln Gln Tyr Thr Asp Trp Leu Val Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Heavy Chain  ,  Light Chain  ,"(10/43)  a heavy chain of seq id no:10 and a light chain of seq id no:43, ("
https://patents.google.com/patent/WO2021237051A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala Val Ser Val Lys Ser Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Ile Ala Val Val Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Ala Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Gly Gly Tyr Leu Ala Ser Asn Tyr Val His Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Ala Val Ile Tyr Lys Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Arg Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Gly Ser Ser Arg Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu ,  VH  ,  VL  ,(2/6) a vh domain having the amino acid sequence of seq id no:2 and a vl domain having the amino acid sequence of seq id no:6; ii
https://patents.google.com/patent/WO2021237051A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Gln Leu Trp Leu Arg Gly Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Pro Val Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Val Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Ala Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Gly Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  VH  ,  VL  ,(20/24) a vh domain having the amino acid sequence of seq id no:20 and a vl domain having the amino acid sequence of seq id no:24; iv
https://patents.google.com/patent/CN112300274A/en, Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Gly Ser Ile Asn Ser Asp Asn Trp Trp Ser Trp Val Arg Gln Thr Pro Glu Lys Gly Leu Glu Trp Ile Gly Glu Val Tyr His Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Ser Ile Ser Val Asp Lys Ser Lys Asn Gln Phe Ser Leu Asn Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gly Ser Thr Ser Ser Asp Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ala Gly Leu Thr Gln Pro Pro Ser Leu Ser Val Ser Pro Gly Gln Thr Ala Arg Ile Thr Cys Ser Gly Asn Ala Leu Pro Lys Gln Tyr Ala Tyr Trp Tyr Arg Gln Arg Pro Gly Gln Ala Pro Glu Leu Val Met Ser Arg Asp Val Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Val Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Ala Asp Asn Ser Gly Thr Phe Val Val Phe Gly Gly Gly Thr Gln Leu Ile Ile Leu , Artificial Sequence, Artificial Sequence,"(1/5)  vh comprises the amino acid sequence as set forth in seq id no:1, and vl comprises the amino acid sequence set forth in seq id no:5;"
https://patents.google.com/patent/CN112300274A/en, Gln Leu Gln Leu Gln Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Phe Gly Glu Phe Gly Phe Val Pro Gly Ala Ser Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Pro Val Leu Thr Gln Pro Pro Ser Val Ser Ala Thr Pro Gly Gln Thr Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Pro Val Asn Trp Tyr Gln Gln Leu Pro Gly Ala Ala Pro Lys Leu Leu Ile Tyr Thr Asn Asp Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Ala Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Val Trp His Asp Ser Leu Asn Thr Tyr Val Phe Gly Thr Gly Thr Glu Leu Thr Val Leu , Artificial Sequence, Artificial Sequence,"(7/9)  vh comprises the amino acid sequence as set forth in seq id no:7, and vl comprises the amino acid sequence set forth in seq id no:9;"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn Asn Gly Leu Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Arg Met Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Thr Ile Ser Tyr Ser Ser Asp Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Leu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg Gln Tyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(227/282) [0146] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:227 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:282"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Tyr Val Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Lys Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(221/276) [0139] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:221 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:276"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Thr Thr Arg Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Tyr Ser Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Ser Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg Gln Tyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(192/248) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:192 and a vl having an amino acid sequence of seq id no:248
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Thr Tyr Ala Phe Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Val Ile Asn Thr Gly Gly Gly Ser Val Thr Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Gly Ala Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Ile Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Ala Ala Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg Gln Tyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(210/265) [0128] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:210 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:265"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Gly Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Val Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Arg Ser Ser Gln Thr Val Leu Tyr Arg Ser Asn Asn Tyr Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(205/259) [0122] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:205 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:259"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Met Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Thr Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(214/269) [0132] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:214 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:269"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly His Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Ala Arg Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Thr Ser Asn Asn Asn Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Gly Ser Thr Arg Gly Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg Gln Tyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(195/251) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:195 and a vl having an amino acid sequence of seq id no:251
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp Tyr His Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Ala Met Ile Val Pro Arg Gly Gly Ser Thr Thr Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Val Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(218/273) [0136] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:218 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:273"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Val Leu His Thr Val Asp Tyr Ala Gln Arg Leu Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Glu Trp Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Phe Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Leu Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(244/296) [0164] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:244 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:296"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Glu Trp Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Asn Ile Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(196/252) [0113] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:196 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:252"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ile Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Thr Leu Gly Thr Tyr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Ser Trp Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Leu Arg Glu Gly Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr His Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(236/271) [0155] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:236 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:271"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ile Thr Tyr Trp Ile Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Gly Glu Ala Arg Tyr Ser Gln Lys Phe Tyr Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Ser Gly Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Asn Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Thr Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(197/253) [0114] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:197 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:253"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Gly Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Tyr Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Val Leu Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Thr Asn Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys His Gln Tyr Tyr Asn Thr Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(240/292) [0159] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:240 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:292"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Gly Glu Ala Arg Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Pro Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr His Ser Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(231/285) [0150] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:231 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:285"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Thr Thr Asn Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly His Trp Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Tyr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr His Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(222/277) [0140] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:222 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:277"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Asn Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Ala Trp Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Arg Cys Thr Ser Ser Leu Ser Leu Gln Asp Arg Ser Asn Asn Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Ala Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(198/254) [0115] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:198 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:254"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Thr Tyr Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asp Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Lys Asn Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Leu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg Gln Tyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(204/258) [0121] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:204 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:258"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Gly Phe Ile Thr Tyr Trp Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Gly Glu Ala Arg Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ile Gln Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Leu Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(247/299) [0167] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:247 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:299"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Met Ile Asn Pro Gly Gly Gly Asn Thr Asn Tyr Ala Glu Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Glu Trp Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Tyr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Gly Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(206/261) [0124] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:206 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:261"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Leu Leu Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(228/280) [0147] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:228 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:280"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Gly Glu Thr Arg Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Gly Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(229/295) [0163] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:229 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:295"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ser Thr Tyr Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Arg Ser Asn Asn Leu His Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Ser Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg Gln Tyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(239/291) [0158] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:239 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:291"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Gly Glu Thr Arg Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Tyr Thr Arg Glu Pro Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(208/263) [0126] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:208 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:263"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Gly Glu Ala Arg Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Ser Gly Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Asn Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Thr Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(200/253) [0117] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:253"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Gly Glu Thr Arg Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Ser Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(229/283) [0148] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:229 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:283"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn Ser Ser Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Ile Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg Gln Tyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(202/256) [0119] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:202 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:256"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gln Ile Asn Pro Ser Gly Asp Ser Thr Arg Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu His Ser Ser Asn Asn Leu Asn Tyr Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Leu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg Gln Tyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(237/289) [0156] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:237 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:289"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn His Ala Ile Ser Trp Val Arg Gln Ala Tyr Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Gly Thr Thr Arg Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Thr Ser Asn Asn Asn Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Ser Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg Gln Tyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(194/250) [0111] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:194 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:250"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Gly Ile Asn Trp Met Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Asn Arg Glu Pro Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Phe Cys His Gln Tyr Tyr Ser Thr Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(207/262) [0125] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:207 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:262"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Lys Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Ile Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Thr Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Val Ile Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(226/281) [0145] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:226 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:281"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Gly Glu Ala Arg Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr His Ser Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(245/297) [0165] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:245 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:297"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Ser Asp Tyr His Val His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val Gly Met Ile Ile Pro Arg His Gly Gly Thr Ala Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Asp Phe Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ala Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(199/255) [0116] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:199 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:255"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Thr Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(235/288) [0154] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:235 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:288"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Ser Thr Ala Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Glu Trp Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ser Ser Leu Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Thr Ala Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(246/298) [0166] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:246 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:298"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly His Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Ala Arg Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Leu Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Gly Ser Thr Arg Gly Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg Gln Tyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(195/260) [0123] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:195 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:260"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asp Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Gln Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Ser Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg Gln Tyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(193/249) [0109] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:193 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:249"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Ser Asp Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(233/280) [0152] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:233 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:280"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Asn Phe Thr Asp Tyr His Ile Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val Gly Met Ile Ile Pro Arg His Gly Gly Thr Ala Tyr Ala Gln Arg Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Leu Thr Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln His Tyr Tyr Asn Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(243/294) [0162] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:243 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:294"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Val Ile Asn Thr Gly Gly Gly Ser Val Thr Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly His Trp Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Phe Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Gly Thr Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(232/286) [0151] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:232 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:286"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ser Val Ile Pro Val Phe Gly Arg Pro Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Glu Trp Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Leu Arg Glu Gly Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Tyr Ala Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(203/257) [0120] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:203 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:257"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Ser Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Phe Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Lys Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(213/268) [0131] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:213 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:268"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Gly Phe Ser Thr Tyr Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val Gly Trp Ile Asn Pro Asn Ser Gly Ala Thr Lys Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Phe His Ser Ser Asn Asn Lys Asn His Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg Gln Tyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(215/270) [0133] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:215 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:270"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Leu Tyr Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr His Thr Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(211/266) [0129] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:211 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:266"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Ser Asp Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asp Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Ser Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg Gln Tyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(219/274) [0137] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:219 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:274"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Glu Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(241/280) [0160] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:241 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:280"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ile Ser Tyr Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Gly Glu Thr Arg Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Ser Asp Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(225/280) [0143] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:225 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:280"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Leu Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Arg Ser Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Arg Ile Leu Ser Tyr Ser Pro Asp Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Ser Tyr Ile Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(242/293) [0161] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:242 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:293"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu His Ser Ala Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Ser Thr Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(220/275) [0138] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:220 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:275"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Pro Phe Thr Asn Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Leu Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Arg Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Phe Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Ile Arg Gly Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys His Gln Tyr Tyr Thr Thr Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(224/279) [0009] the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:224 and a vl having an amino acid sequence of seq id no:279
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Arg Phe Thr Asp Tyr His Leu His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Val Pro Phe Ser Gly Thr Thr Asn Phe Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Glu Thr Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Ser Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(217/272) [0135] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:217 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:272"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Asn Ser His Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Ala Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Val Gly Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Ser Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg Gln Tyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(201/248) [0118] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:201 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:248"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Thr Ala Arg Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Leu Tyr Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Thr Ser Ser Gln Ser Val Leu His Ser Ser Asn Asn Leu Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Ser Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg Gln Tyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(238/290) [0157] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:238 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:290"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Gly Thr Thr Arg Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Leu Pro Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Arg Val Leu Tyr Ser Ser Asn Asn Leu Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Gly Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg Gln Tyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(209/264) [0127] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:209 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:264"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Val Leu Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ala Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(212/267) [0130] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:212 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:267"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Thr Leu Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Ser Trp Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Leu Arg Glu Gly Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr His Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(216/271) [0134] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:216 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:271"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Gly Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Arg Gln Tyr Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(230/284) [0149] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:230 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:284"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Asn Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Leu Phe Thr Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Ser Thr Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(223/278) [0141] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:223 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:278"
https://patents.google.com/patent/WO2021194891A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Gly Phe Ile Ser Tyr Trp Ile Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Leu Glu Pro Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Ser Ser Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(234/287) [0153] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:234 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:287"
https://patents.google.com/patent/CN112125973B/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly Gly Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Arg Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Met Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Gln Gly Asn Gln Thr Leu Arg Tyr Phe Asp Trp Ser Ala Pro Leu Val Thr Phe Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Ser Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Met Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser , Artificial Sequence, Artificial Sequence,"(9/10) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:9, and the light chain amino acid sequence is shown as seq id no:10."
https://patents.google.com/patent/WO2021194896A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Val Tyr Pro Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Ser Tyr Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(70/80) . [0063] in one instance, an antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:70 a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:80 (covid19_p04_g"
https://patents.google.com/patent/WO2021194896A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asn Tyr Ala Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Thr Met Ser Asn Ile Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Arg Val Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(73/81) . [0066] in one instance, an antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:73 a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:81 (covid19_p04_d"
https://patents.google.com/patent/WO2021194896A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Met Asn Arg Asp Gly Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Ser Tyr Tyr Val Gly Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Arg Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Asn Asn Trp Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(76/83) . [0069] in one instance, an antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:76 a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:83 (covid19_p04_e"
https://patents.google.com/patent/WO2021194896A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Pro Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Ser Tyr Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ala Ser Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(79/86) . [0072] in one instance, an antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:79 a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:86 (covid19_r01_b"
https://patents.google.com/patent/WO2021194896A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Ile Ile Tyr Glu Gly Gly Ser Pro His Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Ser Gly Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(78/85) [0009] the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:78 a vl having an amino acid sequence of seq id no:85
https://patents.google.com/patent/WO2021194896A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn His Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Ser Tyr Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Leu Ser Leu Pro Val Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(74/82) . [0067] in one instance, an antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:74 a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:82 (covid19_p04_b"
https://patents.google.com/patent/WO2021194896A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Arg Phe Ser Asp Ala Ala Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Ser Tyr Gly Ile Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(69/80) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:69 a vl having an amino acid sequence of seq id no:80
https://patents.google.com/patent/WO2021194896A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp His Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Thr Ser Gly Asp Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Ser Tyr Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Arg Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Gly Thr Ser Pro Pro Gly Leu Ser Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(77/84) . [0070] in one instance, an antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:77 a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:84 (covid19_r01_a"
https://patents.google.com/patent/WO2021194896A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ser Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Thr Gly Asp Thr Thr Glu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Ser Leu Met Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Arg Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Asn Asn Trp Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(75/83) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:75 a vl having an amino acid sequence of seq id no:83
https://patents.google.com/patent/WO2021194896A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ser Val Thr Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Pro Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Ser Tyr Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(71/80) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:71 a vl having an amino acid sequence of seq id no:80
https://patents.google.com/patent/WO2021194896A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Met Asn Arg Asp Gly Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Ser Tyr Tyr Val Gly Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Asn Asn Trp Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(76/87) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:76 a vl having an amino acid sequence of seq id no:87
https://patents.google.com/patent/WO2021194896A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala Ser His Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Ser Asp Gly Ser Ile Thr Thr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Trp Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(72/80) . [0065] in one instance, an antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:72 a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:80 (covid19_r01_b"
https://patents.google.com/patent/CN111620945A/en,gaggtgcagc tgttgcagca gtcaggggct gaggtgaaga agcctgggtc ctcagtgaag gtctcctgca aggcttctgg aggcaccttc agcagctatg ctatcagctg ggtgcgacag gcccctggac aagggcttga gtggatggga gggatcatcc ctatccttgg tatagcaaac tacgcacaga agttccaggg cagagtcacg attaccgcgg acaaatccac gagcacagcc tacatggagc tgagcagcct gagatctgag gacacggccg tgtattactg tgtgagagaa cgtggatata gtggctacgg ggcggcttac tactttgact actggggcca gggaaccctg gtcaccgtct cctca ,cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc tcctgcactg ggagcagctc caacatcggg gcaggttatg atgtacactg gtaccagcag cttccaggaa cagcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc cctgaccgat tctctggctc caagtctggc acctcagcct ccctggccat cactgggctc caggctgagg atgaggctga ttattactgc cagtcctatg acagcagcct gagtggttcg gtattcggcg gagggaccaa gctgaccgtc cta , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(9/10) as a preferred embodiment of the present invention, the variable region of the antibody light chain is seq id no:10, and the variable region of the antibody heavy chain is seq id no:9."
https://patents.google.com/patent/CN111620945A/en,Glu Val Gln Leu Leu Gln Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg Glu Arg Gly Tyr Ser Gly Tyr Gly Ala Ala Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) preferably, the first variable region is an antibody light chain variable region comprising seq id no:8; wherein said second variable region is an antibody heavy chain variable region comprising the amino acid sequence of seq id no:4."
https://patents.google.com/patent/CN113045646A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Val Val Phe Leu Thr Ile Thr Phe Tyr Tyr Met Asn Lys Phe Arg Asp Lys Gly Phe Asn Pro Ile Val Gly Gly Thr Ser Tyr Pro Gln Lys Phe Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Ser Thr Leu Thr Asp Tyr Thr Lys Gly Ala Glu Arg Tyr Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Gly Leu Glu Trp Ile Gly Asp Leu Asn Pro Ile Asn Gly Gly Thr Ala Tyr Gln Gln Lys Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Ser Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Val His Thr Phe Pro Ala Leu Leu Gln Ser Gly Leu Tyr Thr Met Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Gln Thr Val Thr Cys Ser Val Ala His Pro Ala Ser Ser Thr Thr Val Asp Lys Lys Leu Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Cys Pro Pro Cys Lys Glu Cys His Lys Cys Pro Ala Pro Asn Leu Glu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Asn Ile Lys Asp Val Leu Met Ile Ser Leu Thr Pro Lys Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Ile Arg Val Val Ser Thr Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ser Pro Ile Glu Arg Thr Ile Ser Lys Ile Lys Gly Leu Val Arg Ala Pro Gln Val Tyr Ile Leu Pro Pro Pro Ala Glu Gln Leu Ser Arg Lys Asp Val Ser Leu Thr Cys Leu Val Val Gly Phe Asn Pro Gly Asp Ile Ser Val Glu Trp Thr Ser Asn Gly His Thr Glu Glu Asn Tyr Lys Asp Thr Ala Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Ile Tyr Ser Lys Leu Asn Met Lys Thr Ser Lys Trp Glu Lys Thr Asp Ser Phe Ser Cys Asn Val Arg His Glu Gly Leu Lys Asn Tyr Tyr Leu Lys Lys Thr Ile Ser Arg Ser Pro Gly, Asp Val Val Leu Thr Gln Thr Pro Leu Thr Gln Ser Gln Tyr Ser Asn Gly Lys Ile Tyr Leu Asn Ser Leu Ser Val Thr Ile Gly Val Gln Phe Ser Lys Ile Val Pro Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Ile Ile Tyr Ser Asn Gly Lys Ile Leu Gln Asn Thr Tyr Gln Pro Tyr Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Lys Arg Leu Met Tyr Gln Leu Ser Lys Leu Asp Pro Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Glu Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys , Artificial sequence, Artificial sequence,"(8/10) through analysis, the antibody obtained from the hybridoma cell line 8c4 has light chains and heavy chains with sequences shown as seq id no:10 and 8."
https://patents.google.com/patent/KR20220010456A/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr His Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No.139 HC variable region , No.139 LC variable region ,"(2018/2017)  according to claim 1, the antibody or antigen-binding fragment thereof light chain variable region of the polypeptide sequence of seq id no:2017; and heavy chain variable region of the polypeptide sequence of seq id no:2018 a method comprising "
https://patents.google.com/patent/WO2021252878A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Pro Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Thr Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Gly Tyr Met Glu Leu Arg Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Tyr Thr Arg Gly Ala Phe Phe Gly Glu Ser Leu Ile Gly Gly Phe Asp Asn Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Thr Val Ser Ser Thr Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Asp Thr Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic sequence SARS-CoV-2 S309-v1.7 mAb VH  , Synthetic sequence SARS-CoV-2 S309-v13 mAb VL (VK)  ,"(119/168) in certain embodiments, an antibody or an antigen-binding fragment of the present disclosure comprises a vh comprising or consisting of the sequence according to seq id no:119 and a vl comprising or consisting of the sequence according to seq id no:168 and binds to sars-cov-2 s protein rbd with an ec50 of about 8 to about 22 ng/ml"
https://patents.google.com/patent/WO2021252878A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Pro Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Thr Tyr Gln Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Gly Tyr Met Glu Leu Arg Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Tyr Thr Arg Gly Ala Trp Phe Gly Glu Ser Leu Ile Gly Gly Phe Asp Asn Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Thr Val Ser Ser Thr Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Asp Thr Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic sequence SARS-CoV-2 S309-v1.1 mAb VH  , Synthetic sequence SARS-CoV-2 S309-v13 mAb VL (VK)  ,(113/168) s309-12 comprises an n55q vh variant sequence (seq id no:113) and the wild-type vl sequence (seq id no:168) of s309
https://patents.google.com/patent/WO2021252878A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Pro Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Thr Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Gly Tyr Met Glu Leu Arg Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Tyr Thr Arg Gly Ala Trp Phe Gly Glu Ser Leu Ile Gly Gly Phe Asp Asn Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Thr Val Ser Ser Thr Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Asp Thr Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic sequence SARS-CoV-2 S309-v1 mAb VH  , Synthetic sequence SARS-CoV-2 S309-v13 mAb VL (VK)  ,(105/168) s309-11 comprises the wild-type vh sequence (seq id no:105) and wild-type vl sequence (seq id no:168) of s309
https://patents.google.com/patent/WO2021252878A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Pro Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Phe Ile Ser Thr Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Gly Tyr Met Glu Leu Arg Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Tyr Thr Arg Gly Ala Trp Phe Gly Glu Ser Leu Ile Gly Gly Phe Asp Asn Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Thr Val Ser Ser Thr Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Asp Thr Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic sequence SARS-CoV-2 S309-v2 mAb VH  , Synthetic sequence SARS-CoV-2 S309-v13 mAb VL (VK)  ,"(129/168) in certain embodiments, an antibody or an antigen-binding fragment of the present disclosure comprises a vh comprising or consisting of the amino acid sequence according to seq id no:129 and a vl comprising or consistingof the amino acid sequence according to seq id no:168 and binds to sars-cov-2 s protein rbd with an ec50 of about 8 to about 22 ng/ml"
https://patents.google.com/patent/WO2021252878A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Asp Met His Trp Val Arg Gln Thr Thr Gly Lys Gly Leu Glu Trp Val Ser Thr Ile Gly Thr Ala Gly Asp Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Asp Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Ser Ser Gly Tyr Tyr Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Leu Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ala Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Ile Tyr Tyr Cys Gln Gln Ser Tyr Val Ser Pro Thr Tyr Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Synthetic sequence SARS-CoV-2 S304 mAb VH  , Synthetic sequence SARS-CoV-2 S304 mAb VL (VK)  ,"(79/83) , wherein the vh comprises or consists of the amino acid sequence as set forth in seq id no:79 and the vl comprises or consists of the amino acid sequence as set forth in seq id no:83. "
https://patents.google.com/patent/CN111995674B/en, Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr Ala Met Asn Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Gln Ser Met Leu Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Met Tyr Tyr Cys Val Thr Pro Tyr Tyr Gly Asn Tyr Ala Asp Trp Phe Thr Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Artificial sequence,  Artificial sequence,"(7/8) the heavy chain amino acid sequence of the human-mouse chimeric whole antibody mhc3 is shown as seq id no:7, and the light chain amino acid sequence is shown as seq id no:8."
https://patents.google.com/patent/CN111995674B/en, gaggtgcagc ttgttgagtc tgggggagac ttagtgaagc ctggagggtc cctgaaactc tcctgtgcag cctctggatt caccttcaat acctacgcca tgaactgggt ccgccagact ccaggaaagg gtttggaatg ggttgctcgc ataagaagta aaagtaataa ttatgcaaca tattatgccg attcagtgaa agacaggttc accatctcca gagatgattc gcaaagcatg ctctatctgc aaatgaacaa cttgaaaact gaggacacag ccatgtatta ctgtgtgaca ccctactatg gtaattacgc agactggttt acttactggg gccaaggaac ctcagtcacc gtgtcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaactc ctggggggac cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga , gatgttgtga tgacccagac tccactctcc ctgcctgtca gtcttggaga tcaagcctcc atctcttgca gatctagtca gagccttgta cacagtaatg gaaacaccta tttacattgg tacctgcaga agccaggcca gtctccaaag ctcctgatct acaaagtttc caaccgattt tctggggtcc cagacaggtt cagtggcagt ggatcaggga cagatttcac actcaagatc agcagagtgg aggctgagga tctgggagtt tatttctgct ctcaaagtac acatgttccg tacacgttcg gaggggggac caagttggaa ataaaacgta cggtggcggc gccatctgtc ttcatcttcc cgccatctga tgagcagttg aaatctggta ccgctagcgt tgtgtgcctg ctgaataact tctatcccag agaggccaaa gtacagtgga aggtggataa cgccctccaa tcgggtaact cccaggagag tgtcacagag caggacagca aggacagcac ctacagcctc agcagcaccc tgacgctgag caaagcagac tacgagaaac acaaagtcta cgcctgcgaa gtcacccatc agggcctgag ctcgcccgtc acaaagagct tcaacagggg agagtgttag ,  Artificial sequence,  Artificial sequence,"(11/12) in one embodiment of the invention, the recombinant expression vector for expressing the heavy chain of the antibody is obtained by cloning seq id no:11 (encoding gene of the heavy chain of the antibody) between enzyme cutting sites hind iii and bamh i of pcdna3.1(+) vector; cloning seq id no:12 (coding gene of antibody light chain) between enzyme cutting site hind iii and bamh i of pcdna3.1(+) vector to obtain recombinant expression vector for expressing the light chain of the antibody"
https://patents.google.com/patent/CN113943367A/en, Ala Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Asn Phe Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Thr Ile Ala Ala Asp Gly Ser Ala Ala Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg His Asn Glu Lys Asn Thr Val Asp Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Gly Val Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Phe Gly Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(43) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Ala Val Gln Leu Val Asp Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Asn Phe Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Thr Ile Ala Ala Gly Gly Ser Thr Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg His Asn Glu Lys Asn Thr Val Asp Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Gly Val Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Phe Ala Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(47) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Met Ala Gln Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Val Ser Cys Ala Ala Ser Gly Phe Asn Phe Asn Ile Tyr Asn Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Thr Ile Ala Ala Gly Gly Ser Thr Gly Tyr Ala Asp Pro Val Lys Gly Arg Phe Ala Ile Ser Arg Asp Asn Val Lys Asn Thr Val Asp Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Phe Ser Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(41) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Ala Val Gln Leu Val Asp Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Gly Phe Asn Met Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Thr Ile Ala Arg Asp Gly Ser Thr Gly Tyr Ala Ile Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Lys Asn Thr Val Asp Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Tyr Ala Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(44) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Met Ala Ala Val Gln Leu Val Asp Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Asn Ile Tyr Asn Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Thr Ile Ala Ala Asp Gly Ser Thr Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Lys Asn Lys Val Asp Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Phe Ser Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(36) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Ala Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Asn Ile Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Leu Ala Thr Ile Ala Ala Gly Gly Ser Thr Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ile Lys Asn Lys Val Asp Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Lys Arg Glu Leu Gly Ser Phe Ser Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(40) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Thr Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ala Trp Tyr Arg Gln Ala Pro Gly Lys Glu Cys Glu Trp Val Ala Thr Ile Thr Ile Thr Gly Gly Asn Ser Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys Asn Ala Asp Pro Ser Cys Pro Leu Gly Gln Gly Thr Gln Val Thr Val Ser Ser,, Artificial sequence,,"(50) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Lys Met Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Leu Gln Arg Glu Ser Val Ala Ser Ile Ala Gln Asp Gly Ser Ala Ser Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Lys Asn Thr Val Asp Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala His Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Phe Ser Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(39) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Met Ala Ala Val Gln Leu Val Asp Ser Gly Gly Gly Met Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Asn Ile Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Thr Ile Ala Ala Gly Gly Asn Thr Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Lys Asn Lys Val Asn Leu Gln Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Phe Ser Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(38) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Gln Ala Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Asn Met Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu Leu Val Ala Thr Val Ala Ala Gly Gly Ser Thr Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Lys Met Lys Val Asp Leu Gln Met Asn Ser Leu Lys Leu Glu Asp Thr Ala Val Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Phe Ser Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(37) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Val Phe Asn Met Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Thr Ile Ala Lys Asp Gly Ser Thr Gly Tyr Ala Ile Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Lys Asn Thr Val Asp Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Tyr Gly Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(42) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Ala Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Asn Ile Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Thr Ile Ala Ala Gly Gly Ser Thr Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Lys Asn Lys Val Asp Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Phe Ala Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(46) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Gln Ala Gln Leu Val Glu Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Thr Ser Lys Ser Ala Phe Ala Ile Phe Ala Met Ser Trp Tyr Arg Gln Ala Pro Gly Lys Glu Cys Glu Trp Val Ala Thr Ile Thr Ile Thr Gly Gly Asn Ser Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Gln Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn Ala Asp Pro Gly Cys Pro Leu Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(48) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Arg Ala Gly Glu Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu Cys Glu Trp Val Ala Thr Ile Thr Ile Thr Gly Gly Asn Ser Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Gln Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn Ala Asp Pro Gly Cys Pro Leu Gly Gln Gly Thr Gln Val Thr Val Ser Ser,, Artificial sequence,,"(51) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Met Ala Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Thr Leu Ser Cys Ser Ala Ser Gly Phe Phe Phe Asn Gly Tyr Asn Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Thr Ile Ser Glu Ala Gly Thr Thr Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Lys Asn Thr Val Asp Leu His Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Phe Ser Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(49) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Gln Ala Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Leu Phe Lys Met Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Ser Ile Ala Asn Asp Gly Ser Thr Gly Tyr Gly Asp Ser Val Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Val Lys Asn Thr Val Asp Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala His Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Phe Ser Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Thr ,, Artificial sequence,,"(45) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Met Ala Ala Val Gln Leu Val Asp Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Thr Leu Ser Cys Ser Ala Ser Gly Phe Phe Phe Asn Gly Tyr Asn Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Thr Ile Ser Glu Ala Gly Thr Thr Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Lys Asn Thr Val Asp Leu His Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Phe Ser Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(35) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/WO2021174595A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Pro Tyr Cys Ser Ser Thr Ser Cys His Arg Asp Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp Ser Asp Asp Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Arg Ile Glu Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(7/8)  preferably, it includes: vh shown in seq id no:7 and/or vl shown in seq id no:8."
https://patents.google.com/patent/CN112898416B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/CN112898416B/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Trp Val Ile Cys Ser Ser Thr Ser Cys Tyr Thr Lys Tyr Ser Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ile Ser Asn Ile Gly Ser Ala His Val Ser Trp Tyr Gln Gln Val Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Ser Glu Arg Pro Ser Gly Ile Pro Ala Arg Phe Ser Ala Phe Lys Tyr Gly Thr Ser Ala Thr Leu Asp Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Trp Asp Ile Ser Leu Ser Ala Gly Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) the binding protein of claim 1, comprising the heavy chain variable region of seq id no:4 and the light chain variable region of seq id no:8."
https://patents.google.com/patent/CN113173995A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Leu Thr Arg Asp Thr Ser Ile Thr Thr Val Tyr Met Glu Leu Ser Arg Leu Arg Phe Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Tyr Asp Trp Asn Gln Asn Asn Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Thr Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Phe Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Phe Thr Thr Ser Ser Thr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence, Artificial Sequence,(4/3) the sequence of the variable region vl-2 of the light chain of the scfv-2 is shown as seq id no:3; the sequence of the heavy chain variable region vh-2 of the scfv-2 is shown as seq id no:4.
https://patents.google.com/patent/CN113173995A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Arg Phe Asp Asp His Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Ser Gly Asp Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Ser Ile Ser Arg Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Arg Ser Tyr Gly Pro Pro Asp Val Phe Asn Tyr Glu Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence, Artificial Sequence,"(2/1) wherein the sequence of the variable region vl-1 of the light chain of the scfv-1 is shown in seq id no:1, and the sequence of the variable region vh-1 of the heavy chain of the scfv-1 is shown in seq id no:2"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn Phe Ala Ile Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Val Ile Asn Pro Gly Gly Gly Ser Thr Thr Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(160/200) [0097] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars- cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:160 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 (covid 19 p01 b"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Gly Asn Tyr Pro Ile Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Ala Arg Tyr Arg Pro Ser Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Phe Ser Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Asp Ser Ser Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(166/204) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:166 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:204 (covid 19 p01 h"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Asn Asn Tyr Asp Leu His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Asp Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Leu Glu Thr Val Met Gly Gly Met Val Lys Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Ile Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Gly Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(153/193) the antibody or the antigen-binding fragment can comprise a vh chain having an amino acid sequence of seq id no:153 and a vl chain having an amino acid sequence of seq id no:193
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Asn Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Thr Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Arg Ser Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(171/201) the antibody or the antigen-binding fragment can comprise a vh chain having an amino acid sequence of seq id no:171 and a vl chain having an amino acid sequence of seq id no:201
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Asn Thr Phe Ser Met Phe Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val Gly Val Ile Asn Pro Ile Gly Ser Thr Thr Thr Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Val Ser Ser Ser Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(185/212) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:185 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:212 (covid 19_p 14 f"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Thr Val Met Gly Gly Met Gly Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Phe Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(179/210) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:179 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:210 (covid 19_p 14 b"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn Phe Ala Leu Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Leu Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Arg Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Ala Ser Ser Ser Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(165/203) [0009] the antibody or the antigen-binding fragment can comprise a vh chain having an amino acid sequence of seq id no:165 and a vl chain having an amino acid sequence of seq id no:203
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Asn Arg Phe Ala Met Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Thr Ile Asn Pro Ser Gly Gly Ser Thr Ile Tyr Thr Gln Arg Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Gly His Asp Thr Val Met Gly Gly Met Gly Glu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Thr Asp Ser Ser Ser Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(157/197) [0094] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars- cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:157 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:197 (covid 19 p14 d "
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Pro Phe Ser Ser Tyr Glu Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Thr Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Asp Glu Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Asn Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(164/190) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:164 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:190 (covid 19 p01 h"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Leu Ile Asp Pro Ser Gly Gly Thr Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Val Trp Asp Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Lys Asp Gly Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Arg Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Leu Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(152/192) the antibody or the antigen binding fragment can comprise a vh chain having an amino acid sequence of seq id no:152 and a vl chain having an amino acid sequence of seq id no:192
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Arg Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Thr Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala His Asp Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Tyr Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(155/195)  . [0092] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars- cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:155 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:195 (covid 19_p 13 c"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asp Pro Ile Gly Gly Thr Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Thr Val Gly Phe Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Leu Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(156/196) [0093] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars- cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:156 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:196 (covid 19 p14 c "
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Cys Thr Phe Thr Arg Phe Thr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Thr Pro Ile Phe Gly Ile Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala His Asp Thr Val Met Gly Gly Met Glu Glu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Asn Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(150/190) [0087] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars- cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:150 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:190 (covid 19 p01 e"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Asp Phe Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Gly Met Asp Thr Val Met Gly Gly Met Thr Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser His Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(174/207) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:174 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:207 (covid 19 p13 d"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Val Ile Asp Pro Ser Glu Gly Ser Thr Ser Asn Ala Arg Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Val Ser Asp Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Leu Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(167/205) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:167 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:205 (covid 19 p02 a"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Asn Tyr Glu Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Thr Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(176/200) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:176 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 (covid 19 p13 g "
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Ser Thr Phe Ser Met Phe Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val Gly Val Ile Asn Pro Arg Gly Ser Ser Thr Thr Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Arg Ser Ser Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(168/206) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:168 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:206 (covid 19 p02 a "
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Thr Tyr Trp Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Phe Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(151/191) [0088] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars- cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:151 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:191 (covid 19 p01 e"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ala Phe Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Ser Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Ala Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Val Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Thr Ser Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(188/213) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:188 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:213 (covid 19_p 14 f"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Phe Tyr Met Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Thr Pro Ile Leu Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ile Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Trp Asp Ser Ser Ser Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(177/209) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:177 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:209 (covid 19_p 13 h"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Asp Phe Tyr Leu His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Thr Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Met Glu Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(182/200) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:182 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 (covid 19 p14 c"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Phe Ala Ile Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Ala Leu Ile Asn Pro Ser Ser Gly Thr Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser His Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(186/202) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:186 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:202 (covid 19 p14 f"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ser Phe Ser Arg Phe Pro Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Arg Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Leu Glu Thr Val Met Gly Gly Leu Gln Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(189/200) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:189 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 (covid 19 p14 h "
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Phe His Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Thr Pro Ile Phe Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Leu Glu Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Trp Asp Ser Ser Gly Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(154/194) [0091] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars- cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:154 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:194 (covid 19 p02 h"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Phe Asp Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Tyr Glu Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Tyr Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(161/195) [0098] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars- cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:161 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:195 (covid 19 p01 c"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Glu Ala Glu Tyr Ala His Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Met Glu Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(169/200) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:169 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 (covid 19 p02 c"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Met Phe Thr Glu Phe Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Val Ser Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(170/200) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:170 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 (covid 19 p02 d "
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Asn Phe Ile Asn Tyr Tyr Leu His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Thr Pro Ile Phe Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Lys Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Gly Ser Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(158/198) [0095] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars- cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:158 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:198 (covid 19 p14 g"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Asn Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Thr Pro Ile Phe Gly Thr Ala Lys Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(178/200) the antibody or the antigen-binding fragment of claim 1 or 4, that comprises a vh chain having an amino acid sequence of seq id no:178 and a vl chain having an amino acid sequence of seq id no:200"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ala Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Thr Pro Leu Phe Gly Thr Pro Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Leu Glu Thr Val Met Gly Gly Val Gly Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Val Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(159/199) [0096] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars- cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:159 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:199 (covid 19 p01 b"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Met Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Asn Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Thr Tyr Trp Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Phe Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(187/210) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:187 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:210 (covid 19 p14 f"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Asn Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Thr Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser His Ser Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(171/211) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:171 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:211 (covid 19 p14 e"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Thr Phe Phe Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Tyr Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(172/195) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:172 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:195 (covid 19 p13 b"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Phe Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Glu Ala Glu Tyr Ala His Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Met Glu Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(183/200) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:183 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 (covid 19 p14 d"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Phe Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Leu Glu Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser His Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(163/202) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:163 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:202 (covid 19_p01 g"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Thr Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Val Glu Thr Val Met Gly Gly Met Gln Met Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(184/200) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:184 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 (covid 19_p 14_e01 "
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Asn Ala Phe Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Leu Glu Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Gly Ser Ser Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(175/208) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:175 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:208 (covid 19 p13 d "
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Val Glu Thr Val Met Gly Gly Phe Thr Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(180/200) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:180 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 (covid 19 p14 b"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Val His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Leu Pro Ile Leu Gly Thr Pro His Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Leu Glu Thr Val Met Gly Gly Met Thr Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(181/200) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:181 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 (covid 19_p 14 b"
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Phe His Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Leu Glu Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(173/200) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:173 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 (covid 19 p13 b "
https://patents.google.com/patent/WO2021194951A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn Tyr Thr Ile Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asp Tyr Ala Gln Lys Leu Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ala Leu Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Arg Ser Asp Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(162/201) [0099] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars- cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:162 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:201 (covid 19 p01 e"
https://patents.google.com/patent/WO2021252620A2/en, Met Asp Trp Thr Trp Arg Ile Leu Phe Leu Val Ala Ala Ala Thr Gly Thr His Ala Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Tyr Thr Arg Gly Ala Trp Phe Gly Glu Ser Leu Ile Gly Gly Phe Asp Asn Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Met Val Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser Gly Ala Tyr Gly Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Asp Thr Ser Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Chemically Synethsized  ,  Chemically Synethsized  ,(42/44)  (1) a heavy chain variable region comprising the amino acid sequence of seq id no:42 and a light chain variable region comprising the amino acid sequence of seq id no:44
https://patents.google.com/patent/WO2021252620A2/en, Glu Val Lys Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asp Ser Ser Thr Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Ile Tyr Tyr Gly Ser Pro Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Ser Ile Val Met Thr Gln Thr Pro Lys Phe Leu Leu Val Ser Ala Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ser Asn Asp Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Ser Thr Val Gln Ala Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln Asp Tyr Phe Ser Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg ,  Chemically Synethsized  ,  Chemically Synethsized  ,(100/102)  a heavy chain variable region comprising the amino acid sequence of seq id no:100 and a light chain variable region comprising the amino acid sequence of seq id no:102; (
https://patents.google.com/patent/WO2021252620A2/en, Glu Val Lys Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asp Ser Ser Thr Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Ile Tyr Tyr Gly Ser Pro Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Ser Ile Val Met Thr Gln Thr Pro Lys Phe Leu Leu Val Ser Ala Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ser Asn Asp Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Ser Thr Val Gln Ala Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln Asp Tyr Phe Ser Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Chemically Synethsized  ,  Chemically Synethsized  ,(94/96)  a heavy chain variable region comprising the amino acid sequence of seq id no:94 and a light chain variable region comprising the amino acid sequence of seq id no:96; (
https://patents.google.com/patent/WO2021252620A2/en, Met Asp Phe Gly Leu Ile Phe Phe Ile Val Ala Leu Leu Lys Gly Val Gln Cys Glu Val Lys Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asp Ser Ser Thr Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Ile Tyr Tyr Gly Ser Pro Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Met Lys Ser Gln Thr Gln Val Phe Val Phe Leu Leu Leu Cys Val Ser Gly Ala His Gly Ser Ile Val Met Thr Gln Thr Pro Lys Phe Leu Leu Val Ser Ala Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ser Asn Asp Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Ser Thr Val Gln Ala Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln Asp Tyr Phe Ser Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Chemically Synethsized  ,  Chemically Synethsized  ,(84/92)  a heavy chain variable region comprising the amino acid sequence of seq id no:84 and a light chain variable region comprising the amino acid sequence of seq id no:92; (
https://patents.google.com/patent/WO2021252620A2/en, Glu Val Gln Leu Val Glu Thr Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Gly Ser Gly Ser Asp Tyr Tyr Tyr Tyr Tyr Tyr Met Asp Val Trp Gly Lys Gly Thr Met Val Thr Val Ser Ser Ser Ala Ser Gly Ala Glu Leu , Thr Ser Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Pro Val Ile Tyr Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Asn His Pro Phe Gly Thr Gly Thr Lys Val Thr Leu ,  Chemically Synethsized  ,  Chemically Synethsized  ,(30/38)  a heavy chain variable region comprising the amino acid sequence of seq id no:30 and a light chain variable region comprising the amino acid sequence of seq id no:38; (1
https://patents.google.com/patent/WO2021252620A2/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Glu Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Gly Ser Tyr Ala Gly Gly Thr Phe Gly Ser Tyr Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Trp Ile Asp Ala Ala Asn Gly Asn Thr Lys Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Gly Asp Thr Ser Ala Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Trp Met Thr Thr Arg Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Gln Pro Val Leu Thr Gln Pro Pro Ala Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Phe Trp Tyr Gln Gln Leu Pro Gly Met Ala Pro Lys Leu Leu Ile Ser Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Pro Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Arg Gly Pro Val Phe Gly Gly Gly Thr Arg Val Thr Val Leu ,  Chemically Synethsized  ,  Chemically Synethsized  ,(6/8)  a heavy chain variable region comprising the amino acid sequence of seq id no:6 and a light chain variable region comprising the amino acid sequence of seq id no:8;
https://patents.google.com/patent/WO2021252620A2/en, Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Asp Pro Lys Phe Gln Ala Lys Ala Thr Ile Thr Ala Asn Thr Ser Ser Asn Thr Ala Tyr Leu His Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Pro Tyr Tyr Asp Tyr Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Lys Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Gln Ser Ala Ser Leu Gly Glu Ser Val Thr Ile Thr Cys Leu Ala Ser Gln Thr Ile Gly Thr Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Gln Leu Leu Ile Tyr Ala Ala Thr Ser Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Lys Phe Ser Phe Lys Ile Ser Ser Leu Gln Ala Glu Asp Phe Val Ser Tyr Tyr Cys Gln Gln Leu Tyr Asn Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg ,  Chemically Synethsized  ,  Chemically Synethsized  ,(122/124)  (k) a heavy chain variable region comprising the amino acid sequence of seq id no:122 and a light chain variable region comprising the amino acid sequence of seq id no:124
https://patents.google.com/patent/WO2021252620A2/en, Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Asp Pro Lys Phe Gln Ala Lys Ala Thr Ile Thr Ala Asn Thr Ser Ser Asn Thr Ala Tyr Leu His Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Pro Tyr Tyr Asp Tyr Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Lys Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Gln Ser Ala Ser Leu Gly Glu Ser Val Thr Ile Thr Cys Leu Ala Ser Gln Thr Ile Gly Thr Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Gln Leu Leu Ile Tyr Ala Ala Thr Ser Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Lys Phe Ser Phe Lys Ile Ser Ser Leu Gln Ala Glu Asp Phe Val Ser Tyr Tyr Cys Gln Gln Leu Tyr Asn Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg ,  Chemically Synethsized  ,  Chemically Synethsized  ,(128/130)  a heavy chain variable region comprising the amino acid sequence of seq id no:128 and a light chain variable region comprising the amino acid sequence of seq id no:130. 
https://patents.google.com/patent/WO2021252620A2/en, Met Val Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser Gly Ala Tyr Gly Asp Ile Gln Leu Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Met Asp Trp Thr Trp Arg Ile Leu Phe Leu Val Ala Ala Ala Thr Gly Thr His Ala Gln Met Gln Leu Val Gln Ser Gly Thr Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Ile Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys ,  Chemically Synethsized  ,  Chemically Synethsized  ,(2/4)  a heavy chain variable region comprising the amino acid sequence of seq id no:2 and a light chain variable region comprising the amino acid sequence of seq id no:4;
https://patents.google.com/patent/WO2021252620A2/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Gly Tyr Cys Ser Ser Thr Ser Cys His Ile Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Thr Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Ile Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Met Phe Asp Ser Ser Thr Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Ser Ser Ser Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Chemically Synethsized  ,  Chemically Synethsized  ,(18/20)  a heavy chain variable region comprising the amino acid sequence of seq id no:18 and a light chain variable region comprising the amino acid sequence of seq id no:20; (
https://patents.google.com/patent/WO2021252620A2/en, Met Lys Cys Ser Trp Val Ile Phe Phe Leu Met Ala Val Val Thr Gly Val Asn Ser Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Asp Pro Lys Phe Gln Ala Lys Ala Thr Ile Thr Ala Asn Thr Ser Ser Asn Thr Ala Tyr Leu His Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Pro Tyr Tyr Asp Tyr Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Met Asn Met Leu Thr Gln Leu Leu Gly Leu Leu Leu Leu Trp Phe Ala Gly Gly Lys Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Gln Ser Ala Ser Leu Gly Glu Ser Val Thr Ile Thr Cys Leu Ala Ser Gln Thr Ile Gly Thr Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Gln Leu Leu Ile Tyr Ala Ala Thr Ser Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Lys Phe Ser Phe Lys Ile Ser Ser Leu Gln Ala Glu Asp Phe Val Ser Tyr Tyr Cys Gln Gln Leu Tyr Asn Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Chemically Synethsized  ,  Chemically Synethsized  ,(112/120)  a heavy chain variable region comprising the amino acid sequence of seq id no:112 and a light chain variable region comprising the amino acid sequence of seq id no:120; (
https://patents.google.com/patent/CN113461812A/en, Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Arg Tyr Tyr Ile Tyr Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asn Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Asn Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Thr Ile Phe Ile Thr Thr Val Ile Ala Arg Asp Tyr Trp Gly Gln Gly Thr Leu, Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Glu Tyr Ser Gly Thr Thr Leu Met Gln Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Val Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His Pro Val Glu Glu Asp Asp Val Ala Met Tyr Phe Cys His Gln Ser Arg Glu Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Val Thr Val Ser Ala , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(8/7) the amino acid sequences of the light and heavy chain variable regions of antibody ncov-00d are shown in seq id no:7 and 8, respectively."
https://patents.google.com/patent/CN113461812A/en, Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro Gly Ser Thr Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Arg Tyr Tyr Ile Tyr Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asn Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Asn Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Thr Ile Phe Ile Thr Thr Val Ile Ala Arg Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro Gly Ser Thr Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Glu Tyr Ser Gly Thr Thr Leu Met Gln Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Val Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His Pro Val Glu Glu Asp Asp Val Ala Met Tyr Phe Cys His Gln Ser Arg Glu Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Ser , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(12/11) in one embodiment of the present invention, the amino acid sequences of the light and heavy chains of a whole antibody igg are shown in seq id no:11 and 12, respectively, and the nucleotide sequences encoding the light and heavy chains are shown in seq id no:13-14, respectively."
https://patents.google.com/patent/CN111518202A/en,Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Ser Gly Ser Tyr Tyr Trp Gly Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,Glu Asn Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8)  that specifically bind to a novel coronavirus np protein, wherein the binding protein or antibody of the novel coronavirus np protein comprises or consists of the vl sequence of seq id no:8 and the vh sequence of seq id no:4."
https://patents.google.com/patent/CN111518202A/en,Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(12/16)  wherein the heavy chain variable region comprises an amino acid sequence shown in seq id no:12, and the light chain variable region comprises an amino acid sequence shown in seq id no:16."
https://patents.google.com/patent/CN113999303A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Ile Thr Phe Ser Asp Tyr Tyr Met Tyr Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile Ser Asp Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Asn Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys Val Arg Asp Lys Ser Met Gly Phe Gly Ala Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Glu Ile Val Leu Thr Gln Ser Pro Thr Thr Met Ala Ala Ser Pro Gly Glu Lys Ile Thr Ile Thr Cys Ser Ala Ser Ser Ser Ile Ser Ser Asn Tyr Leu His Trp Tyr Gln Gln Arg Pro Gly Phe Ser Pro Lys Leu Leu Ile Tyr Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Gly Thr Met Glu Ala Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Gly His Ser Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , VH, VL,"(17/18) one of the antibodies was mab #9, whose heavy chain variable region sequence is shown in seq id no:17 and light chain variable region sequence is shown in seq id no:18."
https://patents.google.com/patent/CN113999303A/en, Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Pro Ser Ser Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Asn Ile Glu Asp Tyr Ala Tyr Tyr Ala Pro Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Asp Leu Lys Val Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Gly Arg Gly Gly Tyr Ala Ala Asp Ile Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser, Asp Val Val Met Thr Gln Thr Ala Ser Pro Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Ser Cys Gln Ser Ser Glu Ser Val Tyr Thr Asn Asn Arg Leu Ser Trp Phe Gln Gln Lys Pro Gly Gln Arg Pro Lys Leu Leu Ile Tyr Arg Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Ile Ile Ser Asp Val Gln Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Ala Gly Val Gly Ser Gly Gly Thr Asp Ile Ala Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , VH, VL,"(7/8) the heavy chain variable region sequence is shown as seq id no:7, and the light chain variable region sequence is shown as seq id no:8."
https://patents.google.com/patent/CN112390879B/en, gaggtgcagc tggtggaaag cggacccggc ctggtcaagc cttctgaaac cctgagcctg acctgcaccg tgtccggcgg ctccatctct agcagcagct actactgggg ctggatcaga cagccacctg gaaaaggcct ggaatggatt ggcagcatct actaccgggg cagcacctac tacaacccca gcctgaaaag cagagtgaca atcagcgtgg acacctcaaa gaaccagttt agccttaagc tgagctctgt gaccgccgcc gacaccgccg tgtactactg cgccagacac gtgcggagtg cttattacta cggcagcggc tcttatcggg acgagggcaa ttggttcgac ccctggggcc agggcaccct ggtcaccgtg tccagc , cagagcgtgc tgacccagcc tccaagcgtg tctggagctc ctggacaaag agtgaccatc agctgtacag gcacaagaag caacatcggc gctggccacg atgtgcactg gtaccagcaa ctgcctggca ccgcccctaa gctgctgatc tacggcaaca acaatagacc ttctggcgtg cccgatagat tctccggagc caagtccggc acaagcgcca gcctggccat caccggcctg caggccgagg acgaggccga ttactattgt cagtcttacg acagaaccct gacaagctac gtgttcggca caggaacaaa ggtgaccgtg ctg , VH nucleotides, VL nucleotides,"(9/10)  the amino acid sequences of the preferred heavy and light chain variable regions are shown as seq id no:7 and 8, respectively, the nucleotide sequences of the preferred heavy and light chain variable regions are shown as seq id no:9 and 10, respectively, and the detailed description is shown in table 1 below."
https://patents.google.com/patent/CN112390879B/en, Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Arg Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Val Arg Ser Ala Tyr Tyr Tyr Gly Ser Gly Ser Tyr Arg Asp Glu Gly Asn Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Thr Arg Ser Asn Ile Gly Ala Gly His Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Asn Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ala Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Arg Thr Leu Thr Ser Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , VH amino acids, VL amino acids,"(7/8) the antibody or antigen-binding fragment thereof targeting sars-cov-2 according to claim 1, wherein the amino acid sequence of vh is as shown in seq id no:7; the amino acid sequence of the vl is shown as seq id no:8."
https://patents.google.com/patent/KR20190122283A/en, Leu Pro Glu Phe Gln Val Gln Leu Gln Gln Ser Gly Gly Gly Leu Val Gln Pro Lys Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ile Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Ser Asn Asn Tyr Ala Thr Tyr Cys Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Gln Ser Met Leu Tyr Leu Gln Met Asn Asn Leu Asn Thr Glu Asp Thr Ala Met Tyr Tyr Cys Val Arg Tyr Tyr Gly Gly Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Arg Ser Ser , Glu Leu Asp Ile Val Met Thr Gln Ser Thr Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Ser Val Asn Asn Phe Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Leu Ala Thr Tyr Tyr Cys His Gln Asn Tyr Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ala Cys Thr , VH, VL,"(7/8)  the monoclonal antibody according to claim 1, wherein the monoclonal antibody is a heavy chain comprising a polypeptide sequence of seq id no:7 and a light chain comprising a polypeptide sequence of seq id no:8."
https://patents.google.com/patent/WO2021224606A1/en, caggtgcagc tggtggagtc tgggggagga ttgatgcagg ctgggggctc tctgagactc tcctgtgcag tctctggacg caccttcagt accgctgcca tgggctggtt ccgccaggct ccagggaagg agcgtgagtt tgtagcagct attaggtgga gtggtggtag cgcatactat gcagactccg tgaagggccg attcaccatc tccagagaca aggccaagaa cacggtatat ctgcaaatga acagcctgaa atatgaggac acggccgttt attactgtgc acggacggag aatgttcggt ccctccttag cgactatgcc acttggcctt atgactactg gggccagggg acccaggtca ccgtctcctc a ,,  NbRBD_H11-D4  ,,"(108) in one embodiment, an anti-sars-cov-2 single domain antibody comprising a polynucleotide sequence having at least 70% identity to a sequence selected from the group consisting of seq id no:108, 109, 110, 111 and 112"
https://patents.google.com/patent/WO2021224606A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Met Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Arg Thr Phe Ser Thr Ala Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Arg Trp Ser Gly Gly Ser Ala Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Lys Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Tyr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gln Thr His Tyr Val Ser Tyr Leu Leu Ser Asp Tyr Ala Thr Trp Pro Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  NbRBD_H11-H4  ,,"(88) in one embodiment, an anti-sars-cov-2 single domain antibody comprising an amino acid sequence having at least 70% identity to seq id no:88"
https://patents.google.com/patent/WO2021224606A1/en, caggtgcagc tggtcgagtc tgggggagga ttgatgcagg ctgggggctc tctgagactc tcctgtgcag tctctggacg caccttcagt accgctgcca tgggctggtt ccgccaggct ccagggaagg agcgtgagtt tgtagcagct attaggtgga gtggtggtag cgcatactat gcagactccg tgaagggccg attcaccatc tccagagaca aggccaagaa cacggtatat ctgcaaatga acagcctgaa atatgaggac acggccgttt attactgtgc acaaacgcat tatgtttctt atctccttag cgactatgcc acttggcctt atgactactg gggccagggg acccaggtca ccgtctcctc a ,,  NbRBD_H11-H4  ,,"(109) in one embodiment, an anti-sars-cov-2 single domain antibody comprising a polynucleotide sequence having at least 70% identity to a sequence selected from the group consisting of seq id no:108, 109, 110, 111 and 112. in one embodiment, the polynucleotide sequence has at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity to a sequence selected from the group consisting of seq id no:108, 109, 110, 111 and 112. in one embodiment, the polynucleotide sequence is selected from the group consisting of seq id no:108, 109, 110, 111 and 112. in one embodiment, the polynucleotide sequence is seq id no:109. "
https://patents.google.com/patent/WO2021224606A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Met Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Arg Thr Phe Ser Thr Ala Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Arg Trp Ser Gly Gly Ser Ala Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Lys Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Tyr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Glu Asn Val Arg Ser Leu Leu Ser Asp Tyr Ala Thr Trp Pro Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  NbRBD_H11-D4  ,,"(87) the anti-sars-cov-2 single domain antibody of claim 8, comprising an amino acid sequence selected from the group consisting of: seq id no:87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 and 99"
https://patents.google.com/patent/CN112940111A/en, atgggcagca gccatcatca tcatcatcac agcagcggcc tggtgccgcg cggcagccat atggctagca tgtcggactc agaagtcaat caagaagcta agccagaggt caagccagaa gtcaagcctg agactcacat caatttaaag gtgtccgatg gatcttcaga gatcttcttc aagatcaaaa agaccactcc tttaagaagg ctgatggaag cgttcgctaa aagacagggt aaggaaatgg actccttaag attcttgtac gacggtatta gaatccaagc tgatcagacc cctgaagatt tggacatgga ggataacgat attattgagg ctcacagaga acagattggt ggatcccagg tgcagctgca ggagtctgga ggaggcttgg tgcaggctgg agggtctctg agactctctt gtgccgccag cggacgtact ttctcttcta acgctatggg ctggttccgc caggctccag ggaaggagcg tgagttcgta gcagcgattt cttctggttc tggttctact aactatgcag actccgtgaa gggccgattc accatctcca gagacaacgc caagaacacg gtgtatcttc aaatgaacag cctgaaacct gaggacacgg ccgtttatta ctgtgcagcc gcttaccgtt acaacggtcg tgactactac gaccgttacg actactgggg tcagggtact caggtcaccg tctcctcagc ggccgcatac ccgtacgacg ttccggacta cggttcctga ctcgag ,, Artificial Sequence (Artificial Sequence),,"(1) the expression cassette sequence of the sumo-nano antibody is shown in seq id no:1, and the amino acid sequence is shown in seq id no:2; also shown in fig. 6, the structural regions of his, sumo, nanobody and ha tag are distinguished by non-gray scale or underline, respectively, and correspond to the gray scale or underline portion of the name."
https://patents.google.com/patent/CN112940111A/en, caggtgcagc tgcaggagtc tggaggaggc ttggtgcagg ctggagggtc tctgagactc tcttgtgccg ccagcggacg tactttctct tctaacgcta tgggctggtt ccgccaggct ccagggaagg agcgtgagtt cgtagcagcg atttcttctg gttctggttc tactaactat gcagactccg tgaagggccg attcaccatc tccagagaca acgccaagaa cacggtgtat cttcaaatga acagcctgaa acctgaggac acggccgttt attactgtgc agccgcttac cgttacaacg gtcgtgacta ctacgaccgt tacgactact ggggtcaggg tactcaggtc accgtctcct ca ,, Artificial Sequence (Artificial Sequence),,"(7) the nanobody based on the s protein of coronavirus of claim 1, characterized in that: the nucleotide sequence of the sdab antibody fragment is shown in seq id no:7."
https://patents.google.com/patent/CN112940111A/en, Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Asn Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Ser Gly Ser Gly Ser Thr Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Tyr Arg Tyr Asn Gly Arg Asp Tyr Tyr Asp Arg Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,"(6) a nanobody based on the s protein of a novel coronavirus, characterized in that: comprises an sdab antibody fragment, wherein the amino acid sequence of the sdab antibody fragment is shown in seq id no:6."
https://patents.google.com/patent/CN112940111A/en, Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro Arg Gly Ser His Met Ala Ser Met Ser Asp Ser Glu Val Asn Gln Glu Ala Lys Pro Glu Val Lys Pro Glu Val Lys Pro Glu Thr His Ile Asn Leu Lys Val Ser Asp Gly Ser Ser Glu Ile Phe Phe Lys Ile Lys Lys Thr Thr Pro Leu Arg Arg Leu Met Glu Ala Phe Ala Lys Arg Gln Gly Lys Glu Met Asp Ser Leu Arg Phe Leu Tyr Asp Gly Ile Arg Ile Gln Ala Asp Gln Thr Pro Glu Asp Leu Asp Met Glu Asp Asn Asp Ile Ile Glu Ala His Arg Glu Gln Ile Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Asn Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Ser Gly Ser Gly Ser Thr Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Tyr Arg Tyr Asn Gly Arg Asp Tyr Tyr Asp Arg Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Ala Ala Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Gly Ser,, Artificial Sequence (Artificial Sequence),,"(2) the expression cassette sequence of the sumo-nano antibody is shown in seq id no:1, and the amino acid sequence is shown in seq id no:2; also shown in fig. 6, the structural regions of his, sumo, nanobody and ha tag are distinguished by non-gray scale or underline, respectively, and correspond to the gray scale or underline portion of the name."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe His Tyr Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Ser Gly Gly Gly Arg Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Leu Gln Gly Ser Leu His Tyr Cys Ser Gly Leu Val Gly Glu Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH12  ,,"(93)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Phe Thr Arg Tyr Pro Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Gly Ser Gly Ile Ile Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Val Asp Asn Ala Pro Thr Ser Ser Leu Pro Leu Thr Pro Gly Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH19  ,,"(100)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Leu Asp Val Thr Gly Arg Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Val Tyr Thr Pro Phe Arg Phe Ala Phe Lys Thr Asp Pro Asp Arg Gln Asp His Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH25  ,,"(106)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Leu Ser Leu Glu His Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Asp Ser Ser Gly Gly Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Leu Gln Gly Ser Tyr Tyr Tyr Thr Ser Leu His Gln Thr Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH2  ,,"(83)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Val Ser Met Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Arg Ser Gly Arg Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Arg Asp Gly Gly Leu His Tyr Ala Leu Tyr Val Glu Ala Ser His Tyr Asn Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH24  ,,"(105)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Ser Leu Asp Gly Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Gly Arg Leu Gly Thr Thr Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Lys Arg Ser Thr Trp Phe Gly Cys Ser Thr Leu Asp Asp Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH7  ,,"(88)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Asp Arg Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Ser Gly Gly Thr Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Gly Thr Gln Leu Arg Tyr Gly Cys Ser Arg Gln Ala Arg Arg Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH8  ,,"(89)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Phe Asp Asp Phe Ala Ile Gly Trp Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ser Ala Arg Gly Ile Val Asn Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Leu Val Gly Leu Asn Asp Arg Ser Leu Pro His Glu Ala Glu Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH15  ,,"(96)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly His Thr Gly Ser Thr Tyr Ile Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Arg Ser Gly Ile Leu Arg Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Arg Asp Ser Leu Thr Gly Val Ile Gly Asn Thr Pro Gly Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH17  ,,"(98)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Gly Asn Tyr Glu Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Arg Ser Gly Val Ile Phe Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Arg Phe Arg Ala Gly Leu Val Gln Ser Leu Cys Gln Ser Thr Pro Glu Phe Tyr Gln Asp Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH5  ,,"(86)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Leu Ser Leu Glu His Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Asp Ser Gly Ala Thr Arg Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ser Ala Thr Pro Gly Ala Phe Arg Thr Cys Ala Phe Arg Asp Phe Ser His Leu Ala Asn Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH1  ,,"(82)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Gly Asn Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Leu Ser Gly Asp Ile Ile Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Pro Phe Pro Ser Leu Leu Tyr Cys Ser Leu Cys Pro Ser Asn Pro Glu Phe Cys Arg His Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH6  ,,"(87)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Asp Tyr Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Pro Ser Gly Thr Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Asn Pro Ser Tyr Tyr Tyr Cys Ser Gly Tyr Pro His Glu Tyr Asp Asp Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH11  ,,"(92)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Val Ser Ser Tyr Val Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Arg Ser Gly Ile Ile Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Gln Thr Gln Val Leu Pro Thr Glu Asp Arg Ser Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH18  ,,"(99)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Ala Thr Ser Asp Ile Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Pro Ser Gly Gly Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Ser Pro Ser Trp His Tyr Cys Ser Gly Tyr Glu His Glu Tyr Asp Asp Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH10  ,,"(91)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Arg Leu Gly Gly Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Gly Ser Gly Ile Ile Ser Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Pro Ser Gly Ser Ser Tyr Gly Ser Arg Arg Leu Pro Cys Gly Ile Asp Ser Gln Asp Tyr Gln Thr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH14  ,,"(95)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Leu Thr Leu Asn Asn Asn Thr Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Pro Ser Gly Ile Val Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Val Leu Gln Trp Asn Gly Ala Gly Leu Pro Ser Pro Leu Gly Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH4  ,,"(85)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Leu Ser Thr Tyr Glu Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Val Thr Pro Thr Gly Phe Gly Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Ser Gly Lys Gly Leu Gly Ser Leu Gln Arg Ser Pro Asp Asp Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH27  ,,"(108)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Phe Lys Ser Tyr His Ile Ala Trp Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ser Leu Thr Gly Ala Ser Ile Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Arg Asp Tyr Ala Ser Ser Leu Tyr Cys Ser Arg Asn Glu Ala Met Tyr Ala Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH13  ,,"(94)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Phe Ser Ser Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Ser Gly Gly Ile Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Asn Arg Gly Arg Phe Thr Gly Trp Arg Ser Leu Thr Asp Tyr Thr Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH20  ,,"(101)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Phe Ser Thr Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Pro Ser Arg Ile Ile Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Asp Ser Ser Tyr Gly Gly Arg Leu Gly Arg Arg Ile Asp Asp Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH21  ,,"(102)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Asp Ser Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Thr Lys His Gly Gly Thr Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Asp His Arg Ala Leu Arg Phe Gly Cys Ala Val Val Pro Gly Pro Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH3  ,,"(84)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Ala Ser Gly Arg Thr Ser Ser Thr Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Thr Trp Ser Gly Gly Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Gly Leu Ser Pro Leu Met Leu Thr Ala Ser Arg Arg Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH23  ,,"(104)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Phe Gly Thr Tyr Arg Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Phe Trp Ser Gly Gly Gly Ala Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Arg Ala Pro Thr Thr Gln Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH26  ,,"(107)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Ser Gly Val Ser Thr Gly Ser Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Tyr Thr Ser Val Gly Ser Ile Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Phe Phe Val Pro Phe Gly Asp Thr Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH22  ,,"(103)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Asp Tyr Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Ser Ser Gly Thr Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Leu Gln Gly Ser Tyr Tyr Tyr Thr Ser Leu His Gln Thr Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH9  ,,"(90)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021244089A1/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ser Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Phe Ser Ser Leu Asp Gly Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Thr Arg Gly Ser Ser Trp Tyr Trp Tyr Arg Pro Ser Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  VHH16  ,,"(97)  as an example of this scheme, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN114106160A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Glu Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Val Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile Gly Tyr Phe Asn Pro Tyr Asn Asp Asp Ala Glu Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr Met Val Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Cys Leu Arg Gln Glu Thr Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Asn Tyr Gly Phe Ser Leu Met Asn Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Glu Ala Ser Asn Gln Gly Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His Pro Met Glu Glu Asp Asp Thr Ala Met Tyr Phe Cys His Gln Ser Lys Glu Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , murine antibody S1B-48-2 heavy chain variable region amino acid sequence (), murine antibody S1B-48-2 light chain variable region amino acid sequence (),"(19/20) (i) the vh domain comprises the amino acid sequence as set forth in seq id no:19, or a sequence that is substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical or has one or more amino acid substitutions (e.g., conservative substitutions)) to the sequences described above; and the vl domain comprises the amino acid sequence as set forth in seq id no:20, or a sequence that is substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical or has one or more amino acid substitutions (e.g., conservative substitutions)) to the sequences described above;"
https://patents.google.com/patent/CN114106160A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Val Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Phe Asn Pro Tyr Asn Asp Asp Ala Glu Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Thr Ser Thr Ala Tyr Met Lys Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Leu Arg Gln Glu Thr Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Arg Ala Ser Glu Ser Val Asp Asn Tyr Gly Phe Ser Leu Met Asn Trp Phe Gln Gln Lys Pro Gly Lys Pro Pro Lys Leu Leu Ile Tyr Glu Ala Ser Asn Gln Gly Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Leu Gln Ala Glu Asp Val Ala Val Tyr Phe Cys His Gln Ser Lys Glu Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , humanized antibody hS1B-48-2 heavy chain amino acid sequence (), humanized antibody hS1B-48-2 light chain amino acid sequence (),"(25/26) 9. the antibody of claim 7 or 8, wherein the antibody has a full-length amino acid sequence, its heavy chain has an amino acid sequence as set forth in seq id no:25, and its light chain has an amino acid sequence as set forth in seq id no:26"
https://patents.google.com/patent/CN114106160A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Glu Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Val Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile Gly Tyr Phe Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Cys Leu Arg Gln Arg Ala Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Asn Tyr Gly Phe Ser Phe Met Asn Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Glu Ala Ser Asn Gln Gly Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His Pro Met Glu Glu Asp Asp Thr Ala Met Tyr Phe Cys His Gln Ser Lys Glu Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , murine antibody S1B-64-2 heavy chain variable region amino acid sequence (), murine antibody S1B-64-2 light chain variable region amino acid sequence (),"(23/24) (ii) the vh domain comprises the amino acid sequence as set forth in seq id no:23, or a sequence that is substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical or has one or more amino acid substitutions (e.g., conservative substitutions)) to the sequences described above; and the vl domain comprises the amino acid sequence as set forth in seq id no:24, or a sequence that is substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical or has one or more amino acid substitutions (e.g., conservative substitutions)) to the sequences described above."
https://patents.google.com/patent/CN114106160A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Val Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Phe Asn Pro Tyr Asn Asp Asp Ala Glu Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Thr Ser Thr Ala Tyr Met Lys Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Leu Arg Gln Glu Thr Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Arg Ala Ser Glu Ser Val Asp Asn Tyr Gly Phe Ser Leu Met Asn Trp Phe Gln Gln Lys Pro Gly Lys Pro Pro Lys Leu Leu Ile Tyr Glu Ala Ser Asn Gln Gly Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Leu Gln Ala Glu Asp Val Ala Val Tyr Phe Cys His Gln Ser Lys Glu Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , humanized antibody hS1B-48-2 heavy chain variable region amino acid sequence (), humanized antibody hS1B-48-2 light chain variable region amino acid sequence (),"(21/22) the vh domain comprises the amino acid sequence as set forth in seq id no:21, or a sequence that is substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical or has one or more amino acid substitutions (e.g., conservative substitutions)) to the sequences described above; and the vl domain comprises the amino acid sequence as set forth in seq id no:22, or a sequence that is substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical or has one or more amino acid substitutions (e.g., conservative substitutions)) to the sequences described above."
https://patents.google.com/patent/CN112341541A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Glu Ala Ser Glu Ile Ile Val Asn Arg Asn Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ile Ile Tyr Pro Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Met Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Tyr Gly Asp Phe Tyr Val Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Val Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Gly Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(2/1) the amino acid sequences of the light and heavy chain variable regions of antibody ncov-163 are shown in seq id no:1 and 2, respectively."
https://patents.google.com/patent/WO2021228904A1/en, Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ala Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Thr Gly Tyr Cys Gly Asp Asp Cys Tyr Ile Lys Leu Ile Arg Gly Gly Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Gly Gln Tyr Tyr Asp Phe Trp Ser Gly Tyr Leu Gly Ala Arg Thr Asn Pro His Tyr Tyr Tyr Tyr Met Asp Val Trp Gly Lys Gly Thr Met Val Thr Val Ser Ser , 002_P2A5 Heavy Chain  , 001_P1D6 Heavy Chain  ,"(329/17) in preferred embodiments, the hcvr/lcvr amino acid sequence pair is selected from seq id no:329/333 and 137/141. in another preferred embodiment, said hcvr/lcvr amino acid sequence pair is selected from one of seq id no:17/21, 121/125, 137/141, 161/165, 169/173, 193/197, 241/245, 265/269, 329/333, 345/349, 437/441, 517/521 (e.g., 001_p1d6, 17/"
https://patents.google.com/patent/WO2021228904A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Glu Tyr Tyr Asp Ile Leu Thr Gly Tyr Leu Ala Pro Thr His Tyr Tyr Tyr Tyr Tyr Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Val Gln Leu Val Gln Ser Gly Thr Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Pro Gly Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Val Ala Lys Ser Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Ser Ser Ile Ser Thr Val Tyr Leu Asp Val Thr Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Trp Ala Thr Val Ser Gly Thr Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , 001_P2C9 Heavy Chain  , 001_P1G11 Heavy Chain  ,"(161/89) in another preferred embodiment said first anti-sars-cov-2-s antibody or antigen-binding fragment thereof comprises at least the hcvr/lcvr amino acid sequence pair is seq id no:161/165, 169/173, 193/197, 501/505 and said anti-sars-cov-2-s antibody or antigen binding fragment thereof comprises at least the hcvr/lcvr amino acid sequence pair is seq id no:89/93, 121/125, 137/141, 225/229, 241/245, 249/253, 265/269, 297/301, 313/317, 329/333, 345/349, 369/373, 517/521"
https://patents.google.com/patent/WO2021228904A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Glu Trp Ala Ala Ala Gly Thr Phe Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly His Tyr Pro Tyr Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Arg Thr Leu Ile Tyr Asp Thr Ser Asn Lys Arg Ser Trp Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Ala Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Leu Leu Ser Tyr Ser Gly Val Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , 001_P2C1 Heavy Chain  , 001_P2C1_LC Light Chain  ,"(137/141) in a preferred embodiment, said antibody according to the invention comprises a hcvr having the amino acid sequence of seq id no:137 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity and a lcvr having the amino acid sequence of seq id no:141 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity"
https://patents.google.com/patent/WO2021228904A1/en, Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ala Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Thr Gly Tyr Cys Gly Asp Asp Cys Tyr Ile Lys Leu Ile Arg Gly Gly Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser Asp Gly Asn Thr Phe Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr Gln Val Ser Asn Arg Asp Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Arg Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , 002_P2A5 Heavy Chain  , 002_P2A5_KC Light Chain  ,"(329/333) in a preferred embodiment, said antibody according to the invention comprises a hcvr having the amino acid sequence of seq id no:329 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity and a lcvr having the amino acid sequence of seq id no:333 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity"
https://patents.google.com/patent/WO2021228904A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Gly Gln Tyr Tyr Asp Phe Trp Ser Gly Tyr Leu Gly Ala Arg Thr Asn Pro His Tyr Tyr Tyr Tyr Met Asp Val Trp Gly Lys Gly Thr Met Val Thr Val Ser Ser , Glu Val Gln Leu Val Gln Ser Gly Thr Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Pro Gly Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Val Ala Lys Ser Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Ser Ser Ile Ser Thr Val Tyr Leu Asp Val Thr Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Trp Ala Thr Val Ser Gly Thr Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , 001_P1D6 Heavy Chain  , 001_P1G11 Heavy Chain  ,"(17/89) in another preferred embodiment said first anti-sars-cov-2-s antibody or antigen-binding fragment thereof comprises at least the hcvr/lcvr amino acid sequence pair of seq id no:17/21 , 161/165, 169/173, 501/505 and said anti-sars-cov- 2-s antibody or antigen-binding fragment thereof comprises at least the hcvr/lcvr amino acid sequence pair selected from seq id no:89/93, 121/125, 137/141 , 225/229, 241/245, 249/253, 265/269, 297/301, 313/317, 329/333, 345/349, 369/373 and 517/521"
https://patents.google.com/patent/CN113667016A/en, Glu Val Gln Leu Val Gln Ser Gly Thr Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Ile Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),"(21/22) in one embodiment, the antibody is cr3022, the heavy chain has the amino acid sequence shown in seq id no:21, and the light chain has the amino acid sequence shown in seq id no:22."
https://patents.google.com/patent/CN113667016A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Leu Gly Phe Gly Glu Leu Phe Arg Lys Thr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Ala Ala Ser Thr Arg Ala Thr Ala Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Tyr Asn Lys Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),"(11/16) in one embodiment, the antibody is 89c8, the amino acid sequence of its heavy chain is set forth in seq id no:11, and the amino acid sequence of its light chain is set forth in seq id no:16."
https://patents.google.com/patent/US7750123B2/en,Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly LysSer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Ser TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValAla Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Arg Ser Tyr Tyr Leu Asp Tyr Trp Gly Gln Gly Thr LeuVal Thr Val Ser Ser ,Thr Thr Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly GluArg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Arg Ser Asn LeuAla Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Pro Leu Ile TyrAsp Ala Ser Thr Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly SerGly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro GluAsp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro ThrPhe Gly Gln Gly Thr Lys Val Glu Val Lys,12117PRTHomo sapiens 12,20106PRTHomo sapiens 20,"(12/20) a monoclonal antibody which neutralizes sars-cov, wherein said monoclonal antibody binds to an epitope on the spike protein (s) of sars-cov consisting of amino acids 324 to 503, wherein the antibody neutralizes sars-cov, and wherein said monoclonal antibody comprises a heavy chain variable region (vh) comprising the amino acid sequence of seq id no:12 and a light chain variable region (vl) comprising the amino acid sequence of seq id no:20."
https://patents.google.com/patent/CN113956352A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Ile Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Leu Tyr Ser Gly Gly Ser Thr Asp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Val Leu Thr Gln Thr Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Glu Leu Ser Thr Tyr Pro Val Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , R44 heavy chain full length-IgG1(Artificial Sequence), R44 light chain full length(Artificial Sequence),"(33/35) the monoclonal antibody of claim 17, wherein the amino acid sequence of the heavy chain thereof is identical to the amino acid sequence of seq id no:33, and the amino acid sequence of the light chain is identical to that of seq id no:35 are shown as being identical."
https://patents.google.com/patent/CN113956352A/en, Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Val Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Thr Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Asp Val Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu Pro Arg, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Gly Tyr Ser Gly Ser Gly Ala Asn Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , R157 light chain variable(Artificial Sequence), R157 heavy chain variable(Artificial Sequence),"(27/25) in another preferred embodiment, the present invention provides a monoclonal antibody, or antigen-binding portion thereof, targeting the receptor binding domain of the novel coronavirus sars-cov-2 spike protein, comprising heavy and light chain variable region sequences, wherein the amino acid sequence of the heavy chain variable region is identical to the amino acid sequence of seq id no:25, the amino acid sequence of the light chain variable region is identical to seq id no:27 shown as consistent."
https://patents.google.com/patent/CN113956352A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ile Gly Tyr Ser Ser Ser Gly Ser Asn Tyr Tyr Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Pro Arg, R14 heavy chain variable(Artificial Sequence), R14 light chain variable(Artificial Sequence),"(17/19) the monoclonal antibody or antigen-binding portion thereof according to claim 6, wherein the amino acid sequence of the heavy chain variable region is identical to the amino acid sequence of seq id no:17, the amino acid sequence of the light chain variable region is identical to seq id no:19 are shown as being identical."
https://patents.google.com/patent/CN113956352A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Ile Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Leu Tyr Ser Gly Gly Ser Thr Asp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Thr Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Glu Leu Ser Thr Tyr Pro Val Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , R44 heavy chain variable(Artificial Sequence), R44 light chain variable(Artificial Sequence),"(21/23) the monoclonal antibody or antigen-binding portion thereof according to claim 6, wherein the amino acid sequence of the heavy chain variable region is identical to the amino acid sequence of seq id no:21, the amino acid sequence of the variable region of the light chain is identical to that of seq id no:23, shown in agreement."
https://patents.google.com/patent/CN113956352A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Gly Tyr Ser Gly Ser Gly Ala Asn Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Val Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Thr Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Asp Val Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu Pro Arg, R157 heavy chain variable(Artificial Sequence), R157 light chain variable(Artificial Sequence),"(25/27) the monoclonal antibody or antigen-binding portion thereof according to claim 6, wherein the amino acid sequence of the heavy chain variable region is identical to the amino acid sequence of seq id no:25, the amino acid sequence of the light chain variable region is identical to seq id no:27 shown as consistent."
https://patents.google.com/patent/CN113956352A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Gly Tyr Ser Gly Ser Gly Ala Asn Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Val Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Thr Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Asp Val Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu Pro Arg Thr Ala Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser , R157 heavy chain full length-IgG1(Artificial Sequence), R157 light chain full length(Artificial Sequence),"(37/39) the monoclonal antibody of claim 17, wherein the amino acid sequence of the heavy chain thereof is identical to the amino acid sequence of seq id no:37, and the amino acid sequence of the light chain is identical to that of seq id no:39 are shown as being identical."
https://patents.google.com/patent/CN113956352A/en, Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Pro Arg, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ile Gly Tyr Ser Ser Ser Gly Ser Asn Tyr Tyr Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , R14 light chain variable(Artificial Sequence), R14 heavy chain variable(Artificial Sequence),"(19/17) in a preferred embodiment, the present invention provides a monoclonal antibody, or antigen-binding portion thereof, targeting the receptor binding domain of the novel coronavirus sars-cov-2 spike protein, comprising heavy and light chain variable region sequences, wherein the amino acid sequence of the heavy chain variable region is identical to the amino acid sequence of seq id no:17, the amino acid sequence of the light chain variable region is identical to seq id no:19 are shown as being identical."
https://patents.google.com/patent/CN113956352A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ile Gly Tyr Ser Ser Ser Gly Ser Asn Tyr Tyr Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Pro Arg Thr Ala Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser , R14 heavy chain full length-IgG1(Artificial Sequence), R14 light chain full length(Artificial Sequence),"(29/31) the monoclonal antibody of claim 17, wherein the amino acid sequence of the heavy chain thereof is identical to the amino acid sequence of seq id no:29, and the amino acid sequence of the light chain is identical to that of seq id no:31 are shown as being identical."
https://patents.google.com/patent/CN113956352A/en, Asp Ile Val Leu Thr Gln Thr Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Glu Leu Ser Thr Tyr Pro Val Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Ile Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Leu Tyr Ser Gly Gly Ser Thr Asp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , R44 light chain variable(Artificial Sequence), R44 heavy chain variable(Artificial Sequence),"(23/21) in another preferred embodiment, the present invention provides a monoclonal antibody, or antigen-binding portion thereof, targeting the receptor binding domain of the novel coronavirus sars-cov-2 spike protein, comprising heavy and light chain variable region sequences, wherein the amino acid sequence of the heavy chain variable region is identical to the amino acid sequence of seq id no:21, the amino acid sequence of the variable region of the light chain is identical to that of seq id no:23, shown in agreement."
https://patents.google.com/patent/CN112979793A/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/CN112979793A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Arg Gly Pro Thr Gly Trp Thr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Asn Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ser Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Arg Ser Asn Trp Lys Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) preferably, the antibody comprises the heavy chain variable region shown in seq id no:4 and the light chain variable region shown in seq id no:8."
https://patents.google.com/patent/CN112159469A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Glu Ile Gln Pro Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Ser Pro Gly Gln Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Phe Gly Gly Tyr Asn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser Asn Asn Phe Asp Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser , Artificial Sequence, Artificial Sequence,"(49/50) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:49, and the light chain amino acid sequence is shown as seq id no:50"
https://patents.google.com/patent/CN112159469A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Ile Asp Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence, Artificial Sequence,"(19/20) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:19, and the light chain amino acid sequence is shown as seq id no:20"
https://patents.google.com/patent/CN112159469A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Tyr Gly Asp Tyr Glu Asn Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys, Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Gly Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Leu Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence, Artificial Sequence,"(69/70) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:69, and the light chain amino acid sequence is shown as seq id no:70."
https://patents.google.com/patent/CN112159469A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Val Ser Ser Asn Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Val Ser Leu Leu Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Ile Thr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence, Artificial Sequence,"(9/10) in a preferred embodiment of the invention, the heavy chain amino acid sequence of the antibody or antigen binding fragment thereof is set forth in seq id no:9, and the light chain amino acid sequence is set forth in seq id no:10"
https://patents.google.com/patent/CN112159469A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Phe Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Cys Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Met Leu His Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln His Tyr Asp Asn Leu Pro Gly Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence, Artificial Sequence,"(59/60) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:59, and the light chain amino acid sequence is shown as seq id no:60"
https://patents.google.com/patent/CN112159469A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Val Ala Thr Ile Arg Asp Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys, Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence, Artificial Sequence,"(39/40) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:39, and the light chain amino acid sequence is shown as seq id no:40"
https://patents.google.com/patent/CN112159469A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Ala Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Ser Ser Ala Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Gly Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence, Artificial Sequence,"(29/30) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:29, and the light chain amino acid sequence is shown as seq id no:30"
https://patents.google.com/patent/CN113671184A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asp Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Val Ser Gly Ile Asn Trp Asn Gly Gly Arg Thr Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Tyr Leu Gln His Ser Tyr Phe Asp Leu Leu Leu Pro Asn Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Ile Val Val Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Arg Arg Leu Glu Ala Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , 12-5 VH, 12-5 VL,"(24/25) the vh comprises an amino acid sequence shown as seq id no:24, and the vl comprises an amino acid sequence shown as seq id no:25"
https://patents.google.com/patent/CN113671184A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Glu Ile Asn Val Ser Ser Asn Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Leu Tyr Ala Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Phe Tyr Tyr Cys Ala Arg Glu Ala Tyr Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Leu Leu Asn Ser Tyr Pro Pro Ser Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , 32-1 VH, 32-1 VL,"(21/22) the vh comprises an amino acid sequence shown as seq id no:21, and the vl comprises an amino acid sequence shown as seq id no:22"
https://patents.google.com/patent/CN113671184A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Ile Gly Tyr Ile His Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Arg Ser Arg Leu Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gln Gly Tyr Ser Ser Gly Trp Pro Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Ile Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Asp Ile Pro Ala Arg Phe Ser Asp Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Gly Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , 12-8 VH, 12-8 VL,"(27/28) the vh comprises an amino acid sequence shown as seq id no:27, and the vl comprises an amino acid sequence shown as seq id no:28."
https://patents.google.com/patent/CN114106161A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Phe Leu Ile Glu Trp Val Arg Glu Ala Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile Asn Pro Gly Ser Gly Asp Thr Asn Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys Ala Arg Gln Leu Gly Leu Pro Gly Phe Val Tyr Trp Gly Arg Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr Leu Thr Trp Leu Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile Tyr Arg Ala Asn Arg Leu Val Glu Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Gln Asp Phe Thr Leu Lys Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln His Asp Glu Phe Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , humanized antibody hS1B-73-3 heavy chain variable region amino acid sequence (), humanized antibody hS1B-73-3 light chain variable region amino acid sequence (),"(21/22) the vh domain comprises the amino acid sequence as set forth in seq id no:21, or a sequence that is substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical or has one or more amino acid substitutions (e.g., conservative substitutions)) to the sequences described above; and the vl domain comprises the amino acid sequence as set forth in seq id no:22, or a sequence that is substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical or has one or more amino acid substitutions (e.g., conservative substitutions)) to the sequences described above."
https://patents.google.com/patent/CN114106161A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Phe Leu Ile Glu Trp Val Arg Glu Ala Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile Asn Pro Gly Ser Gly Asp Thr Asn Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys Ala Arg Gln Leu Gly Leu Pro Gly Phe Val Tyr Trp Gly Arg Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr Leu Thr Trp Leu Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile Tyr Arg Ala Asn Arg Leu Val Glu Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Gln Asp Phe Thr Leu Lys Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln His Asp Glu Phe Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , humanized antibody hS1B-73-3 heavy chain amino acid sequence (), humanized antibody hS1B-73-3 light chain amino acid sequence (),"(28/29) 9. the antibody of claim 7 or 8, wherein the antibody has a full-length amino acid sequence, its heavy chain has an amino acid sequence as set forth in seq id no:28, and its light chain has an amino acid sequence as set forth in seq id no:29"
https://patents.google.com/patent/CN114106161A/en, Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Thr Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Ala Phe Thr Asn Phe Leu Ile Glu Trp Val Lys Glu Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile Asn Pro Gly Ser Gly Asp Thr Asn Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Val Tyr Met Gln Leu Ser Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Phe Cys Ala Arg Gln Leu Gly Leu Pro Gly Phe Val Tyr Trp Gly Arg Gly Thr Leu Val Thr Val Ser , Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Val Ser Leu Gly Glu Arg Val Thr Ile Ser Cys Lys Ala Ser Gln Asp Ile Tyr Ser Tyr Leu Thr Trp Leu Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Gln Asp Phe Ser Leu Thr Ile Arg Ser Leu Glu Tyr Glu Asp Met Gly Val Tyr Phe Cys Leu Gln His Asp Glu Phe Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Arg , murine antibody S1B-34-4 heavy chain variable region amino acid sequence (), murine antibody S1B-34-4 light chain variable region amino acid sequence (),"(17/18) (ii) the vh domain comprises the amino acid sequence as set forth in seq id no:17, or a sequence that is substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical or has one or more amino acid substitutions (e.g., conservative substitutions)) to the sequences described above; and the vl domain comprises the amino acid sequence as set forth in seq id no:18, or a sequence that is substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical or has one or more amino acid substitutions (e.g., conservative substitutions)) to the sequences described above;"
https://patents.google.com/patent/CN114106161A/en, Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Thr Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Ala Phe Thr Asn Phe Leu Ile Glu Trp Val Lys Glu Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile Asn Pro Gly Ser Gly Asp Thr Asn Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Val Tyr Met Gln Leu Ser Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Phe Cys Ala Arg Gln Leu Gly Leu Pro Gly Phe Val Tyr Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Val Ser Leu Gly Glu Arg Val Thr Ile Ser Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr Leu Thr Trp Leu Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Gln Asp Phe Ser Leu Thr Ile Arg Ser Leu Glu Tyr Glu Asp Met Gly Val Tyr Tyr Cys Leu Gln His Asp Glu Phe Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Arg , murine antibody S1B-73-3 heavy chain variable region amino acid sequence (), murine antibody S1B-73-3 light chain variable region amino acid sequence (),"(15/16) (i) the vh domain comprises the amino acid sequence as set forth in seq id no:15, or a sequence that is substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical or has one or more amino acid substitutions (e.g., conservative substitutions)) to the sequences described above; and the vl domain comprises the amino acid sequence as set forth in seq id no:16, or a sequence that is substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical or has one or more amino acid substitutions (e.g., conservative substitutions)) to the sequences described above;"
https://patents.google.com/patent/CN114106161A/en, Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Ala Phe Thr Asn Phe Leu Ile Glu Trp Val Lys Glu Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile Asn Pro Gly Ser Gly Asp Thr Asn Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Val Tyr Met Gln Leu Ser Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Phe Cys Ala Arg Gln Leu Gly Leu Pro Gly Phe Val Tyr Trp Gly Arg Gly Thr Leu Val Thr Val Ser , Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly Glu Arg Val Thr Ile Ser Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr Leu Thr Trp Leu Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Gln Asp Phe Ser Leu Thr Ile Ser Ser Leu Glu Tyr Glu Asp Met Gly Val Tyr Tyr Cys Leu Gln His Asp Glu Phe Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Arg , murine antibody S1B-8-2 heavy chain variable region amino acid sequence (), murine antibody S1B-8-2 light chain variable region amino acid sequence (),"(19/20) (iii) the vh domain comprises the amino acid sequence as set forth in seq id no:19, or a sequence that is substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical or has one or more amino acid substitutions (e.g., conservative substitutions)) to the sequences described above; and the vl domain comprises the amino acid sequence as set forth in seq id no:20, or a sequence that is substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical or has one or more amino acid substitutions (e.g., conservative substitutions)) to the sequences described above."
https://patents.google.com/patent/CN111748032B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/CN111748032B/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Gly Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Gly Trp Ser Val Ser Pro Leu Lys Tyr Asn Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Ser Ile Ser Cys Ser Gly Ser Thr Ser Ser Ile Gly Arg Asn Thr Val Ser Trp Phe Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Glu Tyr Tyr Cys Ser Ala Trp His Asp Thr Leu Asn Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) the monoclonal antibody according to claim 1, which comprises a heavy chain variable region consisting of the amino acid sequence shown in seq id no:4 and a light chain variable region consisting of the amino acid sequence shown in seq id no:8."
https://patents.google.com/patent/CN112552399B/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Phe Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala His Leu Gly Gly Phe Ala Asp Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Ala Gly Gln Ala Pro Arg Val Leu Ile Tyr Asp Ala Phe Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Arg Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , synthetic, synthetic,(27/28)  a heavy chain variable region comprising the sequence of seq id no:27 and a light chain variable region comprising the sequence of seq id no:28.
https://patents.google.com/patent/CN112552399B/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Asn Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Arg Ser Ala Tyr Gly Asp Lys Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Gln Glu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , synthetic, synthetic,(17/18)  b) a heavy chain variable region comprising the sequence of seq id no:17 and a light chain variable region comprising the sequence of seq id no:18
https://patents.google.com/patent/CN112552399B/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Ser Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Ala Asn Pro Gly Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Phe Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Arg Val Thr Ile His Tyr Asp Ile Leu Thr Gly Tyr Tyr Ser Asn Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Ala Val Ser Ser, Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Thr Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Ala Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Thr Thr Phe Met Tyr Thr Phe Gly Gln Gly Thr Met Leu Glu Ile Lys , synthetic, synthetic,(7/8)  a heavy chain variable region comprising the sequence of seq id no:7 and a light chain variable region comprising the sequence of seq id no:8; 
https://patents.google.com/patent/CN113943368A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Val Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Ser Gly Thr Ile Asp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Phe Tyr Tyr Cys Thr Lys Asp His Leu Gly Glu Leu Ser Ser Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Pro Val Leu Thr Gln Ser Pro Ser Ala Ser Ala Ser Leu Gly Asp Ser Val Lys Leu Thr Cys Thr Leu Ser Ser Gly His Ser Ser Tyr Ala Ile Ala Trp His Gln Gln Gln Pro Glu Lys Gly Pro Arg Tyr Leu Met Lys Leu Asn Ser Asp Gly Arg His Ser Lys Gly Asp Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Ala Glu Arg Tyr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Thr Trp Gly Thr Gly Ile His Val Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(7/8)  preferably, it comprises: vh shown as seq id no:7 and/or vl shown as seq id no:8."
https://patents.google.com/patent/WO2021244852A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Val Ala Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys ,  VH STE90-C11  ,  VL STE90-C11  ,(1305/1309)  a heavy chain variable region of the amino acid sequence in seq id no:1305 and a light chain variable region of the amino acid sequence in seq id no:1309
https://patents.google.com/patent/WO2021244852A1/en, Gln Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gln Ile Trp Ala Tyr Asp Ser Ser Gly Tyr Pro Val Pro Ala Glu Tyr Phe Gln His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Gly Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gln Leu Pro Ser Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  YU505-A02 VH complete PRT  ,  YU505-A02 VL complete PRT  ,(926/928)  a heavy chain variable region of the amino acid sequence in seq id no:926 and a light chain variable region of the amino acid sequence in seq id no:928
https://patents.google.com/patent/WO2021244852A1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Val Met Gly Leu Asp Val Trp Gly Lys Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Gly Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gln Leu Pro Ser Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly , Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Ile Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  YU536-D04 VH complete PRT  ,  YU536-D04 VL complete PRT  ,(366/368)  a heavy chain variable region of the amino acid sequence in seq id no:366 and a light chain variable region of the amino acid sequence in seq id no:368
https://patents.google.com/patent/WO2021244852A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ser Ile Val Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Phe Met Glu Leu Ser Asn Leu Lys Ser Glu Asp Thr Ala Val Tyr Phe Cys Ala Arg Ser Leu Gly Ala Thr Arg Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Gly Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gln Leu Pro Ser Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly , Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Glu Ala Pro Arg Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Ala Val Asn Trp Tyr Gln Gln Leu Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Tyr Asp Asp Leu Leu Pro Ser Gly Val Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  YU505-E01 VH complete PRT  ,  YU505-E01 VL complete PRT  ,(1066/1068)  a heavy chain variable region of the amino acid sequence in seq id no:1066 and a light chain variable region of the amino acid sequence in seq id no:1068
https://patents.google.com/patent/WO2021244852A1/en, Asp Ile Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Val Ala Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser ,  VL STE90-C11  ,  VH STE90-C11  ,(1309/1305)  with an antibody comprising a heavy  chain variable region of the amino acid sequence in seq id no:1305; and a light chain variable region of the amino acid sequence in seq id no:1309 or with an antibody comprising a heavy chain variable region of the amino acid sequence in seq id no:
https://patents.google.com/patent/WO2021244852A1/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Met Ser Tyr Asp Gly Ser Lys Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Gln Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Gly Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gln Leu Pro Ser Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Ile Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Ala Tyr Tyr Cys His Val Trp Asp Ser Ser Ser Asp His Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  YU505-F05 VH complete PRT  ,  YU505-F05 VL complete PRT  ,(1166/1168)  a heavy chain variable region of the amino acid sequence in seq id no:1166 and a light chain variable region of the amino acid sequence in seq id no:1168
https://patents.google.com/patent/WO2021244852A1/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Ala Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Glu Ser Gly Ser Pro Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Gly Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gln Leu Pro Ser Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Thr Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Ser Ser Leu Ser Val Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  YU537-H11 VH complete PRT  ,  YU537-H11 VL complete PRT  ,(406/408)  and/or a heavy chain variable region of the amino acid sequence in seq id no:406 and a light chain variable region of the amino acid sequence in seq id no:408
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe His Tyr Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Ser Gly Gly Gly Arg Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Leu Gln Gly Ser Leu His Tyr Cys Ser Gly Leu Val Gly Glu Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH12,,"(93) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Phe Thr Arg Tyr Pro Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Gly Ser Gly Ile Ile Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Val Asp Asn Ala Pro Thr Ser Ser Leu Pro Leu Thr Pro Gly Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH19,,"(100) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Leu Asp Val Thr Gly Arg Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Val Tyr Thr Pro Phe Arg Phe Ala Phe Lys Thr Asp Pro Asp Arg Gln Asp His Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH25,,"(106) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Leu Ser Leu Glu His Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Asp Ser Ser Gly Gly Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Leu Gln Gly Ser Tyr Tyr Tyr Thr Ser Leu His Gln Thr Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH2,,"(83) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Val Ser Met Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Arg Ser Gly Arg Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Arg Asp Gly Gly Leu His Tyr Ala Leu Tyr Val Glu Ala Ser His Tyr Asn Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH24,,"(105) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Ser Leu Asp Gly Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Gly Arg Leu Gly Thr Thr Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Lys Arg Ser Thr Trp Phe Gly Cys Ser Thr Leu Asp Asp Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH7,,"(88) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Asp Arg Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Ser Gly Gly Thr Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Gly Thr Gln Leu Arg Tyr Gly Cys Ser Arg Gln Ala Arg Arg Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH8,,"(89) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Phe Asp Asp Phe Ala Ile Gly Trp Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ser Ala Arg Gly Ile Val Asn Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Leu Val Gly Leu Asn Asp Arg Ser Leu Pro His Glu Ala Glu Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH15,,"(96) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly His Thr Gly Ser Thr Tyr Ile Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Arg Ser Gly Ile Leu Arg Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Arg Asp Ser Leu Thr Gly Val Ile Gly Asn Thr Pro Gly Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH17,,"(98) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Gly Asn Tyr Glu Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Arg Ser Gly Val Ile Phe Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Arg Phe Arg Ala Gly Leu Val Gln Ser Leu Cys Gln Ser Thr Pro Glu Phe Tyr Gln Asp Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser,, VHH5,,"(86) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Leu Ser Leu Glu His Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Asp Ser Gly Ala Thr Arg Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ser Ala Thr Pro Gly Ala Phe Arg Thr Cys Ala Phe Arg Asp Phe Ser His Leu Ala Asn Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH1,,"(82) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Gly Asn Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Leu Ser Gly Asp Ile Ile Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Pro Phe Pro Ser Leu Leu Tyr Cys Ser Leu Cys Pro Ser Asn Pro Glu Phe Cys Arg His Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser,, VHH6,,"(87) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Asp Tyr Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Pro Ser Gly Thr Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Asn Pro Ser Tyr Tyr Tyr Cys Ser Gly Tyr Pro His Glu Tyr Asp Asp Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH11,,"(92) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Val Ser Ser Tyr Val Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Arg Ser Gly Ile Ile Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Gln Thr Gln Val Leu Pro Thr Glu Asp Arg Ser Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH18,,"(99) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Ala Thr Ser Asp Ile Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Pro Ser Gly Gly Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Ser Pro Ser Trp His Tyr Cys Ser Gly Tyr Glu His Glu Tyr Asp Asp Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH10,,"(91) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Arg Leu Gly Gly Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Gly Ser Gly Ile Ile Ser Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Pro Ser Gly Ser Ser Tyr Gly Ser Arg Arg Leu Pro Cys Gly Ile Asp Ser Gln Asp Tyr Gln Thr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH14,,"(95) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Leu Thr Leu Asn Asn Asn Thr Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Pro Ser Gly Ile Val Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Val Leu Gln Trp Asn Gly Ala Gly Leu Pro Ser Pro Leu Gly Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH4,,"(85) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Leu Ser Thr Tyr Glu Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Val Thr Pro Thr Gly Phe Gly Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Ser Gly Lys Gly Leu Gly Ser Leu Gln Arg Ser Pro Asp Asp Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH27,,"(108) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Phe Lys Ser Tyr His Ile Ala Trp Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ser Leu Thr Gly Ala Ser Ile Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Arg Asp Tyr Ala Ser Ser Leu Tyr Cys Ser Arg Asn Glu Ala Met Tyr Ala Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH13,,"(94) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Phe Ser Ser Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Ser Gly Gly Ile Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Asn Arg Gly Arg Phe Thr Gly Trp Arg Ser Leu Thr Asp Tyr Thr Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH20,,"(101) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Phe Ser Thr Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Pro Ser Arg Ile Ile Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Asp Ser Ser Tyr Gly Gly Arg Leu Gly Arg Arg Ile Asp Asp Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH21,,"(102) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Asp Ser Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Thr Lys His Gly Gly Thr Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Asp His Arg Ala Leu Arg Phe Gly Cys Ala Val Val Pro Gly Pro Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH3,,"(84) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Ala Ser Gly Arg Thr Ser Ser Thr Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Thr Trp Ser Gly Gly Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Gly Leu Ser Pro Leu Met Leu Thr Ala Ser Arg Arg Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH23,,"(104) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Phe Gly Thr Tyr Arg Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Phe Trp Ser Gly Gly Gly Ala Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Arg Ala Pro Thr Thr Gln Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH26,,"(107) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Ser Gly Val Ser Thr Gly Ser Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Tyr Thr Ser Val Gly Ser Ile Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Phe Phe Val Pro Phe Gly Asp Thr Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH22,,"(103) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Asp Tyr Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Ser Ser Gly Thr Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Leu Gln Gly Ser Tyr Tyr Tyr Thr Ser Leu His Gln Thr Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH9,,"(90) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ser Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Phe Ser Ser Leu Asp Gly Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Thr Arg Gly Ser Ser Trp Tyr Trp Tyr Arg Pro Ser Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH16,,"(97) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/WO2021174594A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg His Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ala Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(7/8)  preferably, it includes: vh shown in seq id no:7 and/or vl shown in seq id no:8."
https://patents.google.com/patent/CN112979791B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/CN112979791B/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Phe Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Trp Phe Gly Glu Thr Trp Glu Gly Met Asp Ala Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Asn Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) the antibody or antigen-binding fragment thereof according to claim 1, wherein the amino acid sequence of the heavy chain variable region is represented by seq id no:4; the amino acid sequence of the light chain variable region is shown in seq id no:8."
https://patents.google.com/patent/CN114044821A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala Asn Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Met Thr Gly Ser Ser Ile Asp Ser Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Glu Leu Leu Trp Phe Gly Asp Leu Leu His Asn Trp Phe Asp Pro Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile His Gly Ala Ser Thr Arg Ala Thr Gly Leu Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Tyr Asp Ser Trp Pro Gly Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg , Homo sapiens, Homo sapiens,"(1/5) in a preferred embodiment, the amino acid sequence of the heavy chain variable region of the antibody is shown in seq id no:1, and the amino acid sequence of the light chain variable region is shown in seq id no:5."
https://patents.google.com/patent/CN113563463A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Gly Ser Glu Tyr Asp Phe Ser Trp Ser Tyr Ile Gly Trp Phe Arg Gln Ala Pro Gly Gln Glu Arg Glu Ala Val Ser Ala Ile Ala Asp His Trp Thr Gln Asp Asp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Thr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Ala Met Ser Ile Gly Trp Pro Glu Leu Phe Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(3)  a neutralizing nanobody shown in seq id no:3 or a functionally active variant thereof;
https://patents.google.com/patent/CN113563463A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Gly Ser Glu Tyr Arg Tyr Ser Asp Trp Thr Ser Gly Trp Phe Arg Gln Ala Pro Gly Gln Glu Arg Glu Ala Val Ser Ala Ile Ala Gly Tyr Asp Asn Thr Pro Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Thr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Ala Trp Tyr Ile Lys Met Asn Ser Asp Met His Val Gln Arg Glu Trp Glu Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(2)  a neutralizing nanobody shown in seq id no:2 or a functionally active variant thereof;
https://patents.google.com/patent/CN113563463A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Gly Ser Glu Tyr Thr Tyr Ser Tyr Ile Tyr Ala Gly Trp Phe Arg Gln Ala Pro Gly Gln Glu Arg Glu Ala Val Ser Ala Ile Ala Gly Glu Asn Tyr Ser Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Thr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Ala Trp Pro Thr Gln Asp Gly Tyr Ala Ala Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(6)  a neutralizing nanobody shown in seq id no:6 or a functionally active variant thereof.
https://patents.google.com/patent/CN113563463A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Gly Ser Glu Tyr Ser Thr Trp Arg His Tyr Val Gly Trp Phe Arg Gln Ala Pro Gly Gln Glu Arg Glu Ala Val Ser Ala Ile Ala Ser Leu Asp Ser Ser Val Ala Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Thr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Ala Ile Glu Thr Val His Gly His Met Ile Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(4)  a neutralizing nanobody or a functionally active variant thereof represented by seq id no:4;
https://patents.google.com/patent/CN113563463A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Gly Ser Glu Tyr Ala Thr Phe Arg His Tyr Ile Gly Trp Phe Arg Gln Ala Pro Gly Gln Glu Arg Glu Ala Val Ser Ala Ile Ala Ala Ala Asn Gly Glu His Ser Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Thr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Ala Ile Val Asp Gly Trp Ile Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(1)  a neutralizing nanobody shown in seq id no:1 or a functionally active variant thereof;
https://patents.google.com/patent/CN113563463A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Gly Ser Glu Tyr Ala Thr Phe Gly His Tyr Ala Gly Trp Phe Arg Gln Ala Pro Gly Gln Glu Arg Glu Ala Val Ser Ala Ile Ala Gly Ala Gly Asp Arg Arg Ala Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Thr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Ala Ile Asp Thr Glu Tyr Gly Gln Asn Ile Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(5)  a neutralizing nanobody shown in seq id no:5 or a functionally active variant thereof;
https://patents.google.com/patent/CN113444169B/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Met Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Leu Pro Met Tyr Gly Asp Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys, Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Arg Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro Glu Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),(22/23) (i) a heavy chain having an amino acid sequence shown in seq id no:22 and a light chain having an amino acid sequence shown in seq id no:23
https://patents.google.com/patent/CN113444169B/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Ala Gly Trp Val Arg Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys, Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Leu Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),(33/34)  a heavy chain with an amino acid sequence shown as seq id no:33 and a light chain with an amino acid sequence shown as seq id no:34.
https://patents.google.com/patent/CN113444169B/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Met Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Leu Pro Met Tyr Gly Asp Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Arg Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro Glu Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),(7/8)  a heavy chain variable region having an amino acid sequence shown in seq id no:7 and a light chain variable region having an amino acid sequence shown in seq id no:8;
https://patents.google.com/patent/CN113444169B/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Ala Gly Trp Val Arg Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Leu Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),(31/32)  heavy chain variable region whose amino acid sequence is shown as seq id no:31 and light chain variable region whose amino acid sequence is shown as seq id no:32.
https://patents.google.com/patent/CN112225797A/en, ttcacgagtc cagcctcaag cagtcaggtc caactgcagc agtctggacc tgatctggcg aggcccgggg cttcagtgaa gctgtcctgc aaggcttctg gcgacacctt cactgaccac tatataatct gggtgaagca gaggactgga cagggccttg aatggattgg agagatttat cctggaaatg gtcatactta ctacaatgag aggttcaagg gcaaggccac actgactgca gacgattcct ccagcacggc ctacatgcag ctcagcagcc tgacatctga ggactctgca gtctatttct gtgcaagatc gaggtactac ggtccctttg cttactgggg ccaagggact ctggtcactg tctctgcggc gcgcctagat , gacattgtga tgacacagtc tccagcctcc ctatctgtat ctgtgggaga aactgtcacc atcacatgtc gagcaagtga gaatatttac agtagtttag catggtatca gcagaaacag ggaaaatctc ctcagctcct ggtctatgtt gcaactgact tagcagatgg tgtgccatca aggttcagtg gcagtggatc aggcacacag tattccctca agatcaacag cctccagtct gaagattttg ggagttatta ctgtcaacat ttttggggta ctccgtggac gttcggtgga ggcaccaagc tggaaatcaa acgggctgat gctgcaccaa ctgtatcc , mouse (Mus musculus), mouse (Mus musculus),"(3/2) preferably, the gene sequence encoding the light chain variable region is shown in seq id no:2; the gene sequence for coding the heavy chain variable region is shown as seq id no:3."
https://patents.google.com/patent/CN112225797A/en, Phe Thr Ser Pro Ala Ser Ser Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Asp Leu Ala Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Asp Thr Phe Thr Asp His Tyr Ile Ile Trp Val Lys Gln Arg Thr Gly Gln Gly Leu Glu Trp Ile Gly Glu Ile Tyr Pro Gly Asn Gly His Thr Tyr Tyr Asn Glu Arg Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Asp Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Ser Arg Tyr Tyr Gly Pro Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Arg Leu Asp , Asp Ile Gln Met Ile Gln Ser Pro Ala Ser Leu Ser Val Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Ser Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val Tyr Val Ala Thr Asp Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Ser Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp Gly Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val Ser , mouse (Mus musculus), mouse (Mus musculus),"(5/4) preferably, the monoclonal antibody has the amino acid sequence of the light chain variable region shown in seq id no:4 and the amino acid sequence of the heavy chain variable region shown in seq id no:5."
https://patents.google.com/patent/US10131704B2/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser TyrAla Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Val Gly Tyr Cys Ser Ser Thr Ser Cys His Ile Gly Ala PheAsp Ile Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser,Glu Thr Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro GlyGlu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser SerIle Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu MetPhe Asp Ser Ser Thr Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile Ser Ser Leu Glu ProGlu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Ser Ser Ser Pro TyrThr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys,14125PRTArtificial SequenceSynthetic polypeptide 14,16107PRTArtificial SequenceSynthetic polypeptide 16,"(14/16) , and neutralizes mers-cov, and wherein the monoclonal antibody comprises a vh amino acid sequence having seq id no:14, and a vl amino acid sequence having seq id no:16."
https://patents.google.com/patent/US10131704B2/en,Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly ArgSer Leu Arg Leu Ser Cys Val Ala Ser Glu Phe Thr Phe Asn Thr TyrGly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValAla Ala Ile Ser Tyr Asp Gly Thr Lys Lys Phe Tyr Ala Asp Ser LeuLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Ser Gly Asp Ser Asp Ala Phe Asp Ile Trp Gly Gln Gly ThrMet Val Thr Val Ser Ser,Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly GlnThr Ala Thr Ile Thr Cys Ser Gly Asp Glu Leu Gly Asp Lys Phe AlaPhe Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile TyrGln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly SerAsn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala LeuAsp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Asn Ser Tyr ValPhe Gly Thr Gly Thr Lys Val Thr Val Leu,240ctccaaatga acagcctgag atctgaggac acggccgtgt attactgtgc gagaagtggt 300gactccgatg cttttgatat ctggggccaa gggacaatgg tcaccgtctc ctca 3542118PRTArtificial SequenceSynthetic polypeptide 2,40gatgaggctg actattactg tcaggcgtgg gacagcaaca gttatgtctt cggaactggg 300accaaggtca ccgtcctagg t 3214106PRTArtificial SequenceSynthetic polypeptide 4,"(2/4) the monoclonal antibody has a heavy chain variable amino acid sequence containing seq id no:2, 6, 10, 14, 18, 22, or 26 and/or a light chain variable amino acid sequence containing seq id no:4, 8, 12, 16, 20, 24 or 28."
https://patents.google.com/patent/CN113563475A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg His Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ala Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Pro Tyr Cys Ser Ser Thr Ser Cys His Arg Asp Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp Ser Asp Asp Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Arg Ile Glu Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys, Asp Ile Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Ser , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(6/8)  further preferably, the bispecific antibody bs-mab-2 has the amino acid sequence of the light chain as shown in seq id no:8 or the amino acid sequence of a protein with the same function obtained by substitution, deletion or insertion of one or more amino acids, and has the amino acid sequence of the heavy chain as shown in seq id no:6 or the amino acid sequence of a protein with the same function obtained by substitution, deletion or insertion of one or more amino acids."
https://patents.google.com/patent/CN113563475A/en, caggttcagt tagttcagag tggagcagaa gtgaagaagc ccggtgcctc tgtgaaagtg tcatgcaaag catcaggata cacatttaca ggatactaca tgcactgggt taggcaggcg cccggtcaag gcctggagtg gatgggcaga atcaacccta actctggcgg gacgaattat gcacagaagt tccagggaag agtgacaatg acaagagata catcaatctc aacagcatac atggaacttt caagacttag atcagatgac actgctgtct actactgcgc acgagtcccg tactgctcat caacatcatg ccacagagat tggtactttg atctttgggg gagaggtaca cttgtgacag tctcatcggg tggaggcgga tcagggggtg gtggctccga agtccagctc gtcgagagtg gtggaggact ggttcaacct ggaggatcac ttagactttc atgcgcagca tcaggattta tcgtgtcatc aaactacatg tcatgggtac gccaggctcc cgggaagggt ctggagtggg tctcggtgat ctactcagga ggatcaacat actacgcaga ttcagtgaaa ggaagattta caatctcaag acacaactca aagaatactc tttaccttca aatgaactca cttagagcag aagacactgc ggtttactac tgcgcaagag aagcgtacgg aatggatgtg tggggccagg gtacaacagt tactgtttcg tctgcgtcca ctaaaggccc ttccgtcttc ccgctggcac cttcatcaaa gtctacttct ggtggaacgg cggctcttgg atgtctggtt aaggactatt tcccggagcc tgtaactgta tcgtggaact caggagcact tacatcagga gtgcacacat ttcctgcagt gcttcaatca tcaggacttt actcactttc atcagtggtg acagtgcctt catcatcact tggaacacaa acatacatct gcaacgtgaa ccacaaacct tcaaacacaa aggttgacaa gaaggtcgag cctaaatcat gcgataagac tcatacatgc cctccttgcc ctgcacctga acttcttgga ggcccgtcgg tgtttttatt cccgccaaaa ccgaaggata cacttatgat ctcaagaaca cctgaagtga catgcgtggt ggtggatgtg tcacacgaag atcctgaagt gaaatttaac tggtacgtgg atggagtgga agtgcacaac gcaaagacta agcctagaga agaacaatac aactcaacat acagagtggt gtcagtgctt acagtgcttc accaagattg gcttaacgga aaggagtata aatgcaaagt gtcaaacaaa gcacttcctg cacctatcga gaagactata tcaaaagcaa aaggacaacc tagagaacct caagtgtaca cacttcctcc ttcaagagat gaacttacaa agaatcaggt gtcacttaca tgtttagtaa agggcttcta cccatctgac atcgcagtgg aatgggaatc aaacggacaa cctgagaata attataagac cactcctcct gtacttgatt cagatggatc attcttcctc tattcaaagt taaccgtgga taaatcaaga tggcaacaag gaaacgtgtt ctcctgttca gtgatgcacg aagcacttca caaccactac acacagaaga gtctatcact ttcacctgga tga , gatatccaaa tgacccagag cccattgagc cttcctgtga cacctggaga acctgcatca atctcatgca gatcatcaca atcacttctt gattcagatg atggaaacac ataccttgat tggtaccttc agaagcccgg tcagtctcct cagctactaa tttatactct atcatacaga gcatcgggcg taccggaccg cttctccgga tcagggtcag ggactgattt caccctaaag atatccagag tggaagcaga agatgtggga gtgtactact gcatgcaaag aatcgaattt cctcttacat ttggaggagg aacaaaggta gagatcaaag gtggaggagg atccggagga ggtggatccg atatcgtgat gacgcagagc cctagctttc tttctgctag tgtaggcgac agagtgacaa tcacatgcag agcatcacaa ggaatctcat cataccttgc atggtaccaa cagaagccgg gaaaggcgcc caagctgctc atatatgctg cctcaactct gcagagtggc gtgccgtctc gcttcagcgg tagcggatcg ggaacagagt ttacacttac aatctcatca cttcaacctg aagatttcgc cacgtactac tgccaacaac ttaactcata ccctccttac acatttggac aaggaacaaa gttagagatc aagcgaaccg tggcagcacc ttcagtgttt atctttcctc cttcagatga acaacttaaa tcaggaactg cgtctgtagt ttgtcttctt aacaacttct atccaagaga agcaaaggta cagtggaaag tggataacgc cctgcagtct ggtaatagcc aagaatcagt gacagaacaa gattcaaagg acagtacata ctcactttca tcaacactta cactttcaaa ggcggactac gagaagcata aggtgtacgc atgcgaagtg acacaccaag gactttcatc acctgtgaca aagtccttca acagaggaga atgctga , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(1/3) the light and heavy chain dna sequences (shown in seq id no:3 and seq id no:1, respectivel"
https://patents.google.com/patent/CN113563475A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg His Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ala Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(32/33) preferably, the amino acid sequence of the heavy chain variable region of monoclonal antibody b38 is shown in seq id no:32, and the amino acid sequence of the light chain variable region of monoclonal antibody b38 is shown in seq id no:33"
https://patents.google.com/patent/CN113563475A/en, gatatccaaa tgacccagag cccattgagc cttcctgtga cacctggaga acctgcatca atctcatgca gatcatcaca atcacttctt gattcagatg atggaaacac ataccttgat tggtaccttc agaagcccgg tcagtctcct cagctactaa tttatactct atcatacaga gcatcgggcg taccggaccg cttctccgga tcagggtcag ggactgattt caccctaaag atatccagag tggaagcaga agatgtggga gtgtactact gcatgcaaag aatcgaattt cctcttacat ttggaggagg aacaaaggta gagatcaaag gtggaggagg atccggagga ggtggatccg atatcgtgat gacgcagagc cctagctttc tttctgctag tgtaggcgac agagtgacaa tcacatgcag agcatcacaa ggaatctcat cataccttgc atggtaccaa cagaagccgg gaaaggcgcc caagctgctc atatatgctg cctcaactct gcagagtggc gtgccgtctc gcttcagcgg tagcggatcg ggaacagagt ttacacttac aatctcatca cttcaacctg aagatttcgc cacgtactac tgccaacaac ttaactcata ccctccttac acatttggac aaggaacaaa gttagagatc aagcgaaccg tggcagcacc ttcagtgttt atctttcctc cttcagatga acaacttaaa tcaggaactg cgtctgtagt ttgtcttctt aacaacttct atccaagaga agcaaaggta cagtggaaag tggataacgc cctgcagtct ggtaatagcc aagaatcagt gacagaacaa gattcaaagg acagtacata ctcactttca tcaacactta cactttcaaa ggcggactac gagaagcata aggtgtacgc atgcgaagtg acacaccaag gactttcatc acctgtgaca aagtccttca acagaggaga atgctga , caggttcagt tagttcagag tggagcagaa gtgaagaagc ccggtgcctc tgtgaaagtg tcatgcaaag catcaggata cacatttaca ggatactaca tgcactgggt taggcaggcg cccggtcaag gcctggagtg gatgggcaga atcaacccta actctggcgg gacgaattat gcacagaagt tccagggaag agtgacaatg acaagagata catcaatctc aacagcatac atggaacttt caagacttag atcagatgac actgctgtct actactgcgc acgagtcccg tactgctcat caacatcatg ccacagagat tggtactttg atctttgggg gagaggtaca cttgtgacag tctcatcggg tggaggcgga tcagggggtg gtggctccga agtccagctc gtcgagagtg gtggaggact ggttcaacct ggaggatcac ttagactttc atgcgcagca tcaggattta tcgtgtcatc aaactacatg tcatgggtac gccaggctcc cgggaagggt ctggagtggg tctcggtgat ctactcagga ggatcaacat actacgcaga ttcagtgaaa ggaagattta caatctcaag acacaactca aagaatactc tttaccttca aatgaactca cttagagcag aagacactgc ggtttactac tgcgcaagag aagcgtacgg aatggatgtg tggggccagg gtacaacagt tactgtttcg tctgcgtcca ctaaaggccc ttccgtcttc ccgctggcac cttcatcaaa gtctacttct ggtggaacgg cggctcttgg atgtctggtt aaggactatt tcccggagcc tgtaactgta tcgtggaact caggagcact tacatcagga gtgcacacat ttcctgcagt gcttcaatca tcaggacttt actcactttc atcagtggtg acagtgcctt catcatcact tggaacacaa acatacatct gcaacgtgaa ccacaaacct tcaaacacaa aggttgacaa gaaggtcgag cctaaatcat gcgataagac tcatacatgc cctccttgcc ctgcacctga acttcttgga ggcccgtcgg tgtttttatt cccgccaaaa ccgaaggata cacttatgat ctcaagaaca cctgaagtga catgcgtggt ggtggatgtg tcacacgaag atcctgaagt gaaatttaac tggtacgtgg atggagtgga agtgcacaac gcaaagacta agcctagaga agaacaatac aactcaacat acagagtggt gtcagtgctt acagtgcttc accaagattg gcttaacgga aaggagtata aatgcaaagt gtcaaacaaa gcacttcctg cacctatcga gaagactata tcaaaagcaa aaggacaacc tagagaacct caagtgtaca cacttcctcc ttcaagagat gaacttacaa agaatcaggt gtcacttaca tgtttagtaa agggcttcta cccatctgac atcgcagtgg aatgggaatc aaacggacaa cctgagaata attataagac cactcctcct gtacttgatt cagatggatc attcttcctc tattcaaagt taaccgtgga taaatcaaga tggcaacaag gaaacgtgtt ctcctgttca gtgatgcacg aagcacttca caaccactac acacagaaga gtctatcact ttcacctgga tga , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(3/1) the light and heavy chain dna sequences (shown in seq id no:3 and seq id no:1, respectively) were cloned into expression vectors pcaggs (available from addgene), respectively, to yield recombinant expression vectors encoding the antibody heavy and light chains, respectively"
https://patents.google.com/patent/CN113563475A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Pro Tyr Cys Ser Ser Thr Ser Cys His Arg Asp Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp Ser Asp Asp Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Arg Ile Glu Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(34/35)  the amino acid sequence of the heavy chain variable region of the monoclonal antibody h4 is shown as seq id no:34, and the amino acid sequence of the light chain variable region of the monoclonal antibody h4 is shown as seq id no:35."
https://patents.google.com/patent/CN113563475A/en, gacatcgtga tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc atcacttgcc gggccagtca gggcattagc agttatttag cctggtatca gcaaaaacca gggaaagccc ctaagctcct gatctatgct gcatccactt tgcaaagtgg ggtcccatca aggttcagcg gcagtggatc tgggacagag ttcactctca caatcagcag cctgcagcct gaagattttg caacttatta ctgtcaacag cttaatagtt accctccgta cacttttggc caggggacca agctggagat caaacgaact gtggctgcac caagcgtgtt tatcttccct cccagcgacg agcagctgaa gagcggcacc gccagcgtgg tctgtctcct gaacaacttc tatcccaggg aggccaaggt ccagtggaaa gtggacaacg ccctgcaaag cggcaatagc caggagtccg tcacagagca ggacagcaag gacagcacct acagcctgtc cagcaccctg accctcagca aggccgacta cgagaagcac aaggtgtacg cttgcgaggt gacccatcag ggcctgtcca gccccgtgac caagtccttc aacaggggcg aatgcagc , gaggtccagc tcgttgagtc cggtggggga ttggtgcaac ctggaggatc acttagactt tcatgcgcag catcaggatt tatcgtgtca tcaaactaca tgtcatgggt acggcaggcg ccagggaaag gcctagagtg ggtttcggtg atctactcag gaggatcaac atactacgca gattcagtga aaggaagatt tacaatctca agacacaact caaagaatac tctttacctt caaatgaact cacttagagc agaagacact gcggtgtact actgcgcacg ggaggcgtac ggaatggatg tgtgggggca gggaacaaca gtcacggtct ctagcgccag caccaaaggc ccgtctgtct ttccactcgc accttcatca aagagcacgt cgggagggac ggctgcgctt ggatgtttag ttaaggacta tttcccagag ccggtcacag ttagctggaa ctcaggagca cttacctcgg gcgttcacac ctttcctgca gtgcttcaat catcaggact ttactcactt tcatcagtgg tgacagtgcc ttcatcatca cttggaacac aaacatacat ctgcaacgtg aaccacaaac cttcaaacac aaaggtagac aagcgagtag aacctaaatc atgcgataag acccatacat gccctccttg ccctgcacct gaacttcttg gaggtccatc ggtattctta tttccgccaa agccgaagga tacacttatg atctcaagaa cacctgaagt gacatgcgtg gtggtggatg tgtcacacga agatcctgaa gtgaaattta actggtacgt ggatggagtg gaagtgcaca acgcaaagac gaagcctaga gaagaacaat acaactcaac atacagagtg gtgtcagtgc ttacagtgct tcaccaagat tggcttaacg gaaaggagta taaatgcaaa gtgtcaaaca aagcacttcc tgcacctatc gagaagacga tatcaaaagc aaaaggacaa cctagagaac ctcaagtgta cacacttcct ccttcaagag atgaacttac aaagaatcag gtgtcactta catgtttagt caagggcttc tacccttcag atatcgcagt ggaatgggaa tcaaacggac aacctgagaa taattataag actacaccac cggtgttgga cagtgacggg agcttcttcc tgtattcaaa gctcactgtg gataaatcaa gatggcaaca aggaaacgtg ttctcgtgtt cagtgatgca cgaagcactt cacaaccact acacacagaa gtcgctgtca ctttcacctg gtggtggaag tcaagttcag ttggtacaga gcggagcaga agtgaagaag cccggtgcga gtgtgaaagt gtcatgcaaa gcatcaggat acacatttac aggatactac atgcactggg tacgacaggc tccgggtcaa ggtttagagt ggatgggcag aatcaaccct aactctggag gcaccaacta cgcacagaag ttccagggaa gagtgacaat gacaagagat acatcaatct caacagcata catggaactt tcaagactta gatcagatga cactgcggtc tattattgtg cacgggtacc ttactgctca tcaacatcat gccacagaga ttggtacttt gatctttggg gaagaggaac acttgtcact gtgtcgtcag gaggcggagg atcagggggt gggggcagcg gcggtggcgg ttctggtgga ggtggcagcg acatccaaat gacacaatca cctctttcac ttcctgtgac acctggagaa cctgcatcaa tctcatgcag atcatcacaa tcacttctgg actcggacga cggcaacaca taccttgatt ggtaccttca gaagccgggt caatcacctc aacttcttat ctacacactt tcatacagag cgtccggagt cccggacaga ttcagcggtt caggatcagg aacagatttc acgttgaaga tttctagagt ggaagcagaa gatgtgggag tgtactactg catgcaaaga atcgaatttc ctcttacatt tggaggtggc acgaaagtgg agatcaaatg a , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(7/5) the light and heavy chain dna sequences (shown in seq id no:7 and seq id no:5, respectively) were cloned into expression vectors pcaggs (available from addgene), respectively, to yield recombinant expression vectors encoding the antibody heavy and light chains, respectively"
https://patents.google.com/patent/CN113563475A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Pro Tyr Cys Ser Ser Thr Ser Cys His Arg Asp Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg His Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ala Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly , Asp Ile Gln Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp Ser Asp Asp Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Arg Ile Glu Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(2/4) preferably, the bispecific antibody bs-mab-1 has the amino acid sequence of the light chain as shown in seq id no:4 or the amino acid sequence of a protein with the same function obtained by substitution, deletion or insertion of one or more amino acids, and has the amino acid sequence of the heavy chain as shown in seq id no:2 or the amino acid sequence of a protein with the same function obtained by substitution, deletion or insertion of one or more amino acids."
https://patents.google.com/patent/CN113563475A/en, gaggtccagc tcgttgagtc cggtggggga ttggtgcaac ctggaggatc acttagactt tcatgcgcag catcaggatt tatcgtgtca tcaaactaca tgtcatgggt acggcaggcg ccagggaaag gcctagagtg ggtttcggtg atctactcag gaggatcaac atactacgca gattcagtga aaggaagatt tacaatctca agacacaact caaagaatac tctttacctt caaatgaact cacttagagc agaagacact gcggtgtact actgcgcacg ggaggcgtac ggaatggatg tgtgggggca gggaacaaca gtcacggtct ctagcgccag caccaaaggc ccgtctgtct ttccactcgc accttcatca aagagcacgt cgggagggac ggctgcgctt ggatgtttag ttaaggacta tttcccagag ccggtcacag ttagctggaa ctcaggagca cttacctcgg gcgttcacac ctttcctgca gtgcttcaat catcaggact ttactcactt tcatcagtgg tgacagtgcc ttcatcatca cttggaacac aaacatacat ctgcaacgtg aaccacaaac cttcaaacac aaaggtagac aagcgagtag aacctaaatc atgcgataag acccatacat gccctccttg ccctgcacct gaacttcttg gaggtccatc ggtattctta tttccgccaa agccgaagga tacacttatg atctcaagaa cacctgaagt gacatgcgtg gtggtggatg tgtcacacga agatcctgaa gtgaaattta actggtacgt ggatggagtg gaagtgcaca acgcaaagac gaagcctaga gaagaacaat acaactcaac atacagagtg gtgtcagtgc ttacagtgct tcaccaagat tggcttaacg gaaaggagta taaatgcaaa gtgtcaaaca aagcacttcc tgcacctatc gagaagacga tatcaaaagc aaaaggacaa cctagagaac ctcaagtgta cacacttcct ccttcaagag atgaacttac aaagaatcag gtgtcactta catgtttagt caagggcttc tacccttcag atatcgcagt ggaatgggaa tcaaacggac aacctgagaa taattataag actacaccac cggtgttgga cagtgacggg agcttcttcc tgtattcaaa gctcactgtg gataaatcaa gatggcaaca aggaaacgtg ttctcgtgtt cagtgatgca cgaagcactt cacaaccact acacacagaa gtcgctgtca ctttcacctg gtggtggaag tcaagttcag ttggtacaga gcggagcaga agtgaagaag cccggtgcga gtgtgaaagt gtcatgcaaa gcatcaggat acacatttac aggatactac atgcactggg tacgacaggc tccgggtcaa ggtttagagt ggatgggcag aatcaaccct aactctggag gcaccaacta cgcacagaag ttccagggaa gagtgacaat gacaagagat acatcaatct caacagcata catggaactt tcaagactta gatcagatga cactgcggtc tattattgtg cacgggtacc ttactgctca tcaacatcat gccacagaga ttggtacttt gatctttggg gaagaggaac acttgtcact gtgtcgtcag gaggcggagg atcagggggt gggggcagcg gcggtggcgg ttctggtgga ggtggcagcg acatccaaat gacacaatca cctctttcac ttcctgtgac acctggagaa cctgcatcaa tctcatgcag atcatcacaa tcacttctgg actcggacga cggcaacaca taccttgatt ggtaccttca gaagccgggt caatcacctc aacttcttat ctacacactt tcatacagag cgtccggagt cccggacaga ttcagcggtt caggatcagg aacagatttc acgttgaaga tttctagagt ggaagcagaa gatgtgggag tgtactactg catgcaaaga atcgaatttc ctcttacatt tggaggtggc acgaaagtgg agatcaaatg a , gacatcgtga tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc atcacttgcc gggccagtca gggcattagc agttatttag cctggtatca gcaaaaacca gggaaagccc ctaagctcct gatctatgct gcatccactt tgcaaagtgg ggtcccatca aggttcagcg gcagtggatc tgggacagag ttcactctca caatcagcag cctgcagcct gaagattttg caacttatta ctgtcaacag cttaatagtt accctccgta cacttttggc caggggacca agctggagat caaacgaact gtggctgcac caagcgtgtt tatcttccct cccagcgacg agcagctgaa gagcggcacc gccagcgtgg tctgtctcct gaacaacttc tatcccaggg aggccaaggt ccagtggaaa gtggacaacg ccctgcaaag cggcaatagc caggagtccg tcacagagca ggacagcaag gacagcacct acagcctgtc cagcaccctg accctcagca aggccgacta cgagaagcac aaggtgtacg cttgcgaggt gacccatcag ggcctgtcca gccccgtgac caagtccttc aacaggggcg aatgcagc , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(5/7) the light and heavy chain dna sequences (shown in seq id no:7 and seq id no:5, respectivel"
https://patents.google.com/patent/CN113698475A/en, Met Gln Ala Ser Val Arg Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Tyr Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Pro Arg Phe Leu Gly Lys Ala Thr Met Thr Thr Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Gly Val Tyr Tyr Cys Lys Val Tyr Asp Gly Tyr Tyr Phe Asp Phe Trp Gly Gln Gly Thr Pro Leu Thr Val Ser Ser , Ala Arg Cys Leu Leu His Trp Thr Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys Trp Gln Ala Thr His Phe Pro His Thr Phe Gly Gly Gly Thr Lys Leu Glu Arg , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(3/4) the amino acid sequence of the heavy chain variable region of the monoclonal antibody a10 for resisting the porcine delta coronavirus n protein is shown as seq id no:3, the amino acid sequence of the light chain variable region is shown as seq id no:4, respectively."
https://patents.google.com/patent/CN113698475A/en, Val Leu Ser Thr Ser Gln Ser Leu Ser Ile Thr Cys Thr Ile Ser Gly Phe Ser Leu Thr Ser Tyr Gly Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Ser Val Gly Asn Thr Thr Tyr Asn Ser Thr Leu Arg Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Gln Val Tyr Gly Asn Ser Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Ala Leu Leu Leu Ser Ser Trp Arg Ser Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His Trp His Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Gly Thr His Val Met Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(1/2) the amino acid sequence of the heavy chain variable region of the monoclonal antibody e8 for resisting the porcine delta coronavirus n protein is shown as seq id no:1, the amino acid sequence of the light chain variable region is shown as seq id no:2 is shown in the specification"
https://patents.google.com/patent/WO2021148884A1/en, Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Thr Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Arg Leu Gln Gly Arg Val Thr Ile Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Tyr Val Leu Thr Gln Thr Pro Trp Val Ser Val Ala Pro Gly Lys Thr Ala Lys Ile Ile Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Thr Gly Gln Ala Pro Val Leu Val Val Tyr Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Thr Arg Val Glu Val Gly Asp Glu Ala Asp Phe Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu ," /note=""Description of Artificial Sequence: Synthetic       polypeptide""  "," /note=""Description of Artificial Sequence: Synthetic       polypeptide""  ","(1/78) an antibody, or antigen-binding fragment thereof, comprising: i) a heavy chain variable region sequence of any one of seq id no:1-77 or 123, and/or ii) a light chain variable region sequence of any one of seq id no:78-122 or 124"
https://patents.google.com/patent/CN112940110A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Phe Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ile Tyr Ala Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Gly Gly Leu Gly Arg Gly Tyr Asp Ile Leu Thr Gly Thr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro Ser Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , Artificial sequence, Artificial sequence,"(56/57) preferably, the monoclonal antibody c10897p3s comprises the heavy chain variable region of seq id no:56 and the light chain variable region of seq id no:57"
https://patents.google.com/patent/CN112940110A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Ser His Gly Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Gly Ala Ala Gly Asp Pro Tyr Tyr Pro Gly Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Val Ala Gly Gly Leu Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Cys Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Ile Tyr Tyr Cys Gln Gln Tyr Tyr Ser Ser Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys, Artificial sequence, Artificial sequence,"(17/18) preferably, the monoclonal antibody comprises the heavy chain variable region shown in seq id no:17 and the light chain variable region shown in seq id no:18"
https://patents.google.com/patent/CN112940110A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Ser Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Val Arg Asp Arg Gly Asn Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Thr Val Val Thr Gln Glu Pro Ser Phe Ser Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Leu Ser Ser Gly Ser Val Ser Thr Ser Tyr Tyr Pro Ser Trp Tyr Gln Gln Thr Pro Gly Gln Ala Pro Arg Thr Leu Ile Tyr Ser Thr Asn Thr Arg Ser Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Leu Gly Asn Lys Ala Ala Leu Thr Ile Thr Gly Ala Gln Ala Asp Asp Glu Ser Asp Tyr Tyr Cys Val Leu Tyr Met Gly Ser Gly Thr Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial sequence, Artificial sequence,"(7/8) preferably, the monoclonal antibody comprises the heavy chain variable region shown in seq id no:7 and the light chain variable region shown in seq id no:8"
https://patents.google.com/patent/CN112940110A/en, Gln Val Gln Phe Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Asp Ala Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Val Gly Trp Ile Asn Ala Gly Ser Gly Asn Thr Glu Phe Pro Gln Lys Phe Arg Gly Arg Val Thr Val Thr Arg Asp Thr Ser Ala Ser Val Leu Tyr Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Val His Thr Asp Gly Val Arg Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Pro Ser Ala Ser Gly Ser Pro Gly Gln Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Thr Tyr Asn Tyr Val Ser Trp Tyr Gln His His Pro Gly Gln Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly His Thr Ala Ser Leu Thr Val Ser Gly Leu Gln Ala Asp Asp Glu Ala Asp Tyr Tyr Cys Thr Ser His Ala Gly Phe Asn Asn Phe Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial sequence, Artificial sequence,"(85/86) preferably, the monoclonal antibody comprises the heavy chain variable region shown in seq id no:85 and the light chain variable region shown in seq id no:86."
https://patents.google.com/patent/CN112940110A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Asn Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Arg Glu Gly Pro Asp Leu Arg Trp Leu Gln Glu Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn Asn Gly Asn Thr Tyr Leu Cys Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr Asn Val Ser Asn Arg Asp Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Leu Gln Ala Thr His Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial sequence, Artificial sequence,"(75/76) preferably, the monoclonal antibody c10543o1s comprises the heavy chain variable region of seq id no:75 and the light chain variable region of seq id no:76"
https://patents.google.com/patent/CN112940110A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Lys Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Ser Arg His Glu Gly Tyr Gly Ser Gly Ser Tyr Tyr Ile Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Tyr Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Phe Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial sequence, Artificial sequence,"(65/66) preferably, the monoclonal antibody comprises the heavy chain variable region shown as seq id no:65 and the light chain variable region shown as seq id no:66"
https://patents.google.com/patent/CN112940110A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Ser Met Ala Gln Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu His Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Ser Cys Ala Ile His Gly Gly Asn Leu Ala Phe Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial sequence, Artificial sequence,"(27/28) preferably, the monoclonal antibody comprises the heavy chain variable region shown in seq id no:27 and the light chain variable region shown in seq id no:28."
https://patents.google.com/patent/CN112940110A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr Phe Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Thr Thr Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Ser Ala Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Val Arg Ser Val Thr Ala Ala Asp Thr Ala Met Tyr Tyr Cys Ala Arg Glu Ser Arg Thr Tyr Asp Gly Ser Gly Tyr Tyr Ile Asp Ser Trp Gly Gln Gly Ala Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Leu Asn Cys Glu Ser Ser His Thr Leu Leu Tyr Ser Leu Asn Asn Lys Ser Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Val Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Val Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys, Artificial sequence, Artificial sequence,"(46/47) preferably, the monoclonal antibody comprises the heavy chain variable region shown in seq id no:46 and the light chain variable region shown in seq id no:47"
https://patents.google.com/patent/CN112940110A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Glu Val Gln Pro Gly Thr Ser Leu Arg Leu Ser Cys Val Thr Ser Gly Phe Thr Phe Ala His Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Thr Trp Ser Asp Gly Ile Arg Arg Tyr Tyr Gly Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Lys Asp Thr Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp His Ser Ile Gly Leu Phe Tyr Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Gln Thr Val Val Thr Gln Glu Pro Ser Phe Ser Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Leu Asn Ser Asp Ser Val Ser Thr Asn Tyr Tyr Pro Ser Trp His Gln Gln Thr Pro Gly Gln Ala Pro Arg Thr Leu Ile Tyr Asn Thr Asn Ile Arg Ser Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Leu Gly Asn Lys Ala Ala Leu Thr Ile Thr Gly Ala Gln Ala Asp Asp Glu Ser Asp Tyr Tyr Cys Val Leu Tyr Met Gly Ser Gly Ile Trp Val Phe Gly Gly Gly Thr Arg Leu Thr Val Leu , Artificial sequence, Artificial sequence,"(37/38) preferably, the monoclonal antibody comprises the heavy chain variable region shown in seq id no:37 and the light chain variable region shown in seq id no:38"
https://patents.google.com/patent/CN112409479A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Thr Leu Ser Cys Gly Ala Ser Gly Phe Thr Phe Glu Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Asp Trp Asn Ser Gly Val Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu His Met Arg Ser Leu Thr Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Val Tyr Ser Glu Ser Gly Ser Gly Ser Tyr Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Gln Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(2/1) the amino acid sequences of the variable regions of the light chain and the heavy chain of antibody ncov-121 are shown as seq id no:1 and 2, respectively."
https://patents.google.com/patent/CN112225797B/en, ttcacgagtc cagcctcaag cagtcaggtc caactgcagc agtctggacc tgatctggcg aggcccgggg cttcagtgaa gctgtcctgc aaggcttctg gcgacacctt cactgaccac tatataatct gggtgaagca gaggactgga cagggccttg aatggattgg agagatttat cctggaaatg gtcatactta ctacaatgag aggttcaagg gcaaggccac actgactgca gacgattcct ccagcacggc ctacatgcag ctcagcagcc tgacatctga ggactctgca gtctatttct gtgcaagatc gaggtactac ggtccctttg cttactgggg ccaagggact ctggtcactg tctctgcggc gcgcctagat , gacattgtga tgacacagtc tccagcctcc ctatctgtat ctgtgggaga aactgtcacc atcacatgtc gagcaagtga gaatatttac agtagtttag catggtatca gcagaaacag ggaaaatctc ctcagctcct ggtctatgtt gcaactgact tagcagatgg tgtgccatca aggttcagtg gcagtggatc aggcacacag tattccctca agatcaacag cctccagtct gaagattttg ggagttatta ctgtcaacat ttttggggta ctccgtggac gttcggtgga ggcaccaagc tggaaatcaa acgggctgat gctgcaccaa ctgtatcc , mouse (Mus musculus), mouse (Mus musculus),"(3/2) the gene of claim 4, wherein the gene encoding the light chain variable region has the sequence shown in seq id no:2; the gene sequence of the coding heavy chain variable region is shown in seq id no:3."
https://patents.google.com/patent/CN112225797B/en, Phe Thr Ser Pro Ala Ser Ser Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Asp Leu Ala Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Asp Thr Phe Thr Asp His Tyr Ile Ile Trp Val Lys Gln Arg Thr Gly Gln Gly Leu Glu Trp Ile Gly Glu Ile Tyr Pro Gly Asn Gly His Thr Tyr Tyr Asn Glu Arg Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Asp Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Ser Arg Tyr Tyr Gly Pro Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Arg Leu Asp , Asp Ile Gln Met Ile Gln Ser Pro Ala Ser Leu Ser Val Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Ser Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val Tyr Val Ala Thr Asp Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Ser Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp Gly Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val Ser , mouse (Mus musculus), mouse (Mus musculus),"(5/4) preferably, the monoclonal antibody has the amino acid sequence of the light chain variable region shown in seq id no:4 and the amino acid sequence of the heavy chain variable region shown in seq id no:5."
https://patents.google.com/patent/CN111732655B/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Thr Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu His Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Asp Tyr Gly Asp Tyr Val Leu Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Thr Tyr Lys Phe Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Gly Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Cys Ser Tyr Ala Gly Ser Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens,  Homo sapiens,"(1/5) in a preferred embodiment, the amino acid sequence of the heavy chain variable region of the antibody is shown in seq id no:1, and the amino acid sequence of the light chain variable region is shown in seq id no:5."
https://patents.google.com/patent/CN113637083A/en, Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Asp Pro Ser Ala Ser Tyr Tyr Leu Asp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(46/50) in some embodiments, the fusion proteins disclosed herein include a polypeptide and an antibody or antigen-binding fragment comprising a vh set forth as seq id no:46, 47, 48, 49, or 107, a vl set forth as seq id no:50, or a biological equivalent of each"
https://patents.google.com/patent/CN113637083A/en, Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Leu Gly Pro Thr Tyr Gly Gly Tyr Ala Arg Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(55/57) in some embodiments, the fusion protein comprises an antibody having a heavy chain comprising a sequence having an amino acid sequence set forth in seq id no:55 and a light chain comprising a sequence having an amino acid sequence set forth in seq id no:57"
https://patents.google.com/patent/CN113637083A/en, Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Leu Gly Pro Thr Tyr Gly Gly Tyr Ala Arg Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(48/50) in some embodiments, the heavy chain variable region of the antibody or antigen-binding fragment comprises the sequence set forth in seq id no:48 and the light chain variable region of the antibody or antigen-binding fragment comprises the sequence set forth in seq id no:50."
https://patents.google.com/patent/CN113637083A/en, Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Thr Ser Tyr Asp Gly Tyr Val Thr Leu Ala Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(56/57) in some embodiments, the fusion protein comprises an antibody having a heavy chain comprising a sequence having an amino acid sequence set forth in seq id no:56 and a light chain comprising a sequence having an amino acid sequence set forth in seq id no:57"
https://patents.google.com/patent/CN113637083A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Pro Phe Gly Ile Asp Asp Ala Tyr Leu Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(108/57) in some embodiments, the fusion protein comprises an antibody having a heavy chain comprising a sequence having an amino acid sequence set forth in seq id no:108 and a light chain comprising a sequence having an amino acid sequence set forth in seq id no:57"
https://patents.google.com/patent/CN113637083A/en, Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Pro Phe Gly Tyr Ser Ala Gly Tyr Leu Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(54/57) in some embodiments, the fusion protein comprises an antibody having a heavy chain comprising a sequence having an amino acid sequence set forth in seq id no:54 and a light chain comprising a sequence having an amino acid sequence set forth in seq id no:57"
https://patents.google.com/patent/CN113637083A/en, Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Thr Ser Tyr Asp Gly Tyr Val Thr Leu Ala Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(49/50) in some embodiments, the heavy chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:49 and the light chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:50."
https://patents.google.com/patent/CN113637083A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Pro Phe Gly Ile Asp Asp Ala Tyr Leu Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(107/50) in some embodiments, the heavy chain variable region of the antibody or antigen-binding fragment comprises the sequence set forth in seq id no:107 and the light chain variable region of the antibody or antigen-binding fragment comprises the sequence set forth in seq id no:50."
https://patents.google.com/patent/CN113637083A/en, Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Pro Phe Gly Tyr Ser Ala Gly Tyr Leu Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(47/50) in some embodiments, the heavy chain variable region of the antibody or antigen-binding fragment comprises the sequence set forth in seq id no:47 and the light chain variable region of the antibody or antigen-binding fragment comprises the sequence set forth in seq id no:50."
https://patents.google.com/patent/CN113637083A/en, Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Asp Pro Ser Ala Ser Tyr Tyr Leu Asp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(53/57) in some embodiments, the fusion protein comprises an antibody having a heavy chain comprising a sequence having an amino acid sequence set forth in seq id no:53 and a light chain comprising a sequence having an amino acid sequence set forth in seq id no:57"
https://patents.google.com/patent/WO2021239949A1/en, Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val His Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Gly Trp Asp Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Ser Trp Ala Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ala Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,HL CV38-183 VH  ,HL CV38-183 VL  ,"(88/89) in one embodiment, the antibody or antibody fragment according to cv38-138 comprises: a heavy chain variable (vh) domain, said vh domain comprising a sequence of at least 70%, 80%, 85%, 90%, at least 95% or complete identity to seq id no:88, and a light chain variable (vl) domain, said vl domain comprising a sequence of at least 70%, 80%, 85%, 90%, at least 95% or complete identity to seq id no:89"
https://patents.google.com/patent/WO2021239949A1/en, Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val His Ser Gln Val Gln Leu Val Gln Ser Glu Ala Glu Val Lys Glu Pro Gly Ala Ser Val Glu Val Ser Cys Lys Ala Ser Gly Tyr Asn Phe Thr Asn Phe Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Gly Tyr Asn Gly Asp Thr Asn Ser Ala Gln Lys Phe Leu Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Gly Ser Asp Asn Tyr Gly Phe Pro Tyr Asn Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Ser Trp Ala Gln Ser Ala Leu Thr Gln Pro Pro Ser Ala Ser Gly Ser Pro Gly Gln Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Leu Gly Ala Tyr His Phe Val Thr Trp Tyr Gln His Tyr Pro Gly Lys Ala Pro Lys Val Met Ile Tyr Gly Val Arg Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu Gln Asp Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Asn Asn Asp Phe Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ser Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,HL CV07-250 VH  ,HL CV07-250 VL  ,"(16/17) in one embodiment, the antibody or antibody fragment comprises vh and vl domains that comprise the sequences according to seq id no:16 and 17, 24 and 25, 32 and 33, 40 and 41 , 48 and 49, 56 and 57, 64 and 65, 72 and 73, 80 and 81 , 88 and 89, 96 and 97, 104 and 105, 112 and 113, 120 and 121 , 128 and 129, 136 and 137, 144 and 145, 152 and 153, and 160 and 161 , respectively"
https://patents.google.com/patent/WO2021239949A1/en, Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val His Ser Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Ser Ser Ser Val Ser Thr Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Val Ile Pro Pro Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val His Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,HK CV07-209 VH  ,HK CV07-209 VL  ,"(56/57) in one embodiment, the antibody or antibody fragment according to cv07-209 comprises: a heavy chain variable (vh) domain, said vh domain comprising a sequence of at least 70%, 80%, 85%, 90%, at least 95% or complete identity to seq id no:56, and a light chain variable (vl) domain, said vl domain comprising a sequence of at least 70%, 80%, 85%, 90%, at least 95% or complete identity to seq id no:57"
https://patents.google.com/patent/CN111793129A/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Arg Phe Asp Asp His Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Ser Gly Asp Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Ser Ile Ser Arg Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Arg Ser Tyr Gly Pro Pro Asp Val Phe Asn Tyr Glu Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val AspGly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu SerLeu Ser Pro Gly Lys ,Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,Artificial Sequence,Artificial Sequence,"(11/12) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:11, and the light chain amino acid sequence is shown as seq id no:12."
https://patents.google.com/patent/CN1826356B/en, Asp?Val?Val?Met?Thr?Gln?Ser?Pro?Pro?Ser?Leu?Pro?Val?Thr?Pro?Gly Glu?Pro?Ala?Ser?Ile?Ser?Cys?Arg?Ser?Ser?Gln?Ser?Leu?Leu?His?Ser Asn?Gly?Tyr?Asn?Tyr?Leu?Asp?Trp?Tyr?Leu?Gln?Lys?Pro?Gly?Gln?Ser Pro?Gln?Leu?Leu?Ile?Tyr?Leu?Gly?Ser?Asn?Arg?Ala?Ser?Gly?Val?Pro Asp?Arg?Phe?Ser?Gly?Ser?Gly?Ser?Gly?Thr?Asp?Phe?Thr?Leu?Lys?Ile Ser?Arg?Val?Glu?Ala?Glu?Asp?Val?Gly?Val?Tyr?Tyr?Cys?Met?Gln?Ala Leu?Gln?Thr?Pro?Leu?Thr?Phe?Gly?Gln?Gly?Thr?Arg?Leu?Glu?Ile?Lys Arg?Ala?Ala , Met?Ala?Gln?Val?Gln?Leu?Val?Gln?Ser?Gly?Ala?Glu?Val?Lys?Lys?Pro Gly?Ala?Ser?Val?Met?Val?Ser?Cys?Lys?Ala?Ser?Gly?Tyr?Thr?Phe?Ser Asn?Tyr?Ala?Met?His?Trp?Val?Arg?Gln?Gly?Pro?Gly?Gln?Arg?Leu?Glu Trp?Met?Gly?Trp?Ile?Asn?Ala?Asp?Lys?Gly?Gln?Thr?Lys?Tyr?Ser?Gln Lys?Phe?Gln?Gly?Arg?Val?Thr?Ile?Thr?Gly?Asp?Thr?Ser?Ala?Ser?Thr Ala?Tyr?Met?Asp?Leu?Ser?Ser?Leu?Arg?Ser?Glu?Asp?Thr?Ala?Val?Tyr Tyr?Cys?Ala?Arg?Gly?Thr?Gly?Tyr?Leu?Arg?Ser?Tyr?His?Gly?Met?Asp Val?Trp?Gly?Gln?Gly?Thr?Thr?Val?Thr?Val?Ser?Ser ,Variable?light?chain?of?SC03-053 		,Variable?heavy?chain?of?SC03-053 		,(437/435)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:437 that comprises the aminoacid sequence of seq id no:435
https://patents.google.com/patent/CN1826356B/en, Gln?Ser?Val?Val?Thr?Gln?Pro?Pro?Ser?Ala?Ser?Gly?Thr?Pro?Gly?Gln Arg?Val?Thr?Ile?Ser?Cys?Ser?Gly?Ser?Ser?Ser?Asn?Ile?Gly?Ser?Asn Thr?Val?Ser?Trp?Tyr?Gln?Gln?Val?Pro?Gly?Thr?Ala?Pro?Lys?Leu?Leu Ile?Tyr?Arg?Asn?Asn?Gln?Arg?Pro?Pro?Gly?Val?Xaa?Asp?Arg?Phe?Ser Gly?Ser?Lys?Ser?Gly?Thr?Ser?Ala?Ser?Xaa?Ala?Ile?Ser?Gly?Leu?Gln Ser?Asp?Asp?Glu?Ala?Phe?Tyr?Tyr?Cys?Ala?Ala?Trp?Asp?Gly?Ser?Xaa Asn?Gly?Leu?Ala?Phe?Gly?Gly?Gly?Thr?Lys?Leu?Thr?Val?Leu?Gly?Ala Ala ,Met?Ala?Glu?Val?Gln?Leu?Val?Glu?Ser?Gly?Ala?Glu?Val?Lys?Lys?Pro Gly?Ser?Ser?Val?Lys?Val?Ser?Cys?Lys?Ala?Ser?Gly?Gly?Thr?Phe?Ser Ser?Tyr?Ala?Ile?Ser?Trp?Val?Arg?Gln?Ala?Pro?Gly?Gln?Gly?Leu?Glu Trp?Met?Gly?Lys?Ile?Ile?Pro?Ile?Leu?Gly?Lys?Val?Thr?Tyr?Ala?Gln Lys?Phe?Gln?Ala?Arg?Val?Thr?Ile?Thr?Ala?Asp?Glu?Ser?Thr?Ser?Thr Ala?Tyr?Leu?Glu?Leu?Ser?Ser?Leu?Arg?Ser?Glu?Asp?Thr?Ala?Val?Phe Tyr?Cys?Ala?Arg?Asp?Gly?Trp?Asp?Leu?Thr?Gly?Ser?Phe?Leu?Gly?Tyr Gly?Met?Asp?Val?Trp?Gly?Gln?Gly?Thr?Thr?Val?Thr?Val?Ser?Ser ,Variable?light?chain?of?SC03-032 		,Variable?heavy?chain?of?SC03-032 		,(353/351)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:353 that comprises the aminoacid sequence of seq id no:351
https://patents.google.com/patent/CN1826356B/en,Asp?Ile?Gln?Met?Thr?Gln?Ser?Pro?Asp?Ser?Leu?Ala?Val?Ser?Leu?Gly Glu?Arg?Ala?Thr?Ile?Asn?Cys?Lys?Ser?Ser?Gln?Ser?Val?Leu?Tyr?Ser Ser?Asn?Asn?Lys?Asn?Tyr?Leu?Ala?Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Gln Pro?Pro?Lys?Leu?LeuIle?Tyr?Trp?Ala Ser?Thr?Arg?Glu?Ser?Gly?Val Pro?Asp?Arg?Phe?Ser?Gly?Ser?Gly?Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr Ile?Ser?Ser?Leu?Gln?Ala?Glu?Asp?Val?Ala?Val?Tyr?Tyr?Cys?Gln?Gln Tyr?Tyr?Ser?Thr?Pro?Leu?Thr?Phe?Gly?Gly?Gly?Thr?Lys?Val?Glu?Ile Lys?Arg?Ala?Ala , Met?Ala?Glu?Val?Gln?Leu?Val?Gln?Ser?Gly?Gly?Gly?Leu?Val?Gln?Pro Gly?Gly?Ser?Leu?Arg?Leu?Ser?Cys?Ala?Ala?Ser?Gly?Phe?Thr?Phe?Ser Ser?Tyr?Ala?Met?His?Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu?Glu Tyr?Val?Ser?Gly?Ile?Ser?Ser?Asn?Gly?Gly?Ser?Thr?Tyr?Tyr?Ala?Asn Ser?Val?Lys?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp?Asn?Ser?Lys?Asn?Thr Leu?Tyr?Leu?Gln?Met?Gly?Ser?Leu?Arg?Ala?Glu?Asp?Met?Ala?Val?Tyr Tyr?Cys?Ala?Arg?Thr?Thr?Asn?Arg?Ala?Phe?Asp?Ile?Trp?Gly?Gln?Gly Thr?Met?Val?Thr?Val?Ser?Ser,Variable?light?chain?of?SC03-050 		,Variable?heavy?chain?of?SC03-050 		,(425/423)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:425 that comprises the aminoacid sequence of seq id no:423
https://patents.google.com/patent/CN1826356B/en,Asp?Ile?Gln?Met?Thr?Gln?Ser?Pro?Asp?Ser?Leu?Ala?Val?Ser?Leu?Gly Glu?Arg?Ala?Thr?Ile?Asn?Cys?Lys?Ser?Ser?Gln?Ser?Ile?Leu?Tyr?Ser Ser?Asn?Ser?Lys?Asn?Tyr?Leu?Gly?Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Gln Pro?Pro?Lys?Leu?Leu?Ile?Tyr?Trp?Ala?Ser?Thr?Arg?Glu?Ser?Gly?Val Pro?Asp?Arg?Phe?Ser?Gly?Ser?Gly?Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr Ile?Ser?Ser?Leu?Gln?Ala?Glu?Asp?Val?Ala?Val?Tyr?Tyr?Cys?Gln?Gln Tyr?Tyr?Ser?Thr?Pro?Tyr?Ser?Phe?Gly?Gln?Gly?Thr?Lys?Val?Glu?Ile Lys?Arg?Ala?Ala ,Met?Ala?Gln?Val?Gln?Leu?Val?Gln?Ser?Gly?Gly?Gly?Leu?Val?Gln?Pro Gly?Gly?Ser?Leu?Arg?Leu?Ser?Cys?Ala?Ala?Ser?Gly?Phe?Thr?Phe?Ser Ser?Tyr?Ala?Met?His?Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu?Glu Tyr?Val?Ser?Gly?Ile?Ser?Ser?Asn?Gly?Gly?Ser?Thr?Tyr?Tyr?Ala?Asn Ser?Val?Lys?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp?Asn?Ser?Lys?Asn?Thr Leu?Tyr?Leu?Gln?Met?Gly?Ser?Leu?Arg?Ala?Glu?Asp?Met?Ala?Val?Tyr Tyr?Cys?Ala?Arg?Thr?Thr?Asn?Arg?Ala?Phe?Asp?Ile?Trp?Gly?Gln?Gly Thr?Met?Val?Thr?Val?Ser?Ser ,Variable?light?chain?of?SC03-026 		,Variable?heavy?chain?of?SC03-026 		,(333/331)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:333 that comprises the aminoacid sequence of seq id no:331
https://patents.google.com/patent/CN1826356B/en, Gln?Ser?Val?Val?Thr?Gln?Pro?Pro?Ser?Val?Ser?Ala?Ala?Pro?Gly?Gln Lys?Ala?Thr?Ile?Ser?Cys?Ser?Gly?Ser?Ser?Ser?Asn?Ile?Gly?Asn?Asn Tyr?Val?Ser?Trp?Tyr?Gln?Gln?Leu?Pro?Gly?Thr?Ala?Pro?Lys?Leu?Leu Ile?Tyr?Asp?Asn?Asn?Lys?Arg?Pro?Ser?Gly?Ile?Pro?Asn?Arg?Phe?Ser Gly?Ser?Lys?Ser?Gly?Thr?Ser?Ala?Thr?Leu?Gly?Ile?Thr?Gly?Leu?Gln Thr?Gly?Asp?Glu?Ala?Asp?Tyr?Tyr?Cys?Gly?Thr?Trp?Asp?Ser?Ser?Leu Ser?Ala?Tyr?Val?Phe?Gly?Thr?Gly?Thr?Lys?Val?Thr?Val?Leu?Gly?Ala Ala , Met?Ala?Gln?Val?Gln?Leu?Val?Glu?Ser?Gly?Ser?Glu?Leu?Lys?Ile?Pro Gly?Ala?Ser?Val?Lys?Val?Ser?Cys?Lys?Ala?Thr?Gly?Tyr?Thr?Phe?Thr Arg?Tyr?Ser?Leu?Asn?Trp?Val?Arg?Gln?Ala?Pro?Gly?Gln?Gly?Leu?Glu Trp?Val?Gly?Trp?Ile?Asn?Thr?Gln?Thr?Gly?Asn?Ser?Asn?Tyr?Gly?Gln Ala?Phe?Ser?Gly?Arg?Phe?Val?Phe?Ser?Leu?Asp?Thr?Ser?Val?Ser?Thr Ala?Tyr?Leu?Gln?Ile?Ser?Ser?Leu?Gln?Ala?Glu?Asp?Thr?Ala?Thr?Tyr Tyr?Cys?Ala?Arg?Lys?Ser?Ala?Gly?Ser?Asn?Ala?Phe?Asp?Ile?Trp?Gly Gln?Gly?Thr?Met?Val?Thr?Val?Ser?Ser ,Variable?light?chain?of?SC03-024 		,Variable?heavy?chain?of?SC03-024 		,(325/323)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:325 that comprises the aminoacid sequence of seq id no:323
https://patents.google.com/patent/CN1826356B/en, Glu?Leu?Thr?Gln?Ser?Pro?Ser?Ser?Leu?Ser?Ala?Ser?Val?Gly?Asp?Arg Val?Thr?Ile?Thr?Cys?Arg?Ala?Ser?Gln?Ser?Ile?Ser?Ser?Tyr?Leu?Asn Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Lys?Ala?Pro?Lys?Leu?Leu?Ile?Tyr?Ala Ala?Ser?Ser?Leu?Gln?Ser?Gly?Val?Pro?Ser?Arg?Phe?Ser?Gly?Ser?Gly Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr?Ile?Ser?Ser?Leu?Gln?Pro?Glu?Asp Phe?Ala?Thr?Tyr?Tyr?Cys?Gln?Gln?Ser?Tyr?Ser?Thr?Pro?Pro?Thr?Phe Gly?Gln?Gly?Thr?Lys?Val?Glu?Ile?Lys?Arg , Met?Ala?Glu?Val?Gln?Leu?Val?Glu?Ser?Gly?Gly?Gly?Val?Val?Gln?Pro Gly?Arg?Ser?Leu?Arg?Leu?Ser?Cys?Ala?Ala?Ser?Gly?Phe?Thr?Phe?Ser Asp?Tyr?Pro?Met?Asn?Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu?Glu Trp?Val?Ser?Ser?Ile?Ser?Gly?Ser?Gly?Gly?Ser?Thr?Tyr?Tyr?Ala?Asp Ser?Val?Lys?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp?Asn?Ser?Lys?Asn?Thr Leu?Tyr?Leu?Gln?Met?Asn?Ser?Leu?Arg?Ala?Glu?Asp?Thr?Ala?Val?Tyr Tyr?Cys?Ala?Lys?Gly?Leu?Phe?Met?Val?Thr?Thr?Tyr?Ala?Phe?Asp?Tyr Trp?Gly?Gln?Gly?Thr?Leu?Val?Thr?Val?Leu?Glu ,Variable?light?chain?of?SC03-001，SC03-002，SC03-003，SC03-004，SC03-005，SC03-007，SC03-008，SC03-009，SC03-010，SC03-013，SC03-014，SC03-016and?SC03-018 		,Variable?heavy?chain?of?SC03-009 		,(41/29)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:41 that comprises the aminoacid sequence of seq id no:29
https://patents.google.com/patent/CN1826356B/en, Glu?Leu?Thr?Gln?Ser?Pro?Ser?Ser?Leu?Ser?Ala?Ser?Val?Gly?Asp?Arg Val?Thr?Ile?Thr?Cys?Arg?Ala?Ser?Gln?Ser?Ile?Ser?Ser?Tyr?Leu?Asn Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Lys?Ala?Pro?Lys?Leu?Leu?Ile?Tyr?Ala Ala?Ser?Ser?Leu?Gln?Ser?Gly?Val?Pro?Ser?Arg?Phe?Ser?Gly?Ser?Gly Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr?Ile?Ser?Ser?Leu?Gln?Pro?Glu?Asp Phe?Ala?Thr?Tyr?Tyr?Cys?Gln?Gln?Ser?Tyr?Ser?Thr?Pro?Pro?Thr?Phe Gly?Gln?Gly?Thr?Lys?Val?Glu?Ile?Lys?Arg , Met?Ala?Glu?Val?Gln?Leu?Val?Glu?Ser?Gly?Gly?Gly?Leu?Val?Gln?Pro Gly?Gly?Ser?Leu?Arg?Leu?Ser?Cys?Ala?Ala?Ser?Gly?Phe?Thr?Phe?Ser Asp?Tyr?Leu?Met?Asn?Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu?Glu Trp?Val?Gly?Arg?Ile?Arg?Ser?Lys?Ala?Asn?Ser?Tyr?Ala?Thr?Ala?Tyr Ala?Ala?Ser?Val?Lys?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp?Asp?Ser?Lys Asn?Thr?Ala?Tyr?Leu?Gln?Met?Asn?Ser?Leu?Lys?Thr?Glu?Asp?Thr?Ala Val?Tyr?Tyr?Cys?Ala?Lys?Asp?Gly?Ser?Arg?Phe?Pro?Ala?Arg?Phe?Asp Tyr?Trp?Gly?Gln?Gly?Thr?Leu?Val?Thr?Val?Leu?Glu ,Variable?light?chain?of?SC03-001，SC03-002，SC03-003，SC03-004，SC03-005，SC03-007，SC03-008，SC03-009，SC03-010，SC03-013，SC03-014，SC03-016and?SC03-018 		,Variable?heavy?chain?of?SC03-004 		,(41/80)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:41 that comprises the aminoacid sequence of seq id no:80
https://patents.google.com/patent/CN1826356B/en, Gln?Ser?Val?Leu?Thr?Gln?Pro?Pro?Ser?Val?Ser?Gly?Ala?Pro?Gly?Gln Arg?Val?Ser?Ile?Ser?Cys?Ser?Gly?Ser?Gly?Ala?Asn?Gly?Gly?Thr?Asp Pro?Val?Ser?Trp?Tyr?Gln?Lys?Phe?Pro?Gly?Thr?Ala?Pro?His?Leu?Leu Ile?Tyr?Asp?Asn?Asn?Lys?Arg?Pro?Ser?Gly?Ile?Pro?Asp?Arg?Phe?Ser Gly?Ser?Lys?Ser?Gly?Ala?Ser?Ala?Thr?Leu?Asp?Ile?Thr?Gly?Leu?Gln Thr?Gly?Asp?Glu?Ala?Asp?Tyr?Tyr?Cys?Gly?Ala?Trp?Asp?Pro?Ser?Leu Ser?Gly?Tyr?Val?Phe?Gly?Thr?Gly?Thr?Gln?Leu?Thr?Val?Leu?Ser?Ala Ala , Met?Ala?Gln?Val?Gln?Leu?Gln?Gln?Trp?Gly?Ala?Gly?Leu?Leu?Lys?Pro Ser?Glu?Thr?Leu?Ser?Leu?Thr?Cys?Ala?Val?Tyr?Gly?Gly?Ser?Phe?Ser Gly?Phe?Tyr?Trp?Ser?Trp?Ile?Arg?Gln?Pro?Pro?Gly?Lys?Gly?Leu?Glu Trp?Ile?Gly?Glu?Ile?Asn?His?Ser?Gly?Ser?Thr?Asn?Tyr?Asn?Pro?Ser Leu?Lys?Ser?Arg?Val?Thr?Ile?Ser?Ala?Asp?Thr?Ser?Lys?Asn?Gln?Phe Ser?Leu?Lys?Leu?Ser?Ser?Val?Thr?Ala?Ala?Asp?Thr?Ala?Val?Tyr?Tyr Cys?Ala?Arg?Arg?Val?Glu?Val?Val?Glu?Tyr?Gln?Leu?Leu?Arg?Pro?Arg Tyr?Lys?Ser?Trp?Phe?Asp?Pro?Trp?Gly?Gln?Gly?Thr?Leu?Val?Thr?Val Ser?Ser ,Variable?liqht?chain?of?SC03-055 		,Variable?heavy?chain?of?SC03-055 		,(445/443)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:445 that comprises the aminoacid sequence of seq id no:443
https://patents.google.com/patent/CN1826356B/en, Glu?Leu?Thr?Gln?Ser?Pro?Ser?Ser?Leu?Ser?Ala?Ser?Val?Gly?Asp?Arg Val?Thr?Ile?Thr?Cys?Arg?Ala?Ser?Gln?Ser?Ile?Ser?Ser?Tyr?Leu?Asn Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Lys?Ala?Pro?Lys?Leu?Leu?Ile?Tyr?Ala Ala?Ser?Ser?Leu?Gln?Ser?Gly?Val?Pro?Ser?Arg?Phe?Ser?Gly?Ser?Gly Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr?Ile?Ser?Ser?Leu?Gln?Pro?Glu?Asp Phe?Ala?Thr?Tyr?Tyr?Cys?Gln?Gln?Ser?Tyr?Ser?Thr?Pro?Pro?Thr?Phe Gly?Gln?Gly?Thr?Lys?Val?Glu?Ile?Lys?Arg , Met?Ala?Glu?Val?Gln?Leu?Val?Glu?Ser?Gly?Gly?Gly?Leu?Val?Gln?Pro Gly?Gly?Ser?Leu?Arg?Leu?Ser?Cys?Ala?Ala?Ser?Gly?Phe?Thr?Phe?Ser Asp?His?Tyr?Met?Asp?Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu?Glu Trp?Val?Gly?Arg?Thr?Arg?Asn?Lys?Ala?Asn?Ser?Tyr?Thr?Thr?Glu?Tyr Ala?Ala?Ser?Val?Lys?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp?Asp?Ser?Lys Asn?Ser?Leu?Tyr?Leu?Gln?Met?Asn?Ser?Leu?Lys?Thr?Glu?Asp?Thr?Ala Val?Tyr?Tyr?Cys?Ala?Arg?Gly?Ile?Ser?Pro?Phe?Tyr?Phe?Asp?Tyr?Trp Gly?Gln?Gly?Thr?Leu?Val?Thr?Val?Ser?Ser ,Variable?light?chain?of?SC03-001，SC03-002，SC03-003，SC03-004，SC03-005，SC03-007，SC03-008，SC03-009，SC03-010，SC03-013，SC03-014，SC03-016and?SC03-018 		,Variable?heavy?chain?of?SC03-014 		,(41/37)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:41 that comprises the aminoacid sequence of seq id no:37
https://patents.google.com/patent/CN1826356B/en, Asp?Ile?Gln?Met?Thr?Gln?Ser?Pro?Asp?Ser?Leu?Ala?Val?Ser?Leu?Gly Glu?Arg?Ala?Thr?Ile?Asn?Cys?Lys?Ser?Ser?Gln?Ser?Val?Leu?Tyr?Ser Ser?Asn?Asn?Lys?Asn?Tyr?Leu?Ala?Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Gln Pro?Pro?Lys?Leu?Leu?Ile?Tyr?Trp?Ala?Ser?Thr?Arg?Glu?Ser?Gly?Val Pro?Asp?Arg?Phe?Ser?Gly?Ser?Gly?Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr Ile?Ser?Ser?Leu?Gln?Ala?Glu?Asp?Val?Ala?Val?Tyr?Tyr?Cys?Gln?Gln Tyr?Tyr?Ser?Thr?Pro?Tyr?Ser?Phe?Gly?Gln?Gly?Thr?Lys?Val?Asp?Ile Lys?Arg?Ala?Ala , Met?Ala?Gln?Val?Gln?Leu?Val?Gln?Ser?Gly?Gly?Gly?Leu?Val?Gln?Pro Gly?Gly?Ser?Leu?Arg?Leu?Ser?Cys?Ala?Ala?Ser?Gly?Phe?Thr?Phe?Ser Ser?Tyr?Ala?Met?His?Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu?Glu Tyr?Val?Ser?Gly?Ile?Ser?Ser?Asn?Gly?Gly?Ser?Thr?Tyr?Tyr?Ala?Asn Ser?Val?Lys?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp?Asn?Ser?Lys?Asn?Thr Leu?Tyr?Leu?Gln?Met?Gly?Ser?Leu?Arg?Ala?Glu?Asp?Met?Ala?Val?Tyr Tyr?Cys?Ala?Arg?Thr?Thr?Asn?Arg?Ala?Phe?Asp?Ile?Trp?Gly?Gln?Gly Thr?Met?Val?Thr?Val?Ser?Ser ,Variable?light?chain?of?SC03-027 		,Variable?heavy?chain?of?SC03-027 		,(337/335)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:337 that comprises the aminoacid sequence of seq id no:335
https://patents.google.com/patent/CN1826356B/en, Ser?Ser?Glu?Leu?Thr?Gln?Asp?Pro?Ala?Val?Ser?Val?Ala?Leu?Gly?Gln Thr?Val?Arg?Ile?Thr?Cys?Gln?Gly?Asp?Ser?Leu?Arg?Ser?Tyr?Tyr?Ala Ser?Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Gln?Ala?Pro?Val?Leu?Val?Ile?Tyr Gly?Lys?Asn?Asn?Arg?Pro?Ser?Gly?Ile?Pro?Asp?Arg?Phe?Ser?Gly?Ser Ser?Ser?Gly?Asn?Thr?Ala?Ser?Leu?Thr?Ile?Thr?Gly?Ala?Gln?Ala?Glu Asp?Glu?Ala?Asp?Tyr?Tyr?Cys?Asn?Gly?Arg?Asp?Ser?Ser?Gly?Asn?His Trp?Val?Phe?Gly?Gly?Gly?Thr?Lys?Leu?Thr?Val?Leu?Gly?Ala?Ala , Met?Ala?Lys?Val?Gln?Leu?Val?Gln?Ser?Gly?Gly?Gly?Leu?Ile?Gln?Pro Gly?Gly?Ser?Leu?Arg?Leu?Ser?Cys?Ala?Ala?Ser?Gly?Phe?Thr?Val?Ser Ser?Asn?Tyr?Met?Ser?Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu?Glu Trp?Val?Ser?Ile?Val?Phe?Ser?Gly?Gly?Ser?Thr?Tyr?Tyr?Ala?Asp?Ser Val?Lys?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp?Asn?Ser?Lys?Asn?Thr?Leu Tyr?Leu?Gln?Met?Asn?Ser?Leu?Arg?Ala?Glu?Asp?Thr?Ala?Val?Tyr?Tyr Cys?Ala?Arg?Asp?Ala?His?Arg?Gly?Phe?Gly?Met?Asp?Val?Trp?Gly?Gln Gly?Thr?Thr?Val?Thr?Val?Ser?Ser ,Variable?light?chain?of?SC03-037 		,Variable?heavy?chain?of?SC03-037 		,(373/371)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:373 that comprises the aminoacid sequence of seq id no:371
https://patents.google.com/patent/CN1826356B/en, Asp?Ile?Gln?Met?Thr?Gln?Ser?Pro?Asp?Ser?Leu?Ala?Val?Ser?Leu?Gly Glu?Arg?Ala?Thr?Ile?Asn?Cys?Arg?Ser?Ser?Gln?Ser?Val?Leu?Tyr?Ser Ser?Asn?Asn?Lys?Asn?Tyr?Leu?Ala?Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Gln Pro?Pro?Lys?Leu?Leu?Ile?Tyr?Trp?Ala?Ser?Thr?Arg?Glu?Ser?Gly?Val Pro?Asp?Arg?Phe?Ser?Gly?Ser?Gly?Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr Ile?Ser?Ser?Leu?Gln?Ala?Glu?Asp?Val?Ala?Val?Tyr?Tyr?Cys?Gln?Gln Tyr?Tyr?Ser?Ser?Pro?Tyr?Ser?Phe?Gly?Gln?Gly?Thr?Lys?Leu?Glu?Ile Lys?Arg?Ala?Ala , Met?Ala?Gln?Val?Gln?Leu?Val?Gln?Ser?Gly?Gly?Gly?Leu?Val?Gln?Pro Gly?Gly?Ser?Leu?Arg?Leu?Ser?Cys?Ala?Ala?Ser?Gly?Phe?Thr?Phe?Ser Ser?Tyr?Ala?Met?His?Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu?Glu Tyr?Val?Ser?Gly?Ile?Ser?Ser?Asn?Gly?Gly?Ser?Thr?Tyr?Tyr?Ala?Asn Ser?Val?Lys?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp?Asn?Ser?Lys?Asn?Thr Leu?Tyr?Leu?Gln?Met?Gly?Ser?Leu?Arg?Ala?Glu?Asp?Met?Ala?Val?Tyr Tyr?Cys?Ala?Arg?Thr?Thr?Asn?Arg?Ala?Phe?Asp?Ile?Trp?Gly?Gln?Gly Thr?Met?Val?Thr?Val?Ser?Ser ,Variable?light?chain?of?SC03-040 		,Variable?heavy?chain?of?SC03-040 		,(385/383)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:385 that comprises the aminoacid sequence of seq id no:383
https://patents.google.com/patent/CN1826356B/en, Asp?Ile?Gln?Met?Thr?Gln?Ser?Pro?Asp?Ser?Leu?Ala?Val?Ser?Leu?Gly Glu?Arg?Ala?Thr?Ile?Asn?Cys?Lys?Ser?Ser?Gln?Lys?Ile?Leu?His?Ser Ser?Asn?Asn?Lys?Asn?Tyr?Leu?Ala?Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Gln Pro?Pro?Lys?Leu?Leu?Ile?Tyr?Trp?Ala?Ser?Thr?Arg?Glu?Ser?Gly?Val Pro?Asp?Arg?Phe?Ser?Gly?Ser?Gly?Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr Ile?Ser?Ser?Leu?Gln?Ala?Glu?Asp?Val?Ala?Val?Tyr?Tyr?Cys?Gln?Gln Tyr?Tyr?Ser?Thr?Pro?Pro?Val?Phe?Gly?Gly?Gly?Thr?Lys?Val?Glu?Ile Lys?Arg?Ala?Ala , Met?Ala?Glu?Val?Gln?Leu?Val?Gln?Ser?Gly?Ser?Glu?Val?Lys?Lys?Pro Gly?Glu?Ser?Leu?Lys?Ile?Ser?Cys?Lys?Gly?Ser?Gly?Tyr?Gly?Phe?Ile Thr?Tyr?Trp?Ile?Gly?Trp?Val?Arg?Gln?Met?Pro?Gly?Lys?Gly?Leu?Glu Trp?Met?Gly?Ile?Ile?Tyr?Pro?Gly?Asp?Ser?Glu?Thr?Arg?Tyr?Ser?Pro Ser?Phe?Gln?Gly?Gln?Val?Thr?Ile?Ser?Ala?Asp?Lys?Ser?Ile?Asn?Thr Ala?Tyr?Leu?Gln?Trp?Ser?Ser?Leu?Lys?Ala?Ser?Asp?Thr?Ala?Ile?Tyr Tyr?Cys?Ala?Gly?Gly?Ser?Gly?Ile?Ser?Thr?Pro?Met?Asp?Val?Trp?Gly Gln?Gly?Thr?Thr?Val?Thr?Val?Ser?Ser ,Variable?light?chain?of?SC03-020 		,Variable?heavy?chain?of?SC03-020 		,(309/307)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:309 that comprises the aminoacid sequence of seq id no:307
https://patents.google.com/patent/CN1826356B/en, Asp?Val?Val?Met?Thr?Gln?Ser?Pro?Asp?Ser?Leu?Ala?Val?Ser?Leu?Gly Glu?Arg?Ala?Thr?Ile?Asn?Cys?Lys?Ser?Ser?Gln?Ser?Val?Leu?His?Ser Ser?Asn?Asn?Lys?Asn?Tyr?Leu?Ala?Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Gln Pro?Pro?Lys?Leu?Leu?Ile?Tyr?Trp?Ala?Ser?Thr?Arg?Gln?Ser?Gly?Val Pro?Asp?Arg?Phe?Ser?Gly?Ser?Gly?Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr Ile?Ser?Ser?Leu?Gln?Ala?Glu?Asp?Val?Ala?Val?Tyr?Tyr?Cys?Gln?Gln Tyr?Tyr?Ser?Thr?Pro?Pro?Thr?Phe?Gly?Gln?Gly?Thr?Lys?Val?Glu?Ile Lys?Arg?Ala?Ala , Met?Ala?Gln?Val?Gln?Leu?Val?Gln?Ser?Gly?Thr?Glu?Val?Lys?Lys?Pro Gly?Glu?Ser?Leu?Lys?Ile?Ser?Cys?Lys?Gly?Ser?Gly?Tyr?Gly?Phe?Ile Thr?Tyr?Trp?Ile?Gly?Trp?Val?Arg?Gln?Met?Pro?Gly?Lys?Gly?Leu?Glu Trp?Met?Gly?Ile?Ile?Tyr?Pro?Gly?Asp?Ser?Glu?Thr?Arg?Tyr?Ser?Pro Ser?Phe?Gln?Gly?Gln?Val?Thr?Ile?Ser?Ala?Asp?Lys?Ser?Ile?Asn?Thr Ala?Tyr?Leu?Gln?Trp?Ser?Ser?Leu?Lys?Ala?Ser?Asp?Thr?Ala?Ile?Tyr Tyr?Cys?Ala?Gly?Gly?Ser?Gly?Ile?Ser?Thr?Pro?Met?Asp?Val?Trp?Gly Gln?Gly?Thr?Thr?Val?Thr?Val?Ser?Ser ,Variable?light?chain?of?SC03-021 		,Variable?heavy?chain?of?SC03-021 		,(313/311)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:313 that comprises the aminoacid sequence of seq id no:311
https://patents.google.com/patent/CN1826356B/en, Glu?Leu?Thr?Gln?Ser?Pro?Ser?Ser?Leu?Ser?Ala?Ser?Val?Gly?Asp?Arg Val?Thr?Ile?Thr?Cys?Arg?Ala?Ser?Gln?Ser?Ile?Ser?Ser?Tyr?Leu?Asn Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Lys?Ala?Pro?Lys?Leu?Leu?Ile?Tyr?Ala Ala?Ser?Ser?Leu?Gln?Ser?Gly?Val?Pro?Ser?Arg?Phe?Ser?Gly?Ser?Gly Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr?Ile?Ser?Ser?Leu?Gln?Pro?Glu?Asp Phe?Ala?Thr?Tyr?Tyr?Cys?Gln?Gln?Ser?Tyr?Ser?Thr?Pro?Pro?Thr?Phe Gly?Gln?Gly?Thr?Lys?Val?Glu?Ile?Lys?Arg , Met?Ala?Glu?Val?Gln?Leu?Val?Glu?Ser?Gly?Gly?Gly?Leu?Val?Gln?Pro Gly?Gly?Ser?Leu?Arg?Leu?Ser?Cys?Ala?Ala?Ser?Gly?Phe?Thr?Phe?Ser Ser?Tyr?Pro?Met?Asn?Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu?Glu Trp?Val?Ser?Ala?Ile?Ser?Gly?Ser?Gly?Gly?Ser?Thr?Tyr?Tyr?Ala?Asp Ser?Val?Lys?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp?Asn?Ser?Lys?Asn?Thr Leu?Tyr?Leu?Gln?Met?Asn?Ser?Leu?Arg?Ala?Glu?Asp?Thr?Ala?Val?Tyr Tyr?Cys?Ala?Arg?Arg?Ser?Tyr?Phe?Arg?Arg?Phe?Asp?Tyr?Trp?Gly?Gln Gly?Thr?Leu?Val?Thr?Val?Leu?Glu ,Variable?light?chain?of?SC03-001，SC03-002，SC03-003，SC03-004，SC03-005，SC03-007，SC03-008，SC03-009，SC03-010，SC03-013，SC03-014，SC03-016and?SC03-018 		,Variable?heavy?chain?of?SC03-003 		,(41/19)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:41 that comprises the aminoacid sequence of seq id no:19
https://patents.google.com/patent/CN1826356B/en, Asp?Ile?Gln?Leu?Thr?Gln?Ser?Pro?Asp?Ser?Leu?Ala?Val?Ser?Leu?Gly Glu?Arg?Ala?Thr?Ile?Asn?Cys?Lys?Ser?Ser?Gln?Ser?Val?Leu?Tyr?Ser Ser?Asn?Asn?Lys?Asn?Tyr?Leu?Ala?Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Gln Pro?Pro?Lys?Leu?Leu?Ile?Tyr?Trp?Ala?Ser?Thr?Arg?Glu?Ser?Gly?Val Pro?Asp?Arg?Phe?Ser?Gly?Ser?Gly?Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr Ile?Ser?Ser?Leu?Gln?Ala?Glu?Asp?Val?Ala?Val?Tyr?Tyr?Cys?Gln?Gln Tyr?Tyr?Ser?Thr?Pro?Leu?Thr?Phe?Gly?Gly?Gly?Thr?Lys?Val?Glu?Ile Lys?Arg?Ala?Ala ,Met?Ala?Glu?Val?Gln?Leu?Val?Glu?Thr?Gly?Gly?Gly?Leu?Val?Gln?Pro Gly?Gly?Ser?Leu?Arg?Leu?Ser?Cys?Ala?Ala?Ser?Gly?Phe?Thr?Phe?Ser Ser?Tyr?Ala?Met?His?Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu?Glu Tyr?Val?Ser?Gly?Ile?Ser?Ser?Asn?Gly?Gly?Ser?Thr?Tyr?Tyr?Ala?Asn Ser?Val?Lys?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp?Asn?Ser?Lys?Asn?Thr Leu?Tyr?Leu?Gln?Met?Gly?Ser?Leu?Arg?Ala?Glu?Asp?Met?Ala?Val?Tyr Tyr?Cys?Ala?Arg?Thr?Thr?Asn?Arg?Ala?Phe?Asp?Ile?Trp?Gly?Gln?Gly Thr?Met?Val?Thr?Val?Ser?Ser ,Variable?light?chain?of?SC03-048 		,Variable?heavy?chain?of?SC03-048 		,(417/415)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:417 that comprises the aminoacid sequence of seq id no:415
https://patents.google.com/patent/CN1826356B/en, Asp?Ile?Gln?Met?Thr?Gln?Ser?Pro?Ser?Ser?Leu?Ser?Ala?Ser?Val?Gly Asp?Arg?Val?Thr?Ile?Thr?Cys?Arg?Ala?Ser?Gln?Gly?Ile?Arg?Asn?Asp Leu?Gly?Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Lys?Ala?Pro?Asn?Leu?Leu?Ile Tyr?Gln?Ala?Ser?Ala?Leu?Gln?Ser?Gly?Val?Pro?Ser?Arg?Phe?Ser?Gly Ser?Glu?Ser?Gly?Ala?Glu?Phe?Thr?Leu?Thr?Ile?Ser?Ser?Leu?His?Pro Asp?Asp?Phe?Ala?Thr?Tyr?Tyr?Cys?Gln?Gln?Tyr?His?Asp?Phe?Pro?Ile Thr?Phe?Gly?Gln?Gly?Thr?Arg?Leu?Glu?Ile?Lys?Arg?Ala?Ala , Met?Ala?Gln?Val?Gln?Leu?Val?Gln?Ser?Gly?Ala?Glu?Val?Lys?Lys?Pro Gly?Ser?Ser?Val?Lys?Val?Ser?Cys?Lys?Ala?Ser?Gly?Gly?Thr?Phe?Ser Arg?Tyr?Ala?Ile?Ser?Trp?Val?Arg?Gln?Ala?Pro?Gly?Gln?Gly?Leu?Glu Trp?Met?Gly?Arg?Ile?Asn?Pro?Ile?Leu?Asn?Leu?Thr?Asn?Tyr?Ala?Gln Lys?Phe?Gln?Gly?Arg?Val?Thr?Ile?Thr?Ala?Asp?Lys?Ser?Thr?Ser?Thr Ala?Tyr?Met?Glu?Met?Ser?Ser?Leu?Arg?Ser?Glu?Asp?Thr?Ala?Ile?Tyr Tyr?Cys?Ala?Ser?Pro?Asp?Ile?Val?Val?Ala?Gly?His?Ala?Ser?Pro?Pro His?Tyr?Thr?Met?Asp?Val?Trp?Gly?Gln?Gly?Thr?Thr?Val?Thr?Val?Ser Ser ,Variable?light?chain?of?SC03-057 		,Variable?heavy?chain?of?SC03-057 		,(453/451)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:453 that comprises the aminoacid sequence of seq id no:451
https://patents.google.com/patent/CN1826356B/en,Asp?Val?Val?Met?Thr?Gln?Ser?Pro?Asp?Ser?Leu?Ala?Val?Ser?Leu?Gly Glu?Arg?Ala?Thr?Ile?Asn?Cys?Lys?Ser?Ser?Gln?Ser?Val?Leu?Tyr?Ser Ser?Asn?Asp?Lys?Asn?Tyr?Leu?Ala?Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Gln Pro?Pro?Lys?Leu?Leu?Ile?Tyr?Trp?Ala?Ser?Thr?Arg?Glu?Ser?Gly?Val Pro?Asp?Arg?Phe?Ser?Gly?Ser?Gly?Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr Ile?Ser?Ser?Leu?Gln?Ala?Glu?Asp?Val?Ala?Val?Tyr?Tyr?Cys?Gln?Gln Tyr?Tyr?Ser?Thr?Pro?Tyr?Ser?Phe?Gly?Gln?Gly?Thr?Lys?Leu?Glu?Ile Lys?Arg?Ala?Ala , Met?Ala?Gln?Met?Gln?Leu?Val?Gln?Ser?Gly?Gly?Gly?Leu?Val?Gln?Pro Gly?Gly?Ser?Leu?Arg?Leu?Ser?Cys?Ala?Ala?Ser?Gly?Phe?Thr?Phe?Ser Ser?Tyr?Ala?Met?His?Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu?Glu Tyr?Val?Ser?Gly?Ile?Ser?Ser?Asn?Gly?Gly?Ser?Thr?Tyr?Tyr?Ala?Asn Ser?Val?Lys?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp?Asn?Ser?Lys?Asn?Thr Leu?Tyr?Leu?Gln?Met?Gly?Ser?Leu?Arg?Ala?Glu?Asp?Met?Ala?Val?Tyr Tyr?Cys?Ala?Arg?Thr?Thr?Asn?Arg?Ala?Phe?Asp?Ile?Trp?Gly?Gln?Gly Thr?Met?Val?Thr?Val?Ser?Ser ,Variable?light?chain?of?SC03-042 		,n?can?be?a，t，c，or?g 		,(393/391)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:393 that comprises the aminoacid sequence of seq id no:391
https://patents.google.com/patent/CN1826356B/en, Ser?Glu?Leu?Thr?Gln?Asp?Pro?Ala?Val?Ser?Val?Ala?Leu?Gly?Gln?Thr Val?Arg?Ile?Thr?Cys?Gln?Gly?Asp?Ser?Leu?Arg?Ser?Tyr?Tyr?Ala?Ser Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Gln?Ala?Pro?Val?Leu?Val?Ile?Tyr?Gly Lys?Asn?Asn?Arg?Pro?Ser?Gly?Ile?Pro?Asp?Arg?Phe?Ser?Gly?Ser?Ser Ser?Gly?Asn?Thr?Ala?Ser?Leu?Thr?Ile?Thr?Gly?Ala?Gln?Ala?Glu?Asp Glu?Ala?Asp?Tyr?Tyr?Cys?Asn?Ser?Arg?Asp?Ser?Ser?Gly?Asn?His?Val Val?Phe?Gly?Gly?Gly?Thr?Lys?Leu?Thr?Val?Leu?Gly , Met?Ala?Gln?Val?Gln?Leu?Val?Gln?Ser?Gly?Ala?Glu?Val?Lys?Lys?Pro Gly?Ala?Ser?Val?Lys?Val?Ser?Cys?Lys?Ala?Ser?Gly?Tyr?Thr?Phe?Thr Ser?Tyr?Gly?Ile?Ser?Trp?Val?Arg?Gln?Ala?Pro?Gly?Gln?Gly?Leu?Glu Trp?Met?Gly?Trp?Ile?Ser?Ala?Tyr?Asn?Gly?Asn?Thr?Asn?Tyr?Ala?Gln Lys?Leu?Gln?Gly?Arg?Val?Thr?Met?Thr?Thr?Asp?Thr?Ser?Thr?Ser?Thr Ala?Tyr?Met?Glu?Leu?Ser?Ser?Leu?Arg?Ser?Asp?Asp?Thr?Ala?Val?Tyr Tyr?Cys?Ala?Arg?Met?Phe?Arg?Lys?Ser?Ser?Phe?Asp?Ser?Trp?Gly?Gln Gly?Thr?Leu?Val?Thr?Val?Ser?Arg ,Variable?light?chain?of?SC03-012?and?SC03-015 		,Variable?heavy?chain?of?SC03-012 		,(45/33)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:45 that comprises the aminoacid sequence of seq id no:33
https://patents.google.com/patent/CN1826356B/en, Glu?Leu?Thr?Gln?Ser?Pro?Ser?Ser?Leu?Ser?Ala?Ser?Val?Gly?Asp?Arg Val?Thr?Ile?Thr?Cys?Arg?Ala?Ser?Gln?Ser?Ile?Ser?Ser?Tyr?Leu?Asn Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Lys?Ala?Pro?Lys?Leu?Leu?Ile?Tyr?Ala Ala?Ser?Ser?Leu?Gln?Ser?Gly?Val?Pro?Ser?Arg?Phe?Ser?Gly?Ser?Gly Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr?Ile?Ser?Ser?Leu?Gln?Pro?Glu?Asp Phe?Ala?Thr?Tyr?Tyr?Cys?Gln?Gln?Ser?Tyr?Ser?Thr?Pro?Pro?Thr?Phe Gly?Gln?Gly?Thr?Lys?Val?Glu?Ile?Lys?Arg ,Met?Ala?Glu?Val?Gln?Leu?Val?Glu?Ser?Gly?Gly?Gly?Val?Val?Gln?Pro Gly?Arg?Ser?Leu?Arg?Leu?Ser?Cys?Ala?Thr?Ser?Gly?Phe?Thr?Phe?Ser Gly?Tyr?Thr?Met?His?Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu?Glu Trp?Val?Ser?Ser?Ile?Ser?Gly?Gly?Ser?Thr?Tyr?Tyr?Ala?Asp?Ser?Arg Lys?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp?Asn?Ser?Lys?Asn?Thr?Leu?Tyr Leu?Gln?Met?Asn?Asn?Leu?Arg?Ala?Glu?Asp?Thr?Ala?Val?Tyr?Tyr?Cys Ala?Lys?Gly?Gly?Gly?Leu?Pro?Tyr?Leu?Ser?Phe?Asp?Tyr?Trp?Gly?Gln Gly?Thr?Leu?Val?Thr?Val?Leu?Glu ,Variable?light?chain?of?SC03-001，SC03-002，SC03-003，SC03-004，SC03-005，SC03-007，SC03-008，SC03-009，SC03-010，SC03-013，SC03-014，SC03-016and?SC03-018 		,Variable?heavy?chain?of?SC03-010 		,(41/31)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:41 that comprises the aminoacid sequence of seq id no:31
https://patents.google.com/patent/CN1826356B/en, Asp?Ile?Gln?Met?Thr?Gln?Ser?Pro?Asp?Ser?Leu?Ala?Val?Ser?Leu?Gly Glu?Arg?Ala?Thr?Ile?Asn?Cys?Lys?Ser?Ser?Gln?Ser?Val?Leu?Tyr?Ser Ser?Asn?Asn?Lys?Asn?Tyr?Leu?Ala?Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Gln Pro?Pro?Lys?Leu?Leu?Ile?Tyr?Trp?Ala?Ser?Thr?Arg?Glu?Ser?Gly?Val Pro?Asp?Arg?Phe?Ser?Gly?Ser?Gly?Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr Ile?Ser?Ser?Leu?Gln?Ala?Glu?Asp?Val?Ala?Val?Tyr?Tyr?Cys?Gln?Gln Tyr?Tyr?Ser?Thr?Pro?Leu?Thr?Phe?Gly?Gln?Gly?Thr?Lys?Val?Glu?Ile Lys?Arg?Ala?Ala , Met?Ala?Glu?Val?Gln?Val?Val?Gln?Ser?Gly?Gly?Gly?Leu?Val?Gln?Pro Gly?Gly?Ser?Leu?Lys?Leu?Ser?Cys?Ala?Ala?Ser?Gly?Phe?Thr?Phe?Ser Ser?Tyr?Ala?Met?His?Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu?Glu Tyr?Val?Ser?Gly?Ile?Ser?Ser?Asn?Gly?Gly?Ser?Thr?Tyr?Tyr?Ala?Asn Ser?Val?Lys?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp?Asn?Ser?Lys?Asn?Thr Leu?Tyr?Leu?Gln?Met?Gly?Ser?Leu?Arg?Ala?Glu?Asp?Met?Ala?Val?Tyr Tyr?Cys?Ala?Arg?Thr?Thr?Asn?Arg?Ala?Phe?Asp?Ile?Trp?Gly?Gln?Gly Thr?Met?Val?Thr?Val?Ser?Ser ,Variable?light?chain?of?SC03-030 		,Variable?heavy?chain?of?SC03-030 		,(345/343)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:345 that comprises the aminoacid sequence of seq id no:343
https://patents.google.com/patent/CN1826356B/en, Asp?Ile?Gln?Leu?Thr?Gln?Ser?Pro?Asp?Ser?Leu?Ala?Val?Ser?Leu?Gly Glu?Arg?Ala?Thr?Ile?Asn?Cys?Lys?Ser?Ser?Gln?Ser?Val?Leu?Tyr?Arg Ser?Asn?Asn?Lys?Asn?Tyr?Leu?Ala?Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Gln Pro?Pro?Lys?Leu?Leu?Ile?Tyr?Trp?Ala?Ser?Thr?Arg?Glu?Ser?Gly?Val Ser?Glu?Arg?Phe?Ser?Gly?Ser?Gly?Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr Ile?Ser?Ser?Leu?Gln?Ala?Glu?Asp?Val?Ala?Val?Tyr?Tyr?Cys?Gln?Gln Tyr?Tyr?Ser?Thr?Pro?Tyr?Ser?Phe?Gly?Gln?Gly?Thr?Lys?Leu?Glu?Ile Lys?Arg?Ala?Ala ,Met?Ala?Gln?Val?Gln?Leu?Val?Gln?Ser?Gly?Gly?Gly?Leu?Val?Gln?Pro Gly?Gly?Ser?Leu?Arg?Leu?Ser?Cys?Ala?Ala?Ser?Gly?Phe?Thr?Phe?Ser Ser?Tyr?Ala?Met?His?Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu?Glu Tyr?Val?Ser?Gly?Ile?Ser?Ser?Asn?Gly?Gly?Ser?Thr?Tyr?Tyr?Ala?Asn Ser?Val?Lys?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp?Asn?Ser?Lys?Asn?Thr Leu?Tyr?Leu?Gln?Met?Gly?Ser?Leu?Arg?Ala?Glu?Asp?Met?Ala?Val?Tyr Tyr?Cys?Ala?Arg?Thr?Thr?Asn?Arg?Ala?Phe?Asp?Ile?Trp?Gly?Gln?Gly Thr?Met?Val?Thr?Val?Ser?Ser ,Variable?light?chain?of?SC03-043 		,Variable?heavy?chain?of?SC03-043 		,(397/395)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:397 that comprises the aminoacid sequence of seq id no:395
https://patents.google.com/patent/CN1826356B/en, Asp?Val?Val?Met?Thr?Gln?Ser?Pro?Asp?Ser?Leu?Ala?Val?Ser?Leu?Gly Glu?Arg?Ala?Thr?Ile?Asn?Cys?Lys?Thr?Ser?His?Asn?Ile?Phe?Ser?Arg Ser?Asn?Asn?Lys?Asp?Tyr?Leu?Ala?Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Gln Pro?Pro?Arg?Leu?Leu?Ile?Tyr?Trp?Ala?Ser?Thr?Arg?Ala?Ser?Gly?Val Pro?Glu?Arg?Phe?Ser?Gly?Ser?Gly?Ser?Gly?Thr?Asp?Phe?Ser?Leu?Thr Ile?Ser?Ser?Leu?Gln?Ala?Glu?Asp?Val?Ala?Val?Tyr?Tyr?Cys?Gln?Gln Tyr?Tyr?Ser?Ser?Pro?Met?Tyr?Ser?Phe?Gly?Gln?Gly?Thr?Lys?Val?Glu Ile?Lys?Arg?Ala?Ala ,Met?Ala?Gln?Val?Gln?Leu?Val?Gln?Ser?Gly?Thr?Glu?Val?Lys?Lys?Pro Gly?Glu?Ser?Leu?Lys?Ile?Ser?Cys?Lys?Gly?Ser?Gly?Tyr?Gly?Phe?Ile Thr?Tyr?Trp?Ile?Gly?Trp?Val?Arg?Gln?Met?Pro?Gly?Lys?Gly?Leu?Glu Trp?Met?Gly?Ile?Ile?Tyr?Pro?Gly?Asp?Ser?Glu?Thr?Arg?Tyr?Ser?Pro Ser?Phe?Gln?Gly?Gln?Val?Thr?Ile?Ser?Ala?Asp?Lys?Ser?Ile?Asn?Thr Ala?Tyr?Leu?Gln?Trp?Ser?Ser?Leu?Lys?Ala?Ser?Asp?Thr?Ala?Ile?Tyr Tyr?Cys?Ala?Gly?Gly?Ser?Gly?Ile?Ser?Thr?Pro?Met?Asp?Val?Trp?Gly Gln?Gly?Thr?Thr?Val?Thr?Val?Ser?Ser ,Variable?light?chain?of?SC03-033 		,Variable?heavy?chain?of?SC03-033 		,(357/355)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:357 that comprises the aminoacid sequence of seq id no:355
https://patents.google.com/patent/CN1826356B/en, Glu?Leu?Thr?Gln?Ser?Pro?Ser?Ser?Leu?Ser?Ala?Ser?Val?Gly?Asp?Arg Val?Thr?Ile?Thr?Cys?Arg?Ala?Ser?Gln?Ser?Ile?Ser?Ser?Tyr?Leu?Asn Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Lys?Ala?Pro?Lys?Leu?Leu?Ile?Tyr?Ala Ala?Ser?Ser?Leu?Gln?Ser?Gly?Val?Pro?Ser?Arg?Phe?Ser?Gly?Ser?Gly Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr?Ile?Ser?Ser?Leu?Gln?Pro?Glu?Asp Phe?Ala?Thr?Tyr?Tyr?Cys?Gln?Gln?Ser?Tyr?Ser?Thr?Pro?Pro?Thr?Phe Gly?Gln?Gly?Thr?Lys?Val?Glu?Ile?Lys?Arg , Met?Ala?Glu?Val?Gln?Leu?Val?Glu?Ser?Gly?Gly?Gly?Leu?Ile?Gln?Pro Gly?Gly?Ser?Leu?Arg?Leu?Ser?Cys?Ala?Ala?Ser?Gly?Phe?Thr?Phe?Ser Gly?Tyr?Thr?Met?Ser?Trp?Val?Arg?Gln?Ala?Pro?Gly?Gln?Gly?Leu?Glu Trp?Val?Ser?Ser?Ile?Ser?Gly?Gly?Ser?Thr?Tyr?Tyr?Ala?Asp?Ser?Arg Lys?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp?Asn?Ser?Lys?Asn?Thr?Leu?Tyr Leu?Gln?Met?Asn?Asn?Leu?Arg?Ala?Glu?Asp?Thr?Ala?Val?Tyr?Tyr?Cys Ala?Lys?Gly?Gly?Gly?Arg?Pro?Tyr?Asn?Pro?Phe?Asp?Tyr?Trp?Gly?Gln Gly?Thr?Leu?Val?Thr?Val?Leu?Glu ,Variable?light?chain?of?SC03-001，SC03-002，SC03-003，SC03-004，SC03-005，SC03-007，SC03-008，SC03-009，SC03-010，SC03-013，SC03-014，SC03-016and?SC03-018 		,Variable?heavy?chain?of?SC03-005 		,(41/21)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:41 that comprises the aminoacid sequence of seq id no:21
https://patents.google.com/patent/CN1826356B/en, Glu?Leu?Thr?Gln?Ser?Pro?Ser?Ser?Leu?Ser?Ala?Ser?Val?Gly?Asp?Arg Val?Thr?Ile?Thr?Cys?Arg?Ala?Ser?Gln?Ser?Ile?Ser?Ser?Tyr?Leu?Asn Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Lys?Ala?Pro?Lys?Leu?Leu?Ile?Tyr?Ala Ala?Ser?Ser?Leu?Gln?Ser?Gly?Val?Pro?Ser?Arg?Phe?Ser?Gly?Ser?Gly Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr?Ile?Ser?Ser?Leu?Gln?Pro?Glu?Asp Phe?Ala?Thr?Tyr?Tyr?Cys?Gln?Gln?Ser?Tyr?Ser?Thr?Pro?Pro?Thr?Phe Gly?Gln?Gly?Thr?Lys?Val?Glu?Ile?Lys?Arg , Met?Ala?Glu?Val?Gln?Leu?Val?Glu?Ser?Gly?Gly?Gly?Val?Val?Gln?Pro Gly?Arg?Ser?Leu?Arg?Leu?Ser?Cys?Ala?Ala?Ser?Gly?Phe?Thr?Phe?Ser Ser?Tyr?Pro?Met?Asn?Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu?Glu Trp?Val?Ser?Ala?Ile?Ser?Gly?Ser?Gly?Gly?Ser?Thr?Tyr?Tyr?Ala?Asp Ser?Val?Lys?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp?Asn?Ser?Lys?Asn?Thr Leu?Tyr?Leu?Gln?Met?Asn?Ser?Leu?Arg?Ala?Glu?Asp?Thr?Ala?Val?Tyr Tyr?Cys?Ala?Arg?Arg?Val?Arg?Pro?Arg?Arg?Phe?Asp?Tyr?Trp?Gly?Gln Gy?Thr?Leu?Val?Thr?Val?Leu?Glu ,Variable?light?chain?of?SC03-001，SC03-002，SC03-003，SC03-004，SC03-005，SC03-007，SC03-008，SC03-009，SC03-010，SC03-013，SC03-014，SC03-016and?SC03-018 		,Variable?heavy?chain?of?SC03-008 		,(41/27)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:41 that comprises the aminoacid sequence of seq id no:27
https://patents.google.com/patent/CN1826356B/en, Asp?Ile?Gln?Met?Thr?Gln?Ser?Pro?Asp?Ser?Leu?Ala?Val?Ser?Leu?Gly Glu?Arg?Ala?Thr?Ile?Asn?Cys?Lys?Ser?Ser?Gln?Ser?Val?Leu?Tyr?Ser Ser?Asn?Asn?Lys?Asn?Tyr?Leu?Ala?Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Gln Pro?Pro?Lys?Leu?Leu?Ile?Tyr?Trp?Ala?Ser?Thr?Arg?Glu?Ser?Gly?Val Pro?Asp?Arg?Phe?Ser?Gly?Ser?Gly?Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr Ile?Ser?Ser?Leu?Gln?Ala?Glu?Asp?Val?Ala?Val?Tyr?Tyr?Cys?Gln?Gln Tyr?Tyr?Ser?Thr?Pro?Leu?Thr?Phe?Gly?Gln?Gly?Thr?Lys?Val?Glu?Ile Lys?Arg?Ala?Ala ,Met?Ala?Glu?Val?Gln?Leu?Val?Gln?Ser?Gly?Gly?Gly?Leu?Val?Gln?pro Gly?Gly?Ser?Leu?Lys?Leu?Ser?Cys?Ala?Ala?Ser?Gly?Phe?Thr?Phe?Ser Ser?Tyr?Ala?Met?His?Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu?Glu Tyr?Val?Ser?Gly?Ile?Ser?Ser?Asn?Gly?Gly?Ser?Thr?Tyr?Tyr?Ala?Asn Ser?Val?Lys?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp?Asn?Ser?Lys?Asn?Thr Leu?Tyr?Leu?Gln?Met?Gly?Ser?Leu?Arg?Ala?Glu?Asp?Met?Ala?Val?Tyr Tyr?Cys?Ala?Arg?Thr?Thr?Asn?Arg?Ala?Phe?Asp?Ile?Trp?Gly?Gln?Gly Thr?Met?Val?Thr?Val?Ser?Ser ,Variable?heavy?chain?of?SC03-058 		,Variable?heavy?chain?of?SC03-058 		,(457/455)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:457 that comprises the aminoacid sequence of seq id no:455
https://patents.google.com/patent/CN1826356B/en, Glu?Ile?Val?Leu?Thr?Gln?Ser?Pro?Ala?Thr?Leu?Ser?Leu?Ser?Pro?Gly Glu?Arg?Ala?Thr?Leu?Ser?Cys?Arg?Ala?Ser?Gln?Ser?Val?Ser?Ser?Tyr Leu?Ala?Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Gln?Ala?Pro?Arg?Leu?Leu?Ile Tyr?Asp?Ala?Ser?Asn?Arg?Ala?Thr?Gly?Ile?Pro?Ala?Arg?Phe?Ser?Gly Ser?Gly?Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr?Ile?Ser?Ser?Leu?Glu?Pro Glu?Asp?Phe?Ala?Val?Tyr?Tyr?Cys?Gln?Gln?Arg?Ser?Asn?Trp?Pro?Pro Ala?Phe?Gly?Gly?Gly?Thr?Lys?Val?Glu?Ile?Lys?Arg?Ala?Ala , Met?Ala?Gln?Met?Gln?Leu?Val?Gln?Ser?Gly?Gly?Gly?Val?Val?Gln?Pro Gly?Arg?Ser?Leu?Arg?Leu?Ser?Cys?Ala?Ala?Ser?Gly?Phe?Thr?Phe?Ser Gly?Tyr?Ala?Met?His?Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu?Glu Trp?Val?Ala?Val?Ile?Ser?Tyr?Asp?Gly?Ser?Asn?Lys?Tyr?Tyr?Ala?Asp Ser?Val?Lys?Gly?Arg?Phe?Ala?Ile?Ser?Arg?Asp?Asn?Ser?Lys?Asn?Thr Leu?Tyr?Leu?Gln?Met?Asn?Ser?Leu?Arg?Ala?Glu?Asp?Thr?Ala?Val?Tyr Tyr?Cys?Ala?Arg?Phe?Pro?Gly?Gly?Thr?Arg?Ser?Arg?Gly?Tyr?Met?Asp Val?Trp?Gly?Lys?Gly?Thr?Thr?Val?Thr?Val?Ser?Ser ,Variable?light?chain?of?SC03-019,Variable?heavy?chain?of?SC03-019 		,(305/303)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:305 that comprises the aminoacid sequence of seq id no:303
https://patents.google.com/patent/CN1826356B/en, Asp?Ile?Gln?Met?Thr?Gln?Ser?Pro?Asp?Ser?Leu?Ala?Val?Ser?Leu?Gly Glu?Arg?Ala?Thr?Ile?Asn?Cys?Lys?Ser?Ser?Gln?Ser?Val?Leu?Tyr?Ser Ser?Asn?Asn?Lys?Asn?Tyr?Leu?Ala?Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Gln Pro?Pro?Lys?Leu?Leu?Ile?Tyr?Trp?Ala?Ser?Thr?Arg?Glu?Ser?Gly?Val Pro?Asp?Arg?Phe?Ser?Gly?Ser?Gly?Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr Ile?Ser?Ser?Leu?Gln?Ala?Glu?Asp?Val?Ala?Val?Tyr?Tyr?Cys?Gln?Gln Tyr?Tyr?Ser?Thr?Pro?Tyr?Thr?Phe?Gly?Gln?Gly?Thr?Lys?Val?Glu?Ile Lys?Arg?Ala?Ala , Met?Ala?Glu?Val?Gln?Leu?Val?Gln?Ser?Gly?Thr?Glu?Val?Lys?Lys?Pro Gly?Glu?Ser?Leu?Lys?Val?Ser?Cys?Lys?Gly?Ser?Gly?Tyr?Gly?Phe?Ile Thr?Tyr?Trp?Ile?Gly?Trp?Val?Arg?Gln?Met?Pro?Gly?Lys?Gly?Leu?Glu Trp?Met?Gly?Ile?Ile?Tyr?Pro?Gly?Asp?Ser?Glu?Thr?Arg?Tyr?Ser?Pro Ser?Phe?Gln?Gly?Gln?Val?Thr?Ile?Ser?Ala?Asp?Lys?Ser?Ile?Asn?Thr Thr?Tyr?Leu?Gln?Trp?Ser?Ser?Leu?Lys?Ala?Ser?Asp?Thr?Ala?Ile?Tyr Tyr?Cys?Ala?Gly?Gly?Ser?Gly?Ile?Ser?Thr?Pro?Met?Asp?Val?Trp?Gly Gln?Gly?Thr?Thr?Val?Thr?Val?Ser?Ser ,Variable?light?chain?of?SC03-052 		,Variable?heavy?chain?of?SC03-052 		,(433/431)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:433 that comprises the aminoacid sequence of seq id no:431
https://patents.google.com/patent/CN1826356B/en, Asp?Ile?Gln?Met?Thr?Gln?Ser?Pro?His?Ser?Leu?Ser?Ala?Ser?Val?Gly Asp?Arg?Val?Thr?Ile?Thr?Cys?Arg?Ala?Ser?Gln?Gly?Ile?Ser?Asn?Tyr Leu?Ala?Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Lys?Val?Pro?Lys?Leu?Leu?Ile Tyr?Ala?Ala?Ser?Thr?Leu?Gln?Ser?Gly?Val?Pro?Ser?Arg?Phe?Ser?Gly Ser?Gly?Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr?Ile?Ser?Ser?Leu?Gln?Pro Glu?Asp?Val?Gly?Val?Tyr?Tyr?Cys?Gln?Gln?Arg?Phe?Arg?Thr?Pro?Val Thr?Phe?Gly?Gln?Gly?Thr?Lys?Leu?Glu?Ile?Lys?Arg , Met?Ala?Glu?Val?Gln?Leu?Val?Glu?Ser?Gly?Gly?Gly?Leu?Val?Gln?Pro Gly?Gly?Ser?Leu?Arg?Leu?Ser?Cys?Ala?Ala?Ser?Gly?Phe?Thr?Phe?Ser Gly?Tyr?Pro?Met?His?Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu?Glu Trp?Val?Ala?Val?Ile?Ser?Tyr?Asp?Gly?Ser?Asn?Lys?Tyr?Tyr?Ala?Asp Ser?Val?Lys?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp?Asn?Ser?Lys?Asn?Thr Leu?Tyr?Leu?Gln?Met?Asn?Ser?Leu?Arg?Ala?Glu?Asp?Thr?Ala?Val?Tyr Tyr?Cys?Ala?Lys?Asp?Gly?Ser?Pro?Arg?Thr?Pro?Ser?Phe?Asp?Tyr?Trp Gly?Gln?Gly?Thr?Leu?Val?Thr?Val?Leu?Glu ,Variable?light?chain?of?SC03-006 		,Variable?heavy?chain?of?SC03-006 		,(43/23)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:43 that comprises the aminoacid sequence of seq id no:23
https://patents.google.com/patent/CN1826356B/en, Glu?Ile?Glu?Leu?Thr?Gln?Ser?Pro?Ala?Thr?Leu?Ser?Leu?Ser?Pro?Gly Glu?Arg?Ala?Thr?Leu?Ser?Cys?Arg?Ala?Ser?Gln?Ser?Val?Ser?Ser?Tyr Leu?Ala?Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Gln?Ala?Pro?Arg?Leu?Leu?Ile Tyr?Asp?Ala?Ser?Asn?Arg?Ala?Thr?Gly?Ile?Pro?Ala?Arg?Phe?Ser?Gly Ser?Gly?Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr?Ile?Ser?Ser?Leu?Glu?Pro Glu?Asp?Phe?Ala?Val?Tyr?Tyr?Cys?Gln?Gln?Arg?Ser?Asn?Trp?Pro?Pro Ala?Phe?Gly?Gly?Gly?Thr?Lys?Val?Glu?Ile?Lys?Arg , Met?Ala?Gln?Val?Gln?Leu?Gln?Glu?Ser?Gly?Ala?Gly?Leu?Leu?Lys?Pro Ser?Glu?Thr?Leu?Ser?Leu?Thr?Cys?Thr?Val?Set?Gly?Gly?Ser?Val?Ser Ser?Gly?Ser?Tyr?Tyr?Trp?Ser?Trp?Ile?Arg?Gln?Pro?Pro?Gly?Lys?Gly Leu?Glu?Trp?Ile?Gly?Tyr?Ile?Tyr?Tyr?Ser?Gly?Ser?Thr?Asn?Tyr?Asn Pro?Ser?Leu?Lys?Ser?Arg?Val?Thr?Ile?Ser?Val?Asp?Thr?Ser?Lys?Asn Gln?Phe?Ser?Leu?Lys?Leu?Ser?Ser?Val?Thr?Ala?Ala?Asp?Thr?Ala?Val Tyr?Tyr?Cys?Ala?Lys?Ser?Arg?Ser?Ala?Gly?Phe?Phe?Asp?Tyr?Trp?Gly Gln?Gly?Thr?Leu?Val?Thr?Val?Ser?Ser ,Variable?light?chain?of?SC03-017 		,Variable?heavy?chain?of?SC03-017 		,(88/84)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:88 that comprises the aminoacid sequence of seq id no:84
https://patents.google.com/patent/CN1826356B/en, Asp?Ile?Gln?Leu?Thr?Gln?Ser?Pro?Asp?Ser?Leu?Ala?Val?Ser?Leu?Gly Glu?Arg?Ala?Thr?Ile?Asn?Cys?Lys?Ser?Ser?Gln?Ser?Val?Leu?Tyr?Ser Ser?Ile?Asn?Lys?Asn?Tyr?Leu?Ala?Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Gln Pro?Pro?Lys?Leu?Leu?Ile?Tyr?Trp?Ala?Ser?Thr?Arg?Glu?Ser?Gly?Val Pro?Asp?Arg?Phe?Ser?Gly?Ser?Gly?Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr Ile?Ser?Ser?Leu?Gln?Ala?Glu?Asp?Val?Ala?Val?Tyr?Tyr?Cys?Gln?Gln Tyr?Tyr?Ser?Thr?Pro?Tyr?Thr?Phe?Gly?Gln?Gly?Thr?Lys?Val?Glu?Ile Lys?Arg?Ala?Ala, Met?Ala?Gln?Met?Gln?Leu?Val?Gln?Ser?Gly?Thr?Glu?Val?Lys?Lys?Pro Gly?Glu?Ser?Leu?Lys?Ile?Ser?Cys?Lys?Gly?Ser?Gly?Tyr?Gly?Phe?Ile Thr?Tyr?Trp?Ile?Gly?Trp?Val?Arg?Gln?Met?Pro?Gly?Lys?Gly?Leu?Glu Trp?Met?Gly?Ile?Ile?Tyr?Pro?Gly?Asp?Ser?Glu?Thr?Arg?Tyr?Ser?Pro Ser?Phe?Gln?Gly?Gln?Val?Thr?Ile?Ser?Ala?Asp?Lys?Ser?Ile?Asn?Thr Ala?Tyr?Leu?Gln?Trp?Ser?Ser?Leu?Lys?Ala?Ser?Asp?Thr?Ala?Ile?Tyr Tyr?Cys?Ala?Gly?Gly?Ser?Gly?Ile?Ser?Thr?Pro?Met?Asp?Val?Trp?Gly Gln?Gly?Thr?Thr?Val?Thr?Val?Ser?Ser ,Variable?light?chain?of?SC03-022 		,Variable?heavy?chain?of?SC03-022 		,(317/315)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:317 that comprises the aminoacid sequence of seq id no:315
https://patents.google.com/patent/CN1826356B/en, Glu?Leu?Thr?Gln?Ser?Pro?Ser?Ser?Leu?Ser?Ala?Ser?Val?Gly?Asp?Arg Val?Thr?Ile?Thr?Cys?Arg?Ala?Ser?Gln?Ser?Ile?Ser?Ser?Tyr?Leu?Asn Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Lys?Ala?Pro?Lys?Leu?Leu?Ile?Tyr?Ala Ala?Ser?Ser?Leu?Gln?Ser?Gly?Val?Pro?Ser?Arg?Phe?Ser?Gly?Ser?Gly Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr?Ile?Ser?Ser?Leu?Gln?Pro?Glu?Asp Phe?Ala?Thr?Tyr?Tyr?Cys?Gln?Gln?Ser?Tyr?Ser?Thr?Pro?Pro?Thr?Phe Gly?Gln?Gly?Thr?Lys?Val?Glu?Ile?Lys?Arg , Ala?Met?Ala?Glu?Val?Gln?Leu?Val?Glu?Ser?Gly?Gly?Gly?Leu?Val?Gln Pro?Gly?Gly?Ser?Leu?Arg?Leu?Ser?Arg?Ala?Ala?Ser?Gly?Phe?Thr?Phe Ser?Asn?Tyr?Pro?Met?Arg?Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu Glu?Trp?Val?Gly?Phe?Ile?Arg?Asn?Lys?Ala?Asn?Gly?Gly?Thr?Thr?Glu Gln?Thr?Thr?Ser?Val?Arg?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp?Asp?Ser Lys?Ser?Ile?Thr?Tyr?Leu?Gln?Met?Asn?Ser?Leu?Arg?Ala?Glu?Asp?Thr Ala?Val?Tyr?Tyr?Cys?Ala?Lys?Tyr?Gly?Ser?Ala?Tyr?Arg?Pro?Pro?Phe Asp?Tyr?Trp?Gly?Gln?Gly?Thr?Leu?Val?Thr?Val?Leu?Glu ,Variable?light?chain?of?SC03-001，SC03-002，SC03-003，SC03-004，SC03-005，SC03-007，SC03-008，SC03-009，SC03-010，SC03-013，SC03-014，SC03-016and?SC03-018 		,Variable?heavy?chain?of?SC03-016 		,(41/82)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:41 that comprises the aminoacid sequence of seq id no:82
https://patents.google.com/patent/CN1826356B/en,Asp?Val?Val?Met?Thr?Gln?Ser?Pro?Asp?Ser?Leu?Ala?Val?Ser?Leu?Gly Glu?Arg?Ala?Thr?Ile?Asn?Cys?Lys?Ser?Ser?Gln?Ser?Val?Leu?Tyr?Ser Ser?Asn?Asn?Lys?Asn?Tyr?Leu?Ala?Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Gln Pro?Pro?Lys?Leu?Leu?Ile?Tyr?Trp?Ala?Ser?Thr?Arg?Glu?Ser?Gly?Val Pro?Asp?Arg?Phe?Ser?Gly?Ser?Gly?Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr Ile?Ser?Ser?Leu?Gln?Ala?Glu?Asp?Val?Ala?Val?Tyr?Tyr?Cys?Gln?Gln Tyr?Tyr?Ser?Thr?Pro?Leu?Thr?Phe?Gly?Gly?Gly?Thr?Lys?Val?Glu?Ile Lys?Arg?Ala?Ala , Met?Ala?Glu?Val?Gln?Leu?Val?Gln?Ser?Gly?Gly?Gly?Leu?Val?Gln?Pro Gly?Gly?Ser?Leu?Arg?Leu?Ser?Cys?Ala?Ala?Ser?Gly?Phe?Thr?Phe?Ser Ser?Tyr?Ala?Met?His?Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu?Glu Tyr?Val?Ser?Gly?Ile?Ser?Ser?Asn?Gly?Gly?Ser?Thr?Tyr?Tyr?Ala?Asn Ser?Val?Lys?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp?Asn?Ser?Lys?Asn?Thr Leu?Tyr?Leu?Gln?Met?Gly?Ser?Leu?Arg?Ala?Glu?Asp?Met?Ala?Val?Tyr Tyr?Cys?Ala?Arg?Thr?Thr?Asn?Arg?Ala?Phe?Asp?Ile?Trp?Gly?Gln?Gly Thr?Met?Val?Thr?Val?Ser?Ser ,Variable?light?chain?of?SC03-047 		,Variable?heavy?chain?of?SC03-047 		,(413/411)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:413 that comprises the aminoacid sequence of seq id no:411
https://patents.google.com/patent/CN1826356B/en, Asp?Ile?Gln?Met?Thr?Gln?Ser?Pro?Asp?Ser?Leu?Ala?Val?Ser?Leu?Gly Glu?Arg?Ala?Thr?Ile?Asn?Cys?Lys?Ser?Ser?Gln?Ser?Val?Leu?Tyr?Ser Ser?Asn?Asn?Lys?Asn?Tyr?Leu?Ala?Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Gln Pro?Pro?Lys?Leu?Leu?Ile?Tyr?Trp?Ala?Ser?Thr?Arg?Glu?Ser?Gly?Val Pro?Asp?Arg?Phe?Ser?Gly?Ser?Gly?Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr Ile?Ser?Ser?Leu?Gln?Ala?Glu?Asp?Val?Ala?Val?Tyr?Tyr?Cys?Gln?Gln Tyr?Tyr?Ser?Thr?Pro?Leu?Tyr?Ser?Phe?Gly?Gln?Gly?Thr?Lys?Val?Glu Ile?Lys?Pro?Ala?Ala , Met?Ala?Glu?Val?Gln?Leu?Val?Gln?Ser?Gly?Ala?Glu?Val?Lys?Lys?Pro Gly?Glu?Ser?Leu?Lys?Ile?Ser?Cys?Lys?Gly?Ser?Gly?Tyr?Gly?Phe?Ile Thr?Tyr?Trp?Ile?Gly?Trp?Val?Arg?Gln?Met?Pro?Gly?Lys?Gly?Leu?Glu Trp?Met?Gly?Ile?Ile?Tyr?Pro?Gly?Asp?Ser?Glu?Thr?Arg?Tyr?Ser?Pro Ser?Phe?Gln?Gly?Gln?Val?Thr?Ile?Ser?Ala?Asp?Lys?Ser?Ile?Asn?Thr Ala?Tyr?Leu?Gln?Trp?Ser?Ser?Leu?Lys?Ala?Ser?Asp?Thr?Ala?Ile?Tyr Tyr?Cys?Ala?Gly?Gly?Ser?Gly?Ile?Ser?Thr?Pro?Met?Asp?Val?Trp?Gly Gln?Gly?Thr?Thr?Val?Thr?Val?Ser?Ser ,Variable?light?chain?of?SC03-035 		,Variable?heavy?chain?of?SC03-035 		,(365/363)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:365 that comprises the aminoacid sequence of seq id no:363
https://patents.google.com/patent/CN1826356B/en,Ser?Ser?Glu?Leu?Thr?Gln?Asp?Pro?Ala?Val?Ser?Val?Ala?Leu?Gly?Gln Thr?Val?Arg?Ile?Thr?Cys?Gln?Gly?Asp?Ser?Leu?Arg?Ser?Tyr?Tyr?Ala Ser?Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Gln?Ala?Pro?Val?Leu?Val?Ile?Tyr Gly?Lys?Asn?Asn?Arg?Pro?Ser?Gly?Ile?Pro?Asp?Arg?Phe?Ser?Gly?Ser Ser?Ser?Gly?Asp?Thr?Ala?Ser?Leu?Thr?Ile?Thr?Gly?Ala?Gln?Ala?Glu Asp?Glu?Ala?Asp?Tyr?Tyr?Cys?Asn?Ser?Arg?Asp?Ser?Ser?Gly?Asn?His Trp?Val?Phe?Gly?Gly?Gly?Thr?Lys?Leu?Thr?Val?Leu?Gly?Ala?Ala , Met?Ala?Glu?Val?Gln?Leu?Val?Gln?Ser?Gly?Gly?Gly?Leu?Ile?Gln?Pro Gly?Gly?Ser?Leu?Arg?Leu?Ser?Cys?Ala?Ala?Ser?Gly?Phe?Thr?Val?Ser Ser?Asn?Tyr?Met?Ser?Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu?Glu Trp?Val?Ser?Ile?Val?Phe?Ser?Gly?Gly?Ser?Thr?Tyr?Tyr?Ala?Asp?Ser Val?Lys?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp?Asn?Ser?Lys?Asn?Thr?Leu Tyr?Leu?Gln?Met?Asn?Ser?Leu?Arg?Ala?Glu?Asp?Thr?Ala?Val?Tyr?Tyr Cys?Ala?Arg?Asp?Ala?His?Arg?Gly?Phe?Gly?Met?Asp?Val?Trp?Gly?Gln Gly?Thr?Thr?Val?Thr?Val?Ser?Ser ,Variable?light?chain?of?SC03-038 		,Variable?heavy?chain?of?SC03-038 		,(377/375)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:377 that comprises the aminoacid sequence of seq id no:375
https://patents.google.com/patent/CN1826356B/en, Asp?Ile?Gln?Leu?Thr?Gln?Ser?Pro?Asp?Ser?Leu?Ala?Val?Ser?Leu?Gly Glu?Arg?Ala?Thr?Ile?Asn?Cys?Lys?Ser?Ser?Gln?Ser?Val?Leu?Tyr?Ser Ser?Asn?Asn?Lys?Asn?Tyr?Leu?Ala?Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Gln Pro?Pro?Lys?Leu?Leu?Ile?Tyr?Trp?Ala?Ser?Thr?Arg?Glu?Ser?Gly?Val Pro?Asp?Arg?Phe?Ser?Gly?Ser?Gly?Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr Ile?Ser?Ser?Leu?Gln?Ala?Glu?Asp?Val?Ala?Val?Tyr?Tyr?Cys?Gln?Gln Tyr?Tyr?Ser?Thr?Pro?Phe?Thr?Phe?Gly?Pro?Gly?Thr?Lys?Val?Asp?Ile Lys?Arg?Ala?Ala , Met?Ala?Gln?Leu?Gln?Leu?Gln?Glu?Ser?Gly?Gly?Gly?Leu?Val?Gln?Pro Gly?Gly?Ser?Leu?Arg?Leu?Ser?Cys?Ala?Ala?Ser?Gly?Phe?Thr?Phe?Ser Ser?Tyr?Ala?Met?His?Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu?Glu Tyr?Val?Ser?Gly?Ile?Ser?Ser?Asn?Gly?Gly?Ser?Thr?Tyr?Tyr?Ala?Asn Ser?Val?Lys?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp?Asn?Ser?Lys?Asn?Thr Leu?Tyr?Leu?Gln?Met?Gly?Ser?Leu?Arg?Ala?Glu?Asp?Met?Ala?Val?Tyr Tyr?Cys?Ala?Arg?Thr?Thr?Asn?Arg?Ala?Phe?Asp?Ile?Trp?Gly?Gln?Gly Thr?Met?Val?Thr?Val?Ser?Ser ,Variable?light?chain?of?SC03-045 		,Variable?heavy?chain?of?SC03-045 		,(405/403)  a variable heavy chain and a variable light chain that comprises the aminoacid sequence of seq id no:405 that comprises the aminoacid sequence of seq id no:403
https://patents.google.com/patent/US11175293B1/en,Met Thr Asn Lys Cys Leu Leu Gln Ile Ala Leu Leu Leu Cys Phe SerThr Thr Ala Leu Ser Met Gly Ala Pro Gln Val Gln Leu Gln Glu SerGly Gly Gly Ser Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys ValAla Ser Gly Tyr Thr Asp Ser Thr Tyr Cys Val Gly Trp Phe Arg GlnAla Pro Gly Lys Glu Arg Glu Gly Val Ala Arg Ile Asn Thr Ile SerGly Arg Pro Trp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile SerGln Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu LysPro Glu Asp Thr Ala Ile Tyr Tyr Cys Thr Leu Thr Thr Ala Asn SerArg Gly Phe Cys Ser Gly Gly Tyr Asn Tyr Lys Gly Gln Gly Thr GlnVal Thr Val Ser Gly Gly Thr Ser Gly Gly Gly Gly Ser Gly Gly GlyGly Ser Gly Gly Gly Gly Ser Ala Ala Ala Arg Phe Pro Asn Ile ThrAsn Leu Cys Pro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala SerVal Tyr Ala Trp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp TyrSer Val Leu Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr GlyVal Ser Pro Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr AlaAsp Ser Phe Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro GlyGln Thr Gly Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp PheThr Gly Cys Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys ValGly Gly Asn Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn LeuLys Pro Phe Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly SerThr Pro Cys Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu GlnSer Tyr Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr ArgVal Val Val Leu Ser Phe Glu Leu Leu His Ala Pro Ala Thr Val CysGly Pro Lys Lys Ser Thr Asn Leu Glu Phe Ser Gly Gly Gly Gly SerGly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Ala Ala Gln Glu CysSer Leu Gln Ser Cys Thr Gln His Gln Pro Tyr Val Val Asp Asp ProCys Pro Ile His Phe Tyr Ser Lys Trp Tyr Ile Arg Val Gly Ala ArgLys Ser Ala Pro Leu Ile Glu Leu Cys Val Asp Glu Ala Gly Ser LysSer Pro Ile Gln Tyr Ile Asp Ile Gly Asn Tyr Thr Val Ser Cys LeuPro Phe Thr Ile Asn Cys Gln Glu Pro Lys Leu Gly Ser Leu Val ValArg Cys Ser Phe Tyr Glu Asp Phe Leu Glu Tyr His Asp Val Arg ValVal Leu Asp Phe Ile Pro Arg Gly Gly Gly Ser Gly Gly Gly Ser GlyGly Gly Ser Ala Trp Ser His Pro Gln Phe Glu Lys Gly Gly Gly SerGly Gly Gly Ser Gly Gly Ser Ala Trp Ser His Pro Gln Phe Glu Lys,,8544PRTArtificial SequenceSynthetic Construct 8,,"(8) other embodiments useful in the assay include “nanonuc” (seq id no:4), “nanoorf8” (seq id no:6), “nanospikeorf8” (seq id no:8), “nanoorf3b” (seq id no:10), and “nanospikeorf3b” (seq id no:12), which refer to the nanobody and sars-cov-2 nucleocapsid, orf 8, surface glycoprotein receptor binding domain and orf 8, orf 3b, and orf 3b and surface glycoprotein receptor binding domains, respectively"
https://patents.google.com/patent/US11175293B1/en,Met Thr Asn Lys Cys Leu Leu Gln Ile Ala Leu Leu Leu Cys Phe SerThr Thr Ala Leu Ser Met Gly Ala Pro Gln Val Gln Leu Gln Glu SerGly Gly Gly Ser Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys ValAla Ser Gly Tyr Thr Asp Ser Thr Tyr Cys Val Gly Trp Phe Arg GlnAla Pro Gly Lys Glu Arg Glu Gly Val Ala Arg Ile Asn Thr Ile SerGly Arg Pro Trp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile SerGln Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu LysPro Glu Asp Thr Ala Ile Tyr Tyr Cys Thr Leu Thr Thr Ala Asn SerArg Gly Phe Cys Ser Gly Gly Tyr Asn Tyr Lys Gly Gln Gly Thr GlnVal Thr Val Ser Gly Glu Phe Gly Gly Gly Ser Gly Gly Gly Ser GlyGly Gly Ser Ala Trp Ser His Pro Gln Phe Glu Lys Gly Gly Gly SerGly Gly Gly Ser Gly Gly Ser Ala Trp Ser His Pro Gln Phe Glu Lys,,14192PRTArtificial SequenceSynthetic Construct 14,,"(14) also described herein are fusion proteins that can serve as negative or positive controls for the method or assay described herein. in one embodiment, the fusion protein “nanocontrol” (seq id no:14) can be used as a negative control. nanocontrol comprises the glycophorin a nanobody domain, but no covid domain. this polypeptide will not react with sars-cov-2-specific antibodies of subjects infected with or convalescing from sars-cov-2 when added to a sample of the subject's blood. this construct serves as a negative control."
https://patents.google.com/patent/US11175293B1/en,Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Met Gln Ala Gly GlySer Leu Arg Leu Ser Cys Ala Val Ser Gly Arg Thr Phe Ser Thr AlaAla Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe ValAla Ala Ile Arg Trp Ser Gly Gly Ser Ala Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Lys Ala Lys Asn Thr Val TyrLeu Gln Met Asn Ser Leu Lys Tyr Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Thr Glu Asn Val Arg Ser Leu Leu Ser Asp Tyr Ala Thr TrpPro Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser,,32126PRTArtificial SequenceSynthetic Construct 32,,(32)  one or more anti-sars co-v-2 nanobody domains comprising 90-99% identity to seq id no:32 and one or more multimerization domains comprising 90-99% identity to seq id no:34 o4 36.
https://patents.google.com/patent/US11175293B1/en,Met Thr Asn Lys Cys Leu Leu Gln Ile Ala Leu Leu Leu Cys Phe SerThr Thr Ala Leu Ser Met Gly Ala Pro Gln Val Gln Leu Val Glu SerGly Gly Gly Leu Met Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys AlaVal Ser Gly Arg Thr Phe Ser Thr Ala Ala Met Gly Trp Phe Arg GlnAla Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Arg Trp Ser GlyGly Ser Ala Tyr TyrAla Asp Ser Val Lys Gly Arg Phe Thr Ile SerArg Asp Lys Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu LysTyr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Glu Asn Val ArgSer Leu Leu Ser Asp Tyr Ala Thr Trp Pro Tyr Asp Tyr Trp Gly GlnGly Thr Gln Val Thr Val Ser Gly Gly Gly Gly Ser Gly Gly Gly GlySer Gly Gly Gly Gly Ser Ile Asp Gln Val Gln Leu Val Glu Ser GlyGly Gly Leu Met Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala ValSer Gly Arg Thr Phe Ser Thr Ala Ala Met Gly Trp Phe Arg Gln AlaPro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Arg Trp Ser Gly GlySer Ala Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser ArgAsp Lys Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys TyrGlu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Glu Asn Val Arg SerLeu Leu Ser Asp Tyr Ala Thr Trp Pro Tyr Asp Tyr Trp Gly Gln GlyThr Gln Val Thr Val Ser Ser Gly Thr Glu Pro Lys Ile Pro Gln ProGln Pro Lys Pro Gln Pro Gln Pro Gln Pro Gln Pro Lys Pro Gln ProLys Pro Glu Pro Glu Gln Arg Met Lys Gln Ile Glu Asp Lys Ile GluGlu Ile Leu Ser Lys Ile Tyr His Ile Glu Asn Glu Ile Ala Arg IleLys Lys Leu Val Gly Glu Arg Pro Arg Gly Gly Gly Ser Gly Gly GlySer Gly Gly Gly Ser Ala Ala Ala Trp Ser His Pro Gln Phe Glu LysGly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Trp Ser His ProGln Phe Glu Lys,,18404PRTArtificial SequenceSynthetic Construct 18,,(18) the nanobody region of the nanolink (seq id no:16) and nanotrim (seq id no:18) constructs binds to the sars-cov-2 surface glycoprotein receptor biding domain (rb
https://patents.google.com/patent/US11175293B1/en,Met Thr Asn Lys Cys Leu Leu Gln Ile Ala Leu Leu Leu Cys Phe SerThr Thr Ala Leu Ser Met Gly Ala Pro Gln Val Gln Leu Gln Glu SerGly Gly Gly Ser Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys ValAla Ser Gly Tyr Thr Asp Ser Thr Tyr Cys Val Gly Trp Phe Arg GlnAla Pro Gly Lys Glu Arg Glu Gly Val Ala Arg Ile Asn Thr Ile SerGly Arg Pro Trp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile SerGln Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu LysPro Glu Asp Thr Ala Ile Tyr Tyr Cys Thr Leu Thr Thr Ala Asn SerArg Gly Phe Cys Ser Gly Gly Tyr Asn Tyr Lys Gly Gln Gly Thr GlnVal Thr Val Ser Gly Gly Thr Ser Gly Gly Gly Gly Ser Gly Gly GlyGly Ser Gly Gly Gly Gly Ser Ala Ala Ala Arg Phe Pro Asn Ile ThrAsn Leu Cys Pro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala SerVal Tyr Ala Trp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp TyrSer Val Leu Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr GlyVal Ser Pro Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr AlaAsp Ser Phe Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro GlyGln Thr Gly Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp PheThr Gly Cys Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys ValGly Gly Asn Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn LeuLys Pro Phe Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly SerThr Pro Cys Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu GlnSer Tyr Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr ArgVal Val Val Leu Ser Phe Glu Leu Leu His Ala Pro Ala Thr Val CysGly Pro Lys Lys Ser Thr Asn Leu Glu Phe Gly Gly Gly Ser Gly GlyGly Ser Gly Gly Gly Ser Ala Trp Ser His Pro Gln Phe Glu Lys GlyGly Gly Ser Gly Gly Gly Ser Gly Gly Ser Ala Trp Ser His Pro GlnPhe Glu Lys,,248Gly Gly Ser Gly Gly Gly Ser Gly Gly Ser Ala Trp Ser His Pro Gln 405 410 415ttc gag aaa tga 1260Phe Glu Lys2419PRTArtificial SequenceSynthetic Construct 2,,"(2) one embodiment described herein is the “nanospike,” (seq id no:2) which refers to the respective nanobody and sars-cov-2 surface glycoprotein receptor “spike” domains of the fusion protein (fig"
https://patents.google.com/patent/US11175293B1/en,Met Phe Val Phe Leu Val Leu Leu Pro Leu Val Ser Ser Gln Cys ValAsn Leu Thr Thr Arg Thr Gln Leu Pro Pro Ala Tyr Thr Asn Ser PheThr Arg Gly Val Tyr Tyr Pro Asp Lys Val Phe Arg Ser Ser Val LeuHis Ser Thr Gln Asp Leu Phe Leu Pro Phe Phe Ser Asn Val Thr TrpPhe His Ala Ile His Val Ser Gly Thr Asn Gly Thr Lys Arg Phe AspAsn Pro Val Leu Pro Phe Asn Asp Gly Val Tyr Phe Ala Ser Thr GluLys Ser Asn Ile Ile Arg Gly Trp Ile Phe Gly Thr Thr Leu Asp SerLys Thr Gln Ser Leu Leu Ile Val Asn Asn Ala Thr Asn Val Val IleLys Val Cys Glu Phe Gln Phe Cys Asn Asp Pro Phe Leu Gly Val TyrTyr His Lys Asn Asn Lys Ser Trp Met Glu Ser Glu Phe Arg Val TyrSer Ser Ala Asn Asn Cys Thr Phe Glu Tyr Val Ser Gln Pro Phe LeuMet Asp Leu Glu Gly Lys Gln Gly Asn Phe Lys Asn Leu Arg Glu PheVal Phe Lys Asn Ile Asp Gly Tyr Phe Lys Ile Tyr Ser Lys His ThrPro Ile Asn Leu Val Arg Asp Leu Pro Gln Gly Phe Ser Ala Leu GluPro Leu Val Asp Leu Pro Ile Gly Ile Asn Ile Thr Arg Phe Gln ThrLeu Leu Ala Leu His Arg Ser Tyr Leu Thr Pro Gly Asp Ser Ser SerGly Trp Thr Ala Gly Ala Ala Ala Tyr Tyr Val Gly Tyr Leu Gln ProArg Thr Phe Leu Leu Lys Tyr Asn Glu Asn Gly Thr Ile Thr Asp AlaVal Asp Cys Ala Leu Asp Pro Leu Ser Glu Thr Lys Cys Thr Leu LysSer Phe Thr Val Glu Lys Gly Ile Tyr Gln Thr Ser Asn Phe Arg ValGln Pro Thr Glu Ser Ile Val Arg Phe Pro Asn Ile Thr Asn Leu CysPro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala Ser Val Tyr AlaTrp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr Ser Val LeuTyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly Val Ser ProThr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala Asp Ser PheVal Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro Gly Gln Thr GlyLys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe Thr Gly CysVal Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys Val Gly Gly AsnTyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu Lys Pro PheGlu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser Thr Pro CysAsn Gly Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu Gln Ser Tyr GlyPhe Gln Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr Arg Val Val ValLeu Ser Phe Glu Leu Leu His Ala Pro Ala Thr Val Cys Gly Pro LysLys Ser Thr Asn Leu Val Lys Asn Lys Cys Val Asn Phe Asn Phe AsnGly Leu Thr Gly Thr Gly Val Leu Thr Glu Ser Asn Lys Lys Phe LeuPro Phe Gln Gln Phe Gly Arg Asp Ile Ala Asp Thr Thr Asp Ala ValArg Asp Pro Gln Thr Leu Glu Ile Leu Asp Ile Thr Pro Cys Ser PheGly Gly Val Ser Val Ile Thr Pro Gly Thr Asn Thr Ser Asn Gln ValAla Val Leu Tyr Gln Asp Val Asn Cys Thr Glu Val Pro Val Ala IleHis Ala Asp Gln Leu Thr Pro Thr Trp Arg Val Tyr Ser Thr Gly SerAsn Val Phe Gln Thr Arg Ala Gly Cys Leu Ile Gly Ala Glu His ValAsn Asn Ser Tyr Glu Cys Asp Ile Pro Ile Gly Ala Gly Ile Cys AlaSer Tyr Gln Thr Gln Thr Asn Ser Pro Arg Arg Ala Arg Ser Val AlaSer Gln Ser Ile Ile Ala Tyr Thr Met Ser Leu Gly Ala Glu Asn SerVal Ala Tyr Ser Asn Asn Ser Ile Ala Ile Pro Thr Asn Phe Thr IleSer Val Thr Thr Glu Ile Leu Pro Val Ser Met Thr Lys Thr Ser ValAsp Cys Thr Met Tyr Ile Cys Gly Asp Ser Thr Glu Cys Ser Asn LeuLeu Leu Gln Tyr Gly Ser Phe Cys Thr Gln Leu Asn Arg Ala Leu ThrGly Ile Ala Val Glu Gln Asp Lys Asn Thr Gln Glu Val Phe Ala GlnVal Lys Gln Ile Tyr Lys Thr Pro Pro Ile Lys Asp Phe Gly Gly PheAsn Phe Ser Gln Ile Leu Pro Asp Pro Ser Lys Pro Ser Lys Arg SerPhe Ile Glu Asp Leu Leu Phe Asn Lys Val Thr Leu Ala Asp Ala GlyPhe Ile Lys Gln Tyr Gly Asp Cys Leu Gly Asp Ile Ala Ala Arg AspLeu Ile Cys Ala Gln Lys Phe Asn Gly Leu Thr Val Leu Pro Pro LeuLeu Thr Asp Glu Met Ile Ala Gln Tyr Thr Ser Ala Leu Leu Ala GlyThr Ile Thr Ser Gly Trp Thr Phe Gly Ala Gly Ala Ala Leu Gln IlePro Phe Ala Met Gln Met Ala Tyr Arg Phe Asn Gly Ile Gly Val ThrGln Asn Val Leu Tyr Glu Asn Gln Lys Leu Ile Ala Asn Gln Phe AsnSer Ala Ile Gly Lys Ile Gln Asp Ser Leu Ser Ser Thr Ala Ser AlaLeu Gly Lys Leu Gln Asp Val Val Asn Gln Asn Ala Gln Ala Leu AsnThr Leu Val Lys Gln Leu Ser Ser Asn Phe Gly Ala Ile Ser Ser ValLeu Asn Asp Ile Leu Ser Arg Leu Asp Lys Val Glu Ala Glu Val GlnIle Asp Arg Leu Ile Thr Gly Arg Leu Gln Ser Leu Gln Thr Tyr ValThr Gln Gln Leu Ile Arg Ala Ala Glu Ile Arg Ala Ser Ala AsnLeu Ala Ala Thr Lys Met Ser Glu Cys Val Leu Gly Gln Ser LysArg Val Asp Phe Cys Gly Lys Gly Tyr His Leu Met Ser Phe ProGln Ser Ala Pro His Gly Val Val Phe Leu His Val Thr Tyr ValPro Ala Gln Glu Lys Asn Phe Thr Thr Ala Pro Ala Ile Cys HisAsp Gly Lys Ala His Phe Pro Arg Glu Gly Val Phe Val Ser AsnGly Thr His Trp Phe Val Thr Gln Arg Asn Phe Tyr Glu Pro GlnIle Ile Thr Thr Asp Asn Thr Phe Val Ser Gly Asn Cys Asp ValVal Ile Gly Ile Val Asn Asn Thr Val Tyr Asp Pro Leu Gln ProGlu Leu Asp Ser Phe Lys Glu Glu Leu Asp Lys Tyr Phe Lys AsnHis Thr Ser Pro Asp Val Asp Leu Gly Asp Ile Ser Gly Ile AsnAla Ser Val Val Asn Ile Gln Lys Glu Ile Asp Arg Leu Asn GluVal Ala Lys Asn Leu Asn Glu Ser Leu Ile Asp Leu Gln Glu LeuGly Lys Tyr Glu Gln Tyr Ile Lys Trp Pro Trp Tyr Ile Trp LeuGly Phe Ile Ala Gly Leu Ile Ala Ile Val Met Val Thr Ile MetLeu Cys Cys Met Thr Ser Cys Cys Ser Cys Leu Lys Gly Cys CysSer Cys Gly Ser Cys Cys Lys Phe Asp Glu Asp Asp Ser Glu ProVal Leu Lys Gly Val Lys Leu His Tyr Thr,,241273PRTSARS-CoV-2 24,,"(24) . in one aspect, the rbd comprises a glycophorin a-binding nanobody comprising 90-99% identity to seq id no:22. in another aspect, the cvd comprises one or more of a spike protein, a nucleocapsid protein, orf8 protein, orf3b protein, or envelope protein comprising 90-99% identity to all or a portion of seq id no:24, 26, 28, or 30."
https://patents.google.com/patent/US11175293B1/en,Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro AlaPro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys ProLys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val ValVal Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr ValAsp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu GlnTyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His GlnAsp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys AlaLeu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln ProArg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met ThrLys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro SerAsp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn TyrLys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu TyrSer Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val PheSer Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln LysSer Leu Ser Leu Ser Pro Gly Lys ,,34232PRTArtificial SequenceSynthetic Construct 34,,(34)  one or more anti-sars co-v-2 nanobody domains comprising 90-99% identity to seq id no:32 and one or more multimerization domains comprising 90-99% identity to seq id no:34 o4 36.
https://patents.google.com/patent/US11175293B1/en,Met Thr Asn Lys Cys Leu Leu Gln Ile Ala Leu Leu Leu Cys Phe SerThr Thr Ala Leu Ser Met Gly Ala Pro Gln Val Gln Leu Gln Glu SerGly Gly Gly Ser Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys ValAla Ser Gly Tyr Thr Asp Ser Thr Tyr Cys Val Gly Trp Phe Arg GlnAla Pro Gly Lys Glu Arg Glu Gly Val Ala Arg Ile Asn Thr Ile SerGly Arg Pro Trp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile SerGln Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu LysPro Glu Asp Thr Ala Ile Tyr Tyr Cys Thr Leu Thr Thr Ala Asn SerArg Gly Phe Cys Ser Gly Gly Tyr Asn Tyr Lys Gly Gln Gly Thr GlnVal Thr Val Ser Gly Gly Thr Ser Gly Gly Gly Gly Ser Gly Gly GlyGly Ser Gly Gly Gly Gly Ser Ala Ala Ala Arg Phe Pro Asn Ile ThrAsn Leu Cys Pro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala SerVal Tyr Ala Trp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp TyrSer Val Leu Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr GlyVal Ser Pro Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr AlaAsp Ser Phe Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro GlyGln Thr Gly Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp PheThr Gly Cys Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys ValGly Gly Asn Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn LeuLys Pro Phe Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly SerThr Pro Cys Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu GlnSer Tyr Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr ArgVal Val Val Leu Ser Phe Glu Leu Leu His Ala Pro Ala Thr Val CysGly Pro Lys Lys Ser Thr Asn Leu Glu Phe Ser Gly Gly Gly Gly SerGly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Ala Ala Met Ala TyrCys Trp Arg Cys Thr Ser Cys Cys Phe Ser Glu Arg Phe Gln Asn HisAsn Pro Gln Lys Glu Met Ala Thr Ser Thr Leu Gln Gly Cys Ser LeuCys Leu Gln Leu Ala Val Val Val Asn Ser Leu Leu Thr Pro Phe AlaArg Cys Cys Trp Pro Glu Phe Gly Gly Gly Ser Gly Gly Gly Ser GlyGly Gly Ser Ala Trp Ser His Pro Gln Phe Glu Lys Gly Gly Gly SerGly Gly Gly Ser Gly Gly Ser Ala Trp Ser His Pro Gln Phe Glu Lys,,12496PRTArtificial SequenceSynthetic Construct 12,,"(12) other embodiments useful in the assay include “nanonuc” (seq id no:4), “nanoorf8” (seq id no:6), “nanospikeorf8” (seq id no:8), “nanoorf3b” (seq id no:10), and “nanospikeorf3b” (seq id no:12), which refer to the nanobody and sars-cov-2 nucleocapsid, orf 8, surface glycoprotein receptor binding domain and orf 8, orf 3b, and orf 3b and surface glycoprotein receptor binding domains, respectively"
https://patents.google.com/patent/US11175293B1/en,Met Thr Asn Lys Cys Leu Leu Gln Ile Ala Leu Leu Leu Cys Phe SerThr Thr Ala Leu Ser Met Gly Ala Pro Gln Val Gln Leu Gln Glu SerGly Gly Gly Ser Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys ValAla Ser Gly Tyr Thr Asp Ser Thr Tyr Cys Val Gly Trp Phe Arg GlnAla Pro Gly Lys Glu Arg Glu Gly Val Ala Arg Ile Asn Thr Ile SerGly Arg Pro Trp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile SerGln Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu LysPro Glu Asp Thr Ala Ile Tyr Tyr Cys Thr Leu Thr Thr Ala Asn SerArg Gly Phe Cys Ser Gly Gly Tyr Asn Tyr Lys Gly Gln Gly Thr GlnVal Thr Val Ser Gly Gly Thr Ser Gly Gly Gly Gly Ser Gly Gly GlyGly Ser Gly Gly Gly Gly Ser Ala Ala Ala Gln Glu Cys Ser Leu GlnSer Cys Thr Gln His Gln Pro Tyr Val Val Asp Asp Pro Cys Pro IleHis Phe Tyr Ser Lys Trp Tyr Ile Arg Val Gly Ala Arg Lys Ser AlaPro Leu Ile Glu Leu Cys Val Asp Glu Ala Gly Ser Lys Ser Pro IleGln Tyr Ile Asp Ile Gly Asn Tyr Thr Val Ser Cys Leu Pro Phe ThrIle Asn Cys Gln Glu Pro Lys Leu Gly Ser Leu Val Val Arg Cys SerPhe Tyr Glu Asp Phe Leu Glu Tyr His Asp Val Arg Val Val Leu AspPhe Ile Pro Arg Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly SerAla Trp Ser His Pro Gln Phe Glu Lys Gly Gly Gly Ser Gly Gly GlySer Gly Gly Ser Ala Trp Ser His Pro Gln Phe Glu Lys,,6317PRTArtificial SequenceSynthetic Construct 6,,"(6) other embodiments useful in the assay include “nanonuc” (seq id no:4), “nanoorf8” (seq id no:6), “nanospikeorf8” (seq id no:8), “nanoorf3b” (seq id no:10), and “nanospikeorf3b” (seq id no:12), which refer to the nanobody and sars-cov-2 nucleocapsid, orf 8, surface glycoprotein receptor binding domain and orf 8, orf 3b, and orf 3b and surface glycoprotein receptor binding domains, respectively"
https://patents.google.com/patent/US11175293B1/en,Met Thr Asn Lys Cys Leu Leu Gln Ile Ala Leu Leu Leu Cys Phe SerThr Thr Ala Leu Ser Met Gly Ala Pro Gln Val Gln Leu Gln Glu SerGly Gly Gly Ser Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys ValAla Ser Gly Tyr Thr Asp Ser Thr Tyr Cys Val Gly Trp Phe Arg GlnAla Pro Gly Lys Glu Arg Glu Gly Val Ala Arg Ile Asn Thr Ile SerGly Arg Pro Trp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile SerGln Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu LysPro Glu Asp Thr Ala Ile Tyr Tyr Cys Thr Leu Thr Thr Ala Asn SerArg Gly Phe Cys Ser Gly Gly Tyr Asn Tyr Lys Gly Gln Gly Thr GlnVal Thr Val Ser Gly Gly Thr Ser Gly Gly Gly Gly Ser Gly Gly GlyGly Ser Gly Gly Gly Gly Ser Ala Ala Ala Met Ser Asp Asn Gly ProGln Asn Gln Arg Asn Ala Pro Arg Ile Thr Phe Gly Gly Pro Ser AspSer Thr Gly Ser Asn Gln Asn Gly Glu Arg Ser Gly Ala Arg Ser LysGln Arg Arg Pro Gln Gly Leu Pro Asn Asn Thr Ala Ser Trp Phe ThrAla Leu Thr Gln His Gly Lys Glu Asp Leu Lys Phe Pro Arg Gly GlnGly Val Pro Ile Asn Thr Asn Ser Ser Pro Asp Asp Gln Ile Gly TyrTyr Arg Arg Ala Thr Arg Arg Ile Arg Gly Gly Asp Gly Lys Met LysAsp Leu Ser Pro Arg Trp Tyr Phe Tyr Tyr Leu Gly Thr Gly Pro GluAla Gly Leu Pro Tyr Gly Ala Asn Lys Asp Gly Ile Ile Trp Val AlaThr Glu Gly Ala Leu Asn Thr Pro Lys Asp His Ile Gly Thr Arg AsnPro Ala Asn Asn Ala Ala Ile Val Leu Gln Leu Pro Gln Gly Thr ThrLeu Pro Lys Gly Phe Tyr Ala Glu Gly Ser Arg Gly Gly Ser Gln AlaSer Ser Arg Ser Ser Ser Arg Ser Arg Asn Ser Ser Arg Asn Ser ThrPro Gly Ser Ser Arg Gly Thr Ser Pro Ala Arg Met Ala Gly Asn GlyGly Asp Ala Ala Leu Ala Leu Leu Leu Leu Asp Arg Leu Asn Gln LeuGlu Ser Lys Met Ser Gly Lys Gly Gln Gln Gln Gln Gly Gln Thr ValThr Lys Lys Ser Ala Ala Glu Ala Ser Lys Lys Pro Arg Gln Lys ArgThr Ala Thr Lys Ala Tyr Asn Val Thr Gln Ala Phe Gly Arg Arg GlyPro Glu Gln Thr Gln Gly Asn Phe Gly Asp Gln Glu Leu Ile Arg GlnGly Thr Asp Tyr Lys His Trp Pro Gln Ile Ala Gln Phe Ala Pro SerAla Ser Ala Phe Phe Gly Met Ser Arg Ile Gly Met Glu Val Thr ProSer Gly Thr Trp Leu Thr Tyr Thr Gly Ala Ile Lys Leu Asp Asp LysAsp Pro Asn Phe Lys Asp Gln Val Ile Leu Leu Asn Lys His Ile AspAla Tyr Lys Thr Phe Pro Pro Thr Glu Pro Lys Lys Asp Lys Lys LysLys Ala Asp Glu Thr Gln Ala Leu Pro Gln Arg Gln Lys Lys Gln GlnThr Val Thr Leu Leu Pro Ala Ala Asp Leu Asp Asp Phe Ser Lys GlnLeu Gln Gln Ser Met Ser Ser Ala Asp Ser Thr Gln Ala Glu Phe GlyGly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Ala Trp Ser His ProGln Phe Glu Lys Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Ser AlaTrp Ser His Pro Gln Phe Glu Lys ,,4632PRTArtificial SequenceSynthetic Construct 4,,"(4) other embodiments useful in the assay include “nanonuc” (seq id no:4), “nanoorf8” (seq id no:6), “nanospikeorf8” (seq id no:8), “nanoorf3b” (seq id no:10), and “nanospikeorf3b” (seq id no:12), which refer to the nanobody and sars-cov-2 nucleocapsid, orf 8, surface glycoprotein receptor binding domain and orf 8, orf 3b, and orf 3b and surface glycoprotein receptor binding domains, respectively"
https://patents.google.com/patent/US11175293B1/en,Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Ser Val Gln Ala Gly GlySer Leu Arg Leu Ser Cys Val Ala Ser Gly Tyr Thr Asp Ser Thr TyrCys Val Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly ValAla Arg Ile Asn Thr Ile Ser Gly Arg Pro Trp Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Gln Asp Asn Ser Lys Asn Thr Val TyrLeu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Ile Tyr Tyr CysThr Leu Thr Thr Ala Asn Ser Arg Gly Phe Cys Ser Gly Gly Tyr AsnTyr Lys Gly Gln Gly Thr Gln Val Thr Val Ser,,22123PRTArtificial SequenceSynthetic Construct 22,,(22)  a glycophorin a-binding nanobody domain comprising 90-99% identity to seq id no:22; (
https://patents.google.com/patent/US11175293B1/en,Met Thr Asn Lys Cys Leu Leu Gln Ile Ala Leu Leu Leu Cys Phe SerThr Thr Ala Leu Ser Met Gly Ala Pro Gln Val Gln Leu Val Glu SerGly Gly Gly Leu Met Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys AlaVal Ser Gly Arg Thr Phe Ser Thr Ala Ala Met Gly Trp Phe Arg GlnAla Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Arg Trp Ser GlyGly Ser Ala Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile SerArg Asp Lys Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu LysTyr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Glu Asn Val ArgSer Leu Leu Ser Asp Tyr Ala Thr Trp Pro Tyr Asp Tyr Trp Gly GlnGly Thr Gln Val Thr Val Ser Gly Gly Gly Gly Ser Gly Gly Gly GlySer Gly Gly Gly Gly Ser Ile Asp Gln Val Gln Leu Val Glu Ser GlyGly Gly Leu Met Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala ValSer Gly Arg Thr Phe Ser Thr Ala Ala Met Gly Trp Phe Arg Gln AlaPro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Arg Trp Ser Gly GlySer Ala Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser ArgAsp Lys Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys TyrGlu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Glu Asn Val Arg SerLeu Leu Ser Asp Tyr Ala Thr Trp Pro Tyr Asp Tyr Trp Gly Gln GlyThr Gln Val Thr Val Ser Ser Gly Thr Gly Gly Gly Gly Ser Gly GlyGly Gly Ser Gly Gly Gly Gly Ser Gly Ser Glu Pro Lys Ser Cys AspLys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly GlyPro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met IleSer Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His GluAsp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val HisAsn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr ArgVal Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly LysGlu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile GluLys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val TyrThr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser LeuThr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu TrpGlu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro ValLeu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val AspLys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met HisGlu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser ProGly Lys Pro Arg Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly SerAla Ala Ala Trp Ser His Pro Gln Phe Glu Lys Gly Gly Gly Ser GlyGly Gly Ser Gly Gly Gly Ser Trp Ser His Pro Gln Phe Glu Lys,,16591PRTArtificial SequenceSynthetic Construct 16,,(16) the nanobody region of the nanolink (seq id no:16
https://patents.google.com/patent/US11175293B1/en,Met Thr Asn Lys Cys Leu Leu Gln Ile Ala Leu Leu Leu Cys Phe SerThr Thr Ala Leu Ser Met Gly Ala Pro Gln Val Gln Leu Gln Glu SerGly Gly Gly Ser Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys ValAla Ser Gly Tyr Thr Asp Ser Thr Tyr Cys Val Gly Trp Phe Arg GlnAla Pro Gly Lys Glu Arg Glu Gly Val Ala Arg Ile Asn Thr Ile SerGly Arg Pro Trp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile SerGln Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu LysPro Glu Asp Thr Ala Ile Tyr Tyr Cys Thr Leu Thr Thr Ala Asn SerArg Gly Phe Cys Ser Gly Gly Tyr Asn Tyr Lys Gly Gln Gly Thr GlnVal Thr Val Ser Gly Gly Thr Ser Gly Gly Gly Gly Ser Gly Gly GlyGly Ser Gly Gly Gly Gly Ser Ala Ala Ala Met Ala Tyr Cys Trp ArgCys Thr Ser Cys Cys Phe Ser Glu Arg Phe Gln Asn His Asn Pro GlnLys Glu Met Ala Thr Ser Thr Leu Gln Gly Cys Ser Leu Cys Leu GlnLeu Ala Val Val Val Asn Ser Leu Leu Thr Pro Phe Ala Arg Cys CysTrp Pro Glu Phe Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly SerAla Trp Ser His Pro Gln Phe Glu Lys Gly Gly Gly Ser Gly Gly GlySer Gly Gly Ser Ala Trp Ser His Pro Gln Phe Glu Lys,,10Ser Gly Gly Ser Ala Trp Ser His Pro Gln Phe Glu Lys 260 26510269PRTArtificial SequenceSynthetic Construct 10,,"(10) other embodiments useful in the assay include “nanonuc” (seq id no:4), “nanoorf8” (seq id no:6), “nanospikeorf8” (seq id no:8), “nanoorf3b” (seq id no:10), and “nanospikeorf3b” (seq id no:12), which refer to the nanobody and sars-cov-2 nucleocapsid, orf 8, surface glycoprotein receptor binding domain and orf 8, orf 3b, and orf 3b and surface glycoprotein receptor binding domains, respectively"
https://patents.google.com/patent/CN111662379B/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Tyr Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Thr Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Glu Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ala Met Phe Leu Gly Asp Ser Ser Gly Leu Thr Gly Leu Asp Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Glu Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Leu Tyr Tyr Cys Gln Gln Arg Gly Asn Trp Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) the antibody or antigen-binding fragment thereof of claim 1, wherein the amino acid sequence of the heavy chain variable region is set forth in seq id no:4 and the amino acid sequence of the light chain variable region is set forth in seq id no:8."
https://patents.google.com/patent/CN113512114A/en, Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Thr Ser Val Arg Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Ser Thr Ser Ala Val Gln Trp Val Arg Gln Ala Arg Gly Gln Arg Leu Glu Trp Ile Gly Trp Ile Ala Val Gly Ser Gly Lys Thr Asp Tyr Leu Gln Lys Phe Gln Glu Arg Val Thr Met Thr Arg Asp Glu Ser Thr Asn Thr Ala Tyr Met Gln Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Pro His Cys Ser Gly Gly Thr Cys Tyr Asp Gly Phe Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Arg Ser Gly Tyr Phe Ala Trp Tyr Gln Gln Arg Pro Gly Arg Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Ala Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Thr Ser Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , BD836 VH, BD836 VL,"(27/28) (b) a heavy chain variable region (vh) comprising seq id no:27 or a variant thereof; and/or, a light chain variable region (vl) comprising seq id no:28 or a variant thereof;"
https://patents.google.com/patent/CN113512114A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Gln Phe Ser Glu Tyr Lys Leu Ile Ser Phe Trp Ile Ala Trp Val Arg Gln Arg Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Asp Asp Ser Asp Thr Lys Tyr Ser Pro Ser Ser Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Arg Thr Ala Tyr Leu Gln Trp Ser Ser Leu Met Ala Ser Asp Thr Ala Met Tyr Tyr Cys Thr Ser Gly Ser Tyr Tyr Gly Thr Leu Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Glu Ile Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Arg Thr Tyr Val Ala Trp Tyr Gln Gln Arg Pro Gly Lys Val Pro Arg Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Arg Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Ala Pro Leu Thr Phe Gly Gly Gly Ala Lys Val Glu Ile Lys , BD812 VH, BD812 VL,"(7/8) preferably, the antibody or antigen-binding fragment thereof comprises: a vh comprising the sequence shown as seq id no:7and a vl comprising the sequence shown as seq id no:8"
https://patents.google.com/patent/CN114002427A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Ile Thr Phe Ser Asp Tyr Tyr Met Tyr Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile Ser Asp Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Asn Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys Val Arg Asp Lys Ser Met Gly Phe Gly Ala Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Glu Ile Val Leu Thr Gln Ser Pro Thr Thr Met Ala Ala Ser Pro Gly Glu Lys Ile Thr Ile Thr Cys Ser Ala Ser Ser Ser Ile Ser Ser Asn Tyr Leu His Trp Tyr Gln Gln Arg Pro Gly Phe Ser Pro Lys Leu Leu Ile Tyr Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Gly Thr Met Glu Ala Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Gly His Ser Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , VH, VL,"(17/18) one of the antibodies was mab #9, whose heavy chain variable region sequence is shown in seq id no:17 and light chain variable region sequence is shown in seq id no:18."
https://patents.google.com/patent/CN114002427A/en, Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Pro Ser Ser Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Asn Ile Glu Asp Tyr Ala Tyr Tyr Ala Pro Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Asp Leu Lys Val Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Gly Arg Gly Gly Tyr Ala Ala Asp Ile Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser, Asp Val Val Met Thr Gln Thr Ala Ser Pro Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Ser Cys Gln Ser Ser Glu Ser Val Tyr Thr Asn Asn Arg Leu Ser Trp Phe Gln Gln Lys Pro Gly Gln Arg Pro Lys Leu Leu Ile Tyr Arg Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Ile Ile Ser Asp Val Gln Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Ala Gly Val Gly Ser Gly Gly Thr Asp Ile Ala Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , VH, VL,"(7/8) the heavy chain variable region sequence is shown as seq id no:7, and the light chain variable region sequence is shown as seq id no:8."
https://patents.google.com/patent/CN111518204B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16)  wherein the heavy chain variable region comprises seq id no:12 and the light chain variable region comprises the amino acid sequence shown in seq id no:16.
https://patents.google.com/patent/CN111518204B/en, gaggtgcagc tgctcgagtc tgggggaggc ttggtaaagc ctggggggtc ccttagactc tcctgtgcag cctctggatt cactttcagt aacgcctgga tgagctgggt ccgccaggct ccagggaagg ggctggagtg ggttggccgt attaaaagca aaactgatgg tgggacaaca gactacgctg cacccgtgaa aggcagattc accatctcaa gagatgattc aaaaaacacg ctgtatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtatta ctgtaccaca gaaggggcta tggttcggcg agttatatac ggtatggacg tctggggcca agggaccacg gtcaccgtct cctca , gagaatgtgc tcacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc ctctcctgca gggccagaca gagtgttagc agcagctact tagcctggta ccagcagaaa cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca gacaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagactggag cctgaagatt ttgcagtgta ttactgtcag cagtatggta gctcaccgat caccttcggc caagggacac gactggagat taaa , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(17/18) as a preferred embodiment of the present invention, the variable region of the antibody light chain is seq id no:18, and the variable region of the antibody heavy chain is seq id no:17."
https://patents.google.com/patent/CN111518204B/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Arg Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Thr Glu Gly Ala Met Val Arg Arg Val Ile Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Asn Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Arg Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) the monoclonal antibody of claim 1, wherein the first variable region is an antibody light chain variable region as set forth in seq id no:8; wherein said second variable region is an antibody heavy chain variable region represented by seq id no:4."
https://patents.google.com/patent/WO2022003530A1/en, Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val His Ser Gln Val Gln Leu Gln Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Leu Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Asn Phe Ile Gly Asp Gly Tyr Asn Tyr Glu Glu Asp Tyr Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val His Ser Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,SEQ ID NO:333 Heavy chain of MAD0103J13  ,SEQ ID NO:334 Light chain of MAD0103J13  ,(333/334) or the heavy chain of said antibody having seq id no:333 and the light chain of said antibody having seq id no:334
https://patents.google.com/patent/WO2022003530A1/en, Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Thr Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Ser Ser Ala Met Gln Trp Val Arg Gln Ala Arg Gly Gln Arg Leu Glu Trp Ile Gly Trp Ile Val Val Gly Ser Gly Asn Thr Asp Tyr Val Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Arg Asp Met Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Pro Tyr Cys Ser Ser Thr Thr Cys His Asp Gly Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser , Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ala Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Gly Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Arg Ser Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr ,SEQ ID NO:25 variable domain of Heavy chain of I14  ,SEQ ID NO:26 variable domain of Light chain of I14  ,(25/26) vh having seq id no:25 and said vl having seq id no:26
https://patents.google.com/patent/WO2022003530A1/en, Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val His Ser Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Thr Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Ser Ser Ala Met Gln Trp Val Arg Gln Ala Arg Gly Gln Arg Leu Glu Trp Ile Gly Trp Ile Val Val Gly Ser Gly Asn Thr Asp Tyr Val Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Arg Asp Met Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Pro Tyr Cys Ser Ser Thr Thr Cys His Asp Gly Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ala Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Gly Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Arg Ser Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr ,SEQ ID NO:27 Heavy chain of I14  ,SEQ ID NO:26 variable domain of Light chain of I14  ,(27/26) >seq id no:26 variable domain of light chain of mad0100i14 eivmtqspgtlslapgeratlscrasqsvsssylgwyqqkpgqaprlliygassra tgipdrfsgsgsgtdftltisrlepedfavyycqqygrspwtfgqgtkveikrt >seq id no:27 heavy chain of mad0100i14 
https://patents.google.com/patent/WO2022003530A1/en, Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Asp Arg Val Met Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Arg Ala Ile Asp Ser Asp Thr Tyr Val Glu Gln Ser His Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val His Ser Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Ser Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,SEQ ID NO:9 Heavy chain of J08  ,SEQ ID NO:10 Light chain of J08  ,"(9/10) 13. the human monoclonal antibody according to any one of the claims from 1 to 12, wherein the heavy chain of said antibody having seq id no:9 and the light chain of said antibody having seq id no:10"
https://patents.google.com/patent/WO2022003530A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu Ser Met His Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Ala Asp Ala Glu Thr Ile Tyr Ala Gln Lys Leu Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ala Leu Pro Ile Thr Met Val Arg Gly Val Gln Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Pro Gly Thr Thr Val Thr Val Ser Ser Ala Ser , Asp Ile Val Met Thr Gln Thr Pro Leu Ser Ser Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr Tyr Cys Met Gln Val Thr Gln Phe Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr ,SEQ ID NO:133 variable domain of Heavy chain of MAD0100F10  ,SEQ ID NO:134 variable domain of Light chain of MAD0100F10  ,(133/134) vh having seq id no:133 and said vl having seq id no:134 or 
https://patents.google.com/patent/WO2022003530A1/en, Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val His Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ile Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Pro Leu Leu Trp Ala Asp Ser Tyr Tyr Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Asn Asn Leu Gly Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile Tyr Ala Ala Ser Thr Leu Gln Arg Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Leu Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr ,SEQ ID NO:45 Heavy chain of F05  ,SEQ ID NO:44 variable domain of Light chain of F05  ,(45/44) >seq id no:44 variable domain of light chain of mad0102f05 aiqmtqspsslsasvgdrvtitcrasqdirnnlgwfqqkpgkapkrliyaastlqr gvpsrfsgsgsgteftltis slqpedf atyy clqhn s ylwtf gqgtkveikrt >seq id no:45 heavy chain of mad0102f05
https://patents.google.com/patent/WO2022003530A1/en, Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val His Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg Asp Leu Tyr Ser Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ala Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Val Asn Ser Tyr Pro Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr ,SEQ ID NO:243 Heavy chain of MAD0008C14  ,SEQ ID NO:242 variable domain of Light chain of MAD0008C14  ,(243/242) >seq id no:242 variable domain of light chain of mad0008c14 aiqmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqs gvpsrfsgsgsgteftltisslqpedfatyycqqvnsyptfgqgtrleikrt >seq id no:243 heavy chain of mad0008c14 
https://patents.google.com/patent/WO2022003530A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Phe Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Tyr Met Ser Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Ser Ser Ser Gly Ser Asn Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys Ala Arg Gly Arg Leu Trp Gly Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp His Leu Leu Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr ,SEQ ID NO:151 variable domain of Heavy chain of MAD0100L19  ,SEQ ID NO:152 variable domain of Light chain of MAD0100L19  ,(151/152) vh having seq id no:151 and said vl having seq id no:152 or 
https://patents.google.com/patent/WO2022003530A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Pro Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Thr Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Met Leu Gly Ile Ala Lys Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ile Val Gly Ala Thr Pro Gly Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser , Asp Ile Val Met Thr Gln Ser Pro Ala Ala Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Trp Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr ,SEQ ID NO:61 variable domain of Heavy chain of MAD0041G12  ,SEQ ID NO:62 variable domain of Light chain of MAD0041G12  ,(61/62) vh having seq id no:61 and said vl having seq id no:62 or 
https://patents.google.com/patent/WO2022003530A1/en, Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Pro Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Thr Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Met Leu Gly Ile Ala Lys Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ile Val Gly Ala Thr Pro Gly Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Val Met Thr Gln Ser Pro Ala Ala Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Trp Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr ,SEQ ID NO:63 Heavy chain of MAD0041G12  ,SEQ ID NO:62 variable domain of Light chain of MAD0041G12  ,(63/62) >seq id no:62 variable domain of light chain of mad0041g12 divmt q sp aals v spgeratl scrasq s v s snl aw y qqkpgq aprlli y gastrat gip arf sgsw sgteftltis slqsedlavyycqqynnwltf gggtkveikrt >seq id no:63 heavy chain of mad0041g12
https://patents.google.com/patent/WO2022003530A1/en, Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Ser Leu Ile Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Val Glu Thr Ile Tyr Ala Gln Asn Leu Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Phe Phe Ala Val Arg Gly Ala Leu Asn Trp Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Leu Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr ,SEQ ID NO:189 Heavy chain of MAD0102F20  ,SEQ ID NO:188 variable domain of Light chain of MAD0102F20  ,(189/188) >seq id no:188 variable domain of light chain of mad0102f20 eivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastrat glparfsgsgsgteftltisslqsedfavyycqqynnwppltfgqgtkleikrt >seq id no:189 heavy chain of mad0102f20 
https://patents.google.com/patent/WO2022003530A1/en, Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val His Ser Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ala Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Gly Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Met Tyr Tyr Cys Ala Lys Asp Gln Asp Asp Ala Tyr Tyr Phe Tyr Tyr Tyr Met Asp Val Trp Gly Lys Gly Thr Ala Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Val Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Gly Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Gly Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr ,SEQ ID NO:99 Heavy chain of MAD0041K22  ,SEQ ID NO:98 variable domain of Light chain of MAD0041K22  ,(99/98) >seq id no:98 variable domain of light chain of mad0041k22 divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprllvygassra tgipgrfsgsgsgtdftltisrlepedfavyycqqyggpltfgggtkveikrt >seq id no:99 heavy chain of mad0041k22
https://patents.google.com/patent/WO2022003530A1/en, Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val His Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ile Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Tyr Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gln Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ala Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Arg His Leu Asn Ser Tyr Pro Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr ,SEQ ID NO:297 Heavy chain of MAD0008D12  ,SEQ ID NO:296 variable domain of Light chain of MAD0008D12  ,(297/296) >seq id no:296 variable domain of light chain of mad0008d12 aiqmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqs gvp srf sgsgsgt qftltis slqpedf at yy crhln s yppitf gqgtrleikrt >seq id no:297 heavy chain of mad0008d12 
https://patents.google.com/patent/WO2022003530A1/en, Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val His Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Phe Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Tyr Met Ser Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Ser Ser Ser Gly Ser Asn Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys Ala Arg Gly Arg Leu Trp Gly Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp His Leu Leu Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr ,SEQ ID NO:153 Heavy chain of MAD0100L19  ,SEQ ID NO:152 variable domain of Light chain of MAD0100L19  ,(153/152) >seq id no:152 variable domain of light chain of mad0100l19 divmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlqt gvpsrfsgsgsgtdftftisslqpediatyycqqydhllitfgqgtrleikrt >seq id no:153 heavy chain ofmad0100l19 
https://patents.google.com/patent/WO2022003530A1/en, Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val His Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Ser Leu Gln Met Asn Ser Leu Arg Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Thr Gly Thr Tyr Asp Phe Trp Ser Asp Asn His Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ala Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Ser Thr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr ,SEQ ID NO:81 Heavy chain of MAD0041I21  ,SEQ ID NO:80 variable domain of Light chain of MAD0041I21  ,(81/80) >seq id no:80 variable domain of light chain of mad0041i21 aiqmtqspsflsasvgdrvtitcrasqgissslawyqqkpgkapklliyaastlqsg vpsrfsgsgs gtef tltis slqpedf at y y c qqln s yp s ttf gggtk veikrt >seq id no:81 heavy chain of mad0041i21 
https://patents.google.com/patent/WO2022003530A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Ser Leu Gln Met Asn Ser Leu Arg Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Thr Gly Thr Tyr Asp Phe Trp Ser Asp Asn His Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser , Ala Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Ser Thr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr ,SEQ ID NO:79 variable domain of Heavy chain of MAD0041I21  ,SEQ ID NO:80 variable domain of Light chain of MAD0041I21  ,(79/80) vh having seq id no:79 and said vl having seq id no:80 or 
https://patents.google.com/patent/WO2022003530A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Asp Arg Val Met Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Arg Ala Ile Asp Ser Asp Thr Tyr Val Glu Gln Ser His Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Ser Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr ,SEQ ID NO:7 variable domain of Heavy chain of J08  ,SEQ ID NO:8 variable domain of Light chain of J08  ,(7/8) vh having seq id no:7 and said vl having seq id no:8
https://patents.google.com/patent/WO2022003530A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ile Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Pro Leu Leu Trp Ala Asp Ser Tyr Tyr Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser Ala Ser , Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Asn Asn Leu Gly Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile Tyr Ala Ala Ser Thr Leu Gln Arg Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Leu Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr ,SEQ ID NO:43 variable domain of Heavy chain of F05  ,SEQ ID NO:44 variable domain of Light chain of F05  ,(43/44) vh having seq id no:43 and said vl having seq id no:44 or 
https://patents.google.com/patent/WO2022003530A1/en, Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Thr Pro Ile Phe His Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Ser Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Thr Gly Asp Gln Gly Val Thr Ala Pro Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Leu Arg Gly Asn Trp Pro Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr ,SEQ ID NO:171 Heavy chain of MAD0101H20  ,SEQ ID NO:170 variable domain of Light chain of MAD0101H20  ,(171/170) >seq id no:170 variable domain of light chain of mad0101h20 eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnrat giparf sgsgsgtdftltis slepedf a v y y c qlrgnwpp wtf gqgtk veikrt >seq id no:171 heavy chain ofmad0101h20
https://patents.google.com/patent/WO2022003530A1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Asn Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly His Ile Phe Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Gly Trp Tyr Leu Tyr Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser , Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Leu Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Gln Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr ,SEQ ID NO:205 variable domain of Heavy chain of MAD0102F22  ,SEQ ID NO:206 variable domain of Light chain of MAD0102F22  ,(205/206) vh having seq id no:205 and said vl having seq id no:206 or 
https://patents.google.com/patent/WO2022003530A1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ala Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Gly Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Met Tyr Tyr Cys Ala Lys Asp Gln Asp Asp Ala Tyr Tyr Phe Tyr Tyr Tyr Met Asp Val Trp Gly Lys Gly Thr Ala Val Thr Val Ser Ser Ala Ser , Asp Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Val Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Gly Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Gly Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr ,SEQ ID NO:97 variable domain of Heavy chain of MAD0041K22  ,SEQ ID NO:98 variable domain of Light chain of MAD0041K22  ,(97/98) vh having seq id no:97 and said vl having seq id no:98 or 
https://patents.google.com/patent/WO2022003530A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Thr Pro Ile Phe His Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Ser Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Thr Gly Asp Gln Gly Val Thr Ala Pro Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Leu Arg Gly Asn Trp Pro Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr ,SEQ ID NO:169 variable domain of Heavy chain of MAD0101H20  ,SEQ ID NO:170 variable domain of Light chain of MAD0101H20  ,(169/170) vh having seq id no:169 and said vl having seq id no:170 or 
https://patents.google.com/patent/WO2022003530A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Ser Leu Ile Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Val Glu Thr Ile Tyr Ala Gln Asn Leu Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Phe Phe Ala Val Arg Gly Ala Leu Asn Trp Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser , Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Leu Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr ,SEQ ID NO:187 variable domain of Heavy chain of MAD0102F20  ,SEQ ID NO:188 variable domain of Light chain of MAD0102F20  ,(187/188) vh having seq id no:187 and said vl having seq id no:188 or 
https://patents.google.com/patent/WO2022003530A1/en, Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Val Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Gly Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Cys Tyr Cys Ala Arg Asp Gly Gly Asp Ile Val Val Val Pro Gly Ala Ser Thr Ser Glu Asn Tyr Tyr Tyr Tyr Tyr Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser Ala Ser , Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp Ser Asp Asp Gly Asn Thr Tyr Leu Asp Trp Cys Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Arg Ile Glu Phe Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr ,SEQ ID NO:115 variable domain of Heavy chain of MAD0041M02  ,SEQ ID NO:116 variable domain of Light chain of MAD0041M02  ,(115/116) vh having seq id no:115 and said vl having seq id no:116 or 
https://patents.google.com/patent/WO2022003530A1/en, Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Ala Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Arg Phe Gln Gly Arg Val Thr Met Thr Glu Asp Ala Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Thr Val Gly Phe Pro Asp Tyr Tyr Asp Ser Ser Val Tyr Leu Arg His Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ala Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Arg Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr ,SEQ ID NO:315 Heavy chain of MAD0102I15  ,SEQ ID NO:314 variable domain of Light chain of MAD0102I15  ,(315/314) >seq id no:314 variable domain of light chain of mad0102i15 aiqmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqs gvp srf s gs gs gtef tltis slqpedf at y y c qqln s yprtf gqgtkleikrt >seq id no:315 heavy chain ofmad0102i15 
https://patents.google.com/patent/WO2022003530A1/en, Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val His Ser Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Asn Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly His Ile Phe Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Gly Trp Tyr Leu Tyr Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Leu Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Gln Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr ,SEQ ID NO:207 Heavy chain of MAD0102F22  ,SEQ ID NO:206 variable domain of Light chain of MAD0102F22  ,(207/206) >seq id no:206 variable domain of light chain of mad0102f22 eivmtqspgtlslspgeratlscrasqsisssylawyqqkpgqaprlllygassrat gipdrf sgsgsgtdftltisrlepedf avyycqq ygs spqtfgqgtkleikrt >seq id no:207 heavy chain of mad0102f22
https://patents.google.com/patent/WO2022003530A1/en, Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Asn Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Arg Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Asp Leu Leu Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asn Asn Tyr Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Lys Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Phe Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr ,SEQ ID NO:279 Heavy chain of MAD0008B07  ,SEQ ID NO:278 variable domain of Light chain of MAD0008B07  ,(279/278) >seq id no:278 variable domain of light chain of mad0008b07 aiqmtqspsslsasvgdrvtitcrasqginnylawfqqkpgkapksliyaasslqs gvpskfsgsgsgtdftltisslqpedfatyycqqynsypftfgqgtrleikrt >seq id no:279 heavy chain of mad0008b07
https://patents.google.com/patent/WO2022003530A1/en, Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val His Ser Gln Val Gln Leu Gln Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Leu Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Asn Phe Ile Gly Asp Gly Tyr Asn Tyr Glu Glu Asp Tyr Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr ,SEQ ID NO:333 Heavy chain of MAD0103J13  ,SEQ ID NO:332 variable domain of Light chain of MAD0103J13  ,(333/332) >seq id no:332 variable domain of light chain of mad0103j13 eivmtqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnrat giparf sgsgsgtdftltis slepedf avyycqqrsnwppftfgpgtkvdikrt >seq id no:333 heavy chain of mad0103j13 
https://patents.google.com/patent/WO2021180218A1/en, Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Thr Asn Thr Gly Asn Pro Thr Tyr Ala Gln Gly Phe Thr Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr Leu Gln Ile Ser Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Gln Gly Gly Ser Ser Trp Tyr Arg Asp Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  VH  ,  VL  ,"(7/8)  preferably, it includes: vh shown in seq id no:7 and/or vl shown in seq id no:8."
https://patents.google.com/patent/CN113004397B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(12/16)  wherein the amino acid sequence of vh is shown as seq id no:12, and the amino acid sequence of vl is shown as seq id no:16."
https://patents.google.com/patent/CN113004397B/en, Gln Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Trp Arg Ser Ser Gly Tyr His Asp Tyr Ser Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Asn Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Arg Gly Val Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8)  wherein, the amino acid sequence of vh is shown as seq id no:4, and the amino acid sequence of vl is shown as seq id no:8."
https://patents.google.com/patent/CN112062838A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Asp Phe Asp Phe Tyr Asp Tyr Glu Met Ser Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Ile Gly Glu Ile His His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Thr Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Val Lys Asp Phe Val Gly Ala Asp Gly Pro Phe Val Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,"(2) preferably, the amino acid sequence of the single domain antibody is shown as seq id no:2."
https://patents.google.com/patent/CN112062838A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ala Ser Ser Gly Tyr Tyr Thr Asp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Ala Asp Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Tyr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Tyr Ser Ala Pro Ser Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,, Artificial Sequence (Artificial Sequence),,"(3) a pharmaceutical composition comprising a pharmaceutically active ingredient, wherein the pharmaceutically active ingredient comprises the neutralizing single domain antibody against sars-cov-2 of the novel coronavirus of any one of claims 1 to 4 and the sars-cov-2 neutralizing antibody 4a3 having the amino acid sequence shown in seq id no:3."
https://patents.google.com/patent/WO2021207152A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Phe Ile Gln Pro Gly Gly Ser Val Arg Leu Ser Cys Ser Ala Ser Gly Phe Asn Val Tyr Asp Asn Tyr Phe Ser Trp Val Arg Gln Ala Pro Gly Arg Gly Pro Glu Trp Val Ser Val Ile Tyr Arg Asp Gly Ala Thr Arg Tyr Ala Glu Ser Val Gln Gly Arg Phe Thr Met Phe Arg Asp Asn Ser Arg Lys Thr Leu Tyr Leu Gln Met Asn Arg Leu Lys Ala Gly Asp Thr Ala Val Tyr Phe Cys Ala Leu Gly Arg Lys Asp Tyr Gly Asp Tyr Tyr Arg Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Thr Ala Thr Leu Ser Cys Arg Ala Gly Gln Ser Val Arg Ser Arg Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Val Leu Ile Tyr Gly Ala Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Arg Leu Glu Pro Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Ala Pro Ser Pro Pro Trp Tyr Ile Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Synthetic construct  ,  Synthetic construct  ,"(38/56) , wherein: vh is seq id no:38, and vl is seq id no:56. in some embodiments, the antibody or antigen binding fragment thereof comprises a light 25 chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en, Glu Val Leu Leu Val Glu Ser Gly Gly Gly Val Ile Gln Pro Gly Ala Ser Leu Arg Leu Ser Cys Glu Pro Ser Gly Thr Thr Val Ser Ser Asn Phe Trp Thr Trp Val Arg Gln Ala Pro Gly Arg Arg Leu Glu His Val Ala Ile Ile Tyr Ser Gly Asp Ala Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Phe Arg Asp Asn Ser Lys Asn Met Leu Phe Leu Glu Met Asn Asn Leu Lys Val Ala Asp Ser Ala Ile Tyr Phe Cys Val Arg Gly Arg Thr Tyr Trp Gly Gln Gly Thr Leu Val Ser Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Asp Thr Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Val Ser Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Pro Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Arg Trp Leu Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  Synthetic construct  ,  Synthetic construct  ,"(43/61) , wherein: vh is seq id no:43, and 10 vl is seq id no:61. in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en, Glu Gly Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Phe Thr Phe Ser Arg Tyr Ala Met Thr Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Thr Ala Ile Pro Tyr Asp Arg Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Met Val Tyr Leu Gln Ala Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Met Arg Thr Ala Val Val Gly Val Thr Pro Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ala Ile Gln Val Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Ile Thr Ile Thr Cys Arg Thr Ser Gln Gly Ile Arg Asp Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Thr Leu Leu Ile Tyr Gly Ala Thr Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Glu Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Leu Phe Ser Phe Gly Pro Gly Thr Lys Val Asp Ile Lys ,  Synthetic construct  ,  Synthetic construct  ,"(47/65) , wherein: vh is seq id no:47, and vl is seq id no:65. in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Asp Gly Ser Ser Val Lys Val Ser Cys Glu Ala Ser Gly Gly Thr Phe Ser Asp Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Thr Asn Tyr Ala Gln Gln Phe Gln Thr Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Ala Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Lys Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Glu Val Asn Tyr Tyr Ser Ala Phe Asp Asp Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Asp Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Asn Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Ala Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Phe Trp Trp Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys ,  Synthetic construct  ,  Synthetic construct  ,"(49/67) , wherein: vh is seq id no:49, and  vl is seq id no:67. in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en, Ala Ile Gln Val Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Ile Thr Ile Thr Cys Arg Thr Ser Gln Gly Ile Arg Asp Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Thr Leu Leu Ile Tyr Gly Ala Thr Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Glu Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Leu Phe Ser Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Glu Gly Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Phe Thr Phe Ser Arg Tyr Ala Met Thr Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Thr Ala Ile Pro Tyr Asp Arg Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Met Val Tyr Leu Gln Ala Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Met Arg Thr Ala Val Val Gly Val Thr Pro Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Synthetic construct  ,  Synthetic construct  ,"(65/47) in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: 25 vh is seq id no:47, and vl is seq id no:65"
https://patents.google.com/patent/WO2021207152A1/en, Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Ile Gly Asp Arg Val Thr Phe Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Glu Pro Pro Lys Leu Leu Ile Tyr Ser Val Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Leu Ala Thr Tyr Tyr Cys Gln His Arg Val Thr Phe Gly Pro Gly Thr Lys Val Gly Ile Lys , Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Pro Pro Gly Gly Ser Leu Gly Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Glu Phe Trp Met Ser Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Gly Gln Asp Gly Asn Ser Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Ser Leu Asn Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Val Tyr Tyr Cys Ala Arg Val Thr Ile Val Ser Ser Phe Thr Asn Arg Phe Asp Pro Trp Gly Gln Gly Val Leu Val Thr Val Ser Ser ,  Synthetic construct  ,  Synthetic construct  ,"(58/40) in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: 15 vh is seq id no:40, and vl is seq id no:58"
https://patents.google.com/patent/WO2021207152A1/en, Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Asp Thr Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ala Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Val Ser Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Pro Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Arg Trp Leu Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Glu Val Leu Leu Val Glu Ser Gly Gly Gly Val Ile Gln Pro Gly Ala Ser Leu Arg Leu Ser Cys Glu Pro Ser Gly Thr Thr Val Ser Ser Asn Phe Trp Thr Trp Val Arg Gln Ala Pro Gly Arg Arg Leu Glu His Val Ala Ile Ile Tyr Ser Gly Asp Ala Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Phe Arg Asp Asn Ser Lys Asn Met Leu Phe Leu Glu Met Asn Asn Leu Lys Val Ala Asp Ser Ala Ile Tyr Phe Cys Val Arg Gly Arg Thr Tyr Trp Gly Gln Gly Thr Leu Val Ser Val Ser Ser ,  Synthetic construct  ,  Synthetic construct  ,"(61/43) 25 in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:43, and vl is seq id no:61"
https://patents.google.com/patent/WO2021207152A1/en, Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Ser Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Lys Phe Met Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Ile Leu Ile Tyr Glu Asp Asn Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Thr Ser Ser Asn Ser Ala Leu Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr His Gly Ser Asp Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Arg Phe Ile Thr Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Arg Gly Leu Glu Trp Met Gly Lys Ile Asp Pro Ser Asp Ser Ser Thr Asn Tyr Ser Pro Ser Phe Gln Gly His Val Ala Ile Ser Val Asp Lys Ser Phe Asn Thr Ala Tyr Leu Gln Trp Ser Arg Leu Asn Thr Ser Asp Thr Ala Met Tyr Tyr Cys Ala Ala Gly Pro Thr Gly Tyr Asp Leu Leu Thr Gly Gln Tyr Phe Pro Tyr Phe Asn Tyr Trp Ala Gln Gly Thr Leu Val Thr Val Ser Ser ,  Synthetic construct  ,  Synthetic construct  ,"(60/42) in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:42, and vl is seq id no:60"
https://patents.google.com/patent/WO2021207152A1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser Ile Ser Ser Gly Arg Asp Tyr Trp Ser Trp Ile Arg Gln Ala Ala Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Thr Thr Gly Ser Ala Asn Tyr Asn His Ser Leu Lys Ser Arg Val Ser Ile Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Met Thr Ser Met Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asn Asp Tyr Ser Asn Tyr Pro Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Tyr Ser Asn Ile Gly Thr Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Val Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Ala Ser Arg Ser Gly Ser Ser Ala Ser Leu Asp Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Gly Ala Leu Ser Val Gly Leu Phe Gly Thr Gly Thr Lys Val Thr Val Leu ,  Synthetic construct  ,  Synthetic construct  ,"(53/71) , wherein: vh is seq id no:53, and vl is seq id no:71. in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en, Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Val Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile His Ala Thr Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Cys Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Glu Ser Tyr Ser Thr Asn Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Glu Val Pro Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Pro Phe Ser Ser Phe Ala Leu Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Thr Ile Asn Thr Asn Gly Gly Thr Thr Tyr Tyr Leu Asp Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Lys Asp Leu Leu Ser His Ser Gly Thr Tyr Ser Ala Gly Ser Thr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ile Val Ser Ser ,  Synthetic construct  ,  Synthetic construct  ,"(69/51) in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:51, and vl is seq id no:69"
https://patents.google.com/patent/WO2021207152A1/en, Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Ser Gly Glu Ala Pro Ser Leu Val Ile Tyr Ala Ala Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Gly Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Ser Leu Leu Trp Thr Phe Gly Gln Gly Thr Arg Val Glu Ile Lys , Gln Val Gln Leu Gly Gln Ser Gly Ala Glu Leu Lys Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala His Lys Phe Gln Gly Arg Val Ser Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Phe Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Leu Glu Ser Lys Leu Gly Tyr Gly Tyr Gly Gly Ser Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Synthetic construct  ,  Synthetic construct  ,"(72/54) 5 in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:54, and vl is seq id no:72"
https://patents.google.com/patent/WO2021207152A1/en, Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Phe Ile Asn Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Ser Tyr Ser Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Gly Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Val Ser Gly Ile Asn Val Asn Gly Tyr Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu Gln Met Ile Ser Leu Thr Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Val Lys Glu Asp Thr Pro Leu Val Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Synthetic construct  ,  Synthetic construct  ,"(68/50) in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:50, and vl is seq id no:68"
https://patents.google.com/patent/WO2021207152A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Val Tyr Pro Met His Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Gln Tyr Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu His Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Phe Tyr Cys Ala Arg Asp Arg Ser Ala Thr Tyr Tyr Gly Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Ser Ala Ser Trp Tyr Gln Gln Lys Pro Ser Gln Ala Pro Val Leu Val Ile Tyr Ala Asn Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Asn Ser Gly Asn His Pro Val Ile Phe Gly Gly Gly Thr Thr Leu Thr Val Leu ,  Synthetic construct  ,  Synthetic construct  ,"(45/63) , wherein: vh is seq id no:45, and vl is seq id no:63. 5 in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en, Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Thr Ala Thr Leu Ser Cys Arg Ala Gly Gln Ser Val Arg Ser Arg Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Val Leu Ile Tyr Gly Ala Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Arg Leu Glu Pro Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Ala Pro Ser Pro Pro Trp Tyr Ile Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Glu Val Gln Leu Val Glu Ser Gly Gly Gly Phe Ile Gln Pro Gly Gly Ser Val Arg Leu Ser Cys Ser Ala Ser Gly Phe Asn Val Tyr Asp Asn Tyr Phe Ser Trp Val Arg Gln Ala Pro Gly Arg Gly Pro Glu Trp Val Ser Val Ile Tyr Arg Asp Gly Ala Thr Arg Tyr Ala Glu Ser Val Gln Gly Arg Phe Thr Met Phe Arg Asp Asn Ser Arg Lys Thr Leu Tyr Leu Gln Met Asn Arg Leu Lys Ala Gly Asp Thr Ala Val Tyr Phe Cys Ala Leu Gly Arg Lys Asp Tyr Gly Asp Tyr Tyr Arg Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Synthetic construct  ,  Synthetic construct  ,"(56/38) 5 in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:38, and vl is seq id no:56"
https://patents.google.com/patent/WO2021207152A1/en, Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ala Leu Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Ile Asn Thr Gly Lys Pro Thr Tyr Ala Gln Gly Phe Thr Gly Arg Phe Val Leu Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr Leu Gln Ile Ser Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Phe Asp Leu Val Val Pro Ser Ala Thr Tyr Pro Pro Phe Tyr Tyr His Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Thr Tyr Tyr Ala Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Ile Leu Val Ile Tyr Gly Lys Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Asp Gln Thr Phe Tyr Val Phe Gly Thr Gly Thr Gln Val Thr Val Leu ,  Synthetic construct  ,  Synthetic construct  ,"(41/59) , wherein:  vh is seq id no:41, and vl is seq id no:59. in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en, Glu Ile Val Met Thr Gln Ser Pro Asp Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Asn Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Ala Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Phe Trp Trp Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys , Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Asp Gly Ser Ser Val Lys Val Ser Cys Glu Ala Ser Gly Gly Thr Phe Ser Asp Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Thr Asn Tyr Ala Gln Gln Phe Gln Thr Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Ala Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Lys Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Glu Val Asn Tyr Tyr Ser Ala Phe Asp Asp Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,  Synthetic construct  ,  Synthetic construct  ,"(67/49) in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:49, and  vl is seq id no:67"
https://patents.google.com/patent/WO2021207152A1/en, Asp Ile Val Met Thr Gln Ser Pro Arg Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Thr Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Ala Ser Asn Arg Ala Ser Gly Val Pro Gly Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Asp Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys , Gln Leu Arg Leu Gln Ala Ser Gly Pro Gly Leu Val Arg Pro Ser Val Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Ala Ser Val Lys Ser Asp Lys Ser Tyr Trp Gly Trp Phe Arg Gln Ser Pro Gly Lys Gly Leu Ala Ser Ile Ala Thr Ile Tyr Tyr Asn Gly Asn Val Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Leu Ser Leu Asp Thr Ser Thr Asn Gln Leu Ser Leu Lys Met Arg Ser Val Thr Ala Ala Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Leu Asp Tyr Ser Lys Gln Thr Trp Gly Gln Gly Ile Leu Val Thr Val Ser Ser ,  Synthetic construct  ,  Synthetic construct  ,"(57/39) in some embodiments, the antibody or antigen binding fragment thereof comprises a light 10 chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:39, and vl is seq id no:57"
https://patents.google.com/patent/WO2021207152A1/en, Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Ser Ala Ser Trp Tyr Gln Gln Lys Pro Ser Gln Ala Pro Val Leu Val Ile Tyr Ala Asn Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Asn Ser Gly Asn His Pro Val Ile Phe Gly Gly Gly Thr Thr Leu Thr Val Leu , Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Val Tyr Pro Met His Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Gln Tyr Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu His Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Phe Tyr Cys Ala Arg Asp Arg Ser Ala Thr Tyr Tyr Gly Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Synthetic construct  ,  Synthetic construct  ,"(63/45)  in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:45, and vl is seq id no:63"
https://patents.google.com/patent/WO2021207152A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Pro Pro Gly Gly Ser Leu Gly Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Glu Phe Trp Met Ser Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Gly Gln Asp Gly Asn Ser Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Ser Leu Asn Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Val Tyr Tyr Cys Ala Arg Val Thr Ile Val Ser Ser Phe Thr Asn Arg Phe Asp Pro Trp Gly Gln Gly Val Leu Val Thr Val Ser Ser , Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Ile Gly Asp Arg Val Thr Phe Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Glu Pro Pro Lys Leu Leu Ile Tyr Ser Val Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Leu Ala Thr Tyr Tyr Cys Gln His Arg Val Thr Phe Gly Pro Gly Thr Lys Val Gly Ile Lys ,  Synthetic construct  ,  Synthetic construct  ,"(40/58) , wherein: 30 vh is seq id no:40, and vl is seq id no:58. in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Gln Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Arg Phe Asp Ile Phe Asp Ile Asn Trp Val Arg Gln Ala Ser Gly Gln Gly Pro Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala His Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Ser Ser Thr Asn Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Phe Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Val Glu Arg Thr Gly Asn Val Gly Phe Gly Tyr Tyr Ala Met Asp Val Trp Gly Gln Gly Thr Thr Val Ile Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Thr Asn Tyr Leu Asn Trp Tyr Gln Gln Arg Pro Gly Lys Ala Pro Arg Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Gly Thr Phe Tyr Cys Gln Gln Thr Tyr Ser Ser Pro Ser Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Met Lys ,  Synthetic construct  ,  Synthetic construct  ,"(37/55) , wherein: vh is seq id no:37, and vl is seq id no:55. 5 in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en, Ala Ile Gln Val Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Ile Thr Ile Thr Cys Arg Thr Ser Gln Gly Ile Arg Asp Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Thr Leu Leu Ile Tyr Gly Ala Thr Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Glu Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Leu Phe Ser Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Glu Gly Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Phe Thr Phe Ser Arg Tyr Ala Met Thr Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Thr Ala Ile Pro Tyr Asp Arg Phe Tyr Ala Asp Ser Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Met Val Tyr Leu Gln Ala Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Met Arg Thr Ala Val Val Gly Val Thr Pro Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Synthetic construct  ,  Synthetic construct  ,"(70/52) in some embodiments, the antibody or antigen binding fragment thereof comprises a light 30 chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:52, and vl is seq id no:70"
https://patents.google.com/patent/WO2021207152A1/en, Glu Gly Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Phe Thr Phe Ser Arg Tyr Ala Met Thr Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Thr Ala Ile Pro Tyr Asp Arg Phe Tyr Ala Asp Ser Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Met Val Tyr Leu Gln Ala Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Met Arg Thr Ala Val Val Gly Val Thr Pro Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ala Ile Gln Val Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Ile Thr Ile Thr Cys Arg Thr Ser Gln Gly Ile Arg Asp Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Thr Leu Leu Ile Tyr Gly Ala Thr Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Glu Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Leu Phe Ser Phe Gly Pro Gly Thr Lys Val Asp Ile Lys ,  Synthetic construct  ,  Synthetic construct  ,"(52/70) , wherein: vh is seq id no:52, and vl is seq id no:70.  in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en, Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Pro Asn Ile Gly Asn Asn Lys Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Val Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Ala Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Val Trp Asp Asp Ser Leu Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Glu Val His Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Ala Val Ser Gly Tyr Tyr Met Ile Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Phe Thr Ser Gly Arg Thr Tyr Tyr Ala Asp Ser Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Ser Lys Asn Thr Leu Tyr Leu Gln Met Asp Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Phe Leu Pro Val Tyr Asn Asn Gly Trp Ser Tyr Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Synthetic construct  ,  Synthetic construct  ,"(64/46) 5 in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:46, and vl is seq id no:64"
https://patents.google.com/patent/WO2021207152A1/en, Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Thr Tyr Tyr Ala Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Ile Leu Val Ile Tyr Gly Lys Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Asp Gln Thr Phe Tyr Val Phe Gly Thr Gly Thr Gln Val Thr Val Leu , Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ala Leu Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Ile Asn Thr Gly Lys Pro Thr Tyr Ala Gln Gly Phe Thr Gly Arg Phe Val Leu Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr Leu Gln Ile Ser Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Phe Asp Leu Val Val Pro Ser Ala Thr Tyr Pro Pro Phe Tyr Tyr His Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,  Synthetic construct  ,  Synthetic construct  ,"(59/41) in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein:  vh is seq id no:41, and vl is seq id no:59"
https://patents.google.com/patent/WO2021207152A1/en, Glu Val His Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Ala Val Ser Gly Tyr Tyr Met Ile Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Phe Thr Ser Gly Arg Thr Tyr Tyr Ala Asp Ser Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Ser Lys Asn Thr Leu Tyr Leu Gln Met Asp Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Phe Leu Pro Val Tyr Asn Asn Gly Trp Ser Tyr Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Pro Asn Ile Gly Asn Asn Lys Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Val Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Ala Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Val Trp Asp Asp Ser Leu Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Synthetic construct  ,  Synthetic construct  ,"(46/64) , wherein: vh is seq id no:46, and vl is seq id no:64. in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en, Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Phe Leu Phe Cys Ser Val Ser Gly Gly Ser Ile Ser Ile Ser Thr His Tyr Trp Glu Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Phe Tyr Ser Ser Gly Thr Thr Tyr Tyr Asn Pro Ser Leu Lys Gly Arg Val Thr Ile Ser Ala Asp Thr Ser Lys Ser Gln Ile Ser Leu Lys Met Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Arg Pro Gln Tyr Leu Leu Leu Ser Met Thr Thr Gly Arg Arg His His Asp Phe Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Thr Cys Lys Ser Ser Gln Ser Val Leu Phe Gly Ser Asn Asn Glu Asn Tyr Leu Ala Trp Tyr Gln Lys Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Asn Thr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Val Lys ,  Synthetic construct  ,  Synthetic construct  ,"(48/66) , wherein: vh is seq id no:48, and 30 vl is seq id no:66. in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ile Ile Ser Gly Gly Ser Val Ser Ser Gly Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Tyr Ile Gly Tyr Ile Phe Tyr Ser Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr His Cys Ala Ser Leu Pro Thr Tyr Gly Ser Gly Arg Trp Gly Ile Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Ile Trp Leu Thr Trp Tyr Gln Gln Arg Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ala Leu Gln Arg Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Thr Thr Tyr Phe Cys Gln Gln Gly Asn Ser Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  Synthetic construct  ,  Synthetic construct  ,"(44/62) , wherein: vh is seq id no:44, and vl is seq id no:62.  in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Arg Phe Ile Thr Tyr Trp Ile Ser Trp Val Arg Gln Met Pro Gly Arg Gly Leu Glu Trp Met Gly Lys Ile Asp Pro Ser Asp Ser Ser Thr Asn Tyr Ser Pro Ser Phe Gln Gly His Val Ala Ile Ser Val Asp Lys Ser Phe Asn Thr Ala Tyr Leu Gln Trp Ser Arg Leu Asn Thr Ser Asp Thr Ala Met Tyr Tyr Cys Ala Ala Gly Pro Thr Gly Tyr Asp Leu Leu Thr Gly Gln Tyr Phe Pro Tyr Phe Asn Tyr Trp Ala Gln Gly Thr Leu Val Thr Val Ser Ser , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Ser Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Lys Phe Met Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Ile Leu Ile Tyr Glu Asp Asn Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Thr Ser Ser Asn Ser Ala Leu Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr His Gly Ser Asp Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Synthetic construct  ,  Synthetic construct  ,"(42/60) , wherein: 5 vh is seq id no:42, and vl is seq id no:60. in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en, Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Tyr Ser Asn Ile Gly Thr Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Val Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Ala Ser Arg Ser Gly Ser Ser Ala Ser Leu Asp Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Gly Ala Leu Ser Val Gly Leu Phe Gly Thr Gly Thr Lys Val Thr Val Leu , Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser Ile Ser Ser Gly Arg Asp Tyr Trp Ser Trp Ile Arg Gln Ala Ala Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Thr Thr Gly Ser Ala Asn Tyr Asn His Ser Leu Lys Ser Arg Val Ser Ile Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Met Thr Ser Met Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asn Asp Tyr Ser Asn Tyr Pro Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Synthetic construct  ,  Synthetic construct  ,"(71/53)  in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:53, and vl is seq id no:71"
https://patents.google.com/patent/WO2021207152A1/en, Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Thr Asn Tyr Leu Asn Trp Tyr Gln Gln Arg Pro Gly Lys Ala Pro Arg Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Gly Thr Phe Tyr Cys Gln Gln Thr Tyr Ser Ser Pro Ser Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Met Lys , Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Gln Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Arg Phe Asp Ile Phe Asp Ile Asn Trp Val Arg Gln Ala Ser Gly Gln Gly Pro Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala His Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Ser Ser Thr Asn Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Phe Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Val Glu Arg Thr Gly Asn Val Gly Phe Gly Tyr Tyr Ala Met Asp Val Trp Gly Gln Gly Thr Thr Val Ile Val Ser Ser ,  Synthetic construct  ,  Synthetic construct  ,"(55/37) in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:37, and vl is seq id no:55"
https://patents.google.com/patent/WO2021207152A1/en, Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Thr Cys Lys Ser Ser Gln Ser Val Leu Phe Gly Ser Asn Asn Glu Asn Tyr Leu Ala Trp Tyr Gln Lys Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Asn Thr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Val Lys , Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Phe Leu Phe Cys Ser Val Ser Gly Gly Ser Ile Ser Ile Ser Thr His Tyr Trp Glu Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Phe Tyr Ser Ser Gly Thr Thr Tyr Tyr Asn Pro Ser Leu Lys Gly Arg Val Thr Ile Ser Ala Asp Thr Ser Lys Ser Gln Ile Ser Leu Lys Met Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Arg Pro Gln Tyr Leu Leu Leu Ser Met Thr Thr Gly Arg Arg His His Asp Phe Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,  Synthetic construct  ,  Synthetic construct  ,"(66/48) in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: 15 vh is seq id no:48, and vl is seq id no:66"
https://patents.google.com/patent/WO2021207152A1/en, Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Ile Trp Leu Thr Trp Tyr Gln Gln Arg Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ala Leu Gln Arg Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Thr Thr Tyr Phe Cys Gln Gln Gly Asn Ser Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ile Ile Ser Gly Gly Ser Val Ser Ser Gly Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Tyr Ile Gly Tyr Ile Phe Tyr Ser Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr His Cys Ala Ser Leu Pro Thr Tyr Gly Ser Gly Arg Trp Gly Ile Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Synthetic construct  ,  Synthetic construct  ,"(62/44) in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:44, and vl is seq id no:62"
https://patents.google.com/patent/WO2021207152A1/en, Glu Val Pro Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Pro Phe Ser Ser Phe Ala Leu Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Thr Ile Asn Thr Asn Gly Gly Thr Thr Tyr Tyr Leu Asp Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Lys Asp Leu Leu Ser His Ser Gly Thr Tyr Ser Ala Gly Ser Thr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ile Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Val Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile His Ala Thr Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Cys Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Glu Ser Tyr Ser Thr Asn Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Synthetic construct  ,  Synthetic construct  ,"(51/69) , wherein: vh is seq id no:51, and vl is seq id no:69. in some embodiments, the antibody or antigen binding fragment thereof comprises a light 30 chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en, Gly Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Val Ser Gly Ile Asn Val Asn Gly Tyr Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu Gln Met Ile Ser Leu Thr Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Val Lys Glu Asp Thr Pro Leu Val Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Phe Ile Asn Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Ser Tyr Ser Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  Synthetic construct  ,  Synthetic construct  ,"(50/68) , wherein: vh is seq id no:50, and 5 vl is seq id no:68. in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en, Gln Leu Arg Leu Gln Ala Ser Gly Pro Gly Leu Val Arg Pro Ser Val Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Ala Ser Val Lys Ser Asp Lys Ser Tyr Trp Gly Trp Phe Arg Gln Ser Pro Gly Lys Gly Leu Ala Ser Ile Ala Thr Ile Tyr Tyr Asn Gly Asn Val Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Leu Ser Leu Asp Thr Ser Thr Asn Gln Leu Ser Leu Lys Met Arg Ser Val Thr Ala Ala Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Leu Asp Tyr Ser Lys Gln Thr Trp Gly Gln Gly Ile Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Arg Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Thr Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Ala Ser Asn Arg Ala Ser Gly Val Pro Gly Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Asp Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys ,  Synthetic construct  ,  Synthetic construct  ,"(39/57) , wherein: vh is seq id no:39, and vl is seq id no:57. in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/KR20160145813A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Val Ala Ser Glu Phe Thr Phe Asn Thr Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Ala Ile Ser Tyr Asp Gly Thr Lys Lys Phe Tyr Ala Asp Ser Leu Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Gly Asp Ser Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Thr Ile Thr Cys Ser Gly Asp Glu Leu Gly Asp Lys Phe Ala Phe Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Leu Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Asn Ser Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , Synthetic polypeptide, Synthetic polypeptide,"(2/4)  the monoclonal antibody comprises a heavy chain variable amino acid sequence comprising a heavy chain variable amino acid sequence comprising seq id no:2, 6, 10, 14, 18, 22 or 26 and / or a light chain variable comprising seq id no:4, 8, 12, 16, 20, amino acid sequence."
https://patents.google.com/patent/CN113929774A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Gly Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Leu Ile Ser Asn Asp Gly Thr Ile Asp Ser Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Arg Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Lys Glu Gln Leu Val Pro Thr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Pro Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Gly Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(7/8)  preferably, it comprises: vh shown as seq id no:7 and/or vl shown as seq id no:8."
https://patents.google.com/patent/WO2022027037A1/en, Asp Val Gln Leu Gln Glu Ser Gly Pro Ser Leu Val Arg Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Thr Gly Phe Ser Ile Asn Ser Asp Ser Tyr Trp Ile Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Tyr Ile Gly Tyr Thr Phe Tyr Ser Gly Ile Thr Tyr Tyr Asn Pro Ser Leu Glu Ser Arg Thr Tyr Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Gly Tyr Asp Leu Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Asn Ser Leu Gln Pro Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His His Tyr Val Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,(4/21)  of a heavy chain variable domain that comprises seq id no:4 and a light chain variable domain that comprises seq id no:21; (sct-oa002
https://patents.google.com/patent/WO2022027037A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Ala Ile Asn Ser Asn Gly Gly Ser Thr Tyr Tyr Pro Asp Thr Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg His Tyr Gly Asn Tyr Val Asp Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Ser His Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Leu Leu Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser Thr Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(12/36) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:12 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:36"
https://patents.google.com/patent/WO2022027037A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr Tyr Met His Trp Val Lys Gln Ser Pro Glu Lys Ser Leu Glu Trp Ile Gly Glu Ile Asn Pro Ser Thr Gly Gly Thr Thr Tyr Asn Gln Lys Phe Lys Ala Lys Ala Thr Leu Thr Val Asp Lys Tyr Ser Ser Thr Ala Tyr Met Gln Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Gly Arg Arg Asn Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Glu Tyr Tyr Gly Thr Ser Leu Met Gln Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Val Ala Ser Asn Val Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His Pro Val Glu Glu Asp Asp Ile Ala Val Tyr Phe Cys Gln Gln Ser Arg Lys Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(10/25) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:10 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:25"
https://patents.google.com/patent/WO2022027037A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr Ala Met Ser Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Val Ala Ala Ile Asn Ser Asn Gly Gly Ser Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg His Tyr Gly Asn Tyr Val Asp Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Arg Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Ser Ser Val Ser His Met His Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Lys Leu Leu Ile Tyr Ser Thr Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Ser Leu Thr Ile Ser Ser Gln Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys His Gln Trp Ser Thr Trp Thr Phe Gly Gly Gly Thr Lys Val Val Ile Asn ,  SCT-Oa019 mature heavy chain variable domain protein sequence  ,  SCT-Oa019 mature light chain variable domain protein sequence  ,"(123/124) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:123 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:124"
https://patents.google.com/patent/WO2022027037A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Arg Tyr Trp Met His Trp Met Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Glu Ile Asn Pro Ser Asn Gly Gly Ser Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr Met Asp Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Leu Thr Gly Thr Arg Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Arg Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Ser Ser Val Asn Tyr Met Tyr Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Lys Leu Leu Ile Tyr Asp Thr Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Ser Leu Thr Ile Ser Ser Gln Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Trp Asn Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  SCT-Oa020 mature heavy chain variable domain protein sequence  ,  SCT-Oa020 mature light chain variable domain protein sequence  ,"(125/126) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:125 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:126"
https://patents.google.com/patent/WO2022027037A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Glu Ala Asn Asn His Ala Thr Asn Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Arg Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Ser Gly Ile Tyr Tyr Cys Thr Gly Leu Leu Gly Arg Lys Asp Ser Trp Gly Pro Gly Thr Ser Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Val Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Ser Gly Thr Glu Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(8/31) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:8 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:31"
https://patents.google.com/patent/WO2022027037A1/en, Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser Tyr Met Gly Ile Gly Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu Trp Leu Ala His Ile Trp Trp Asn Asp Asp Lys Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Asn Asn Gln Val Phe Leu Lys Ile Thr Ser Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr Cys Ala Gln Asn Gly Leu Gly Tyr Tyr Asp Gly Ser Tyr Trp Tyr Phe Asp Val Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Ser Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Asp Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(20/32) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:20 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95% , or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:32"
https://patents.google.com/patent/WO2022027037A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ala Ile Tyr Pro Gly Asn Ser Asp Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Leu Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Gly Asp Tyr Pro Leu Phe Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gly Asn Ile Asp Asn Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Val Tyr Asn Ala Lys Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Ser Tyr Tyr Cys Gln His Phe Trp Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  SCT-Oa021 mature heavy chain variable domain protein sequence  ,  SCT-Oa021 mature light chain variable domain protein sequence  ,"(127/128) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:127 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:128"
https://patents.google.com/patent/WO2022027037A1/en, Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Phe Asn Met Gly Val Gly Trp Phe Arg Gln Pro Ser Gly Lys Gly Leu Glu Trp Leu Ala His Ile Trp Trp Asp Asp Asp Glu Tyr Tyr Asn Pro Ala Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Phe Leu Lys Ile Ala Asn Val Asp Thr Ala Asp Ala Ala Thr Tyr Tyr Cys Ala Arg Met Arg Tyr Tyr Tyr Asp Gly Thr Tyr Ser Val Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Gln Ile Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile His Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(19/35) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95% , or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:19 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95% , or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:35"
https://patents.google.com/patent/WO2022027037A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Leu Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Phe Ser Arg Asp Asp Ser Lys Ser Arg Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Ala Gly Ile Tyr Tyr Cys Ser Gly Leu Leu Thr Gly Pro Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Thr Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(5/30) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:5 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:30"
https://patents.google.com/patent/WO2022027037A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr Gln Met His Trp Val Lys Gln Ser Pro Glu Lys Ser Leu Glu Trp Ile Gly Glu Ile Asn Pro Ser Thr Gly Gly Thr Thr Tyr Asn Gln Lys Phe Lys Ala Lys Ala Thr Leu Thr Val Asp Lys Phe Ser Ser Thr Ala Tyr Met Gln Leu Lys Thr Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Ser Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Ile Arg Asp Arg Val Asn Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Ile Ala Val Ala Trp Tyr Gln Glu Lys Pro Gly Gln Ser Pro Lys Val Leu Ile Tyr Ser Thr Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Leu Gln His Tyr Gly Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(9/29) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:9 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:29"
https://patents.google.com/patent/WO2022027037A1/en, Gln Val Gln Met Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Arg Tyr Trp Met His Trp Met Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Ser Asn Gly Gly Ser Asn Tyr Asn Glu Lys Phe Lys Ser Lys Ala Thr Leu Thr Val Asp Gln Ser Ser Asn Thr Ala Phe Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Leu Thr Gly Thr Arg Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Gln Ile Phe Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Asn Tyr Met Tyr Trp Phe Gln Gln Lys Pro Gly Ser Ser Pro Arg Leu Leu Ile Tyr Asp Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Thr Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Asn Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(18/34) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95% , or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:18 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95% , or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:34"
https://patents.google.com/patent/WO2022027037A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Asp Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Arg Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Val Asn Tyr Gly Tyr Ser Leu Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Val Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val Tyr Ala Ala Thr Asn Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Ser Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp Gly Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(6/24) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:6 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:24"
https://patents.google.com/patent/WO2022027037A1/en, Glu Val Lys Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ser Gly Leu Leu Thr Gly Pro Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Thr Thr Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  SCT-Oa018 mature heavy chain variable domain protein sequence  ,  SCT-Oa018 mature light chain variable domain protein sequence  ,"(121/122) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:121 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:122"
https://patents.google.com/patent/WO2022027037A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Arg Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Ala Val Asn Tyr Gly Tyr Ser Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Pro Val Ser Ala , Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Val Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Asp Asn Ile Tyr Gly Asn Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val Tyr Ala Ala Thr Asn Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Ser Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Leu Trp Gly Ala Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(7/23) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:7 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:23"
https://patents.google.com/patent/WO2022027037A1/en, Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asn Ile His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Asp Gly Tyr Tyr Arg Val His Ala Leu Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly Glu Lys Ile Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Phe Tyr Thr Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(15/26) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:15 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:26"
https://patents.google.com/patent/WO2022027037A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Ala Ile Asn Ser Asn Gly Gly Ser Thr Tyr Tyr Pro Gly Thr Val Arg Asp Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg His Asp Gly Asn Tyr Val Asn Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Ile Asp Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Leu Ile Tyr Asp Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(13/37) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:13 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:37"
https://patents.google.com/patent/WO2022027037A1/en, Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ser Leu His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Ile Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Asp Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Asp Gly His Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Leu Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Arg ,  Mus musculus  ,  Mus musculus  ,"(16/28) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:16 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:28"
https://patents.google.com/patent/WO2022027037A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Arg Leu Val Gln Pro Lys Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr Ala Met Tyr Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Gln Ser Ser Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Gln Ser Met Leu Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Met Tyr Tyr Cys Val Arg Gly Gly Ser Asp Gly Tyr Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(14/33) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:14 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:33"
https://patents.google.com/patent/WO2022027037A1/en, Glu Val Gln Leu Gln Gln Ser Gly Thr Val Leu Ala Arg Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Ser Asp Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Lys Leu Thr Ala Val Thr Ser Ala Asn Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Asn Glu Asp Ser Ala Val Tyr Tyr Cys Thr Arg Glu Gly Asp Tyr Pro Leu Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly Asn Ile Asp Asn Phe Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Pro Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp Ser Thr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(11/22) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:11 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:22"
https://patents.google.com/patent/WO2022027037A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Thr Ile His Trp Val Lys Gln Ser Pro Gly Gln Gly Leu Glu Trp Ile Gly Trp Ile Tyr Pro Gly Ser Gly Asn Ser Lys Tyr Asn Asp Lys Phe Lys Gly Lys Ala Thr Met Thr Ala Gly Glu Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Gly Glu Gly Ser Tyr Tyr Ser Tyr Glu Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Asn Ile Gln Lys Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Phe Tyr Ser Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Ala Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(17/27) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95% , or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:17 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95% , or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:27"
https://patents.google.com/patent/CN113461813B/en, Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met Gly Val Gly Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Ser Asn Gln Val Phe Leu Lys Ile Ala Ile Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Met Ala Val Pro Gly Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Gln Met Gln Ser Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Thr Ser Gln Asp Ile Ser Asn Tyr Leu His Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln Asp Asp Ile Ala Thr Tyr Phe Cys Gln His Gly Asn Ser Leu Pro Trp Thr Phe Gly Arg Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(14/13) the companion antibody of claim 1, wherein said first detection antibody comprises a light chain variable region of seq id no:13 and a heavy chain variable region of seq id no:14."
https://patents.google.com/patent/CN113461813B/en, Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met Gly Val Gly Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Ser Asn Gln Val Phe Leu Lys Ile Ala Ile Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Met Ala Val Pro Gly Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Gln Met Gln Ser Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Thr Ser Gln Asp Ile Ser Asn Tyr Leu His Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln Asp Asp Ile Ala Thr Tyr Phe Cys Gln His Gly Asn Ser Leu Pro Trp Thr Phe Gly Arg Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(16/15) the companion antibody of claim 1, wherein said second detection antibody comprises a light chain variable region of seq id no:15 and a heavy chain variable region of seq id no:16."
https://patents.google.com/patent/CN113912709A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Thr Trp Leu Arg Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn His Phe Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , VacW-215 heavy chain variable region, VacW-215 light chain variable region,"(17/18) the variable region of the heavy chain sequence of vacw-215 is the sequence shown in seq id no:17, and the variable region of the light chain sequence is the sequence shown in seq id no:18."
https://patents.google.com/patent/CN113912709A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Pro Asn Tyr Tyr Asp Ser Ser Gly Leu Gly Ile Val Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Phe Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Val Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , VacW-120 heavy chain variable region, VacW-120 light chain variable region,"(7/8) the variable region of the heavy chain sequence of vacw-120 is the sequence shown in seq id no:7, and the variable region of the light chain sequence is the sequence shown in seq id no:8"
https://patents.google.com/patent/CN113912709A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Met Glu Tyr Pro Tyr Gly Gly Val Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Arg Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , VacW-201 heavy chain variable region, VacW-201 light chain variable region,"(11/12) the variable region of the heavy chain sequence of vacw-201 is the sequence shown in seq id no:11, and the variable region of the light chain sequence is the sequence shown in seq id no:12"
https://patents.google.com/patent/CN113912709A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Arg Ser Tyr Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Leu Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Thr Gly Ala Pro Val Glu Ser Ala Ala Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Pro Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , VacW-105 heavy chain variable region, VacW-105 light chain variable region,"(5/6) the variable region of the heavy chain sequence of vacw-105 is the sequence shown in seq id no:5, and the variable region of the light chain sequence is the sequence shown in seq id no:6"
https://patents.google.com/patent/CN113912709A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Glu Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Met Glu Tyr Pro Tyr Gly Gly Ile Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Arg Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , VacW-212 heavy chain variable region, VacW-212 light chain variable region,"(15/16) the variable region of the heavy chain sequence of vacw-212 is shown as seq id no:15, and the variable region of the light chain sequence is shown as seq id no:16"
https://patents.google.com/patent/CN113912709A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Val Ile Asn Pro Ser Gly Gly Asn Thr Arg Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Phe Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Pro Ser Lys Leu Leu Trp Phe Gly Glu Leu His Ile Leu Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser, Gln Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly His Tyr Pro Tyr Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Arg Thr Leu Ile Tyr Asp Thr Ser Asn Lys His Ser Trp Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Ala Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Leu Leu Ser Tyr Ser Ser Ala Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , VacW-92 heavy chain variable region, VacW-92 light chain variable region,"(3/4) the variable region of the heavy chain sequence of vacw-92 is the sequence shown in seq id no:3, and the variable region of the light chain sequence is the sequence shown in seq id no:4"
https://patents.google.com/patent/CN113912709A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ile Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Met Ser Phe Asp Gly Ser Ile Lys Tyr Tyr Gly Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Val Gln Gly Tyr Tyr Asp Arg Ser Gly Tyr Tyr Asn Leu Asp Tyr Asn Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , VacW-209 heavy chain variable region, VacW-209 light chain variable region,"(13/14) the variable region of the heavy chain sequence of vacw-209 is the sequence shown in seq id no:13, and the variable region of the light chain sequence is the sequence shown in seq id no:14"
https://patents.google.com/patent/CN113912709A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Ser Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ser Leu Val Ala Tyr Pro Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Ala Ile Gln Leu Thr Gln Ser Pro Phe Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Ala Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Val Asp Thr Tyr Gln Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , VacW-138 heavy chain variable region, VacW-138 light chain variable region,"(9/10) the variable region of the heavy chain sequence of vacw-138 is the sequence shown in seq id no:9, and the variable region of the light chain sequence is the sequence shown in seq id no:10"
https://patents.google.com/patent/CN113912709A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ala Pro His Trp Asn Ala Asp Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , VacW-89 heavy chain variable region, VacW-89 light chain variable region,"(1/2) the variable region of the heavy chain sequence of vacw-89 is the sequence shown in seq id no:1, and the variable region of the light chain sequence is the sequence shown in seq id no:2"
https://patents.google.com/patent/CN113402602A/en, Ala Ile Arg Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Gly Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Leu Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , VL(Artificial Sequence), VL(Artificial Sequence),"(34/44) still further, the amino acid sequence of vh of the antibody is selected from one of seq id no:2-seq id number 4, seq id no:14; and/or the amino acid sequence of the vl of the antibody is selected from one of seq id no:32-seq id no:34 and seq id no:44."
https://patents.google.com/patent/CN113402602A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Glu Asp Ala Gly Tyr Tyr Tyr Asp Ser Ser Gly Tyr Tyr Tyr Pro Lys Ala His Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ile Arg Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Ser Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gln Glu Arg Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Gly Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Leu Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys, VH_VL(Artificial Sequence), VH_VL(Artificial Sequence),"(218/228) further, the amino acid sequence of the scfv single-chain antibody is one of seq id no:216-seq id no:218 and seq id no:228. more specifically, the scfv single-chain antibodies are hts0422, hts0433, hts0446 and hts0483 in table 1 below, and the sequences of their heavy chains, light chains and their variable regions are also shown in table 1."
https://patents.google.com/patent/KR20220010411A/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr His Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No.139 HC variable region , No.139 LC variable region ,"(2018/2017)  according to claim 1, the antibody or antigen-binding fragment thereof light chain variable region of the polypeptide sequence of seq id no:2017; and heavy chain variable region of the polypeptide sequence of seq id no:2018 a method comprising "
https://patents.google.com/patent/WO2021226249A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ile Ile Tyr Pro Gly Gly Ser Thr Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Leu Gly Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Thr Trp Leu Val Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile Tyr Gly Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  mAb S1D2   VH  ,  mAb S1D2   VL  ,(6/7) in some embodiments an antigen binding protein as provided herein is or comprises an igg antibody having the heavy chain variable region of seq id no:6 and the light chain variable region of seq id no:7
https://patents.google.com/patent/CN111793129B/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Arg Phe Asp Asp His Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Ser Gly Asp Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Ser Ile Ser Arg Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Arg Ser Tyr Gly Pro Pro Asp Val Phe Asn Tyr Glu Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser , Artificial Sequence, Artificial Sequence,"(11/12) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:11, and the light chain amino acid sequence is shown as seq id no:12."
https://patents.google.com/patent/WO2021233433A1/en, Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Asn Ala Met Ile Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Thr Ile Thr Asp Ser Gly Asn Thr His Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala Ser Thr Thr Val Asp Leu Lys Met Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Gly Thr Ala His Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Gln Val Leu Thr Gln Thr Ala Ser Ser Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Ser Cys Gln Ser Ser Gln Ser Val Tyr Ser Asn Trp Leu Ala Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro Lys Arg Leu Ile Tyr Ser Ala Ser Thr Leu Asp Ser Gly Val Ser Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Val Gln Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Leu Gly Asn Tyr Asp Tyr Ser Ser Ala Asp Phe Ala Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys ,  BS-R1B8ɱ  ,  BS-R1B8ɱ  ,"(6/7)  the heavy chain variable region includes the amino acid sequence shown in seq id no:6, and the light chain variable region includes the amino acid sequence shown in seq id no:7;"
https://patents.google.com/patent/WO2021233433A1/en, Gln Ser Leu Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Ser Cys Thr Ala Ser Gly Phe Ser Leu Ser Ser Tyr Tyr Met Ser Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Gly Asp Lys Asp Ser Asp Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Ile Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Pro Leu Tyr Ala Asn Thr Tyr Asn Tyr Gly Met Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Ala Tyr Asp Met Thr Gln Thr Pro Ala Ser Val Glu Leu Ala Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Asn Ile Phe Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asp Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Tyr Thr Leu Thr Ile Ser Gly Val Gln Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gln His Phe Ser Gly Ser Asn Ile Asp Asn Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys ,  BS-R2B17ɱ  ,  BS-R2B17ɱ  ,"(12/13)  the heavy chain variable region includes the amino acid sequence shown in seq id no:12, and the light chain variable region includes the amino acid sequence shown in seq id no:13;"
https://patents.google.com/patent/WO2021233433A1/en, Ala Ile Glu Met Thr Gln Ser Pro Pro Ser Leu Ser Ala Ser Val Gly Glu Thr Val Arg Ile Arg Cys Leu Ala Ser Glu Asp Ile Tyr Ser Gly Ile Ser Trp Tyr Gln Gln Lys Pro Glu Lys Pro Pro Thr Leu Leu Ile Tyr Gly Ala Ser Asn Leu Glu Ser Gly Val Pro Pro Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Gly Gly Val Gln Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Leu Gly Gly Tyr Ser Tyr Ser Ser Thr Gly Leu Thr Phe Gly Ala Gly Thr Lys Val Glu Ile Lys , Cys Thr Val Ser Gly Phe Ser Leu Asn Asn Tyr Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Ile Ile Tyr Pro Ser Gly Thr Asp Tyr Ala Thr Trp Ala Thr Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Glu Met Thr Ser Leu Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Gly Ser Trp Tyr Tyr Gly Met Asp Ile Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser ,  BS-R2B7ɱ  ,  BS-R2B7ɱ  ,"(4/5)  the heavy chain variable region includes the amino acid sequence shown in seq id no:4, and the light chain variable region includes the amino acid sequence shown in seq id no:5;"
https://patents.google.com/patent/WO2021233433A1/en, Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Asn Tyr Ala Leu Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Ser Ser Gly Asp Thr Thr Phe Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala Ser Thr Thr Val Asp Leu Lys Met Thr Ser Leu Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ser Arg Gly Asp Ile Tyr Ser Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Ala Asp Ile Val Met Thr Gln Thr Pro Ser Ser Val Ser Ser Ala Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Glu Ser Ile Ser Ser Arg Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Leu Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Arg Gly Ser Gly Thr Glu Tyr Thr Leu Thr Ile Ser Asp Leu Glu Cys Ala Asp Gly Ala Thr Tyr Tyr Cys Gln Gly Asp Ser Asp Ser Ser Ser Tyr Val Gly Gly Phe Gly Gly Gly Thr Glu Val Val Val Lys ,  BS-R2B30ɱ  ,  BS-R2B30ɱ  ,"(14/15)  the heavy chain variable region includes the amino acid sequence shown in seq id no:14, and the light chain variable region includes the amino acid sequence shown in seq id no:15;"
https://patents.google.com/patent/WO2021233433A1/en, Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Arg Ser Ala Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Ile Gly Ile Ile Ser Ser Asn Ser Asn Asn Thr Asn Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Arg Ile Thr Ser Pro Thr Ile Asp Asp Thr Ala Thr Tyr Phe Cys Ala Arg Ala Tyr Ala Ser Asn Ser Gly Tyr Tyr Pro Ile Pro Tyr Phe Asn Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Ala Leu Val Met Thr Gln Thr Pro Ser Ser Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Asn Cys Gln Ala Ser Gln Asn Ile Tyr Arg Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Arg Pro Lys Leu Leu Ile Tyr Gly Ala Ser Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Tyr Thr Leu Thr Ile Ser Asp Leu Glu Cys Asp Asp Ala Ala Thr Tyr Tyr Cys His Cys Ala Tyr Tyr Ser Gly Ser Gly Asp Leu Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys ,  4G6ɱ  ,  4G6ɱ  ,"(16/17)  the heavy chain variable region includes the amino acid sequence shown in seq id no:16, and the light chain variable region includes the amino acid sequence shown in seq id no:17;"
https://patents.google.com/patent/WO2021233433A1/en, Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Gly Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Ser Tyr Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Asp Ala Ser Asn Gly Asn Thr Trp Tyr Ala Thr Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Asp Leu Lys Met Thr Ser Leu Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Gly Phe Ala Thr Met Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Ala Tyr Asp Met Thr Gln Thr Pro Ala Ser Val Glu Val Ala Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Thr Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Met Tyr Phe Ala Ser Thr Leu Thr Ser Gly Val Ser Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Gly Val Glu Cys Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Gly Phe Gly Asn Ile Asn Val Asp Asn Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys ,  BS-R2B2ɱ  ,  BS-R2B2ɱ  ,"(2/3)  the heavy chain variable region includes the amino acid sequence shown in seq id no:2, and the light chain variable region includes the amino acid sequence shown in seq id no:3;"
https://patents.google.com/patent/WO2021233433A1/en, Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Val Pro Gly Phe Ser Leu Ser Asp Tyr Val Val Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Gly Ile Gly Thr Ile Tyr Thr Gly Gly Gly Ala Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Thr Ser Thr Thr Val Asp Leu Lys Met Thr Ser Leu Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Gly Thr Thr Thr Tyr Thr Ile Asp Met Ala Phe Asn Leu Trp Gly Pro Gly Ser Leu Val Thr Val Ser Ser , Ala Asp Ile Val Met Thr Gln Thr Pro Ala Ser Val Ser Glu Pro Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Asn Leu Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Gly Ala Ser Ile Leu Glu Ser Gly Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Ala Asp Ala Gly Thr Tyr Tyr Cys Gln Ala Leu Tyr Arg Ser Thr Ser Gly Ser Tyr Gly Ala Pro Phe Gly Gly Arg Thr Glu Val Val Val Lys ,  12D3ɱ  ,  12D3ɱ  ,"(18/19)  the heavy chain variable region comprises the amino acid sequence shown in seq id no:18, and the light chain variable region comprises the amino acid sequence shown in seq id no:19; or"
https://patents.google.com/patent/WO2021233433A1/en, Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Val Ser Gly Ile Asp Leu Ser Ser Asn Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Ala Ile Tyr Leu Ser Gly Ser Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Thr Ser Thr Thr Val Asp Leu Lys Met Thr Ser Leu Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Tyr Gly Tyr Ser Val Gly Thr Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Ala Asp Ile Val Met Thr Gln Thr Pro Ala Ser Val Ser Glu Pro Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Trp Tyr Leu Ser Trp Tyr Gln Gln Lys Leu Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Asn Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Asn Asn Tyr Asp Thr Thr Ser Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys ,  39G6ɱ  ,  39G6ɱ  ,"(20/21)  the heavy chain variable region includes the amino acid sequence shown in seq id no:20, and the light chain variable region includes the amino acid sequence shown in seq id no:21."
https://patents.google.com/patent/WO2021233433A1/en, Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Asn Asn Tyr Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Ile Ile Tyr Pro Ser Gly Thr Asp Tyr Ala Thr Trp Ala Thr Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Glu Met Thr Ser Leu Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Gly Ser Trp Tyr Tyr Gly Met Asp Ile Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Gln Val Leu Thr Gln Thr Pro Ser Ser Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Ser Cys Gln Ser Thr Gln Ser Val Asp Asn Met Asn Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Gly Val Gln Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Thr Tyr Tyr Asn Ser Gly Trp Tyr Thr Pro Phe Gly Gly Gly Thr Glu Val Val Val Lys ,  BS-R2B12ɱ  ,  BS-R2B12ɱ  ,"(8/9)  the heavy chain variable region includes the amino acid sequence shown in seq id no:8, and the light chain variable region includes the amino acid sequence shown in seq id no:9;"
https://patents.google.com/patent/WO2021233433A1/en, Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Met Pro Gly Gly Ser Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Asn Asn Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Ile Ile Gly Ser Ser Gly Ser Thr Tyr Tyr Ala Thr Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Gly Leu Lys Ile Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Gly Asp Ser Phe Gly Asp Ala Tyr Val Leu Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ala Pro Ser Ser Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Asn Cys Gln Ala Ser Gln Ser Val Ser Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Gly Ala Ser Asn Leu Glu Ser Gly Val Pro Ser Arg Phe Arg Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Gly Met Lys Ala Glu Asp Val Ala Thr Tyr Tyr Cys His Gln His Ser Asn Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Val Glu Ile Lys ,  BS-R2B15ɱ  ,  BS-R2B15ɱ  ,"(10/11)  the heavy chain variable region includes the amino acid sequence shown in seq id no:10, and the light chain variable region includes the amino acid sequence shown in seq id no:11;"
https://patents.google.com/patent/CN112062840A/en, Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro Arg Gly Ser His Met Ala Ser Met Ser Asp Ser Glu Val Asn Gln Glu Ala Lys Pro Glu Val Lys Pro Glu Val Lys Pro Glu Thr His Ile Asn Leu Lys Val Ser Asp Gly Ser Ser Glu Ile Phe Phe Lys Ile Lys Lys Thr Thr Pro Leu Arg Arg Leu Met Glu Ala Phe Ala Lys Arg Gln Gly Lys Glu Met Asp Ser Leu Arg Phe Leu Tyr Asp Gly Ile Arg Ile Gln Ala Asp Gln Thr Pro Glu Asp Leu Asp Met Glu Asp Asn Asp Ile Ile Glu Ala His Arg Glu Gln Ile Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Asn Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Ser Gly Ser Gly Ser Thr Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Tyr Arg Tyr Asn Gly Arg Asp Tyr Tyr Asp Arg Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Ala Ala Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Gly Ser,, Artificial Sequence (Artificial Sequence),,"(2) a nanobody based on the s protein of a novel coronavirus, characterized in that: the amino acid sequence of the expression cassette sequence of the nano antibody is shown in seq id no:2."
https://patents.google.com/patent/CN112062840A/en, atgggcagca gccatcatca tcatcatcac agcagcggcc tggtgccgcg cggcagccat atggctagca tgtcggactc agaagtcaat caagaagcta agccagaggt caagccagaa gtcaagcctg agactcacat caatttaaag gtgtccgatg gatcttcaga gatcttcttc aagatcaaaa agaccactcc tttaagaagg ctgatggaag cgttcgctaa aagacagggt aaggaaatgg actccttaag attcttgtac gacggtatta gaatccaagc tgatcagacc cctgaagatt tggacatgga ggataacgat attattgagg ctcacagaga acagattggt ggatcccagg tgcagctgca ggagtctgga ggaggcttgg tgcaggctgg agggtctctg agactctctt gtgccgccag cggacgtact ttctcttcta acgctatggg ctggttccgc caggctccag ggaaggagcg tgagttcgta gcagcgattt cttctggttc tggttctact aactatgcag actccgtgaa gggccgattc accatctcca gagacaacgc caagaacacg gtgtatcttc aaatgaacag cctgaaacct gaggacacgg ccgtttatta ctgtgcagcc gcttaccgtt acaacggtcg tgactactac gaccgttacg actactgggg tcagggtact caggtcaccg tctcctcagc ggccgcatac ccgtacgacg ttccggacta cggttcctga ctcgag ,, Artificial Sequence (Artificial Sequence),,"(1) the nanobody based on the s protein of coronavirus of claim 1, characterized in that: the nucleotide sequence of the expression cassette sequence of the nano antibody is shown in seq id no:1."
https://patents.google.com/patent/WO2021203053A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Pro Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Phe Ile Ser Thr Tyr Asn Ala Asn Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Gly Tyr Met Glu Leu Arg Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Tyr Thr Arg Gly Ala Phe Phe Gly Glu Ser Leu Ile Gly Gly Phe Asp Asn Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Thr Val Ser Ser Thr Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Asp Thr Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic sequence SARS-CoV-2 S309-v2.9 mAb VH  , Synthetic sequence SARS-CoV-2 S309-v13 mAb VL (VK)  ,"(172/168) ""s309-15"" comprises a w50f/g56a/w105f vh variant (seq id no:172) and the wild-type vl sequence of s309 (seq id no:168)"
https://patents.google.com/patent/WO2021203053A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Pro Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Thr Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Gly Tyr Met Glu Leu Arg Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Tyr Thr Arg Gly Ala Phe Phe Gly Glu Ser Leu Ile Gly Gly Phe Asp Asn Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Thr Val Ser Ser Thr Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Asp Thr Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic sequence SARS-CoV-2 S309-v1.7 mAb VH  , Synthetic sequence SARS-CoV-2 S309-v13 mAb VL (VK)  ,"(119/168) ""s309-14"" comprises a w105f vh variant sequence (seq id no:119) and the wild- type vl sequence (seq id no:168) of s309"
https://patents.google.com/patent/WO2021203053A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Pro Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Thr Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Gly Tyr Met Glu Leu Arg Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Tyr Thr Arg Gly Ala Trp Phe Gly Glu Ser Leu Ile Gly Gly Phe Asp Asn Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Thr Val Ser Ser Thr Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Asp Thr Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic sequence SARS-CoV-2 S309-v1 mAb VH  , Synthetic sequence SARS-CoV-2 S309-v13 mAb VL (VK)  ,"(105/168) ""s309-11"" comprises the wild-type vh sequence (seq id no:105) and the wild-type vl sequence (seq id no:168) of s309"
https://patents.google.com/patent/WO2021203053A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Pro Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Phe Ile Ser Thr Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Gly Tyr Met Glu Leu Arg Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Tyr Thr Arg Gly Ala Trp Phe Gly Glu Ser Leu Ile Gly Gly Phe Asp Asn Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Thr Val Ser Ser Thr Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Asp Thr Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic sequence SARS-CoV-2 S309-v2 mAb VH  , Synthetic sequence SARS-CoV-2 S309-v13 mAb VL (VK)  ,"(129/168) ""s309-13"" comprises a w50f mutation in vh (seq id no:129) and the wild-type vl sequence (seq id no:168) of s309"
https://patents.google.com/patent/CN114106163A/en, gaggtccagc tggtcgagtc cggcggcggc ctggtgcagc ctggcggctc cctgcggctg agctgcgctg cttctggctt cacattctcc gatgcctgga tggattgggt gcgacaggct cctggcaaag gcttggactg ggttgcccag atccggaaca aggccaactc ccacgccacc aactacgccg actccgtcaa gggcagattt accatctctc gcgacgattc taagaactcc gtgtatctgc agatgaactc tctgaagacc gaggataccg ccgtctacta ctgcatcaga ggcctgacag gctacgtgct ggactactgg ggccagggca ccaccgtgac cgtgtcctcc gcaagcacca agggaccttc tgtgtttcct ctggccccat gtagtcgctc aacttccgag agcaccgcag cactgggatg cctggtgaag gattacttcc cagaacccgt cacagtgtct tggaacagtg gggccctgac aagcggtgtc cacacttttc cagctgtgct gcagtcatcc ggactgtact ctctgagctc tgtggtcact gtgcccagtt caaatttcgg gacccagaca tatacttgta acgtggacca taagccttcc aataccaagg tcgataaaac agtggtggaa tgtccacctt gcccagctcc accagtcgca ggacctagcg tgttcctgtt tcctccaaag cccaaagaca cactgatgat ctcacgcaca cctgaggtca cttgcgtggt cgtggacgtg tcccacgagg accctgaagt ccagtttaac tggtacgtgg atggcgtcga agtgcataat gccaagacca aaccaagaga ggaacagttc aactccacat ttcgcgtcgt gagcgtgctg actgtcgtgc accaggactg gctgaacggc aaggagtata agtgtaaagt gagcaataag ggcctgcctg ctccaatcga gaaaaccatt tctaagacaa aaggccagcc cagagaacct caggtgtaca cactgccccc ttcccgcgag gaaatgacta agaaccaggt cagcctgacc tgcctggtga aaggttttta tcccagtgac atcgccgtgg agtgggaatc aaatggccag cctgagaaca attacaagac taccccaccc atgctggact cagatggttc cttctttctg tattcaaagc tgaccgtgga taaatccagg tggcagcagg gcaacgtctt ctcttgtagt gtgatgcatg aggctctgca caatcattac acacagaagt cactgtccct gagcccaggc aag , gatatccaga tgacccagtc tccatcttcc ctctccgcat ctgtgggcga tagagtgacg atcacctgca aggcttccca gaacgtgcgg acagccgtgg cttggtacca acaaaagcct ggccagtctc ccaaggctct gatcttcctg gccagcaacc ggcacaccgg cgtccctgac agattctccg ggtccggctc tggcaccgac ttcaccctca ccatcagtag cctgcagcct gaagacttcg ccacctactt ctgcctgcag cactggaact accctctgac cttcggcgga ggcaccaaag tggagatcaa acgtactgtc gctgcaccaa gcgtgttcat ttttcctcca tctgacgaac agctgaagtc tggaaccgct agtgtcgtgt gcctgctgaa caatttttac cccagggagg caaaggtcca gtggaaagtg gataacgccc tgcagagcgg caattctcag gagagtgtga ccgaacagga ctcaaaggat tccacatata gcctgtcatc cactctgacc ctgagcaaag ctgactacga gaagcacaaa gtctatgcat gcgaagtgac ccatcaggga ctgagctctc ctgtgacaaa gtctttcaac cggggggagt gc , humanized antibody hS1B-30-3 heavy chain nucleic acid sequence (), light chain nucleic acid sequence of humanized antibody hS1B-30-3 (),"(24/25) in a preferred embodiment of the invention, the dna molecule encoding the heavy chain of the above antibody has the amino acid sequence shown in seq id no:24; and/or, the dna molecule encoding the light chain of the antibody has the amino acid sequence shown in seq id no:25."
https://patents.google.com/patent/CN112979791A/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/CN111592594A/en,Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Thr Asn Thr Gly Asn Pro Thr Tyr Ala Gln Gly Phe Thr Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr Leu Gln Ile Ser Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Gln Gly Gly Ser Ser Trp Tyr Arg Asp Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys AlaSer Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,Homo sapiens,Homo sapiens,"(7/8)  preferably, it comprises: vh shown as seq id no:7 and/or vl shown as seq id no:8."
https://patents.google.com/patent/CN111732654B/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Val Ser Asp Phe Asp Trp Leu Tyr Arg Ser His Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Gln Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Artificial sequence, Artificial sequence,"(7/8) specifically, the sequences of the light chain variable region and the heavy chain variable region are respectively the same as seq id no:8 and seq id no:7."
https://patents.google.com/patent/CN112979790B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/CN113683692A/en, Gln Val Gln Leu Gln Gln Pro Glu Ala Glu Leu Met Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Thr Phe Thr Ser Tyr Ala Ile Glu Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile Gly Val Ile Ser Thr Gly Asn Gly Ser Asn Asp Lys Phe Lys Gly Lys Ala Thr Met Thr Val Thr Ser Ser Asn Thr Ala Tyr Met Gln Leu Ala Arg Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Gly Ile His Tyr Phe Gly Phe Tyr Ala Tyr Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Ser , Asp Ile Val Leu Ser Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Glu Lys Val Thr Met Ser Cys Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Ile Tyr Ser Thr Arg Glu Ser Gln Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Glu Ala Ser Asp Tyr Ala Val Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr , artificial sequence, artificial sequence,"(15/16) the heavy chain variable region of b is shown as seq id no:15, and the light chain variable region is shown as seq id no:16."
https://patents.google.com/patent/CN113683692A/en, Gln Val Gln Leu Gln Gln Pro Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Gly Ser Gly Tyr Thr Phe Thr Asp Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile Gly Trp Ile Gln Thr Glu Thr Gly Asp Pro Thr Tyr Phe Lys Gly Arg Phe Ala Phe Thr Leu Glu Thr Ser Ala Thr Ala Tyr Met Gln Leu Ser Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Gly Ser Asp Tyr Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly Gln Arg Ala Thr Ile Ser Cys Lys Thr Ser Ala Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Trp Tyr Trp Glu Ser Thr Gln His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Thr Val Gln Ser Glu Asp Tyr Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr , artificial sequence, artificial sequence,"(13/14) in some embodiments, the heavy chain variable region of a is as set forth in seq id no:13 and the light chain variable region is as set forth in seq id no:14."
https://patents.google.com/patent/CN111246884A/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Ile Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Ser Lys Tyr Thr Glu Lys Phe Gln Gly Arg Val Thr Met Thr Ser Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Thr Tyr Tyr Tyr Gly Ser Ala Leu Phe Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Glu Asn Pro Asn Gly Asn Thr Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Arg Val Ser Lys Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Leu Gln Leu Thr His Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,CD19 (8B8-018) VH,CD19 (8B8-018) VL,"(39/40) (b) heavy chain variable region (v) comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of seq id no:39hcd19), and a light chain variable region (v) comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of seq id no:40lcd19)。"
https://patents.google.com/patent/CN111246884A/en,Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ile Gly Ser Gly Ala Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Trp Phe Gly Gly Phe Asn Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Thr Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Asn Val Gly Ser Arg Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Gly Ile Met Leu Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,FAP(4B9) VH,FAP(4B9) VL,"(21/22) more particularly, the antigen-binding domain capable of specifically binding fap comprises a heavy chain variable region (v) comprising the amino acid sequence of seq id no:21hfap) and light chain variable region (v) comprising the amino acid sequence of seq id no:22lfap)。"
https://patents.google.com/patent/CN111246884A/en,Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser His Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Trp Ala Ser Gly Glu Gln Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Trp Leu Gly Asn Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Arg Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Ile Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Gly Gln Val Ile Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,FAP(28H1) VH,FAP(28H1) VL,"(23/24) (b) heavy chain variable region (v) comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of seq id no:23hfap), and a light chain variable region (v) comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of seq id no:24lfap)。"
https://patents.google.com/patent/CN111246884A/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser GlyTyr Thr Phe Thr Asp Tyr Ile Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Ser Lys Tyr Thr Glu Lys Phe Gln Gly Arg Val Thr Met Thr Ser Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Thr Tyr Tyr Tyr Gly Pro Gln Leu Phe Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Glu Thr Ser Thr Gly Thr Thr Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Arg Val Ser Lys Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Leu Gln Leu Leu Glu Asp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,CD19 (8B8-2B11) VH,CD19 (8B8-2B11) VL,"(37/38) more particularly, an antigen-binding domain capable of specifically binding fap comprises (a) a heavy chain variable region (v) comprising the amino acid sequence of seq id no:37hcd19) and a light chain variable region (v) comprising the amino acid sequence of seq id no:38lcd19)。"
https://patents.google.com/patent/WO2021260532A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gln Glu Ala Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Leu Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Arg Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(6/5)  a vl amino acid sequence of seq id no:5 and a vh amino acid sequence of seq id no:6; 
https://patents.google.com/patent/WO2021260532A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Ser Gly Thr Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Glu Asn Arg Gly Tyr Ser Ser Arg Trp Tyr Asp Pro Glu Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Arg Ile Thr Cys Ser Ala Asp Ala Leu Pro Lys Gln Tyr Ala Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp His Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(4/3)  a vl amino acid sequence of seq id no:3 and a vh amino acid sequence of seq id no:4; 
https://patents.google.com/patent/WO2021260532A1/en, Gln Met Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Arg Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Trp Ile Asn Ala Gly Asn Gly Lys Thr Lys Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Leu Tyr Tyr Tyr Asp Ser Ser Gly Ser Thr Gln Ser Asp Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(26/25)  or xiii) a vl amino acid sequence of seq id no:25 and a vh amino acid sequence of seq id no:26
https://patents.google.com/patent/WO2021260532A1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Val Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Met Glu Ala Gly Gly Met Asp Val Trp Gly Gln Gly Ser Thr Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Pro Ser Ala Ser Gly Ser Pro Gly Gln Ser Val Thr Ile Ser Cys Thr Ala Ser Ser Ser Asp Ile Gly Ala Ser Asn His Val Ala Trp Tyr Gln Gln Asn Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Gly Val Ser Gly Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser Asn Ile Leu Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(18/17)  a vl amino acid sequence of seq id no:17 and a vh amino acid sequence of seq id no:18; 
https://patents.google.com/patent/WO2021260532A1/en, Glu Val His Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Val Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Gly Ser Gly Asp Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(12/11)  a vl amino acid sequence of seq id no:11 and a vh amino acid sequence of seq id no:12; 
https://patents.google.com/patent/WO2021260532A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Leu Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Asp Ala Gln Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Ser Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(24/23)  xii) a vl amino acid sequence of seq id no:23 and a vh amino acid sequence of seq id no:24
https://patents.google.com/patent/WO2021260532A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Gly Met Thr Trp Val Arg Gln Val Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Asn Trp Asn Gly Gly Thr Thr Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr His Cys Ala Arg Ile Tyr Cys Gly Asp Asp Cys Tyr Ser Leu Val Ile Trp Gly Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Val Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Ile Tyr Val Phe Gly Ser Gly Thr Lys Val Thr Val Leu , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(22/21)  a vl amino acid sequence of seq id no:21 and a vh amino acid sequence of seq id no:22; x
https://patents.google.com/patent/WO2021260532A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Arg Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Asp Thr Ala Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Met Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(8/7)  a vl amino acid sequence of seq id no:7 and a vh amino acid sequence of seq id no:8; 
https://patents.google.com/patent/WO2021260532A1/en, Gln Met Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Val Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Ser Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Gly Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Gly Pro Arg Pro Val Val Lys Ala Tyr Gly Glu Leu Asp Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Ile Gly Gly Tyr Glu Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Ile Ile Tyr Asp Val Arg Asp Arg Pro Ser Gly Ile Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Ile Ile Ser Ser Leu Gln Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Phe Ser Tyr Thr Ser Ser Gly Thr Tyr Val Phe Gly Ser Ala Thr Lys Val Thr Val Leu , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(20/19)  x) a vl amino acid sequence of seq id no:19 and a vh amino acid sequence of seq id no:20
https://patents.google.com/patent/WO2021260532A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Thr Tyr Trp Ile Asn Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Arg Ile Asp Pro Ser Asp Ser Tyr Thr Asn Tyr Ser Pro Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Gly Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Asp Asn Ser Asp Tyr Ser Gly Leu Ser Glu Tyr Phe Gln His Trp Gly Gln Gly Thr Met Val Thr Ile Ser Ser , Glu Leu Gly Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly Ser Asn Val Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asp Tyr Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Asp Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(16/15)  a vl amino acid sequence of seq id no:15 and a vh amino acid sequence of seq id no:16; 
https://patents.google.com/patent/WO2021260532A1/en, Gln Met Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly His Thr Ile Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Val Trp Asp Ser Ser Gly Tyr Ser Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Arg Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(10/9)  a vl amino acid sequence of seq id no:9 and a vh amino acid sequence of seq id no:10; 
https://patents.google.com/patent/WO2021260532A1/en, Gln Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Val Thr Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Ile Ser Pro Met Leu Arg Gly Asp Asn Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Arg Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Glu Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(14/13)  a vl amino acid sequence of seq id no:13 and a vh amino acid sequence of seq id no:14; 
https://patents.google.com/patent/KR101255861B1/en, Met Ala Gln Met Gln Leu Val Gln Ser Gly Thr Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Ile Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Ala , Variable heavy chain of SC03-022 , Variable light chain of SC03-022 ,"(6/10)  the second immunoglobulin comprises a heavy chain variable region comprising the amino acid sequence of seq id no:6 and a light chain variable region comprising the amino acid sequence of seq id no:10, or having at least 97% sequence homology therewith"
https://patents.google.com/patent/KR101255861B1/en, Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp His Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Arg Thr Arg Asn Lys Ala Asn Ser Tyr Thr Thr Glu Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ile Ser Pro Phe Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg , Variable heavy chain of SC03-014 , Variable light chain of SC03-014 ,"(4/8)  the first immunoglobulin comprises a heavy chain variable region comprising the amino acid sequence of seq id no:4 and a light chain variable region comprising the amino acid sequence of seq id no:8, or has at least 97% sequence homology to them"
https://patents.google.com/patent/CN107646038B/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile Gly Trp Ile Tyr Pro Gly Asp Gly Asn Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Ala Thr Leu Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Tyr Ser Asn Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser Arg Thr Arg Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Thr Gln Ser Phe Ile Leu Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , synthetic constructs, synthetic constructs,(19/20) /α cd3(mab 1; vh seq id no:19/vl seq id no:20
https://patents.google.com/patent/CN107646038B/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asn Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Phe Thr Ile Ser Val Asp Lys Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Pro Leu Ile Tyr Ala Pro Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Phe Asn Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg , synthetic constructs, synthetic constructs,(31/32)  vh seq id no:31/vl seq id no:32)/α cd3(mab 1
https://patents.google.com/patent/CN110627797A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Phe Ile Asp Ser Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Pro Lys Phe Gln Gly Arg Val Thr Phe Thr Thr Asp Thr Ser Ala Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Asn Glu Gly Thr Pro Thr Gly Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Phe Ile Asp Ser Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Pro Lys Phe Gln Gly Arg Val Thr Phe Thr Thr Asp Thr Ser Ala Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Asn Glu Gly Thr Pro Thr Ala Val Pro Asn Leu Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Val Ala Gly Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ," synthetic sequence of integrin resistant alpha v beta 6, RHF"," synthetic sequence of integrin resistant alpha v beta 6, RHFB6",(5/6) an antibody comprising a heavy chain variable region sequence derived from the amino acid sequence of seq id no:5 and a light chain variable region sequence derived from the amino acid sequence of seq id no:6.
https://patents.google.com/patent/CN110627797A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Phe Ile Asp Ser Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Pro Lys Phe Gln Gly Arg Val Thr Phe Thr Thr Asp Thr Ser Ala Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Asn Glu Gly Thr Pro Thr Ala Val Pro Asn Leu Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Val Ala Gly Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Asn Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Ser Ala Ser Ser Ser Val Ser Tyr Met His Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ," synthetic sequence of integrin resistant alpha v beta 6, RHFB6"," synthetic sequence for integrin-resistant alpha v beta 6, RKF",(6/8)  an antibody comprising a heavy chain having the amino acid sequence shown in seq id no:6 and a light chain having the amino acid sequence shown in seq id no:8 without a signal sequence
https://patents.google.com/patent/CN110627797A/en, ggcagtttcc tggctgaaca cgccagccca atacttaaag agagcaactc ctgactccga tagagactgg atggacccac aagggtgaca gcccaggcgg accgatcttc ccatcccaca tcctccggcg cgatgccaaa aagaggctga cggcaactgg gccttctgca gagaaagacc tccgcttcac tgccccggct ggtcccaagg gtcaggaaga tggattcata cctgctgatg tggggactgc tcacgttcat catggtgcct ggctgccagg cagagctctg tgacgatgac ccgccagaga tcccacacgc cacattcaaa gccatggcct acaaggaagg aaccatgttg aactgtgaat gcaagagagg tttccgcaga ataaaaagcg ggtcactcta tatgctctgt acaggaaact ctagccactc gtcctgggac aaccaatgtc aatgcacaag ctctgccact cggaacacaa cgaaacaagt gacacctcaa cctgaagaac agaaagaaag gaaaaccaca gaaatgcaaa gtccaatgca gccagtggac caagcgagcc ttccaggtca ctgcagggaa cctccaccat gggaaaatga agccacagag agaatttatc atttcgtggt ggggcagatg gtttattatc agtgcgtcca gggatacagg gctctacaca gaggtcctgc tgagagcgtc tgcaaaatga cccacgggaa gacaaggtgg acccagcccc agctcatatg cacaggtgaa atggagacca gtcagtttcc aggtgaagag aagcctcagg caagccccga aggccgtcct gagagtgaga cttcctgcct cgtcacaaca acagattttc aaatacagac agaaatggct gcaaccatgg agacgtccat atttacaaca gagtaccagg tagcagtggc cggctgtgtt ttcctgctga tcagcgtcct cctcctgagt gggctcacct ggcagcggag acagaggaag agtagaagaa caatctagaa aaccaaaaga acaagaattt cttggtaaga agccgggaac agacaacaga agtcatgaag cccaagtgaa atcaaaggtg ctaaatggtc gcccaggaga catccgttgt gcttgcctgc gttttggaag ctctgaagtc acatcacagg acacggggca gtggcaacct tgtctctatg ccagctcagt cccatcagag agcgagcgct acccacttct aaatagcaat ttcgccgttg aagaggaagg gcaaaaccac tagaactctc catcttattt tcatgtatat gtgttcatta aagcatgaat ggtatggaac tctctccacc ctatatgtag tataaagaaa agtaggttta cattcatctc attccaactt cccagttcag gagtcccaag gaaagcccca gcactaacgt aaatacacaa cacacacact ctaccctata caactggaca ttgtctgcgt ggttcctttc tcagccgctt ctgactgctg attctcccgt tcacgttgcc taataaacat ccttcaagaa ctctgggctg ctacccagaa atcattttac ccttggctca atcctctaag ctaaccccct tctactgagc cttcagtctt gaatttctaa aaaacagagg ccatggcaga ataatctttg ggtaacttca aaacggggca gccaaaccca tgaggcaatg tcaggaacag aaggatgaat gaggtcccag gcagagaatc atacttagca aagttttacc tgtgcgttac taattggcct ctttaagagt tagtttcttt gggattgcta tgaatgatac cctgaatttg gcctgcacta atttgatgtt tacaggtgga cacacaaggt gcaaatcaat gcgtacgttt cctgagaagt gtctaaaaac accaaaaagg gatccgtaca ttcaatgttt atgcaaggaa ggaaagaaag aaggaagtga agagggagaa gggatggagg tcacactggt agaacgtaac cacggaaaag agcgcatcag gcctggcacg gtggctcagg cctataaccc cagctcccta ggagaccaag gcgggagcat ctcttgaggc caggagtttg agaccagcct gggcagcata gcaagacaca tccctacaaa aaattagaaa ttggctggat gtggtggcat acgcctgtag tcctagccac tcaggaggct gaggcaggag gattgcttga gcccaggagt tcgaggctgc agtcagtcat gatggcacca ctgcactcca gcctgggcaa cagagcaaga tcctgtcttt aaggaaaaaa agacaagatg agcataccag cagtccttga acattatcaa aaagttcagc atattagaat caccgggagg ccttgttaaa agagttcgct gggcccatct tcagagtctc tgagttgttg gtctggaata gagccaaatg ttttgtgtgt ctaacaattc ccaggtgctg ttgctgctgc tactattcca ggaacacact ttgagaacca ttgtgttatt gctctgcacg cccacccact ctcaactccc acgaaaaaaa tcaacttcca gagctaagat ttcggtggaa gtcctggttc catatctggt gcaagatctc ccctcacgaa tcagttgagt caacattcta gctcaacaac atcacacgat taacattaac gaaaattatt catttgggaa actatcagcc agttttcact tctgaagggg caggagagtg ttatgagaaa tcacggcagt tttcagcagg gtccagattc agattaaata actattttct gtcatttctg tgaccaacca catacaaaca gactcatctg tgcactctcc ccctccccct tcaggtatat gttttctgag taaagttgaa aagaatctca gaccagaaaa tatagatata tatttaaatc ttacttgagt agaactgatt acgacttttg ggtgttgagg ggtctataag atcaaaactt ttccatgata atactaagat gttatcgacc atttatctgt ccttctctca aaagtgtatg gtggaatttt ccagaagcta tgtgatacgt gatgatgtca tcactctgct gttaacatat aataaattta ttgctattgt ttataaaaga ataaatgata tttttt , gctgggcaaa gccggtggca agggcctccc ctgccgctgt gccaggcagg cagtgccaaa tccggggagc ctggagctgg ggggagggcc ggggacagcc cggccctgcc ccctcccccg ctgggagccc agcaacttct gaggaaagtt tggcacccat ggcgtggcgg tgccccagga tgggcagggt cccgctggcc tggtgcttgg cgctgtgcgg ctgggcgtgc atggccccca ggggcacgca ggctgaagaa agtcccttcg tgggcaaccc agggaatatc acaggtgccc ggggactcac gggcaccctt cggtgtcagc tccaggttca gggagagccc cccgaggtac attggcttcg ggatggacag atcctggagc tcgcggacag cacccagacc caggtgcccc tgggtgagga tgaacaggat gactggatag tggtcagcca gctcagaatc acctccctgc agctttccga cacgggacag taccagtgtt tggtgtttct gggacatcag accttcgtgt cccagcctgg ctatgttggg ctggagggct tgccttactt cctggaggag cccgaagaca ggactgtggc cgccaacacc cccttcaacc tgagctgcca agctcaggga cccccagagc ccgtggacct actctggctc caggatgctg tccccctggc cacggctcca ggtcacggcc cccagcgcag cctgcatgtt ccagggctga acaagacatc ctctttctcc tgcgaagccc ataacgccaa gggggtcacc acatcccgca cagccaccat cacagtgctc ccccagcagc cccgtaacct ccacctggtc tcccgccaac ccacggagct ggaggtggct tggactccag gcctgagcgg catctacccc ctgacccact gcaccctgca ggctgtgctg tcagacgatg ggatgggcat ccaggcggga gaaccagacc ccccagagga gcccctcacc tcgcaagcat ccgtgccccc ccatcagctt cggctaggca gcctccatcc tcacacccct tatcacatcc gcgtggcatg caccagcagc cagggcccct catcctggac ccactggctt cctgtggaga cgccggaggg agtgcccctg ggccccccta agaacattag tgctacgcgg aatgggagcc aggccttcgt gcattggcaa gagccccggg cgcccctgca gggtaccctg ttagggtacc ggctggcgta tcaaggccag gacaccccag aggtgctaat ggacataggg ctaaggcaag aggtgaccct ggagctgcag ggggacgggt ctgtgtccaa tctgacagtg tgtgtggcag cctacactgc tgctggggat ggaccctgga gcctcccagt acccctggag gcctggcgcc cagtgaagga accttcaact cctgccttct cgtggccctg gtggtatgta ctgctaggag cagtcgtggc cgctgcctgt gtcctcatct tggctctctt ccttgtccac cggcgaaaga aggagacccg ttatggagaa gtgtttgaac caacagtgga aagaggtgaa ctggtagtca ggtaccgcgt gcgcaagtcc tacagtcgtc ggaccactga agctaccttg aacagcctgg gcatcagtga agagctgaag gagaagctgc gggatgtgat ggtggaccgg cacaaggtgg ccctggggaa gactctggga gagggagagt ttggagctgt gatggaaggc cagctcaacc aggacgactc catcctcaag gtggctgtga agacgatgaa gattgccatc tgcacgaggt cagagctgga ggatttcctg agtgaagcgg tctgcatgaa ggaatttgac catcccaacg tcatgaggct catcggtgtc tgtttccagg gttctgaacg agagagcttc ccagcacctg tggtcatctt acctttcatg aaacatggag acctacacag cttcctcctc tattcccggc tcggggacca gccagtgtac ctgcccactc agatgctagt gaagttcatg gcagacatcg ccagtggcat ggagtatctg agtaccaaga gattcataca ccgggacctg gcggccagga actgcatgct gaatgagaac atgtccgtgt gtgtggcgga cttcgggctc tccaagaaga tctacaatgg ggactactac cgccagggac gtatcgccaa gatgccagtc aagtggattg ccattgagag tctagctgac cgtgtctaca ccagcaagag cgatgtgtgg tccttcgggg tgacaatgtg ggagattgcc acaagaggcc aaaccccata tccgggcgtg gagaacagcg agatttatga ctatctgcgc cagggaaatc gcctgaagca gcctgcggac tgtctggatg gactgtatgc cttgatgtcg cggtgctggg agctaaatcc ccaggaccgg ccaagtttta cagagctgcg ggaagatttg gagaacacac tgaaggcctt gcctcctgcc caggagcctg acgaaatcct ctatgtcaac atggatgagg gtggaggtta tcctgaaccc cctggagctg caggaggagc tgacccccca acccagccag accctaagga ttcctgtagc tgcctcactg cggctgaggt ccatcctgct ggacgctatg tcctctgccc ttccacaacc cctagccccg ctcagcctgc tgataggggc tccccagcag ccccagggca ggaggatggt gcctgagaca accctccacc tggtactccc tctcaggatc caagctaagc actgccactg gggaaaactc caccttccca cttttccacc ccacgcctta tccccacttg cagccctgtc ttcctaccta tcccacctcc atcccagaca ggtccctccc cttctctgtg cagtagcatc accttgaaag cagtagcatc accatctgta aaaggaaggg gttggattgc aatatctgaa gccctcccag gtgttaacat tccaagactc tagagtccaa ggtttaaaga gtctagattc aaaggttcta ggtttcaaag atgctgtgag tctttggttc taaggacctg aaattccaaa gtctctaatt ctattaaagt gctaaggttc taaggcaaaa aaaaaaaaaa aaaaaaa , Intelligent people, Intelligent people,"(142/144) for example, a heavy chain variable region amino acid sequence selected from the group consisting of seq id no:142 and variants and a light chain variable region amino acid sequence selected from the group consisting of seq id no:144 and variants"
https://patents.google.com/patent/CN110627797A/en, Glu Asn Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Ser Ala Ser Ser Ser Val Ser Tyr Met His Trp Leu Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Leu Thr Ser Asn Leu Ala Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asn Tyr Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Ser Gln Ser Asn Asn Phe Ala Thr His Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Arg Trp Asn Asn Phe Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ," synthetic sequence anti-integrin alpha v beta 6, RKFL36L50"," synthetic sequence anti-PSMA, deimmunized VH 4' 5",(9/24) an antibody or antigen-binding fragment comprising a heavy chain variable domain comprising the amino acid sequence of seq id no:9 and a light chain variable domain comprising the amino acid sequence of seq id no:24.
https://patents.google.com/patent/CN110627797A/en, Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Ser Ala Ser Ser Ser Val Ser Tyr Met His Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Asn Tyr Gly Ile Ser Phe Met Asn Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Gln Gly Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Lys Glu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ," synthetic sequence of anti-integrin alpha v beta 6, RKC"," synthetic sequence anti-CD 33, CD33 Hum195 VK",(10/12)  an antibody comprising a heavy chain having the amino acid sequence shown in seq id no:10 and a light chain having the amino acid sequence shown in seq id no:12 without a signal sequence
https://patents.google.com/patent/CN110627797A/en, Glu Asn Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Ser Ala Ser Ser Ser Val Ser Tyr Met His Trp Leu Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Leu Thr Ser Asn Leu Ala Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Phe Ala Phe Thr Asp Ser Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Pro Lys Phe Gln Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr Leu Gln Ile Ser Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Gly Thr Pro Thr Ala Val Pro Asn Leu Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Val Ala Gly Pro Tyr Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ," synthetic sequence anti-integrin alpha v beta 6, RKFL36L50"," synthetic sequence of integrin-resistant protein alpha v beta 6, RHAB6.2","(9/3) for example, seq id no:3 and 9 for the light chain and heavy chain, respectively"
https://patents.google.com/patent/CN110627797A/en, Glu Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Arg Val Thr Met Thr Cys Ser Ala Ser Ser Gly Val Asn Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Thr Ser Pro Arg Arg Trp Ile Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Pro Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Arg Gly Ser Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ," synthetic sequence anti-CD 19, CD 19B 4 resurfaced VK"," synthetic sequence anti Her2, Herceptin VL chain",(14/16)  an antibody comprising a heavy chain having the amino acid sequence shown in seq id no:14 and a light chain having the amino acid sequence shown in seq id no:16 without a signal sequence.
https://patents.google.com/patent/WO2021218879A1/en, atggagttgg gactgagctg gattttcctt ttggctattt taaaaggtgt ccagtgtgag gtgaaactgg tggagtctgg aggaggactg gtgaagcctg gaggctccct gagactgtcc tgtgctgcct ctggcttcac cttcagcaac tatgggatga gttgggtgag acaggctcct ggcaagagat tggagtgggt ggctgagatt tcctctggag gctcctacac ctactaccct gacacagtga caggcaggtt caccatcagc agggacaatg ccaagaacac cctctacctc caaatgaact ccctgagggc tgaggacaca gcagtctact actgtgccag gttcagatat gatggaggag gaggcacagt ggactactgg ggacaaggca ccctggtgac agtgtccagc gctagcacca agggcccatc ggtcttcccc ctggcaccct cctccaagag cacctctggg ggcacagcgg ccctgggctg cctggtcaag gactacttcc ccgaaccggt gacggtgtcg tggaactcag gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacccagacc tacatctgca acgtgaatca caagcccagc aacaccaagg tggacaagaa agttgagccc aaatcttgtg acaaaactca cacatgccca ccgtgcccag cacctgaact cctgggggga ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggacccct gaggtcacgt gcgtggtggt ggacgtgagc cacgaagacc ccgaggtcaa gttcaactgg tacgtggacg gcgtggaggt gcataatgcc aagacaaagc cgcgggagga gcagtacaac agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag gagtacaagt gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc aaagccaaag ggcagccccg agaaccacag gtgtacaccc tgcccccatc ccgggatgag ctgaccaaga accaggtcag cctgacctgc ctggtcaaag gcttctatcc cagcgacatc gccgtggagt gggagagcaa tgggcagccg gagaacaact acaagaccac gcctcccgtg ctggactccg acggctcctt cttcctctac agcaagctca ccgtggacaa gagcaggtgg cagcagggga acgtcttctc atgctccgtg atgcatggcg ctctgcacaa ccactacacg cagaagagcc tctccctgtc tccgggtaaa tga , atgggctggt cctgtatcat cctgttcctg gtggctacag ccacaggagt gcatagtgag attgtgctga cccagagccc tgccaccctg tccctgagcc ctggagagag ggctaccctg tcctgtaggg catctgagtc tgtggacaac tatggcatct cctttatgaa ctggttccaa cagaagcctg gacaagcccc aagactgctg atttatgctg ccagcaacca gggctctgga gtgcctgcca ggttctctgg ctctggctct ggcacagact tctccctgac catctcctcc ttggaacctg aggactttgc tgtctacttc tgtcaacaga gcaaggaggt gccaaggacc tttggacaag gcaccaaggt ggagattaag cgtacggtgg ctgcaccatc tgtcttcatc ttcccgccat ctgatgagca gttgaaatct ggaactgcct ctgttgtgtg cctgctgaat aacttctatc ccagagaggc caaagtacag tggaaggtgg ataacgccct ccaatcgggt aactcccagg agagtgtcac agagcaggac agcaaggaca gcacctacag cctcagcagc accctgacgc tgagcaaagc agactacgag aaacacaaag tctacgcctg cgaagtcacc catcagggcc tgagctcgcc cgtcacaaag agcttcaaca ggggagagtg ttag ,  The sequence is artificially sequence.  ,  The sequence is artificially sequence.  ,(50/27)  the cov2-hb27-fe4-igg1 heavy chain (seq id no:50) expression vector and cov2-hb27 light chain (seq id no:27) expression vector plasmids were extracted and transfected into hek-293 (fut8 gene knockou
https://patents.google.com/patent/WO2021218879A1/en, Met Glu Leu Gly Leu Ser Trp Ile Phe Leu Leu Ala Ile Leu Lys Gly Val Gln Cys Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Arg Leu Glu Trp Val Ala Glu Ile Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Thr Val Thr Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Phe Arg Tyr Asp Gly Gly Gly Gly Thr Val Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys ,,  The sequence is artificially sequence.  ,,"(18/20)  its heavy chain containing signal peptide the amino acid sequence of the light chain and the light chain are shown in seq id no:18/19, respectively, which respectively include the heavy chain/light chain signal peptide amino acid sequence (seq id no:20/21) connected in sequence"
https://patents.google.com/patent/WO2021218879A1/en, atggagttgg gactgagctg gattttcctt ttggctattt taaaaggtgt ccagtgtgag gtgaaactgg tggagtctgg aggaggactg gtgaagcctg gaggctccct gagactgtcc tgtgctgcct ctggcttcac cttcagcaac tatgggatga gttgggtgag acaggctcct ggcaagagat tggagtgggt ggctgagatt tcctctggag gctcctacac ctactaccct gacacagtga caggcaggtt caccatcagc agggacaatg ccaagaacac cctctacctc caaatgaact ccctgagggc tgaggacaca gcagtctact actgtgccag gttcagatat gatggaggag gaggcacagt ggactactgg ggacaaggca ccctggtgac agtgtccagc gcaagcacca agggcccatc ggtcttcccc ctggcaccct cctccaagag cacctctggg ggcacagcgg ccctgggctg cctggtcaag gactacttcc ccgaaccggt gacggtgtcg tggaactcag gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacccagacc tacatctgca acgtgaatca caagcccagc aacaccaagg tggacaagaa agttgagccc aaatcttgtg acaaaactca cacatgccca ccgtgcccag cacctgaact cctgggggga ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggacccct gaggtcacgt gcgtggtggt ggacgtgagc cacgaagacc ccgaggtcaa gttcaactgg tacgtggacg gcgtggaggt gcataatgcc aagacaaagc cgcgggagga gcagtacaac agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag gagtacaagt gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc aaagccaaag ggcagccccg agaaccacag gtgtacaccc tgcccccatc ccgggatgag ctgaccaaga accaggtcag cctgacctgc ctggtcaaag gcttctatcc cagcgacatc gccgtggagt gggagagcaa tgggcagccg gagaacaact acaagaccac gcctcccgtg ctggactccg acggctcctt cttcctctac agcaagctca ccgtggacaa gagcaggtgg cagcagggga acgtcttctc atgctccgtg atgcatgagg ctctgcacaa ccactacacg cagaagagcc tctccctgtc tccgggtaaa tga , atgggctggt cctgtatcat cctgttcctg gtggctacag ccacaggagt gcatagtgag attgtgctga cccagagccc tgccaccctg tccctgagcc ctggagagag ggctaccctg tcctgtaggg catctgagtc tgtggacaac tatggcatct cctttatgaa ctggttccaa cagaagcctg gacaagcccc aagactgctg atttatgctg ccagcaacca gggctctgga gtgcctgcca ggttctctgg ctctggctct ggcacagact tctccctgac catctcctcc ttggaacctg aggactttgc tgtctacttc tgtcaacaga gcaaggaggt gccaaggacc tttggacaag gcaccaaggt ggagattaag cgtacggtgg ctgcaccatc tgtcttcatc ttcccgccat ctgatgagca gttgaaatct ggaactgcct ctgttgtgtg cctgctgaat aacttctatc ccagagaggc caaagtacag tggaaggtgg ataacgccct ccaatcgggt aactcccagg agagtgtcac agagcaggac agcaaggaca gcacctacag cctcagcagc accctgacgc tgagcaaagc agactacgag aaacacaaag tctacgcctg cgaagtcacc catcagggcc tgagctcgcc cgtcacaaag agcttcaaca ggggagagtg ttag ,  The sequence is artificially sequence.  ,  The sequence is artificially sequence.  ,"(26/27)  the cov2-hb27 heavy chain (seq id no:26) expression vector and cov2-hb27 light chain (seq id no:27) expression vector plasmids were extracted, transfected into hek-293 (fut8 gene knockou"
https://patents.google.com/patent/CN113493506A/en, gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc tcctgtgcag cctctggatt cacctttagc agctttgcca tgagctgggt ccgccaggct ccagggaagg ggctggagtg ggtctcagct attagtggta gtggtggtag cacatactac gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa cacgctgtat ttgcaaatga acagcctgag agccgaggac acggccgtat attactgtgc gaaagatccg gatggttcgg ggagttggta ctttgactac tggggccagg gaaccctggt caccgtctcc tcagcgtcga ccaagggccc atcggtcttc cccctggcac cctcctccaa gagcacctct gggggcacag cggccctggg ctgcctggtc aaggactact tccccgaacc cgtgacggtg tcgtggaact caggcgccct gaccagcggc gtgcacacct tcccggctgt cctacagtcc tcaggactct actccctcag cagcgtggtg accgtgccct ccagcagctt gggcacccag acctacatct gcaacgtgaa tcacaagccc agcaacacca aggtggacaa gaaagttgag cccaaatctt gtgacaaaac tcacacatgc ccaccgtgcc cagcacctga actcctgggg ggaccgtcag tcttcctctt ccccccaaaa cccaaggaca ccctcatgat ctcccggacc cctgaggtca catgcgtggt ggtggacgtg agccacgaag accctgaggt caagttcaac tggtacgtgg acggcgtgga ggtgcataat gccaagacaa agccgcggga ggagcagtac aacagcacgt accgtgtggt cagcgtcctc accgtcctgc accaggactg gctgaatggc aaggagtaca agtgcaaggt ctccaacaaa gccctcccag cccccatcga gaaaaccatc tccaaagcca aagggcagcc ccgagaacca caggtgtaca ccctgccccc atcccgggat gagctgacca agaaccaggt cagcctgacc tgcctggtca aaggcttcta tcccagcgac atcgccgtgg agtgggagag caatgggcag ccggagaaca actacaagac cacgcctccc gtgctggact ccgacggctc cttcttcctc tacagcaagc tcaccgtgga caagagcagg tggcagcagg ggaacgtctt ctcatgctcc gtgatgcatg aggctctgca caaccactac acgcagaaga gcctctccct gtctccgggt aaa , tcctatgtgc tgactcagcc accctcagtg tcagtggccc caggaaagac ggccaggatt acctgtgggg gaaacaacat tggaagtaaa agtgtgcact ggtaccagca gaagccaggc caggcccctg tgctggtcat ctattatgat agcgaccggc cctcagggat ccctgagcga ttctctggct ccaactctgg gaacaccgcc accctgacca tcagcagggt cgaagccggg gatgaggccg actattactg tcaggtgtgg gatagtagta gtgatcatca tgtcttcgga actgggacca aggtcaccgt cctaggtcag cccaaggctg ccccctcggt cactctgttc ccaccctcga gtgaggagct tcaagccaac aaggccacac tggtgtgtct cataagtgac ttctacccgg gagccgtgac agtggcctgg aaggcagata gcagccccgt caaggcggga gtggagacca ccacaccctc caaacaaagc aacaacaagt acgcggccag cagctacctg agcctgacgc ctgagcagtg gaagtcccac agaagctaca gctgccaggt cacgcatgaa gggagcaccg tggagaagac agtggcccct acagaatgtt ca , Artificial sequence, Artificial sequence,"(42/44) the heavy chain coding region is seq id no:42 and the light chain coding region is seq id no:44, the above steps are carried out to obtain an antibody solution of p2c-1d 5."
https://patents.google.com/patent/CN113493506A/en, caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct ccaggcaagg ggctggagtg ggtggcagtt atatggtatg atggaagtaa taaatactat gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagaggggca gctatggttt ggcttgacta ctggggccag ggaaccctgg tcaccgtctc ctcagcgtcg accaagggcc catcggtctt ccccctggca ccctcctcca agagcacctc tgggggcaca gcggccctgg gctgcctggt caaggactac ttccccgaac ccgtgacggt gtcgtggaac tcaggcgccc tgaccagcgg cgtgcacacc ttcccggctg tcctacagtc ctcaggactc tactccctca gcagcgtggt gaccgtgccc tccagcagct tgggcaccca gacctacatc tgcaacgtga atcacaagcc cagcaacacc aaggtggaca agaaagttga gcccaaatct tgtgacaaaa ctcacacatg cccaccgtgc ccagcacctg aactcctggg gggaccgtca gtcttcctct tccccccaaa acccaaggac accctcatga tctcccggac ccctgaggtc acatgcgtgg tggtggacgt gagccacgaa gaccctgagg tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg caccaggact ggctgaatgg caaggagtac aagtgcaagg tctccaacaa agccctccca gcccccatcg agaaaaccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc catcccggga tgagctgacc aagaaccagg tcagcctgac ctgcctggtc aaaggcttct atcccagcga catcgccgtg gagtgggaga gcaatgggca gccggagaac aactacaaga ccacgcctcc cgtgctggac tccgacggct ccttcttcct ctacagcaag ctcaccgtgg acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat gaggctctgc acaaccacta cacgcagaag agcctctccc tgtctccggg taaa , cagtctgccc tgactcagcc tcgctcagtg tccgggtctc ctggacagtc agtcaccatc tcctgcactg gaaccagcag tgatgttggt ggttataact atgtctcctg gtaccaacag cacccaggca aagcccccaa actcatgatt tatgatgtca gtaagcggcc ctcaggggtc cctgatcgct tctctggctc caagtctggc aacacggcct ccctgaccat ctctgggctc caggctgagg atgaggctga ttattactgc tgctcatatg caggcagcta cactttcgtg gtattcggcg gagggaccaa gctgaccgtc ctaggtcagc ccaaggctgc cccctcggtc actctgttcc caccctcgag tgaggagctt caagccaaca aggccacact ggtgtgtctc ataagtgact tctacccggg agccgtgaca gtggcctgga aggcagatag cagccccgtc aaggcgggag tggagaccac cacaccctcc aaacaaagca acaacaagta cgcggccagc agctacctga gcctgacgcc tgagcagtgg aagtcccaca gaagctacag ctgccaggtc acgcatgaag ggagcaccgt ggagaagaca gtggccccta cagaatgttc a , Artificial sequence, Artificial sequence,"(22/24) the heavy chain coding region is seq id no:22 and the light chain coding region is seq id no:24, the above steps are carried out to obtain an antibody solution of p2b-2g 4."
https://patents.google.com/patent/CN113493506A/en, caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc tcctgcaagg cttctggagg caccttcagc agctatgcta tcatctgggt gcgacaggcc cctggacaag ggcttgagtg gatgggaggg atcatcccta tctttggtac agcaaactac gcacagaagt tccagggcag agtcacgatt accgcggacg aatccacgag cacagcctac atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagagtggta acggggtact actttgacta ctggggccag ggaaccctgg tcaccgtctc ctcagcgtcg accaagggcc catcggtctt ccccctggca ccctcctcca agagcacctc tgggggcaca gcggccctgg gctgcctggt caaggactac ttccccgaac ccgtgacggt gtcgtggaac tcaggcgccc tgaccagcgg cgtgcacacc ttcccggctg tcctacagtc ctcaggactc tactccctca gcagcgtggt gaccgtgccc tccagcagct tgggcaccca gacctacatc tgcaacgtga atcacaagcc cagcaacacc aaggtggaca agaaagttga gcccaaatct tgtgacaaaa ctcacacatg cccaccgtgc ccagcacctg aactcctggg gggaccgtca gtcttcctct tccccccaaa acccaaggac accctcatga tctcccggac ccctgaggtc acatgcgtgg tggtggacgt gagccacgaa gaccctgagg tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg caccaggact ggctgaatgg caaggagtac aagtgcaagg tctccaacaa agccctccca gcccccatcg agaaaaccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc catcccggga tgagctgacc aagaaccagg tcagcctgac ctgcctggtc aaaggcttct atcccagcga catcgccgtg gagtgggaga gcaatgggca gccggagaac aactacaaga ccacgcctcc cgtgctggac tccgacggct ccttcttcct ctacagcaag ctcaccgtgg acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat gaggctctgc acaaccacta cacgcagaag agcctctccc tgtctccggg taaa , gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccagggga aagagccacc ctctcctgca gggccagtca gagtgttagc agctacttag cctggtacca acagaaacct ggccaggctc ccaggctcct catctatgat gcatccaaca gggccactgg catcccagcc aggttcagtg gcagtgggtc tgggacagac ttcactctca ccatcagcag cctagagcct gaagattttg cagtttatta ctgtcagcag cgtagcaact ggccttcttt tggccagggg accaagctgg agatcaaacg tacggtggct gcaccatctg tcttcatctt cccgccatct gatgagcagt tgaaatctgg aactgcctct gttgtgtgcc tgctgaataa cttctacccc agagaagcca aagtgcagtg gaaggtggac aacgccctgc agagcggaaa cagccaggaa agcgtgacag agcaggattc caaggattcc acatacagcc tgagcagcac actgacactg tccaaggccg actacgagaa gcacaaggtg tacgcctgcg aagtgacaca ccagggactg tcctcccctg tgacaaagag cttcaacaga ggagaatgc , Artificial sequence, Artificial sequence,"(38/40) the heavy chain coding region is seq id no:38 and the light chain coding region is seq id no:40, the above steps are carried out to obtain an antibody solution which is a p2c-1c10 antibody solution."
https://patents.google.com/patent/CN113493506A/en, gaagtgcagc tggtggagtc tgggggaggc ttggtacagc ctggcaggtc cctgagactc tcctgtgcag cctctggatt cacctttgat gattatgcca tgcactgggt ccggcaagtt ccagggaagg gcctggagtg ggtctcaggt attagttgga atggtggtat cataggctac gcggactctg tgaagggccg attcaccatc tccagagaca acgccaagac ttccctgtat ctgcaaatga acagtctgag agctgaggac acggccttgt attactgtgc aaaagtcgcg ggaagggggg attacgacta ttactatggt atggacgtct ggggccaagg gaccacggtc accgtctcct cagcgtcgac caagggccca tcggtcttcc ccctggcacc ctcctccaag agcacctctg ggggcacagc ggccctgggc tgcctggtca aggactactt ccccgaaccc gtgacggtgt cgtggaactc aggcgccctg accagcggcg tgcacacctt cccggctgtc ctacagtcct caggactcta ctccctcagc agcgtggtga ccgtgccctc cagcagcttg ggcacccaga cctacatctg caacgtgaat cacaagccca gcaacaccaa ggtggacaag aaagttgagc ccaaatcttg tgacaaaact cacacatgcc caccgtgccc agcacctgaa ctcctggggg gaccgtcagt cttcctcttc cccccaaaac ccaaggacac cctcatgatc tcccggaccc ctgaggtcac atgcgtggtg gtggacgtga gccacgaaga ccctgaggtc aagttcaact ggtacgtgga cggcgtggag gtgcataatg ccaagacaaa gccgcgggag gagcagtaca acagcacgta ccgtgtggtc agcgtcctca ccgtcctgca ccaggactgg ctgaatggca aggagtacaa gtgcaaggtc tccaacaaag ccctcccagc ccccatcgag aaaaccatct ccaaagccaa agggcagccc cgagaaccac aggtgtacac cctgccccca tcccgggatg agctgaccaa gaaccaggtc agcctgacct gcctggtcaa aggcttctat cccagcgaca tcgccgtgga gtgggagagc aatgggcagc cggagaacaa ctacaagacc acgcctcccg tgctggactc cgacggctcc ttcttcctct acagcaagct caccgtggac aagagcaggt ggcagcaggg gaacgtcttc tcatgctccg tgatgcatga ggctctgcac aaccactaca cgcagaagag cctctccctg tctccgggta aa , cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc tcctgcactg ggagcagctc caacatcggg gcaggttatg atgtacactg gtaccagcaa cttccaggaa cagcccccaa actcctcatc tatggtaaca acaatcgccc ctcaggggtc cctgaccgat tctctggctc caagtctggc acctcagcct ccctggccat cactgggctc caggctgagg atgaggctga ttattactgc cagtcctatg acagcagcct gagtggttcg gtattcggcg gagggaccaa gctgaccgtc ctaggtcagc ccaaggctgc cccctcggtc actctgttcc caccctcgag tgaggagctt caagccaaca aggccacact ggtgtgtctc ataagtgact tctacccggg agccgtgaca gtggcctgga aggcagatag cagccccgtc aaggcgggag tggagaccac cacaccctcc aaacaaagca acaacaagta cgcggccagc agctacctga gcctgacgcc tgagcagtgg aagtcccaca gaagctacag ctgccaggtc acgcatgaag ggagcaccgt ggagaagaca gtggccccta cagaatgttc a , Artificial sequence, Artificial sequence,"(6/8) the heavy chain coding region is seq id no:6 and the light chain coding region is seq id no:8, the above procedure was carried out to obtain an antibody solution of p2a-1a 9."
https://patents.google.com/patent/CN113493506A/en, caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc tcctgtgcag cgtctggatt caccttcagg agctatggca tgcactgggt ccgccaggct ccaggcaagg ggctggagtg ggtggcagtt atctggtatg atggaagtaa taaatactat gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatata gagatagtag tggtaaatat tgactactgg ggccagggaa ccctggtcac cgtctcctca gcgtcgacca agggcccatc ggtcttcccc ctggcaccct cctccaagag cacctctggg ggcacagcgg ccctgggctg cctggtcaag gactacttcc ccgaacccgt gacggtgtcg tggaactcag gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacccagacc tacatctgca acgtgaatca caagcccagc aacaccaagg tggacaagaa agttgagccc aaatcttgtg acaaaactca cacatgccca ccgtgcccag cacctgaact cctgggggga ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggacccct gaggtcacat gcgtggtggt ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg tacgtggacg gcgtggaggt gcataatgcc aagacaaagc cgcgggagga gcagtacaac agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag gagtacaagt gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc aaagccaaag ggcagccccg agaaccacag gtgtacaccc tgcccccatc ccgggatgag ctgaccaaga accaggtcag cctgacctgc ctggtcaaag gcttctatcc cagcgacatc gccgtggagt gggagagcaa tgggcagccg gagaacaact acaagaccac gcctcccgtg ctggactccg acggctcctt cttcctctac agcaagctca ccgtggacaa gagcaggtgg cagcagggga acgtcttctc atgctccgtg atgcatgagg ctctgcacaa ccactacacg cagaagagcc tctccctgtc tccgggtaaa , gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg tttcagcaga ggccaggcca atctccaagg cgcctaattt ataaggtttc tatctgggac tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg tacacttttg gccaggggac caagctggag atcaaacgta cggtggctgc accatctgtc ttcatcttcc cgccatctga tgagcagttg aaatctggaa ctgcctctgt tgtgtgcctg ctgaataact tctaccccag agaagccaaa gtgcagtgga aggtggacaa cgccctgcag agcggaaaca gccaggaaag cgtgacagag caggattcca aggattccac atacagcctg agcagcacac tgacactgtc caaggccgac tacgagaagc acaaggtgta cgcctgcgaa gtgacacacc agggactgtc ctcccctgtg acaaagagct tcaacagagg agaatgc , Artificial sequence, Artificial sequence,"(34/36) the heavy chain coding region is seq id no:34 and the light chain coding region is the dna molecule shown in seq id no:36, the above procedure was carried out to obtain an antibody solution of p2c-1c 8."
https://patents.google.com/patent/CN113493506A/en, gaggtgcagc tggtggagtc tgggggaggc ttggtccagc ctggggggtc cctgagactc tcctgtgcag cctctggaat caccgtcagt agcaactaca tgaactgggt ccgccaggct ccagggaagg ggctggagtg ggtctcactt atttatagcg gtggtagcac atactacgca gactccgtga agggcagatt caccatctcc agagacaatt ccaagaacac gttgtatctt caaatgaaca gcctgagagc cgaggacacg gctgtgtatc actgtgcgag agatctggtg gtatacggta tggacgtctg gggccaaggg accacggtca ccgtctcctc agcgtcgacc aagggcccat cggtcttccc cctggcaccc tcctccaaga gcacctctgg gggcacagcg gccctgggct gcctggtcaa ggactacttc cccgaacccg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc ctctccctgt ctccgggtaa a , gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc ctctcctgca gggccagtca gagtgttagc agcagctact tagcctggta ccagcagaaa cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca gacaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagactggag cctgaagatt ttgcagtgta ttactgtcag cagtatggta gctcacccac ttttggccag gggaccaagc tggagatcaa acgtacggtg gctgcaccat ctgtcttcat cttcccgcca tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctac cccagagaag ccaaagtgca gtggaaggtg gacaacgccc tgcagagcgg aaacagccag gaaagcgtga cagagcagga ttccaaggat tccacataca gcctgagcag cacactgaca ctgtccaagg ccgactacga gaagcacaag gtgtacgcct gcgaagtgac acaccaggga ctgtcctccc ctgtgacaaa gagcttcaac agaggagaat gc , Artificial sequence, Artificial sequence,"(46/48) the heavy chain coding region is seq id no:46 and the light chain coding region is seq id no:48, the above steps are carried out to obtain an antibody solution of p2c-1f 11."
https://patents.google.com/patent/CN113493506A/en, caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc tcctgtgcag cctctggatt caccttcagt gactactaca tgagctggat ccgccaggct ccagggaagg ggctggagtg ggtttcatac attagtagta gtggtagtac catatactac gcagactctg tgaagggccg attcaccatc tccagggaca acgccaagaa ctcactgtat ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatttt tctcatcagc agctggtacc ttcctggggc cagggaaccc tggtcaccgt ctcctcagcg tcgaccaagg gcccatcggt cttccccctg gcaccctcct ccaagagcac ctctgggggc acagcggccc tgggctgcct ggtcaaggac tacttccccg aacccgtgac ggtgtcgtgg aactcaggcg ccctgaccag cggcgtgcac accttcccgg ctgtcctaca gtcctcagga ctctactccc tcagcagcgt ggtgaccgtg ccctccagca gcttgggcac ccagacctac atctgcaacg tgaatcacaa gcccagcaac accaaggtgg acaagaaagt tgagcccaaa tcttgtgaca aaactcacac atgcccaccg tgcccagcac ctgaactcct ggggggaccg tcagtcttcc tcttcccccc aaaacccaag gacaccctca tgatctcccg gacccctgag gtcacatgcg tggtggtgga cgtgagccac gaagaccctg aggtcaagtt caactggtac gtggacggcg tggaggtgca taatgccaag acaaagccgc gggaggagca gtacaacagc acgtaccgtg tggtcagcgt cctcaccgtc ctgcaccagg actggctgaa tggcaaggag tacaagtgca aggtctccaa caaagccctc ccagccccca tcgagaaaac catctccaaa gccaaagggc agccccgaga accacaggtg tacaccctgc ccccatcccg ggatgagctg accaagaacc aggtcagcct gacctgcctg gtcaaaggct tctatcccag cgacatcgcc gtggagtggg agagcaatgg gcagccggag aacaactaca agaccacgcc tcccgtgctg gactccgacg gctccttctt cctctacagc aagctcaccg tggacaagag caggtggcag caggggaacg tcttctcatg ctccgtgatg catgaggctc tgcacaacca ctacacgcag aagagcctct ccctgtctcc gggtaaa , gacatccagt tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc atcacttgcc gggccagtca gggcattagc agttatttag cctggtatca gcaaaaacca gggaaagccc ctaagctcct gatctatgct gcatccactt tgcaaagtgg ggtcccatca aggttcagcg gcagtggatc tgggacagaa ttcactctca caatcagcag cctgcagcct gaagattttg caacttatta ctgtcaacag cttaatagtt acccgctcac tttcggcgga gggaccaagg tggagatcaa acgtacggtg gctgcaccat ctgtcttcat cttcccgcca tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctac cccagagaag ccaaagtgca gtggaaggtg gacaacgccc tgcagagcgg aaacagccag gaaagcgtga cagagcagga ttccaaggat tccacataca gcctgagcag cacactgaca ctgtccaagg ccgactacga gaagcacaag gtgtacgcct gcgaagtgac acaccaggga ctgtcctccc ctgtgacaaa gagcttcaac agaggagaat gc , Artificial sequence, Artificial sequence,"(30/32) the heavy chain coding region is seq id no:30 and the light chain coding region is seq id no:32, the above procedure was carried out to obtain an antibody solution of p2c-1a 3."
https://patents.google.com/patent/CN113493506A/en, gaagtgcagc tggtggagtc tgggggagac ttggtacagc ctggcaggtc cctgagactc tcctgcgcag cctctggatt cgcctttgat gattatgcca tgcactgggt ccggcaagct ccagggaagg gcctggagtg ggtctcaggt agtacttgga atagtgggac catagcctat gcggactctg tgaagggccg attcaccatc tccagagaca acgccaagaa gtccctgtat ctgcaaatga acagtctgag aactgaggac acggccttat attactgtgc aaagttgggg ggctacagtg actacgatta cccgaggccg ggagaccact attacggttt ggacgtctgg ggccaaggga ccacggtcac cgtctcctca gcgtcgacca agggcccatc ggtcttcccc ctggcaccct cctccaagag cacctctggg ggcacagcgg ccctgggctg cctggtcaag gactacttcc ccgaacccgt gacggtgtcg tggaactcag gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacccagacc tacatctgca acgtgaatca caagcccagc aacaccaagg tggacaagaa agttgagccc aaatcttgtg acaaaactca cacatgccca ccgtgcccag cacctgaact cctgggggga ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggacccct gaggtcacat gcgtggtggt ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg tacgtggacg gcgtggaggt gcataatgcc aagacaaagc cgcgggagga gcagtacaac agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag gagtacaagt gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc aaagccaaag ggcagccccg agaaccacag gtgtacaccc tgcccccatc ccgggatgag ctgaccaaga accaggtcag cctgacctgc ctggtcaaag gcttctatcc cagcgacatc gccgtggagt gggagagcaa tgggcagccg gagaacaact acaagaccac gcctcccgtg ctggactccg acggctcctt cttcctctac agcaagctca ccgtggacaa gagcaggtgg cagcagggga acgtcttctc atgctccgtg atgcatgagg ctctgcacaa ccactacacg cagaagagcc tctccctgtc tccgggtaaa , cagtctgccc tgactcagcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc tcctgcactg gaaccagcag tgatgttggg agttataacc ttgtctcctg gtaccaacag cacccaggca aagtccccaa actcttgatt tatgatgtca ataagcggcc ctcagggatt tccaatcgct tctctggctc caagtctggc aacacggcct ccctgaccat ctctgggctc caggctgagg acgaggctga ttattactgc agatcatata cagacagcaa cacttatgtc ttcggaactg ggaccaaggt caccgtccta ggtcagccca aggctgcccc ctcggtcact ctgttcccac cctcgagtga ggagcttcaa gccaacaagg ccacactggt gtgtctcata agtgacttct acccgggagc cgtgacagtg gcctggaagg cagatagcag ccccgtcaag gcgggagtgg agaccaccac accctccaaa caaagcaaca acaagtacgc ggccagcagc tacctgagcc tgacgcctga gcagtggaag tcccacagaa gctacagctg ccaggtcacg catgaaggga gcaccgtgga gaagacagtg gcccctacag aatgttca , Artificial sequence, Artificial sequence,"(2/4) the heavy chain coding region is seq id no:2 and the light chain coding region is seq id no:4, the above steps are carried out to obtain an antibody solution of p2a-1a 8."
https://patents.google.com/patent/CN113493506A/en, caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc acctgcactg tctctggtta ctccatcagc agtggttact actggggctg gatccggcag cccccaggga aggggctgga gtggattggg agtatctatc atagtgggag cacctactac aacccgtccc tcaagactcg agtcaccata tcagtagaca cgtccaagaa ccagttctcc ctgaagctga gctctgtgac cgccgcagac acggccgtct attactgtgc gagagcggtg gtagggattg tagtagtacc agctgccggt cgtcgggctt ttgatatctg gggccaaggg acaatggtca ccgtctcctc agcgtcgacc aagggcccat cggtcttccc cctggcaccc tcctccaaga gcacctctgg gggcacagcg gccctgggct gcctggtcaa ggactacttc cccgaacccg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc ctctccctgt ctccgggtaa a , cagtctgccc tgactcagcc tccctccgcg tccgggtctc ctggacagtc agtcaccatc tcctgcactg gaaccagcag tgacgttggt ggttataact atgtctcctg gtaccaacag cacccaggca aagcccccaa actcatgatt tatgaggtca gtaagcggcc ctcaggggtc cctgatcgct tctctggctc caagtctggc aacacggcct ccctgaccgt ctctgggctc caggctgagg atgaggctga ttattactgc agctcatatg caggcagcaa caatttggtg ttcggcggag ggaccaagct gaccgtccta ggtcagccca aggctgcccc ctcggtcact ctgttcccac cctcgagtga ggagcttcaa gccaacaagg ccacactggt gtgtctcata agtgacttct acccgggagc cgtgacagtg gcctggaagg cagatagcag ccccgtcaag gcgggagtgg agaccaccac accctccaaa caaagcaaca acaagtacgc ggccagcagc tacctgagcc tgacgcctga gcagtggaag tcccacagaa gctacagctg ccaggtcacg catgaaggga gcaccgtgga gaagacagtg gcccctacag aatgttca , Artificial sequence, Artificial sequence,"(18/20) the heavy chain coding region is seq id no:18 and the light chain coding region is seq id no:20, the above procedure was carried out to obtain an antibody solution of p2b-2f 6."
https://patents.google.com/patent/CN113493506A/en, caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc tcctgcaagg cttctggata caccttcacc ggctactata tgcactgggt gcgacaggcc cctggacaag ggcttgagtg gatgggacgg atcaacccta acagtggtgg cacaaactat gcacagaagt ttcagggcag ggtcaccatg accagggaca cgtccatcag cacagcctac atggagctga gcaggctgag atctgacgac acggccgtgt attactgtgc gagagtcccc tattgtagta gtaccagctg ccatcgggac tggtacttcg atctctgggg ccgtggcacc ctggtcactg tctcctcagc gtcgaccaag ggcccatcgg tcttccccct ggcaccctcc tccaagagca cctctggggg cacagcggcc ctgggctgcc tggtcaagga ctacttcccc gaacccgtga cggtgtcgtg gaactcaggc gccctgacca gcggcgtgca caccttcccg gctgtcctac agtcctcagg actctactcc ctcagcagcg tggtgaccgt gccctccagc agcttgggca cccagaccta catctgcaac gtgaatcaca agcccagcaa caccaaggtg gacaagaaag ttgagcccaa atcttgtgac aaaactcaca catgcccacc gtgcccagca cctgaactcc tggggggacc gtcagtcttc ctcttccccc caaaacccaa ggacaccctc atgatctccc ggacccctga ggtcacatgc gtggtggtgg acgtgagcca cgaagaccct gaggtcaagt tcaactggta cgtggacggc gtggaggtgc ataatgccaa gacaaagccg cgggaggagc agtacaacag cacgtaccgt gtggtcagcg tcctcaccgt cctgcaccag gactggctga atggcaagga gtacaagtgc aaggtctcca acaaagccct cccagccccc atcgagaaaa ccatctccaa agccaaaggg cagccccgag aaccacaggt gtacaccctg cccccatccc gggatgagct gaccaagaac caggtcagcc tgacctgcct ggtcaaaggc ttctatccca gcgacatcgc cgtggagtgg gagagcaatg ggcagccgga gaacaactac aagaccacgc ctcccgtgct ggactccgac ggctccttct tcctctacag caagctcacc gtggacaaga gcaggtggca gcaggggaac gtcttctcat gctccgtgat gcatgaggct ctgcacaacc actacacgca gaagagcctc tccctgtctc cgggtaaa , gatattgtga tgacccagac tccactctcc ctgcccgtca cccctggaga gccggcctcc atctcctgca ggtctagtca gagcctcttg gatagtgatg atggaaacac ctatttggac tggtacctgc agaagccagg gcagtctcca cagctcctga tctatacgct ttcctatcgg gcctctggag tcccagacag gttcagtggc agtgggtcag gcactgattt cacactgaaa atcagcaggg tggaggctga ggatgttgga gtttattact gcatgcaacg tatagagttt ccgctcactt tcggcggagg gaccaaggtg gagatcaaac gtacggtggc tgcaccatct gtcttcatct tcccgccatc tgatgagcag ttgaaatctg gaactgcctc tgttgtgtgc ctgctgaata acttctaccc cagagaagcc aaagtgcagt ggaaggtgga caacgccctg cagagcggaa acagccagga aagcgtgaca gagcaggatt ccaaggattc cacatacagc ctgagcagca cactgacact gtccaaggcc gactacgaga agcacaaggt gtacgcctgc gaagtgacac accagggact gtcctcccct gtgacaaaga gcttcaacag aggagaatgc , Artificial sequence, Artificial sequence,"(10/12) the heavy chain coding region is seq id no:10 and the light chain coding region is seq id no:12, the above procedure was carried out to obtain an antibody solution of p2a-1a 10."
https://patents.google.com/patent/CN113493506A/en, gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctcagactc tcctgtgtcg cctctggatt ctccttcaat cgatatagta tgaattggct ccgccagact ccacggaagg ggctggagtg gctttcatac atcagtgcca gtggaaacac catatactac gctgactctg tgaggggccg attcaccacc tccagagaca atgccaagaa cacactgtat ctgcaaatga acagcctgcg agacgacgac acggctgtct atttctgtgc gcgacccgct atggttcggg aggggaccta caactggttc gacccctggg gccagggaac cctggtcacc gtctcctcag cgtcgaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaacccgtg acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaaa gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaactc ctggggggac cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg cctcccgtgc tggactccga cggctccttc ttcctctaca gcaagctcac cgtggacaag agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac cactacacgc agaagagcct ctccctgtct ccgggtaaa , gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc ctctcctgca gggccagtca gagtgttagc aacgactact tagcctggta ccagcagaaa cctggccagg ctcccaggct cctcatctac tatgcatcca gcagggccac tggcatccca gacaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagactggag cctggagatt ctgcagtgta ttactgtcag cagtatggtg actcacctcc gatcaccttc ggccaaggga cacgactgga gattaaacgt acggtggctg caccatctgt cttcatcttc ccgccatctg atgagcagtt gaaatctgga actgcctctg ttgtgtgcct gctgaataac ttctacccca gagaagccaa agtgcagtgg aaggtggaca acgccctgca gagcggaaac agccaggaaa gcgtgacaga gcaggattcc aaggattcca catacagcct gagcagcaca ctgacactgt ccaaggccga ctacgagaag cacaaggtgt acgcctgcga agtgacacac cagggactgt cctcccctgt gacaaagagc ttcaacagag gagaatgc , Artificial sequence, Artificial sequence,"(14/16) the heavy chain coding region is seq id no:14 and the light chain coding region is the dna molecule shown in seq id no:16, the above procedure was carried out to obtain an antibody solution of p2a-1b 3."
https://patents.google.com/patent/CN113493506A/en, gaagtgcagc tggtggagtc tgggggaggc ttggtacagc ctggcaggtc cctgagactc tcctgtgcag cctctggatt cacctttgat gattatgcca tgcactgggt ccggcaagct ccagggaagg gcctggagtg ggtctcaggt attagttgga atggtggtat cataggctat gcggactctg tgaagggccg attcaccatc tccagagaca acgccaagac ttccctgtat ctgcaaatga acagtctgaa acctgaggac acggccttgt attactgtgc aaaagtcgcg ggaagggggg attacgacta ctactacggt atggacgtct ggggccaagg gaccacggtc accgtctcct cagcgtcgac caagggccca tcggtcttcc ccctggcacc ctcctccaag agcacctctg ggggcacagc ggccctgggc tgcctggtca aggactactt ccccgaaccc gtgacggtgt cgtggaactc aggcgccctg accagcggcg tgcacacctt cccggctgtc ctacagtcct caggactcta ctccctcagc agcgtggtga ccgtgccctc cagcagcttg ggcacccaga cctacatctg caacgtgaat cacaagccca gcaacaccaa ggtggacaag aaagttgagc ccaaatcttg tgacaaaact cacacatgcc caccgtgccc agcacctgaa ctcctggggg gaccgtcagt cttcctcttc cccccaaaac ccaaggacac cctcatgatc tcccggaccc ctgaggtcac atgcgtggtg gtggacgtga gccacgaaga ccctgaggtc aagttcaact ggtacgtgga cggcgtggag gtgcataatg ccaagacaaa gccgcgggag gagcagtaca acagcacgta ccgtgtggtc agcgtcctca ccgtcctgca ccaggactgg ctgaatggca aggagtacaa gtgcaaggtc tccaacaaag ccctcccagc ccccatcgag aaaaccatct ccaaagccaa agggcagccc cgagaaccac aggtgtacac cctgccccca tcccgggatg agctgaccaa gaaccaggtc agcctgacct gcctggtcaa aggcttctat cccagcgaca tcgccgtgga gtgggagagc aatgggcagc cggagaacaa ctacaagacc acgcctcccg tgctggactc cgacggctcc ttcttcctct acagcaagct caccgtggac aagagcaggt ggcagcaggg gaacgtcttc tcatgctccg tgatgcatga ggctctgcac aaccactaca cgcagaagag cctctccctg tctccgggta aa , cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc tcctgcactg ggagcagctc caacatcggg gcaggttatg atgtacactg gtaccagcaa cttccaggaa cagcccccaa actcctcatc tatgggaaca acaatcggcc ctcaggggtc cctgaccgat tctctggctc caagtctggc acctcagcct ccctggccat cactgggctc caggctgagg atgaggctga ttattactgc cagtcctatg acagcagcct gagtggttcg gtattcggcg gagggaccaa gctgaccgtc ctaggtcagc ccaaggctgc cccctcggtc actctgttcc caccctcgag tgaggagctt caagccaaca aggccacact ggtgtgtctc ataagtgact tctacccggg agccgtgaca gtggcctgga aggcagatag cagccccgtc aaggcgggag tggagaccac cacaccctcc aaacaaagca acaacaagta cgcggccagc agctacctga gcctgacgcc tgagcagtgg aagtcccaca gaagctacag ctgccaggtc acgcatgaag ggagcaccgt ggagaagaca gtggccccta cagaatgttc a , Artificial sequence, Artificial sequence,"(26/28) the heavy chain coding region is seq id no:26 and the light chain coding region is the dna molecule shown in seq id no:28, the above procedure was carried out to obtain an antibody solution of p2b-2g 11."
https://patents.google.com/patent/CN113667010A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Leu Gly Phe Gly Glu Leu Phe Arg Lys Thr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Ala Ala Ser Thr Arg Ala Thr Ala Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Tyr Asn Lys Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),"(11/22)  the heavy chain variable region shown as seq id no:11, and the light chain variable region shown as seq id no:22."
https://patents.google.com/patent/CN113667010A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Arg Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Thr Asp Leu Pro Lys Thr Arg Tyr Phe Asp Trp Leu Phe His Ser Asp Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ala Ile Ser Thr Ser Leu Ala Trp Tyr His Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),"(6/17)  the heavy chain variable region as set forth in seq id no:6, and the light chain variable region as set forth in seq id no:17;"
https://patents.google.com/patent/CN113667010A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Arg Tyr Tyr Asp Ile Leu Thr Gly Tyr Leu Arg Pro Pro Ser Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Lys Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Thr Ser Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),"(4/15)  the heavy chain variable region as set forth in seq id no:4, and the light chain variable region as set forth in seq id no:15;"
https://patents.google.com/patent/CN113667010A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Arg Tyr Tyr Asp Ile Leu Thr Gly Tyr Leu Arg Pro Pro Ser Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Asn Tyr Phe Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ser Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Asn Thr Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),"(7/18)  the heavy chain variable region as set forth in seq id no:7, and the light chain variable region as set forth in seq id no:18;"
https://patents.google.com/patent/CN113667010A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Glu Thr Pro Gly Phe Asp Glu Ser Ile Ala Ala Ala Leu Gly Gly Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Leu Trp Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),(8/19)  the heavy chain variable region as set forth in seq id no:8 and the light chain variable region as set forth in seq id no:19;
https://patents.google.com/patent/CN113667010A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Arg Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Met Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Thr Asp Leu Pro Lys Thr Arg Tyr Phe Asp Trp Leu Phe His Ser Asp Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Leu Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),(3/14)  the heavy chain variable region as set forth in seq id no:3 and the light chain variable region as set forth in seq id no:14;
https://patents.google.com/patent/CN113667010A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Arg Tyr Tyr Asp Ile Leu Thr Gly Tyr Leu Arg Pro Pro Ser Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),"(1/12)  a heavy chain variable region as set forth in seq id no:1, and a light chain variable region as set forth in seq id no:12;"
https://patents.google.com/patent/CN113667010A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Gly Arg Gly Tyr Phe Asp Trp Leu Phe Arg Ser Asp Lys Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),(10/21)  the heavy chain variable region shown as seq id no:10 and the light chain variable region shown as seq id no:21; or
https://patents.google.com/patent/CN113667010A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Gly Arg Gly Tyr Phe Asp Trp Leu Phe Arg Ser Asp Lys Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly His Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),"(5/16)  the heavy chain variable region as set forth in seq id no:5, and the light chain variable region as set forth in seq id no:16;"
https://patents.google.com/patent/CN113667010A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Gly Arg Gly Tyr Phe Asp Trp Leu Phe Arg Ser Asp Lys Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly His Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Arg Ser Gln Val Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),"(2/13)  the heavy chain variable region as set forth in seq id no:2, and the light chain variable region as set forth in seq id no:13;"
https://patents.google.com/patent/CN113667010A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly His Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asp His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Ser Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Gly Arg Gly Tyr Phe Asp Trp Leu Phe Arg Ser Asp Lys Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly His Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Arg Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Ser Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),(9/20)  the heavy chain variable region as set forth in seq id no:9 and the light chain variable region as set forth in seq id no:20;
https://patents.google.com/patent/CN113683687A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Gly Asp Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Leu Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Val Ser Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Thr Arg Asp Thr Arg Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(22/28) cs 3: the heavy chain variable region comprises or consists of the amino acid sequence shown as seq id no:22, and the light chain variable region comprises or consists of the amino acid sequence shown as seq id no:28"
https://patents.google.com/patent/CN113683687A/en, Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Val Gly Arg Gly Tyr Ser Tyr Gly Phe Leu Pro Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Leu Ser Leu Pro Ala Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asp Gly Tyr Ser Tyr Leu His Trp Tyr Val Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Ser Ala Asp Ser Asn Arg Ala Ser Gly Val Pro Gly Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Asp Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(20/26) cs 1: the heavy chain variable region comprises or consists of the amino acid sequence shown as seq id no:20, and the light chain variable region comprises or consists of the amino acid sequence shown as seq id no:26"
https://patents.google.com/patent/CN113683687A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Gly Asp Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Val Ile Ser Glu Val Arg Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Thr Arg Asp Thr Arg Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(22/29) cs 4: the heavy chain variable region comprises or consists of the amino acid sequence shown as seq id no:22, and the light chain variable region comprises or consists of the amino acid sequence shown as seq id no:29"
https://patents.google.com/patent/CN113683687A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Asp Val Tyr Gly Gly Asn Ser Arg Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ala Val Leu Thr Gln Pro Ser Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Glu Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(25/33) cs 8: the heavy chain variable region comprises or consists of the amino acid sequence shown as seq id no:25 and the light chain variable region comprises or consists of the amino acid sequence shown as seq id no:33.
https://patents.google.com/patent/CN113683687A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Gly Asp Tyr Ser Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Ala Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ala Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Thr Arg Asp Thr Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(24/32) cs 7: the heavy chain variable region comprises or consists of the amino acid sequence shown as seq id no:24, and the light chain variable region comprises or consists of the amino acid sequence shown as seq id no:32"
https://patents.google.com/patent/CN113683687A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Gly Asp Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ala Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Val Ile Ser Glu Val Arg Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Thr Arg Asp Thr Arg Val Phe Gly Gly Gly Thr Gln Val Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(22/31) cs 6: the heavy chain variable region comprises or consists of the amino acid sequence shown as seq id no:22, and the light chain variable region comprises or consists of the amino acid sequence shown as seq id no:31"
https://patents.google.com/patent/CN113683687A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Arg Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Gly Asp Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Val Ile Ser Glu Val Arg Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Thr Arg Asp Thr Arg Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(23/30) cs 5: the heavy chain variable region comprises or consists of the amino acid sequence shown as seq id no:23, and the light chain variable region comprises or consists of the amino acid sequence shown as seq id no:30"
https://patents.google.com/patent/CN113683687A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Gly Asp Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Val Ile Ser Glu Val Arg Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Thr Arg Asp Thr Arg Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(21/27) cs 2: the heavy chain variable region comprises or consists of the amino acid sequence shown as seq id no:21, and the light chain variable region comprises or consists of the amino acid sequence shown as seq id no:27"
https://patents.google.com/patent/CN113583115A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Leu Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ile Ile Phe Thr Gly Gly Ser Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg His Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Ser Tyr Tyr Asp Val Ser Gly Trp Gly Val Gly Arg Leu Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ser Ser Gln Ser Val Tyr Asp Asn Asn Trp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Ala Gly Gly Tyr Ser Gly Asn Ile Phe Ala Phe Gly Gln Gly Thr Lys Leu Glu Ile Leu , h3F4-1-VH, h3F4-1/ h3F4-2/h3F4-3/h3F4-4-VL,(15/19)  a vh comprising the sequence shown as seq id no:15 and a vl comprising the sequence shown as seq id no:19;
https://patents.google.com/patent/CN113583115A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Leu Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ile Ile Phe Thr Gly Gly Ser Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg His Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Thr Ser Tyr Tyr Asp Val Ser Gly Trp Gly Val Gly Arg Leu Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ser Ser Gln Ser Val Tyr Asp Asn Asn Trp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Ala Gly Gly Tyr Ser Gly Asn Ile Phe Ala Phe Gly Gln Gly Thr Lys Leu Glu Ile Leu , h3F4-3-VH, h3F4-1/ h3F4-2/h3F4-3/h3F4-4-VL,(17/19) (3) a vh comprising the sequence shown as seq id no:17 and a vl comprising the sequence shown as seq id no:19
https://patents.google.com/patent/CN113583115A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Leu Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Ile Ile Phe Thr Gly Gly Ser Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg His Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Ser Tyr Tyr Asp Val Ser Gly Trp Gly Val Gly Arg Leu Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ser Ser Gln Ser Val Tyr Asp Asn Asn Trp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Ala Gly Gly Tyr Ser Gly Asn Ile Phe Ala Phe Gly Gln Gly Thr Lys Leu Glu Ile Leu , h3F4-2-VH, h3F4-1/ h3F4-2/h3F4-3/h3F4-4-VL,(16/19)  a vh comprising the sequence shown as seq id no:16 and a vl comprising the sequence shown as seq id no:19;
https://patents.google.com/patent/CN113583115A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ile Ile Phe Thr Gly Gly Ser Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg His Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Ser Tyr Tyr Asp Val Ser Gly Trp Gly Val Gly Arg Leu Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ser Ser Gln Ser Val Tyr Asp Asn Asn Trp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Ala Gly Gly Tyr Ser Gly Asn Ile Phe Ala Phe Gly Gln Gly Thr Lys Leu Glu Ile Leu , h3F4-4-VH, h3F4-1/ h3F4-2/h3F4-3/h3F4-4-VL,(18/19)  a vh comprising the sequence shown as seq id no:18 and a vl comprising the sequence shown as seq id no:19.
https://patents.google.com/patent/CN113583115A/en, Gln Ser Val Lys Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Ile Ile Phe Thr Gly Gly Ser Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Ile Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Thr Ser Tyr Tyr Asp Val Ser Gly Trp Gly Val Gly Arg Leu Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Pro Met Leu Thr Gln Thr Ala Ser Ser Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Ser Cys Gln Ser Ser Gln Ser Val Tyr Asp Asn Asn Trp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Ala Gly Gly Tyr Ser Gly Asn Ile Phe Ala Phe Gly Gly Gly Thr Glu Leu Glu Ile Leu , 3F4 VH, 3F4 VL,"(1/2) preferably, the antibody or antigen-binding fragment thereof comprises: a vh comprising the sequence shown as seq id no:1 and a vl comprising the sequence shown as seq id no:2."
https://patents.google.com/patent/CN113797333A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Met Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Leu Pro Met Tyr Gly Asp Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys, Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Arg Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro Glu Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(9/10)  preferably, antibody cb6 has the heavy chain amino acid sequence shown as seq id no:9 and the light chain amino acid sequence shown as seq id no:10."
https://patents.google.com/patent/CN113797333A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Met Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Leu Pro Met Tyr Gly Asp Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Arg Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro Glu Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(7/8)  preferably, antibody cb6 has the amino acid sequence shown in seq id no:7 for the heavy chain variable region and seq id no:8 for the light chain variable region"
https://patents.google.com/patent/WO2021218947A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Val Asp Thr Ala Met Val Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Glu Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ala Ser Tyr Ala Tyr Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ser Ala Ala Ser Ile Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Gly His Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Ile Ile Pro Tyr Ser Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  VH  ,  VL  ,"(721/1081) , wherein the vh comprises a sequence selected from seq id no:721-1080 and 3111-3145 having at least 80 %, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99% identity sequence, and/or the vl therein the sequence comprising and selected from seq id no:1081-1440 and 3146-3180 has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98 %, 99%, or 99% identity sequence."
https://patents.google.com/patent/CN113249337B/en, Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Arg Asn Tyr Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Ile Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Ser Pro Leu Ile Arg Ser Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Ala, Asp Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Leu His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Leu Ser Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Phe Ser Leu Thr Ile Ser Ser Met Glu Val Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(17/19) the amino acid sequence of the heavy chain variable region of the antibody bg1 is shown as seq id no:17, and the amino acid sequence of the light chain variable region is shown as seq id no:19"
https://patents.google.com/patent/CN113249337B/en, Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Ser Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Glu Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Gln Gly Arg Phe Asp Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Ala Thr Ala Thr Tyr Phe Cys Ser Arg Gly Gly Tyr Asp Ser Asp Gly Gly Tyr Tyr Ala Leu Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys , Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly Glu Thr Val Thr Ile Ala Cys Gly Thr Thr Glu Asn Ile Tyr Gly Ala Leu Asn Trp Tyr Gln Arg Lys Gln Gly Lys Ser Pro Gln Leu Leu Ile Tyr Gly Ala Ile Asn Leu Val Asp Gly Met Ser Ser Arg Phe Ser Gly Ser Gly Ser Gly Arg Gln Tyr Ser Leu Lys Ile Ser Ser Leu His Pro Asp Asp Val Ala Thr Tyr Tyr Cys Gln Asn Val Leu Ser Pro Pro Phe Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(7/9) the amino acid sequence of the heavy chain variable region of the antibody dg8 is shown as seq id no:7, and the amino acid sequence of the light chain variable region is shown as seq id no:9"
https://patents.google.com/patent/WO2021222935A2/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Glu Gly Trp Glu Leu Pro Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ile Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Glu Gly Arg Pro Ser Asp Ile Val Val Val Val Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ," /note=""Description of Artificial Sequence: Synthetic       polypeptide""  "," /note=""Description of Artificial Sequence: Synthetic       polypeptide""  ","(57/1) in some embodiments, the first antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region comprising the respective amino acid sequences of seq id no:57-58 and the second antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region comprising the respective amino acid sequences of seq id no:1-2, 55-56, 57-58, 65-66, 81-82, or 85-86"
https://patents.google.com/patent/CN112076316A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Thr Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu His Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Asp Tyr Gly Asp Tyr Val Leu Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Thr Tyr Lys Phe Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Gly Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Cys Ser Tyr Ala Gly Ser Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens,  Homo sapiens,"(1/5) the antibody composition of claim 1, wherein the amino acid sequence of the heavy chain variable region of the monoclonal antibody that specifically binds to the s protein receptor binding region of sars-cov-2 is set forth in seq id no:1, and the amino acid sequence of the light chain variable region is set forth in seq id no:5."
https://patents.google.com/patent/CN112076316A/en, Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Met Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ser Thr Ala Val Ala Gly Thr Pro Asp Leu Phe Asp Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Leu Ser Ser Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Thr Gln Ala Thr Gln Phe Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys ,  Homo sapiens,  Homo sapiens,"(11/12) the antibody composition of claim 4, wherein the amino acid sequence of the heavy chain variable region of the antibody that specifically binds to the n-terminal domain of the s protein of sars-cov-2 is set forth in seq id no:11, and the amino acid sequence of the light chain variable region is set forth in seq id no:12."
https://patents.google.com/patent/CN114057870A/en, Glu Val Lys Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asp Ser Arg Thr Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Ile Ser Lys Val Arg Ser Glu Asp Thr Gly Leu Tyr Tyr Cys Ala Arg Pro Ala Arg Ala Thr Trp Asp Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Val Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Gly Asn Leu Ala Trp Tyr Gln Gln Lys Gln Gly Ser Pro Thr Gln Phe Leu Val Tyr Ala Ala Thr Asn Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Asn Ser Leu Gln Ser Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp Asp Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(15/16) the labeled antibody for detecting the delta mutant strain of the novel coronavirus according to claim 1, wherein the amino acid sequence of the heavy chain is shown as seq id no:15 or the amino acid sequence of the protein with the same function obtained by replacing, deleting or inserting one or more amino acids, and the amino acid sequence of the light chain is shown as seq id no:16 or the amino acid sequence of the protein with the same function obtained by replacing, deleting or inserting one or more amino acids."
https://patents.google.com/patent/CN111647076A/en,Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Asp Phe Tyr Phe Ala Asp Tyr Glu Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg Glu Trp His Ser Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,, Artificial Sequence (Artificial Sequence),,"(8) preferably, the amino acid sequence of the single domain antibody is shown in one of seq id no:5 to seq id no:8."
https://patents.google.com/patent/CN111647076A/en,Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Asp Phe Ala Phe Ser Ser Tyr Glu Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile His His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Leu Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Asp Phe Gly His Leu Gly Gln Met Ala Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,, Artificial Sequence (Artificial Sequence),,"(5) preferably, the amino acid sequence of the single domain antibody is shown in one of seq id no:5 to seq id no:8."
https://patents.google.com/patent/US10822379B1/en,Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser GlnThr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser AsnSer Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu GluTrp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr AlaVal Ser Val Lys Ser Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys AsnGln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala ValTyr Tyr Cys Ala Arg Glu Gln Gln Gln Leu Val Pro His Tyr Tyr TyrTyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser SerAla Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser LysSer Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp TyrPhe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr SerGly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr SerLeu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln ThrTyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp LysLys Val Glu Pro Lys Ser Cys Asp Lys Thr Ser,Asp Val Val Met Thr Gln Ser Pro Ser Val Ser Gly Ser Pro Gly GlnSer Val Thr Ile Ser Cys Thr Gly Thr Thr Ser Asp Val Gly Gly TyrAsn Tyr Val Ser Trp Tyr Gln Gln Arg Pro Gly Lys Ala Pro Lys LeuMet Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg PheSer Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly LeuGln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser SerSer Thr Leu Phe Gly Thr Gly Thr Lys Leu Thr Val Leu Gly Gln ProLys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu LeuGln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr ProGly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys AlaGly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr AlaAla Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His ArgSer Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys ThrVal Ala Pro Thr Glu Cys Ser,24235PRTArtificialheavy chain variable region of an antigen binder 24,32215PRTArtificiallight chain variable region of an antigen binder 32,"(24/32) in some cases, a binder (e.g., an antibody, antigen binding fragment, and/or antibody domain) provided herein can include (a) a heavy chain variable domain that includes an amino acid sequence having 100 percent identity to the amino acid sequence set forth in seq id no:24 and/or (b) a light chain variable domain that includes an amino acid sequence having 100 percent identity to the amino acid sequence set forth in seq id no:32."
https://patents.google.com/patent/US10822379B1/en,Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Ser TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr ValSer Ala Ile Ser Thr Asp Gly Gly Ser Thr Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysAla Lys Thr Tyr Tyr Asp Phe Trp Arg Thr Tyr Tyr Gly Met Asp ValTrp Gly Gln Gly Thr Met Val Thr Val Ser Ser,Glu Ala Thr Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Arg Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro TyrThr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg,40123PRTArtificialheavy chain variable region of an antigen binder 40,48108PRTArtificiallight chain variable region of an antigen binder 48,"(40/48) in some cases, a binder (e.g., an antibody, antigen binding fragment, and/or antibody domain) provided herein can include (a) a heavy chain variable domain that includes an amino acid sequence having 100 percent identity to the amino acid sequence set forth in seq id no:40 and/or (b) a light chain variable domain that includes an amino acid sequence having 100 percent identity to the amino acid sequence set forth in seq id no:48."
https://patents.google.com/patent/US10822379B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser AsnTyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val LysGly Arg Phe Thr Ile Ser Arg His Asn Ser Lys Asn Thr Leu Tyr LeuGln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys AlaArg Gly Tyr Gly Asp Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr LeuVal Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro LeuAla Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly CysLeu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn SerGly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln SerSer Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser SerLeu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser AsnThr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys,Asp Val Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro GlyGlu Lys Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser TyrLeu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu IleTyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln AlaGlu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro LeuThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala AlaPro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser GlyThr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu AlaLys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser GlnGlu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu SerSer Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val TyrAla Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys SerPhe Asn Arg Gly Glu Cys ,8220PRTArtificialheavy chain variable region of an antigen binder 8,16214PRTArtificiallight chain variable region of an antigen binder 16,"(8/16) in some cases, a binder (e.g., an antibody, antigen binding fragment, and/or antibody domain) provided herein can include (a) a heavy chain variable domain that includes an amino acid sequence having 100 percent identity to the amino acid sequence set forth in seq id no:8 and/or (b) a light chain variable domain that includes an amino acid sequence having 100 percent identity to the amino acid sequence set forth in seq id no:16."
https://patents.google.com/patent/US10822379B1/en,Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn TyrAla MetThr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Thr Ile Ala Gly Ser Gly Asp Asn Thr Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Asp Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Arg Tyr Tyr Thr Met Asp Val Trp Gly Gln Gly Thr LeuVal Thr Val Ser Ser ,Gln Ser Val Val Thr Gln Pro Pro Ser Ala Ser Gly Ser Pro Gly GlnSer Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly TyrAsn His Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys LeuLeu Ile Tyr Glu Val Ser Glu Arg Pro Ser Gly Val Pro Asp Arg PheSer Gly Ser Lys Ser Asp Asn Lys Ala Ser Leu Thr Ile Ile Gly LeuGln Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser SerLeu Ser Gly Ser Leu Phe Gly Thr Gly Thr Lys Leu Thr Val Leu Arg,56117PRTArtificialheavy chain variable region of an antigen binder 56,64112PRTArtificiallight chain variable region of an antigen binder 64,"(56/64) in some cases, a binder (e.g., an antibody, antigen binding fragment, and/or antibody domain) provided herein can include (a) a heavy chain variable domain that includes an amino acid sequence having 100 percent identity to the amino acid sequence set forth in seq id no:56 and/or (b) a light chain variable domain that includes an amino acid sequence having 100 percent identity to the amino acid sequence set forth in seq id no:64."
https://patents.google.com/patent/KR20220012800A/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr His Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No.139 HC variable region , No.139 LC variable region ,"(2018/2017)  in one embodiment of the present invention, the binding molecule comprises a light chain variable region of the polypeptide sequence of seq id no:2017; and a heavy chain variable region of the polypeptide sequence of seq id no:2018."
https://patents.google.com/patent/CN112898415A/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/CN112062838B/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Asp Phe Asp Phe Tyr Asp Tyr Glu Met Ser Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Ile Gly Glu Ile His His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Thr Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Val Lys Asp Phe Val Gly Ala Asp Gly Pro Phe Val Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,"(2) preferably, the amino acid sequence of the single domain antibody is shown as seq id no:2."
https://patents.google.com/patent/CN112062838B/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ala Ser Ser Gly Tyr Tyr Thr Asp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Ala Asp Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Tyr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Tyr Ser Ala Pro Ser Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,, Artificial Sequence (Artificial Sequence),,"(3) a pharmaceutical composition comprising a pharmaceutically active ingredient, wherein the pharmaceutically active ingredient comprises the neutralizing single domain antibody against sars-cov-2 of the novel coronavirus of any one of claims 1 to 3 and the sars-cov-2 neutralizing antibody 4a3 having the amino acid sequence shown in seq id no:3."
https://patents.google.com/patent/CN112285348B/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met Gly Leu Ile Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Val Arg Gly Glu Asn Trp Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Tyr His Arg Ser Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(3/4)  the heavy chain and light chain amino acid sequences of the antibody 2 are respectively shown as seq id no:3 and seq id no:4
https://patents.google.com/patent/CN112285348B/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Tyr Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Ser Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Asn Asp Tyr Asp Glu Gly Glu Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Leu Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(1/2)  the heavy chain and light chain amino acid sequences of the antibody 1 are respectively shown as seq id no:1 and seq id no:2
https://patents.google.com/patent/CN111518202B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/CN111518202B/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Ser Gly Ser Tyr Tyr Trp Gly Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Asn Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) the monoclonal antibody of claim 1, comprising the heavy chain variable region of seq id no:4 and the light chain variable region of seq id no:8."
https://patents.google.com/patent/CN112175073A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Thr Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Thr Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Ser Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Thr Asp Tyr Tyr Asp Ser Ser Gly Tyr Ser Tyr Gly Met Asp Val Trp Gly His Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Gly Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Asn Phe Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence, Artificial Sequence,"(19/20) in a preferred embodiment of the invention, the heavy chain amino acid sequence of the antibody or antigen binding fragment thereof is set forth in seq id no:19, and the light chain amino acid sequence is set forth in seq id no:20"
https://patents.google.com/patent/CN112175073A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Trp Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asn Thr Ala Val Tyr Tyr Cys Ala Arg Glu Pro Leu Tyr Cys Ser Ser Thr Ser Cys Tyr Val Ala Ser Gly Leu Glu Asp Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys, Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser , Artificial Sequence, Artificial Sequence,"(29/30) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:29, and the light chain amino acid sequence is shown as seq id no:30"
https://patents.google.com/patent/CN112175073A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Gly Asp Tyr Ala Met Ser Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Phe Ile Arg Ser Lys Ala Tyr Gly Gly Thr Thr Glu Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Asp Arg Tyr Ala Arg Tyr Asp Ile Leu Thr Gly Leu Ser Pro Ala Gly Ala Asp Tyr Phe Tyr Tyr Ala Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys, Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Gln Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence, Artificial Sequence,"(39/40) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:39, and the light chain amino acid sequence is shown as seq id no:40."
https://patents.google.com/patent/CN112175073A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Thr Trp Asn Ser Gly Thr Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys His His Gln Ile Ala Val Ala Gly Asp Ala Glu Asp Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Gln Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Arg Ser Asp Arg Val Val Phe Gly Gly Gly Thr Lys Leu Thr Ala Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser , Artificial Sequence, Artificial Sequence,"(9/10) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:9, and the light chain amino acid sequence is shown as seq id no:10"
https://patents.google.com/patent/CN112940087A/en, Glu Val Lys Leu Gln Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Ser Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile Ser Asn Gly Gly Gly Tyr Ile Tyr Tyr Leu Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Gly Arg Pro Arg Pro Glu Lys Glu Phe Ile Ser Thr Ser Thr Ala Met Asp His Trp Gly Gln Gly Thr Thr Val Thr , Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Glu Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Tyr Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(27/28) the sequencing results were as follows: the amino acid sequences of the heavy chain variable region and the light chain variable region of the monoclonal antibody are respectively shown in seq id no:27 and seq id no:28
https://patents.google.com/patent/CN112979792B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/CN114106159A/en, gaagtgcagc tggtccaatc cggcgctgaa gtcaaaaagc ctggctcctc cgtgaaggtg tcttgcaagg cctctggcta ctccttcacc gactactggc tgcactgggt gcggcaggct cctggccagg gcctggaatg gatcggcatg ctggacccct ccgacggcga gacaagactg aaccagaagt tcaaggacaa ggctaccctg accgtggaca agtcaactac caccgcttac atgcagctgt cctctctgag gtccgaggac accgctgtgt actattgcgc cagaagacac ttcggctacg acttcgatta ctggggccaa ggcaccaccg tgacagtgtc ctccgcaagc accaagggac cttctgtgtt tcctctggcc ccatgtagtc gctcaacttc cgagagcacc gcagcactgg gatgcctggt gaaggattac ttcccagaac ccgtcacagt gtcttggaac agtggggccc tgacaagcgg tgtccacact tttccagctg tgctgcagtc atccggactg tactctctga gctctgtggt cactgtgccc agttcaaatt tcgggaccca gacatatact tgtaacgtgg accataagcc ttccaatacc aaggtcgata aaacagtggt ggaatgtcca ccttgcccag ctccaccagt cgcaggacct agcgtgttcc tgtttcctcc aaagcccaaa gacacactga tgatctcacg cacacctgag gtcacttgcg tggtcgtgga cgtgtcccac gaggaccctg aagtccagtt taactggtac gtggatggcg tcgaagtgca taatgccaag accaaaccaa gagaggaaca gttcaactcc acatttcgcg tcgtgagcgt gctgactgtc gtgcaccagg actggctgaa cggcaaggag tataagtgta aagtgagcaa taagggcctg cctgctccaa tcgagaaaac catttctaag acaaaaggcc agcccagaga acctcaggtg tacacactgc ccccttcccg cgaggaaatg actaagaacc aggtcagcct gacctgcctg gtgaaaggtt tttatcccag tgacatcgcc gtggagtggg aatcaaatgg ccagcctgag aacaattaca agactacccc acccatgctg gactcagatg gttccttctt tctgtattca aagctgaccg tggataaatc caggtggcag cagggcaacg tcttctcttg tagtgtgatg catgaggctc tgcacaatca ttacacacag aagtcactgt ccctgagccc aggcaag , gatatcgtga tgacccagtc ccctagcagc ctgcctgtga cccctggaca gcccgcctcc atcagctgca gatcctccaa gtccctgctg cactccaacg gcaacaccta cctgtactgg ttcctgcaga agcccggcaa gagccctcag ctgctgatat accggatgtc caacctggct tctggcgtgc ctgaccggtt ttctggcagc gggtcaggaa cagattttac actgaagatt tcaagagtgg aagccgagga tgtgggcgtg tactactgca tgcagcacct ggagtacccc ctgaccttcg gcggcggcac caaggtggaa atcaagcgta ctgtcgctgc accaagcgtg ttcatttttc ctccatctga cgaacagctg aagtctggaa ccgctagtgt cgtgtgcctg ctgaacaatt tttaccccag ggaggcaaag gtccagtgga aagtggataa cgccctgcag agcggcaatt ctcaggagag tgtgaccgaa caggactcaa aggattccac atatagcctg tcatccactc tgaccctgag caaagctgac tacgagaagc acaaagtcta tgcatgcgaa gtgacccatc agggactgag ctctcctgtg acaaagtctt tcaaccgggg ggagtgc , humanized antibody hS1B-91-3 heavy chain nucleic acid sequence (), light chain nucleic acid sequence of humanized antibody hS1B-91-3 (),"(24/25) in a preferred embodiment of the invention, the dna molecule encoding the heavy chain of the above antibody has the amino acid sequence shown in seq id no:24; and/or, the dna molecule encoding the light chain of the antibody has the amino acid sequence shown in seq id no:25."
https://patents.google.com/patent/CN113527472A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Ala Ser Glu Lys Tyr Tyr Leu Asp Ser Leu Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gly Ile Leu Trp Phe Gly Asp Tyr Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Leu Tyr Ala Ala Ser Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Tyr Ser Thr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , MW07-HL, MW07-VL,"(10/9) antibody or fragment thereof specific for the sars-cov-2s protein according to claim 6 or 7, wherein the heavy chain variable region of the antibody or fragment thereof is identical to the heavy chain variable region of seq id no:10 has a sequence homology of 70% or more; the light chain variable region is identical to seq id no:9 has a sequence homology of 70% or more."
https://patents.google.com/patent/CN112239501B/en, Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Arg Lys Leu Ser Cys Ala Ala Ser Gly Val Thr Phe Ser Thr Phe Ala Met His Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Val Ala Tyr Leu Asn Ser Ala Ser Asn Leu Ile Tyr Tyr Ala Asp Thr Leu Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Pro Lys Asn Thr Leu Phe Leu Gln Met Thr Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Thr Arg His Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Cys Gly Cys Lys Pro Cys Ile Cys Thr Val Pro Glu Val Ser Ser Val Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu Thr Ile Thr Leu Thr Pro Lys Val Thr Cys Val Val Val Asp Ile Ser Lys Asp Asp Pro Glu Val Gln Phe Ser Trp Phe Val Asp Asp Val Glu Val His Thr Ala Gln Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser Val Ser Glu Leu Pro Ile Met His Gln Asp Trp Leu Asn Gly Lys Glu Phe Lys Cys Arg Val Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile Pro Pro Pro Lys Glu Gln Met Ala Lys Asp Lys Val Ser Leu Thr Cys Met Ile Thr Asp Phe Phe Pro Glu Asp Ile Thr Val Glu Trp Gln Trp Asn Gly Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met Asp Thr Asp Gly Ser Tyr Phe Val Tyr Ser Lys Leu Asn Val Gln Lys Ser Asn Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val Leu His Glu Gly Leu His Asn His His Thr Glu Lys Ser Leu Ser His Ser Pro Gly Lys , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Ile Asp Tyr Asp Gly Asp Ser Phe Met Asn Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Val Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Asn Glu Asp Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys , Artificial sequence, Artificial sequence,"(14/13) mu.g of an external control antibody was used as a control, and the electrophoretogram showed two bands, 1 of which mr was 50kd (heavy chain, seq id no:14) and the other mr was 28kd (light chain, seq id no:13), as shown in fig"
https://patents.google.com/patent/WO2021196268A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Tyr Ser Ser Ser Trp Leu Leu Gln Ser Phe Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asn Ile Gln Leu Thr Gln Ser Pro Val Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Leu Thr Cys Arg Ala Ser Gln Gly Ile Gly Tyr Ser Leu Val Trp Tyr Gln Lys Lys Pro Gly Thr Ala Pro Lys Leu Leu Ile Phe Asp Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Ser Ala Thr Tyr Tyr Cys Gln Gln Val Ile His Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  P16-A3 HC ,  P16-A3 LC ,"(17/18)  seq id no:17 or a heavy chain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to it, and seq id no:18 or a light chain sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with it; or"
https://patents.google.com/patent/WO2021196268A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Ala Thr Leu Met Asn Asn Lys Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  P17-A11 VH ,  P17-A11 VL ,"(3/4)  heavy chain variable region and light chain variable region, wherein the heavy chain variable region comprises the sequence of seq id no:3 or has at least 90%, 91%, 92%, 93%, 94%, 95% therewith , 96%, 97%, 98%, or 99% identity sequence, and the light chain variable region includes the sequence of seq id no:4 or has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequences;"
https://patents.google.com/patent/WO2021196268A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Tyr Ser Ser Ser Trp Leu Leu Gln Ser Phe Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asn Ile Gln Leu Thr Gln Ser Pro Val Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Leu Thr Cys Arg Ala Ser Gln Gly Ile Gly Tyr Ser Leu Val Trp Tyr Gln Lys Lys Pro Gly Thr Ala Pro Lys Leu Leu Ile Phe Asp Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Ser Ala Thr Tyr Tyr Cys Gln Gln Val Ile His Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  P16-A3 VH ,  P16-A3 VL ,"(1/2)  heavy chain variable region and light chain variable region, wherein the heavy chain variable region comprises the sequence of seq id no:1 or has at least 90%, 91%, 92%, 93%, 94%, 95% therewith , 96%, 97%, 98%, or 99% identity sequence, and the light chain variable region includes the sequence of seq id no:2 or has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequences; or"
https://patents.google.com/patent/WO2021196268A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Ala Thr Leu Met Asn Asn Lys Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  P17-A11 HC ,  P17-A11 LC ,"(19/20)  seq id no:19 or a heavy chain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to it, and seq id no:20 or a light chain sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with it;"
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe His Tyr Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Ser Gly Gly Gly Arg Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Leu Gln Gly Ser Leu His Tyr Cys Ser Gly Leu Val Gly Glu Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,VHH12,,"(93) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Phe Thr Arg Tyr Pro Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Gly Ser Gly Ile Ile Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Val Asp Asn Ala Pro Thr Ser Ser Leu Pro Leu Thr Pro Gly Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,VHH19,,"(100) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Leu Asp Val Thr Gly Arg Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Val Tyr Thr Pro Phe Arg Phe Ala Phe Lys Thr Asp Pro Asp Arg Gln Asp His Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,VHH25,,"(106) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Leu Ser Leu Glu His Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Asp Ser Ser Gly Gly Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Leu Gln Gly Ser Tyr Tyr Tyr Thr Ser Leu His Gln Thr Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,VHH2,,"(83) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Val Ser Met Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Arg Ser Gly Arg Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Arg Asp Gly Gly Leu His Tyr Ala Leu Tyr Val Glu Ala Ser His Tyr Asn Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,VHH24,,"(105) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Ser Leu Asp Gly Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Gly Arg Leu Gly Thr Thr Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Lys Arg Ser Thr Trp Phe Gly Cys Ser Thr Leu Asp Asp Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,VHH7,,"(88) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Asp Arg Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Ser Gly Gly Thr Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Gly Thr Gln Leu Arg Tyr Gly Cys Ser Arg Gln Ala Arg Arg Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,VHH8,,"(89) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Phe Asp Asp Phe Ala Ile Gly Trp Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ser Ala Arg Gly Ile Val Asn Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Leu Val Gly Leu Asn Asp Arg Ser Leu Pro His Glu Ala Glu Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,VHH15,,"(96) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly His Thr Gly Ser Thr Tyr Ile Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Arg Ser Gly Ile Leu Arg Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Arg Asp Ser Leu Thr Gly Val Ile Gly Asn Thr Pro Gly Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,VHH17,,"(98) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Gly Asn Tyr Glu Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Arg Ser Gly Val Ile Phe Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Arg Phe Arg Ala Gly Leu Val Gln Ser Leu Cys Gln Ser Thr Pro Glu Phe Tyr Gln Asp Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser,,VHH5,,"(86) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Leu Ser Leu Glu His Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Asp Ser Gly Ala Thr Arg Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ser Ala Thr Pro Gly Ala Phe Arg Thr Cys Ala Phe Arg Asp Phe Ser His Leu Ala Asn Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,VHH1,,"(82) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Gly Asn Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Leu Ser Gly Asp Ile Ile Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Pro Phe Pro SerLeu Leu Tyr Cys Ser Leu Cys Pro Ser Asn Pro Glu Phe Cys Arg His Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser,,VHH6,,"(87) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Asp Tyr Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Pro Ser Gly Thr Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Asn Pro Ser Tyr Tyr Tyr Cys Ser Gly Tyr Pro His Glu Tyr Asp Asp Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,VHH11,,"(92) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Val Ser Ser Tyr Val Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Arg Ser Gly Ile Ile Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Gln Thr Gln Val Leu Pro Thr Glu Asp Arg Ser Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,VHH18,,"(99) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Ala Thr Ser Asp Ile Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Pro Ser Gly Gly Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Ser Pro Ser Trp His Tyr Cys Ser Gly Tyr Glu His Glu Tyr Asp Asp Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,VHH10,,"(91) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Arg Leu Gly Gly Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Gly Ser Gly Ile Ile Ser Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Pro Ser Gly Ser Ser Tyr Gly Ser Arg Arg Leu Pro Cys Gly Ile Asp Ser Gln Asp Tyr Gln Thr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser,,VHH14,,"(95) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Leu Thr Leu Asn Asn Asn Thr Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Pro Ser Gly Ile Val Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Val Leu Gln Trp Asn Gly Ala Gly Leu Pro Ser Pro Leu Gly Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,VHH4,,"(85) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Leu Ser Thr Tyr Glu Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Val Thr Pro Thr Gly Phe Gly Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Ser Gly Lys Gly Leu Gly Ser Leu Gln Arg Ser Pro Asp Asp Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,VHH27,,"(108) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Phe Lys Ser Tyr His Ile Ala Trp Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ser Leu Thr Gly Ala Ser Ile Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Arg Asp Tyr Ala Ser Ser Leu Tyr Cys Ser Arg Asn Glu Ala Met Tyr Ala Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,VHH13,,"(94) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Phe Ser Ser Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Ser Gly Gly Ile Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu MetAsn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Asn Arg Gly Arg Phe Thr Gly Trp Arg Ser Leu Thr Asp Tyr Thr Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,VHH20,,"(101) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Phe Ser Thr Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Pro Ser Arg Ile Ile Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Asp Ser Ser Tyr Gly Gly Arg Leu Gly Arg Arg Ile Asp Asp Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,VHH21,,"(102) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Asp Ser Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Thr Lys His Gly Gly Thr Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Asp His Arg Ala Leu Arg Phe Gly Cys Ala Val Val Pro Gly Pro Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,VHH3,,"(84) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Ala Ser Gly Arg Thr Ser Ser Thr Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Thr Trp Ser Gly Gly Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Gly Leu Ser Pro Leu Met Leu Thr Ala Ser Arg Arg Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser,,VHH23,,"(104) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Phe Gly Thr Tyr Arg Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Phe Trp Ser Gly Gly Gly Ala Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Arg Ala Pro Thr Thr Gln Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser,,VHH26,,"(107) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Ser Gly Val Ser Thr Gly Ser Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Tyr Thr Ser Val Gly Ser Ile Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Phe Phe Val Pro Phe Gly Asp Thr Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser,,VHH22,,"(103) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Asp Tyr Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Ser Ser Gly Thr Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Leu Gln Gly Ser Tyr Tyr Tyr Thr Ser Leu His Gln Thr Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,VHH9,,"(90) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077A/en,Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ser Ile Gly Trp Phe ArgGln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Phe Ser Ser Leu Asp Gly Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Thr Arg Gly Ser Ser Trp Tyr Trp Tyr Arg Pro Ser Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,VHH16,,"(97) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN113512113A/en, Gln Met Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Thr Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Asn Ser Ala Met Gln Trp Val Arg Gln Ala Arg Gly Gln Arg Leu Glu Trp Val Gly Trp Ile Val Val Ala Ser Gly Asn Ala Asn Ser Ala Arg Arg Phe His Asp Arg Val Thr Ile Thr Ser Asp Met Ser Thr Ser Thr Ala Tyr Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Leu Asn His Cys Ser Asn Thr Thr Cys Leu Asp Gly Phe Asp Ile Trp Gly Gln Gly Thr Met Val Ser Val Ser Ser Ala Ser , Glu Ile Val Leu Thr Gln Ser Pro Val Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Arg Asn Ser Leu Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Ala Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Val Val Tyr Tyr Cys Gln Gln His Gly Ser Ser Pro Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Phe Lys Arg Thr ,  Homo sapiens,  Homo sapiens,"(1/3) an antibody composition comprising a first antibody and a second antibody, wherein the amino acid sequences of the variable region of the heavy chain and the variable region of the light chain of the first antibody are represented by seq id no:1 and seq id no:3, respectively, and the amino acid sequences of the variable region of the heavy chain and the variable region of the light chain of the second antibody are represented by:"
https://patents.google.com/patent/CN113512113A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Thr Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ser Phe Ser Asn Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Ala Thr Leu Gly Ile Ser Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Pro Ile Thr Asn Phe Gly Val Leu Ile Glu Val Asp Ala Phe His Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser , Glu Ile Val Leu Thr Gln Ser Pro Phe Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Gly Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Leu Ala Pro Arg Leu Leu Ile Tyr Asp Gly Ser Ser Arg Ala Thr Asp Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Met Tyr Tyr Cys Gln Gln Tyr Ser Thr Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr ,  Homo sapiens,  Homo sapiens,"(9/11)  seq id no:9 and seq id no:11; in the present invention, an antibody having the amino acid sequences of the variable region of the heavy chain and the variable region of the light chain is designated as ""cz-d7""."
https://patents.google.com/patent/CN107889491B/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Glu Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Ile Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Gly Glu Tyr Ser Gly Tyr Asp Thr Asp Pro Gln Tyr Ser Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Gly Asp Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Ile Leu Leu Ile Tyr Gly Thr Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Ser Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys , human (Homo sapiens), human (Homo sapiens),"(1/5) in one embodiment, each polypeptide of the dimer may comprise a vh domain shown in seq id no:1 and a v κ domain shown in seq id no:5, which are the vh and vl domains, respectively, present in metrizumab."
https://patents.google.com/patent/CN107889491B/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Glu Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Ile Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Gly Glu Tyr Ser Gly Tyr Asp Thr Asp Pro Gln Tyr Ser Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Gln Gly Ile Gly Asp Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Ile Leu Leu Ile Tyr Gly Thr Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Ser Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys , human (Homo sapiens), human (Homo sapiens),"(1/6) the isolated binding protein of claim 1 or 2, wherein said vh domain consists of the amino acid sequence set forth in seq id no:1 and said vl domain consists of the amino acid sequence set forth in seq id no:6."
https://patents.google.com/patent/CN107889491B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Glu Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Ile Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Gly Glu Tyr Ser Gly Tyr Asp Thr Pro Ala Ser Pro Asp Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Gln Gly Ile Gly Asp Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Ile Leu Leu Ile Tyr Gly Thr Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Ser Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys , human (Homo sapiens), human (Homo sapiens),(2/6) the vh domain may be replaced with a vh domain having the sequence shown in seq id no:2; the vl domain may be replaced with a vl domain having the sequence shown in seq id no:6
https://patents.google.com/patent/CN107889491B/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Glu Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Ile Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Gly Glu Tyr Ser Gly Tyr Asp Thr Asp Pro Gln Tyr Ser Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys , Glu Trp Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Gly Asp Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Ile Leu Leu Ile Tyr Gly Thr Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Ser Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , human (Homo sapiens), human (Homo sapiens),(11/10)  (light chain seq id no:10 and heavy chain seq id no:11
https://patents.google.com/patent/CN113150129A/en, Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Gly Arg Ser Leu Asn Asn Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Asn Tyr Asn Gly Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Asn Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser Ala Ser Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Synthesis, Artificial Synthesis,"(12/16) the heavy chain variable region of the scfv-32 sequence comprises an amino acid sequence which is at least 70% homologous to the amino acid sequence shown in seq id no:12, and the light chain variable region of the scfv-32 sequence comprises an amino acid sequence which is at least 70% homologous to the amino acid sequence shown in seq id no:16."
https://patents.google.com/patent/CN113150129A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Thr Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Thr Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Thr Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Gly Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Arg Glu Arg Trp Leu Gln Leu His Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Pro Val Leu Thr Gln Pro Pro Ser Val Ser Glu Ala Pro Arg Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Thr Asn Ala Val Asn Trp Tyr Gln Gln Leu Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr His Asn Asp Leu Leu Pro Ser Gly Val Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Arg Leu Asn Gly Arg Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , Artificial Synthesis, Artificial Synthesis,"(4/8) in certain preferred embodiments, the heavy chain variable region of the scfv-27 sequence of the single chain antibody comprises an amino acid sequence that is at least 70% homologous to the amino acid sequence set forth in seq id no:4, and the light chain variable region of the single chain antibody comprises an amino acid sequence that is at least 70% homologous to the amino acid sequence set forth in seq id no:8"
https://patents.google.com/patent/WO2021233834A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Ser Asp Tyr Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Arg Ser Ser Thr Tyr Ile Tyr Tyr Ala Asp Ser Leu Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met His Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Lys Trp Glu Leu Pro Arg Gly Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln His Tyr Asp Asn Leu Pro Ile Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  CVH-6 Variable Sequence Region HC  ,  CVH-6 Variable Sequence Region LC  ,(47/48)  (iii) a variable heavy chain (vh) comprising the amino acid sequence of seq id no:47 and a variable light chain (vl) comprising the amino acid sequence of seq id no:48
https://patents.google.com/patent/WO2021233834A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asp Val Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Arg Ile Lys Ser Lys Ile Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Thr Ala Gly Ser Tyr Tyr Tyr Asp Thr Val Gly Pro Gly Leu Pro Glu Gly Lys Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Met Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Ile Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  2130 Variable Sequence Region HC  ,  2130 Variable Sequence Region LC  ,(23/24)  or (ii) a variable heavy chain (vh) comprising the amino acid sequence of seq id no:23 and a variable light chain (vl) comprising the amino acid sequence of seq id no:24. 
https://patents.google.com/patent/WO2021233834A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg His Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Leu Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Gly Phe Tyr Tyr Gly Gly Ala Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Ser Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Gly Ile Asn Arg Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  2103 Variable Sequence Region HC  ,  2103 Variable Sequence Region LC  ,"(53/54) in some aspects, the antibody or antigen binding fragment thereof comprises a vh comprising the amino acid sequence of seq id no:53 and a vl comprising the amino acid sequence of seq id no:54"
https://patents.google.com/patent/WO2021233834A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asp Asp Tyr Asp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Asn Trp Asn Gly Gly Ser Thr Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr His Cys Ala Val Ile Met Ser Pro Ile Pro Arg Tyr Ser Gly Tyr Asp Trp Ala Gly Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala Ser Trp Tyr Gln Gln Lys Pro Gly Gln Val Pro Ile Leu Val Ile Tyr Asp Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Asn Ala Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  2094 Variable Sequence Region HC  ,  2094 Variable Sequence Region LC  ,"(7/8) in some aspects, the antibody or antigen-binding fragment thereof comprises a vh comprising the amino acid sequence of seq id no:7 and a vl comprising the amino acid sequence of seq id no:8"
https://patents.google.com/patent/WO2021233834A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Gly Ser Phe Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met Gly Arg Met Asn Ser Asn Ser Gly Asn Thr Ala Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg Met Arg Ser Gly Trp Pro Thr His Gly Arg Pro Asp Asp Phe Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Ala Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile Gly Ser Tyr Thr Ile Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Asp Gln Arg Thr Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Phe Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Asn Asn Tyr Tyr Cys Ala Val Trp Asp Asp Ser Leu Asn Gly Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  2096 Variable Sequence Region HC  ,  2096 Variable Sequence Region LC  ,"(15/16) 10. the antibody or antigen-binding fragment thereof of any one of claims 7-9, wherein the antibody the antibody or antigen-binding fragment thereof comprises (i) a variable heavy chain (vh) comprising the amino acid sequence of seq id no:15 and a variable light chain (vl) comprising the amino acid sequence of seq id no:16"
https://patents.google.com/patent/WO2021233834A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Phe Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Ile Tyr Ala Gln Lys Phe Arg Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Asp Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Gly Asp Tyr Pro Asp Ala Phe Asp Ile Trp Gly Gln Gly Ser Met Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Thr Pro Leu Ser Ser Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Phe Asn Trp Leu Gln Gln Arg Pro Gly Gln Pro Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr His Cys Met Gln Ala Thr His Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  CVH-5 Variable Sequence Region HC  ,  CVH-5 Variable Sequence Region LC  ,"(61/62) in some aspects, the antibody or antigen-binding fragment thereof comprises the the vh of seq id no:61 and/or the vl of seq id no:62"
https://patents.google.com/patent/WO2021233834A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Arg Ser Asn Tyr Met Thr Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Thr Tyr Gly Leu Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Thr Ala Pro Asn Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Leu Leu Asn Ser His Pro Leu Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys ,  2165 Variable Sequence Region HC  ,  2165 Variable Sequence Region LC  ,(31/32)  (ii) a variable heavy chain (vh) comprising the amino acid sequence of seq id no:31 and a variable light chain (vl) comprising the amino acid sequence of seq id no:32
https://patents.google.com/patent/WO2021233834A1/en, Gln Met Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Thr Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Met Ser Ser Ala Val Gln Trp Val Arg Gln Ala Arg Gly Gln Arg Leu Glu Trp Ile Gly Trp Ile Val Ile Gly Ser Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln Glu Arg Val Thr Ile Thr Arg Asp Met Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Pro Tyr Cys Ser Ser Ile Ser Cys Asn Asp Gly Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Gly Ser Ser Arg Gly Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  2196 Variable Sequence Region HC  ,  2196 Variable Sequence Region LC  ,"(39/40) 4. the antibody or antigen-binding fragment thereof of any one of claims 1-3, wherein the antibody or antigen-binding fragment comprises (i) a variable heavy chain (vh) comprising the amino acid sequence of seq id no:39 and a variable light chain (vl) comprising the amino acid sequence of seq id no:40"
https://patents.google.com/patent/CN112409488A/en, Glu Val Gln Leu Glu Glu Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Phe Gly Tyr Thr Phe Thr Asn His His Ile Asn Trp Met Lys Gln Arg Pro Gly Gln Gly Leu Asp Trp Ile Gly Tyr Val Asn Pro Tyr Asn Asp Tyr Thr Lys Tyr Ser Gln Asn Phe Lys Gly Lys Ala Thr Leu Ser Val Asp Arg Ser Ser Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Trp Arg Asp Tyr Asp Arg Asp Trp Tyr Phe Asp Val Trp Gly Ala Gly Thr Thr Val Ile Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly Asp Arg Val Ser Leu Ser Cys Arg Ala Ser Gln Ser Ile Arg Asp Tyr Leu Tyr Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Ser Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Pro Glu Asp Val Gly Val Tyr Tyr Cys Gln Asn Gly His Ser Phe Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg , heavy chain variable region, light chain variable region,"(4/8) in a specific embodiment, the amino acid sequence of the heavy chain variable region is seq id no:4 and the amino acid sequence of the light chain variable region is seq id no:8."
https://patents.google.com/patent/CN111333722A/en,Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Glu Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser Ala Met His Trp Val Arg Gln Ala Ser Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Arg Ser Lys Pro Asn Ser Tyr Ala Thr Ala Tyr Ala Ala Ser Val Thr Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Ser Val Cys Ser Gly Gly Ser Cys Tyr Gln Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Pro Thr Ser Pro Lys Val Thr Ser Gly Gln Ala Gly Gln ,Glu Leu Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Arg Asn Val Leu Tyr Ser Pro Asn Asn Lys Asn Tyr Leu Gly Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Ser Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Glu Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys His Gln Tyr Phe Ser Thr Leu Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(28/29)  or the amino acid sequence of the heavy chain variable region of the neutralizing antibody is seq id no:28, and the amino acid sequence of the light chain variable region of the neutralizing antibody is seq id no:29"
https://patents.google.com/patent/CN111333722A/en,Glu Val Gln Leu ValGlu Ser Gly Gly Gly Leu Val Met Pro Gly Arg Ser Leu Arg Leu Ser Cys Arg His Ser Gly Phe Thr Phe Ala Asp Tyr Thr Met Asn Trp Phe Arg Gln Val Pro Gly Lys Gly Leu Glu Trp Ile Gly Phe Ile Arg Ser Lys Thr Tyr Gly Gly Thr Ala Glu Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile Ala Tyr Leu Glu Met Asn Ser Leu Asn Thr Glu Asp Thr Gly Val Tyr Arg Cys Thr Arg Ile Ser Gly Tyr Tyr Gly Ala Gly Ser Gly Gly Ala Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,Glu Leu Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Tyr Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(30/31)  the amino acid sequence of the heavy chain variable region of the neutralizing antibody is seq id no:30, and the amino acid sequence of the light chain variable region is seq id no:31"
https://patents.google.com/patent/CN111333722A/en,Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp Val Ala Leu Ile Ser Ser Asp Gly Ser Val Thr Tyr Phe Thr Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Gly Trp Asp Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser,Ser Gln Ser Val Leu Thr Gln Pro Pro Ser Met Ser Leu Ala Pro Gly Gln Thr Ala Thr Ile Thr Cys Ala Gly Thr Asn Ile Gly Arg Lys Tyr Val His Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Val Leu Val Met Ser Asp Asn Asp Asp Arg Pro Ser Gly Ile Pro GluArg Phe Ser Ala Ser Asn Ser Gly His Thr Ala Thr Leu Ile Ile Asn Arg Val Glu Val Asp Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Thr Thr Tyr Ser Arg Pro Val Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(32/33)  the amino acid sequence of the heavy chain variable region of the neutralizing antibody is seq id no:32, and the amino acid sequence of the light chain variable region is seq id no:33."
https://patents.google.com/patent/CN111333722A/en,Glu Val Lys Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Leu Asn Phe Gly Thr Ser Val Met His Trp Val Arg Gln Val Gln Gly Thr Gly Leu Leu Trp Val Ser Arg Ile Asp Ser Gly Gly Thr Ser Ile Thr Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Val Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Gly Val Tyr Tyr Cys Ser Thr Asp Ser Gly Ser Ile Gly Glu Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Pro Thr Ser Pro Lys Val Thr Ser Gly Gln Ala Gly Gln,Glu Leu Gln Met Thr Gln Ser Pro Ser Pro Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Gly Gln Asn Ile Arg Gly Tyr Val Asn Trp Tyr Gln His Lys Ala Gly Glu Ala Pro Lys Leu Leu Ile Tyr His Ala Ser Asn Leu Gln Ser Gly Leu Pro Leu Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Ser Leu Gln Pro Glu Asp Phe Ala Ile Tyr Tyr Cys Gln Gln Ser His Asp Thr Leu Thr Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(26/27) preferably, the amino acid sequence of the heavy chain variable region of the neutralizing antibody or antigen binding fragment thereof is seq id no:26, and the amino acid sequence of the light chain variable region is seq id no:27"
https://patents.google.com/patent/CN113735969A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Thr Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Ser Phe Ser Asn Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Thr His Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Phe Cys Val Lys Asp Arg Thr Asp Trp Glu Leu Ile Arg Gly Tyr Phe Gly His Trp Gly Gln Gly Thr Gln Ile Thr Val Ser Ser , Asp Ile Val Met Thr Gln Thr Pro Ser Ser Leu Ser Leu Ser Pro Gly Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Glu Asn Ile Ile Asn Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln Ser Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ile Ile Trp Pro Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys Arg ,  Homo sapiens,  Homo sapiens,"(1/5) in a preferred embodiment, the heavy chain variable region of the monoclonal antibody has the amino acid sequence shown in seq id no:1, and the light chain variable region has the amino acid sequence shown in seq id no:5."
https://patents.google.com/patent/CN112898416A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Trp Val Ile Cys Ser Ser Thr Ser Cys Tyr Thr Lys Tyr Ser Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ile Ser Asn Ile Gly Ser Ala His Val Ser Trp Tyr Gln Gln Val Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Ser Glu Arg Pro Ser Gly Ile Pro Ala Arg Phe Ser Ala Phe Lys Tyr Gly Thr Ser Ala Thr Leu Asp Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Trp Asp Ile Ser Leu Ser Ala Gly Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8)  that specifically bind to a novel coronavirus np protein, wherein the binding protein or antibody of the novel coronavirus np protein comprises or consists of the vl sequence of seq id no:8 and the vh sequence of seq id no:4."
https://patents.google.com/patent/CN112898416A/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/CN113817051A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Ile Thr Val Ser Ser Asn Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Met Glu Val Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Pro Val Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Ser Ile Thr Cys Ser Gly Asp Asn Leu Gly Asn Lys Tyr Val Ser Trp Tyr Glu Gln Lys Pro Gly Gln Ser Pro Val Val Val Ile Tyr Arg Asp Thr Gln Arg Pro Ser Gly Ile Pro Glu Arg Tyr Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Leu Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Thr Thr Ala Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial sequence, Artificial sequence,"(7/8) specifically, the sequences of the light chain variable region and the heavy chain variable region are respectively the same as seq id no:8 and seq id no:7."
https://patents.google.com/patent/CN114031685A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Thr Trp Asn Ser Gly Thr Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu His Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Asn Ser Asp Tyr Ser Gly Tyr Tyr Trp Glu Leu Glu Asn Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Phe Asp Ser Ser Leu Ser Gly Val Val Phe Gly Gly Gly Thr Arg Leu Thr Val Leu , Homo sapiens, Homo sapiens,"(1/5) in a preferred embodiment, the amino acid sequence of the heavy chain variable region of the antibody is shown in seq id no:1, and the amino acid sequence of the light chain variable region is shown in seq id no:5."
https://patents.google.com/patent/CN111518203B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/CN111518203B/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Trp Arg His Ser Ser Gly Trp Asp Asn Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Glu Asn Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Leu Leu Gly Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) the monoclonal antibody or antigen-binding portion thereof according to claim 1, wherein the heavy chain variable region of the monoclonal antibody or antigen-binding portion thereof has an amino acid sequence shown in seq id no:4, and the light chain variable region of the monoclonal antibody or antigen-binding portion thereof has an amino acid sequence shown in seq id no:8."
https://patents.google.com/patent/CN113999302A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Ile Thr Phe Ser Asp Tyr Tyr Met Tyr Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile Ser Asp Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Asn Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys Val Arg Asp Lys Ser Met Gly Phe Gly Ala Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Glu Ile Val Leu Thr Gln Ser Pro Thr Thr Met Ala Ala Ser Pro Gly Glu Lys Ile Thr Ile Thr Cys Ser Ala Ser Ser Ser Ile Ser Ser Asn Tyr Leu His Trp Tyr Gln Gln Arg Pro Gly Phe Ser Pro Lys Leu Leu Ile Tyr Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Gly Thr Met Glu Ala Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Gly His Ser Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , VH, VL,"(17/18) one of the antibodies was mab #9, whose heavy chain variable region sequence is shown in seq id no:17 and light chain variable region sequence is shown in seq id no:18."
https://patents.google.com/patent/CN113999302A/en, Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Pro Ser Ser Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Asn Ile Glu Asp Tyr Ala Tyr Tyr Ala Pro Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Asp Leu Lys Val Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Gly Arg Gly Gly Tyr Ala Ala Asp Ile Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser, Asp Val Val Met Thr Gln Thr Ala Ser Pro Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Ser Cys Gln Ser Ser Glu Ser Val Tyr Thr Asn Asn Arg Leu Ser Trp Phe Gln Gln Lys Pro Gly Gln Arg Pro Lys Leu Leu Ile Tyr Arg Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Ile Ile Ser Asp Val Gln Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Ala Gly Val Gly Ser Gly Gly Thr Asp Ile Ala Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , VH, VL,"(7/8) the heavy chain variable region sequence is shown as seq id no:7, and the light chain variable region sequence is shown as seq id no:8."
https://patents.google.com/patent/CN111647076B/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Asp Phe Tyr Phe Ala Asp Tyr Glu Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg Glu Trp His Ser Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,"(8) preferably, the amino acid sequence of the single domain antibody is shown in one of seq id no:5 to seq id no:8."
https://patents.google.com/patent/CN111647076B/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Asp Phe Ala Phe Ser Ser Tyr Glu Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile His His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Leu Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Asp Phe Gly His Leu Gly Gln Met Ala Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,"(5) preferably, the amino acid sequence of the single domain antibody is shown in one of seq id no:5 to seq id no:8."
https://patents.google.com/patent/WO2021229561A1/en, Gln Ser Ala Leu Thr Gln Pro Val Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Arg Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Ile Ile Tyr Asp Val Lys Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Arg Ser Ser Thr Leu Asp Val Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Pro Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Gly Pro Ala Ile Ala Ala Ala Ala Thr Gly Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(193/194)  or i. a heavy chain variable region comprising the amino acid sequence denoted by seq id no:193 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:194, or a variant thereof"
https://patents.google.com/patent/WO2021229561A1/en, Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Val Thr Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp His Val Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Phe Thr Phe Glu Asp Tyr Asp Met Gln Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Gly Gly Ile Ile Gly Tyr Gly Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Gly Glu Asp Thr Ala Leu Tyr Ser Cys Ala Lys Ala Leu His Ser Gly Asp Asp Ser Gly Gln Gln Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(147/148) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:147 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:148, or a variant thereof; or m"
https://patents.google.com/patent/WO2021229561A1/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Val Thr Val Ser Ser Asn Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gln Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Ala Ile Arg Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Gly Ser Trp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Ala Gly Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(25/26) (e) a heavy chain variable region of the amino acid sequence denoted by seq id no:25 or a variant thereof and a light chain variable region of the amino acid sequence denoted by seq id no:26, or a variant thereof"
https://patents.google.com/patent/WO2021229561A1/en, Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Arg Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys ,,  Homo sapiens  ,,(199/200) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:199 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:200
https://patents.google.com/patent/WO2021229561A1/en, Gln Ser Val Leu Thr Gln Pro Pro Ser Ile Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Xaa Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Thr Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Asp Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Gly Ser Asp Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,  Xaa can be any naturally occurring amino acid  ,  Homo sapiens  ,"(153/154) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:153 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:154, or a variant thereof; or p"
https://patents.google.com/patent/WO2021229561A1/en, Gln Val Thr Leu Lys Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu His Val Ser Ala Ile Ser Ser Asp Gly Gly Ile Thr Tyr Phe Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Phe Leu Gln Met Ser Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Asp Gln Asp Ser Asn Ser Trp Tyr Asp Ala Phe Asp Ile Trp Gly Arg Gly Thr Met Val Thr Val Ser Ser , Val Ile Trp Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(27/28) (f) a heavy chain variable region of the amino acid sequence denoted by seq id no:27 or a variant thereof and a light chain variable region of the amino acid sequence denoted by seq id no:28, or a variant thereof"
https://patents.google.com/patent/WO2021229561A1/en, Gln Met Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Thr Tyr Val Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu His Val Ser Gly Ile Ser Ser Asp Gly Gly Ile Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Asp Gln Asp Ser Ser Ser Trp Tyr Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asn Ile Arg Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Thr Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys His Gln Thr Tyr Thr Ser Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(19/20) (b) a heavy chain variable region of the amino acid sequence denoted by seq id no:19 or a variant thereof and a light chain variable region of the amino acid sequence denoted by seq id no:20, or a variant thereof"
https://patents.google.com/patent/WO2021229561A1/en, Ser Ser Val Leu Thr Gln Pro Arg Ser Val Ser Gly Thr Pro Gly Gln Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Val Pro Lys Leu Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Ser Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ile Ser Ser Thr Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Pro Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Leu Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Gly Pro Ala Ile Ala Ala Ala Ala Thr Gly Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(159/160) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:159 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:160, or a variant thereof; or s"
https://patents.google.com/patent/WO2021229561A1/en, Asp Ile Val Met Thr Gln Ser Pro Leu Ser Ser Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Thr Gln Phe Pro Ile Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Gln Met Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Phe Asp Gly Ser Asn Lys Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp His Asp Asp Gly Tyr Tyr Phe Tyr Tyr Tyr Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(197/198) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:197 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:198, or a variant thereof; or l"
https://patents.google.com/patent/WO2021229561A1/en, Val Ile Arg Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys , Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Ala Glu Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Glu Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Ala Pro Ala Ile Thr Gly Ser Pro Glu Ala Tyr Ser Tyr Tyr Tyr Ser Val Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(175/176) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:175 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:176, or a variant thereof"
https://patents.google.com/patent/WO2021229561A1/en, Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Ala Ala Ser Ser Arg Ala Thr Gly Thr Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys , Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Arg Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Val Ser Leu Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(171/172) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:171 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:172, or a variant thereof; or y"
https://patents.google.com/patent/WO2021229561A1/en, Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Val Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ser Phe Ser Ser Tyr Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Thr Val Tyr Tyr Cys Ala Arg Asp Arg Gly Tyr Ser Ser Ser Gly Ser Asn Tyr Tyr Met Asp Val Trp Gly Lys Gly Thr Met Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(151/152) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:151 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:152, or a variant thereof; or o"
https://patents.google.com/patent/WO2021229561A1/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg His Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Ser Val Arg Gly Gly Met Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Val Ser Pro Glu Ile Ile Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(21/22) (c) a heavy chain variable region of the amino acid sequence denoted by seq id no:21 or a variant thereof and a light chain variable region of the amino acid sequence denoted by seq id no:22, or a variant thereof"
https://patents.google.com/patent/WO2021229561A1/en, Gln Met Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Leu Val Thr Ala Pro Ser Tyr Glu Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Ile Thr Val Ser Ser , Asn Phe Met Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser His His His Val Val Phe Gly Gly Gly Thr Lys Gly Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,"(23/24) (d) a heavy chain variable region of the amino acid sequence denoted by seq id no:23 or a variant thereof and a light chain variable region of the amino acid sequence denoted by seq id no:24, or a variant thereof"
https://patents.google.com/patent/WO2021229561A1/en, Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Gln Thr Ala Lys Ile Thr Cys Gly Glu Asn Asn Ile Gly Arg Arg Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Phe Asn Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Met Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Gly Ser Asp His Val Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Gln Trp Val Ser Tyr Ile Ser Ser Ser Gly Asn Thr Met Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp His Gly Ile Gly Tyr Glu Thr Glu Gly Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(149/150) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:149 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:150, or a variant thereof; or n"
https://patents.google.com/patent/WO2021229561A1/en, Ala Ile Arg Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asp Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Arg Asn Tyr Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(173/174) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:173 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:174, or a variant thereof; or z"
https://patents.google.com/patent/WO2021229561A1/en, Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Pro Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Ile Gly Gly Tyr Asn Leu Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Gly Thr Lys Arg Pro Ser Gly Val Ser Tyr Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser Pro Thr Leu Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Thr Thr Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Met Ala Tyr Gln Val Tyr Tyr Tyr Asp Ser Ser Gly Tyr Tyr Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(185/186) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:185 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:186, or a variant thereof; or f"
https://patents.google.com/patent/WO2021229561A1/en, Asp Ile Val Met Thr Gln Thr Pro Leu Ser Ser Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro Pro Arg Leu Leu Ile His Lys Thr Ser Asn Arg Phe Phe Gly Val Pro Glu Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Leu Gln Ala Thr Gln Phe Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ser Pro Ala Val Arg Gly Ser Pro Ser Asn Phe Tyr Tyr Tyr His Gly Met Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(177/178) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:177 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:178, or a variant thereof; or b"
https://patents.google.com/patent/WO2021229561A1/en, Leu Ala Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ala Lys Ser Val His Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Val Leu Val Val Phe Asp Asp Ser Asp Arg Pro Pro Gly Ile Pro Glu Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp His Val Ile Phe Gly Gly Gly Thr Lys Val Thr Val Leu , Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Arg Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(145/146) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:145 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:146, or a variant thereof; or l"
https://patents.google.com/patent/WO2021229561A1/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Thr Tyr Val Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu His Val Ser Gly Ile Ser Ser Asp Gly Gly Ile Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Asp Gln Asp Ser Ser Ser Trp Tyr Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Leu Gly Lys Ala Pro Lys Leu Leu Thr Tyr Ala Ala Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Ala Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Thr Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(17/18) (a) a heavy chain variable region of the amino acid sequence denoted by seq id no:17 or a variant thereof and a light chain variable region of the amino acid sequence denoted by seq id no:18, or a variant thereof"
https://patents.google.com/patent/WO2021229561A1/en, Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Gly Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Leu Ala Pro Met Leu Leu Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Ala Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Ser Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Val Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Ala Gly Glu Trp Gly Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(165/166) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:165 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:166, or a variant thereof; or v"
https://patents.google.com/patent/WO2021229561A1/en, Asn Phe Met Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Ser Ile Thr Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Val Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , Gln Val Gln Leu Val Gln Ser Gly Ala Gly Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Pro Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ser Arg Val Ala Gly Thr Pro Asn Trp Phe His Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(191/192) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:191 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:192, or a variant thereof; or i"
https://patents.google.com/patent/WO2021229561A1/en, Gln Ser Val Val Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Ser Ser Ser Asp Ile Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Phe Glu Gly Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Arg Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Ala Glu Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Arg Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Val Ala Ala Pro Val Ile Thr Gly Ser Pro Glu Ala Tyr Ser Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(179/180) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:179 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:180, or a variant thereof; or c"
https://patents.google.com/patent/WO2021229561A1/en, Asn Phe Met Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Lys Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ala Trp Asp Asp Ser Leu Arg Gly Tyr Val Phe Gly Pro Gly Thr Lys Val Thr Val Leu , Gln Val Gln Leu Gln Glu Ser Gly Ala Glu Val Lys Lys Leu Gly Leu Ser Glu Gly Leu Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Ala Glu Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Ala Pro Val Ile Thr Gly Ser Pro Glu Ala Tyr Ser Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(183/184) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:183 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:184, or a variant thereof; or e"
https://patents.google.com/patent/WO2021229561A1/en, Gln Ser Val Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Gln Trp Val Ala Leu Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gly Ser Gly Trp Tyr Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(189/190) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:189 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:190, or a variant thereof; or h"
https://patents.google.com/patent/WO2021229561A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Gly Leu Ser Cys Ala Ala Ser Gly Val Thr Val Ser Ser Asn Tyr Met Asn Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Ala Val Ala Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ile Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(29/30) (g) a heavy chain variable region of the amino acid sequence denoted by seq id no:29 or a variant thereof and a light chain variable region of the amino acid sequence denoted by seq id no:30, or a variant thereof"
https://patents.google.com/patent/WO2021229561A1/en, Gln Ser Ala Leu Thr Gln Pro Arg Ser Val Ser Gly Ser Leu Gly Gln Ser Val Thr Ile Ser Cys Ala Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Arg Val Ser Trp Tyr Gln Gln Thr Pro Gly Thr Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Asp Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ser Ser Ser Ser Thr Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Arg Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Gly Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(161/162) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:161 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:162, or a variant thereof; or t"
https://patents.google.com/patent/WO2021229561A1/en, Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Arg Val Thr Leu Ser Cys Thr Gly Asn Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Ala Ala Pro Lys Leu Leu Ile Tyr Gly Asn Thr Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Leu Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Ala Glu Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Ala Pro Val Ile Thr Gly Ser Pro Glu Ala Tyr Ser Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(155/156) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:155 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:156, or a variant thereof; or q"
https://patents.google.com/patent/WO2021229561A1/en, Gln Ser Ala Leu Thr Gln Pro Ala Ser Leu Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Leu Val Ser Trp Tyr Gln Gln His Pro Gly Lys Thr Pro Lys Val Ile Ile Tyr Glu Val Thr Asn Arg Ala Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Gln Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Arg Thr Ser Thr Leu Asp Val Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Thr Thr Gly Ser Thr Ser Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Met Ala Tyr Gln Val Tyr Tyr Tyr Asp Ser Ser Gly Tyr Tyr Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(181/182) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:181 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:182, or a variant thereof; or d"
https://patents.google.com/patent/WO2021229561A1/en, Ser Tyr Glu Leu Thr Gln Pro Arg Ser Ile Ser Gly Ser Pro Gly Gln Ser Val Ala Ile Ser Cys Thr Gly Thr Asn Asn Asp Ile Gly Gly Tyr Asn Leu Val Ser Trp Tyr Gln Gln His Pro Gly Lys Val Pro Lys Leu Met Ile Tyr Glu Val Asp Gln Arg Pro Ser Gly Val Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Asp Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Thr Asp Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr Asn Thr His Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Ala Glu Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Ala Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Ala Pro Val Ile Thr Gly Ser Pro Glu Ala Tyr Ser Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(157/158) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:157 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:158, or a variant thereof; or r"
https://patents.google.com/patent/WO2021229561A1/en, Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser His Asp Ile Gly Gly Tyr Val Ala Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Thr Ser Ser Arg Ala Thr Gly Ile Ala Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Thr Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Arg Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(169/170) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:169 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:170, or a variant thereof; or x"
https://patents.google.com/patent/WO2021229561A1/en, Val Ile Arg Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Asn Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Gly Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Val Pro Pro Ser Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Arg Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ile Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Asp Val Val Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(163/164) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:163 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:164, or a variant thereof; or u"
https://patents.google.com/patent/WO2021229561A1/en, Ser Tyr Glu Leu Ile Gln Glu Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Asn Arg Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Asp Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Asn Ser Gly Asn His Pro Phe Gly Gly Gly Thr Lys Val Thr Val Leu , Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Ala Glu Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Ala Pro Val Ile Thr Gly Ser Pro Glu Ala Tyr Ser Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(195/196) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:195 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:196, or a variant thereof; or k"
https://patents.google.com/patent/WO2021229561A1/en, Gln Ser Ala Leu Thr Gln Pro Ala Ser Ala Ser Gly Ser Pro Gly Gln Ser Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asp Val Gly Gly Tyr Asn Phe Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Ile Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu Gln Ala Asp Asp Glu Ala Leu Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser Asn Asn Tyr Val Phe Gly Pro Gly Thr Lys Val Thr Val Leu , Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Pro Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Gly Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ser Arg Val Ala Gly Thr Pro Asn Trp Phe His Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(187/188) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:187 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:188, or a variant thereof; or g"
https://patents.google.com/patent/WO2021229561A1/en, Leu Pro Gly Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Pro Ile Ile Phe Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Phe Thr Phe Glu Asp Tyr Asp Met Gln Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Gly Gly Ile Ile Gly Tyr Gly Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Gly Glu Asp Thr Ala Leu Tyr Ser Cys Ala Lys Ala Leu His Ser Gly Asp Asp Ser Gly Gln Gln Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(143/144) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:143 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:144, or a variant thereof; or k"
https://patents.google.com/patent/WO2021229561A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg His Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Ser Val Arg Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Pro Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(31/32)  a heavy chain variable region of the amino acid sequence denoted by seq id no:31 or a variant thereof and a light chain variable region of the amino acid sequence denoted by seq id no:32, or a variant thereof. "
https://patents.google.com/patent/WO2021229561A1/en, Asp Ile Val Met Thr Gln Thr Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Val Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Ile Thr Pro Tyr Ser Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Arg Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(167/168) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:167 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:168, or a variant thereof; or w"
https://patents.google.com/patent/WO2021229561A1/en, Gln Ser Ala Leu Thr Gln Pro Pro Ser Ala Ser Gly Ser Pro Gly Gln Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ala Phe Asn Tyr Val Ser Trp Tyr Gln His His Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Val Thr Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu Leu Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Tyr Ala Gly Ser Asn Asn Phe Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , Gln Val Gln Leu Val Gln Ser Gly Gly Arg Val Val Arg Pro Gly Val Pro Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Val Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Ala Pro Leu Gly Glu Leu Leu Pro Gly Asp Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,  Homo sapiens  ,  Homo sapiens  ,"(141/142) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:141 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:142, or a variant thereof; or j "
https://patents.google.com/patent/WO2021180604A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Ser Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ala Gly Ile Pro Val Ala Gly Leu Ala Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys ,   Homo sapiens  ,   Homo sapiens  ,(6/5)  virus neutralization assay for the 49fl antibody having the vh domain of seq id no:6 and the vl domain of seq id no:5 (sup. 42-2
https://patents.google.com/patent/WO2021180604A1/en, Gln Val His Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Gly Pro Gly Lys Gly Leu Glu Gly Val Ala Gly Ile Trp Phe Asp Gly Ser His Glu Tyr Tyr Ala Asp Ala Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Glu Met Ser Ser Leu Arg Ala Gly Asp Thr Gly Ile Tyr Tyr Cys Ala Arg Gly Gly Asp Ile Leu Thr Pro Trp Gly Gln Gly Ser Leu Val Ile Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Phe Arg Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr His Cys Gln Gln Tyr Asn Ser Trp Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys ,   Homo sapiens  ,   Homo sapiens  ,"(4/3) in some embodiments, the antibody comprises a light chain variable region of the amino acid sequence of seq id no:3 and a heavy chain variable region of the amino acid sequence of seq id no:4"
https://patents.google.com/patent/WO2021180604A1/en, Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Gly Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Gly Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,   Homo sapiens  ,   Homo sapiens  ,(47/48) the vh domain of the 49fl antibody can bind to either of the alternative vl domains of seq id no:47 and 48
https://patents.google.com/patent/WO2021180604A1/en, Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Gly Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Ser Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ala Gly Ile Pro Val Ala Gly Leu Ala Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys ,   Homo sapiens  ,   Homo sapiens  ,"(73/75) , wherein the antibody comprises two heavy and two light chains, wherein each heavy chain comprises the amino acid sequence of seq id no:75,  and wherein each light chain comprises the amino acid sequence of seq id no:73."
https://patents.google.com/patent/WO2021180604A1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ser Val Ser Gly Gly Ser Ile Ser Ser His Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn His Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Val Leu Leu Trp Phe Gly Glu Pro Ile Phe Glu Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Pro Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,   Homo sapiens  ,   Homo sapiens  ,"(65/66) , wherein the antibody comprises two heavy and two tight chains,  wherein each heavy chain comprises the amino acid sequence of seq id no:65, and wherein each light chain comprises the amino acid sequence of seq id no:66. "
https://patents.google.com/patent/WO2021180604A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Ser Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ala Gly Ile Pro Val Ala Gly Leu Ala Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Gly Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,   Homo sapiens  ,   Homo sapiens  ,"(6/47) in some embodiments, the antibody comprises a light chain variable region of the amino acid sequence of seq id no:47 and a heavy chain variable region of the amino acid sequence of seq id no:6"
https://patents.google.com/patent/WO2021180604A1/en, Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Pro Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ser Val Ser Gly Gly Ser Ile Ser Ser His Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn His Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Val Leu Leu Trp Phe Gly Glu Pro Ile Phe Glu Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser ,   Homo sapiens  ,   Homo sapiens  ,"(9/10) , wherein the antibody comprises two heavy and two light chains, wherein each heavy chain comprises a heavy chain variable region of the amino acid sequence of seq id no:10, and wherein each light chain comprises a light chain variable region of the amino acid sequence of seq id no:9. "
https://patents.google.com/patent/WO2021180604A1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ser Val Ser Gly Gly Ser Ile Ser Ser His Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn His Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Val Leu Leu Trp Phe Gly Glu Pro Ile Phe Glu Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Pro Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,   Homo sapiens  ,   Homo sapiens  ,"(10/9) in some embodiments, the antibody comprises a heavy chain variable region of the amino acid sequence of seq id no:10 and a light chain variable region of the amino acid sequence of seq id no:9"
https://patents.google.com/patent/WO2021180604A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Gly Pro Gly Lys Gly Leu Glu Gly Val Ala Gly Ile Trp Phe Asp Gly Ser His Glu Tyr Tyr Ala Asp Ala Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Glu Met Ser Ser Leu Arg Ala Gly Asp Thr Gly Ile Tyr Tyr Cys Ala Arg Gly Gly Asp Ile Leu Thr Pro Trp Gly Gln Gly Ser Leu Val Ile Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Phe Arg Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr His Cys Gln Gln Tyr Asn Ser Trp Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys ,   Homo sapiens  ,   Homo sapiens  ,"(7/3) in some embodiments, the antibody comprises a light chain variable region of the amino acid sequence of seq id no:3 and a heavy chain variable region of the amino acid sequence of seq id no:7"
https://patents.google.com/patent/WO2021180604A1/en, Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Pro Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ser Val Ser Gly Gly Ser Ile Ser Ser His Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn His Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Val Leu Leu Trp Phe Gly Glu Pro Ile Phe Glu Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys ,   Homo sapiens  ,   Homo sapiens  ,"(66/65) , wherein the antibody comprises two heavy and two light chains, wherein each heavy chain comprises the amino acid sequence of seq id no:65, and wherein each light chain comprises the amino acid sequence of seq id no:66."
https://patents.google.com/patent/WO2021180604A1/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ile Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Gly Ser Gly Asn His Ile His Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ser Lys Ser Thr Leu Tyr Leu His Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Gly Gly Leu Tyr Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Glu Thr Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Asn Asn Trp Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys ,   Homo sapiens  ,   Homo sapiens  ,"(2/1) in some embodiments, the antibody comprises a light chain variable region of the amino acid sequence of seq id no:1 and a heavy chain variable region of the amino acid sequence of seq id no:2"
https://patents.google.com/patent/WO2021180604A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Ser Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ala Gly Ile Pro Val Ala Gly Leu Ala Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Gly Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,   Homo sapiens  ,   Homo sapiens  ,"(6/48) in some embodiments, the antibody comprises a light chain variable region of the amino acid sequence of seq id no:48 and a heavy chain variable region of the amino acid sequence of seq id no:6"
https://patents.google.com/patent/WO2021180604A1/en, Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Gly Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Gly Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,   Homo sapiens  ,   Homo sapiens  ,"(48/47) the vh domain of the 49fl antibody can bind to either of the alternative vl domains of seq id no:47 and 48. accordingly, in some embodiments, the first antibody is an anti-sars2-s antibody that binds to the same epitope as an antibody comprising a light chain variable region of the amino acid sequence of seq id no:47 and a heavy chain variable region of the amino acid sequence of seq id no:6. in some embodiments, the first antibody is an anti-sars2-s antibody that binds to the same epitope as an antibody comprising a light chain variable region of the amino acid sequence of seq id no:48 and a heavy chain variable region of the amino acid sequence of seq id no:6. "
https://patents.google.com/patent/WO2022029494A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Gln Leu Val Arg Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile Asp Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Arg Phe Lys Asp Lys Ala Thr Leu Thr Val Asp Arg Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Ser Leu Leu Arg Gly Val Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Cys , Ser Ile Val Met Thr Gln Thr Pro Lys Phe Leu Leu Val Ser Ala Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ser Asn Asp Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Ser Thr Val Gln Ala Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Ser ,  Synthetic peptide  ,  Synthetic peptide  ,"(17/18) in some embodiments, the first antibody or antigen-binding fragment thereof comprises a heavy chain variable region amino acid sequence having at least 70% identity to seq id no:17 and a light chain variable region amino acid sequence having at least 70% identity to seq id no:18"
https://patents.google.com/patent/WO2022029494A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Gln Leu Val Arg Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile Asp Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Arg Phe Lys Asp Lys Ala Thr Leu Thr Val Asp Arg Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Ser Leu Leu Arg Gly Val Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Ser Ile Val Met Thr Gln Thr Pro Lys Phe Leu Leu Val Ser Ala Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ser Asn Asp Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Ser Thr Val Gln Ala Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Synthetic peptide  ,  Synthetic peptide  ,"(7/8) in some embodiments, the first antibody or antigen-binding fragment thereof comprises a heavy chain variable region amino acid sequence having at least 70% identity to seq id no:7 and a light chain variable region amino acid sequence having at least 70% identity to seq id no:8"
https://patents.google.com/patent/WO2022029494A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Tyr Trp Gly Ser Gly Tyr His Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Cys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Pro Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Arg Ser Ser Asp Leu Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Ser Ser ,  Synthetic peptide  ,  Synthetic peptide  ,"(15/16) in some embodiments, the second antibody or antigen-binding fragment thereof comprises a heavy chain variable region amino acid sequence having at least 70% identity to seq id no:15 and a light chain variable region amino acid sequence having at least 70% identity to seq id no:16"
https://patents.google.com/patent/WO2021186190A1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ala Gly Asn Ser Lys Leu Arg Phe Phe Asp Trp Leu Leu Thr Met Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Asp Ile Gln Leu Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Ala Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(50/58) preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising or consisting of seq id no:50 and a light chain variable region comprising or consisting of seq id no:58"
https://patents.google.com/patent/WO2021186190A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Trp Ile Asn Ala Gly Asn Gly Asn Thr Lys Tyr Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg His Met Val Val Pro Ala Ala Val Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ala Ile Gln Leu Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Gly Thr Phe Gly Gln Gly Thr Lys Trp Ile Ser Asn ,  Homo sapiens  ,  Homo sapiens  ,"(18/26) preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising or consisting of seq id no:18 and a light chain variable region comprising or consisting of seq id no:26"
https://patents.google.com/patent/WO2021186190A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Gly Thr Ala Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Phe Gly Gly Pro Ser Val Trp Leu Leu Leu Leu Leu Leu Arg Tyr Gly Arg , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,"(66/74) preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising or consisting of seq id no:66 and a light chain variable region comprising or consisting of seq id no:74"
https://patents.google.com/patent/WO2021186190A1/en, Leu Val Gln Leu Gln Glu Ser Gly Pro Arg Leu Val Thr Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser Arg His Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Met Gly Leu Glu Trp Ile Gly Ser Ile Asp Tyr Ser Gly Gly Thr Tyr Cys Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Glu Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Val Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gln Val Gly His Ser Gly Arg Gly His Asn Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Tyr Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Phe Leu Ile Tyr Ala Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ser Ser Val Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(34/42) preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising or consisting of seq id no:34 and a light chain variable region comprising or consisting of seq id no:42"
https://patents.google.com/patent/KR20220010402A/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr His Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No.139 HC variable region , No.139 LC variable region ,"(2018/2017)  according to claim 1, the antibody or antigen-binding fragment thereof light chain variable region of the polypeptide sequence of seq id no:2017; and heavy chain variable region of the polypeptide sequence of seq id no:2018 a method comprising "
https://patents.google.com/patent/CN111303279B/en, caggttcagc tggtggaaag cggtggtgga ttagtgcaac caggtggaag cctccgcctg agctgcgccg cgtcaggtgg taacgctgct gaacgtatgg ctgggtggtt ccgtcaggct ccgggcaaag gcctggaagc agttgcggcc atttactacg ctaaattcgg tccgtattac gcggattccg ttaagggccg ttttacgatc agccgtgata attcaaagaa cacgctttat ctgcagatga acagcctgcg cgctgaagat actgcggtct actattgcgc ggcagaagct ttcgttcagt ctccgtactc tggttctcat actactaaat attggggcca ggggacccaa gtaacagtta gcagt ,, Artificial Sequence (Artificial Sequence),,(8) the nucleic acid molecule encoding the single domain antibody 3f11 is shown in seq id no:8.
https://patents.google.com/patent/CN111303279B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Gly Asn Ala Ala Glu Arg Met Ala Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Ala Val Ala Ala Ile Tyr Tyr Ala Lys Phe Gly Pro Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Glu Ala Phe Val Gln Ser Pro Tyr Ser Gly Ser His Thr Thr Lys Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(3)  a single domain antibody as set forth in seq id no:3 or a functionally active variant thereof;
https://patents.google.com/patent/CN111303279B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ala Gln Ser Lys Trp Ala Tyr Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Ala Val Ala Ala Ile Asp Val Ala Thr Gly Pro Trp Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala His His Ile Pro Thr Lys His Pro Ala Phe Pro Asp Phe Arg Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(2)  a single domain antibody as set forth in seq id no:2 or a functionally active variant thereof;
https://patents.google.com/patent/CN111303279B/en, caggttcagc tggtggaaag cggtggtgga ttagtgcaac caggtggaag cctccgcctg agctgcgccg cgtcaggtgc tgacgctttc gttatcatcg gtgggtggtt ccgtcaggct ccgggcaaag gcctggaagc agttgcggcc attgcttgga ctgaccagca tgaatattac gcggattccg ttaagggccg ttttacgatc agccgtgata attcaaagaa cacgctttat ctgcagatga acagcctgcg cgctgaagat actgcggtct actattgcgc ggcacaggac tctgcttaca tcaaatctaa aggttctcgt gcttacgaat attggggcca ggggacccaa gtaacagtta gcagt ,, Artificial Sequence (Artificial Sequence),,(6) the nucleic acid molecule encoding the single domain antibody 1e2 is shown in seq id no:6.
https://patents.google.com/patent/CN111303279B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asn Ile Asp Ser Thr Arg Tyr His Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Ala Val Ala Ala Ile Lys Gly Val Trp Pro Glu Asp Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Asp Gln Tyr Glu Trp Trp Val Pro Gly Glu Val Gly Pro Tyr Leu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(4)  a single domain antibody as set forth in seq id no:4 or a functionally active variant thereof;
https://patents.google.com/patent/CN111303279B/en, caggttcagc tggtggaaag cggtggtgga ttagtgcaac caggtggaag cctccgcctg agctgcgccg cgtcaggtaa catcgactct actcgttacc atgggtggtt ccgtcaggct ccgggcaaag gcctggaagc agttgcggcc attaaaggtg tttggccgga agactattac gcggattccg ttaagggccg ttttacgatc agccgtgata attcaaagaa cacgctttat ctgcagatga acagcctgcg cgctgaagat actgcggtct actattgcgc ggcagaccag tacgaatggt gggttccggg tgaagttggt ccgtacctgt attggggcca ggggacccaa gtaacagtta gcagt ,, Artificial Sequence (Artificial Sequence),,(9) the nucleic acid molecule encoding the single domain antibody 4d8 is shown in seq id no:9.
https://patents.google.com/patent/CN111303279B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ala Asp Ala Phe Val Ile Ile Gly Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Ala Val Ala Ala Ile Ala Trp Thr Asp Gln His Glu Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Gln Asp Ser Ala Tyr Ile Lys Ser Lys Gly Ser Arg Ala Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(1)  a single domain antibody as set forth in seq id no:1 or a functionally active variant thereof;
https://patents.google.com/patent/CN111303279B/en, caggttcagc tggtggaaag cggtggtgga ttagtgcaac caggtggaag cctccgcctg agctgcgccg cgtcaggtct ggctcagtct aaatgggctt acgggtggtt ccgtcaggct ccgggcaaag gcctggaagc agttgcggcc attgacgttg ctactggtcc gtggtattac gcggattccg ttaagggccg ttttacgatc agccgtgata attcaaagaa cacgctttat ctgcagatga acagcctgcg cgctgaagat actgcggtct actattgcgc ggcacatcat atcccgacta aacatccggc tttcccggac ttccgtgact attggggcca ggggacccaa gtaacagtta gcagt ,, Artificial Sequence (Artificial Sequence),,(7) the nucleic acid molecule encoding the single domain antibody 2f2 is shown in seq id no:7.
https://patents.google.com/patent/CN111303279B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Gln Ala Val Val Phe Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Ala Val Ala Ala Ile His Val Pro Ala Lys Asn Arg Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala His Tyr Glu Phe Asn Asp Phe Val Trp Gln Gly Tyr Ser Ser Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(5)  a single domain antibody as set forth in seq id no:5 or a functionally active variant thereof.
https://patents.google.com/patent/CN111303279B/en, caggttcagc tggtggaaag cggtggtgga ttagtgcaac caggtggaag cctccgcctg agctgcgccg cgtcaggtcg tcaggctgtt gttttcgggt ggttccgtca ggctccgggc aaaggcctgg aagcagttgc ggccattcat gttccggcta aaaaccgtta ttacgcggat tccgttaagg gccgttttac gatcagccgt gataattcaa agaacacgct ttatctgcag atgaacagcc tgcgcgctga agatactgcg gtctactatt gcgcggcaca ttacgaattc aacgacttcg tttggcaggg ttactcttct gactattggg gccaggggac ccaagtaaca gttagcagt ,, Artificial Sequence (Artificial Sequence),,(10) the nucleic acid molecule encoding the single domain antibody 5f8 is shown in seq id no:10.
https://patents.google.com/patent/WO2021239935A1/en, Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Leu Arg Phe Ala Met Asn Trp Leu Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asp Thr Asn Thr Gly Thr Pro Thr Tyr Ala Gln Gly Phe Thr Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr Leu Gln Ile Ser Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Leu Arg Gly Ala Asn Leu Val Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Val Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Gln Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Phe Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Heavy chain of antibody FnC1t2p1_G5  , Light chain of antibody FnC1t2p1_G5  ,"(11/12) , fnc1t2p1_g5 (with the variable region heavy chain amino acid sequence of seq id no:11 and the variable region light chain amino acid sequence of seq id no:12"
https://patents.google.com/patent/WO2021239935A1/en, Gln Met Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Thr Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Ser Ser Ala Val Gln Trp Val Arg Gln Ala Arg Gly Gln Arg Leu Glu Trp Ile Gly Trp Ile Val Val Gly Ser Gly Asn Thr Asp Tyr Ala Gln Lys Phe Gln Glu Arg Val Thr Ile Thr Arg Asp Val Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Pro Arg Cys Ser Gly Gly Ser Cys Tyr Asp Gly Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln His Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Cys Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Heavy chain of antibody MnC5t2p1_G1  , Light chain of antibody MnC5t2p1_G1  ,"(25/26) , mnc5t2p1_g1 (with the variable region heavy chain amino acid sequence of seq id no:25 and the variable region light chain amino acid sequence of seq id no:26"
https://patents.google.com/patent/WO2021239935A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Asn Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val Gly Trp Ile His Ser Leu Ser Gly Gly Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Leu Thr Arg Asp Ala Pro Ile Arg Thr Ala Tyr Met Glu Leu Ser Gly Leu Gly Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Ser Val Ala Thr Ile Thr Asp Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Gly Asp Ile Gly Ser Tyr Asn Leu Val Ser Trp Tyr Gln Gln Tyr Pro Gly Lys Ala Pro Lys Leu Ile Ile Tyr Glu Ala Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Phe Ala Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Cys Ser Tyr Ala Gly Val Arg Thr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Heavy chain of antibody CnC2t1p1_G6  , Light chain of antibody CnC2t1p1_G6  ,"(41/42) , cnc2t1p1_g6 (with the variable region heavy chain amino acid sequence of seq id no:41 and the variable region light chain amino acid sequence of seq id no:42"
https://patents.google.com/patent/WO2021239935A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly His Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Val Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Gly Gly Ile Leu Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Arg Ser Leu Arg Thr Asp Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Leu Arg Arg Gln Asp Tyr Tyr Ala Asp Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Leu Ser Ala Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Asn Ser Phe Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Val , Heavy chain of antibody MnC4t2p1_E6  , Light chain of antibody MnC4t2p1_E6  ,"(51/52) , mnc4t2p1_e6 (with the variable region heavy chain amino acid sequence of seq id no:51 and the variable region light chain amino acid sequence of seq id no:52"
https://patents.google.com/patent/WO2021239935A1/en, Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Leu Arg Phe Ala Met Asn Trp Leu Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asp Thr Asn Thr Gly Thr Pro Thr Tyr Ala Gln Gly Phe Thr Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr Leu Gln Ile Ser Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Leu Arg Gly Ala Asn Leu Val Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Val Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Gln Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Phe Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Heavy chain of antibody FnC1t2p1_D4  , Light chain of antibody FnC1t2p1_D4  ,"(9/10) , fnc1t2p1_d4 (with the variable region heavy chain amino acid sequence of seq id no:9 and the variable region light chain amino acid sequence of seq id no:10"
https://patents.google.com/patent/WO2021239935A1/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn Tyr Ala Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Asp Ser Gly Asp Arg Thr Tyr Asn Ala Asp Ser Val Lys Gly Arg Phe Ser Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu His Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Leu Ala Ser Gly Ser Tyr Phe Gly Gly Ala Asn Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Pro Val Thr Ser Asp His Tyr Pro Tyr Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Thr Thr Leu Ile Tyr Asp Thr Asn Asn Lys His Ser Trp Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Ala Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Leu Leu Ser Tyr Thr Gly Ala Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Heavy chain of antibody MnC1t3p1_G9  , Light chain of antibody MnC1t3p1_G9  ,"(35/36) , mnc1t3p1_g9 (with the variable region heavy chain amino acid sequence of seq id no:35 and the variable region light chain amino acid sequence of seq id no:36"
https://patents.google.com/patent/WO2021239935A1/en, Gln Met Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Thr Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Ser Ser Ala Val Gln Trp Val Arg Gln Ala Arg Gly Gln Arg Leu Glu Trp Ile Gly Trp Ile Val Val Gly Ser Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln Glu Arg Val Thr Ile Thr Arg Asp Met Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Pro His Cys Ser Ser Thr Ile Cys Tyr Asp Gly Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Val Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Heavy chain of antibody HbnC3t1p1_C6  , Light chain of antibody HbnC3t1p1_C6  ,"(1/2) 2. antibody or binding fragment according to claim 1 , wherein the antibody or binding fragment thereof comprises the combination of the variable region heavy chain sequence and of the variable region light chain sequence of one antibody selected from the group comprising hbnc3t1p1_c6 (with the variable region heavy chain amino acid sequence of seq id no:1 and the variable region light chain amino acid sequence of seq id no:2"
https://patents.google.com/patent/WO2021239935A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Gly Asp Tyr Ala Met Ser Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Phe Ile Arg Ser Lys Ala Tyr Gly Gly Thr Thr Glu Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Val Arg Arg Leu Trp Phe Gly Ser Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Gly Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Heavy chain of antibody CnC2t1p1_E12  , Light chain of antibody CnC2t1p1_E12  ,"(27/28) , cnc2t1p1_e12 (with the variable region heavy chain amino acid sequence of seq id no:27 and the variable region light chain amino acid sequence of seq id no:28"
https://patents.google.com/patent/WO2021239935A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Glu Leu Leu Gly Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Leu Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Gly Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Cys Ser Tyr Ala Gly Ser Ser Thr Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Heavy chain of antibody CnC2t1p1_B4  , Light chain of antibody CnC2t1p1_B4  ,"(19/20) , cnc2t1p1_b4 (with the variable region heavy chain amino acid sequence of seq id no:19 and the variable region light chain amino acid sequence of seq id no:20"
https://patents.google.com/patent/WO2021239935A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Thr Gly Phe Thr Phe Arg Arg Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Gly Ile Leu Phe Asp Gly Ser Asn Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Ser Arg Asn Thr Leu Tyr Leu Gln Leu Asn Ser Leu Arg Arg Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Gly Asp Tyr Glu Trp Glu Leu Leu Glu Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Asp Asn Trp Leu Ala Trp Tyr Gln Glu Lys Pro Gly Lys Ala Pro Lys Val Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Arg Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Gly Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr His Ser Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys , Heavy chain of antibody HbnC3t1p1_F4  , Light chain of antibody HbnC3t1p1_F4  ,"(21/22) , hbnc3t1p1_f4 (with the variable region heavy chain amino acid sequence of seq id no:21 and the variable region light chain amino acid sequence of seq id no:22"
https://patents.google.com/patent/WO2021239935A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Ser Ser Ser Ser Asn Thr Arg Tyr Tyr Thr Asp Ser Val Met Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Ser Lys Gly Phe Cys Ser Gly Gly Ser Cys Ser Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Val Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Val Val Tyr Tyr Cys His Gln Tyr Gly Ser Ser Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Heavy chain of antibody MnC4t1p1_A11  , Light chain of antibody MnC4t1p1_A11  ,"(53/54) , mnc4t1p1_a11 (with the variable region heavy chain amino acid sequence of seq id no:53 and the variable region light chain amino acid sequence of seq id no:54"
https://patents.google.com/patent/WO2021239935A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Arg Asn Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Ile Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Ala Arg Arg Pro Val Val Thr Asp Thr Met Ala Tyr Tyr Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Leu Ser Leu Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Thr Trp Thr Phe Gly Gln Gly Thr Lys Ala Glu Ile Lys Arg , Heavy chain of antibody HbnC2t1p2_D9  , Light chain of antibody HbnC2t1p2_D9  ,"(23/24) , hbnc2t1p2_d9 (with the variable region heavy chain amino acid sequence of seq id no:23 and the variable region light chain amino acid sequence of seq id no:24"
https://patents.google.com/patent/WO2021239935A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly His Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Val Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Gly Gly Ile Leu Asp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu His Met Arg Ser Leu Arg Thr Asp Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Leu Arg Arg Gln Asp Tyr Tyr Ala Asp Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Ile Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Leu Ser Ala Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Asn Ser Phe Pro Phe Thr Phe Gly Pro Gly Thr Ile Val Asp Val , Heavy chain of antibody MnC4t2p1_B3  , Light chain of antibody MnC4t2p1_B3  ,"(15/16) , mnc4t2p1_b3 (with the variable region heavy chain amino acid sequence of seq id no:15 and the variable region light chain amino acid sequence of seq id no:16"
https://patents.google.com/patent/WO2021239935A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Tyr Gly Asp Tyr Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Ser Gly Ala Ser Ser Arg Ala Ala Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Arg Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Heavy chain of antibody HbnC3t1p2_B10  , Light chain of antibody HbnC3t1p2_B10  ,"(5/6) , hbnc3t1p2_b10 with the variable region heavy chain amino acid sequence of seq id no:5 and the variable region light chain amino acid sequence of seq id no:6"
https://patents.google.com/patent/WO2021239935A1/en, Gln Leu Gln Val Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Asn His Tyr Phe Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Ala Trp Ile Gly Ser Met His Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Val Asn Tyr Tyr Asp Arg Asn Gly Tyr Tyr Arg Asn Asp Gly Phe Asp Ile Arg Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp Leu Gly Trp Tyr Glu Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile Tyr Ala Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Thr Tyr Pro Phe Thr Phe Gly Pro Gly Thr Arg Val Asp Ile Lys , Heavy chain of antibody MnC4t1p1_A10  , Light chain of antibody MnC4t1p1_A10  ,"(49/50) , mnc4t1p1_a10 (with the variable region heavy chain amino acid sequence of seq id no:49 and the variable region light chain amino acid sequence of seq id no:50"
https://patents.google.com/patent/WO2021239935A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Thr Gly Phe Thr Phe Arg Arg Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Gly Ile Leu Phe Asp Gly Ser Asn Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Ser Arg Asn Thr Leu Tyr Leu Gln Leu Asn Ser Leu Arg Arg Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Gly Asp Tyr Glu Trp Glu Leu Leu Glu Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Asp Asn Trp Leu Ala Trp Tyr Gln Glu Lys Pro Gly Lys Ala Pro Lys Val Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Arg Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Gly Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr His Ser Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Complete heavy chain of antibody DZIF-10c (HbnC3t1p1_F4(-K))  , Complete light chain of antibody DZIF-10c (HbnC3t1p1_F4(-K))  ,(229/230) ; heavy chain sequence of seq id no:229 and light chain sequence of seq id no:230
https://patents.google.com/patent/WO2021239935A1/en, Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ile Phe Ile Asn Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Thr Asn Thr Gly Asn Pro Thr Tyr Ala Gln Asp Phe Thr Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Leu Ser Thr Ala Tyr Leu Gln Ile Ser Ser Leu Glu Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ile Gly Ser Arg Asn Ser Leu Gly Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser His Ser Val Asp Arg Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Leu Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Leu Tyr Tyr Cys Gln His Phe Gly Thr Ser Ser Val Thr Phe Gly Arg Gly Thr Arg Leu Glu Ile Lys , Heavy chain of antibody MnC4t2p2_A4  , Light chain of antibody MnC4t2p2_A4  ,"(47/48) , mnc4t2p2_a4 (with the variable region heavy chain amino acid sequence of seq id no:47 and the variable region light chain amino acid sequence of seq id no:48"
https://patents.google.com/patent/WO2021239935A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Gly Ala Arg Phe Gly Glu Ser Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Gly Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Heavy chain of antibody MnC2t1p1_A3  , Light chain of antibody MnC2t1p1_A3  ,"(17/18) , mnc2t1p1_a3 (with the variable region heavy chain amino acid sequence of seq id no:17 and the variable region light chain amino acid sequence of seq id no:18"
https://patents.google.com/patent/WO2021239935A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Arg Tyr Thr Ile Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Asp Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Leu Asp Tyr Phe Gly Ser Arg Asn Ser Gly Trp Thr Tyr Thr Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asn Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Pro Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Leu Tyr Ser Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Heavy chain of antibody MnC2t2p1_C11  , Light chain of antibody MnC2t2p1_C11  ,"(7/8) , mnc2t2p1_c11 (with the variable region heavy chain amino acid sequence of seq id no:7 and the variable region light chain amino acid sequence of seq id no:8"
https://patents.google.com/patent/WO2021239935A1/en, Gln Met Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Thr Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Ser Ser Ser Ala Val Gln Trp Val Arg Gln Ala Arg Gly Gln Arg Leu Glu Trp Ile Gly Trp Ile Val Val Gly Ser Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Arg Asp Met Ser Thr Arg Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Ala Pro Tyr Cys Ser Ser Thr Arg Cys Tyr Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Arg Ser Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Heavy chain of antibody HbnC3t1p2_C6  , Light chain of antibody HbnC3t1p2_C6  ,"(13/14) , hbnc3t1p2_c6 (with the variable region heavy chain amino acid sequence of seq id no:13 and the variable region light chain amino acid sequence of seq id no:14"
https://patents.google.com/patent/WO2021239935A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Asn Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Asn Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val Gly Trp Ile His Ser Leu Ser Gly Gly Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Leu Thr Arg Asp Ala Ser Ile Arg Thr Ala Tyr Met Glu Leu Ser Arg Leu Gly Ser Asp Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Ala Ser Val Ser Thr Ile Thr Asp Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Gly Asp Val Gly Ser Tyr Asn Leu Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Val Ile Tyr Glu Ala Thr Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Phe Ala Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Cys Ser Tyr Ala Gly Val Arg Thr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Heavy chain of antibody CnC2t1p1_E8  , Light chain of antibody CnC2t1p1_E8  ,"(33/34) , cnc2t1p1_e8 (with the variable region heavy chain amino acid sequence of seq id no:33 and the variable region light chain amino acid sequence of seq id no:34"
https://patents.google.com/patent/WO2021239935A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Ser Gly Tyr Asp Ser Ser Gly Tyr Trp Gly Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Ala Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Heavy chain of antibody CnC2t1p1_B10  , Light chain of antibody CnC2t1p1_B10  ,"(39/40) , cnc2t1p1_b10 (with the variable region heavy chain amino acid sequence of seq id no:39 and the variable region light chain amino acid sequence of seq id no:40"
https://patents.google.com/patent/WO2021239935A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Thr Thr Asp Cys Ser Ser Thr Ser Cys Trp Ser Leu Asp Phe Trp Ser Gly Tyr Tyr Thr Gly Gly Arg Glu Lys Ile Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Gly Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Heavy chain of antibody FnC1t1p2_A5  , Light chain of antibody FnC1t1p2_A5  ,"(43/44) , fnc1t1p2_a5 (with the variable region heavy chain amino acid sequence of seq id no:43 and the variable region light chain amino acid sequence of seq id no:44"
https://patents.google.com/patent/WO2021239935A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Gly Asp Tyr Ala Met Ser Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Phe Ile Arg Ser Lys Ala Tyr Gly Gly Thr Thr Glu Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Val Arg Arg Leu Trp Phe Gly Ser Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Gly Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Heavy chain of antibody CnC2t1p1_D6  , Light chain of antibody CnC2t1p1_D6  ,"(29/30) , cnc2t1p1_d6 (with the variable region heavy chain amino acid sequence of seq id no:29 and the variable region light chain amino acid sequence of seq id no:30"
https://patents.google.com/patent/WO2021239935A1/en, Gln Leu Gln Val Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Asn His Tyr Phe Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Ala Trp Ile Gly Ser Met His Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Val Asn Tyr Tyr Asp Arg Asn Gly Tyr Tyr Arg Asn Asp Gly Phe Asp Ile Arg Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp Leu Gly Trp Tyr Glu Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile Tyr Ala Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Thr Tyr Pro Phe Thr Phe Gly Pro Gly Thr Arg Val Asp Ile Lys , Heavy chain of antibody MnC4t2p1_D10  , Light chain of antibody MnC4t2p1_D10  ,"(45/46) , mnc4t2p1_d10 (with the variable region heavy chain amino acid sequence of seq id no:45 and the variable region light chain amino acid sequence of seq id no:46"
https://patents.google.com/patent/WO2021239935A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Phe Gly Asp Phe Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Val Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Heavy chain of antibody HbnC3t1p1_G4  , Light chain of antibody HbnC3t1p1_G4  ,"(3/4) , hbnc3t1p1_g4 (with the variable region heavy chain amino acid sequence of seq id no:3 and the variable region light chain amino acid sequence of seq id no:4"
https://patents.google.com/patent/WO2021239935A1/en, Gln Leu Gln Val Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Asn His Tyr Phe Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Ala Trp Ile Gly Ser Met His Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Leu Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Val Asn Tyr Tyr Asp Arg Asn Gly Tyr Tyr Arg Asn Asp Gly Phe Asp Ile Arg Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp Leu Gly Trp Tyr Glu Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile Tyr Ala Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Thr Tyr Pro Phe Thr Phe Gly Pro Gly Thr Arg Val Asp Ile Lys , Heavy chain of antibody MnC4t2p1_F5  , Light chain of antibody MnC4t2p1_F5  ,"(55/56) , and mnc4t2p1_f5 (with the variable region heavy chain amino acid sequence of seq id no:55 and the variable region light chain amino acid sequence of seq id no:56"
https://patents.google.com/patent/WO2021239935A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Gly Ala Arg Phe Gly Glu Ser Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Gly Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Heavy chain of antibody MnC2t1p1_C5  , Light chain of antibody MnC2t1p1_C5  ,"(31/32) , mnc2t1p1_c5 (with the variable region heavy chain amino acid sequence of seq id no:31 and the variable region light chain amino acid sequence of seq id no:32"
https://patents.google.com/patent/WO2021239935A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Leu Tyr Tyr Cys Ala Lys Asp Ile Asn Tyr Asp Ser Gly Gly Tyr His Lys Asn Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Glu Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Asn Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Heavy chain of antibody HbnC4t1p1_D5  , Light chain of antibody HbnC4t1p1_D5  ,"(37/38) , hbnc4t1p1_d5 (with the variable region heavy chain amino acid sequence of seq id no:37 and the variable region light chain amino acid sequence of seq id no:38"
https://patents.google.com/patent/CN111620946B/en, Glu Val Gln Leu Leu Glu Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Arg Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Pro Glu Val Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Thr Thr Pro Phe Ser Ser Ser Phe Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Ala Pro Ser Val Ser Gly Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) the heavy chain variable region of the monoclonal antibody or antigen-binding portion thereof of the invention comprises an amino acid sequence that is at least 80% homologous to the amino acid sequence set forth in seq id no:4, and the light chain variable region of the monoclonal antibody or antigen-binding portion thereof of the invention comprises an amino acid sequence that is at least 80% homologous to the amino acid sequence set forth in seq id no:8."
https://patents.google.com/patent/CN112521494A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Ile Thr Val Ser Ser Asn Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Met Glu Val Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Leu Pro Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Val Glu Asn Asp Asn Val Asn Trp Phe Gln Gln Gln Val Pro Gly Ser Thr Pro Lys Leu Val Ile Tyr Asn Asp Arg Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Tyr Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Val Ala Trp Asp Ala Ser Leu Gln Ser Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , Artificial sequence, Artificial sequence,"(7/8) specifically, the sequences of the light chain variable region and the heavy chain variable region are respectively the same as seq id no:8 and seq id no:7."
https://patents.google.com/patent/CN113956353A/en, gaggtccagc tgcagcagtc tggacctgag ctggtgaagc ctggggcttc agtgaaggta tcctgcaagg cttctggtta ttcattcact gactacaaca tgttctgggt gaagcagagc catggaaaga gccttgagtg gattggatat tttgatcctt acaatggtgg tactaactac aaccagaagt tcaagggcaa ggccacattg actgttgaca agtcctccag cacagccttc atgcatctca acaacctgac atctgaggac tctgcagtct attactgtgc aagagagaac gatatgacta cgacggttta ctatgctatg gactactggg gtcaaggaac cacggtcact gtctc , attgttctca cccagtctcc agcactcatg tctgcatctc caggggagaa ggtcaccatg acctgcagtg ccagctcaag tgtgaattac atttactggt accagcagag gccaagatcc tcccccaaac cctggattta tctcacatcc aacctggctt ctggagtccc tgctcgcttc agtggcagtg ggtctgggac ctcttactct ctcacaatta gcagcatgga ggctgaagat gctgccactt attactgcca gcagtggaat agtaacccgc tcacgttcgg tgctgggacc aagctggagc tgaaa , Artificial Sequence, Artificial Sequence,"(15/19) specifically, the dna sequence of the heavy chain variable region of the mouse anti-sads-cov n protein monoclonal antibody 4b10 is shown as seq id no:15; the dna sequence of the light chain variable region of the mouse anti-sads-cov n protein monoclonal antibody 4b10 is shown in seq id no:19"
https://patents.google.com/patent/CN113956353A/en, caggtgcaac tgaagcagtc tggggctgag ctggtgaggc ctggggtctc agtgaagatt tcctgcaagg gttctggcta cacattcact gattatgctg tgcactgggt gaagcagagt catgcaaaga gtctagagtg gattggagtt tttagtactt actatggtaa tgctaactac aaccagaact tcaagggcaa ggccacaatg accgtagaca aatcctccaa cacagcctat atggaacttg ccagactgac atctgaggat tctgccatct attactgtgc aagaggaggg gattactacg gtagtagcaa cgtagactat gctatggact actggggtca aggaacctca , gaaaatgtgc tcacccagtc tcctgcttcc ttagctgtat ctctggggca gagggccacc atctcataca gggccagcaa aagtgtcagt acatctggct atagttatat gcactggaac caacagaaac caggacagcc acccagactc ctcatctatc ttgtatccaa cctagaatct ggggtccctg ccaggttcag tggcagtggg tctgggacag acttcaccct caacatccat cctgtggagg aggaggatgc tgcaacctat tactgtcagc acattaggga gcttacacgt tcggaggggg gaccaagctg gagctga , Artificial Sequence, Artificial Sequence,(16/20) the dna sequence of the heavy chain variable region of the mouse anti-sads-cov n protein monoclonal antibody 4b10 is shown as seq id no:16; the dna sequence of the light chain variable region of the mouse anti-sads-cov n protein monoclonal antibody 6e8 is shown in seq id no:20.
https://patents.google.com/patent/CN113956353A/en, caggtgcaac tgaagcagtc tggggctgag ctggtgaggc ctggggtctc agtgaagatt tcctgcaagg gttctggcta cacattcact gattatgctg tgcactgggt gaagcagagt catgcaaaga gtctagagtg gattggagtt tttagtactt actatggtaa tgctaactac aaccagaact tcaagggcaa ggccacaatg accgtagaca aatcctccaa cacagcctat atggaacttg ccagactgac atctgaggat tctgccatct attactgtgc aagaggaggg gattactacg gtagtagcaa cgtagactat gctatggact actggggtca aggaacctca , attgttctca cccagtctcc agcactcatg tctgcatctc caggggagaa ggtcaccatg acctgcagtg ccagctcaag tgtgaattac atttactggt accagcagag gccaagatcc tcccccaaac cctggattta tctcacatcc aacctggctt ctggagtccc tgctcgcttc agtggcagtg ggtctgggac ctcttactct ctcacaatta gcagcatgga ggctgaagat gctgccactt attactgcca gcagtggaat agtaacccgc tcacgttcgg tgctgggacc aagctggagc tgaaa , Artificial Sequence, Artificial Sequence,(16/19)  the dna sequence of the light chain variable region of the mouse anti-sads-cov n protein monoclonal antibody 4b10 is shown in seq id no:19. the dna sequence of the heavy chain variable region of the mouse anti-sads-cov n protein monoclonal antibody 4b10 is shown as seq id no:16
https://patents.google.com/patent/CN113956353A/en, gaggtccagc tgcagcagtc tggacctgag ctggtgaagc ctggggcttc agtgaaggta tcctgcaagg cttctggtta ttcattcact gactacaaca tgttctgggt gaagcagagc catggaaaga gccttgagtg gattggatat tttgatcctt acaatggtgg tactaactac aaccagaagt tcaagggcaa ggccacattg actgttgaca agtcctccag cacagccttc atgcatctca acaacctgac atctgaggac tctgcagtct attactgtgc aagagagaac gatatgacta cgacggttta ctatgctatg gactactggg gtcaaggaac cacggtcact gtctc , caggtgcaac tgaagcagtc tggggctgag ctggtgaggc ctggggtctc agtgaagatt tcctgcaagg gttctggcta cacattcact gattatgctg tgcactgggt gaagcagagt catgcaaaga gtctagagtg gattggagtt tttagtactt actatggtaa tgctaactac aaccagaact tcaagggcaa ggccacaatg accgtagaca aatcctccaa cacagcctat atggaacttg ccagactgac atctgaggat tctgccatct attactgtgc aagaggaggg gattactacg gtagtagcaa cgtagactat gctatggact actggggtca aggaacctca , Artificial Sequence, Artificial Sequence,"(15/16) 3. the dna sequence of the heavy chain variable region and the light chain variable region of the monoclonal antibody for resisting the porcine acute diarrhea syndrome coronavirus n protein of claim 2, wherein the dna sequence of the heavy chain variable region of the monoclonal antibody for resisting the porcine acute diarrhea syndrome coronavirus n protein is shown as seq id no:15 or seq id no:16"
https://patents.google.com/patent/KR20220012810A/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr His Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No.139 HC variable region , No.139 LC variable region ,"(2018/2017)  in one embodiment of the present invention, the binding molecule comprises a light chain variable region of the polypeptide sequence of seq id no:2017; and a heavy chain variable region of the polypeptide sequence of seq id no:2018."
https://patents.google.com/patent/CN112961222A/en, Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Leu Val Lys Leu Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr Tyr Ile Tyr Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Trp Ile Asp Pro Glu Asn Gly Tyr Thr Ile Tyr Asp Pro Lys Phe Gln Gly Lys Ala Ser Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Gly Ser Ser Phe Ala Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Thr Leu Thr Leu Ser Val Thr Ile Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Gly Ala His Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val Ser , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(9/8) the monoclonal antibody has the amino acid sequences of the light chain variable region and the heavy chain variable region of clone 11d5 shown in seq id no:8 and seq id no:9.
https://patents.google.com/patent/CN112961222A/en, Gln Val Gln Leu Lys Glu Ser Gly Glu Thr Val Arg Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Ser Val His Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Glu Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Asn Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Ile Tyr Phe Cys Thr Arg Ser Thr Ala Thr Ser Asp Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Pro Lys Leu Val Tyr Pro Leu Ala Pro , Asp Ile Leu Met Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Val Leu Ile Tyr Thr Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Thr Asn Ala Asp Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala Pro Thr Val Ser , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(7/6) the amino acid sequences of the variable region of the light chain and the variable region of the heavy chain of the monoclonal antibody clone4g1 are respectively shown as seq id no:6 and 7
https://patents.google.com/patent/CN113557431A/en, Val Asn Leu Thr Thr Arg Thr Gln Leu Pro Pro Ala Tyr Thr Asn Ser Phe Thr Arg Gly Val Tyr Tyr Pro Asp Lys Val Phe Arg Ser Ser Val Leu His Ser Thr Gln Asp Leu Phe Leu Pro Phe Phe Ser Asn Val Thr Trp Phe His Ala Ile His Val Ser Gly Thr Asn Gly Thr Lys Arg Phe Asp Asn Pro Val Leu Pro Phe Asn Asp Gly Val Tyr Phe Ala Ser Thr Glu Lys Ser Asn Ile Ile Arg Gly Trp Ile Phe Gly Thr Thr Leu Asp Ser Lys Thr Gln Ser Leu Leu Ile Val Asn Asn Ala Thr Asn Val Val Ile Lys Val Cys Glu Phe Gln Phe Cys Asn Asp Pro Phe Leu Gly Val Tyr Tyr His Lys Asn Asn Lys Ser Trp Met Glu Ser Glu Phe Arg Val Tyr Ser Ser Ala Asn Asn Cys Thr Phe Glu Tyr Val Ser Gln Pro Phe Leu Met Asp Leu Glu Gly Lys Gln Gly Asn Phe Lys Asn Leu Arg Glu Phe Val Phe Lys Asn Ile Asp Gly Tyr Phe Lys Ile Tyr Ser Lys His Thr Pro Ile Asn Leu Val Arg Asp Leu Pro Gln Gly Phe Ser Ala Leu Glu Pro Leu Val Asp Leu Pro Ile Gly Ile Asn Ile Thr Arg Phe Gln Thr Leu Leu Ala Leu His Arg Ser Tyr Leu Thr Pro Gly Asp Ser Ser Ser Gly Trp Thr Ala Gly Ala Ala Ala Tyr Tyr Val Gly Tyr Leu Gln Pro Arg Thr Phe Leu Leu Lys Tyr Asn Glu Asn Gly Thr Ile Thr Asp Ala Val Asp Cys Ala Leu Asp Pro Leu Ser Glu Thr Lys Cys Thr Leu Lys Ser Phe Thr Val Glu Lys Gly Ile Tyr Gln Thr Ser Asn Phe Arg Val Gln Pro Thr Glu Ser Ile Val Arg Phe Pro Asn Ile Thr Asn Leu Cys Pro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala Ser Val Tyr Ala Trp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr Ser Val Leu Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly Val Ser Pro Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala Asp Ser Phe Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro Gly Gln Thr Gly Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe Thr Gly Cys Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys Val Gly Gly Asn Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu Lys Pro Phe Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser Thr Pro Cys Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu Gln Ser Tyr Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr Arg Val Val Val Leu Ser Phe Glu Leu Leu His Ala Pro Ala Thr Val Cys Gly Pro Lys Lys Ser Thr Asn Leu Val Lys Asn Lys Cys Val Asn Phe Asn Phe Asn Gly Leu Thr Gly Thr Gly Val Leu Thr Glu Ser Asn Lys Lys Phe Leu Pro Phe Gln Gln Phe Gly Arg Asp Ile Ala Asp Thr Thr Asp Ala Val Arg Asp Pro Gln Thr Leu Glu Ile Leu Asp Ile Thr Pro Cys Ser Phe Gly Gly Val Ser Val Ile Thr Pro Gly Thr Asn Thr Ser Asn Gln Val Ala Val Leu Tyr Gln Asp Val Asn Cys Thr Glu Val Pro Val Ala Ile His Ala Asp Gln Leu Thr Pro Thr Trp Arg Val Tyr Ser Thr Gly Ser Asn Val Phe Gln Thr Arg Ala Gly Cys Leu Ile Gly Ala Glu His Val Asn Asn Ser Tyr Glu Cys Asp Ile Pro Ile Gly Ala Gly Ile Cys Ala Ser Tyr Gln Thr Gln Thr Asn Ser Pro Arg Arg Ala Arg , Met Ser His His His His His His His His Ser Pro Met Tyr Ser Ile Ile Thr Pro Asn Ile Leu Arg Leu Glu Ser Glu Glu Thr Met Val Leu Glu Ala His Asp Ala Gln Gly Asp Val Pro Val Thr Val Thr Val His Asp Phe Pro Gly Lys Lys Leu Val Leu Ser Ser Glu Lys Thr Val Leu Thr Pro Ala Thr Asn His Met Gly Asn Val Thr Phe Thr Ile Pro Ala Asn Arg Glu Phe Lys Ser Glu Lys Gly Arg Asn Lys Phe Val Thr Val Gln Ala Thr Phe Gly Thr Gln Val Val Glu Lys Val Val Leu Val Ser Leu Gln Ser Gly Ile Glu Gly Arg Met Tyr Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Tyr Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln, SARS-CoV-2S1 domain derived from S protein, SARS-CoV-2 antibody-reactive SEQ ID NO: 1-derived peptides,(1/48) seq id no:48 (peptide derived from seq id no:1 with gst fusion reactive with sars-cov-2 antibody) mshhhhhhhhspmysiitpnilrleseetmvleahdaqgdvpv tvtvhdfpgkklvlssektvltpatnhmgnvtftipanrefkse kgrnkfvtvqatfgtqvvekvvlvslqsgiegrmygfqptngv gyqygfqptngvgyq
https://patents.google.com/patent/US7728110B2/en,Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly ThrSer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrGly Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValAla Val Ile Trp Tyr Asp Gly Ser Asn Lys Phe Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Pro Leu Gly Tyr Cys Ser Ser Thr Ser Cys Ser Tyr PheAsp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn TrpLeu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Arg Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Asn Phe Pro LeuThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys,58125PRTHomo sapiens 58,60107PRTHomo sapiens 60,"(58/60)  domains that are at least 99% identical in amino acid sequence to the vl domain shown as seq id no:60 and the vh domain shown as seq id no:58, respectively, of the monoclonal antibody 3c7."
https://patents.google.com/patent/US10301377B2/en,Gln Val Gln Leu Gln Gln Ser Gly Gly Glu Leu Val Lys Pro Gly AlaSer Val Lys Leu Ser Cys Lys Thr Ser Gly Phe Thr Phe Ser Ser SerTyr Ile Ser Trp Leu Lys Gln Lys Pro Gly Gln Ser Leu Glu Trp IleAla Trp Ile Tyr Ala Gly Thr Gly Gly Thr Glu Tyr Asn Gln Lys PheThr Gly Lys Ala Gln Val Thr Val Asp Thr Ser Ser Ser Thr Ala TyrMet Gln Phe Ser Ser Leu Thr Thr Glu Asp Ser Ala Ile Tyr Tyr CysAla Arg Gly Gly Ser Ser Phe Ala Met Asp Tyr Trp Gly Gln Gly ThrSer Val Thr Val Ser Ser ,Gln Leu Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu GlyGln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Asn TyrGly Ile Ser Phe Met Asn Trp Phe Gln Gln Lys Pro Gly Gln Pro ProLys Leu Leu Ile His Thr Ala Ser Asn Gln Gly Ser Gly Val Pro AlaArg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile HisPro Val Glu Asp Asp Asp Thr Ala Met Tyr Phe Cys Gln Gln Ser GluGlu Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys,115118PRTMus Musculus 115,117111PRTMus Musculus 117,"(115/117) the vh and the vl of the second isolated monoclonal antibody comprise the amino acid sequences set forth as seq id no:115 and 117, respectively (g"
https://patents.google.com/patent/US10301377B2/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Thr TyrAla Leu Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Asn Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Gly Ser Arg Ser Ser Ser Ser Ala Glu Tyr Phe Gln His TrpGly Gln Gly Thr Leu Val Thr Val Ser Ser,Gln Ser Ala Leu Thr Gln Pro Arg Ser Val Ser Gly Ser Pro Gly GlnSer Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly TyrAsn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys LeuMet Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg PheSer Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly LeuGln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Cys Ser Tyr Ala Gly SerTyr Thr Leu Glu Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu,48122PRTHomo Sapiens 48,50112PRTHomo Sapiens 50,"(48/50) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:48 and 50, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection."
https://patents.google.com/patent/US10301377B2/en,Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly GlySer Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg TyrAla Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp ValAla Thr Ile Asn Asn Gly Gly Ser Tyr Ser Tyr Tyr Pro Asp Ser ValLys Gly Arg Leu Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu TyrLeu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Leu Tyr Tyr CysAla Arg His Tyr Asp Tyr Asp Gly Tyr Tyr Tyr Thr Met Asp Phe TrpGly Gln Gly Thr Ser Val Thr Val Ser Ser,Asp Val Leu Met Thr Gln Ile Pro Leu Ser Leu Pro Val Ser Leu GlyAsp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His SerAsn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Lys Pro Leu Ile Tyr Lys Val Ser Asn Arg Ile Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln GlySer His Val Pro Tyr Thr Phe Gly Gly Gly Thr Asn Leu Glu Ile LysArg,127122PRTMus Musculus 127,129113PRTMus Musculus 129,"(127/129) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:127 and 129, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection."
https://patents.google.com/patent/US10301377B2/en,Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser GluThr Leu Ser Leu Thr Cys Ala Val Ser Gly Gly Ser Ile Ser Ser AsnTyr Trp Tyr Trp Ile Arg Gln Ser Pro Val Lys Gly Leu Glu Trp IleGly Tyr Ile Tyr Gly Gly Ser Gly Gly Thr Glu Tyr Asn Pro Ser LeuLys Ser Arg Val Thr Ile Ser Thr Asp Thr Ser Lys Asn Gln Phe PheLeu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr CysAla Arg Ser Phe Tyr Ser Trp Asn Gly Glu Ser Trp Gly Gln Gly ValVal Val Thr Val Ser Ser ,Asp Ile Gln Met Ser Gln Thr Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asn Asp TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Tyr Gly Asn Ser Leu Ala Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Asp Ser Phe Pro LeuThr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys,52118PRTMacaca Mulatta 52,54107PRTMacaca Mulatta 54,"(52/54) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:52 and 54, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection."
https://patents.google.com/patent/US10301377B2/en,Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Val Val Arg Pro Ser GluThr Leu Ser Leu Ser Cys Ala Val Ser Gly Gly Ser Ile Ser Asp SerTyr Arg Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu TrpVal Gly Tyr Ile Phe Ala Thr Gly Thr Thr Thr Asn Tyr Asn Pro SerLeu Lys Ser Arg Val Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln PheSer Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr TyrCys Ala Arg Glu Pro Phe Lys Tyr Cys Ser Gly Gly Val Cys Tyr AlaHis Lys Asp Asn Ser Leu Asp Val Trp Gly Gln Gly Val Leu Val ThrVal Ser Ser ,Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro GlyGlu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser AsnLeu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu IleHis Ser Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser GlySer Gly Ser Gly Thr Glu Phe Ser Leu Thr Ile Ser Ser Leu Glu AlaGlu Asp Val Gly Val Tyr His Cys Tyr Gln His Ser Ser Gly Tyr ThrPhe Gly Pro Gly Thr Lys Leu Asp Ile Lys,60tggggccagg gagttctggt caccgtctcc tca 3936131PRTmacaca mulatta 6,80aggttcagtg gcagcgggtc tgggacagag ttcagtctca ccatcagcag tctggaggct 240gaagatgttg gagtttatca ctgctatcag catagcagcg ggtacacttt cggccccggg 300accaaactgg atatcaaa 3188106PRTmacaca mulatta 8,"(6/8) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:6 and 8, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection."
https://patents.google.com/patent/US10301377B2/en,Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Arg Pro Gly ValSer Val Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp TyrAla Ile His Trp Val Lys Gln Ser His Ala Lys Ser Leu Glu Trp IleGly Val Phe Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys PheLys Gly Arg Ala Thr Met Thr Val Asp Lys Ser Ser Ser Thr Ala TyrMet Glu Leu Ala Arg Leu Thr Ser Glu Asp Ser Ala Ile Tyr Tyr CysAla Arg Lys Ser Tyr Tyr Val Asp Tyr Val Asp Ala Met Asp Tyr TrpGly Gln Gly Thr Ser Val Thr Val Ser Ser,Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu GlyGln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Asn TyrGly Ile Ser Phe Met Asn Trp Phe Gln Gln Lys Pro Gly Gln Pro ProLys Leu Leu Ile Ser Ala Thr Ser Asn Gln Gly Ser Gly Val Pro AlaArg Phe Ile Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile HisPro Val Glu Glu Asp Asp Thr Ala Met Tyr Phe Cys Gln Gln Ser LysGlu Val Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys,119122PRTMus Musculus 119,121111PRTMus Musculus 121,"(119/121) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:119 and 121, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection."
https://patents.google.com/patent/US10301377B2/en,Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly His Ile Phe Thr Ser TyrVal Ile Asn Trp Leu Gln Glu Ala Pro Gly Gln Gly Phe Glu Trp MetGly Gly Ile His Pro Gly Asn Gly Gly Arg Asp Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Met Ser Thr Ser Thr Val TyrMet Glu Leu Arg Ser Leu Arg Ser Glu Asp Met Ala Val Tyr Tyr CysAla Ala Ser Ser Gly Ser Tyr Gly Val Ser Ser Leu Asp Val Trp GlyArg Gly Val Leu Val Thr Val Ser Ser,Gln Ser Ala Leu Thr Gln Pro Pro Ser Leu Ser Ala Ser Pro Gly AlaSer Ala Arg Leu Pro Cys Thr Leu Ser Ser Asp Leu Ser Val Gly SerLys Asn Met Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ala Pro Arg LeuPhe Leu Tyr Tyr Tyr Ser Asp Ser Asp Lys Gln Leu Gly Pro Gly ValPro Asn Arg Val Ser Gly Ser Lys Glu Thr Ser Ser Asn Thr Ala PheLeu Leu Ile Ser Gly Leu Gln Pro Glu Asp Glu Ala Asp Tyr Tyr CysGln Val Tyr Asp Ser Ser Ala Asn Trp Val Phe Gly Gly Gly Thr ArgLeu Thr Val Leu ,56121PRTMacaca Mulatta 56,58116PRTMacaca Mulatta 58,"(56/58) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:56 and 58, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection."
https://patents.google.com/patent/US10301377B2/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ile TyrAla Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Glu Gly Gly His Gln Gly Tyr Cys Ser Gly Gly Ser Cys TyrAsp Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Ala Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Thr Pro Ala Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys,360accctggtca ccgtctcctc a 38136127PRTHomo Sapiens 36,111111PRTArtificial SequenceAntibody variable region 111,"(36/111) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:36 and 111, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection."
https://patents.google.com/patent/US10301377B2/en,Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly GlySer Leu Lys Leu Ser Cys Ala Ala Ser Gly PheThr Phe Ser Ser TyrAla Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp ValAla Thr Ile Ser Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Glu Asn Thr Leu TyrLeu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr CysVal Arg Asp Gly Asn Ser Met Asp Tyr Trp Gly Gln Gly Thr Ser ValThr Val Ser Ser ,Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu GlyAsp Arg Val Thr Ile Ile Cys Arg Ala Ser Gln Asp Ile Asn Asn TyrLeu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu IleTyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu GlnGlu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Ala Asn Thr Leu Pro ProThr Phe Gly Ala Gly Thr Lys Leu Glu Leu Arg,123116PRTMus Musculus 123,125107PRTMus Musculus 125,"(123/125) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:123 and 125, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection."
https://patents.google.com/patent/US10301377B2/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ile TyrAla Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Glu Gly Gly His Gln Gly Tyr Cys Ser Gly Gly Ser Cys TyrAsp Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Thr Pro Ala Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys,360accctggtca ccgtctcctc a 38136127PRTHomo Sapiens 36,38111PRTHomo Sapiens 38,"(36/38) the vh and the vl of the first isolated monoclonal antibody comprise the amino acid sequences set forth as seq id no:36 and 38, respectively (c"
https://patents.google.com/patent/US10301377B2/en,Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser GluThr Leu Ser Leu Thr Cys Ala Val Ser Gly Gly Ser Ile Ser Ser AsnTyr Trp Asn Trp Ile Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp IleGly Tyr Ile Tyr Gly Gly Ser Gly Ser Thr Thr Tyr Asn Pro Ser LeuLys Ser Arg Val Ala Ile Ser Thr Asp Thr Ser Lys Asp Gln Phe SerLeu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr CysAla Arg Leu Leu Pro Leu Gly Gly Gly Tyr Cys Phe Asp Tyr Trp GlyGln Gly Val Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Thr Pro Phe Thr Leu Pro Val Thr Pro GlyGlu Ala Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Phe Asp SerAsp Tyr Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly GlnSer Pro Gln Leu Leu Ile Tyr Met Leu Ser Asn Arg Ala Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu LysIle Ser Arg Val Glu Ala Glu Asp Val Gly Leu Tyr Tyr Cys Met GlnSer Val Glu Tyr Pro Phe Thr Phe Gly Pro Gly Thr Lys Leu Asp IleLys,240ctgaagctga gctctgtgac cgccgcggac accgccgtat attactgtgc gagactgctg 300cccttagggg ggggatactg ctttgactac tggggccagg gagtcctggt caccgtctcc 360tca 3632121PRTmacaca mulatta 2,40atcagccggg tggaggctga ggatgttggg ttatattact gcatgcaaag tgtagagtat 300ccattcactt tcggccccgg gaccaaactg gatatcaaa 3394113PRTmacaca mulatta 4,"(2/4) 3. the isolated monoclonal antibody of claim 1, wherein the vh and the vl comprise the amino acid sequences set forth as:(a) seq id no:2 and 4, respectively (jc57-"
https://patents.google.com/patent/US10301377B2/en,Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser GluThr Leu Ser Leu Thr Cys Ala Val Ser Gly Asp Ser Ile Ser Ser AsnTyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp IleGly Arg Phe Ser Gly Ser Gly Gly Ser Thr Asp Phe Asn Pro Ser LeuLys Ser Arg Val Thr Ile Ser Thr Asp Thr Ser Lys Asn Gln Phe SerLeu Asn Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr CysAla Lys Thr Tyr Ser Gly Thr Phe Asp Tyr Trp Gly Gln Gly Val LeuVal Thr Val Ser Ser ,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Asn Asn TyrLeu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Pro Leu IleTyr Tyr Ala Ser Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser GlySer Arg Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln LeuGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Asn Ser Pro TyrSer Phe Gly Gln Gly Thr Lys Val Glu Ile Lys,10117PRTmacaca mulatta 10,12107PRTmacaca mulatta 12,"(10/12) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:10 and 12, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection."
https://patents.google.com/patent/US10301377B2/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ile TyrAla Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Glu Gly Gly His Gln Gly Tyr Cys Ser Gly Gly Ser Cys TyrAsp Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Ser Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Thr Pro Ala Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys,360accctggtca ccgtctcctc a 38136127PRTHomo Sapiens 36,110111PRTArtificial SequenceAntibody variable region 110,"(36/110) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:36 and 110, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection"
https://patents.google.com/patent/US10301377B2/en,Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser GluThr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser SerSer Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu GluTrp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro SerLeu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln PheSer Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr TyrCys Ala Ser Leu Leu Arg Pro Leu Ile Tyr Cys Ser Gly Gly Ser CysThr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly GlnSer Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly TyrAsn Tyr Val Ser Trp Cys Gln Gln His Pro Gly Lys Ala Pro Lys LeuMet Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg PheSer Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly LeuGln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser AsnIle Thr Leu Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu,40tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattactg tgcgagcctc 300ttaaggcccc tgatttattg tagtggtggt agctgcaccg actactgggg ccagggaacc 360ctggtcaccg tctcctca 37840126PRTHomo Sapiens 40,42110PRTHomo Sapiens 42,"(40/42) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:40 and 42, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection."
https://patents.google.com/patent/US10301377B2/en,Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp TyrTyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Tyr Ile Ser Ser Ser Gly Ser Thr Ile Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Val Gly Leu Gly Ser Gly Trp Tyr Asp Trp Phe Asp Pro TrpGly Gln Gly Thr Leu Val Thr Val Ser Ser,Gln Ser Ala Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly GlnArg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala SerTyr Asp Val His Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Lys LeuLeu Ile Tyr Gly Asn Thr Asn Arg Pro Ser Gly Val Pro Asp Arg PheSer Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly LeuGln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser SerLeu Ser Gly Val Val Phe Ser Gly Gly Thr Lys Leu Thr Val Leu,44122PRTHomo Sapiens 44,46111PRTHomo Sapiens 46,"(44/46) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:44 and 46, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection."
https://patents.google.com/patent/CN111560070B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16)  wherein the heavy chain variable region comprises seq id no:12 and the light chain variable region comprises the amino acid sequence shown in seq id no:16.
https://patents.google.com/patent/CN111560070B/en, caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc tcctgcaagg cttctggagg caccttcagc agctatgcta tcagctgggt gcgacaggcc cctggacaag ggcttgagtg gatgggaggg atcatcccta tctttggtac agcaaactac gcacagaagt tccagggcag agtcacgatt accgcggacg aatccacgag cacagcctac atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagaggaggt tgggtgattt gtagtagtac cagctgctac actaagtact cctactacgg tatggacgtc tggggccaag ggaccacggt caccgtctcc tca , cagagcgtgc tcacgcagcc gccctcagtg tctgcggccc caggacagaa ggtcaccatc tcctgctctg gaagcagctc caacattggg aataattatg tatcctggta ccagcagctc ccaggaacag cccccaaact cctcatttat gacaataata agcgaccctc agggattcct gaccgattct ctggctccaa gtctggcacg tcagccaccc tgggcatcac cggactccag actggggacg aggccgatta ttactgcgga acgtgggata gcagcctgat tgcccggttg ttcggcggag ggaccaagct gaccgtccta , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(17/18) as a preferred embodiment of the present invention, the variable region of the antibody light chain is seq id no:18, and the variable region of the antibody heavy chain is seq id no:17."
https://patents.google.com/patent/CN111560070B/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Trp Val Ile Cys Ser Ser Thr Ser Cys Tyr Thr Lys Tyr Ser Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ile Ala Arg Leu Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) the monoclonal antibody of claim 1, wherein the first variable region is an antibody light chain variable region as set forth in seq id no:8; the second variable region is an antibody heavy chain variable region which is represented by seq id no:4."
https://patents.google.com/patent/KR102233689B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Ser Ser Gly Gly Thr Lys Asp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Ile Gly Val Tyr Tyr Thr Thr Val Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ser Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , VH, VL,(7/17)  a heavy chain variable region consisting of the amino acid sequence of seq id no:7 and a light chain variable region consisting of the amino acid sequence of seq id no:17
https://patents.google.com/patent/KR102233689B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Ser Ser Gly Gly Ser Thr Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Arg Ala Trp Gly Trp Val Glu Val Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Arg Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Phe Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , VH, VL,(5/15)  a heavy chain variable region consisting of the amino acid sequence of seq id no:5 and a light chain variable region consisting of the amino acid sequence of seq id no:15
https://patents.google.com/patent/KR102233689B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Glu Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Ser Ser Gly Gly Thr Lys Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Thr Gly Val Gly Leu Thr Ser Thr Phe Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Thr Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Phe Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , VH, VL,(4/14)  a heavy chain variable region consisting of the amino acid sequence of seq id no:4 and a light chain variable region consisting of the amino acid sequence of seq id no:14
https://patents.google.com/patent/KR102233689B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Glu Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Glu Val Thr Gly Tyr Ala Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Trp Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , VH, VL,(2/12)  a heavy chain variable region consisting of the amino acid sequence of seq id no:2 and a light chain variable region consisting of the amino acid sequence of seq id no:12
https://patents.google.com/patent/KR102233689B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Glu Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Ser Ser Gly Gly Thr Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Ser Gly Tyr Ser Trp Val Ser Val Phe Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , VH, VL,(10/20)  or a heavy chain variable region consisting of the amino acid sequence of seq id no:10 and a light chain variable region consisting of the amino acid sequence of seq id no:20
https://patents.google.com/patent/KR102233689B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Arg Glu Tyr Ser Gly Arg Val Phe Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Phe Tyr Ala Thr Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , VH, VL,(6/16)  a heavy chain variable region consisting of the amino acid sequence of seq id no:6 and a light chain variable region consisting of the amino acid sequence of seq id no:16
https://patents.google.com/patent/KR102233689B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Ser Ser Gly Ser Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Trp His Gly Gly Gly Trp Gln Val Tyr Thr Ala Phe Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Trp Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , VH, VL,"(1/11)  the method of claim 1, the antibody or antigen-binding fragment thereof a heavy chain variable region consisting of the amino acid sequence of seq id no:1 and a light chain variable region consisting of the amino acid sequence of seq id no:11"
https://patents.google.com/patent/KR102233689B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Glu Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Ser Ser Gly Ser Ser Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Ile Gly Leu Tyr Trp Thr Ser Val Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Gly Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , VH, VL,(8/18)  a heavy chain variable region consisting of the amino acid sequence of seq id no:8 and a light chain variable region consisting of the amino acid sequence of seq id no:18
https://patents.google.com/patent/KR102233689B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Ser Ser Gly Ser Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gln Leu Tyr Ala Gly Trp Ile Thr Tyr Trp Gly Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Phe Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , VH, VL,(3/13)  a heavy chain variable region consisting of the amino acid sequence of seq id no:3 and a light chain variable region consisting of the amino acid sequence of seq id no:13
https://patents.google.com/patent/KR102233689B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Arg Ile Ser Ser Ser Gly Ser Ser Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Arg Glu Tyr Gly Gly Glu Val Tyr Ala Phe Asp His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Phe Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , VH, VL,(9/19)  a heavy chain variable region consisting of the amino acid sequence of seq id no:9 and a light chain variable region consisting of the amino acid sequence of seq id no:19
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe Thr Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Val Tyr Tyr Cys Ala Arg Asp Pro Ser Thr Val Thr Gly Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Lys Ile Ser Cys Gly Gly Asp Ser Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Asn Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ile Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Homo sapiens  ,  Homo sapiens  ,(5743/5744)  a heavy chain comprising seq id no:5743 and a light chain comprising seq id no:5744. 
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Tyr Ala Ala Thr Phe Gly Val Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ser Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Ala Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,"(5361/5362) in some embodiments, provided herein is an antibody comprising a heavy chain comprising seq id no:5361 and a light chain comprising seq id no:5362"
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gln Gly Gly Gly Gly Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,"(5319/5320) [00112] in some embodiments, provided herein is an antibody comprising a heavy chain comprising seq id no:5319 and a light chain comprising seq id no:5320"
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr Ala Leu His Trp Val Arg Gln Gly Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Tyr Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Ala Gly Gly Gly Tyr Tyr Asn His Tyr Asp Pro Cys Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Asp Phe Gln Ser Val Thr Pro Lys Glu Lys Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Ser Ser Leu His Trp Tyr Gln Gln Lys Pro Asp Gln Ser Pro Lys Leu Leu Ile Lys Tyr Ala Ser Gln Ser Phe Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Ser Ser Ser Leu Pro His Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(3605/3606)  the vh set forth as seq id no:3605 and the vl set forth as seq id no:3606; (x
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Val Gly Gly Tyr Ser Tyr Leu Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,"(5583/5584) in other embodiments, such antibodies comprise a heavy chain comprising seq id no:5583 and a light chain comprising seq id no:5584"
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Ser Gly Gly Ser Tyr Phe Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Homo sapiens  ,  Homo sapiens  ,"(5577/5578) in other embodiments, such antibodies comprise a heavy chain comprising seq id no:5577 and a light chain comprising seq id no:5578"
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Ser Ser Gly Gly Tyr Gln Gly Pro Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Leu Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(1269/1270)  the vh set forth as seq id no:1269 and the vl set forth as seq id no:1270; (
https://patents.google.com/patent/WO2021183359A1/en, His Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ala Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Pro Glu Trp Met Gly Trp Met Ile Pro Asn Ile Gly Asn Thr Gly Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Ser Arg Leu Phe Asn Asp Phe Gly Leu Arg His Glu Ala Pro Val Asp Phe Trp Gly Gln Gly Thr Arg Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Tyr Ser Ser Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Val Leu Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Homo sapiens  ,  Homo sapiens  ,(5733/5734)  a heavy chain comprising seq id no:5733 and a light chain comprising seq id no:5734; or (
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Asn Lys Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys Ala Arg Asp Tyr Arg Tyr Phe Asp Trp Leu Leu Ser Gln Ile Asp Leu Glu Ile Asp Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5717/5718)  a heavy chain comprising seq id no:5717 and a light chain comprising seq id no:5718; or (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Asp Tyr Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Met Ser Ser Ser Gly Arg Thr Ile Tyr Tyr Ala Asn Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys Ala Arg Asp Gly Leu Arg Pro Pro Asp Tyr Trp Gly Gln Gly Thr Pro Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly His Ser Ile Ala Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Leu Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Ala Thr Lys Arg Pro Ala Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Cys Ser Tyr Ala Gly Ser Ser Thr Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(3421/3422)  the vh set forth as seq id no:3421 and the vl set forth as seq id no:3422; (c
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Ala Asp Thr Pro His Tyr Ser Gly Tyr Asp Phe Leu Ser Val Gly Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Phe Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ala Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,"(5329/5330) in some embodiments, provided herein is an antibody comprising a heavy chain comprising seq id no:5329 and a light chain comprising seq id no:5330"
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ser Gly Ser Gly Ser Tyr Leu Ser His Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Thr Ile Ser Arg Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Asn Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(3515/3516)  the vh set forth as seq id no:3515 and the vl set forth as seq id no:3516; (x
https://patents.google.com/patent/WO2021183359A1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Ser Pro Ser Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala His His Thr Ile Thr Arg Ile Asn Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Ala Thr Ser Ser Asp Val Gly Ala Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Homo sapiens  ,  Homo sapiens  ,(5723/5724)  a heavy chain comprising seq id no:5723 and a light chain comprising seq id no:5724; or (
https://patents.google.com/patent/WO2021183359A1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Ile Ser Gly Val Gly Val Gly Trp Leu Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Ser Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Lys Met Thr Asn Ile Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala His His Ser Ile Ser Thr Ile Phe Asp His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Ala Thr Ser Ser Asp Val Gly Asp Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Phe Glu Val Ser Asp Arg Pro Ser Gly Ile Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Thr Ser Ser Ala Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Homo sapiens  ,  Homo sapiens  ,(5735/5736)  a heavy chain comprising seq id no:5735 and a light chain comprising seq id no:5736; or (
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Ser Ser Ser Ser Ser Thr Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gly Ala Arg Thr Pro Trp Asp Ile Val Val Val Pro Ala Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Arg Ser Pro Asn Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,"(5345/5346) in some embodiments, provided herein is an antibody comprising a heavy chain comprising seq id no:5345 and a light chain comprising seq id no:5346"
https://patents.google.com/patent/WO2021183359A1/en, Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Ser Glu Lys Val Asp Phe Trp Ser Gly Gly Pro Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ile Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(1167/1168)  a vh set forth as seq id no:1167 and a vl set forth as seq id no:1168; (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Gly Ser Gly Asn Tyr Tyr Asn Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Thr Val Ser Ser Asn Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1123/1124)  a vh set forth as seq id no:1123 and a vl set forth as seq id no:1124; (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Ser Pro Ala Ala Ala Gly Thr Ser Gln Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Thr Pro Leu Ser Ser Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Thr Gln Phe Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(779/780)  the vh set forth as seq id no:779 and the vl set forth as seq id no:780; (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Pro Glu Glu Lys Ser Ser Glu Ile Gly Glu Leu Val Gly Trp Gly Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Ser Ile Ile Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala Cys Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(1111/1112)  the vh set forth as seq id no:1111 and the vl set forth as seq id no:1112; (
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly His Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Arg Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,"(5357/5358) in some embodiments, provided herein is an antibody comprising a heavy chain comprising seq id no:5357 and a light chain comprising seq id no:5358"
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Thr Glu Val Gly Ala Thr Ser Glu Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Arg Ile Thr Cys Ser Gly Asp Ala Leu Pro Lys Gln Tyr Ala Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Val Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Ala Asp Ser Ser Gly Thr Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Homo sapiens  ,  Homo sapiens  ,"(5339/5340) in some embodiments, provided herein is an antibody comprising a heavy chain comprising seq id no:5339 and a light chain comprising seq id no:5340"
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Thr Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Val Ser Tyr Asp Ser Ser Gly Tyr Tyr Asn Asn Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Tyr Ser Tyr Pro Val Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5715/5716)  a heavy chain comprising seq id no:5715 and a light chain comprising seq id no:5716; or (
https://patents.google.com/patent/WO2021183359A1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Ser Pro Ser Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala His His Ser Leu Ser Ser Ile Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Asp Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(1157/1158)  the vh set forth as seq id no:1157 and the vl set forth as seq id no:1158; (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Leu Ser Ser Tyr Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asp Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Thr Thr Ala Tyr Met Asp Leu Ser Ser Leu Gly Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Ser Ala Pro Lys Asp Trp Ser Ser Gly Phe Asp Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser Asp Gly Lys Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Ala Gly Gln Pro Pro Gln Leu Leu Ile Tyr Glu Val Ser Asn Arg Phe Ser Gly Val Pro Glu Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ser Val Gln Leu Pro Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Thr Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5721/5722)  a heavy chain comprising seq id no:5721 and a light chain comprising seq id no:5722; or (
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Pro Tyr Gly Gly Asn Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Gln Thr Ile Tyr Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Phe Leu Ile Tyr Ala Ala Ser Ser Phe Gln Asn Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1243/1244)  the vh set forth as seq id no:1243 and the vl set forth as seq id no:1244; (
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Gly Asp Gln Leu Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,"(5353/5354) in some embodiments, provided herein is an antibody comprising a heavy chain comprising seq id no:5353 and a light chain comprising seq id no:5354"
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Leu Ser Gly Ser Tyr Arg Ser Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1267/1268)  a vh set forth as seq id no:1267 and a vl set forth as seq id no:1268; or (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Pro Asp Tyr Tyr Asp Phe Trp Ser Gly Tyr Phe Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,"(5325/5326) in some embodiments, the foregoing antibody comprises a heavy chain comprising seq id no:5325 and a light chain comprising seq id no:5326"
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Pro Tyr Gly Gly Asn Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1121/1122)  the vh set forth as seq id no:1121 and the vl set forth as seq id no:1122; (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Gln Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gln Gly Glu Pro Tyr Cys Ser Ala Gly Asn Cys Tyr Ser Gly Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Arg Ile Thr Cys Ser Ala Asp Ala Leu Pro Lys Gln Tyr Ala Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Val Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Gly Asp Ser Ser Gly Thr Pro Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(3845/3846)  (jj) the vh set forth as seq id no:3845 and the vl set forth as seq id no:3846
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Ile Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Glu Trp Ala Tyr Tyr Gly Ser Gly Ser Tyr Leu Gly Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Val Thr Val Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5725/5726)  a heavy chain comprising seq id no:5725 and a light chain comprising seq id no:5726; or (
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Lys Ser Ser Gly Ser Gly Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1039/1040)  the vh set forth as seq id no:1039 and the vl set forth as seq id no:1040; (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr Ala Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Arg Gly Gly Tyr Arg Ser Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Asn Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(921/922)  the vh set forth as seq id no:921 and the vl set forth as seq id no:922; (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Ser Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Lys Gly Gly Ser Tyr Ser Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Gln Ser Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,"(5337/5338) in some embodiments, provided herein is an antibody comprising a heavy chain comprising seq id no:5337 and a light chain comprising seq id no:5338"
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Gly Asp Gln Leu Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1133/1134)  the vh set forth as seq id no:1133 and the vl set forth as seq id no:1134; (
https://patents.google.com/patent/WO2021183359A1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Asn Gly Val Gly Met Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Tyr Trp Asp Asp Asp Gln Phe Tyr Ser Pro Ser Leu Lys Ser Arg Leu Thr Ile Thr Arg Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Gln Ala Phe Tyr Glu Ser Phe Gly Phe Tyr Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Ile Ile Ser Cys Thr Arg Ser Ile Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Ile Val Val Phe Glu Asp Asn Glu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Arg Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Gly Ser Ser Glu Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(3275/3276)  the vh set forth as seq id no:3275 and the vl set forth as seq id no:3276; (
https://patents.google.com/patent/WO2021183359A1/en, Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Gly Asp Tyr Ala Met Ser Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Phe Ile Arg Ser Lys Ala Tyr Gly Gly Thr Thr Glu Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Phe Gly Ile Asp Tyr Asp Tyr Ile Trp Gly Ser Tyr Arg Tyr Thr Thr Leu Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys ,  Homo sapiens  ,  Homo sapiens  ,"(5322/5323) in some embodiments, provided herein is an antibody comprising a heavy chain comprising seq id no:5322 and a light chain comprising seq id no:5323"
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Leu Ser Gly Ser Tyr Arg Ser Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,"(5589/5590) in other embodiments, such antibodies comprise a heavy chain comprising seq id no:5589 and a light chain comprising seq id no:5590"
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly Gly Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Thr Thr Met Val Arg Gly Val Ile Arg Leu Asp His Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Leu Phe Gly Thr Gly Thr Lys Val Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(867/868)  a vh set forth as seq id no:867 and a vl set forth as seq id no:868; (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly Gly Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Thr Thr Met Val Arg Gly Val Ile Arg Leu Asp His Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Leu Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Homo sapiens  ,  Homo sapiens  ,"(5581/5582) in other embodiments, such antibodies comprise a heavy chain comprising seq id no:5581 and a light chain comprising seq id no:5582"
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Trp Thr Gln Ser Ser Gly Tyr Asp Tyr Tyr Tyr Gly Leu Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Arg Ile Thr Cys Ser Gly Asp Ala Leu Pro Lys Gln Tyr Ala Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Val Val Ile Tyr Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Val Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Ala Asp Ser Ser Gly Thr Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Homo sapiens  ,  Homo sapiens  ,"(5335/5336) in some embodiments, the foregoing antibody comprises a heavy chain comprising seq id no:5335 and a light chain comprising seq id no:5336"
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Lys Ser Ser Gly Ser Gly Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,"(5341/5342) in some embodiments, provided herein is an antibody comprising a heavy chain comprising seq id no:5341 and a light chain comprising seq id no:5342"
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Thr Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Pro Met Ala Tyr Ile Leu Val Val Val Ala Ala Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Ile Val Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Leu Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(3835/3836)  the vh set forth as seq id no:3835 and the vl set forth as seq id no:3836; (j
https://patents.google.com/patent/WO2021183359A1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Ile Ser Gly Val Gly Val Gly Trp Leu Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Ser Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Lys Met Thr Asn Ile Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala His His Ser Ile Ser Thr Ile Phe Asp His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Ala Thr Ser Ser Asp Val Gly Asp Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Phe Glu Val Ser Asp Arg Pro Ser Gly Ile Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Thr Ser Ser Ala Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(4949/4950)  the vh set forth as seq id no:4949 and the vl set forth as seq id no:4950; (n
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Pro Glu Glu Lys Ser Ser Glu Ile Gly Glu Leu Val Gly Trp Gly Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Ser Ile Ile Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala Cys Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Homo sapiens  ,  Homo sapiens  ,"(5349/5350) in some embodiments, provided herein is an antibody comprising a heavy chain comprising seq id no:5349 and a light chain comprising seq id no:5350"
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Tyr Ala Ala Thr Phe Gly Val Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ser Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Ala Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1251/1252)  the vh set forth as seq id no:1251 and the vl set forth as seq id no:1252; (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Pro Gly Arg Asp Phe Trp Ser Gly Tyr Tyr Phe Gly Ala Pro Asp Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Lys Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,"(5331/5332) in some embodiments, provided herein is an antibody comprising a heavy chain comprising seq id no:5331 and a light chain comprising seq id no:5332"
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Val Ala Gly Thr Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Gly Gly Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5347/5348) in some embodiments the foregoing antibody comprises a heavy chain comprising seq id no:5347 and a light chain comprising seq id no:5348
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Asn Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Pro Thr Trp Phe Gly Glu Leu Pro Ser Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,"(5343/5344) in some embodiments, provided herein is an antibody comprising a heavy chain comprising seq id no:5343 and a light chain comprising seq id no:5344"
https://patents.google.com/patent/WO2021183359A1/en, Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ser Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr His Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Gly Leu Arg Val Val Ile Thr Phe Gly Gly Val Ile Pro Lys Gly Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(761/762)  a vh set forth as seq id no:761 and a vl set forth as seq id no:762; (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala Thr Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Leu Ile Ser His Asp Gly Ser Asn Lys His Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Gly Thr Ala Ile Tyr Tyr Cys Ala Arg Glu Ser Leu Glu Ala Ala Ala Pro Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Thr Ile Ile Cys Ser Gly Asp Lys Leu Gly Glu Lys Tyr Ala Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Ala Leu Val Ile Tyr Gln Asp Arg Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Asn Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Pro Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Homo sapiens  ,  Homo sapiens  ,"(5591/5592) in other embodiments, such antibodies comprise a heavy chain comprising seq id no:5591 and a light chain comprising seq id no:5592"
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Arg Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Asp Thr Arg Asp Glu Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Arg Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(3853/3854)  (kk the vh set forth as seq id no:3853 and the vl set forth as seq id no:3854
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Pro Asp Tyr Tyr Asp Phe Trp Ser Gly Tyr Phe Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(891/892)  the vh set forth as seq id no:891 and the vl set forth as seq id no:892; (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ala Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Asp Asp Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Glu Gly Val Phe Thr Ile Gly Asp Arg Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Ser Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Thr Val Val Thr Gln Glu Pro Ser Phe Ser Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Leu Ser Ser Gly Ser Val Ser Thr Ser Tyr Tyr Pro Ser Trp Tyr Gln Gln Thr Pro Gly Gln Ala Pro Arg Thr Leu Ile Tyr Asn Thr Asn Thr Arg Ser Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Leu Gly Asn Lys Ala Ala Leu Thr Ile Thr Gly Ala Gln Ala Asp Asp Glu Ser Asp Tyr Tyr Cys Val Leu Tyr Met Gly Ser Gly Ile Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Homo sapiens  ,  Homo sapiens  ,(5737/5738)  a heavy chain comprising seq id no:5737 and a light chain comprising seq id no:5738; or (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Asn Asn Lys Tyr Tyr Gly Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Ala Asp Thr Pro His Tyr Ser Gly Tyr His Phe Leu Ser Val Gly Tyr Tyr Phe Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Tyr Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Gln Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(5131/5132)  the vh set forth as seq id no:5131 and the vl set forth as seq id no:5132; (p
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Ser Gly Gly Ser Tyr Phe Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(727/728)  a vh set forth as seq id no:727 and a vl set forth as seq id no:728; (
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Asp Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Tyr Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asp Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Arg Gly Asn Glu Tyr Ala Leu Thr His Tyr Tyr Tyr Tyr Ala Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Tyr Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Ser Tyr Ser Thr Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(5217/5218)  (pp) the vh set forth as seq id no:5217 and the vl set forth as seq id no:5218
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asp Asp Tyr Asp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Gly Gly Asn Thr Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr His Cys Ala Val Ile Met Ser Pro Ile Pro Arg Tyr Ser Gly Tyr Asp Trp Ala Gly Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala Ser Trp Tyr Gln Gln Lys Pro Gly Gln Val Pro Ile Leu Val Ile Tyr Asp Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Asn Ala Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Homo sapiens  ,  Homo sapiens  ,(5713/5714)  a heavy chain comprising seq id no:5713 and a light chain comprising seq id no:5714; or (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Ser Ser Gly Gly Tyr Gln Gly Pro Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Leu Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Homo sapiens  ,  Homo sapiens  ,"(5365/5366) in some embodiments, provided herein is an antibody comprising a heavy chain comprising seq id no:5365 and a light chain comprising seq id no:5366"
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Tyr Tyr Glu Ala Arg His Tyr Tyr Tyr Tyr Tyr Ala Met Asp Val Trp Gly Gln Gly Thr Ala Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,"(5363/5364)  comprising administering to a patient a pharmaceutical composition comprising an antibody that comprises a heavy chain comprising seq id no:5363 and a light chain comprising seq id no:5364, and at least one additional antibody that binds sars-cov-2 (e.g., cb6 or "
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Pro Tyr Gly Gly Asn Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,"(5351/5352) in some embodiments, the foregoing antibody comprises a heavy chain comprising seq id no:5351 and a light chain comprising seq id no:5352"
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Trp Thr Gln Ser Ser Gly Tyr Asp Tyr Tyr Tyr Gly Leu Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Arg Ile Thr Cys Ser Gly Asp Ala Leu Pro Lys Gln Tyr Ala Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Val Val Ile Tyr Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Val Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Ala Asp Ser Ser Gly Thr Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(983/984)  the vh set forth as seq id no:983 and the vl set forth as seq id no:984; (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr Ala Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Arg Gly Gly Tyr Arg Ser Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Asn Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,"(5327/5328) in some embodiments, provided herein is an antibody comprising a heavy chain comprising seq id no:5327 and a light chain comprising seq id no:5328"
https://patents.google.com/patent/WO2021183359A1/en, Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ser Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr His Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Gly Leu Arg Val Val Ile Thr Phe Gly Gly Val Ile Pro Lys Gly Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Homo sapiens  ,  Homo sapiens  ,"(5579/5580) in other embodiments, such antibodies comprise a heavy chain comprising seq id no:5579 and a light chain comprising seq id no:5580"
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ala Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Asp Asp Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Glu Gly Val Phe Thr Ile Gly Asp Arg Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Ser Val Ser Ser , Gln Thr Val Val Thr Gln Glu Pro Ser Phe Ser Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Leu Ser Ser Gly Ser Val Ser Thr Ser Tyr Tyr Pro Ser Trp Tyr Gln Gln Thr Pro Gly Gln Ala Pro Arg Thr Leu Ile Tyr Asn Thr Asn Thr Arg Ser Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Leu Gly Asn Lys Ala Ala Leu Thr Ile Thr Gly Ala Gln Ala Asp Asp Glu Ser Asp Tyr Tyr Cys Val Leu Tyr Met Gly Ser Gly Ile Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(5029/5030)  the vh set forth as seq id no:5029 and the vl set forth as seq id no:5030; (o
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Ser Ser Ser Ser Ser Thr Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gly Ala Arg Thr Pro Trp Asp Ile Val Val Val Pro Ala Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Arg Ser Pro Asn Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1103/1104)  the vh set forth as seq id no:1103 and the vl set forth as seq id no:1104; (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Pro Glu Leu Ser Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asn Ala Glu Thr Ile Tyr Thr Gln Lys Phe Gln Gly Arg Leu Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Thr Ser Phe Val Leu Met Pro Ala Ala Leu Gly Asp Tyr Ser Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Thr Pro Leu Ser Ser Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Thr Gln Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(3361/3362)  the vh set forth as seq id no:3361 and the vl set forth as seq id no:3362; (a
https://patents.google.com/patent/WO2021183359A1/en, Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Pro Ile Met Ile Thr Phe Gly Gly Val Thr Gly His Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(979/980)  the vh set forth as seq id no:979 and the vl set forth as seq id no:980; (
https://patents.google.com/patent/WO2021183359A1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Asn Gly Val Gly Met Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Tyr Trp Asp Asp Asp Gln Phe Tyr Ser Pro Ser Leu Lys Ser Arg Leu Thr Ile Thr Arg Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Gln Ala Phe Tyr Glu Ser Phe Gly Phe Tyr Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Ile Ile Ser Cys Thr Arg Ser Ile Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Ile Val Val Phe Glu Asp Asn Glu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Arg Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Gly Ser Ser Glu Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Homo sapiens  ,  Homo sapiens  ,(5707/5708)  a heavy chain comprising seq id no:5707 and a light chain comprising seq id no:5708; or (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Tyr Ser Gly Ser Tyr Gln Ser Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,"(5321/5322) in some embodiments, provided herein is an antibody comprising a heavy chain comprising seq id no:5321 and a light chain comprising seq id no:5322"
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Gly Ser Gly Asn Tyr Tyr Asn Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Thr Val Ser Ser Asn Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,"(5585/5586) in other embodiments, such antibodies comprise a heavy chain comprising seq id no:5585 and a light chain comprising seq id no:5586"
https://patents.google.com/patent/WO2021183359A1/en, Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Pro Ile Met Ile Thr Phe Gly Gly Val Thr Gly His Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,"(5333/5334) in some embodiments, provided herein is an antibody comprising a heavy chain comprising seq id no:5333 and a light chain comprising seq id no:5334"
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Pro Tyr Gly Gly Asn Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Gln Thr Ile Tyr Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Phe Leu Ile Tyr Ala Ala Ser Ser Phe Gln Asn Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,"(5359/5360) in some embodiments, provided herein is an antibody comprising a heavy chain comprising seq id no:5359 and a light chain comprising seq id no:5360"
https://patents.google.com/patent/WO2021183359A1/en, Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Ser Glu Lys Val Asp Phe Trp Ser Gly Gly Pro Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ile Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Homo sapiens  ,  Homo sapiens  ,"(5587/5588) in other embodiments, such antibodies comprise a heavy chain comprising seq id no:5587 and a light chain comprising seq id no:5588"
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Thr Glu Val Gly Ala Thr Ser Glu Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Arg Ile Thr Cys Ser Gly Asp Ala Leu Pro Lys Gln Tyr Ala Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Val Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Ala Asp Ser Ser Gly Thr Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(1035/1036)  the vh set forth as seq id no:1035 and the vl set forth as seq id no:1036; (
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Pro Ala Gly Ile Val Val Gly Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Phe Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr His Ser Ser Asn Pro His Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(1143/1144)  the vh set forth as seq id no:1143 and the vl set forth as seq id no:1144; (x
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gln Gly Gly Gly Gly Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(729/730)  the vh set forth as seq id no:729 and the vl set forth as seq id no:730; (
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Val Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Ser Gly Asp Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Ser Leu Tyr Val Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Leu Tyr Tyr Cys Val Lys Asp Arg Gly Gly Ser Gly Trp Asp Leu Asn His Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Val Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Tyr Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Glu Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Val Lys Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(3365/3366)  the vh set forth as seq id no:3365 and the vl set forth as seq id no:3366; (b
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Asn Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Pro Thr Trp Phe Gly Glu Leu Pro Ser Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1069/1070)  the vh set forth as seq id no:1069 and the vl set forth as seq id no:1070; (
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Val Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ile Ser Gly Asp Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Ser Leu Tyr Val Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Leu Tyr Tyr Cys Val Lys Asp Arg Gly Gly Ser Gly Trp Asp Leu Asn His Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Val Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Tyr Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Glu Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Val Lys Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5711/5712)  a heavy chain comprising seq id no:5711 and a light chain comprising seq id no:5712; or (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Asn Asn Lys Tyr Tyr Gly Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Ala Asp Thr Pro His Tyr Ser Gly Tyr His Phe Leu Ser Val Gly Tyr Tyr Phe Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Tyr Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Gln Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5739/5740)  a heavy chain comprising seq id no:5739 and a light chain comprising seq id no:5740; or (
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Glu Asp Tyr Ala Met His Trp Val Arg Gln Val Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Ser Gly Thr Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Arg Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Val Gly Phe Gly Glu Leu Leu Tyr Tyr Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Homo sapiens  ,  Homo sapiens  ,(5729/5730)  a heavy chain comprising seq id no:5729 and a light chain comprising seq id no:5730; or (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Thr Asn Thr Gly Asn Pro Thr Tyr Ala Gln Gly Phe Thr Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr Leu Gln Ile Thr Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Trp Glu Val Pro Ala Pro Tyr Tyr Ser Tyr Tyr Tyr Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu His Ser Asp Gly Lys Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Ser Gly Gln Ser Pro Gln Leu Leu Ile Tyr Glu Ile Ser Asp Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asn Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ser Ile Gln Leu Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(3447/3448)  the vh set forth as seq id no:3447 and the vl set forth as seq id no:3448; (d
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Tyr Tyr Glu Ala Arg His Tyr Tyr Tyr Tyr Tyr Ala Met Asp Val Trp Gly Gln Gly Thr Ala Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1255/1256)  the vh set forth as seq id no:1255 and the vl set forth as seq id no:1256; (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Asn Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Leu Leu Gly Thr Val Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ala Gly Gly Ile Thr Ile Phe Gly Val Glu His Tyr Tyr Tyr Tyr Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Thr Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser His Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Pro Met Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5727/5728)  a heavy chain comprising seq id no:5727 and a light chain comprising seq id no:5728; or (
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Val Trp Val Ser His Ile Asn Ser Asp Gly Ser Ser Thr Ser Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Leu Arg Tyr Phe Asp Leu Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Glu Ala Pro Arg Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Ala Val Asn Trp Tyr Gln Gln Leu Pro Gly Lys Ala Pro Lys Leu Leu Ile Phe Tyr Asp Asp Leu Leu Pro Ser Gly Val Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Homo sapiens  ,  Homo sapiens  ,(5719/5720) a heavy chain comprising seq id no:5719 and a light chain comprising seq id no:5720; or (
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Asp Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Tyr Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asp Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Arg Gly Asn Glu Tyr Ala Leu Thr His Tyr Tyr Tyr Tyr Ala Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Tyr Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Ser Tyr Ser Thr Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5741/5742)  a heavy chain comprising seq id no:5741 and a light chain comprising seq id no:5742; or (
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly His Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Arg Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1225/1226)  the vh set forth as seq id no:1225 and the vl set forth as seq id no:1226; (
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr His Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ile Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Thr Pro Tyr Cys Gly Gly Asp Cys Ser Phe Gly Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Leu Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Glu Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(3725/3726)  the vh set forth as seq id no:3725 and the vl set forth as seq id no:3726; (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Pro Gly Arg Asp Phe Trp Ser Gly Tyr Tyr Phe Gly Ala Pro Asp Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Lys Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(973/974)  the vh set forth as seq id no:973 and the vl set forth as seq id no:974; (
https://patents.google.com/patent/WO2021183359A1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Ser Pro Ser Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala His His Ser Leu Ser Ser Ile Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Asp Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Homo sapiens  ,  Homo sapiens  ,"(5355/5356) in some embodiments, provided herein is an antibody comprising a heavy chain comprising seq id no:5355 and a light chain comprising seq id no:5356"
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe Thr Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Val Tyr Tyr Cys Ala Arg Asp Pro Ser Thr Val Thr Gly Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Lys Ile Ser Cys Gly Gly Asp Ser Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Asn Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ile Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(5311/5312)  a heavy chain variable region set forth as seq id no:5311 and a light chain variable region set forth as seq id no:5312. 
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Glu Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met Gly Arg Met Thr Leu Asn Ser Gly Asn Thr Gly Tyr Ala Gln Asn Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Gly Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Met Arg Ser Gly Trp Pro Thr His Gly Arg Pro Asp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile Gly Ser Tyr Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Leu Ala Trp Asp Asp Ser Arg Asn Gly Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Homo sapiens  ,  Homo sapiens  ,(5731/5732)  a heavy chain comprising seq id no:5731 and a light chain comprising seq id no:5732; or (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Pro Glu Leu Ser Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asn Ala Glu Thr Ile Tyr Thr Gln Lys Phe Gln Gly Arg Leu Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Thr Ser Phe Val Leu Met Pro Ala Ala Leu Gly Asp Tyr Ser Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Val Met Thr Gln Thr Pro Leu Ser Ser Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Thr Gln Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5709/5710)  a heavy chain comprising seq id no:5709 and a light chain comprising seq id no:5710; or (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Ser Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Lys Gly Gly Ser Tyr Ser Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Gln Ser Phe Gly Pro Gly Thr Lys Val Asp Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1029/1030)  the vh set forth as seq id no:1029 and the vl set forth as seq id no:1030; (
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu His Val Ser Gly Ile Ser Ser Asn Gly Gly Ser Thr Tyr Tyr Ala Asn Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Asp Leu Gln Met Gly Ser Leu Arg Ala Glu Asp Met Ala Val Tyr Tyr Cys Ala Arg Ser Leu Phe Leu Ser Gly Tyr Val Tyr Phe Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ala Asn Leu Gly Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(3649/3650)  the vh set forth as seq id no:3649 and the vl set forth as seq id no:3650; (h
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Gly Asp Tyr Ala Met Ser Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Phe Ile Arg Ser Lys Ala Tyr Gly Gly Thr Thr Glu Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Phe Gly Ile Asp Tyr Asp Tyr Ile Trp Gly Ser Tyr Arg Tyr Thr Thr Leu Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(873/874)  the vh set forth as seq id no:873 and the vl set forth as seq id no:874; (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Ala Asp Thr Pro His Tyr Ser Gly Tyr Asp Phe Leu Ser Val Gly Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Phe Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ala Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(961/962)  the vh set forth as seq id no:961 and the vl set forth as seq id no:962; (
https://patents.google.com/patent/WO2021183359A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Tyr Ser Gly Ser Tyr Gln Ser Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(763/764)  the vh set forth as seq id no:763 and the vl set forth as seq id no:764; (
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Ser Ser Thr Gly Ser Ser Ile Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ala Lys Asn Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Met Tyr Tyr Tyr Gly Ser Gly Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Val Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Thr Thr Pro Pro Ala Phe Gly Pro Gly Thr Lys Val Asp Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(3873/3874)  the vh set forth as seq id no:3873 and the vl set forth as seq id no:3874; (m
https://patents.google.com/patent/WO2021183359A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Val Ala Gly Thr Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Gly Gly Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1107/1108)  the vh set forth as seq id no:1107 and the vl set forth as seq id no:1108; (
https://patents.google.com/patent/WO2021183359A1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Ser Pro Ser Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala His His Thr Ile Thr Arg Ile Asn Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Ala Thr Ser Ser Asp Val Gly Ala Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(3647/3648)  the vh set forth as seq id no:3647 and the vl set forth as seq id no:3648; (g
https://patents.google.com/patent/CN112552399A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Phe Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala His Leu Gly Gly Phe Ala Asp Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Ala Gly Gln Ala Pro Arg Val Leu Ile Tyr Asp Ala Phe Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Arg Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , synthetic, synthetic,(27/28)  a heavy chain variable region comprising the sequence of seq id no:27 and a light chain variable region comprising the sequence of seq id no:28.
https://patents.google.com/patent/CN112552399A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Asn Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Arg Ser Ala Tyr Gly Asp Lys Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Gln Glu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , synthetic, synthetic,(17/18)  b) a heavy chain variable region comprising the sequence of seq id no:17 and a light chain variable region comprising the sequence of seq id no:18
https://patents.google.com/patent/CN112552399A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Ser Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Ala Asn Pro Gly Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Phe Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Arg Val Thr Ile His Tyr Asp Ile Leu Thr Gly Tyr Tyr Ser Asn Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Ala Val Ser Ser, Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Thr Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Ala Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Thr Thr Phe Met Tyr Thr Phe Gly Gln Gly Thr Met Leu Glu Ile Lys , synthetic, synthetic,(7/8)  a heavy chain variable region comprising the sequence of seq id no:7 and a light chain variable region comprising the sequence of seq id no:8; 
https://patents.google.com/patent/CN113388028A/en, Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Glu Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Ile Thr Gly Thr Thr Phe Ser Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Ala Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),"(17/19) the human antibody or fragment thereof of claim 3, wherein the antibody heavy chain variable region that inhibits binding of ace2 to sars-cov-2s1 by steric hindrance effect is seq id no:17 and the light chain variable region is seq id no:19."
https://patents.google.com/patent/CN113388028A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Phe Ser Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Val Leu Gly Ile Ala Asn Tyr Ala Gln Glu Val Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys Thr Thr Asp Arg Phe Val Glu Pro Ala Thr Gly Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Ser Asn Trp Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),"(9/11) the human antibody or fragment thereof of claim 3, wherein the heavy chain variable region of the antibody having the same binding site as ace2 on sars-cov-2s1 protein is selected from seq id no:9, 13 and the light chain variable region is selected from seq id no:11, 15."
https://patents.google.com/patent/CN111269313B/en, Gln Ile Gln Leu Gln Gln Ser Gly Ala Ser Leu Val Arg Pro Gly Ala Leu Val Lys Leu Ser Cys Lys Ala Ser Asp Ser His Tyr Tyr Ser Gln Ser Leu His Trp Val Lys Gln Arg Pro Val Gln Gly Leu Glu Trp Ile Gly Asp Ile Gly Ser Ala Asp Asn Ser Thr Lys Tyr Ala Pro Pro Phe Leu Gly Lys Ala Gln Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ile Arg Tyr Ala Ser Ser Gly Trp Gly Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Ile Thr Gln Ser Pro Ala Leu Met Ala Asp Ser Pro Gly Glu Lys Val Thr Ile Thr Cys Asp Tyr Ser Glu Glu Ile Ser Met Ser Tyr Leu Ala Trp Tyr Gln Gln Ser Ser Gly Ile Ser Pro Lys Pro Trp Ile Tyr Thr Thr Ala Gly Leu Ala Pro Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Thr Ser Ala Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Ser Ser Ala Ser Ser Leu Pro Cys Arg Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , 2 Ambystoma laterale x Ambystoma jeffersonianum, 2 Ambystoma laterale x Ambystoma jeffersonianum,"(9/10) an anti-n protein monoclonal antibody characterized by: wherein the heavy chain variable region amino acid sequence of the antibody is seq id no:9, the amino acid sequence of the light chain variable region sequence is seq id no:10."
https://patents.google.com/patent/WO2015179535A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Ser Tyr Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Arg Gly Ser Gly His Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Asp Gly Ser Ile Val Gly Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Thr Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , synthetic  , synthetic  ,"(2/10) the pharmaceutical composition of any one of claims 20 - 23, wherein the first antibody or antigen-binding fragment thereof comprises a hcvr, wherein the hcvr comprises an amino acid sequence selected from the group consisting of seq id no:2, 18, 66, 114, 170, and 218; and a lcvr, wherein the lcvr comprises an amino acid sequence selected from the group consisting of seq id no:10, 26, 74, 106, 162, and 226"
https://patents.google.com/patent/WO2021173753A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Pro Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Thr Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Gly Tyr Met Glu Leu Arg Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Tyr Thr Arg Gly Ala Phe Phe Gly Glu Ser Leu Ile Gly Gly Phe Asp Asn Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Thr Val Ser Ser Thr Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Asp Thr Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic sequence SARS-CoV-2 S309-v1.7 mAb VH  , SARS-CoV-2 S309-v13 mAb VL (VK)  ,"(119/168) ""s309-14"" comprises a w105f vh variant sequence (seq id no:119) and the wild- type vl sequence (seq id no:168) of s309"
https://patents.google.com/patent/WO2021173753A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Pro Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Phe Ile Ser Thr Tyr Asn Ala Asn Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Gly Tyr Met Glu Leu Arg Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Tyr Thr Arg Gly Ala Phe Phe Gly Glu Ser Leu Ile Gly Gly Phe Asp Asn Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Thr Val Ser Ser Thr Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Asp Thr Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , SARS-CoV-2 S309-v2.9 mAb VH  , SARS-CoV-2 S309-v13 mAb VL (VK)  ,"(172/168) ""s309-15"" comprises a w50f/g56a/w105f vh variant (seq id no:172) and the wild-type vl sequence of s309 (seq id no:168)"
https://patents.google.com/patent/WO2021173753A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Pro Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Thr Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Gly Tyr Met Glu Leu Arg Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Tyr Thr Arg Gly Ala Trp Phe Gly Glu Ser Leu Ile Gly Gly Phe Asp Asn Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Thr Val Ser Ser Thr Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Asp Thr Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic sequence SARS-CoV-2 S309-v1 mAb VH  , SARS-CoV-2 S309-v13 mAb VL (VK)  ,"(105/168) ""s309-11"" comprises the wild-type vh sequence (seq id no:105) and the wild-type vl sequence (seq id no:168) of s309"
https://patents.google.com/patent/WO2021173753A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Pro Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Phe Ile Ser Thr Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Gly Tyr Met Glu Leu Arg Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Tyr Thr Arg Gly Ala Trp Phe Gly Glu Ser Leu Ile Gly Gly Phe Asp Asn Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Thr Val Ser Ser Thr Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Asp Thr Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic sequence SARS-CoV-2 S309-v2 mAb VH  , SARS-CoV-2 S309-v13 mAb VL (VK)  ,"(129/168) ""s309-13"" comprises a w50f mutation in vh (seq id no:129) and the wild-type vl sequence (seq id no:168) of s309"
https://patents.google.com/patent/WO2021173753A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Asp Met His Trp Val Arg Gln Thr Thr Gly Lys Gly Leu Glu Trp Val Ser Thr Ile Gly Thr Ala Gly Asp Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Asp Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Ser Ser Gly Tyr Tyr Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Leu Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ala Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Ile Tyr Tyr Cys Gln Gln Ser Tyr Val Ser Pro Thr Tyr Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Synthetic sequence SARS-CoV-2 S304 mAb VH  , Synthetic sequence SARS-CoV-2 S304 mAb VL (VK)  ,"(79/83) in still further embodiments, an antigen or an antigen-binding fragment of the present disclosure comprises a vh comprising or consisting of the amino acid sequence according to seq id no:79 and a vl comprising or consisting of the amino acid sequence according to seq id no:83 and is capable of neutralizing a sars- cov-2 infection, or a virus pseudotyped with sars-cov-2, with an ic50 of about 16 to about 20 μg/ml"
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr TyrAsp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asp Pro Ile Gly Gly Thr Thr Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Thr Val Gly Phe Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser LeuTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,198118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 198,239109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 239,"(198/239) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:198 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:239."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ala PheTyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Ile Ser Gly Thr Ala Asn Tyr Ala Gln LysPheGln Gly Arg Ala Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Glu Val Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro ValLeu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Thr Ser AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,231118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 231,272109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 272,"(231/272) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:231 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:272."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Asn Asn TyrAsp Leu His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Ile Phe Asp Thr Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Leu Glu Thr Val Met Gly Gly Met Val Lys Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Ile Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Gly AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,195118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 195,236109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 236,"(195/236) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:195 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:236."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser PheAla Ile Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetAla Leu Ile Asn Pro Ser Ser Gly Thr Thr Ser Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Glu Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser HisTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,229118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 229,270109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 270,"(229/270) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:229 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:270."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ser Phe Ser Arg PhePro Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Arg PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Leu Glu Thr Val Met Gly Gly Leu Gln Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,232118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 232,273109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 273,"(232/273) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:232 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:273."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Asn Thr Phe Ser Met PheAla Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp ValGly Val Ile Asn Pro Ile Gly Ser Thr Thr Thr Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Val Ser Ser Ser AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,228118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 228,269109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 269,"(228/269) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:228 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:269."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly PheTyr Met Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Thr Pro Ile Leu Gly Thr Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Glu Ile Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Trp Asp Ser Ser Ser AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,219118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 219,260109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 260,"(219/260) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:219 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:260."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp PheTyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Leu Glu Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser HisTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,205118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 205,246109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 246,"(205/246) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:205 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:246."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Ser TyrTyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Val Ile Asp Pro Ser Glu Gly Ser Thr Ser Asn Ala Arg Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysVal Ser Asp Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val ValTyr Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser LeuTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,209118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 209,250109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 250,"(209/250) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:209 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:250."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser PheTyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Ile Phe Gly Glu Ala Glu Tyr Ala His Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Met Glu Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,225118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 225,266109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 266,"(225/266) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:225 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:266."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser PheAsp Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Tyr Glu Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser TyrTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,203118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 203,244109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 244,"(203/244) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:203 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:244."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Asn TyrAsp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Thr Pro Ile Phe Gly Thr Ala Lys Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,220118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 220,261109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 261,"(220/261) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:220 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:261."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser TyrAsp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Thr Phe Phe Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser TyrTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,214118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 214,255109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 255,"(214/255) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:214 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:255."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser TyrTyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Leu Ile Asp Pro Ser Gly Gly Thr Thr Ser Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysVal Trp Asp Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly LysThr Ala Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Lys Asp Gly Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Arg Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser LeuTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,194118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 194,235109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 235,"(194/235) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:194 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:235."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser PheHis Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Thr Pro Ile Phe Gly Ile Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Leu Glu Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Trp Asp Ser Ser Gly AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,196118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 196,237109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 237,"(196/237) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:196 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:237."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser TyrTyr Val His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Leu Pro Ile Leu Gly Thr Pro His Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Leu Glu Thr Val Met Gly Gly Met Thr Ala Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,223118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 223,264109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 264,"(223/264) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:223 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:264."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Gly Asn TyrPro Ile Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Tyr Pro Gly Asp Ser Asp Ala Arg Tyr Arg Pro Ser PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Phe Ser Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Asp Ser Ser AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,208118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 208,249109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 249,"(208/249) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:208 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:249."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Asp PheAsp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysGly Met Asp Thr Val Met Gly Gly Met Thr Ser Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser His AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,216118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 216,257109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 257,"(216/257) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:216 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:257."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser TyrAla Ile Ser Trp Met Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Asn Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Thr Tyr Trp Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser PheTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,230118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 230,271109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 271,"(230/271) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:230 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:271."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Asp PheTyr Leu His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Thr Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Met Glu Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,224118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 224,265109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 265,"(224/265) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:224 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:265."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ala TyrTyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Thr Pro Leu Phe Gly Thr Pro Ser Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Leu Glu Thr Val Met Gly Gly Val Gly Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaVal Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,201118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 201,242109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 242,"(201/242) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:201 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:242."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser TyrThr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Thr Val Met Gly Gly Met Gly Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser PheTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,221118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 221,262109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 262,"(221/262) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:221 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:262."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Asn Phe Ile Asn TyrTyr Leu His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Thr Pro Ile Phe Gly Ile Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Glu Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Lys Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Gly Ser AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,200118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 200,241109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 241,"(200/241) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:241."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Arg TyrAsp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asn Pro Ser Gly Gly Ser Thr Thr Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla His Asp Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser TyrTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,197118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 197,238109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 238,"(197/238) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:197 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:238."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser TyrTyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Thr Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Val Glu Thr Val Met Gly Gly Met Gln Met Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,226118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 226,267109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 267,"(226/267) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:226 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:267."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn TyrThr Ile Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp LeuGly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asp Tyr Ala Gln Lys LeuGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Ala Leu Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Arg Ser AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,204118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 204,245109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 245,"(204/245) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:204 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:245."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser TyrGly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Val Glu Thr Val Met Gly Gly Phe Thr Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,222118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 222,263109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 263,"(222/263) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:222 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:263."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Asn TyrGlu Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Thr Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,218118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 218,259109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 259,"(218/259) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:218 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:259."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp PheHis Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Leu Glu Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,215118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 215,256109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 256,"(215/256) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:215 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:256."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Met Phe Thr Glu PheTyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Val Ser Gly Thr Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Glu Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,212118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 212,253109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 253,"(212/253) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:212 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:253."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Pro Phe Ser Ser TyrGlu Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Thr Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Asp Glu Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Asn AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,206118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 206,247109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 247,"(206/247) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:206 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:247."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Asn Ala PheTyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Leu Glu Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Gly Ser Ser AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,217118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 217,258109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 258,"(217/258) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:217 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:258."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser TyrTyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Ile Phe Gly Glu Ala Glu Tyr Ala His Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Met Glu Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,211118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 211,252109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 252,"(211/252) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:211 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:252."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn PheAla Leu Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Leu Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Arg PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Ser Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Ala Ser Ser Ser AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,207118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 207,248109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 248,"(207/248) an antibody or an antigen-binding fragment that selectively binds to a sars-cov-2, wherein the antibody or the antigen-binding fragment comprises a vh chain having an amino acid sequence of seq id no:207 and a vl chain having an amino acid sequence of seq id no:248."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Asn Arg PheAla Met Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Thr Ile Asn Pro Ser Gly Gly Ser Thr Ile Tyr Thr Gln Arg PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysGly His Asp Thr Val Met Gly Gly Met Gly Glu Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Thr Asp Ser Ser Ser AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,199118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 199,240109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 240,"(199/240) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:199 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:240."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Asn TyrAsp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Thr Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Arg Ser AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,213118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 213,254109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 254,"(213/254) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:213 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:254."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Asn TyrAsp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Thr Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser His Ser AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,227118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 227,268109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 268,"(227/268) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:227 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:268."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn PheAla Ile Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Val Ile Asn Pro Gly Gly Gly Ser Thr Thr Tyr Ala Gln Thr PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,202118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 202,243109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 243,"(202/243) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:202 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:243."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Ser Thr Phe Ser Met PheAla Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp ValGly Val Ile Asn Pro Arg Gly Ser Ser Thr Thr Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Arg Ser Ser AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr ValLeu Ala,210118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 210,251109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 251,"(210/251) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:210 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:251."
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Cys Thr Phe Thr Arg PheThr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Thr Pro Ile Phe Gly Ile Thr Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla His Asp Thr Val Met Gly Gly Met Glu Glu Trp Gly Gln Gly ThrLeu ValThr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Asn AspTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,192118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 192,233109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 233,"(192/233) in further embodiments, the 2dd8-derived antibody or antigen-binding fragment comprises a vl having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to any one of seq id no:233-273, and a vh having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to any one of seq id no:192-232"
https://patents.google.com/patent/US11028150B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr TyrAsp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Thr Tyr Trp Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Ser Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro GlyLys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys SerVal His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val IleTyr Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser GlySer Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu AlaGly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser PheTyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ala,193118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 193,234109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 234,"(193/234) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:193 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:234."
https://patents.google.com/patent/KR102229225B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Arg Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asp Asn Tyr Val Ser Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asp Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 3 HC variable region, No. 3 LC variable region,(114/113)  a) the light chain variable region set forth in seq id no:113; and b) an antibody comprising the heavy chain variable region set forth in seq id no:114; 
https://patents.google.com/patent/KR102229225B1/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 13 HC variable region, No. 13 LC variable region,(134/133)  a) the light chain variable region set forth in seq id no:133; and b) an antibody comprising the heavy chain variable region set forth in seq id no:134; 
https://patents.google.com/patent/KR102229225B1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Glu Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Arg Gly Tyr Ser Gly Tyr Gly Ser Thr Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 11 HC variable region, No. 11 LC variable region,(130/129)  a) the light chain variable region set forth in seq id no:129; and b) an antibody comprising a heavy chain variable region set forth in seq id no:130; 
https://patents.google.com/patent/KR102229225B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No. 6 HC variable region, No. 6 LC variable region,(120/119)  a) the light chain variable region set forth in seq id no:119; and b) an antibody comprising the heavy chain variable region set forth in seq id no:120; 
https://patents.google.com/patent/KR102229225B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Ser Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Asn Asn Leu Ser Ala Gly Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , No. 9 HC variable region, No. 9 LC variable region,(126/125)  a) the light chain variable region set forth in seq id no:125; and b) an antibody comprising the heavy chain variable region set forth in seq id no:126; 
https://patents.google.com/patent/KR102229225B1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 15 HC variable region, No. 15 LC variable region,(138/137)  a) the light chain variable region set forth in seq id no:137; and b) an antibody comprising the heavy chain variable region set forth in seq id no:138; 
https://patents.google.com/patent/KR102229225B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Val Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 10 HC variable region, No. 10 LC variable region,(128/127)  a) the light chain variable region set forth in seq id no:127; and b) an antibody comprising the heavy chain variable region set forth in seq id no:128; 
https://patents.google.com/patent/KR102229225B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Met Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 16 HC variable region, No. 16 LC variable region,(140/139)  a) the light chain variable region set forth in seq id no:139; and b) an antibody comprising a heavy chain variable region set forth in seq id no:140; 
https://patents.google.com/patent/KR102229225B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ser Leu Val Ser Gly Arg Tyr Cys Ser Gly Val Thr Cys Tyr Ser Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , No. 1 HC variable region, No. 1 LC variable region,(110/109)  a) the light chain variable region set forth in seq id no:109; and b) an antibody comprising the heavy chain variable region set forth in seq id no:110; 
https://patents.google.com/patent/KR102229225B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Thr Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Ser Ile Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Val Lys Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Pro Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu , No. 17 HC variable region, No. 17 LC variable region,(142/141)  a) the light chain variable region set forth in seq id no:141; and b) an antibody comprising the heavy chain variable region set forth in seq id no:142; and 
https://patents.google.com/patent/KR102229225B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 7 HC variable region, No. 7 LC variable region,(122/121)  a) the light chain variable region set forth in seq id no:121; and b) an antibody comprising the heavy chain variable region set forth in seq id no:122; 
https://patents.google.com/patent/KR102229225B1/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ser Leu Val Ser Gly Arg Tyr Cys Ser Gly Val Thr Cys Tyr Ser Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asp Leu Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , No. 2 HC variable region, No. 2 LC variable region,(112/111)  a) the light chain variable region set forth in seq id no:111; and b) an antibody comprising the heavy chain variable region set forth in seq id no:112; 
https://patents.google.com/patent/KR102229225B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Val Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Arg Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 5 HC variable region, No. 5 LC variable region,(118/117)  a) the light chain variable region set forth in seq id no:117; and b) an antibody comprising the heavy chain variable region set forth in seq id no:118; 
https://patents.google.com/patent/KR102229225B1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Arg Gly Tyr Ser Gly Tyr Gly Ser Thr Tyr Tyr Ser Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 12 HC variable region, No. 12 LC variable region,(132/131)  a) the light chain variable region set forth in seq id no:131; and b) an antibody comprising the heavy chain variable region set forth in seq id no:132; 
https://patents.google.com/patent/KR102229225B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys Ala Val Asn Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 14 HC variable region, No. 14 LC variable region,(136/135)  a) the light chain variable region set forth in seq id no:135; and b) an antibody comprising the heavy chain variable region set forth in seq id no:136; 
https://patents.google.com/patent/KR102229225B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No. 4 HC variable region, No. 4 LC variable region,(116/115)  a) the light chain variable region set forth in seq id no:115; and b) an antibody comprising the heavy chain variable region set forth in seq id no:116; 
https://patents.google.com/patent/KR102229225B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Thr Ser Asn Ile Gly Asn Asn Phe Val Ser Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asp Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 8 HC variable region, No. 8 LC variable region,(124/123)  a) the light chain variable region set forth in seq id no:123; and b) an antibody comprising the heavy chain variable region set forth in seq id no:124; 
https://patents.google.com/patent/KR102229225B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 18 HC variable region, No. 18 LC variable region,(144/143)  a) the light chain variable region set forth in seq id no:143; and b) an antibody comprising a heavy chain variable region set forth in seq id no:144. 
https://patents.google.com/patent/CN112961238A/en, atgggcagca gccatcatca tcatcatcac agcagcggcc tggtgccgcg cggcagccat atggctagca tgtcggactc agaagtcaat caagaagcta agccagaggt caagccagaa gtcaagcctg agactcacat caatttaaag gtgtccgatg gatcttcaga gatcttcttc aagatcaaaa agaccactcc tttaagaagg ctgatggaag cgttcgctaa aagacagggt aaggaaatgg actccttaag attcttgtac gacggtatta gaatccaagc tgatcagacc cctgaagatt tggacatgga ggataacgat attattgagg ctcacagaga acagattggt ggatcccagg tgcagctgca ggagtctgga ggaggcttgg tgcaggctgg agggtctctg agactctctt gtgccgccag cggatacacc aacagtcgct actacatggg ctggttccgc caggctccag ggaaggagcg tgagttcgta gcagcgattt ctgctattgg tcgcacatac tatgcagact ccgtgaaggg ccgattcacc atctccagag acaacgccaa gaacacggtg tatcttcaaa tgaacagcct gaaacctgag gacacggccg tttattactg tgcagccgac tcttctctgg ctggtctgcg tggtcgtctg tacgactact ggggtcaggg tactcaggtc accgtctcct cagcggccgc atacccgtac gacgttccgg actacggttc ctgactcgag ,, Artificial Sequence (Artificial Sequence),,"(1) the expression cassette sequence of the sumo-nano antibody is shown in seq id no:1, and the amino acid sequence is shown in seq id no:2; also shown in fig. 6, the structural regions of his, sumo, nanobody and ha tag are distinguished by different gray scales or underlines, respectively, and correspond to the gray scale or underline portion in the name."
https://patents.google.com/patent/CN112961238A/en, caggtgcagc tgcaggagtc tggaggaggc ttggtgcagg ctggagggtc tctgagactc tcttgtgccg ccagcggata caccaacagt cgctactaca tgggctggtt ccgccaggct ccagggaagg agcgtgagtt cgtagcagcg atttctgcta ttggtcgcac atactatgca gactccgtga agggccgatt caccatctcc agagacaacg ccaagaacac ggtgtatctt caaatgaaca gcctgaaacc tgaggacacg gccgtttatt actgtgcagc cgactcttct ctggctggtc tgcgtggtcg tctgtacgac tactggggtc agggtactca ggtcaccgtc tcctca ,, Artificial Sequence (Artificial Sequence),,"(7) the nanobody of claim 1, based on the s1 subunit of the s protein of a novel coronavirus, characterized in that: the nucleotide sequence of the sdab antibody fragment is shown in seq id no:7."
https://patents.google.com/patent/CN112961238A/en, Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Asn Ser Arg Tyr Tyr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Ala Ile Gly Arg Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Asp Ser Ser Leu Ala Gly Leu Arg Gly Arg Leu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,"(6) a nanobody based on the s1 subunit of the s protein of a novel coronavirus is disclosed, which comprises an sdab antibody fragment, wherein the amino acid sequence of the sdab antibody fragment is shown as seq id no:6."
https://patents.google.com/patent/CN112961238A/en, Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro Arg Gly Ser His Met Ala Ser Met Ser Asp Ser Glu Val Asn Gln Glu Ala Lys Pro Glu Val Lys Pro Glu Val Lys Pro Glu Thr His Ile Asn Leu Lys Val Ser Asp Gly Ser Ser Glu Ile Phe Phe Lys Ile Lys Lys Thr Thr Pro Leu Arg Arg Leu Met Glu Ala Phe Ala Lys Arg Gln Gly Lys Glu Met Asp Ser Leu Arg Phe Leu Tyr Asp Gly Ile Arg Ile Gln Ala Asp Gln Thr Pro Glu Asp Leu Asp Met Glu Asp Asn Asp Ile Ile Glu Ala His Arg Glu Gln Ile Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Asn Ser Arg Tyr Tyr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Ala Ile Gly Arg Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Asp Ser Ser Leu Ala Gly Leu Arg Gly Arg Leu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Ala Ala Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Gly Ser,, Artificial Sequence (Artificial Sequence),,"(2) the expression cassette sequence of the sumo-nano antibody is shown in seq id no:1, and the amino acid sequence is shown in seq id no:2; also shown in fig. 6, the structural regions of his, sumo, nanobody and ha tag are distinguished by different gray scales or underlines, respectively, and correspond to the gray scale or underline portion in the name."
https://patents.google.com/patent/US7396914B2/en,Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val His Pro Gly GlySer Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Ser TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Ile Gly Thr Gly Gly Gly Thr Tyr Tyr Ala Asp Ser Val LysGly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr LeuGln Met Asn Ser Leu Arg Ala Glu Asp Met Ala Val Tyr Tyr Cys AlaArg,Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro GlyGlu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser TyrLeu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu IleTyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu ProGlu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro LeuThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys,18 97 PRT SARS-Associated Coronavirus 18,21 107 PRT SARS-Associated Coronavirus 21,"(18/21) the invention also provides isolated monoclonal antibodies, or antigen-binding portions thereof, that include: (a) a heavy chain variable region that is the product of or derived from a human vh dp44, vh 3-23, or vh 3-7 gene (which encode the amino acid sequences set forth in seq id no:18, 19 and 20, respectively); (b) a light chain variable region that is the product of or derived from a human vk l6 gene (which encodes the amino acid sequences set forth in seq id no:21); and (c) specifically bind to the s protein."
https://patents.google.com/patent/US7396914B2/en,Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Xaa Pro Gly GlySer Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Ser TyrAsp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Val Val Gly Thr Gly Asp Gly Thr Tyr Tyr Ala Asp Ser Val LysGly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr LeuGln Met Asn Ser Leu Arg Ala Glu Asp Met Ala Val Tyr Tyr Cys AlaArg Asp Gln Trp Trp Gly Ser Asp Tyr,Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro GlyGlu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser TyrLeu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu IleTyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu ProGlu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro LeuThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys,17 105 PRT SARS-Associated Coronavirus VARIANT 13 Xaa = Lys or Gln 17,14 107 PRT SARS-Associated Coronavirus 14,"(17/14) in another embodiment, the antibody includes a heavy chain variable region including the amino acid sequence of seq id no:17 and a light chain variable region including the amino acid sequence of seq id no:14."
https://patents.google.com/patent/US7396914B2/en,Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val His Pro Gly GlySer Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Ser TyrAsp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Val Val Gly Thr Gly Asp Gly Thr Tyr Tyr Ala Asp Ser Val LysGly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr LeuGln Met Asn Ser Leu Arg Ala Glu Asp Met Ala Val Tyr Tyr Cys AlaArg Asp Gln Trp Trp Gly Ser Asp Tyr Trp Gly Gln Gly Thr Leu ValThr Val Ser Ser,Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro GlyGlu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser TyrLeu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu IleTyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu ProGlu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro LeuThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys,13 116 PRT SARS-Associated Coronavirus 13,14 107 PRT SARS-Associated Coronavirus 14,(13/14)  and antigen binding portions thereof. the vh amino acid sequence of 201.2 is shown in seq id no:13. the vl amino acid sequence of 201.2 is shown in seq id no:14.
https://patents.google.com/patent/CN112666350B/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Arg Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Thr Arg His Gly Thr Arg Gly Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Glu Val Gln Leu Gln Gln Ser Val Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Pro Ser Gly Phe Asn Ile Lys Asp Thr Tyr Met His Trp Val Gln Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Arg Ile Asp Pro Ala Asn Gly Tyr Ala Lys Tyr Ala Pro Lys Phe Gln Gly Lys Ala Thr Ile Ser Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Asp Ile Tyr Pro Tyr Val Ile Gly Phe Ser Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(1/3) wherein, the amino acid sequences of the heavy chain variable region and the light chain variable region of a first monoclonal antibody (namely a labeled antibody) for resisting the novel coronavirus s protein are respectively shown as seq id no:1-2; the amino acid sequences of the heavy and light chain variable regions of the second monoclonal antibody (i.e., the coating antibody) against the novel coronavirus s protein are shown in seq id no:3-4, respectively."
https://patents.google.com/patent/CN112666350B/en, Glu Val Gln Leu Gln Gln Ser Val Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Pro Ser Gly Phe Asn Ile Lys Asp Thr Tyr Met His Trp Val Gln Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Arg Ile Asp Pro Ala Asn Gly Tyr Ala Lys Tyr Ala Pro Lys Phe Gln Gly Lys Ala Thr Ile Ser Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Asp Ile Tyr Pro Tyr Val Ile Gly Phe Ser Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly Glu Arg Val Ser Leu Thr Cys Arg Ala Ser Gln Glu Ile Ser Gly Tyr Leu Ser Trp Leu Gln Gln Lys Pro Asp Gly Thr Ile Lys Arg Leu Ile Tyr Ala Ala Ser Thr Leu Asp Ser Gly Val Pro Glu Arg Phe Ser Gly Ser Trp Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser Glu Asp Phe Ala Asp Tyr Tyr Cys Leu Gln Tyr Ala Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(3/4)  the amino acid sequences of the heavy and light chain variable regions of the second antibody (2) are shown in seq id no:3 and seq id no:4, respectively."
https://patents.google.com/patent/CN112666350B/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Arg Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Thr Arg His Gly Thr Arg Gly Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln Tyr Trp Asn Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(1/2)  are respectively shown as seq id no:1 and seq id no:2; the amino acid sequences of the heavy and light chain variable regions of the second antibody (
https://patents.google.com/patent/WO2021238854A1/en, Glu Val Leu Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Phe Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Tyr Gly Asn Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Leu Leu Thr Gln Ser Pro Ala Ile Leu Ser Val Ser Pro Gly Glu Arg Val Ser Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Ser Ile His Trp Tyr His Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Ser Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Ser Asn Asn Trp Pro Thr Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  5B7D7ɱ  ,  5B7D7ɱ  ,"(6/7)  the amino acid sequence of the heavy chain variable region is shown in seq id no:6, and the amino acid sequence of the light chain variable region is shown in seq id no:7;"
https://patents.google.com/patent/WO2021238854A1/en, Glu Val Leu Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Ser Gly Phe Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Gly Tyr Gly Asn Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Leu Leu Thr Gln Ser Pro Ala Ile Leu Ser Val Ser Pro Gly Glu Arg Val Ser Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Ser Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Ser Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Ser Asn Ser Trp Pro Thr Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  11D5D3ɱ  ,  11D5D3ɱ  ,"(12/13)  the amino acid sequence of the heavy chain variable region is shown in seq id no:12, and the amino acid sequence of the light chain variable region is shown in seq id no:13."
https://patents.google.com/patent/WO2021238854A1/en, Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Asp Pro Lys Phe Gln Ala Lys Ala Thr Ile Thr Ala Asn Thr Ser Ser Asn Thr Ala Tyr Leu His Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Pro Tyr Tyr Asp Tyr Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Gln Ser Ala Ser Leu Gly Glu Ser Val Thr Ile Thr Cys Leu Ala Ser Gln Thr Ile Gly Thr Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Gln Leu Leu Ile Tyr Ala Ala Thr Ser Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Lys Phe Ser Phe Lys Ile Ser Ser Leu Gln Ala Glu Asp Phe Val Ser Tyr Tyr Cys Gln Gln Leu Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  5E10G8ɱ  ,  5E10G8ɱ  ,"(4/5)  the amino acid sequence of the heavy chain variable region is shown in seq id no:4, and the amino acid sequence of the light chain variable region is shown in seq id no:5;"
https://patents.google.com/patent/WO2021238854A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Gln Leu Val Arg Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asn Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile Asp Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Arg Gly Leu Val Asp Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ala Ala Pro Ser Val Pro Val Thr Pro Gly Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr Trp Phe Leu Gln Arg Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Arg Met Ser Asn Leu Ala Ser Gly Val Pro Asp Arg Phe Ser Asp Ser Gly Ser Gly Thr Ala Phe Thr Leu Arg Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln His Leu Glu Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys ,  6D11F2ɱ  ,  6D11F2ɱ  ,"(2/3)  the amino acid sequence of the heavy chain variable region is shown in seq id no:2, and the amino acid sequence of the light chain variable region is shown in seq id no:3;"
https://patents.google.com/patent/WO2021238854A1/en, Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Asp Tyr Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp Met Gly Tyr Ile Ser Tyr Ser Gly Asn Thr Gly Tyr Asn Pro Ser Leu Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Gly Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Phe Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  4A1D10ɱ  ,  4A1D10ɱ  ,"(8/9)  the amino acid sequence of the heavy chain variable region is shown in seq id no:8, and the amino acid sequence of the light chain variable region is shown in seq id no:9;"
https://patents.google.com/patent/WO2021238854A1/en, Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Ser Gly Gly Ser Thr Asp Tyr Asn Ala Ala Phe Ile Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Phe Lys Met Tyr Ser Leu His Ser Asn Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Asn Ser Asn Asp Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Ser Ser Gly Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Phe Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Arg Glu Leu Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  10G6H5ɱ  ,  10G6H5ɱ  ,"(10/11)  the amino acid sequence of the heavy chain variable region is shown in seq id no:10, and the amino acid sequence of the light chain variable region is shown in seq id no:11; or"
https://patents.google.com/patent/US10759846B2/en,Gln Val Gln Leu Gln Gln Ser Gly Gly Glu Leu Val Lys Pro Gly AlaSer Val Lys Leu Ser Cys Lys Thr Ser Gly Phe Thr Phe Ser Ser SerTyr Ile Ser Trp Leu Lys Gln Lys Pro Gly Gln Ser Leu Glu Trp IleAla Trp Ile Tyr Ala Gly Thr Gly Gly Thr Glu Tyr Asn Gln Lys PheThr Gly Lys Ala Gln Val Thr Val Asp Thr Ser Ser Ser Thr Ala TyrMet Gln Phe Ser Ser Leu Thr Thr Glu Asp Ser Ala Ile Tyr Tyr CysAla Arg Gly Gly Ser Ser Phe Ala Met Asp Tyr Trp Gly Gln Gly ThrSer Val Thr Val Ser Ser ,Gln Leu Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu GlyGln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Asn TyrGly Ile Ser Phe Met Asn Trp Phe Gln Gln Lys Pro Gly Gln Pro ProLys Leu Leu Ile His Thr Ala Ser Asn Gln Gly Ser Gly Val Pro AlaArg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile HisPro Val Glu Asp Asp Asp Thr Ala Met Tyr Phe Cys Gln Gln Ser GluGlu Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys,115118PRTMus Musculus 115,117111PRTMus Musculus 117,"(115/117) the vh and the vl of the second isolated monoclonal antibody comprise the amino acid sequences set forth as seq id no:115 and 117, respectively (g"
https://patents.google.com/patent/US10759846B2/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Thr TyrAla Leu Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala TyrMet Glu Leu Asn Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Gly Ser Arg Ser Ser Ser Ser Ala Glu Tyr Phe Gln His TrpGly Gln Gly Thr Leu Val Thr Val Ser Ser,Gln Ser Ala Leu Thr Gln Pro Arg Ser Val Ser Gly Ser Pro Gly GlnSer Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly TyrAsn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys LeuMet Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg PheSer Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly LeuGln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Cys Ser Tyr Ala Gly SerTyr Thr Leu Glu Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu,48122PRTHomo Sapiens 48,50112PRTHomo Sapiens 50,"(48/50) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:48 and 50, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection."
https://patents.google.com/patent/US10759846B2/en,Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly GlySer Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg TyrAla Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp ValAla Thr Ile Asn Asn Gly Gly Ser Tyr Ser Tyr Tyr Pro Asp Ser ValLys Gly Arg Leu Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu TyrLeu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Leu Tyr Tyr CysAla Arg His Tyr Asp Tyr Asp Gly Tyr Tyr Tyr Thr Met Asp Phe TrpGly Gln Gly Thr Ser Val Thr Val Ser Ser,Asp Val Leu Met Thr Gln Ile Pro Leu Ser Leu Pro Val Ser Leu GlyAsp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His SerAsn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Lys Pro Leu Ile Tyr Lys Val Ser Asn Arg Ile Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln GlySer His Val Pro Tyr Thr Phe Gly Gly Gly Thr Asn Leu Glu Ile LysArg,127122PRTMus Musculus 127,129113PRTMus Musculus 129,"(127/129) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:127 and 129, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection."
https://patents.google.com/patent/US10759846B2/en,Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser GluThr Leu Ser Leu Thr Cys Ala Val Ser Gly Gly Ser Ile Ser Ser AsnTyr Trp Tyr Trp Ile Arg Gln Ser Pro Val Lys Gly Leu Glu Trp IleGly Tyr Ile Tyr Gly Gly Ser Gly Gly Thr Glu Tyr Asn Pro Ser LeuLys Ser Arg Val Thr Ile Ser Thr Asp Thr Ser Lys Asn Gln Phe PheLeu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr CysAla Arg Ser Phe Tyr Ser Trp Asn Gly Glu Ser Trp Gly Gln Gly ValVal Val Thr Val Ser Ser ,Asp Ile Gln Met Ser Gln Thr Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asn Asp TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Tyr Gly Asn Ser Leu Ala Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Asp Ser Phe Pro LeuThr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys,52118PRTMacaca Mulatta 52,54107PRTMacaca Mulatta 54,"(52/54) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:52 and 54, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection."
https://patents.google.com/patent/US10759846B2/en,Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Val Val Arg Pro Ser GluThr Leu Ser Leu Ser Cys Ala Val Ser Gly Gly Ser Ile Ser Asp SerTyr Arg Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu TrpVal Gly Tyr Ile Phe Ala Thr Gly Thr Thr Thr Asn Tyr Asn Pro SerLeu Lys Ser Arg Val Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln PheSer Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr TyrCys Ala Arg Glu Pro Phe Lys Tyr Cys Ser Gly Gly Val Cys Tyr AlaHis Lys Asp Asn Ser Leu Asp Val Trp Gly Gln Gly Val Leu Val ThrVal Ser Ser ,Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro GlyGlu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser AsnLeu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu IleHis Ser Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser GlySer Gly Ser Gly Thr Glu Phe Ser Leu Thr Ile Ser Ser Leu Glu AlaGlu Asp Val Gly Val Tyr His Cys Tyr Gln His Ser Ser Gly Tyr ThrPhe Gly Pro Gly Thr Lys Leu Asp Ile Lys,60tggggccagg gagttctggt caccgtctcc tca 3936131PRTmacaca mulatta 6,80aggttcagtg gcagcgggtc tgggacagag ttcagtctca ccatcagcag tctggaggct 240gaagatgttg gagtttatca ctgctatcag catagcagcg ggtacacttt cggccccggg 300accaaactgg atatcaaa 3188106PRTmacaca mulatta 8,"(6/8) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:6 and 8, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection."
https://patents.google.com/patent/US10759846B2/en,Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Arg Pro Gly ValSer Val Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp TyrAla Ile His Trp Val Lys Gln Ser His Ala Lys Ser Leu Glu Trp IleGly Val Phe Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys PheLys Gly Arg Ala Thr Met Thr Val Asp Lys Ser Ser Ser Thr Ala TyrMet Glu Leu Ala Arg Leu Thr Ser Glu Asp Ser Ala Ile Tyr Tyr CysAla Arg Lys Ser Tyr Tyr Val Asp Tyr Val Asp Ala Met Asp Tyr TrpGly Gln Gly Thr Ser Val Thr Val Ser Ser,Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu GlyGln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Asn TyrGly Ile Ser Phe Met Asn Trp Phe Gln Gln Lys Pro Gly Gln Pro ProLys Leu Leu Ile Ser Ala Thr Ser Asn Gln Gly Ser Gly Val Pro AlaArg Phe Ile Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile HisPro Val Glu Glu Asp Asp Thr Ala Met Tyr Phe Cys Gln Gln Ser LysGlu Val Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys,119122PRTMus Musculus 119,121111PRTMus Musculus 121,"(119/121) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:119 and 121, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection."
https://patents.google.com/patent/US10759846B2/en,Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly His Ile Phe Thr Ser TyrVal Ile Asn Trp Leu Gln Glu Ala Pro Gly Gln Gly Phe Glu Trp MetGly Gly Ile His Pro Gly Asn Gly Gly Arg Asp Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Met Ser Thr Ser Thr Val TyrMet Glu Leu Arg Ser Leu Arg Ser Glu Asp Met Ala Val Tyr Tyr CysAla Ala Ser Ser Gly Ser Tyr Gly Val Ser Ser Leu Asp Val Trp GlyArg Gly Val Leu Val Thr Val Ser Ser,Gln Ser Ala Leu Thr Gln Pro Pro Ser Leu Ser Ala Ser Pro Gly AlaSer Ala Arg Leu Pro Cys Thr Leu Ser Ser Asp Leu Ser Val Gly SerLys Asn Met Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ala Pro Arg LeuPhe Leu Tyr Tyr Tyr Ser Asp Ser Asp Lys Gln Leu Gly Pro Gly ValPro Asn Arg Val Ser Gly Ser Lys Glu Thr Ser Ser Asn Thr Ala PheLeu Leu Ile Ser Gly Leu Gln Pro Glu Asp Glu Ala Asp Tyr Tyr CysGln Val Tyr Asp Ser Ser Ala Asn Trp Val Phe Gly Gly Gly Thr ArgLeu Thr Val Leu ,56121PRTMacaca Mulatta 56,58116PRTMacaca Mulatta 58,"(56/58) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:56 and 58, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection."
https://patents.google.com/patent/US10759846B2/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ile TyrAla Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Glu Gly Gly His Gln Gly Tyr Cys Ser Gly Gly Ser Cys TyrAsp Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Ala Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Thr Pro Ala Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys,360accctggtca ccgtctcctc a 38136127PRTHomo Sapiens 36,111111PRTArtificial SequenceAntibody variable region 111,"(36/111) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:36 and 111, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection."
https://patents.google.com/patent/US10759846B2/en,Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly GlySer Leu Lys Leu Ser Cys Ala Ala Ser Gly PheThr Phe Ser Ser TyrAla Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp ValAla Thr Ile Ser Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Glu Asn Thr Leu TyrLeu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr CysVal Arg Asp Gly Asn Ser Met Asp Tyr Trp Gly Gln Gly Thr Ser ValThr Val Ser Ser ,Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu GlyAsp Arg Val Thr Ile Ile Cys Arg Ala Ser Gln Asp Ile Asn Asn TyrLeu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu IleTyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu GlnGlu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Ala Asn Thr Leu Pro ProThr Phe Gly Ala Gly Thr Lys Leu Glu Leu Arg,123116PRTMus Musculus 123,125107PRTMus Musculus 125,"(123/125) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:123 and 125, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection."
https://patents.google.com/patent/US10759846B2/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ile TyrAla Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Glu Gly Gly His Gln Gly Tyr Cys Ser Gly Gly Ser Cys TyrAsp Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Thr Pro Ala Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys,360accctggtca ccgtctcctc a 38136127PRTHomo Sapiens 36,38111PRTHomo Sapiens 38,"(36/38) the vh and the vl of the first isolated monoclonal antibody comprise the amino acid sequences set forth as seq id no:36 and 38, respectively (c"
https://patents.google.com/patent/US10759846B2/en,Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser GluThr Leu Ser Leu Thr Cys Ala Val Ser Gly Gly Ser Ile Ser Ser AsnTyr Trp Asn Trp Ile Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp IleGly Tyr Ile Tyr Gly Gly Ser Gly Ser Thr Thr Tyr Asn Pro Ser LeuLys Ser Arg Val Ala Ile Ser Thr Asp Thr Ser Lys Asp Gln Phe SerLeu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr CysAla Arg Leu Leu Pro Leu Gly Gly Gly Tyr Cys Phe Asp Tyr Trp GlyGln Gly Val Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Thr Pro Phe Thr Leu Pro Val Thr Pro GlyGlu Ala Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Phe Asp SerAsp Tyr Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly GlnSer Pro Gln Leu Leu Ile Tyr Met Leu Ser Asn Arg Ala Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu LysIle Ser Arg Val Glu Ala Glu Asp Val Gly Leu Tyr Tyr Cys Met GlnSer Val Glu Tyr Pro Phe Thr Phe Gly Pro Gly Thr Lys Leu Asp IleLys,240ctgaagctga gctctgtgac cgccgcggac accgccgtat attactgtgc gagactgctg 300cccttagggg ggggatactg ctttgactac tggggccagg gagtcctggt caccgtctcc 360tca 3632121PRTmacaca mulatta 2,40atcagccggg tggaggctga ggatgttggg ttatattact gcatgcaaag tgtagagtat 300ccattcactt tcggccccgg gaccaaactg gatatcaaa 3394113PRTmacaca mulatta 4,"(2/4) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:2 and 4, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection."
https://patents.google.com/patent/US10759846B2/en,Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser GluThr Leu Ser Leu Thr Cys Ala Val Ser Gly Asp Ser Ile Ser Ser AsnTyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp IleGly Arg Phe Ser Gly Ser Gly Gly Ser Thr Asp Phe Asn Pro Ser LeuLys Ser Arg Val Thr Ile Ser Thr Asp Thr Ser Lys Asn Gln Phe SerLeu Asn Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr CysAla Lys Thr Tyr Ser Gly Thr Phe Asp Tyr Trp Gly Gln Gly Val LeuVal Thr Val Ser Ser ,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Asn Asn TyrLeu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Pro Leu IleTyr Tyr Ala Ser Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser GlySer Arg Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln LeuGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Asn Ser Pro TyrSer Phe Gly Gln Gly Thr Lys Val Glu Ile Lys,10117PRTmacaca mulatta 10,12107PRTmacaca mulatta 12,"(10/12) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:10 and 12, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection."
https://patents.google.com/patent/US10759846B2/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly SerSer Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ile TyrAla Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Glu Gly Gly His Gln Gly Tyr Cys Ser Gly Gly Ser Cys TyrAsp Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Ser Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Thr Pro Ala Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys,360accctggtca ccgtctcctc a 38136127PRTHomo Sapiens 36,110111PRTArtificial SequenceAntibody variable region 110,"(36/110) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:36 and 110, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection"
https://patents.google.com/patent/US10759846B2/en,Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser GluThr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser SerSer Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu GluTrp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro SerLeu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln PheSer Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr TyrCys Ala Ser Leu Leu Arg Pro Leu Ile Tyr Cys Ser Gly Gly Ser CysThr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly GlnSer Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly TyrAsn Tyr Val Ser Trp Cys Gln Gln His Pro Gly Lys Ala Pro Lys LeuMet Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg PheSer Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly LeuGln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser AsnIle Thr Leu Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu,40tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattactg tgcgagcctc 300ttaaggcccc tgatttattg tagtggtggt agctgcaccg actactgggg ccagggaacc 360ctggtcaccg tctcctca 37840126PRTHomo Sapiens 40,42110PRTHomo Sapiens 42,"(40/42) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:40 and 42, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection."
https://patents.google.com/patent/US10759846B2/en,Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp TyrTyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Tyr Ile Ser Ser Ser Gly Ser Thr Ile Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Val Gly Leu Gly Ser Gly Trp Tyr Asp Trp Phe Asp Pro TrpGly Gln Gly Thr Leu Val Thr Val Ser Ser,Gln Ser Ala Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly GlnArg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala SerTyr Asp Val His Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Lys LeuLeu Ile Tyr Gly Asn Thr Asn Arg Pro Ser Gly Val Pro Asp Arg PheSer Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly LeuGln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser SerLeu Ser Gly Val Val Phe Ser Gly Gly Thr Lys Leu Thr Val Leu,44122PRTHomo Sapiens 44,46111PRTHomo Sapiens 46,"(44/46) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:44 and 46, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection."
https://patents.google.com/patent/WO2022029011A1/en, Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Ile Ile Ser Ser Ser Gly Ser Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Ile Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Val Gly Ala Gly Tyr Ala Gly Tyr Gly Tyr Asp Asn Tyr Tyr Gly Met Asp Pro Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ala Ala Ser Val Gly Asp Thr Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Ile Gly Tyr Gly Leu Asn Trp Tyr Gln Gln Lys Leu Gly Ile Ala Pro Lys Leu Leu Ile Tyr Gly Ala Asn Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Glu Thr Asp Tyr Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Ala Gly Ile Tyr Tyr Cys Gln Gln Gly Tyr Ser Thr Pro Leu Thr Phe Gly Ala Gly Thr Lys Val Glu Ile Lys ,  HC VR  ,  LC VR  ,"(33/37)  a vh comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:33 and a vl comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:37; "
https://patents.google.com/patent/WO2022029011A1/en, Gln Glu Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Glu Ser Leu Lys Leu Ser Cys Lys Ala Ser Gly Ile Asp Phe Ser Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala Tyr Ile Tyr Pro Gly Phe Gly Ile Thr Asn Tyr Ala Asn Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ala Gln Asn Thr Val Phe Leu Gln Met Thr Ser Leu Thr Ala Ser Asp Thr Ala Thr Tyr Phe Cys Thr Arg Ala Tyr Ala Ser Ser Ser Gly Tyr Tyr Ile His Tyr Phe Asn Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ala Ala Ser Val Gly Asp Thr Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Ile Gly Tyr Gly Leu Asn Trp Tyr Gln Gln Lys Leu Gly Ile Ala Pro Lys Leu Leu Ile Tyr Gly Ala Asn Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Glu Thr Asp Tyr Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Ala Gly Ile Tyr Tyr Cys Gln Gln Ala Tyr Ser Thr Pro Leu Thr Phe Gly Ala Gly Thr Lys Val Glu Ile Lys ,  HC VR  ,  LC VR  ,"(65/69)  a vh comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:65 and a vl comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:69; "
https://patents.google.com/patent/WO2022029011A1/en, Gln Ser Leu Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Ile Ile Ser Ser Ser Gly Ser Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Ile Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Asp Ala Ser Ser Arg Gly Tyr Tyr Tyr Tyr Tyr Gly Met Asp Pro Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ala Ala Ser Val Gly Asp Thr Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Ile Gly Tyr Gly Leu Asn Trp Tyr Gln Gln Lys Leu Gly Ile Ala Pro Lys Leu Leu Ile Tyr Gly Ala Asn Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Glu Thr Asp Tyr Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Ala Gly Ile Tyr Tyr Cys Gln Gln Gly Tyr Ser Thr Pro Leu Thr Phe Gly Ala Gly Thr Lys Val Glu Ile Lys ,  HC VR  ,  LC VR  ,"(17/21)  a vh comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:17 and a vl comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:21; "
https://patents.google.com/patent/WO2022029011A1/en, Gln Met Gln Leu Val Gln Ser Gly Thr Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Ile Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val , Asp Ile Gln Leu Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  HC VR  ,  LC VR  ,"(121/125)  a vh comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:121 and a vl comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:125. "
https://patents.google.com/patent/WO2022029011A1/en, Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Asn Asn Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Ile Ile Ser Ser Ser Gly Asn Thr Tyr Tyr Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Ile Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Asp Ser Tyr Pro Gly Tyr Ser Pro Tyr Tyr Gly Met Asp Pro Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ala Ala Ser Val Gly Asp Thr Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Ile Ala Tyr Gly Leu Asn Trp Tyr Gln Gln Lys Leu Gly Ile Thr Pro Lys Leu Leu Ile Tyr Gly Ala Asn Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Glu Thr His Tyr Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Ala Gly Ile Tyr Tyr Cys Gln Gln Gly Tyr Asn Thr Pro Pro Thr Phe Gly Ala Gly Thr Lys Val Glu Ile Lys ,  HC VR  ,  LC VR  ,"(49/53)  a vh comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:49 and a vl comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:53; "
https://patents.google.com/patent/WO2022029011A1/en, Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Lys Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Ile Ile Ser Ser Gly Gly Ser Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Asp Leu Lys Ile Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Ala Gly Tyr Pro Gly Tyr Ser Pro His Tyr Phe Asn Ile Trp Gly Pro Gly Thr Leu Val Thr Val Ser Leu , Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ala Ala Ser Val Gly Asp Thr Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Ile Gly Tyr Glu Leu Asn Trp Tyr Gln Gln Lys Leu Gly Ile Ala Pro Lys Leu Leu Ile Tyr Gly Ala Asn Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Thr Gly Ser Gly Ser Glu Thr Asp Tyr Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Ala Gly Ile Tyr Tyr Cys Gln Gln Gly Tyr Ser Thr Pro Pro Thr Phe Gly Ala Gly Thr Lys Val Glu Ile Lys ,  HC VR  ,  LC VR  ,"(1/5)  a vh comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:1 and a vl comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:5; "
https://patents.google.com/patent/WO2022029011A1/en, Gln Ser Leu Glu Glu Ser Gly Gly Gly Leu Val Lys Pro Glu Gly Ser Leu Thr Leu Thr Cys Lys Ala Ser Gly Phe Asp Leu Asn Thr Tyr Tyr Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala Cys Ile Ala Thr Ser Asp Ser Gly His Thr Ala Tyr Ala Ser Trp Ala Arg Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr Leu Gln Met Thr Gly Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala Arg Gly Gly Arg Ser Val Gly Asp Gly Val Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Thr Pro Ala Ser Val Glu Ala Ala Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asp Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Ser Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Ser Tyr Leu Tyr Val Glu Ser Gly Ser His Gly Phe Gly Phe Gly Gly Gly Thr Glu Val Val Val Arg ,  HC VR  ,  LC VR  ,"(89/93)  a vh comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:89 and a vl comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:93; "
https://patents.google.com/patent/WO2022029011A1/en, Gln Ser Leu Glu Glu Ser Gly Gly Gly Leu Val Lys Pro Glu Gly Ser Leu Thr Leu Thr Cys Lys Ala Ser Gly Phe Asp Leu Asn Thr Tyr Tyr Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala Cys Ile Gly Thr Ser Asp Ser Gly His Thr Ala Tyr Ala Ser Trp Ala Arg Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr Leu Gln Met Thr Gly Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala Arg Gly Gly Arg Ser Val Gly Asp Gly Val Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Thr Pro Ala Ser Val Glu Ala Ala Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Asp Ala Phe Asp Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Ser Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Ser Tyr Leu Tyr Gly Glu Ser Gly Ser His Gly Phe Gly Phe Gly Gly Gly Thr Glu Val Val Val Arg ,  HC VR  ,  LC VR  ,"(97/101)  a vh comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:97 and a vl comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:101; "
https://patents.google.com/patent/WO2022029011A1/en, Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Ile Ile Asn Ser Gly Arg Ser Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Ile Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Asp Ala Thr Ser Ile Gly Tyr Tyr Arg Tyr Tyr Gly Met Asp Pro Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ala Ala Ser Val Gly Asp Thr Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Ile Gly Tyr Gly Leu Asn Trp Tyr Gln Gln Lys Leu Gly Ile Ala Pro Lys Leu Leu Ile Tyr Gly Ala Asn Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Glu Thr Asp Tyr Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Ala Gly Ile Tyr Tyr Cys Gln Gln Gly Tyr Ser Thr Pro Leu Thr Phe Gly Ala Gly Thr Lys Val Glu Ile Lys ,  HC VR  ,  LC VR  ,"(25/29)  a vh comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:25 and a vl comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:29; "
https://patents.google.com/patent/WO2022029011A1/en, Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Ile Ile Ser Ser Ser Gly Ser Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Ile Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Ala Met Tyr Pro Gly Tyr Ser Thr Gly Val Tyr Asn Ile Trp Gly Pro Gly Thr Leu Val Thr Val Ser Leu , Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ala Ala Ser Val Gly Asp Thr Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Ile Gly Tyr Glu Leu Asn Trp Tyr Gln Gln Lys Leu Gly Ile Ala Pro Lys Leu Leu Ile Tyr Gly Ala Asn Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Glu Thr Asp Tyr Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Ala Gly Ile Tyr Tyr Cys Gln Gln Gly Tyr Asn Thr Pro Asn Thr Phe Gly Ala Gly Thr Lys Val Glu Ile Lys ,  HC VR  ,  LC VR  ,"(9/13)  a vh comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:9 and a vl comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:13; "
https://patents.google.com/patent/WO2022029011A1/en, Gln Ser Leu Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Ile Ile Tyr Val Ser Gly Ser Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Met Thr Ser Leu Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Val Asp Tyr Ser Thr Gly Trp Pro Leu Phe Asn Ile Trp Gly Pro Gly Thr Leu Val Thr Val Ser Leu , Ala Gln Val Leu Thr Gln Thr Ala Ser Pro Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Asn Cys Gln Ser Ser Gln Ser Val Tyr Asp Asn Asn Trp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Gly Ala Ser Ile Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu Ser Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Gly Cys Ser Gly Asn Thr Phe Val Phe Gly Gly Gly Thr Glu Val Val Val Lys ,  HC VR  ,  LC VR  ,"(113/117)  a vh comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:113 and a vl comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:117. "
https://patents.google.com/patent/WO2022029011A1/en, Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Ile Ile Ser Ser Ser Gly Thr Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Pro Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Ile Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Gly Gly Ala Gly Tyr Gly Tyr Ala His Tyr Tyr Gly Met Asp Pro Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ala Ala Ser Val Gly Asp Thr Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Ile Gly Tyr Gly Leu Asn Trp Tyr Gln Gln Lys Leu Gly Ile Ala Pro Lys Leu Leu Ile Tyr Gly Ala Asn Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Glu Thr Asp Tyr Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Ala Gly Ile Tyr Tyr Cys Gln Gln Gly Tyr Ser Thr Pro Leu Thr Phe Gly Ala Gly Thr Lys Val Glu Ile Lys ,  HC VR  ,  LC VR  ,"(41/45)  a vh comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:41 and a vl comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:45; "
https://patents.google.com/patent/WO2022029011A1/en, Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Asp Gly Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala Cys Ile Ala Ala Gly Ser Ser Gly Ser Thr Tyr Tyr Ala Thr Trp Ala Gln Gly Arg Phe Thr Ile Ser Lys Ser Ser Ser Thr Thr Val Thr Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala Gly Glu Asp Tyr Thr Gly Asn Asn Tyr Tyr Ala Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Ala Ile Asp Met Thr Gln Thr Pro Ser Pro Val Ser Ala Val Val Gly Asp Thr Val Thr Ile Asn Cys Gln Ala Ser Glu Asn Ile Tyr Ser Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Phe Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Val His Ser Asp Asp Ala Ala Ile Tyr Tyr Cys Gln Gln Thr Gly Thr Tyr Ser Asp Ala Asp Asn Thr Phe Gly Gly Gly Thr Glu Val Val Val Lys ,  HC VR  ,  LC VR  ,"(105/109)  a vh comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:105 and a vl comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:109; "
https://patents.google.com/patent/WO2022029011A1/en, Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Ser Tyr Trp Ile Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Cys Ile Tyr Thr Gly Ser Gly Ser Thr Trp Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala Arg Gly Tyr Gly Ser Tyr Met Tyr Asp Phe Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Asp Val Val Met Thr Gln Thr Pro Ala Ser Val Glu Ala Ala Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Thr Ala Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Ala Ile Ser Asp Leu Glu Ser Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Ala Asp Gly Ser Ser Ser Ser Phe Gly Gly Gly Thr Glu Val Val Val Lys ,  HC VR  ,  LC VR  ,"(73/77)  a vh comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:73 and a vl comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:77; "
https://patents.google.com/patent/WO2022029011A1/en, Gln Glu Gln Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Glu Gly Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Asn Tyr Trp Ile Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Cys Ile Tyr Ile Gly Ser Gly Asp Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala Arg Ser Tyr Thr Pro Gly Ser Tyr Tyr Asn Met Asn Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Asp Val Val Met Thr Gln Thr Pro Ser Ser Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Asn Cys Gln Ala Ser Gln Gln Ile Ser Asn Glu Leu Ser Trp Tyr Gln Gln Lys Ser Gly Gln Pro Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asp Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Ser Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Ser Thr Gly Gly Ala Ser Ser Asp Gly Asn Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys ,  HC VR  ,  LC VR  ,"(81/85)  a vh comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:81 and a vl comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:85; "
https://patents.google.com/patent/WO2022029011A1/en, Gln Glu Glu Leu Lys Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Thr Leu Ser Cys Lys Ala Ser Gly Phe Asp Phe Ser Ser Tyr Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Val Ile Tyr Ala Ser Lys Gly Ser Thr Asp Tyr Ala Ser Trp Val Asn Gly Arg Phe Thr Ile Ser Ser Asp Asn Ala Gln Asn Thr Val Asp Leu Gln Met Asn Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ser Lys Arg Phe Tyr Thr Tyr Gly Tyr Ala Gly Tyr Ala Tyr Ala His Tyr Tyr Tyr Gly Met Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ala Ala Ser Val Gly Asp Thr Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Ile Gly Tyr Gly Leu Asn Trp Tyr Gln Gln Lys Leu Gly Ile Ala Pro Lys Leu Leu Ile Tyr Gly Ala Asp Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Glu Thr Asp Tyr Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Ala Gly Ile Tyr Tyr Cys Gln Gln Gly Tyr Ser Thr Pro Leu Thr Phe Gly Ala Gly Thr Lys Val Glu Ile Lys ,  HC VR  ,  LC VR  ,"(57/61)  a vh comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:57 and a vl comprising a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identity to the sequence of seq id no:61; "
https://patents.google.com/patent/WO2021158521A1/en, Gln Val Lys Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Asn Ala Met His Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Val Ala Leu Ile Ser Tyr Asp Glu Arg Asn Lys Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg His Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gln Met Arg Val Val Val Val Ser Asn Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr Glu Val Ser Asn Trp Asp Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Thr His Trp Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Synthetic sequence nCoV-19 mAb VH  , Synthetic sequence nCoV-19 mAb VL (Vk)  ,(309/317) antibody ncov-19 comprises the vh sequence of seq id no:309 and the vl sequence of seq id no:317
https://patents.google.com/patent/WO2021158521A1/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ala Ser Tyr Ala Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Thr Ile Ser Gly Gly Gly Gly Asp Thr Tyr Ser Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Leu Glu Ser Ala Thr Gln Pro Leu Gly Tyr Tyr Phe Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Arg Ile Thr Cys Ser Gly Asp Ala Leu Pro Lys Gln Tyr Ala Phe Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Val Leu Val Ile Ser Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Val Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys His Ser Ala Asp Ile Ser Ala Thr Ser Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Val , Synthetic sequence nCoV-3 mAb VH  , Synthetic sequence nCoV-3 mAb VL  ,(5/13) antibody ncov-3 comprises the vh sequence of seq id no:5 and the vl sequence of seq id no:13
https://patents.google.com/patent/WO2021158521A1/en, Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Thr Glu Met Cys Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asp Lys Tyr Tyr Ser Thr Ser Leu Arg Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Met Phe Gly Arg Lys Arg Leu Ala Pro Thr Gly Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Lys Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Cys Leu Gly Ser Tyr Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Synthetic sequence nCoV-20 mAb VH  , Synthetic sequence nCoV-20 mAb VL (Vk)  ,(101/109) antibody ncov-20 comprises the vh sequence of seq id no:101 and the vl sequence of seq id no:109
https://patents.google.com/patent/WO2021158521A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu Ala Val Ile Ser Ser Asp Gly Arg Ile Lys Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Met Ser Arg Asp Ser Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Arg Phe Gln Phe Ala Arg Ser Trp Tyr Gly Asp Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser , Ala Val Ala Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Asn Gln Ser Leu Val Tyr Ser Asp Gly Asn Ile Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Met Arg Leu Ile Tyr Arg Val Ser Asn Arg Asp Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic sequence nCoV-10 mAb VH  , Synthetic sequence nCoV-10 mAb VL (Vk)  ,(21/29) antibody ncov- 10 comprises the vh sequence of seq id no:21 and the vl sequence of seq id no:29
https://patents.google.com/patent/WO2021158521A1/en, Gln Val Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glu Thr Leu Thr Leu Thr Cys Thr Val Ser Val Phe Ser Leu Ser Asn Ala Arg Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala His Ile Phe Ser Ser Asp Gln Lys Ser Tyr Ser Thr Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Ser Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Glu Asp Thr Gly Thr Tyr Tyr Cys Ala Arg Ile Asn Thr Ala Ala Tyr Asp Tyr Asp Ser Thr Thr Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Thr Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Leu Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Leu Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic sequence nCoV-6 mAb VH  , Synthetic sequence nCoV-6 mAb VL (Vk)  ,(69/77) antibody ncov-6 comprises the vh sequence of seq id no:69 and the vl sequence of seq id no:77
https://patents.google.com/patent/WO2021158521A1/en, Gln Met Gln Leu Val Gln Ser Gly Pro Glu Met Lys Lys Pro Gly Thr Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Ser Lys Thr Thr Leu Gln Trp Val Arg Gln Ala Arg Gly Gln Arg Pro Glu Trp Ile Gly Trp Ile Val Leu Gly Ser Gly Asn Thr Asn Tyr Ala His Tyr Phe Gln Ala Arg Val Thr Ile Thr Arg Asp Met Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Ser Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Glu Met Ala Thr Ile Gln Asn Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Asn Tyr Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile Tyr Ala Ala Ser Ser Leu Pro Gly Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Ser Tyr Ser Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Synthetic sequence nCoV-5 mAb VH  , Synthetic sequence nCoV-5 mAb VL (Vk)  ,(197/205) antibody ncov-5 comprises the vh sequence of seq id no:197 and the vl sequence of seq id no:205
https://patents.google.com/patent/WO2021158521A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Ser Phe Gly Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu Ala Leu Ile Ser Asp Glu Gly Arg Ile Lys Tyr Tyr Ala Asn Ser Val Lys Gly Arg Phe Phe Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Gly Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Val Lys Gly His Ile Val Val Met Thr Ser Leu Asp Tyr Trp Gly Gln Gly Ala Leu Val Thr Val Ser Ser , Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Ser Ser Asp Gly Asp Thr Ser Leu Ser Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr Glu Val Ser Asn Arg Asp Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Synthetic sequence nCoV-12 mAb VH  , Synthetic sequence nCoV-12 mAb VL (Vk)  ,(181/189) antibody ncov-12 comprises the vh sequence of seq id no:181 and the vl sequence of seq id no:189
https://patents.google.com/patent/WO2021158521A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Gly Ser Ser Ser Thr Tyr Ile Tyr Ser Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Met Asn Ser Leu Phe Leu Gln Met Lys Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Phe Glu Arg Tyr Tyr Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Thr Ser Asn Ile Gly Thr Asn Val Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Trp Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Val Ala Trp Asp Asp Ile Leu Asn Ala Val Val Phe Ala Gly Gly Thr Lys Leu Thr Val Leu , Synthetic sequence nCoV-13 mAb VH  , Synthetic sequence nCoV-13 mAb VL  ,(357/365) antibody ncov-13 comprises the vh sequence of seq id no:357 and the vl sequence of seq id no:365
https://patents.google.com/patent/WO2021158521A1/en, Glu Val Leu Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Val Val Ser Gly Phe Thr Phe Asp Tyr Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Ser Asp Asn Thr Asp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Ile Ser Leu Val Phe Trp Ser Val Asn Pro Pro Arg Asn Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Arg Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile Tyr Thr Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic sequence nCoV-8 mAb VH  , Synthetic sequence nCoV-8 mAb VL (Vk)  ,(261/269) (figure 1c.) antibody ncov-8 comprises the vh sequence of seq id no:261 and the vl sequence of seq id no:269
https://patents.google.com/patent/WO2021158521A1/en, Gln Glu Gln Val Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Lys Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Leu Asn Asp Phe Ala Ile His Trp Val Arg Gln Ala Pro Gly Lys Arg Leu Glu Trp Val Ala Ile Ile Ser Tyr Asp Gly Arg Val Lys Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Ser Val His Leu Gln Met Asp Ser Leu Arg Pro Glu Asp Thr Gly Leu Tyr Tyr Cys Ala Arg Asp Ser Ser Trp Gln Ser Thr Gly Trp Pro Ile Asn Trp Phe Asp Arg Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Gln Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Leu Ser Ser Leu Ala Trp Tyr Gln His Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Glu Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Synthetic sequence nCoV-7 mAb VH  , Synthetic sequence nCoV-7 mAb VL (Vk)  ,(277/285) antibody ncov-7 comprises the vh sequence of seq id no:277 and the vl sequence of seq id no:285
https://patents.google.com/patent/WO2021158521A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Arg Gln Pro Gly Thr Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Met Asn Asn Asp Ile Thr Trp Val Arg Gln Ala Pro Gly Gln Val Leu Gln Trp Met Gly Trp Ile Arg Pro Ser Asn Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Leu Thr Thr Asp Thr Ser Thr Asn Thr Ala His Met Glu Leu Arg Ser Leu Lys Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gln Ser His Ser Thr Arg Gly Gly Trp His Phe Ser Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Pro Ser Gln Pro Ile Ser Tyr Phe Leu Asn Trp Tyr Gln Gln Thr Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Ser Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Synthetic sequence nCoV-18 mAb VH  , Synthetic sequence nCoV-18 mAb VL (Vk)  ,(245/253) antibody ncov-18 comprises the vh sequence of seq id no:245 and the vl sequence of seq id no:253
https://patents.google.com/patent/WO2021158521A1/en, Gly Phe Thr Leu Arg Thr Ser Ser Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Asn Asp Gly Ala Thr Lys Phe Tyr Ala Asp Ala Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Asn Asn Lys Ile Tyr Leu Gln Leu Asn Gly Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Thr Arg His Tyr Ser His Gly Leu Asn Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Asn Val Ser Ser , Glu Arg Val Met Thr Gln Ser Pro Val Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Thr Thr Phe Gly Gln Gly Thr Arg Leu Asp Ile Lys , Synthetic sequence nCoV-4 mAb VH  , Synthetic sequence nCoV-4 mAb VL (Vk)  ,(117/125) (figure ib.) antibody ncov-4 comprises the vh sequence of seq id no:117 and the vl sequence of seq id no:125
https://patents.google.com/patent/WO2021158521A1/en, Gln Ala Gln Leu Val Glu Ser Gly Gly Ala Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn Tyr Ala Met His Trp Val Arg Gln Ala Pro Ala Thr Gly Leu Gln Trp Leu Ala Val Ile Thr Ser Asp Gly Arg Asn Lys Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asp Ser Leu Arg Gly Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Gln Arg Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Thr Val Ala Val Ser Ser , Asp Val Val Leu Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser Asp Gly Asp Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr Gln Val Ser Asn Arg Asp Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Ser His Trp Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Synthetic sequence nCoV-1 mAb VH  , Synthetic sequence nCoV-1 mAb VL (Vk)  ,(325/333) antibody ncov-1 comprises the vh sequence of seq id no:325 and the vl sequence of seq id no:333
https://patents.google.com/patent/WO2021158521A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Phe Ile Ser Tyr Asp Gly Ser Asn Ile Gln Tyr Ala Asp Ser Val Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Met Tyr Tyr Cys Ala Lys Asp Leu Phe Gly Tyr Cys Arg Ser Thr Ser Cys Glu Ser Leu Asp Asp Trp Gly Gln Gly Ala Leu Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Thr Gly Tyr Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic sequence nCoV-16 mAb VH  , Synthetic sequence nCoV-16 mAb VL (Vk)  ,(85/93) (figure 1 a.) antibody ncov-16 comprises the vh sequence of seq id no:85 and the vl sequence of seq id no:93
https://patents.google.com/patent/WO2021158521A1/en, Gln Val Gln Leu Val His Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Arg Val Ser Cys Lys Ala Ser Gly Tyr Thr Tyr Thr Ala Tyr Tyr Ile His Trp Leu Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Ala Asp Asn Gly Asp Thr His Ser Val Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Asn Thr Ala Tyr Leu Glu Val Ser Arg Leu Lys Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Val Pro Val Gly Thr Gly Trp Val Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Ser Val Thr Ile Ser Cys Arg Ala Ser Gln Thr Ile Asn Asn Phe Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile Tyr Gly Ala Tyr Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Val Ala Ile Tyr Tyr Cys Gln Gln Ser Leu Ser Met Val Thr Phe Gly Gln Gly Thr Arg Leu Asp Ile Lys , Synthetic sequence nCoV-14 mAb VH  , Synthetic sequence nCoV-14 mAb VL (Vk)  ,(213/221) antibody ncov-14 comprises the vh sequence of seq id no:213 and the vl sequence of seq id no:221
https://patents.google.com/patent/WO2021158521A1/en, Leu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Phe Asp Gly Arg Asn Lys Phe Tyr Ala Asp Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Phe Leu Glu Leu Asp Ser Leu Thr Thr Glu Asp Thr Ala Phe Tyr Tyr Cys Ala Arg Asp Asp Asn Leu Asp Arg His Trp Pro Leu Arg Leu Gly Gly Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Asp Leu Leu Tyr Asn Asp Gly Gly Thr Asp Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr Arg Val Ser Asn Arg Asp Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Ser Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr Tyr Cys Met Gln Gly Ala His Trp Pro Pro Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys , Synthetic sequence nCoV-11 mAb VH  , Synthetic sequence nCoV-11 mAb VL (Vk)  ,(341/349) antibody ncov-11 comprises the vh sequence of seq id no:341 and the vl sequence of seq id no:349
https://patents.google.com/patent/WO2021158521A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Thr Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Gly Asp Tyr Ala Leu Ser Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Phe Ile Arg Ser Lys Ala Tyr Gly Gly Thr Thr Glu Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Gln Ile Ile Val Tyr Leu Gln Met Asp Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Ser Trp Ile His Arg Ile Val Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Glu Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Ile Tyr Leu Asn Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Glu Ala Ser Asn Leu Lys Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Synthetic sequence nCoV-15 mAb VH  , Synthetic sequence nCoV-15 mAb VL (Vk)  ,(165/173) antibody ncov-15 comprises the vh sequence of seq id no:165 and the vl sequence of seq id no:173
https://patents.google.com/patent/WO2021158521A1/en, Gln Val Leu Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Met Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Thr Lys Phe Tyr Ala Asp Ser Val Arg Gly Arg Phe Pro Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Val Ser Val Glu Gly Tyr Thr Ser Gly Trp Tyr Leu Gly Thr Leu Asp Phe Trp Gly Gln Gly Thr Pro Val Thr Val Ser Ser , Glu Arg Val Met Thr Gln Phe Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Ile Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Gly Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Synthetic sequence nCoV-9 mAb VH  , Synthetic sequence nCoV-9 mAb VL (Vk)  ,(229/237) antibody ncov-9 comprises the vh sequence of seq id no:229 and the vl sequence of seq id no:237
https://patents.google.com/patent/WO2021158521A1/en, Asp Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr Ala Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Thr Met Ser Ala Ser Gly Asp Ser Thr Asn Asp Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Pro Leu Arg Asn Tyr Gly Asp Leu Leu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asn Ile His Arg Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Thr Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Phe Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Synthetic sequence nCoV-2 mAb VH  , Synthetic sequence nCoV-2 mAb VL (Vk)  ,(293/301) antibody ncov-2 comprises the vh sequence of seq id no:293 and the vl sequence of seq id no:301
https://patents.google.com/patent/CN111303279A/en,caggttcagc tggtggaaag cggtggtgga ttagtgcaac caggtggaag cctccgcctg agctgcgccg cgtcaggtgg taacgctgct gaacgtatgg ctgggtggtt ccgtcaggct ccgggcaaag gcctggaagc agttgcggcc atttactacg ctaaattcgg tccgtattac gcggattccg ttaagggccg ttttacgatc agccgtgata attcaaagaa cacgctttat ctgcagatga acagcctgcg cgctgaagat actgcggtct actattgcgc ggcagaagct ttcgttcagt ctccgtactc tggttctcat actactaaat attggggcca ggggacccaa gtaacagtta gcagt ,, Artificial Sequence (Artificial Sequence),,(8) the nucleic acid molecule encoding the single domain antibody 3f11 is shown in seq id no:8.
https://patents.google.com/patent/CN111303279A/en,Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Gly Asn Ala Ala Glu Arg Met Ala Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Ala Val Ala Ala Ile Tyr Tyr Ala Lys Phe Gly Pro Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Glu Ala Phe Val Gln Ser ProTyr Ser Gly Ser His Thr Thr Lys Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(3)  a single domain antibody as set forth in seq id no:3 or a functionally active variant thereof;
https://patents.google.com/patent/CN111303279A/en,Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ala Gln Ser Lys Trp Ala Tyr Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Ala Val Ala Ala Ile Asp Val Ala Thr Gly Pro Trp Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala His His Ile Pro Thr Lys His Pro Ala Phe Pro Asp Phe Arg Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(2)  a single domain antibody as set forth in seq id no:2 or a functionally active variant thereof;
https://patents.google.com/patent/CN111303279A/en,caggttcagc tggtggaaag cggtggtgga ttagtgcaac caggtggaag cctccgcctg agctgcgccg cgtcaggtgc tgacgctttc gttatcatcg gtgggtggtt ccgtcaggct ccgggcaaag gcctggaagc agttgcggcc attgcttgga ctgaccagca tgaatattac gcggattccg ttaagggccg ttttacgatc agccgtgata attcaaagaa cacgctttat ctgcagatga acagcctgcg cgctgaagat actgcggtct actattgcgc ggcacaggac tctgcttaca tcaaatctaa aggttctcgt gcttacgaat attggggcca ggggacccaa gtaacagtta gcagt ,, Artificial Sequence (Artificial Sequence),,(6) the nucleic acid molecule encoding the single domain antibody 1e2 is shown in seq id no:6.
https://patents.google.com/patent/CN111303279A/en,Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asn Ile Asp Ser Thr Arg Tyr His Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Ala Val Ala Ala Ile Lys Gly Val Trp Pro Glu Asp Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Asp Gln Tyr Glu Trp Trp Val Pro Gly Glu Val Gly Pro Tyr Leu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(4)  a single domain antibody as set forth in seq id no:4 or a functionally active variant thereof;
https://patents.google.com/patent/CN111303279A/en,caggttcagc tggtggaaag cggtggtgga ttagtgcaac caggtggaag cctccgcctg agctgcgccg cgtcaggtaa catcgactct actcgttacc atgggtggtt ccgtcaggct ccgggcaaag gcctggaagc agttgcggcc attaaaggtg tttggccgga agactattac gcggattccg ttaagggccg ttttacgatc agccgtgata attcaaagaa cacgctttat ctgcagatga acagcctgcg cgctgaagat actgcggtct actattgcgc ggcagaccag tacgaatggt gggttccggg tgaagttggt ccgtacctgt attggggcca ggggacccaa gtaacagtta gcagt ,, Artificial Sequence (Artificial Sequence),,(9) the nucleic acid molecule encoding the single domain antibody 4d8 is shown in seq id no:9.
https://patents.google.com/patent/CN111303279A/en,Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ala Asp Ala Phe Val Ile Ile Gly Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Ala Val Ala Ala Ile Ala Trp Thr Asp Gln His Glu Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Gln Asp Ser Ala Tyr Ile Lys Ser Lys Gly Ser Arg Ala Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(1)  a single domain antibody as set forth in seq id no:1 or a functionally active variant thereof;
https://patents.google.com/patent/CN111303279A/en,caggttcagc tggtggaaag cggtggtgga ttagtgcaac caggtggaag cctccgcctg agctgcgccg cgtcaggtct ggctcagtct aaatgggctt acgggtggtt ccgtcaggct ccgggcaaag gcctggaagc agttgcggcc attgacgttg ctactggtcc gtggtattac gcggattccg ttaagggccg ttttacgatc agccgtgata attcaaagaa cacgctttat ctgcagatga acagcctgcg cgctgaagat actgcggtct actattgcgc ggcacatcat atcccgacta aacatccggc tttcccggac ttccgtgact attggggcca ggggacccaa gtaacagtta gcagt ,, Artificial Sequence (Artificial Sequence),,(7) the nucleic acid molecule encoding the single domain antibody 2f2 is shown in seq id no:7.
https://patents.google.com/patent/CN111303279A/en,Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Gln Ala Val Val Phe Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Ala Val Ala Ala Ile His Val Pro Ala Lys Asn Arg Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala His Tyr Glu Phe Asn Asp Phe Val Trp Gln Gly Tyr Ser Ser Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(5)  a single domain antibody as set forth in seq id no:5 or a functionally active variant thereof.
https://patents.google.com/patent/CN111303279A/en,caggttcagc tggtggaaag cggtggtgga ttagtgcaac caggtggaag cctccgcctg agctgcgccg cgtcaggtcg tcaggctgtt gttttcgggt ggttccgtca ggctccgggc aaaggcctgg aagcagttgc ggccattcat gttccggcta aaaaccgtta ttacgcggat tccgttaagg gccgttttac gatcagccgt gataattcaa agaacacgct ttatctgcag atgaacagcc tgcgcgctga agatactgcg gtctactatt gcgcggcaca ttacgaattc aacgacttcg tttggcaggg ttactcttct gactattggg gccaggggac ccaagtaaca gttagcagt ,, Artificial Sequence (Artificial Sequence),,(10) the nucleic acid molecule encoding the single domain antibody 5f8 is shown in seq id no:10.
https://patents.google.com/patent/CN112979794B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/CN112979794B/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Ser Gly Ser Tyr Tyr Trp Gly Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Asn Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) the antibody of claim 1, wherein said antibody comprises the heavy chain variable region of seq id no:4 and the light chain variable region of seq id no:8."
https://patents.google.com/patent/KR20200020411A/en, Leu Pro Glu Phe Gln Val Lys Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Arg Gly Leu Ser Cys Glu Gly Ser Gly Phe Thr Phe Ser Gly Phe Trp Met Ser Trp Val Arg Gln Thr Pro Gly Lys Thr Leu Glu Trp Ile Gly Asp Ile Asn Ser Asp Gly Ser Ile Ile Asn Tyr Ala Pro Ser Ile Lys Asp Arg Phe Thr Ile Phe Arg Asp Asn Asp Lys Thr Thr Leu Tyr Leu Gln Met Ser Asn Val Arg Ser Glu Asp Thr Ala Thr Tyr Phe Cys Ser Ile Tyr Tyr Asp Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Lys Thr Thr Pro Pro Ser Val Tyr Arg Ser Ser , Glu Leu Asp Ile Val Leu Thr Gln Ser Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly Ser His Val Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ala Cys Thr , VH, VL,"(7/8)  the monoclonal antibody according to claim 1, wherein the monoclonal antibody is a heavy chain comprising a polypeptide sequence of seq id no:7 and a light chain comprising a polypeptide sequence of seq id no:8."
https://patents.google.com/patent/WO2021190980A1/en, Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Glu Tyr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Thr Ile Ser Trp Ser Gly Gly Ser Thr Tyr Tyr Thr Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Asp Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Gly Leu Gly Thr Val Val Ser Glu Trp Asp Tyr Asp Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,,  Synthetic  ,,"(307) optionally, the antigen is a viral antigen (eg, a coronavirus or sars-cov or sars-cov-2 antigen, such as rbd or spike antigen) and each single variable domain is an anti-viral antigen variable domain (eg, nanobody or vh or vhh) disclosed herein, such as a variable domain that comprises the amino acid sequence of qb-gb (seq id no:307), qb-dd, qb-bg or qb-fe)"
https://patents.google.com/patent/WO2021190980A1/en, Asp Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Leu Asp Tyr Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Ser Ser Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Thr Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Val Pro Ser Thr Tyr Tyr Ser Gly Thr Tyr Tyr Tyr Thr Cys His Pro Gly Gly Met Asp Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Lys Lys Lys Pro Leu Asp Gly Glu Tyr Phe Thr Leu Gln Ile Arg Gly Arg Glu Arg Phe Glu Met Phe Arg Glu Leu Asn Glu Ala Leu Glu Leu Lys Asp Ala Gln Ala Gly Lys Glu Pro Gly ,,  Synthetic  ,,"(289)   table 34: amino acid sequences of a binding domain (nb-112, seq id no:288) and polypeptides (seq id no:289 & 290) for use in the present invention.   table 35: amino acid sequences of nb-112 based quad polypeptides with an intact hinge region.  table 36: antibody single variable domains (a) the amino acid sequence of an anti-hrsv protein f nanobody for use as a binding domain in the present invention)"
https://patents.google.com/patent/WO2021190980A1/en, atgagcctcg ggctcctgtg ctgtggggcc ttttctctcc tgtgggcagg tccagtgaat gccggtgtca ctcagacccc aaaattccag gtcctgaaga caggacagag catgacactg cagtgtgccc aggatatgaa ccatgaatac atgtcctggt atcgacaaga cccaggcatg gggctgaggc tgattcatta ctcagttgcc atccagacaa ctgaccaagg agaagtcccc aatggctaca atgtctccag atcaaccatc gaggatttcc cgctcaggct gctgtcggct gctccctccc agacatctgt gtacttctgt gccagcagtt acctggggaa caccggggag ctgttttttg gagaaggctc taggctgacc gtactggagg acctgaaaaa cgtgttccca cccgaggtcg ctgtgtttga gccatcagaa gcagagatct cccacaccca aaaggccaca ctggtgtgcc tggccacagg cttctacccc gaccatgtgg agctgagctg gtgggtgaat gggaaggagg tgcacagtgg ggtctgcaca gacccgcagc ccctcaagga gcagcccgcc ctcaatgact ccagatacgc tctgagcagc cgcctgaggg tctcggccac cttctggcag gacccccgca accacttccg ctgtcaagtc cagttctacg ggctctcgga gaatgacgag tggacccagg atagggccaa acccgtcacc cagatcgtca gcgccgaggc ctggggtaga gcagacctaa cagacagaga atgggcagaa gagtggaaac atcttgacca tctgttaaac tgcataatgg acatggtaga aaaaacaagg cgatctctca ccgtactaag gcggtgtcaa gaagcagacc gggaagaatt gaattactgg atccggcggt acagtgacgc cgag , atgagcctcg ggctcctgtg ctgtggggcc ttttctctcc tgtgggcagg tccagtgaat gccggtgtca ctcagacccc aaaattccag gtcctgaaga caggacagag catgacactg cagtgtgccc aggatatgaa ccatgaatac atgtcctggt atcgacaaga cccaggcatg gggctgaggc tgattcatta ctcagttgcc atccagacaa ctgaccaagg agaagtcccc aatggctaca atgtctccag atcaaccatc gaggatttcc cgctcaggct gctgtcggct gctccctccc agacatctgt gtacttctgt gccagcagtt acctggggaa caccggggag ctgttttttg gagaaggctc taggctgacc gtactggagg acctgaaaaa cgtgttccca cccgaggtcg ctgtgtttga gccatcagaa gcagagatct cccacaccca aaaggccaca ctggtgtgcc tggccacagg cttctacccc gaccatgtgg agctgagctg gtgggtgaat gggaaggagg tgcacagtgg ggtctgcaca gacccgcagc ccctcaagga gcagcccgcc ctcaatgact ccagatacgc tctgagcagc cgcctgaggg tctcggccac cttctggcag gacccccgca accacttccg ctgtcaagtc cagttctacg ggctctcgga gaatgacgag tggacccagg atagggccaa acccgtcacc cagatcgtca gcgccgaggc ctggggtaga gcagacggag gaggtgggag cctaacagac agagaatggg cagaagagtg gaaacatctt gaccatctgt taaactgcat aatggacatg gtagaaaaaa caaggcgatc tctcaccgta ctaaggcggt gtcaagaagc agaccgggaa gaattgaatt actggatccg gcggtacagt gacgccgag ,  Synthetic  ,  Synthetic  ,"(17/18)  cr3022/3013 or cr3022/3014). [00335] in a configuration, the polypeptide of the invention comprises one or more binding sites for human tmprss2 protein, for example, the polypeptide comprises a binding site for tmprss2 protein as disclosed in us20190300625, eg, the vh/vl pair of any anti-tmprss2 antibody disclosed in us20190300625, eg wherein the binding site comprises seq id no:17 and 18 disclosed in us20190300625"
https://patents.google.com/patent/WO2021190980A1/en, Asp Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Leu Asp Tyr Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Ser Ser Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Thr Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Val Pro Ser Thr Tyr Tyr Ser Gly Thr Tyr Tyr Tyr Thr Cys His Pro Gly Gly Met Asp Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,,  Synthetic  ,,"(288) [00437] optionally, the bd is a single variable domain (also referred to as a domain antibody or dab, eg, a nanobody or vhh, eg, a single variable domain comprising seq id no:288, preferably nb-112)"
https://patents.google.com/patent/WO2021190980A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Ala Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Gly Ser Asp Tyr Gly Asp Tyr Leu Leu Val Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Leu Thr Ser Ile Ser Thr Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Synthetic  ,  Synthetic  ,"(262/263)  or (d) wherein the multimer comprises 4 copies of an antigen binding site, wherein the binding site comprises a vh/vl pair, wherein the vh and vl respectively comprise the amino acid sequences of seq id no:262 and 263, 264 and 265, or 266 and 267"
https://patents.google.com/patent/WO2021222128A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Thr Val Val His Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(81/82)  a heavy chain variable domain (vh) comprising amino acid sequence seq id no:81 and a light chain variable domain (vl) comprising amino acid sequence seq id no:82
https://patents.google.com/patent/WO2021222128A1/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Gly Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ala Gly Ala Val Gly Tyr Tyr Asp Ser Asn Gly Tyr Tyr Tyr Asp Val Asp Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(233/234)  a heavy chain variable domain (vh) comprising amino acid sequence seq id no:233 and a light chain variable domain (vl) comprising amino acid sequence seq id no:234
https://patents.google.com/patent/WO2021222128A1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Val Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Glu Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Ser Ser Gln Arg Pro Asp Gly Asn Leu Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Gln Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Thr Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp His Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(241/242)  or a heavy chain variable domain (vh) comprising amino acid sequence seq id no:241 and a light chain variable domain (vl) comprising amino acid sequence seq id no:242. 
https://patents.google.com/patent/WO2021222128A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Thr Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Leu His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Thr Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Gly Arg Arg Tyr Ser Ser Ser Asp Asp Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Asn Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ile Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,"(9/10) in some embodiments, the antibody or derivative thereof comprises: a heavy chain variable domain (vh) comprising amino acid sequence seq id no:9 and a light chain variable domain (vl) comprising amino acid sequence seq id no:10"
https://patents.google.com/patent/WO2021222128A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Gly Asp Tyr Ala Met Ser Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Phe Ile Arg Ser Lys Ala Tyr Gly Gly Thr Thr Glu Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Val His His Cys Ser Gly Gly Ser Cys Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Val Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(223/224)  a heavy chain variable domain (vh) comprising amino acid sequence seq id no:223 and a light chain variable domain (vl) comprising amino acid sequence seq id no:224
https://patents.google.com/patent/WO2021222128A1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Thr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Asp Ser Tyr Gly Ser Gly Ser Thr Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Arg Ile Thr Cys Ser Gly Asp Ala Leu Pro Lys Gln Tyr Ala Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Val Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Ala Asp Ser Ser Gly Thr Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(221/222)  a heavy chain variable domain (vh) comprising amino acid sequence seq id no:221 and a light chain variable domain (vl) comprising amino acid sequence seq id no:222
https://patents.google.com/patent/WO2021222128A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Val Ile Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Asp Val Ser Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Gln Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(55/56)  a heavy chain variable domain (vh) comprising amino acid sequence seq id no:55 and a light chain variable domain (vl) comprising amino acid sequence seq id no:56
https://patents.google.com/patent/WO2021222128A1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Ser Ser Gly Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Pro Leu Ser Leu Arg Leu Arg Tyr Asn Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,"(1/2) in some embodiments, the monoclonal antibody or derivative thereof comprises a heavy chain variable domain (vh) comprising amino acid sequence seq id no:1 and a light chain variable domain (vl) comprising amino acid sequence seq id no:2"
https://patents.google.com/patent/WO2021222128A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Ala Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gln Val Ser Pro Tyr Cys Gly Gly Asp Cys Pro Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Gln Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Gly Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Phe Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Thr Ser Asp His Pro Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(135/136)  a heavy chain variable domain (vh) comprising amino acid sequence seq id no:135 and a light chain variable domain (vl) comprising amino acid sequence seq id no:136
https://patents.google.com/patent/WO2021222128A1/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Thr Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Arg Val His Tyr Asp Ile Leu Thr Gly Phe Tyr Gly Gly Ala Leu Ile Thr Arg Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Leu His Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(175/176)  a heavy chain variable domain (vh) comprising amino acid sequence seq id no:175 and a light chain variable domain (vl) comprising amino acid sequence seq id no:176
https://patents.google.com/patent/WO2021222128A1/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Asn Ser Phe Thr Ser Tyr Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg His Arg Asn Tyr Asp Ile Leu Thr Gly Tyr Arg Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(109/110)  a heavy chain variable domain (vh) comprising amino acid sequence seq id no:109 and a light chain variable domain (vl) comprising amino acid sequence seq id no:110
https://patents.google.com/patent/KR20170005133A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Phe Thr Phe Ser Ser Tyr Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Arg Gly Ser Gly His Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Asp Gly Ser Ile Val Gly Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Ser Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Thr Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Ser Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , synthetic , synthetic ,"(2/10) the method of any of claims 20 to 23 wherein the first antibody or antigen-binding fragment thereof is an hcvr, wherein the hcvr is selected from the group consisting of seq id no:2, 18, 66, 114, 170, lt; / rti &gt; and lcvr, wherein the lcvr comprises an amino acid sequence selected from the group consisting of seq id no:10, 26, 74, 106, 162, and 226."
https://patents.google.com/patent/CN111560070A/en,Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16)  wherein the heavy chain variable region comprises seq id no:12 and the light chain variable region comprises the amino acid sequence shown in seq id no:16.
https://patents.google.com/patent/CN111560070A/en,caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc tcctgcaagg cttctggagg caccttcagc agctatgcta tcagctgggt gcgacaggcc cctggacaag ggcttgagtg gatgggaggg atcatcccta tctttggtac agcaaactac gcacagaagt tccagggcag agtcacgatt accgcggacg aatccacgag cacagcctac atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagaggaggt tgggtgattt gtagtagtac cagctgctac actaagtact cctactacgg tatggacgtc tggggccaag ggaccacggt caccgtctcc tca ,cagagcgtgc tcacgcagcc gccctcagtg tctgcggccc caggacagaa ggtcaccatc tcctgctctg gaagcagctc caacattggg aataattatg tatcctggta ccagcagctc ccaggaacag cccccaaact cctcatttat gacaataata agcgaccctc agggattcct gaccgattct ctggctccaa gtctggcacg tcagccaccc tgggcatcac cggactccag actggggacg aggccgatta ttactgcgga acgtgggata gcagcctgat tgcccggttg ttcggcggag ggaccaagct gaccgtccta , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(17/18)  preferably, the antibody light chain variable region is seq id no:18, and the variable region of the antibody heavy chain is seq id no:17."
https://patents.google.com/patent/CN111560070A/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Trp Val Ile Cys Ser Ser Thr Ser Cys Tyr Thr Lys Tyr Ser Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser,Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr TrpAsp Ser Ser Leu Ile Ala Arg Leu Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) preferably, the first variable region is an antibody light chain variable region that is seq id no:8; wherein said second variable region is an antibody heavy chain variable region represented by seq id no:4."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly His Thr Phe Ser Ser Tyr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Asp Trp Ser Gly Asp Glu Ala Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Asp Arg Gly Leu Ser Tyr Tyr Tyr Asp Arg Thr Gln Glu Tyr Gly Ile Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, SP11,,"(74) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Gly Ser Arg Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Pro Asp Ser Val Ser Tyr Tyr Gly Trp Ser Leu Asn Pro Tyr Glu Tyr Asp Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-4,,"(67) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly His Thr Phe Ser Arg Phe Gly Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Arg Asn Asp Gly Gly Phe Pro Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Thr Ser Pro Glu Ser Gly Arg Tyr Asp Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-6,,"(69) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Arg Thr Leu Arg Ser Phe Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Ser Trp Ser Gly Asp Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Gly Gly His Thr Ile Asn His Asp Ile Ile Ser Pro Asp Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-12,,"(75) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Leu Thr Gly Ser Thr Phe Val Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Arg Trp Thr Tyr Gly Arg Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Arg Glu Gly Tyr Arg Gly Ser Ala Tyr Gln Thr Ser Asp Phe Asp Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-13,,"(76) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Asp Thr Phe Asn Asn Tyr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Ala Arg Ser Gly Arg Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Asp Pro Ala Pro Leu Trp Phe Ala Trp Thr Ser Asp Met Ala Lys Tyr Lys Phe Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-20,,"(83) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Ala Ser Gly Arg Ser Thr His Arg Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Met Pro Gly Gly Gly Phe Pro Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Arg Ser Glu Thr Gly Glu Tyr Asp Asn Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-14,,"(77) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Leu Asp Tyr Tyr Arg Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Ser Ser Ser Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Thr Gly Pro Leu Thr Tyr Tyr Ser Gly Arg Tyr Tyr Leu Gly Gly Cys Phe Asp Thr Tyr Ala Met Asp Phe Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-15,,"(78) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Ser Ile Ala Ser Ile Thr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ser Asn Ser Arg Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Tyr Val Asn Thr Leu Arg Ala Glu Met Pro Glu Ala Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-19,,"(82) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Leu Asp Tyr Tyr Thr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Thr Ser Ser Ala Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Ala Pro Gly Ala Tyr Tyr Ser Gly Thr Tyr Tyr Arg Ala Cys His Ser Ala Gly Met Glu Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-3,,"(66) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Ser Ser Arg Asp Gly Arg Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Asn His Leu Thr Tyr Tyr Ser Gly Ser Tyr Tyr Phe Pro Tyr Glu Tyr His Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-8,,"(71) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Arg Cys Thr Phe Asn Trp Asp Gly Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Ser Trp Ser Gly Gln Glu Pro Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Ala Gln Tyr Thr Gly Ala Ser Tyr Ser Ile Leu Arg Asp Gln Val Gly Tyr Asp Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser,, VHH-9,,"(72) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Arg Thr Phe Ser Ser Tyr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Ser Trp Thr Gly Asp Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Asp Arg Gly Leu Ser Tyr Tyr Tyr Tyr Arg Thr Gln Asp Tyr Asp Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-2,,"(65) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Arg Thr Phe Ser Ser Tyr Thr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Ser Arg Ser Gly Gly Gly Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Val Ser Arg Arg Val Leu Leu Thr Asp Thr Pro Arg Asp Tyr Asp Arg Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-16,,"(79) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Arg Ile Pro Ser Trp Asn Ile Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Arg Trp Thr Ser Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Trp Arg Arg Gly Gly Val Gln Gln Ile Ser Thr Gly Ser His Asp Tyr Asp Pro Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-21,,"(84) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Thr Arg Thr Phe Ser Asn Tyr Asn Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Ser Arg Ala Gly Ala Glu Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Ala Arg Val Met Gly Val Ser Pro Ala Ile Tyr Asn Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-10,,"(73) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Arg Ala Val Thr Ile Tyr His Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Ser Pro Ser Arg Val Ile Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Thr Arg Gly Ser Phe Asp Arg Asn Arg Val Asn Tyr Asp Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-1,,"(64) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Arg Thr Phe Ser Val Gly Glu Val Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Arg Trp Gly Ser Glu Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Thr Glu Lys Val Tyr Ser Ala Tyr Tyr Tyr Tyr Ser Arg Asp Arg Leu Tyr Asp Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser,, VHH-7,,"(70) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Arg Thr Ser Ser Arg Tyr Val Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Thr Ser Thr Gly Phe Gly Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Asp Thr Ser Leu Leu Thr Arg Arg Pro Ser Asp Ser Ala Ser Pro Tyr Asp Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-18,,"(81) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Asn Thr Leu Asp Tyr Tyr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Lys Ser Ser Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ile Gly Pro Leu Thr Tyr Tyr Ser Gly Arg Tyr Tyr Phe Pro Tyr Asp Tyr Asp Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-17,,"(80) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Gly Thr Phe Ser Arg Ser Gly Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Arg Ala Asp Val Gly Phe Pro Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Thr Ser Leu Gln Ser Gly Lys Tyr Asp Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-5,,"(68) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN111303280B/en, Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Met Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ser Thr Ala Val Ala Gly Thr Pro Asp Leu Phe Asp Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Leu Ser Ser Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Thr Gln Ala Thr Gln Phe Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys ,  Homo sapiens,  Homo sapiens,"(1/5) in a preferred embodiment, the amino acid sequence of the heavy chain variable region of the antibody is shown in seq id no:1, and the amino acid sequence of the light chain variable region is shown in seq id no:5."
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Tyr Ser Tyr Ile Ser Asn Ser Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Gly Ser Thr Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala His Arg Phe Gln Thr Arg Val Arg Thr Thr Asn Pro Ile Glu Ser Glu Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(8) f5 nanobody: has the sequence shown in seq id no:8
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Gln Ala Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Val Ile Phe Ser Leu Asn Tyr Met Gly Trp Tyr Arg Gln Ala Ala Gly Lys Gly Arg Glu Leu Val Ala Thr Ile Asn Arg Ser Gly Gly Ala Ser Tyr Gly Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Asp Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr AlaVal Tyr Tyr Cys Ala Asn Val Ile Gly Thr Val Asn Ala Tyr Gly Ala Ala Ser Lys Pro Ala Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(3) b9 nanobody: has the sequence shown in seq id no:3
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Thr Asp Val Ala Tyr Trp Ser Trp Leu Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met Gly Ala Ile Ala Ser Ser Gly Ser Thr Tyr Asn Ser Pro Phe Phe Gly Ser Arg Thr Phe Ile Ser Arg Asp Thr Ser Lys Ser Gln Phe Thr Leu Gln Leu Ser Ser Val Thr Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ile Ala Val Arg Asp Pro His Tyr Val Gly Val Gly Gly Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(19) h6 nanobody: has the sequence shown in seq id no:19.
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ala Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile His Ser Gly Gly Asp Asn Thr Asn Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Pro Gly Pro Gly Phe Thr Thr Met Asp Arg Ser Gln Ala Arg Ile Ala Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(7) f4 nanobody: has the sequence shown in seq id no:7
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Asn Ser Arg Tyr Tyr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Ala Ile Gly Arg Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ser Asp Arg Leu Ser Gly Leu Arg Ser Tyr Gly Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(14) g3 nanobody: has the sequence shown in seq id no:14
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Gln Ala Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ser Thr Gly Ser Ile Phe Ser Gly Asp Val Asp Gly Val Gly Trp Phe Arg Arg Ala Pro Gly Lys Glu Arg Glu Leu Leu Ala Arg Ile Arg Asp Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Gly Asp Asp Ala Met Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Phe Gly His Thr His Met Val Arg Pro Gly Ser Thr Val Met Ile Met Tyr Trp Asp Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,"(9) f8 nanobody: has the sequence shown in seq id no:9, and ("
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr Asp Phe Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Thr Ala Asn Gly Gly Ser Thr Phe Tyr Ala Gly Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ala Lys Asn Val Val Ser Leu Gln Met Ser Ser Leu Thr Leu Glu AspThr Ala Val Tyr Tyr Cys Ala Arg Thr Ser Glu Ala Arg Tyr Arg Gly Tyr Pro Arg Phe Arg Val Met Phe Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(17) h3 nanobody: has the sequence shown in seq id no:17
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Asn Ser Arg Tyr Tyr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Ala Ile Gly Arg Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Asp Ser Ser Leu Ala Gly Leu Arg Gly Arg Leu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(15) c7 nanobody: has the sequence shown in seq id no:15
https://patents.google.com/patent/CN111825762A/en,Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Pro Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asp Asn Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Lys Leu His Thr Gly Val Leu Asn Thr Tyr Tyr Ala Asn Ser Val Lys Gly Arg Phe Thr Ile Ser Thr Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Gln Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Phe Gly Pro Ala Pro Lys Pro Gln Asn Val Leu Thr Thr Ala Leu Pro Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(5) e6 nanobody: has the sequence shown in seq id no:5
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Thr Phe Ser Ser Asn Ala Met Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Asn Trp Gly Ser Ser Ser Thr Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Tyr Leu Ser Ser Ser Arg Ser Gly Asp Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(13) f1 nanobody: has the sequence shown in seq id no:13
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Ser Ser Gln Thr Val Ser Leu Thr Cys Ser Asp Ser Gly Gly Ser Ile Thr Thr Thr His Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Ala Tyr Ile Gly Asp Thr Phe Tyr Asn Ser Ser Leu Lys Ser Arg Thr Ala Ile Ser Trp Asp Thr Ser Lys Asn Gln Phe Thr Leu His Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Asp Arg Asn Arg Val Arg Gly Tyr Asp Pro Cys Leu His Gly Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(18) h4 nanobody: has the sequence shown in seq id no:18
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Gln Ala Ser Gly Gly Gly Leu Val Gln Thr Gly Gly Ser Leu Arg Leu Ser Cys Ala Ser Ser Gly Arg Ala Phe Thr Leu Asn Glu Val Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Thr Ile Thr Arg Gly Gly Asp Ile Asn Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Thr Arg Asp Asn Ala Arg Asn Thr Leu Tyr Leu Gln Met Thr Asn Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Pro Arg Asn Gly Ser Pro Ser Val Phe Glu Ile Leu Leu Val Ser Val Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(1) b4 nanobody: has the sequence shown in seq id no:1
https://patents.google.com/patent/CN111825762A/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ala Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp Val Ser Val Ile Glu Ser Ser Gly Ser Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Tyr Val Val Pro Tyr Ala Ile Ala Ala Gly Ala Pro Asp Gln Ile Gly Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(10) g2 nanobody: has the sequence shown in seq id no:10
https://patents.google.com/patent/CN111825762A/en,Asp Val Gln Leu Gln Ala Ser Gly Gly Gly Leu Val Gln Gly Gly Gly Ser Leu Arg Val Ser Cys Thr Tyr Ser Gly Arg Thr Phe Ser Arg Asn Ile Met Gly Trp Phe Arg Gln Ser Pro Gly Lys Thr Arg Glu Phe Val Ala Ala Ile Gly Trp Ser Arg Val Thr Thr Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Met Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Gly Ala Val Pro Ala His Gln Ile Gly Phe Arg Ser Thr Thr Leu Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(2) b6 nanobody: has the sequence shown in seq id no:2
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Thr Ser Ser Ser Tyr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Ser Gly Gly Ser Arg Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Leu Ala Ser Ser Gly Tyr Ser Arg Asp Tyr Gly Ala Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(12) a1 nanobody: has the sequence shown in seq id no:12
https://patents.google.com/patent/CN111825762A/en,Asp Val Gln Leu Gln Ala Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Arg Phe Thr Phe Ser Thr Tyr Trp Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Phe Asn Ile Gly Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Phe Gly Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Pro Leu Leu Ala Ser Ala Phe Val Leu Met Tyr Gly Ser Arg His Leu Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(6) e7 nanobody: has the sequence shown in seq id no:6
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Gln Ala Ser Gly Gly Gly Trp Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Thr Trp Val Arg Gln Ala Leu Gly Lys Gly Leu Glu Trp Val Ser Asp Ile Asn Tyr Gly Gly His Thr Ser Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Val Ala Met Leu Pro Phe Leu Thr Ala Val Thr Pro Arg Pro Gly Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(4) e3 nanobody: has the sequence shown in seq id no:4
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Ala Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Leu Ser Ser Asn Trp Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Thr Leu Ile Arg Pro Thr Asn Gly Asn Lys Asp Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Pro Arg Val Arg Leu Lys Val Arg Phe Gln Asp Arg Val Met Val Thr Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(11) g5 nanobody: has the sequence shown in seq id no:11
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Thr Phe Ser Ser Tyr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Trp Gly Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ser Tyr Gly Tyr Leu Asp Leu Asp Leu Pro Ala Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(16) d4 nanobody: has the sequence shown in seq id no:16
https://patents.google.com/patent/CN113563464A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Phe Ile Val Ser Arg Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Thr Gly Leu Glu Trp Val Ser Val Ile Tyr Pro Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asp Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Tyr Gly Asp Phe Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser , Glu Ile Val Met Thr Gln Ser Pro Val Ser Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Gly Val Ala Ser Asn Leu Ala Trp Tyr Gln Gln Lys Ala Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Thr Leu Gln Ser Glu Asp Ser Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asp Arg Pro Arg Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr ,  Homo sapiens,  Homo sapiens,"(1/3)  seq id no:1 and seq id no:3; in the present invention, an antibody having the amino acid sequences of the variable regions of the heavy chain and the variable regions of the light chain is designated as ""sw-c11"", or"
https://patents.google.com/patent/CN113563464A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ala Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Met Ala Ile Tyr Tyr Cys Ala Arg Asp Leu Ser Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser , Asp Ile Gln Leu Thr Gln Phe Pro Phe Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Thr Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Arg Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Leu Leu Asn Ser Tyr Pro Val His Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr ,  Homo sapiens,  Homo sapiens,"(5/7)  seq id no:5 and seq id no:7; in the present invention, an antibody having the amino acid sequences of the variable regions of the heavy chain and the variable regions of the light chain is named ""wjq-g10"", or"
https://patents.google.com/patent/CN113563464A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Thr Tyr Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile His Asn Ser Gly Asn Pro Val Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Glu Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Ala Leu Arg Tyr Ser Thr Ser Trp Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser , Glu Ile Val Leu Thr Gln Ser Pro Val Ser Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Phe Ile Tyr Asp Ala Ser Lys Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr ,  Homo sapiens,  Homo sapiens,"(9/11)  seq id no:9 and seq id no:11, the antibody having the amino acid sequences of the variable region of the heavy chain and the variable region of the light chain in one embodiment of the present invention is named ""wjq-c11""."
https://patents.google.com/patent/WO2021195418A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Arg Ser Asn Tyr Met Thr Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Thr Tyr Gly Leu Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Thr Ala Pro Asn Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Leu Leu Asn Ser His Pro Leu Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys ,  COV2-2165 heavy  ,  COV2-2165 light  ,(21/22) (c) a heavy chain variable sequence comprising the amino acid sequence of seq id no:21 and/or a light chain variable sequence comprising the amino acid sequence of seq id no:22
https://patents.google.com/patent/WO2021195418A1/en, Gln Met Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Thr Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Met Ser Ser Ala Val Gln Trp Val Arg Gln Ala Arg Gly Gln Arg Leu Glu Trp Ile Gly Trp Ile Val Ile Gly Ser Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln Glu Arg Val Thr Ile Thr Arg Asp Met Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Pro Tyr Cys Ser Ser Ile Ser Cys Asn Asp Gly Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Gly Ser Ser Arg Gly Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  COV2-2838 heavy  ,  COV2-2838 light  ,(23/24)  a heavy chain variable sequence comprising the amino acid sequence of seq id no:23 and/or a light chain variable sequence comprising the amino acid sequence of seq id no:24; 
https://patents.google.com/patent/WO2021195418A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Arg Ser Asn Tyr Met Thr Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Thr Tyr Gly Leu Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Thr Ala Pro Asn Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Leu Leu Asn Ser His Pro Leu Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys ,  COV2-2952 heavy  ,  COV2-2952 light  ,(25/26)  a heavy chain variable sequence comprising the amino acid sequence of seq id no:25 and/or a light chain variable sequence comprising the amino acid sequence of seq id no:26; 
https://patents.google.com/patent/WO2021195418A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asp Asp Tyr Asp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Asn Trp Asn Gly Gly Ser Thr Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr His Cys Ala Val Ile Met Ser Pro Ile Pro Arg Tyr Ser Gly Tyr Asp Trp Ala Gly Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala Ser Trp Tyr Gln Gln Lys Pro Gly Gln Val Pro Ile Leu Val Ile Tyr Asp Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Asn Ala Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  COV2-2094 heavy  ,  COV2-2094 light  ,(35/36) (i) a heavy chain variable sequence comprising the amino acid sequence of seq id no:35 and/or a light chain variable sequence comprising the amino acid sequence of seq id no:36
https://patents.google.com/patent/WO2021195418A1/en, Gln Met Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Thr Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Met Ser Ser Ala Val Gln Trp Val Arg Gln Ala Arg Gly Gln Arg Leu Glu Trp Ile Gly Trp Ile Val Ile Gly Ser Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln Glu Arg Val Thr Ile Thr Arg Asp Met Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Pro Tyr Cys Ser Ser Ile Ser Cys Asn Asp Gly Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Gly Ser Ser Arg Gly Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  COV2-2196 heavy  ,  COV2-2196 light  ,(33/34)  a heavy chain variable sequence comprising the amino acid sequence of seq id no:33 and/or a light chain variable sequence comprising the amino acid sequence of seq id no:34; 
https://patents.google.com/patent/WO2021195418A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asp Asp Tyr Asp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Asn Trp Asn Gly Gly Ser Thr Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr His Cys Ala Val Ile Met Ser Pro Ile Pro Arg Tyr Ser Gly Tyr Asp Trp Ala Gly Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala Ser Trp Tyr Gln Gln Lys Pro Gly Gln Val Pro Ile Leu Val Ile Tyr Asp Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Asn Ala Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  COV2-2514 heavy  ,  COV2-2514 light  ,(27/28)  a heavy chain variable sequence comprising the amino acid sequence of seq id no:27 and/or a light chain variable sequence comprising the amino acid sequence of seq id no:28; 
https://patents.google.com/patent/WO2021195418A1/en, Glu Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Thr Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Met Ser Ser Ala Val Gln Trp Val Arg Gln Ala Arg Gly Gln Arg Leu Glu Trp Ile Gly Trp Ile Val Ile Gly Ser Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln Glu Arg Val Thr Ile Thr Arg Asp Met Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Pro Tyr Cys Ser Ser Ile Ser Cys Asn Asp Gly Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Gly Ser Ser Arg Gly Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  COV2-3025 heavy  ,  COV2-3025 light  ,(31/32)  a heavy chain variable sequence comprising the amino acid sequence of seq id no:31 and/or a light chain variable sequence comprising the amino acid sequence of seq id no:32; 
https://patents.google.com/patent/WO2021195418A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asp Val Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Arg Ile Lys Ser Lys Ile Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Thr Ala Gly Ser Tyr Tyr Tyr Asp Thr Val Gly Pro Gly Leu Pro Glu Gly Lys Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Met Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Ile Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  COV2-2130 heavy  ,  COV2-2130 light  ,(39/40)  a heavy chain variable sequence comprising the amino acid sequence of seq id no:39 and/or a light chain variable sequence comprising the amino acid sequence of seq id no:40; 
https://patents.google.com/patent/WO2021195418A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Gly Ser Phe Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met Gly Arg Met Asn Ser Asn Ser Gly Asn Thr Ala Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg Met Arg Ser Gly Trp Pro Thr His Gly Arg Pro Asp Asp Phe Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Ala Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile Gly Ser Tyr Thr Ile Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Asp Gln Arg Thr Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Phe Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Asn Asn Tyr Tyr Cys Ala Val Trp Asp Asp Ser Leu Asn Gly Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  COV2-2391 heavy  ,  COV2-2391 light  ,(29/30)  a heavy chain variable sequence comprising the amino acid sequence of seq id no:29 and/or a light chain variable sequence comprising the amino acid sequence of seq id no:30; 
https://patents.google.com/patent/WO2021195418A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Gly Ser Phe Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met Gly Arg Met Asn Ser Asn Ser Gly Asn Thr Ala Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg Met Arg Ser Gly Trp Pro Thr His Gly Arg Pro Asp Asp Phe Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Ala Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile Gly Ser Tyr Thr Ile Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Asp Gln Arg Thr Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Phe Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Asn Asn Tyr Tyr Cys Ala Val Trp Asp Asp Ser Leu Asn Gly Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  COV2-2096 heavy  ,  COV2-2096 light  ,(37/38)  a heavy chain variable sequence comprising the amino acid sequence of seq id no:37 and/or a light chain variable sequence comprising the amino acid sequence of seq id no:38. 
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValAla Val Ile Ser His Asp Ala Ser Asn Lys Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Met Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln ThrLeu Gln Met Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,372 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 372,433 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 433,"(372/433) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:372 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:433."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp HisTyr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValAla Ala Ile Gly Ala Ser Gly Glu Ser Thr Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Gln Arg Asp Asn Ser Arg Asp Tyr Phe Pro Leu Trp Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Tyr SerAsp Gly Asp Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Ile Arg Ala Pro Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln SerIle Gln Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,390 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 390,451 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 451,"(390/451) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:390 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:451."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Val Ile Ser Ala Ser Gly Gly Asn Thr Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Arg Ser Leu Leu His ThrAsn Gly Leu Asn Tyr Ile Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Thr Gln AlaLeu Gln Thr Pro Ile Ser Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,426 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 426,488 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 488,"(426/488) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:426 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:488."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrGly Met His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Val Ser Ala Ser Gly Asp Arg Thr His Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Thr Pro Leu Gly Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,428 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 428,490 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 490,"(428/490) an antibody or an antigen-binding fragment that selectively binds to a sars-cov-2, that comprises a vh chain having an amino acid sequence of seq id no:428 and a vl chain having an amino acid sequence of seq id no:490."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Ile Ser Arg Ser Gly Asp Ser Ala Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Leu Gln ThrLeu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,409 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 409,471 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 471,"(409/471) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:409 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:471."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr TyrGly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Thr Ile Ser Gly Asn Gly Val Ser Thr Ser Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr SerAsp Gly Tyr Thr Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Gln Val Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Thr Pro Ala Leu Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg ,389 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 389,450 <211> LENGTH: 114 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 450,"(389/450) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:389 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:450."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrGly Met His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Val Ile Thr Gly Asp Gly Arg Asn Lys Phe Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaAla Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,410 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 410,472 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 472,"(410/472) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:410 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:472."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Ile Gly Thr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val LysGly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr LeuGln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys ValThr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His AspMet Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Ile Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln ValLeu Arg Thr Pro Ile Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,373 <211> LENGTH: 126 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 373,434 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 434,"(373/434) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:373 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:434."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Thr SerAla Val Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Gln Arg Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Tyr SerAsp Gly Asp Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Ile Arg Ala Pro Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln GlyLeu Glu Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,397 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 397,459 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 459,"(397/459) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:397 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:459."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn SerAsp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Gly Ile Ser Gly Gly Gly Ala Gly Thr Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Tyr Arg Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His SerAsn Gly Asp Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Ile Arg Ala Pro Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln SerTyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,400 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 400,462 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 462,"(400/462) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:400 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:462."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrGly Met His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Val Ser Ala Ser Gly Asp Arg Thr His Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Thr Pro Leu Gly Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,411 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 411,473 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 473,"(411/473) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:411 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:473."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Asn TyrGly Met His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Gly Ile Asp Gly Ser Gly Gly Thr Ala His Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asp Arg Ala Pro Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln GlyLeu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,423 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 423,485 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 485,"(423/485) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:423 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:485."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Thr Asn TyrAla Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Ile Ser Gly Ser Gly Gly Ser Thr His Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Pro Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln ValLeu Gln Thr Pro Phe Ser Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,386 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 386,447 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 447,"(386/447) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:386 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:447."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Arg Phe Ser Asp HisPro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValAla Val Ile Thr Gly Ser Gly Arg Asn Lys Phe Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His ArgAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Thr Gln SerLeu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,371 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 371,432 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 432,"(371/432) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:371 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:432."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn SerAsp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Arg Ile Asn Gly Asp Gly Ser Thr Thr Gly Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Thr Gly Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Asp Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Ile Arg Ala Pro Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln SerTyr Ile Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,392 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 392,453 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 453,"(392/453) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:392 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:453."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrGly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValAla Ala Ile Ser Gly Ser Gly Gly Ser Thr His Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His IleAsn Gly Tyr Asn Tyr Leu Asp Trp Phe Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Asn Pro Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,394 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 394,456 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 456,"(394/456) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:394 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:456."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Val Ser Ser Ser Gly Gly Ser Pro Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His SerAsp Gly Asp Asn Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Ser Gly Ser Tyr Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln GlyThr His Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,427 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 427,489 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 489,"(427/489) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:427 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:489."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrGly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Ile Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln SerGln Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,413 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 413,475 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 475,"(413/475) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:413 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:475."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe His Asp TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValAla Val Thr Ser Tyr Asp Gly Asn Thr Lys Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Val Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln GlyTyr Asn Met Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,398 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 398,460 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 460,"(398/460) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:398 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:460."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Ile Ser Ala Ser Ser Ala Gly Ala Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Asn Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Gly Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln SerTyr Thr Pro Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,393 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 393,454 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 454,"(393/454) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:393 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:454."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Ser TyrAla Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Ile Ser Gly Ser Gly Gly Asp Thr Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His ArgAsn Gly Tyr Asn Tyr Val Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Arg IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaArg Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,424 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 424,486 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 486,"(424/486) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:424 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:486."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Gly Ile Ser Ser Gly Gly Ser Gly Thr His Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Gln Gly Ser Asn Arg Asp Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,404 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 404,466 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 466,"(404/466) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:404 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:466."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Lys Phe Asn Thr TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Ile Ser Ile Thr Gly Gly Asn Thr Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln AlaTyr Ser Phe Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,416 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 416,478 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 478,"(416/478) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:416 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:478."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asn Asp TyrGly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Ile Ser Gly Ser Gly Gly Asn Thr Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln GlyLeu Gln Thr Pro Gly Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,412 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 412,474 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 474,"(412/474) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:412 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:474."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp TyrAla Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Gly Val Ser Trp Asn Gly Ser Arg Thr His Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro LeuThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,368 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 368,429 <211> LENGTH: 108 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 429,"(368/429) in further embodiments, the 6nb6-derived antibody or antigen-binding fragment comprises a vl having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to any one of seq id no:429-454 and 456-490, and a vh having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to any one of seq id no:368-428"
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Val Ser Ser Ser Gly Gly Ser Pro Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His SerAsp Gly Asp Asn Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Ser Gly Ser Tyr Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln GlyThr His Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,382 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 382,443 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 443,"(382/443) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:382 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:443."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Arg TyrGly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Gly Ile Ser Ala Asp Gly Gly Thr Ala Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Gln SerAsn Gly Asp Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln GlyLeu His Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,402 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 402,464 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 464,"(402/464) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:402 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:464."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrGly Met His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Val Ser Ala Ser Gly Asp Arg Thr His Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Ala Ala Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln GlyLeu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,406 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 406,468 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 468,"(406/468) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:406 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:468."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Arg Phe Asn Thr TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValAla Val Ile Ser Ser Ser Gly Arg Asn Lys Phe Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser His Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Leu Pro His Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,407 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 407,469 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic  polypeptide <400> SEQUENCE: 469,"(407/469) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:407 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:469."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Phe Asn Asn TyrAla Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Gly Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Gln Arg Asp Asn Pro Val Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Tyr SerAsp Gly Asp Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Ile Arg Ala Pro Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,418 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 418,480 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 480,"(418/480) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:418 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:480."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Gly Val Ser Trp Asn Gly Ser Arg Thr His Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Tyr SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Arg Thr Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,425 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 425,487 <211> LENGTH: 112 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 487,"(425/487) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:425 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:487."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrGly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Tyr Ser Gly Ser Gly Gly Tyr Thr Tyr Phe Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu His IleAsn Gly Phe Asn Tyr Leu Asp Trp Phe Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Pro Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln SerLeu Gln Asn Pro Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,396 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 396,458 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 458,"(396/458) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:396 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:458."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Thr Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Thr Pro Pro Lys Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,408 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 408,470 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 470,"(408/470) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:408 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:470."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Ile Ser Gly Ser Gly Asp Asn Thr Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Thr Pro Leu Gly Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,421 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 421,483 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 483,"(421/483) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:421 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:483."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrGly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Gly Val Ser Ala Ser Gly Gly Gly Pro Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Phe Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Thr Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Thr Pro Ala Leu Thr Phe Gly Gly Gly Thr Lys Val Glu IleLys Arg ,405 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 405,467 <211> LENGTH: 114 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 467,"(405/467) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:405 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:467."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Asn TyrGly Met His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Gly Ile Asp Gly Ser Gly Gly Thr Ala His Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaGln Gln Thr Pro Ile Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,403 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 403,465 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 465,"(403/465) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:403 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:465."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Ser Ser TyrAla Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Gly Ile Ser Gly Ser Gly Gly Gly Ala Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Gln SerAsn Gly Tyr Asn Tyr Met Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Thr Ser Asn Arg Ala Ala Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln SerTyr Gly Pro Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,384 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 384,445 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 445,"(384/445) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:384 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:445."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Ser TyrGly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Gln SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Tyr Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Ala Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,387 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 387,448 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 448,"(387/448) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:387 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:448."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrSer Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Gly Ile Ser Gly Ser Gly Asp Arg Thr Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysSer Met Gln Arg Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Tyr SerAsp Gly Asp Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Ile Arg Ala Pro Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln SerVal Gln Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg,399 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 399,461 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 461,"(399/461) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:399 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:461."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Arg Phe Asp Asp PheGly Met His Trp Tyr Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Thr Ser Gly Gly Gly Ser Ile Thr Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln ThrLeu His Thr Pro Gly Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,417 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 417,479 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 479,"(417/479) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:417 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:479."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Val Ile Ser Gly Ser Gly Arg Asn Thr Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Pro Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaAla His Trp Pro Ile Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,370 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 370,431 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 431,"(370/431) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:370 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:431."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValAla Val Val Ser Arg Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Gln Arg Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His SerAsn Gly Asp Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Ile Arg Ala Pro Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln SerTyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,395 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 395,457 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 457,"(395/457) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:395 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:457."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrGly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValAla Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Glu Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ile Gln AlaLeu Gln Thr Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,420 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 420,482 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 482,"(420/482) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:420 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:482."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValAla Val Ile Ser Ser Ser Gly Arg Asn Lys Phe Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Ser Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Thr Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,422 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 422,484 <211> LENGTH: 112 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 484,"(422/484) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:422 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:484."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Gly Val Ser Ala Ser Gly Gly Gly Pro Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleThr Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,415 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 415,477 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 477,"(415/477) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:415 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:477."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Ser Ser PheGly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Ile Ser Asp Ser Gly Asp Ala Thr Gln Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Pro Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu His Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,375 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 375,436 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 436,"(375/436) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:375 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:436."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Val Ser Thr Thr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asp Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln ThrLeu His Thr Pro Gly Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,374 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 374,435 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 435,"(374/435) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:374 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:435."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Arg Ser TyrGly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValAla Val Ile Ser Ser Asp Gly Arg Asn Lys Phe Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Phe Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Asp Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Arg Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,414 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 414,476 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 476,"(414/476) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:414 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:476."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Ile Gly Ala Gly Gly Gly Thr Tyr Tyr Ala Asp Ser Val LysGly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr LeuGln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys ValThr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His AspMet Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln ThrLeu Gln Thr Pro Arg Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,378 <211> LENGTH: 126 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 378,439 <211> LENGTH: 112 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 439,"(378/439) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:378 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:439."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValAla Val Ile Ser Tyr Asp Gly Asn Tyr Gln Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaIle Gln Asn Arg Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,385 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 385,446 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 446,"(385/446) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:385 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:446."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrGly Met His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Val Ser Ala Ser Gly Asp Arg Thr His Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Arg Leu Ala Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Tyr Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Thr Pro Ser Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,380 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 380,441 <211> LENGTH: 112 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 441,"(380/441) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:380 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:441."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValAla Val Ile Ser Ser Asp Gly Arg Asn Lys Phe Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Asn Asn Tyr Met Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Ala Ser Gln Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Arg Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,379 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 379,440 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 440,"(379/440) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:379 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:440."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Val Gly Asp Ser Gly Arg Ser Thr Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,377 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 377,438 <211> LENGTH: 112 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 438,"(377/438) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:377 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:438."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrGly Met His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Val Ser Ala Ser Gly Asp Arg Thr His Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His SerAsp Gly Tyr Thr Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Val Gly Ser Tyr Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaSer Gln Trp Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,388 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 388,449 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 449,"(388/449) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:388 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:449."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser HisThr Ile Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp LeuSer His Ile Ser Ser Ser Gly Ser Thr Thr Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Gln Arg Asp Asn Ser Arg Asp Met Ser Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp SerAsn Gly Phe Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Ser Arg Ala Pro Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln SerTyr Asn Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,391 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 391,452 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 452,"(391/452) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:391 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:452."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrGly Val His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValAla Val Ile Ser His Asp Gly Lys Lys Lys Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Val Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Thr Pro Arg Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,401 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 401,463 <211> LENGTH: 112 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 463,"(401/463) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:401 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:463."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Ile Gly Ala Gly Gly Gly Thr Tyr Tyr Ala Asp Ser Val LysGly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr LeuGln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys ValThr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His AspMet Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Tyr SerAsp Gly Asp Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,369 <211> LENGTH: 126 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 369,430 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 430,"(369/430) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:369 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:430."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrGly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValAla Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Asp Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Gly Gly Ser Asn Gly Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,376 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 376,437 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 437,"(376/437) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:376 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:437."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValAla Val Ile Ser Ser Ser Gly Arg Asn Lys Phe Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln AlaLeu Gln Thr Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,381 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 381,442 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 442,"(381/442) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:381 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:442."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Asn TyrAla Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Gly Val Ser Trp Asn Gly Ser Arg Thr His Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Ser Ser Arg Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Val Gln AlaLeu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,383 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 383,444 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 444,"(383/444) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:383 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:444."
https://patents.google.com/patent/US11053304B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Phe Ser Leu TyrGly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValAla Val Ile Thr Ser Asp Gly Arg Ser Lys Phe Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysVal Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe HisAsp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro GlyGlu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His SerAsn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Gln Leu Leu Ile Tyr Leu Ser Ser Asn Arg Ala Ser Gly Val ProAsp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys IleSer Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln GlyLeu Gln Ser Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile LysArg ,419 <211> LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 419,481 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 481,"(419/481) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:419 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:481."
https://patents.google.com/patent/WO2021211775A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Gly Val Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Asn Leu Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ala Val Ile Thr Ile Phe Gly Val Val Ile Gly Lys Ser Gly Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Glu Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Ala Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Synthetic sequence SARS-CoV-2 S2X2-v1 mAb VH  , Synthetic sequence SARS-CoV-2 S2X2-v1 mAb VL(VK)  ,"(200/204)  a second antibody or antigen-binding fragment comprising, a vh comprising or consisting of the amino acid sequence as set forth in seq id no:200 and a vl comprising of consisting of the amino acid sequence as set forth in seq id no:204. "
https://patents.google.com/patent/WO2021211775A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Pro Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Thr Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Gly Tyr Met Glu Leu Arg Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Tyr Thr Arg Gly Ala Trp Phe Gly Glu Ser Leu Ile Gly Gly Phe Asp Asn Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Thr Val Ser Ser Thr Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Asp Thr Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic sequence SARS-CoV-2 S309 mAb VH  , Synthetic sequence SARS-CoV-2 S309 mAb VL(VK)  ,"(172/176) (i)a first antibody or antigen-binding fragment, comprising a vh comprising or consisting of the amino acid sequence as set forth in seq id no:172 and a vl comprising or consisting of the amino acid sequence as set forth in seq id no:176"
https://patents.google.com/patent/WO2021211775A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ser Val Tyr Tyr Cys Ala Arg Asp Arg Gln Tyr Ser Gly Ser Pro Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Thr Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Gly Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic sequence SARS-CoV-2 S2H7-v1 mAb VH  , Synthetic sequence SARS-CoV-2 S2H7-v1 mAb VL(VK)  ,"(22/26) , wherein the vh comprises or consists of the amino acid sequence as set forth in seq id no:22 and the vl comprises or consists of the amino acid sequence as set forth in seq id no:26, and wherein the antibody or antigen-binding fragment is capable of binding to a sars-cov-2 surface glycoprotein ("
https://patents.google.com/patent/WO2021211775A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Asp Ser Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ala Gly Phe Thr Phe Ser Ser Tyr Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Leu Ser Ser Gly Tyr Ser Gly Tyr Ala Gly Asn Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly His Tyr Pro Tyr Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Arg Thr Leu Ile Tyr Asp Thr Ser Asn Lys His Ser Trp Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Ala Arg Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Leu Leu Ser Tyr Ser Gly Ala Arg Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Synthetic sequence SARS-CoV-2 S2H13-v1 mAb VH  , Synthetic sequence SARS-CoV-2 S2H13-v1 mAb VL  ,"(37/41) , wherein the vh comprises or consists of the amino acid sequence as set forth in seq id no:37 and the vl comprises or consists of the amino acid sequence as set forth in seq id no:41, and wherein the antibody or antigen-binding fragment is capable of binding to a sars-cov-2 surface glycoprotein ("
https://patents.google.com/patent/WO2021211775A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Arg Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Thr Gly Ser Glu Thr Tyr Tyr Tyr Asp Ser Ser Gly Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Gln Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Synthetic sequence SARS-CoV-2 S2H14-v1 mAb VH                , Synthetic sequence SARS-CoV-2 S2H14-v1 mAb VL                ,"(54/58) , wherein the vh comprises or consists of the amino acid sequence as set forth in seq id no:54 and the vl comprises or consists of the amino acid sequence as set forth in seq id no:58, and wherein the antibody or antigen-binding fragment is capable of binding to a sars-cov-2 surface glycoprotein ("
https://patents.google.com/patent/CN114106166A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Thr Leu Ser Cys Gly Ala Ser Gly Phe Thr Phe Glu Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Asp Trp Asn Ser Gly Val Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu His Met Arg Ser Leu Thr Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Val Tyr Ser Glu Ser Gly Ser Gly Ser Tyr Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Ala Ile Ser Cys Ser Gly Ser Thr Ser Asn Ile Gly Asp Asn Phe Val Ser Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu Leu Tyr Asp Asp Ala Arg Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Val Tyr Phe Cys Ser Thr Trp Asp Asn Ser Leu Asn Val Val Leu Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(2/1) the amino acid sequences of the light and heavy chain variable regions of antibody d2 are shown in seq id no:1 and 2, respectively."
https://patents.google.com/patent/CN113501872A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Ser Gly Thr Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Leu Asn Arg Leu Gly Val Glu Asp Thr Ala Leu Tyr Tyr Cys Val Lys Asp Ile Tyr Tyr Arg Asp Arg Asn Leu Gly Phe Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Ile Gly Asp Thr Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Asp Asn Tyr Leu His Trp Tyr Gln Lys Lys Pro Gly Ile Ala Pro Lys Leu Leu Ile Ser Ala Thr Ser Thr Leu Glu Asn Gly Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ile Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly His Ser Val Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Val Arg , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(8/7) preferably, the amino acid sequence of the light chain variable region of the antibody sk1 is shown as seq id no:7, and the amino acid sequence of the heavy chain variable region is shown as seq id no:8."
https://patents.google.com/patent/CN113834933A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Ile Val Ser Arg Asn Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Val Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Glu Ser Gln Asn Thr Leu Tyr Leu Gln Met Asn Arg Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys Ala Arg Asp Leu Gly Pro Arg Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(1/2)  the heavy chain and light chain amino acid sequences of the neutralizing antibody are respectively shown as seq id no:1 and 2.
https://patents.google.com/patent/CN112980885A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Phe Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala His Leu Gly Gly Phe Ala Asp Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Ala Gly Gln Ala Pro Arg Val Leu Ile Tyr Asp Ala Phe Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Arg Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , (1)..(119), (1)..(109),(27/28)  a heavy chain variable region comprising the sequence of seq id no:27 and a light chain variable region comprising the sequence of seq id no:28.
https://patents.google.com/patent/CN112980885A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Asn Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Arg Ser Ala Tyr Gly Asp Lys Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Gln Glu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , (1)..(122), (1)..(109),(17/18)  b) a heavy chain variable region comprising the sequence of seq id no:17 and a light chain variable region comprising the sequence of seq id no:18
https://patents.google.com/patent/CN112980885A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Ser Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Ala Asn Pro Gly Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Phe Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Arg Val Thr Ile His Tyr Asp Ile Leu Thr Gly Tyr Tyr Ser Asn Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Ala Val Ser Ser, Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Thr Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Ala Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Thr Thr Phe Met Tyr Thr Phe Gly Gln Gly Thr Met Leu Glu Ile Lys , (1)..(129), (1)..(108),(7/8)  a heavy chain variable region comprising the sequence of seq id no:7 and a light chain variable region comprising seq id no:8; 
https://patents.google.com/patent/WO2021197340A1/en, Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Asp Pro Ser Ala Ser Tyr Tyr Leu Asp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  人工序列(Artificial Sequence)  ,  人工序列(Artificial Sequence)  ,"(46/50) in some embodiments, the heavy chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:46, and the light chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:50"
https://patents.google.com/patent/WO2021197340A1/en, Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Leu Gly Pro Thr Tyr Gly Gly Tyr Ala Arg Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  人工序列(Artificial Sequence)  ,  人工序列(Artificial Sequence)  ,"(55/57) in some embodiments, the heavy chain of the antibody comprises the amino acid sequence shown in seq id no:55, and the light chain of the antibody comprises the amino acid sequence shown in seq id no:57"
https://patents.google.com/patent/WO2021197340A1/en, Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Leu Gly Pro Thr Tyr Gly Gly Tyr Ala Arg Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  人工序列(Artificial Sequence)  ,  人工序列(Artificial Sequence)  ,"(48/50) in some embodiments, the heavy chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:48, and the light chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:50"
https://patents.google.com/patent/WO2021197340A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Pro Phe Gly Ile Asp Asp Ala Tyr Leu Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  人工序列(Artificial Sequence)  ,  人工序列(Artificial Sequence)  ,"(108/57) in some embodiments, the heavy chain of the antibody comprises the amino acid sequence shown in seq id no:108, and the light chain of the antibody comprises the amino acid sequence shown in seq id no:57."
https://patents.google.com/patent/WO2021197340A1/en, Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Thr Ser Tyr Asp Gly Tyr Val Thr Leu Ala Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  人工序列(Artificial Sequence)  ,  人工序列(Artificial Sequence)  ,"(56/57) in some embodiments, the heavy chain of the antibody comprises the amino acid sequence shown in seq id no:56, and the light chain of the antibody comprises the amino acid sequence shown in seq id no:57"
https://patents.google.com/patent/WO2021197340A1/en, Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Pro Phe Gly Tyr Ser Ala Gly Tyr Leu Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  人工序列(Artificial Sequence)  ,  人工序列(Artificial Sequence)  ,"(54/57) in some embodiments, the heavy chain of the antibody comprises the amino acid sequence shown in seq id no:54 and the light chain of the antibody comprises the amino acid sequence shown in seq id no:57"
https://patents.google.com/patent/WO2021197340A1/en, Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Thr Ser Tyr Asp Gly Tyr Val Thr Leu Ala Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  人工序列(Artificial Sequence)  ,  人工序列(Artificial Sequence)  ,"(49/50) in some embodiments, the heavy chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:49, and the light chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:50"
https://patents.google.com/patent/WO2021197340A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Pro Phe Gly Ile Asp Asp Ala Tyr Leu Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  人工序列(Artificial Sequence)  ,  人工序列(Artificial Sequence)  ,"(107/50) in some embodiments, the heavy chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:107, and the light chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:50"
https://patents.google.com/patent/WO2021197340A1/en, Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Pro Phe Gly Tyr Ser Ala Gly Tyr Leu Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  人工序列(Artificial Sequence)  ,  人工序列(Artificial Sequence)  ,"(47/50) in some embodiments, the heavy chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:47, and the light chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:50"
https://patents.google.com/patent/WO2021197340A1/en, Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Asp Pro Ser Ala Ser Tyr Tyr Leu Asp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  人工序列(Artificial Sequence)  ,  人工序列(Artificial Sequence)  ,"(53/57) in some embodiments, the heavy chain of the antibody comprises the amino acid sequence shown in seq id no:53, and the light chain of the antibody comprises the amino acid sequence shown in seq id no:57"
https://patents.google.com/patent/WO2021190500A1/en, atgggctggt ccctgattct gctgttcctg gtggctgtgg ctaccagggt gctgagtgag gtccaacttg tccagtctgg agcagaggtg aagaagcctg gagccacagt gaagatttcc tgtaaggtgt ctggctactc cttcaccaac tactacatcc actgggtgaa gcaggctcct ggcaagtcct tggagtggat tggctacatt gacccattca atggaggcac ctctgacaac ctgaagttca agggagcagc caccctgaca gcagacacca gcacagacac agcctatatg gaactgtcct ccctgaggtc tgaggacaca gcagtctact actgtgccag gtctgaatat gacccatact atgtgatgga ctactgggga caaggcacca cagtgacagt gtccagcgca agcaccaagg gcccatcggt cttccccctg gcaccctcct ccaagagcac ctctgggggc acagcggccc tgggctgcct ggtcaaggac tacttccccg aaccggtgac ggtgtcgtgg aactcaggcg ccctgaccag cggcgtgcac accttcccgg ctgtcctaca gtcctcagga ctctactccc tcagcagcgt ggtgaccgtg ccctccagca gcttgggcac ccagacctac atctgcaacg tgaatcacaa gcccagcaac accaaggtgg acaagaaagt tgagcccaaa tcttgtgaca aaactcacac atgcccaccg tgcccagcac ctgaactcct ggggggaccg tcagtcttcc tcttcccccc aaaacccaag gacaccctca tgatctcccg gacccctgag gtcacgtgcg tggtggtgga cgtgagccac gaagaccccg aggtcaagtt caactggtac gtggacggcg tggaggtgca taatgccaag acaaagccgc gggaggagca gtacaacagc acgtaccgtg tggtcagcgt cctcaccgtc ctgcaccagg actggctgaa tggcaaggag tacaagtgca aggtctccaa caaagccctc ccagccccca tcgagaaaac catctccaaa gccaaagggc agccccgaga accacaggtg tacaccctgc ccccatcccg ggatgagctg accaagaacc aggtcagcct gacctgcctg gtcaaaggct tctatcccag cgacatcgcc gtggagtggg agagcaatgg gcagccggag aacaactaca agaccacgcc tcccgtgctg gactccgacg gctccttctt cctctacagc aagctcaccg tggacaagag caggtggcag caggggaacg tcttctcatg ctccgtgatg catgaggctc tgcacaacca ctacacgcag aagagcctct ccctgtctcc gggtaaatga , atgggctggt cctgtatcat cctgttcctg gtggctacag ccacaggagt gcatagtgag attgtgctga cccagagccc tgacttccag tctgtgacac caaaggagaa ggtgaccatc acttgtaggg caagccagag catctccagc aacctgcact ggtatcaaca gaagcctgac cagagcccaa aactgctgat taaatatgcc agccagagca tctctggcat cccaagcagg ttctctggct ctggctctgg cacagacttc accctgacca tcaactcctt ggaggctgag gactttggca tctacttctg tcaacagacc aacttctggc catacacctt tggacaaggc accaaattgg agattaagcg tacggtggct gcaccatctg tcttcatctt cccgccatct gatgagcagt tgaaatctgg aactgcctct gttgtgtgcc tgctgaataa cttctatccc agagaggcca aagtacagtg gaaggtggat aacgccctcc aatcgggtaa ctcccaggag agtgtcacag agcaggacag caaggacagc acctacagcc tcagcagcac cctgacgctg agcaaagcag actacgagaa acacaaagtc tacgcctgcg aagtcaccca tcagggcctg agctcgcccg tcacaaagag cttcaacagg ggagagtgtt aa ,  (1)..(57)  ,  (1)..(57)  ,"(26/27)  extract sars-2-h014 heavy chain (seq id no:26) expression vector, sars-2-h014 light chain (seq id no:27) expression vector plasmids, transfect hek-293 (fut8 gene knockou"
https://patents.google.com/patent/WO2021190500A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Met Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Tyr Ile His Trp Val Lys Gln Ser His Gly Lys Gly Leu Glu Trp Leu Gly Phe Ile Asp Pro Phe Asn Gly Gly Thr Ser Tyr Asn Leu Lys Phe Lys Gly Glu Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Phe Ile His Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Ser Asp Tyr Asp Pro Tyr Tyr Ala Leu Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Asp Thr Leu Ser Val Thr Pro Gly Asp Ser Val Ser Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Asn Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Thr Glu Asp Phe Gly Ile Tyr Phe Cys Gln Gln Thr Asn Phe Trp Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  小家鼠(Mus musculus)  ,  小家鼠(Mus musculus)  ,(65/66)  sars-2-mh202 antibody heavy chain variable region amino acid sequence (seq id no:65) and light chain variable region amino acid sequence (seq id no:66)
https://patents.google.com/patent/WO2021190500A1/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Thr Val Lys Ile Ser Cys Lys Val Ser Gly Tyr Ser Phe Thr Asn Tyr Tyr Ile His Trp Val Lys Gln Ala Pro Gly Lys Ser Leu Glu Trp Ile Gly Tyr Ile Asp Pro Phe Asn Gly Gly Thr Ser Asp Asn Leu Lys Phe Lys Gly Ala Ala Thr Leu Thr Ala Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Glu Tyr Asp Pro Tyr Tyr Val Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Asp Phe Gln Ser Val Thr Pro Lys Glu Lys Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Asn Leu His Trp Tyr Gln Gln Lys Pro Asp Gln Ser Pro Lys Leu Leu Ile Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Glu Ala Glu Asp Phe Gly Ile Tyr Phe Cys Gln Gln Thr Asn Phe Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  智人(Homo sapiens)  ,  智人(Homo sapiens)  ,"(22/23) the 4 humanized antibodies the amino acid sequence of the variable region of the heavy chain is seq id no:22/51/74/94, and the amino acid sequence of the variable region of the light chain is seq id no:23/52/75/95"
https://patents.google.com/patent/WO2021190500A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Met Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asn Tyr Tyr Ile His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Tyr Ile Asp Pro Phe Asn Gly Gly Thr Ser Asp Asn Leu Lys Phe Lys Gly Ala Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met His Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Ser Glu Tyr Asp Pro Tyr Tyr Val Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly Asp Ser Val Ser Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Asn Asn Leu His Trp Tyr Gln Gln Arg Ser His Glu Ser Pro Arg Leu Leu Ile Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Thr Glu Asp Phe Gly Phe Tyr Phe Cys Gln Gln Ser Ala Phe Trp Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  小家鼠(Mus musculus)  ,  小家鼠(Mus musculus)  ,(43/44)  sars-2-mh157 antibody heavy chain variable region amino acid sequence (seq id no:43) and light chain variable region amino acid sequence ( seq id no:44)
https://patents.google.com/patent/WO2021190500A1/en, Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Tyr Ile His Trp Val Lys Gln Ser His Gly Lys Gly Leu Glu Trp Leu Gly Phe Ile Asp Pro Phe Asn Gly Gly Thr Ser Tyr Asn Leu Lys Phe Lys Gly Glu Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Phe Ile His Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Ser Asp Tyr Asp Pro Tyr Tyr Ala Leu Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly Asp Ser Val Ser Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Asn Asn Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Thr Glu Asp Phe Gly Ile Tyr Phe Cys Gln Gln Thr Asn Phe Trp Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  小家鼠(Mus musculus)  ,  小家鼠(Mus musculus)  ,(88/89)  sars-2-mh697 antibody the amino acid sequence of the heavy chain variable region (seq id no:88) and the amino acid sequence of the light chain variable region (seq id no:89).
https://patents.google.com/patent/CN107226864A/en, Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ala Ser Gln Ser Val Asp Phe Asp Gly Asp Ser Phe Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Thr Thr Ser Asn Leu Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Asp Phe Asp Gly Asp Ser Phe Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Thr Thr Ser Ser Leu Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Ser Asn Ser Asp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,The anti-CD16A light chain variable districts (Hu3G8VL-1) of humanization,The anti-CD16A light chain variable districts (Hu3G8VL-43) of humanization,"(73/74) a kind of exemplary cd16 associated proteins are mouse 3g8 antibody.the amino of vh and vl domains comprising humanization 3g8acid sequence is described in fig. 2,9,14, and is listed in seq id no:9、seq id no:11、seq id no:12、seq id no:14、seq id no:15、seq id no:16、seq id no:18、seq id no:19、seq id no:20、seq idno:21、seq id no:22、seq id no:70、seq id no:71、seq id no:72、seq id no:73 and seqid no:74。"
https://patents.google.com/patent/CN107226864A/en, Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Ser Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Asn Pro Ala Tyr Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser , Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Gln Ile Asn Pro Ala Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,The anti-CD16A weight chain variable districts (Hu3G8VH-22) of humanization,The anti-CD16A weight chain variable districts (Hu3G8VH-5) of humanization,"(72/71) in order to explain rather than limit, the examples of available cd16a double antibodies is comprising at least one vh domain and extremelythe cd16a double antibodies of a few vl domain, wherein vh domains come from hu3g8vh-1, hu3g8vh-22 or hu3g8vh-5(it is seq id no respectively:70、seq id no:72 and seq id no:71"
https://patents.google.com/patent/CN107226864A/en, Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Asp Phe Asp Gly Asp Ser Phe Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Thr Thr Ser Ser Leu Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Ser Asn Ser Asp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Ser Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Asn Pro Ala Tyr Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser ,The anti-CD16A light chain variable districts (Hu3G8VL-43) of humanization,The anti-CD16A weight chain variable districts (Hu3G8VH-22) of humanization,"(74/72)  (it is seq id respectively with hu3g8vl-1, hu3g8vl-22 or hu3g8vl-43no:73、seq id no:72 and seq id no:or hu3g8vh-5 (seq id no:74"
https://patents.google.com/patent/CN112538111A/en, Met Ala Trp Val Trp Thr Leu Leu Phe Leu Met Ala Ala Ala Gln Ser Ile Gln Ala Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Ser Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Glu Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Gly Ser Asp Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Met Asp Ser Gln Ala Gln Val Leu Met Leu Leu Leu Leu Trp Val Ser Gly Thr Cys Gly Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(2/1) a new coronavirus single-chain antibody sequentially comprises a light chain variable region and a heavy chain variable region from an n section to a c end, wherein the amino acid sequence of the light chain variable region is shown as seq id no:1, and the amino acid sequence of the heavy chain variable region is shown as seq id no:2."
https://patents.google.com/patent/CN113004395B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/CN113004395B/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Ala Tyr Gly Pro Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Asn Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Ile Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) the heavy chain variable region of the monoclonal antibody or antigen-binding portion thereof of the present invention comprises an amino acid sequence that is at least 80% homologous to the amino acid sequence set forth in seq id no:4, and the light chain variable region of the monoclonal antibody or antigen-binding portion thereof of the present invention comprises an amino acid sequence that is at least 80% homologous to the amino acid sequence set forth in seq id no:8."
https://patents.google.com/patent/CN113735970A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Thr Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser His Tyr Val Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Asp Trp Val Ala Ile Ile Ser Phe Asp Gly Ser Ser Gln Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asp Thr Leu Tyr Leu Gln Met His Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ile His Gly Gly Thr Tyr Tyr Tyr Asp Lys Asn Ile Leu Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ala Ile Arg Met Thr Gln Ser Pro Pro Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Thr Asn Tyr Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Thr Phe Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys Arg ,  Homo sapiens,  Homo sapiens,"(1/5) in a preferred embodiment, the amino acid sequence of the heavy chain variable region of the antibody is shown in seq id no:1, and the amino acid sequence of the light chain variable region is shown in seq id no:5."
https://patents.google.com/patent/WO2021194965A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Val Asn Pro Ser Ser Gly Ser Thr Thr Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Arg Gly Ser Ala Ala Ile Ala Met Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Asn Glu Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(196/219) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:196 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:219"
https://patents.google.com/patent/WO2021194965A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Ile Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Pro Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Asp Tyr Gly Asp Tyr Gly Arg Leu Glu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Tyr Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(201/224) [0093] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:201 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:224"
https://patents.google.com/patent/WO2021194965A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr His Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Met Gly Met Gly Arg Asp Gly Tyr Asn Ser Arg Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Thr Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Met Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(200/223) [0092] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:223"
https://patents.google.com/patent/WO2021194965A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Met Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asp Pro His Ser Gly Ala Thr Asn Tyr Ala His Ser Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Glu Gly Gly Ser Tyr Trp Thr Gly Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Ala Val Ser Ser Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(202/225) [0094] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:202 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:225"
https://patents.google.com/patent/WO2021194965A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Glu Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Asp Gly Ser Ser Thr Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Tyr Ser Tyr Asp His Asp Gln Ile Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Val Ser Gln Gly Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ile Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(212/235) [0106] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:212 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:235"
https://patents.google.com/patent/WO2021194965A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Asp Thr Phe Ser Asn Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ile Gly Thr Thr Val Val Thr Pro Phe Gly Tyr Trp Gly Gln Gly Thr Leu Val Asn Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Glu Ser Val Ser Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Gly Tyr Lys Asn Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(192/215) [0084] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:192 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:215"
https://patents.google.com/patent/WO2021194965A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Tyr Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Met Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Asp Thr Ile Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Asn Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Asn Gly Phe Pro Leu Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(213/236) [0107] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:213 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:236"
https://patents.google.com/patent/WO2021194965A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Asn Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Met Asp Ile Val Val Val Pro Trp Leu Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ala Ile Thr Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(204/227) [0096] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:204 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:227"
https://patents.google.com/patent/WO2021194965A1/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Ser Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Val Ser Ala Ile Ser Arg Asn Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Gly Thr Leu Ile Thr Thr Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Tyr Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Thr Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(194/217) [0086] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:194 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:217"
https://patents.google.com/patent/WO2021194965A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Ser Asn Ser Gly Ser Thr Gly Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Trp Met Ala Tyr Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Tyr Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Ile Ser Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(211/234) [0105] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:211 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:234"
https://patents.google.com/patent/WO2021194965A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Arg Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Thr Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Ala Pro His Asp Tyr Ile Trp Gly Ser Tyr Arg Pro Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Asp Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Glu Ala Ser Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys His Gln Tyr Leu Ser Ser Pro Glu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(209/232) the antibody or the antigen binding fragment can comprise a vh having an amino acid sequence of seq id no:209 and a vl having an amino acid sequence of seq id no:232
https://patents.google.com/patent/WO2021194965A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Asn Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Thr Arg Tyr Gly Gly Asn Ser Arg Ser Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln His Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ala Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Gly Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(203/226)  [0095] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:203 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:226. (covid19 p11 d"
https://patents.google.com/patent/WO2021194965A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Asn Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Gly Val Asp Thr Ala Thr Leu Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Gly Ala Ser Thr Leu Ser Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Thr Pro Tyr Ser Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(205/228) [0097] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:205 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:228"
https://patents.google.com/patent/WO2021194965A1/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe His Tyr Tyr Thr Tyr Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Arg Ile Asn Thr Asp Gly Tyr Tyr Thr Tyr Tyr Asp Tyr Ser Val Arg Gly Leu Phe Thr Tyr Ser Arg Asn Tyr Ser Lys Asn Leu Leu Tyr Leu Leu Met Asn Leu Leu Lys Thr Asp Asp Thr Ala Val Tyr Tyr Cys Ala Ile Ile Leu Pro Gly Ala Pro Pro Gly Thr Leu Gly Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Tyr Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Ile Ser Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(214/237) [0110] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:214 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:237"
https://patents.google.com/patent/WO2021194965A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Ala Arg Asn Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Thr Asp Pro Val Leu Glu Trp Phe Gly Tyr Ser Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Phe Ser Ser Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(208/231) [0009] the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:208 and a vl having an amino acid sequence of seq id no:231
https://patents.google.com/patent/WO2021194965A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Lys Thr Gly Asp Thr Asn Tyr Ala Gln Glu Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Ser Gly Tyr Tyr Phe Gly Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(207/230) [0100] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:207 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:230"
https://patents.google.com/patent/WO2021194965A1/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Asn Tyr Asp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Gly Phe Lys Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Arg Met Asn Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gln Val Arg Gly Ser Gly Pro Gln Val Val Val Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Gly Ile Arg Asn Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(193/216) [0085] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:193 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:216"
https://patents.google.com/patent/WO2021194965A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Ser Tyr Pro Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Ser Tyr Asp Thr Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Ser Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(198/221) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:198 and a vl having an amino acid sequence of seq id no:221
https://patents.google.com/patent/WO2021194965A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asp Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Val Thr Pro Gly Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Thr Ile Tyr Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Ile Ser Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(210/233) [0104] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:210 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:233"
https://patents.google.com/patent/WO2021194965A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Arg Ser Thr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Gly Tyr Ser Ser Ser Ser Gly Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Asn Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Thr Phe Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(195/218) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:195 and a vl having an amino acid sequence of seq id no:218
https://patents.google.com/patent/WO2021194965A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Thr Ser Tyr His Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Leu Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Phe Glu Arg Phe Gly Glu Leu Val Pro Glu Thr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(197/220) [0089] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:197 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:220"
https://patents.google.com/patent/WO2021194965A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Asn Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Val Gln Asn Tyr Tyr Gly Ser Gly Ser Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Pro Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(206/229) [0099] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:206 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:229"
https://patents.google.com/patent/WO2021194965A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Asn Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Val Ile Asn Pro Ser Ala Gly Ser Thr Ser Tyr Ala His Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Ala His Ser Ser Ser Trp Tyr Ser Asp Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(199/222) [0091] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:199 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:222"
https://patents.google.com/patent/CN111718411A/en,Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Asp Ile Leu Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser,Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial sequence, Artificial sequence,"(7/8) specifically, the sequences of the light chain variable region and the heavy chain variable region are respectively the same as seq id no:8 and seq id no:7."
https://patents.google.com/patent/WO2022018040A2/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Gly Ser Gly Tyr Tyr Thr His Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ," /note=""Description of Artificial Sequence: Synthetic       polypeptide""  "," /note=""Description of Artificial Sequence: Synthetic       polypeptide""  ","(55/64) [0011] in some aspects, the antibody or antigen-binding fragment thereof provided herein comprises the variable heavy chain (vh) amino acid sequence and the variable light chain (vl) amino acid sequence selected from the group consisting of: (a) seq id no:55 and seq id no:64, respectively"
https://patents.google.com/patent/WO2005012360A2/en, Ala Met Ala Gin Val Gin Leu Gin Glu Ser Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Val Ser Ser Gly Ser Tyr Tyr Trp Ser Trp Ile Arg Gin Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gin Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ser Arg Ser Ala Gly Phe Phe Asp Tyr Trp Gly Gin Gly Thr leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Glu Leu Thr Gin Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gin Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gin Gin Lys Pro Gly Gin Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly lie Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gin Gin Arg Ser Asn Trp Pro Pro Ala Phe Gly Gly Gly Thr Lys Val Glu lie Lys Arg Ala Ala Ala , Ala Met Ala Glu Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Gin Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gl y Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala lie Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Phe Asn Pro Phe Thr Ser Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Glu Leu Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gin Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gin Se Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr lie Ser Ser Leu Gin Pro Glu Asp Phe Ala Thr Ty r Tyr Cys Gin Gin Ser Tyr Ser Thr Pro Pro Thr Phe Gly Gin Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala , SC03-017 , SC03-018 ,"(94/96) no: 93 and seq id no:95, respectively. the amino acid sequences of the scfv's called sc03-016, sc03-017 and sc03-018 are shown in seq id no:92, seq id no:94 and seq id no:96, respectively. the vh and vl gene identity (see tomlinson im, williams sc, ignatovitch o, corbett sj, winter g. v-base sequence"
https://patents.google.com/patent/WO2016138160A1/en, Gln Val Gln Leu Gln Gln Ser Gly Gly Glu Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Thr Ser Gly Phe Thr Phe Ser Ser Ser Tyr Ile Ser Trp Leu Lys Gln Lys Pro Gly Gln Ser Leu Glu Trp Ile Ala Trp Ile Tyr Ala Gly Thr Gly Gly Thr Glu Tyr Asn Gln Lys Phe Thr Gly Lys Ala Gln Val Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr Met Gln Phe Ser Ser Leu Thr Thr Glu Asp Ser Ala Ile Tyr Tyr Cys Ala Arg Gly Gly Ser Ser Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Gln Leu Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Asn Tyr Gly Ile Ser Phe Met Asn Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile His Thr Ala Ser Asn Gln Gly Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His Pro Val Glu Asp Asp Asp Thr Ala Met Tyr Phe Cys Gln Gln Ser Glu Glu Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus Musculus  ,  Mus Musculus  ,"(115/117)  the vh and the vl of the second isolated monoclonal antibody comprise the amino acid sequences set seq id no:115 and 117, respectively (g"
https://patents.google.com/patent/WO2016138160A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Thr Tyr Ala Leu Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Asn Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Ser Ser Ser Ser Ala Glu Tyr Phe Gln His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Arg Ser Val Ser Gly Ser Pro Gly Gln Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Cys Ser Tyr Ala Gly Ser Tyr Thr Leu Glu Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo Sapiens  ,  Homo Sapiens  ,"(48/50) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:48 and 50, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection"
https://patents.google.com/patent/WO2016138160A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile Asn Asn Gly Gly Ser Tyr Ser Tyr Tyr Pro Asp Ser Val Lys Gly Arg Leu Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg His Tyr Asp Tyr Asp Gly Tyr Tyr Tyr Thr Met Asp Phe Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Val Leu Met Thr Gln Ile Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Pro Leu Ile Tyr Lys Val Ser Asn Arg Ile Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly Ser His Val Pro Tyr Thr Phe Gly Gly Gly Thr Asn Leu Glu Ile Lys Arg ,  Mus Musculus  ,  Mus Musculus  ,"(127/129) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:127 and 129, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection"
https://patents.google.com/patent/WO2016138160A1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Gly Ser Ile Ser Ser Asn Tyr Trp Tyr Trp Ile Arg Gln Ser Pro Val Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Gly Gly Ser Gly Gly Thr Glu Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Thr Asp Thr Ser Lys Asn Gln Phe Phe Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Phe Tyr Ser Trp Asn Gly Glu Ser Trp Gly Gln Gly Val Val Val Thr Val Ser Ser , Asp Ile Gln Met Ser Gln Thr Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asn Asp Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Tyr Gly Asn Ser Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Asp Ser Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys ,  Macaca Mulatta  ,  Macaca Mulatta  ,"(52/54) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:52 and 54, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection"
https://patents.google.com/patent/WO2016138160A1/en, Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Val Val Arg Pro Ser Glu Thr Leu Ser Leu Ser Cys Ala Val Ser Gly Gly Ser Ile Ser Asp Ser Tyr Arg Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val Gly Tyr Ile Phe Ala Thr Gly Thr Thr Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Pro Phe Lys Tyr Cys Ser Gly Gly Val Cys Tyr Ala His Lys Asp Asn Ser Leu Asp Val Trp Gly Gln Gly Val Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile His Ser Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Ser Leu Thr Ile Ser Ser Leu Glu Ala Glu Asp Val Gly Val Tyr His Cys Tyr Gln His Ser Ser Gly Tyr Thr Phe Gly Pro Gly Thr Lys Leu Asp Ile Lys ,  macaca mulatta  ,  macaca mulatta  ,"(6/8) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:6 and 8, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection"
https://patents.google.com/patent/WO2016138160A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Arg Pro Gly Val Ser Val Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr Ala Ile His Trp Val Lys Gln Ser His Ala Lys Ser Leu Glu Trp Ile Gly Val Phe Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe Lys Gly Arg Ala Thr Met Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Ala Arg Leu Thr Ser Glu Asp Ser Ala Ile Tyr Tyr Cys Ala Arg Lys Ser Tyr Tyr Val Asp Tyr Val Asp Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Asn Tyr Gly Ile Ser Phe Met Asn Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Ser Ala Thr Ser Asn Gln Gly Ser Gly Val Pro Ala Arg Phe Ile Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His Pro Val Glu Glu Asp Asp Thr Ala Met Tyr Phe Cys Gln Gln Ser Lys Glu Val Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus Musculus  ,  Mus Musculus  ,"(119/121) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:119 and 121, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection"
https://patents.google.com/patent/WO2016138160A1/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly His Ile Phe Thr Ser Tyr Val Ile Asn Trp Leu Gln Glu Ala Pro Gly Gln Gly Phe Glu Trp Met Gly Gly Ile His Pro Gly Asn Gly Gly Arg Asp Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Met Ser Thr Ser Thr Val Tyr Met Glu Leu Arg Ser Leu Arg Ser Glu Asp Met Ala Val Tyr Tyr Cys Ala Ala Ser Ser Gly Ser Tyr Gly Val Ser Ser Leu Asp Val Trp Gly Arg Gly Val Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Pro Ser Leu Ser Ala Ser Pro Gly Ala Ser Ala Arg Leu Pro Cys Thr Leu Ser Ser Asp Leu Ser Val Gly Ser Lys Asn Met Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ala Pro Arg Leu Phe Leu Tyr Tyr Tyr Ser Asp Ser Asp Lys Gln Leu Gly Pro Gly Val Pro Asn Arg Val Ser Gly Ser Lys Glu Thr Ser Ser Asn Thr Ala Phe Leu Leu Ile Ser Gly Leu Gln Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Val Tyr Asp Ser Ser Ala Asn Trp Val Phe Gly Gly Gly Thr Arg Leu Thr Val Leu ,  Macaca Mulatta  ,  Macaca Mulatta  ,"(56/58) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:56 and 58, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection"
https://patents.google.com/patent/WO2016138160A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ile Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly His Gln Gly Tyr Cys Ser Gly Gly Ser Cys Tyr Asp Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Ala Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Ala Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Homo Sapiens  ,  Antibody variable region  ,"(36/111) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:36 and 111, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection"
https://patents.google.com/patent/WO2016138160A1/en, Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile Ser Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Glu Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Val Arg Asp Gly Asn Ser Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ile Cys Arg Ala Ser Gln Asp Ile Asn Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Ala Asn Thr Leu Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Arg ,  Mus Musculus  ,  Mus Musculus  ,"(123/125) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:123 and 125, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection"
https://patents.google.com/patent/WO2016138160A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ile Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly His Gln Gly Tyr Cys Ser Gly Gly Ser Cys Tyr Asp Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Ala Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Homo Sapiens  ,  Homo Sapiens  ,"(36/38)  the vh and the vl of the first isolated monoclonal antibody comprise the amino acid sequences set seq id no:36 and 38, respectively (c"
https://patents.google.com/patent/WO2016138160A1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Gly Ser Ile Ser Ser Asn Tyr Trp Asn Trp Ile Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Gly Gly Ser Gly Ser Thr Thr Tyr Asn Pro Ser Leu Lys Ser Arg Val Ala Ile Ser Thr Asp Thr Ser Lys Asp Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Pro Leu Gly Gly Gly Tyr Cys Phe Asp Tyr Trp Gly Gln Gly Val Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Thr Pro Phe Thr Leu Pro Val Thr Pro Gly Glu Ala Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Phe Asp Ser Asp Tyr Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Met Leu Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Leu Tyr Tyr Cys Met Gln Ser Val Glu Tyr Pro Phe Thr Phe Gly Pro Gly Thr Lys Leu Asp Ile Lys ,  macaca mulatta  ,  macaca mulatta  ,"(2/4) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:2 and 4, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection"
https://patents.google.com/patent/WO2016138160A1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Asp Ser Ile Ser Ser Asn Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Arg Phe Ser Gly Ser Gly Gly Ser Thr Asp Phe Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Thr Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Lys Thr Tyr Ser Gly Thr Phe Asp Tyr Trp Gly Gln Gly Val Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Asn Asn Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Pro Leu Ile Tyr Tyr Ala Ser Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Leu Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Asn Ser Pro Tyr Ser Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  macaca mulatta  ,  macaca mulatta  ,"(10/12) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:10 and 12, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection"
https://patents.google.com/patent/WO2016138160A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ile Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly His Gln Gly Tyr Cys Ser Gly Gly Ser Cys Tyr Asp Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Ser Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Ala Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Homo Sapiens  ,  Antibody variable region  ,"(36/110) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:36 and 110, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection"
https://patents.google.com/patent/WO2016138160A1/en, Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Ser Leu Leu Arg Pro Leu Ile Tyr Cys Ser Gly Gly Ser Cys Thr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Cys Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Asn Ile Thr Leu Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu ,  Homo Sapiens  ,  Homo Sapiens  ,"(40/42) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:40 and 42, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection"
https://patents.google.com/patent/WO2016138160A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Ser Ser Ser Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Gly Leu Gly Ser Gly Trp Tyr Asp Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Ser Tyr Asp Val His Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Thr Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Val Val Phe Ser Gly Gly Thr Lys Leu Thr Val Leu ,  Homo Sapiens  ,  Homo Sapiens  ,"(44/46) in some embodiments, the antibody or antigen binding fragment includes a vh and a vl comprising the amino acid sequences set forth as seq id no:44 and 46, respectively, and can specifically bind to mers-cov s protein and neutralize mers-cov infection"
https://patents.google.com/patent/CN112250763A/en, Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Glu Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Asp Thr Ala Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Pro Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu His Thr Val Ala Pro Val Tyr Gly Phe Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Artificial sequence, Artificial sequence,(3/4)  an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in seq id no:3; and a light chain variable region comprising the amino acid sequence set forth in seq id no:4;
https://patents.google.com/patent/CN112250763A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Tyr Ser Ser Ser Trp Leu Leu Gln Ser Phe Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asn Ile Gln Leu Thr Gln Ser Pro Val Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Leu Thr Cys Arg Ala Ser Gln Gly Ile Gly Tyr Ser Leu Val Trp Tyr Gln Lys Lys Pro Gly Thr Ala Pro Lys Leu Leu Ile Phe Asp Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Ser Ala Thr Tyr Tyr Cys Gln Gln Val Ile His Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Artificial sequence, Artificial sequence,(11/12)  an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in seq id no:11; and a light chain variable region comprising the amino acid sequence set forth in seq id no:12.
https://patents.google.com/patent/CN113583114A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Thr Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Met Trp Asn Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Val Ala Ala Ala Gly Ser Ser Ser Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Phe Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Leu Tyr Ser Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , amino acid sequence of heavy chain variable region (VH) of 5C6, 5C6 light chain variable region (VL) amino acid sequence,"(9/10) preferably, the antibody or antigen-binding fragment thereof comprises: a vh comprising the sequence shown as seq id no:9 and a vl comprising the sequence shown as seq id no:10."
https://patents.google.com/patent/CN113583114A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Leu Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Ile Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Thr Thr Val Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Pro Pro Tyr Asn Trp Asn Gly Pro Leu Arg Ser Gln Arg Phe Asp Cys Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln His Tyr Asp Asn Leu Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , 6G9 amino acid sequence of heavy chain variable region (VH), 6G9 light chain variable region (VL) amino acid sequence,"(17/18) preferably, the antibody or antigen-binding fragment thereof comprises: a vh comprising the sequence shown as seq id no:17 and a vl comprising the sequence shown as seq id no:18."
https://patents.google.com/patent/CN113583114A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Arg Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Leu Val Ala Ser Tyr Arg Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Val Ser Leu Ser Ala Ser Ile Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Thr Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys His Gln Tyr Asp Asn Leu Pro Val Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , amino acid sequence of 3C11 heavy chain variable region (VH), 3C11 light chain variable region (VL) amino acid sequence,"(1/2) preferably, the antibody or antigen-binding fragment thereof comprises: a vh comprising the sequence shown as seq id no:1 and a vl comprising the sequence shown as seq id no:2."
https://patents.google.com/patent/CN114057868A/en, caggtgcagc tgaagcagtc aggacctggc ctagtgcagc cctcacagaa cctgtccatt acctacacat tctctggttt cttattaagc tgctatgttg aatactggga gcgccattct ccaggaaagg gtctggagtg gctgggagtg atatggagtg gtgtttacac agactataat gctgctttca tatccagatt gagcatcagc aaggacaact ccaagagcca agttttcttt aaaatgaaca gtctgcaacc tgatgacaca gccatttact actgtacaag attggggaac tacggtgcct ggtttgttta ctggggccaa gggactcttg tcactgtttc tgca , gacatccagg aaactcagag tccagcctcc ctaggtgcaa gtgtgggaga aactgttaccatcacatgtc gagcaagtga gaatatttac agttatttag catggtatca gcagaaacag ggaaaaagtc cacagctcct ggtttataat gcaaaaattt tagcagaagg tgtgccatca aggttcagtg gcagtggatc aggcacacag tttagtctga agatcaacag cctgcagcct gaagattttg ggagttatta ctgtcaacat aattttgata ctcctcccac gttcggaggg gggaccaagc tggaaataaa acgg , hybridoma cell 8C3D6 (strain 8C3D6 hybridoma), hybridoma cell 8C3D6 (strain 8C3D6 hybridoma),"(5/6) the monoclonal antibody 8c3d6 heavy chain variable region by seq id no:5 or its degenerate sequence coding, its light chain variable region by seq id no:6 or its degenerate sequence coding."
https://patents.google.com/patent/CN114057868A/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Arg Pro Gly Val Ser Val Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr Val Met His Trp Val Lys Gln Ser His Ala Gln Ser Leu Glu Trp Ile Gly Leu Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Met Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Ala Arg Leu Thr Ser Asp Asp Ser Ala Ile Tyr Tyr Cys Ala Lys Trp Asp Asp Asn Asn Pro Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr Leu Thr Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile Tyr Arg Ala Asn Arg Leu Leu Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr Glu Asp Val Gly Ile Tyr Tyr Cys Leu Gln Tyr Gly Glu Phe Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg , hybridoma cell line 3A11 (strain 3A11 hybridomya), hybridoma cell line 3A11 (strain 3A11 hybridomya),(3/4)  the protein sequences of the heavy chain variable region and the light chain variable region of the monoclonal antibody 3a11 are respectively shown as seq id no:3 and seq id no:4.
https://patents.google.com/patent/CN114057868A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Asp Leu Val Lys Pro Gly Ala Ser Leu Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Leu Tyr Trp Val Gln Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Ile Asn Pro Asn Asn Gly Gly Thr Arg Tyr Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Tyr Asp Tyr Arg Arg Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Ile Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asp Glu Asp Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys , hybridoma cell line 5E2 (strain 5E2 hybridoma), hybridoma cell line 5E2 (strain 5E2 hybridoma),"(1/2)  more preferably, the antibody or fragment thereof is monoclonal antibody 5e2, the heavy chain variable region of monoclonal antibody 5e2 is shown as seq id no:1, and the light chain variable region is shown as seq id no:2."
https://patents.google.com/patent/CN114057868A/en, atgtgcagct ggtggagtcc tgggcgaggc ttagtgcatc ctcgagggtc ccgtaaactc tcctgtgcag cctctcgatt cactttcagc agctttcgaa tgcactgggt tcgtcatgct ccagaaaatg ggctggagtg ggtcgcatat attagtggtg gcagtagtac catcttctat gcagacgcat tgaatggccg attcaccatc tccagagaca atcccaataa caccctgttc ctgcaaatga ccagtctaag gtctgaggac acggccatgt attactgtgc aagatggccc tttgcttact ggggccacgg gactctggtc actgtctctg ca , ggaattgtga tgacacagtc tccatcctcc ctgactgtga cagcacgaga gagagtcact atgagctgca gatccagtca gagtctgtta aacagtgaaa atcacagaaa ctacttgacc tggttccagc agaaaccagg gcagcctcct agactgttga tctactgggc atccactagg gattctgggg tccctgatcg cttcacaggc agtcgatctc gaacagattt cactctcacc atcagccgtg tgcagtctga aggactggca gtttattact gtcagaatga ttatagttat ccgctcacgt tcggtgctgg gaccagactg gagctggca , hybridoma cell 6D4A8 (strain 6D4A8 hybridoma), hybridoma cell 6D4A8 (strain 6D4A8 hybridoma),"(7/8) the heavy chain variable region of monoclonal antibody 6d4a8 is encoded by seq id no:7 or a degenerate sequence thereof, and the light chain variable region is encoded by seq id no:8 or a degenerate sequence thereof."
https://patents.google.com/patent/CN113929773A/en, Ser Ser Gln Val Gln Ala Gln Gln Asp Cys Trp Glu Leu Gly Leu Arg Glu Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr Asn Met Tyr Trp Val Lys Gln Ser His Arg Lys Ser Leu Glu Trp Ile Gly Tyr Ile Asp Pro Tyr Asn Gly Gly Thr Ser Tyr Asn Gln Lys Ser Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met His Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Ile Tyr Asn Trp Cys Lys Lys, Phe Thr Ala Ile Leu Ser Ile Tyr Met Gly Glu Gly His Tyr Val Leu Gln Asn Gln Phe Lys Ser Lys Leu His Val Leu Val Pro Ala Glu Ala Arg Ile Val Ser Pro Ala Leu Asp Leu Gln Gly Ile Gln Pro Ile Phe Trp Gly Pro Arg Gln Val Gln Gly Ala Val Asp Gln Gly Leu Ile Phe Ile Glu Asn Gln Gln Glu Trp Arg Leu Lys Asp Leu Gly Ile Tyr Phe Cys Leu Gln Val Thr His Ser Arg Thr Arg Ser Glu Gly Asp Gln Ala Glu Ile Asn Ala Ser Thr , SARS-CoV-2, SARS-CoV-2,"(3/4)  the amino acid sequence of the heavy chain variable region of the monoclonal antibody 6b11 is shown in seq id no:3, and the amino acid sequence of the light chain variable region is shown in seq id no:4. the method comprises the following specific steps:"
https://patents.google.com/patent/CN111732654A/en,Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Val Ser Asp Phe Asp Trp Leu Tyr Arg Ser His Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Gln Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Artificial sequence, Artificial sequence,"(7/8) specifically, the sequences of the light chain variable region and the heavy chain variable region are respectively the same as seq id no:8 and seq id no:7."
https://patents.google.com/patent/CN113004396B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(12/16)  wherein the amino acid sequence of vh is shown as seq id no:12, and the amino acid sequence of vl is shown as seq id no:16."
https://patents.google.com/patent/CN113004396B/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Ser Pro Ser Gly Gly Trp Tyr Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Asn Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Arg Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8)  wherein, the amino acid sequence of vh is shown as seq id no:4, and the amino acid sequence of vl is shown as seq id no:8."
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Gly Gly Arg Gly Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met Phe Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Arg Leu Leu Ile Tyr Asp Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Asn Ser Tyr Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(183/374) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:183 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:374"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Trp Met Gln Trp Ile Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Glu Ile Asp Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Arg Tyr Tyr Gly Ser Arg Arg Asp Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Gln Ile Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Leu Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(162/346) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:162 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:346"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Tyr Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asn Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Val Asn Ser Asn Trp Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Thr Ser Leu Ala Met Ser Leu Gly Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Ser Ile Ile Gly Thr Asn Leu Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Phe His Ala Ser Asn Leu Glu Thr Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp Pro Val Glu Gly Asp Asp Val Ala Ile Tyr Tyr Cys Leu Gln Ser Arg Lys Ile Pro Tyr Ala Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(110/267) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:110 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:267"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Ile Thr Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Lys Gly Leu Ser Phe Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(18/296) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:18 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:296"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Thr Gly Tyr Thr Phe Thr Gly Tyr Trp Ile Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile Gly Glu Ile Leu Pro Gly Ser Gly Ser Thr Asn Ser Asn Glu Lys Phe Lys Gly Lys Ala Thr Phe Thr Ala Asp Pro Ser Ser Asn Thr Val Tyr Met Gln Leu Ser Ser Leu Thr Thr Glu Asp Ser Ala Ile Tyr Tyr Cys Ala Ser Ser Gly Thr Asp Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Ser Tyr Leu Leu Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Phe His Arg Ser Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(173/361) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:173 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:361"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Val Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asn Tyr Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala His Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Gly His Pro Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Pro Ile Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(53/263) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:53 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:263"
https://patents.google.com/patent/WO2021213520A1/en, Asp Val Gln Leu Gln Glu Ser Gly Pro Ser Leu Val Arg Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Thr Gly Phe Ser Ile Asn Ser Asp Cys Tyr Trp Ile Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Tyr Ile Gly Tyr Thr Phe Tyr Ser Gly Ile Thr Tyr Tyr Asn Pro Ser Leu Glu Ser Arg Thr Tyr Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Thr Thr Arg Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Arg Leu Leu Ile Tyr Asp Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Tyr Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(7/376) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:7 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:376"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Leu Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Thr Arg Arg Val Thr Ser Gly Gly Asp Tyr Trp Gly Arg Gly Asn Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Ala Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Phe Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Val Lys ,  Mus musculus  ,  Mus musculus  ,"(13/291) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:13 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:291"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met His Trp Val Lys Gln Ser Pro Gly Lys Ser Leu Glu Trp Ile Gly Tyr Ile Asn Pro Asp Asn Gly Gly Pro Asn Tyr Asn Gln Lys Phe Lys Gly Met Ala Thr Leu Thr Val Asn Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Val Asn Ser Asn Trp Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Met Ser Leu Gly Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Ser Ile Ile Gly Thr Asn Leu Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Phe His Ala Ser Asn Leu Glu Thr Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp Pro Val Glu Glu Asp Asp Val Ala Ile Tyr Tyr Cys Leu Gln Ser Arg Lys Ile Pro Tyr Thr Phe Gly Gly Gly Thr Glu Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(112/233) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:112 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:233"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Pro Gly Thr Glu Leu Val Arg Pro Gly Thr Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Asn Ile Asp Pro Ser Asn Gly Asp Thr Asn Tyr Asn Glu Lys Phe Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Gly Ser Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Leu Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Phe Glu Tyr Tyr Gly Thr Ser Phe Met Gln Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His Pro Val Glu Glu Asp Asp Ile Ala Met Tyr Phe Cys Gln Gln Ser Arg Lys Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(172/244) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:172 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:244"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr Tyr Met Asn Trp Val Lys Gln Ser Pro Glu Lys Ser Leu Glu Trp Ile Gly Glu Ile Asn Pro Ser Thr Gly Gly Thr Thr Tyr Asn Gln Lys Phe Lys Ala Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Arg Ala Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Glu Tyr Tyr Gly Thr Ser Leu Val Gln Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Val Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His Pro Val Glu Glu Asp Asp Ile Ala Met Tyr Phe Cys Gln Gln Thr Arg Lys Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(93/248) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:93 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:248"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Leu Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Asp Asp Gly Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Asp Asp Asp Tyr Asp Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Gly Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Ile Leu Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(155/324) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:155 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:324"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Ser Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met Asp Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Asn Ile Tyr Pro Ser Asp Ser Glu Thr His Tyr Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Ile Thr Gly Thr Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(168/273) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:168 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:273"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Val Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Arg Leu Gly Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Ile Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(50/295) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:50 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:295"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Tyr Ile Lys Asp Asp Tyr Leu His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Trp Ile Asp Pro Glu Asn Gly Asp Ala Glu Tyr Ala Ser Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Thr Leu Ile Tyr Tyr Tyr Gly Ser Asn Ser Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly Gly Lys Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Asn Phe Leu Ala Trp Tyr Gln His Lys Pro Gly Lys Gly Pro Arg Leu Leu Ile His Tyr Thr Ser Thr Leu Gln Pro Gly Ile Pro Ser Arg Phe Ser Gly Gly Gly Ser Gly Arg Asp Tyr Ser Phe Thr Ile Ser Asn Leu Glu Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Asp Leu Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(70/207) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:70 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:207"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Thr Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Arg Leu Gly Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Thr Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(36/305) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:36 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:305"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Gly Lys Asn Tyr Ala Thr Asp Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(26/260) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:26 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:260"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Tyr Ile Asn Pro Asp Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asn Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Val Asn Ser Asn Trp Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Ser Ile Ile Gly Ala Asn Leu Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr His Ala Ser Asn Leu Glu Thr Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp Pro Val Glu Glu Asp Asp Ile Ala Ile Tyr Tyr Cys Leu Gln Ser Arg Lys Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(108/238) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:108 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:238"
https://patents.google.com/patent/WO2021213520A1/en, Asp Val Gln Leu Gln Glu Ser Gly Pro Ser Leu Val Arg Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Thr Gly Phe Ser Ile Asn Ser Asp Cys Tyr Trp Ile Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Tyr Ile Gly Tyr Thr Phe Tyr Ser Gly Ile Thr Tyr Tyr Asn Pro Ser Leu Glu Ser Arg Thr Tyr Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Thr Thr Arg Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asn Ser Ser Leu Pro Ile Asn Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(7/225) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:7 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:225"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Ile Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Trp Asp Asn Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Val Ser Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser Gly His Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Gly Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn Asp His Arg Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(80/281) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:80 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:281"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Glu Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Asp Phe Gly Pro Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Ile Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Thr Ser Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Arg Asn Tyr Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(185/371) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:185 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:371"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Thr Trp Gly Tyr Thr Asn Tyr Val Glu Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Cys Ala Ser Leu Gly Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Tyr Asn Tyr Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(65/193) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:65 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:193"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met Gly Met Ile Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Phe Leu Gln Ile Asn Asn Leu Lys Asp Glu Asp Thr Ala Thr Tyr Phe Cys Val Arg Glu Gly Ser Ser Pro Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Met Ser Leu Gly Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Ser Ile Ile Gly Thr Asn Leu Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr His Ala Ser Asn Leu Glu Thr Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp Pro Val Glu Glu Asp Asp Val Ala Ile Tyr Tyr Cys Leu Gln Ser Arg Lys Ile Pro Cys Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(143/234) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:143 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:234"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Lys Asn Gly Gly Thr Val Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Gly Leu Thr Ser Glu Asp Thr Ala Val Tyr Phe Cys Ala Arg Asp Gly Ser Lys Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Val Ser Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser Gly Tyr Gln Lys Ile Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Gly Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn Asp His Thr Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(79/286) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:79 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:286"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Lys Asn His Ala Thr Asp Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Gln Ile Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Ala Cys Arg Ala Ser Ser Ser Ile Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ser Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser His Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(21/342) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:21 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:342"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Val Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Ser His Leu Thr Gly Ile Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(37/297) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:37 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:297"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asn Tyr Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Ala Trp Val Ala His Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Gly His Pro Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(41/260) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:41 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:260"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Gly Thr Ala Tyr Met Asp Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Ser Cys Ala Arg Ser Tyr Tyr Gly Ser Gln Tyr Gln Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Thr Asn Glu Asp Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(101/242) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:101 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:242"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Met Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr Ser Met Asn Trp Val Lys Gln Ser Pro Glu Lys Ser Leu Glu Trp Leu Gly Glu Ile Asn Pro Ser Thr Gly Gly Thr Thr Tyr Asn Gln His Phe Lys Ala Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Ala Gly Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Ile Val Leu Thr Gln Ser Leu Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Glu Tyr Tyr Gly Thr Ser Leu Met Gln Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Val Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His Pro Val Glu Glu Asp Asp Ile Ala Val Tyr Phe Cys Gln Gln Ser Arg Lys Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(75/228) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:75 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:228"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr Ser Met Asn Trp Val Lys Gln Ser Pro Glu Lys Ser Leu Glu Trp Ile Gly Glu Ile Asn Pro Ser Thr Gly Thr Thr Thr Tyr Asn Gln Lys Phe Lys Ala Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Ala Gly Ser Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Ala Ile Ser Cys Arg Ala Ser Glu Ser Val Glu Tyr Tyr Gly Thr Ser Leu Met Gln Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Val Asp Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His Pro Val Glu Glu Asp Asp Ile Ala Met Tyr Phe Cys Gln Gln Ser Arg Lys Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(92/241) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:92 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:241"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp Tyr Met Asn Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Thr Leu Ile Tyr Tyr Tyr Gly Ser Cys Pro Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly Gly Lys Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Lys Tyr Ile Ala Trp Tyr Gln His Lys Pro Gly Lys Gly Pro Arg Leu Leu Ile His Tyr Thr Ser Thr Leu Gln Pro Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Arg Asp Tyr Ser Phe Ser Ile Ser Asn Leu Glu Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Asn Leu Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(69/205) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:69 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:205"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Tyr Thr His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Arg Pro Asn Trp Asp Val Val Asp Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Arg Ser Gly Val Asn Tyr Ile Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Arg Leu Leu Ile Tyr Asp Thr Phe Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Thr Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(25/369) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:25 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:369"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Asn Leu Glu Glu Ser Gly Gly Val Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Lys Asn His Ala Thr Asp Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Val Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Phe Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(55/261) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:55 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:261"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Ile Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Asp Asp Asp Tyr Asp Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Phe Cys Ser Gln Ser Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(154/335) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:154 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:335"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Asp Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met Gly Leu Ile Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Pro Tyr Phe Cys Val Arg Gly Gly Tyr Gly Asn Tyr Val Arg Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Ser Ser Ser Phe Ser Val Ser Leu Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Ile Tyr Asn Arg Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Lys Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Gln Asn Thr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(128/213) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:128 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:213"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Asn Leu Ile Tyr Tyr Tyr Gly Ser Ser Pro Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly Gly Lys Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Asn Tyr Ile Ala Trp Tyr Gln His Lys Pro Gly Lys Gly Pro Arg Leu Leu Ile His Tyr Thr Ser Thr Leu Gln Pro Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Arg Asp Tyr Ser Phe Ser Ile Asn Asn Leu Glu Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Asn Leu Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(64/209) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:64 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:209"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr Ser Met Asn Trp Val Lys Gln Ser Pro Glu Lys Ser Leu Glu Trp Ile Gly Glu Ile Asn Pro Ser Thr Gly Gly Thr Thr Tyr Asn Gln Lys Phe Lys Ala Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Ile Gln Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Ala Gly Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Arg Glu Asn Leu Glu Tyr Tyr Gly Thr Ser Leu Met Gln Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Val Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His Pro Val Glu Glu Asp Asp Ile Ala Met Tyr Phe Cys Gln Gln Ser Arg Lys Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(90/243) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:90 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:243"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met Gly Leu Ile Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Val Arg Gly Glu Asn Trp Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Tyr His Arg Ser Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(141/356) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:141 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:356"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Val Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Arg Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg His Gly Thr Arg Gly Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Glu Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Phe Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln Tyr Trp Ile Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(116/290) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:116 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:290"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Gly Gly Arg Gly Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Gln Phe Val Leu Pro Gln Ser Pro Ala Ile Met Pro Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met Phe Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Arg Leu Leu Ile Tyr Asp Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Tyr Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(183/341) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:183 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:341"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Lys Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Pro Leu Ser Asn Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(29/296) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:29 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:296"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Val Glu Ser Glu Gly Gly Leu Val Gln Pro Gly Ser Ser Met Lys Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Asp Tyr Tyr Met Ala Trp Val Arg Gln Val Pro Glu Lys Gly Leu Glu Trp Val Ala Asn Ile Asn Tyr Asp Gly Ser Ser Ile Tyr Tyr Leu Asp Ser Leu Lys Ser Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ile Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Glu Gly Ala Ala Gln Ala Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Gln Ile Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Asn Ser Asn Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(47/345) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:47 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:345"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Val Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Gly Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Arg Gly Leu Ser Tyr Thr Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(51/297) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:51 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:297"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Asn Leu Ile Tyr Tyr Tyr Gly Ser Ser Pro Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly Gly Lys Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Asn Tyr Ile Ala Trp Cys Gln His Lys Pro Gly Lys Gly Pro Arg Leu Leu Ile His Tyr Thr Ser Thr Leu Gln Pro Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Arg Asp Tyr Ser Phe Ser Ile Asn Asn Leu Glu Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Asn Leu Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(64/208) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:64 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:208"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Tyr Tyr Phe Ala Leu Tyr Tyr Ser Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Arg Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Val Ser His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(102/320) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:102 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:320"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Ser His Leu Thr Trp Ile Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(33/297) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:33 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:297"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Gly Gly Asn Trp Asp Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly Gln Pro Ala Ser Phe Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Phe Gln Arg Pro Gly Gln Ser Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(152/338) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:152 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:338"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Thr Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Met Asn Trp Val Lys Gln Arg His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Asn Asn Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Tyr Gly Ser Gly Trp Gly Phe Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Gly Thr Tyr Pro Tyr Thr Phe Gly Gly Gly Ser Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(115/307) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:115 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:307"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Ile Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Lys Asn His Ala Thr Asp Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Ser Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(9/265) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:9 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:265"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Asn Asn His Ala Thr Asp Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Val Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(23/257) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:23 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:257"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Phe Ser Gly Val Ala Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Ser Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Gly Gly Asn Trp Asp Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly Asp Arg Val Ser Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Asn Tyr Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Thr Glu Asp Phe Gly Met Tyr Phe Cys Gln Gln Ser Tyr Ile Trp Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(148/266) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:148 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:266"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Trp Met His Trp Met Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile His Pro Asn Ser Gly Ser Thr Asn Tyr Asn Glu Lys Phe Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Arg Gly Tyr Tyr Ser Asn Tyr Gly Asp Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Ile Ser Cys Ser Ala Ser Ser Ser Val Ser Tyr Met Tyr Trp Tyr Gln Gln Lys Ser Gly Ser Ser Pro Lys Ser Trp Ile His Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Tyr His Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(161/366) the antibody, or antigen binding fragment thereof, of claim 5, wherein the vh has the amino acid sequence of seq id no:161, and the vl has the amino acid sequence of seq id no:366"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Asn Leu Ile Tyr Tyr Tyr Gly Ser Ser Pro Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu His Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(64/326) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:64 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:326"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Val Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Gly Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Arg Gly Leu Ser Tyr Thr Met Asp Ser Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ile Val Arg Thr Ala Val Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(38/313) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:38 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:313"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr Leu Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met Gly Met Ile Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Leu Cys Val Arg Gly Gly Tyr Gly Asn Tyr Val Arg Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Ser Ser Ser Phe Ser Val Ser Leu Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Ile Tyr Asn Arg Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile Ser Gly Ala Thr Ser Leu Glu Thr Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Lys Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Asn Ile Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Val Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(135/212) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:135 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:212"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr Ala Met His Gly Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met Gly Met Ile Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Val Asn Ser Asn Leu Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Leu Ser Leu Gly Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Ser Ile Ile Gly Thr Asn Leu Ile Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr His Thr Ser Asn Leu Glu Thr Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp Pro Val Glu Glu Asp Asp Val Ala Ile Tyr Tyr Cys Leu Gln Ser Arg Lys Ile Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(133/230) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:133 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:230"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Pro Gly Thr Glu Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ala Ser Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Asn Ile Asn Pro Ser Asp Gly Asp Thr Asn Tyr Asn Glu Lys Phe Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Thr Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Gly Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Glu Tyr Tyr Gly Thr Gly Phe Met Gln Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile His Ala Ala Ala Asn Val Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His Pro Val Glu Glu Asp Asp Ile Ala Met Tyr Phe Cys Gln Gln Ser Arg Lys Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(171/245) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:171 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:245"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Trp Asp Asn Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Val Ser Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser Gly Tyr Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Gly Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn Asp His Arg Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(83/287) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:83 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:287"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr Gln Met Asn Trp Val Lys Gln Ser Pro Glu Lys Ser Leu Glu Trp Ile Gly Glu Ile Asn Pro Arg Thr Gly Gly Thr Thr Tyr Asn Gln Lys Phe Lys Ala Lys Ala Thr Leu Thr Val Asp Ile Ser Ser Ser Thr Ala Tyr Met Gln Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Ala Gly Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Ile Val Leu Thr Gln Ser Pro Val Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Glu Tyr Tyr Gly Thr Ser Leu Met Gln Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Val Asp Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His Pro Val Glu Glu Asp Asp Ile Ala Met Tyr Phe Cys Gln Gln Ser Arg Lys Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(89/268) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:89 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:268"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Ser Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met Asp Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Asn Ile Tyr Pro Ser Asp Ser Glu Thr His Tyr Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Ile Thr Gly Thr Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Asn Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ser Lys ,  Mus musculus  ,  Mus musculus  ,"(169/271) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:169 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:271"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Trp Asp Asn Ala Met Asp Tyr Trp Gly Pro Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Val Ser Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser Gly His Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Gly Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn Asp His Thr Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(82/282) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:82 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:282"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Arg Gln Leu Thr Gly Thr Arg Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Thr Leu Ile Phe Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(16/303) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:16 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:303"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asp Asn Gly Gly Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Trp Asp Asn Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Val Ser Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Phe Asn Ser Gly His Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Gly Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Ile Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn Asp His Arg Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(78/277) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:78 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:277"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Ile Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Asn Asn His Ala Thr Asp Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Val Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(40/262) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:40 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:262"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Phe Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Asn Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ser Thr Tyr Phe Cys Ala Arg Asp Asp Asp Tyr Asp Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Val Val Leu Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Phe Ser Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Arg Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Ile Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(146/321) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:146 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:321"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe Gln Gly Lys Ser Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Gly Asp Ser Asn Tyr Arg Tyr Ala Leu Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Asn Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile Tyr Tyr Thr Ser Thr Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(68/219) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:68 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:219"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Arg Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Ala Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Asp Phe Gly Pro Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Ser Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Ile Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Thr Ser Pro Lys Arg Trp Ile Tyr Asp Thr Ser Glu Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Arg Ser Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(186/370) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:186 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:370"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Asp Asp Asp Tyr Glu Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Ile Gln Met Thr Gln Ser Ser Ser Ser Phe Ser Val Ser Leu Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Ile Tyr Asn Arg Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Lys Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Ser Thr Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(151/215) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:151 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:215"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met Gly Leu Ile Tyr Thr Asp Thr Gly Asp Pro Thr Tyr Ala Glu Glu Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ser Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Val Arg Gly Glu Asn Trp Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Tyr His Arg Ser Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(139/356) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:139 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:356"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Leu Leu Ser Ser Leu Thr Ser Ala Asp Thr Ala Val Tyr Tyr Cys Thr Gly Asp Ser Asn Tyr Arg Tyr Ala Leu Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Gly Thr His Ile Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(63/336) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:63 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:336"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ser Arg Asp Asp Asp Tyr Asp Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Ile Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(153/328) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:153 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:328"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr Pro Met His Trp Met Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met Gly Met Ile Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Arg Asp Tyr Gly Gly Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Asn Pro Asp Gly Thr Val Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(136/226) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:136 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:226"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Lys Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Pro Leu Ser Asn Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ser Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(28/302) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:28 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:302"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Phe Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile Gly Gln Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Asn Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Gly Gly Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Met Ser Leu Gly Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Ser Ile Ile Gly Thr Asn Leu Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Phe His Ala Ser Asn Leu Glu Thr Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp Pro Val Glu Glu Asp Asp Val Ala Ile Tyr Tyr Cys Leu Gln Ser Lys Lys Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(178/232) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:178 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:232"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Gly Met His Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Val Ala Tyr Ile Ser Ser Gly Ser Ser Thr Ile Tyr Tyr Ala Asp Thr Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Phe Leu Gln Met Thr Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg Arg Val Tyr Asp Phe Asp Val Ser Tyr Ala Met Asp Tyr Trp Gly Arg Gly Thr Ser Val Thr Val Ser Ser , Ser Ile Val Met Thr Gln Thr Pro Lys Phe Leu Leu Val Ser Ala Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ser His Asp Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Leu Thr Gly Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Ser Thr Val Gln Ala Ala Asp Leu Ala Val Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Pro Phe Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(121/381) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:121 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:381"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Lys Asn His Ala Thr Asp Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Tyr Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(21/256) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:21 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:256"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Leu Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Ile Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Thr Tyr Tyr Cys Ile Arg Arg Val Thr Ser Gly Gly Asp Tyr Trp Gly Arg Gly Asn Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(11/300) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:11 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:300"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp Tyr Ile His Trp Met Lys Leu Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Trp Ile Asp Pro Glu Lys Ala Val Thr Glu Tyr Ala Ser Arg Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Asn Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Leu Pro Leu Tyr Tyr Asp Tyr Pro Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Pro Ser Leu Gly Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Asn Tyr Leu Arg Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Gln Asp Tyr Ala Leu Thr Ile Ser Ser Leu Glu Tyr Glu Asp Met Ala Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(58/199) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:58 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:199"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Met Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Val Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Asp Trp Asp Asn Ala Met Asp Tyr Trp Gly Pro Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Val Ser Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser Gly His Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Gly Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn Asp His Thr Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(86/282) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:86 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:282"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met Gly Met Ile Tyr Ser Asp Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Arg Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Val Arg Gly Glu Asn Trp Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Tyr His Arg Ser Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(142/356) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:142 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:356"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Lys Asn His Ala Thr Asp Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Phe Met His Trp Tyr His Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(21/253) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:21 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:253"
https://patents.google.com/patent/WO2021213520A1/en, Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Ser Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr Ser Gly Tyr Tyr Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp Met Gly Tyr Ile Ser Tyr Asp Asp Ser Asn Ser Tyr Asn Pro Ser Leu Lys Asn Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe Leu Lys Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Glu Gly Arg Gln Asn Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Thr Ser Pro Tyr Thr Phe Gly Gly Gly Thr Asn Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(5/274) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:5 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:274"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Asn Asn His Ala Thr Asp Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Val Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(23/264) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:23 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:264"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Asn Asn His Ala Thr Asp Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Ile Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(23/229) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:23 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:229"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Tyr Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Ser Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Asn Asp Tyr Asp Glu Gly Glu Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Leu Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(189/308) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:189 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:308"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly His Thr Phe Thr Asp Tyr Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Lys Asn Gly Gly Asn Ser Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Met Asp Tyr Tyr Asp Leu His Trp Tyr Phe Asp Val Trp Gly Ser Gly Thr Thr Val Thr Val Ser Ser , Asp Val Val Leu Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Tyr Gly Asp Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(88/322) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:88 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:322"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Met Arg Asn Lys Ala Asn Asn His Ala Thr Asp Tyr Gly Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(27/254) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:27 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:254"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Gly Gly Arg Gly Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met Phe Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Arg Leu Leu Ile Tyr Asp Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Asn Ser Tyr Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Arg ,  Mus musculus  ,  Mus musculus  ,"(183/375) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:183 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:375"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Leu Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Met Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Trp Asp Asn Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Val Ser Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser Gly Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Gly Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn Asp His Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(74/285) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:74 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:285"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile His Pro Asn Ser Gly Asn Thr Asn Tyr Asn Ala Lys Phe Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Gly Arg Arg Gly Tyr Tyr Ser Asn Tyr Gly Asp Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Phe Pro Gly Glu Lys Val Thr Ile Ser Cys Ser Ala Ser Ser Ser Val Ser Tyr Met Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Ser Trp Ile Tyr Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Thr Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Tyr His Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(163/351) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:163 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:351"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ser Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn His Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ser Val Tyr Phe Cys Ala Arg Asp Gly Tyr Pro Arg Tyr Tyr Ala Leu Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(124/309) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:124 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:309"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Glu Gly Ile Tyr Gly Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Tyr His Arg Ser Gln Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(99/357) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:99 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:357"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Gly Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Asn Tyr Gly Ser Ser Gln Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(61/198) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:61 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:198"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Asp Asp Asp Tyr Glu Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His Trp Asn Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(151/325) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:151 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:325"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Arg Gln Leu Thr Gly Thr Arg Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Thr Leu Ile Phe Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Val Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(16/304) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:16 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:304"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Thr Gly Tyr Thr Phe Thr Gly Tyr Trp Leu Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile Gly Glu Ile Leu Pro Gly Ser Gly Lys Thr Asn Ser Asn Glu Lys Phe Lys Gly Lys Ala Thr Phe Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Thr Glu Asp Ser Ala Ile Tyr Tyr Cys Ala Ser Ser Gly Thr Asp Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Pro Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Phe His Arg Ser Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(174/358) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:174 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:358"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe Arg Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Tyr Gly Ser Pro Trp Gly Phe Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(104/310) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:104 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:310"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Glu Gly Thr Tyr Gly Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Ser Ser Tyr Leu Ser Val Ser Leu Gly Gly Arg Val Thr Ile Pro Cys Arg Ala Ser Asp His Ile Asn Asn Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Lys Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Ser Thr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(98/217) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:98 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:217"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Arg Asp Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile Gly Gln Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Gln Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Leu Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met Tyr Trp Tyr Gln Gln Lys Pro Arg Ser Ser Pro Lys Pro Trp Ile Tyr Leu Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(176/379) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:176 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:379"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Asp Phe Gly Pro Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Met Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Thr Ser Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Arg Ser Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(182/372) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:182 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:372"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Ser Ser Gln Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met Gly Val Ser Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val Phe Leu Lys Ile Thr Ser Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Arg Ala Asn Gly Tyr Tyr Ala Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Thr Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Met Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(191/315) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:191 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:315"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Lys Asn His Ala Thr Asp Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Phe Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(21/236) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:21 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:236"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr Ala Ile Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu Gly Ile Ile Trp Thr Thr Gly Gly Thr Asn Tyr Asn Ser Ala Leu Lys Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Arg Tyr Tyr Cys Ala Arg Asn Trp Val Asp Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Leu Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(158/308) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:158 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:308"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Gly Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Gly Arg Asp Asp Asp Tyr Asp Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(129/337) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:129 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:337"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Thr Gly Tyr Thr Phe Thr Gly Tyr Trp Val Glu Trp Ile Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile Gly Glu Ile Leu Pro Gly Ser Gly Ser Ser Asn Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Val Asn Met Gln Leu Ser Ser Leu Thr Thr Glu Asp Ser Ala Ile Tyr Tyr Cys Ala Ser Ser Gly Thr Asp Phe Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Ser Tyr Phe His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Phe His Arg Ser Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(175/353) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:175 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:353"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Ser Lys Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Val Ser Ala Gly Glu Lys Val Thr Leu Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser Gly His Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Asn Pro Gly Gln Pro Pro Lys Leu Leu Ile Phe Gly Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn Asp His Arg Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(81/276) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:81 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:276"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr Ser Met Asn Trp Val Lys Gln Ser Pro Glu Lys Ser Leu Glu Trp Ile Gly Glu Ile Asn Pro Ser Thr Gly Gly Thr Thr Tyr Asn Gln Lys Phe Lys Ala Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Ala Gly Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Phe Ala , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Glu Tyr Tyr Gly Thr Ser Leu Leu Gln Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Val Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His Pro Val Glu Glu Asp Asp Ile Ala Met Tyr Phe Cys Gln Gln Ser Arg Lys Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(91/246) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:91 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:246"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Phe Ser Gly Val Ala Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Ser Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Gly Gly Asn Trp Asp Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly Gln Pro Ala Ser Phe Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Thr Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(148/339) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:148 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:339"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Arg Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Thr Arg His Gly Thr Arg Gly Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln Tyr Trp Asn Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(100/301) the antibody, or antigen binding fragment thereof, of claim 5, wherein the vh has the amino acid sequence of seq id no:100, and the vl has the amino acid sequence of seq id no:301"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Asp Asp Asp Tyr Asp Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Ile Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Leu Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(150/327) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:150 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:327"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Cys Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Thr Gly Gly Thr Thr Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Ala Asn Trp Val Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Asn Ser Leu Gln Pro Glu Asp Phe Gly Thr Tyr Tyr Cys Gln His His Tyr Gly Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(94/201) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:94 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:201"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Asp Phe Lys Trp Met Gly Met Thr Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Asp Ser Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Thr Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Val Arg Gly Gly Tyr Gly Asn Tyr Val Arg Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Ser Ser Ser Phe Ser Val Ser Leu Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Ile Tyr Asn Arg Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Lys Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Asn Ile Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(137/214) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:137 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:214"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser Trp Met Thr Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Glu Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Ala Leu Trp Leu Pro Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Thr Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Thr Tyr Met Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Arg Leu Leu Ile Tyr Asp Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Asn Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(187/378) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:187 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:378"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Tyr Tyr Tyr Ala Leu Tyr Tyr Ser Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Val Ser His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(103/319) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:103 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:319"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Tyr Ile Asn Pro Asp Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe Lys Gly Lys Ala Ala Leu Thr Ile Asn Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Val Asn Ser Asn Trp Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Ser Ile Ile Gly Ala Asn Leu Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr His Ala Ser Asn Leu Glu Thr Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp Pro Val Glu Glu Asp Asp Ile Ala Ile Tyr Tyr Cys Leu Gln Ser Arg Lys Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(107/238) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:107 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:238"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Arg Tyr Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile Gly Gln Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Val Gln Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Leu Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met Tyr Trp Tyr Gln Gln Lys Pro Arg Ser Ser Pro Lys Pro Trp Ile Tyr Leu Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(177/380) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:177 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:380"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Arg Gln Leu Thr Gly Thr Arg Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Phe Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Thr Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Met Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(16/192) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:16 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:192"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Phe Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Val Tyr Thr Phe Thr Glu Tyr Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met Gly Trp Ile His Thr Tyr Ser Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Trp Arg Phe Tyr Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(127/331) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:127 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:331"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Thr Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Arg Gln Leu Ala Gly Thr Arg Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr His Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Val Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(39/270) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:39 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:270"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Tyr Gly Ser Arg Gly Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Gln Ile Val Leu Thr Pro Ser Pro Ala Ile Met Ser Ala His Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Asn Tyr Met Phe Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Arg Leu Leu Ile Tyr Asp Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Tyr Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(184/347) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:184 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:347"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Ile Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Asn Asn His Ala Thr Asp Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Tyr Ile His Trp Tyr Gln Gln Gln Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(40/258) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:40 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:258"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Leu Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Asn Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Thr Arg Arg Val Thr Ser Gly Gly Asp Tyr Trp Gly Arg Gly Asn Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(12/296) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:12 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:296"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Glu Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Ser Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Arg Gly Leu Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(15/297) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:15 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:297"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Thr Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Val Ile Ala Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Gly Ile Gly Trp Pro Leu Gly His Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(170/330) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:170 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:330"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp Tyr Ile His Trp Val Lys Gln Arg Pro Asp Gln Gly Leu Glu Trp Ile Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Ala Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Asn Phe Gly Ser Ser Gln Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Asn Tyr Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(59/195) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:59 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:195"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ser Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Ala Asn Trp Val Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Asn Ser Leu Gln Pro Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His His Tyr Gly Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(95/200) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:95 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:200"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Tyr Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Arg Pro Asn Trp Asp Val Val Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Arg Ser Asp Ile Asn Tyr Ile Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Arg Leu Leu Ile Tyr Asp Thr Phe Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Thr Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(24/368) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:24 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:368"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Trp Asp Thr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Val Ser Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser Gly Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Gly Ala Ser Thr Arg Glu Phe Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn Asp His Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(84/284) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:84 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:284"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys Gly Glu Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Tyr Gly Ser Arg Gly Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Phe Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met Phe Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Arg Leu Leu Ile Tyr Asp Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Asn Thr Tyr Pro Pro Thr Phe Gly Ala Gly Thr Asn Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(181/348) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:181 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:348"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Lys Glu Asp Thr Ala Thr Tyr Phe Cys Ser Arg Asp Asp Asp Tyr Asp Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Ile Gln Met Thr Gln Ser Ser Ser Ser Phe Ser Val Ser Leu Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Ile Phe Asn Arg Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Lys Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Thr Ile Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(149/211) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:149 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:211"
https://patents.google.com/patent/WO2021213520A1/en, Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Ser Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr Ser Gly Tyr Tyr Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp Met Gly Tyr Ile Ser Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu Lys Asn Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe Leu Lys Leu Asn Ser Val Thr Ile Glu Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Glu Gly Thr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Phe Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Thr Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Met Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(6/192) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:6 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:192"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Met Arg Asn Lys Ala Asn Asn His Ala Thr Asp Tyr Gly Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Gly Phe Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(27/250) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:27 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:250"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Phe Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Gly Val Ala Ser Gly Phe Thr Phe Asn Asn Tyr Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Val Asp Trp Glu Glu Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Phe Cys Gln His Ser Trp Glu Ile Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(8/259) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:8 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:259"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Gly Leu His Trp Val Arg Gln Ala Pro Glu Asn Gly Leu Glu Trp Val Ala Tyr Ile Ser Ser Gly Ser Ser Thr Ile Tyr Tyr Ala Asp Thr Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Phe Leu Gln Met Thr Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Arg Leu Tyr Asp Tyr Asp Val Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asn Val Val Leu Thr Gln Thr Pro Lys Phe Leu Leu Val Ser Ala Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ser Tyr Asp Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Tyr Ala Phe Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Ser Thr Val Gln Ala Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln Asp Tyr Asn Ser Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(120/340) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:120 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:340"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Asn Asn His Ala Thr Asp Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(23/254) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:23 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:254"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Val Gly Tyr Ile Asn Pro Asp Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asn Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Tyr Cys Val Asn Ser Asn Trp Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Ser Ile Ile Gly Ala Asn Leu Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Phe His Ala Ser Asn Leu Glu Thr Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp Pro Val Glu Glu Asp Asp Ile Ala Ile Tyr Phe Cys Leu Gln Ser Arg Lys Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(111/237) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:111 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:237"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Met Arg Pro Gly Ser Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met Asp Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Asn Ile Tyr Pro Ser Asp Ser Glu Thr His Tyr Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Ile Thr Gly Thr Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(160/273) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:160 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:273"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Gly Gly Asn Trp Asp Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly Asp Arg Val Ser Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Asn Tyr Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Thr Glu Asp Phe Gly Met Tyr Phe Cys Gln Gln Ser Tyr Ile Trp Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(152/266) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:152 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:266"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Phe Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Ala Ala Thr Tyr Phe Cys Ala Arg Asp Asp Asp Tyr Asp Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Val Gly Met Thr Gln Thr Pro Leu Ser Leu Pro Val Arg Leu Gly Ala Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(147/317) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:147 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:317"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp Tyr Ile His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe Gln Asp Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr His Tyr Gly Ser Ser Tyr Ala Phe Tyr Ala Leu Asp Cys Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile Tyr Tyr Ile Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(60/222) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:60 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:222"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Arg Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Met Asn Trp Met Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Gly Tyr Asn Gln Lys Phe Arg Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Thr Arg Met Asp Tyr Tyr Asp Leu Gln Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Tyr Gly Asn Thr Tyr Leu His Trp Phe Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(113/332) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:113 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:332"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Val Glu Ser Glu Gly Gly Leu Val Gln Pro Gly Ser Ser Met Lys Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Asp Tyr Tyr Met Ala Trp Val Arg Gln Val Pro Glu Lys Gly Leu Glu Trp Val Ala Asn Ile Asn Tyr Asp Gly Ile Ser Thr Phe Tyr Leu Asp Ser Leu Lys Ser Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ile Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Glu Gly Ala Ala Gln Ala Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Gln Ile Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser Leu Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Ser Trp Ile Tyr Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Ile Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(46/343) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:46 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:343"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met Gly Met Ile Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Phe Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Val Arg Ser Arg Leu Leu Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Phe Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Val Asn Thr Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(144/221) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:144 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:221"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr Ala Ile Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu Gly Ile Ile Trp Thr Thr Gly Gly Thr Asn Tyr Asn Ser Ala Leu Lys Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Arg Tyr Tyr Cys Ala Arg Asn Trp Val Asp Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Leu Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(156/311) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:156 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:311"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Lys Asn His Ala Thr Asp Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Phe Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(21/252) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:21 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:252"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Val Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Ala Ile Ser Arg Asp Asp Ser Lys Arg Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Thr Tyr Tyr Cys Ile Arg Gly Leu Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Phe Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(43/293) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:43 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:293"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Val Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Arg Leu Gly Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(50/260) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:50 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:260"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe Gln Gly Lys Ala Thr Ile Thr Thr Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Asn Leu Leu Tyr Tyr Tyr Asp Ser Ser Tyr Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Arg Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Phe Leu Gly Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile Ser Arg Ala Ser Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(67/227) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:67 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:227"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Asp Thr Phe Thr Asp Tyr Tyr Ile Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Gly Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Thr Arg Met Asp Tyr Tyr Asp Leu His Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Tyr Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Arg Pro Gly Gln Ser Pro Asn Leu Leu Ile Tyr Lys Val Ser Val Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(87/334) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:87 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:334"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Arg Ala Glu Phe Val Arg Pro Gly Ala Ser Val Met Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp Asn Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Ala Tyr Ala Ser Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Asn Phe Gly Ser Ser Gln Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Ile Ser Tyr Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(118/194) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:118 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:194"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Trp Ile Asp Pro Asp Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Asp Asp Thr Ala Val Tyr Tyr Cys Thr Thr Leu Ile Tyr Tyr Tyr Gly Ser Cys Ser Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly Gly Lys Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Lys Tyr Ile Ala Trp Tyr Gln His Lys Pro Gly Lys Gly Pro Arg Leu Leu Ile His Tyr Thr Ser Thr Leu Gln Pro Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Arg Asp Tyr Ser Phe Ser Ile Ser Asn Leu Glu Pro Glu Asp Ile Val Thr Tyr Tyr Cys Leu Gln Tyr Asp Asn Leu Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(62/206) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:62 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:206"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Val Phe Ser Ser Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Tyr Gly Ser Arg Gly Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Thr Tyr Met Phe Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Arg Leu Leu Ile Tyr Asp Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Tyr Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(190/377) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:190 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:377"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Arg Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Tyr Ile Tyr Pro Asn Asn Gly Gly Asn Gly Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Ala Gly Pro Pro Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Ile Gln Met Thr Gln Ser Ser Ser Tyr Leu Ser Val Ser Leu Gly Gly Arg Val Thr Ile Pro Cys Arg Ala Ser Asp His Ile Asn Asn Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Lys Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Ser Thr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(114/217) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:114 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:217"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Lys Asn His Ala Thr Asp Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Val Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(21/262) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:21 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:262"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Ser Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met Asp Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly His Ile Tyr Pro Ser Asp Ser Glu Thr His Tyr Asn Gln Glu Phe Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Ile Thr Gly Thr Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(167/275) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:167 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:275"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr Leu Met His Trp Val Lys Gln Ala Pro Gly Lys Asp Phe Lys Trp Met Gly Met Thr Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Val Arg Gly Gly Tyr Gly Asn Tyr Val Arg Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Ser Ser Ser Phe Ser Val Ser Leu Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Ile Tyr Asn Arg Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Lys Asp Tyr Thr Leu Ser Thr Thr Ser Val Gln Thr Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Asn Thr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(134/216) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:134 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:216"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Val Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Val Ile Asn Pro Tyr Asn Gly Gly Ala Ser Tyr Ser Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Arg Leu Ala Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Asn Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(117/316) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:117 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:316"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met Gly Leu Ile Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Val Arg Gly Glu Asn Trp Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Pro Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Tyr His Arg Ser Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(140/359) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:140 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:359"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ser Arg Asp Asp Asp Tyr Asp Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Asn Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Thr Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(153/323) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:153 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:323"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Gly Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Ser His Leu Thr Gly Ile Phe Asp Tyr Trp Gly Gln Ala Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(30/297) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:30 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:297"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile His Pro Asn Ser Gly Asn Thr Asn Tyr Asn Glu Lys Phe Lys Ser Lys Ala Ile Leu Thr Val Asp Lys Ser Ser Ser Thr Val Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Gly Arg Arg Gly Tyr Tyr Ser Asn Tyr Gly Asp Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Ile Ser Cys Ser Ala Ser Ser Ser Val Ser Tyr Met Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Ser Trp Ile Tyr Arg Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Tyr His Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(164/365) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:164 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:365"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Asn Asn His Ala Thr Asp Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Tyr Ile His Trp Tyr Gln Gln Gln Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(23/258) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:23 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:258"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Lys Asn His Ala Thr Asp Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Met Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Thr Ser Pro Thr Arg Trp Ile Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Ala Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Arg Ser Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(21/373) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:21 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:373"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Ala Met Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Ser Lys Leu Thr Gly Pro Asn Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(19/296) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:19 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:296"
https://patents.google.com/patent/WO2021213520A1/en, Gln Gly Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Trp Ile Val Trp Ala Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile Gly Glu Ile Tyr Pro Gly Gly Gly Tyr Thr Asn Tyr Asn Glu Asn Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Phe Ser Ser Leu Thr Ser Glu Asp Ser Ala Ile Tyr Tyr Cys Ala Arg Ser Lys Gly Leu Thr Gly Thr Leu Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Phe Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asp Thr Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(126/220) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:126 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:220"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Trp Asp Asn Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Val Ser Ala Gly Glu Lys Val Thr Met Ser Cys Arg Ser Ser Gln Ser Leu Leu Asn Ser Gly His Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln Pro Pro Lys Leu Leu Ile Phe Gly Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn Asp His Arg Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(83/288) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:83 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:288"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Gly Lys Asn Tyr Ala Thr Asp Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Gln Ile Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr Ala Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Gly Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(26/344) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:26 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:344"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ser Arg Asp Asp Asp Tyr Asp Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser His Ser Thr Leu Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(153/329) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:153 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:329"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile His Pro Asn Ser Gly Ser Thr Asn Tyr Asn Glu Lys Leu Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Gly Arg Arg Gly Tyr Tyr Ser Asn Tyr Gly Asp Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Ile Ser Cys Ser Ala Ser Ser Ser Val Ser Tyr Met Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Ser Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Tyr His Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(166/363) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:166 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:363"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Arg Thr Ala Tyr Met Glu Phe Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Glu Gly Ile Tyr Gly Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp Ile Phe Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Tyr His Arg Ser Gln Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(97/354) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:97 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:354"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Phe Thr Phe Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Trp Asp Asn Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Val Ser Ala Gly Glu Arg Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser Gly His Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Gly Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Ser Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn Asp His Arg Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(76/289) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:76 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:289"
https://patents.google.com/patent/WO2021213520A1/en, Gln Gly Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Thr Gly Tyr Arg Phe Thr Gly Tyr Trp Ile Glu Trp Ile Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Glu Ile Leu Pro Gly Ser Gly Ser Thr Asn Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Phe Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Thr Glu Asp Ser Ala Ile Tyr Tyr Cys Ala Ser Ser Gly Thr Asp Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Tyr Ser Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Phe His Arg Ser Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(125/362) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:125 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:362"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Val Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Pro Ser Gly Phe Asn Ile Lys Asp Thr Tyr Met His Trp Val Gln Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Arg Ile Asp Pro Ala Asn Gly Tyr Ala Lys Tyr Ala Pro Lys Phe Gln Gly Lys Ala Thr Ile Ser Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Asp Ile Tyr Pro Tyr Val Ile Gly Phe Ser Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly Glu Arg Val Ser Leu Thr Cys Arg Ala Ser Gln Glu Ile Ser Gly Tyr Leu Ser Trp Leu Gln Gln Lys Pro Asp Gly Thr Ile Lys Arg Leu Ile Tyr Ala Ala Ser Thr Leu Asp Ser Gly Val Pro Glu Arg Phe Ser Gly Ser Trp Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser Glu Asp Phe Ala Asp Tyr Tyr Cys Leu Gln Tyr Ala Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(119/202) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:119 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:202"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Asp Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr Ser Met Asn Trp Val Lys Gln Ser Pro Glu Lys Ser Leu Glu Trp Ile Gly Glu Ile Asn Pro Asn Thr Gly Asp Thr Thr Tyr Asn Gln Arg Phe Lys Ala Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Ala Gly Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Glu Tyr Tyr Gly Thr Ser Leu Met Gln Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Val Asp Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His Pro Val Glu Glu Asp Asp Val Ala Met Tyr Phe Cys Gln Gln Ser Arg Lys Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(72/247) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:72 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:247"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asp Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Asp Phe Gly Pro Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Met Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Thr Ser Pro Thr Arg Trp Ile Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Ala Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Arg Ser Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(180/373) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:180 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:373"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met Gly Leu Ile Tyr Ser Asp Thr Gly Glu Pro Thr His Ala Glu Glu Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Val Arg Gly Glu Asn Trp Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Arg Val Thr Leu Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Tyr His Arg Ser Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(138/352) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:138 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:352"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Lys Asn Gln Ala Thr Asn Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Ile Trp Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Leu Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(22/255) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:22 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:255"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Glu Gly Thr Tyr Gly Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Thr Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Phe His His Ser Gln Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(98/360) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:98 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:360"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Asn Ala Ile Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Thr Gly Gly Gly Ile Asn Tyr Asn Ser Ala Leu Lys Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys Met Asn Ser Leu Glu Thr Asp Asp Thr Ala Arg Tyr Tyr Cys Ala Arg Trp Asp Tyr Tyr Tyr Gly Ser Arg Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(157/223) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:157 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:223"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile His Pro Asn Ser Gly Ser Thr Asn Tyr Asn Glu Lys Phe Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Thr Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Gly Arg Arg Gly Phe Tyr Ser Asn Tyr Gly Asp Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Ile Ser Cys Ser Ala Ser Ser Ser Val Ser Tyr Met Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Ser Trp Ile Cys Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Tyr His Asn Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(165/364) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:165 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:364"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Trp Asp Asn Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Val Ser Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser Gly His Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Gly Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Phe Cys Gln Asn Asp His Arg Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(83/280) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:83 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:280"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Thr Asn Gly Gly Thr Val Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Trp Asp Asn Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Val Ser Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser Gly Asp Gln Met His Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Gly Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn Asp His Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(85/279) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:85 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:279"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Leu Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gly Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Thr Arg Arg Val Thr Ser Gly Gly Asp Tyr Trp Gly Arg Gly Asn Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(10/296) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:10 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:296"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Ser Ser His Leu Thr Gly Ile Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(31/297) the antibody, or antigen binding fragment thereof, of claim 5, wherein the vh has the amino acid sequence of seq id no:31, and the vl has the amino acid sequence of seq id no:297"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Val Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Arg Gly Ile Thr Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ile Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(52/294) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:52 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:294"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Tyr Ile Asn Pro Asn Asp Gly Gly Thr Asn Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asn Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Val Asn Ser Asn Trp Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Ser Ile Ile Gly Ala Asn Leu Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr His Ala Ser Asn Leu Glu Thr Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp Pro Val Glu Glu Asp Asp Ile Ala Ile Tyr Tyr Cys Leu Gln Ser Arg Lys Ile Pro Tyr Thr Phe Gly Gly Gly Thr Asn Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(109/239) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:109 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:239"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Ser His Leu Thr Gly Ile Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(32/297) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:32 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:297"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Asn Asp Tyr Asp Glu Gly Glu Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Phe Asn Ser Tyr Pro Leu Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(188/306) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:188 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:306"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met Gly Met Ile Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Val Arg Ser Gly Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Met Ser Leu Gly Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Ser Ile Ile Gly Ala Asn Leu Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Phe His Ala Ser Asn Leu Glu Thr Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp Pro Val Glu Glu Asp Asp Val Ala Ile Tyr Tyr Cys Leu Gln Ser Arg Lys Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(132/231) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:132 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:231"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Lys Glu Asp Thr Ala Thr Tyr Phe Cys Ser Arg Asp Asp Asp Tyr Asp Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(149/337) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:149 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:337"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Tyr Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Lys Asn His Ala Thr Asp Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Lys Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Gly Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Ala Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(44/240) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:44 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:240"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Ala Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Ser His Leu Ser Gly Ile Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val His Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(17/292) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:17 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:292"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Glu Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Trp Ile Glu Pro Asp Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe Gln Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Thr Leu Ile Tyr Tyr Tyr Gly Ser Ala Ser Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly Gly Lys Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Lys Tyr Ile Ala Trp Tyr Gln His Lys Pro Gly Lys Gly Pro Arg Leu Leu Ile His Tyr Thr Ser Thr Leu Gln Pro Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Arg Asp Tyr Ser Phe Ser Ile Arg Asn Leu Glu Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Asn Leu Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(57/204) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:57 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:204"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Tyr Ile Asn Pro Asp Asn Gly Asp Thr Thr Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asn Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Val Asn Ser Asn Trp Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Met Ser Leu Gly Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Ser Ile Ile Gly Thr Asn Leu Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr His Ala Ser Asn Leu Glu Thr Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp Pro Val Glu Glu Asp Asp Val Ala Ile Tyr Tyr Cys Leu Gln Ser Arg Lys Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(106/235) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:106 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:235"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Tyr Tyr Phe Ala Leu Tyr Tyr Ser Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Ser Ser Tyr Leu Ser Val Ser Leu Gly Gly Arg Val Thr Ile Thr Cys Lys Ala Ser Asp His Ile Asn Asn Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Lys Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Ser Ile Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(102/218) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:102 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:218"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ser Ile His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Thr Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Asp Gly Tyr Pro Arg Tyr Tyr Ala Leu Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Thr Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(123/312) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:123 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:312"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Asp Leu Val Lys Pro Gly Ser Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Trp Asp His Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Val Ser Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser Gly Asn Gln Glu Thr Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Gly Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn Asp His Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(73/283) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:73 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:283"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Leu Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Thr Arg Arg Val Thr Ser Gly Gly Asp Tyr Trp Gly Arg Gly Asn Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(13/296) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:13 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:296"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr Gly Ile His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Ser Gly Gly Ser Thr Tyr Tyr Asn Ala Ala Phe Ile Ser Arg Leu Ser Ile Ser Lys Asp Ile Ser Lys Ser Gln Val Phe Phe Lys Met Asn Ser Leu Gln Ala Asp Asp Thr Ala Thr Tyr Tyr Cys Ala Ser Pro Lys Trp Asp Asp Ala Leu Asp Tyr Trp Gly Gln Gly Ser Ser Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Ser Ser Ser Tyr Leu Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Ser Ser Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(159/367) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:159 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:367"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Tyr Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Lys Asn His Ala Thr Asp Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Gly Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Ala Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(44/249) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:44 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:249"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Asn Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Arg Gly Ile Thr Tyr Phe Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(35/296) [0044] the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:35 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:296"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Cys Ala Glu Ser Val Lys Gly Ser Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Arg Gly Leu Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Asn ,  Mus musculus  ,  Mus musculus  ,"(14/298) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:14 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:298"
https://patents.google.com/patent/WO2021213520A1/en, Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Ser Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr Ser Gly Tyr Tyr Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp Met Gly Tyr Ile Ser Tyr Asp Asp Ser Asn Ser Tyr Asn Pro Ser Leu Lys Asn Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe Leu Lys Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Glu Gly Arg Gln Asn Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ala Ser Pro Tyr Thr Phe Gly Gly Gly Thr Asn Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(5/272) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:5 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:272"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Val Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Ser Ala Glu Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Arg Leu Gly Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(49/296) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:49 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:296"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Asn Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Lys Asn His Ala Thr Asp Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Val Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Phe Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(54/261) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:54 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:261"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asn Tyr Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala His Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Gly His Pro Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Pro Ile Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(42/263) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:42 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:263"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Thr Tyr Gly Ser Ser Tyr Val Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(66/224) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:66 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:224"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Gly Tyr Lys Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Met Asp Tyr Tyr Asp Leu His Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Tyr Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(96/333) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:96 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:333"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Tyr Tyr Tyr Ala Leu Tyr Tyr Ser Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Val Ser His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(103/318) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:103 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:318"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr Ser Leu Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Ser Leu Ile Glu Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Val Ile Asn Pro Gly Ser Gly Gly Thr Asn Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Arg Ile Arg Asp Tyr Gly Thr Ser Val Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly Glu Arg Val Ser Leu Thr Cys Arg Ala Ser Gln Glu Ile Ser Gly Tyr Leu Ser Trp Leu Gln Gln Lys Pro Asp Gly Thr Ile Lys Arg Leu Ile Tyr Ala Ala Ser Thr Leu Asp Ser Gly Val Pro Lys Arg Phe Ser Gly Ser Arg Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser Glu Asp Phe Ala Asp Tyr Tyr Cys Leu Gln Cys Ala Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(179/203) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:179 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:203"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Glu Ser Leu Glu Trp Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Val Phe Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Trp Asp Asn Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Val Ser Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser Gly Asp Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Gly Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn Asp His Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(77/278) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:77 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:278"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Leu Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Tyr Ile Lys Asp Asp Ser Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Trp Ile Asp Pro Glu Ser Gly Asp Thr Glu Tyr Ala Ser Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Thr Leu Pro Leu Tyr Tyr Asp Tyr Val Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr Leu Arg Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(56/197) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:56 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:197"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile His Pro Asn Ser Gly Asn Thr Asn Tyr Asn Ala Lys Phe Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Gly Arg Arg Gly Tyr Tyr Ser Asn Tyr Gly Asp Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Phe Pro Gly Glu Lys Val Thr Ile Ser Cys Ser Ala Ser Ser Ser Val Ser Tyr Met Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Ser Trp Ile Tyr Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Tyr His Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(163/350) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:163 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:350"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Pro Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Ala Ser His Leu Thr Gly Ile Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(48/299) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:48 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:299"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Val Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Met Arg Asn Lys Ala Asn Asn His Ala Thr Asp Tyr Gly Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Gly Phe Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(45/250) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:45 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:250"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala His Asn His Ala Thr Asp Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Phe Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Asp Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(20/251) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:20 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:251"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Thr Tyr Gly Met Ser Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Tyr Ala Gly Val Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Lys Tyr Phe Cys Thr Arg Asp Asp Asp Tyr Asp Gly Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(131/337) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:131 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:337"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met Gly Met Ile Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Val Arg Gly Glu Asn Trp Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Pro Leu Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Asn Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Tyr His Arg Ser Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(145/355) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:145 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:355"
https://patents.google.com/patent/WO2021213520A1/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Glu Tyr Thr Leu Thr Glu Tyr Leu Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met Gly Met Ile Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Val Arg Gly Gly Tyr Gly Asn Tyr Val Arg Trp Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Ser Ser Ser Phe Ser Glu Ser Leu Gly Asp Arg Val Thr Ile Ile Cys Lys Ala Ser Glu Asp Ile Tyr Asn Arg Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Met Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr Glu Asp Val Ala Ser Tyr Tyr Cys Gln Gln Tyr Trp Asn Ile Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(130/210) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:130 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:210"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Val Ser Gly Phe Asn Ile Lys Asp Asp Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Asn Ser Gly Ser Ser Gln Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Phe Leu Ile Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(71/196) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:71 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:196"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Lys Asn His Ala Thr Asp Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Thr Val Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp Glu Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(21/260) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:21 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:260"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Met His Trp Val Lys Gln Ser His Ala Lys Ser Leu Glu Trp Ile Gly Tyr Ile Asp Pro Asn Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asn Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Val Asn Ser Asn Trp Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Met Ser Leu Gly Lys Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Ser Ile Ile Gly Thr Asn Leu Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr His Ala Ser Asn Leu Glu Thr Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp Pro Val Glu Glu Asp Asp Val Ala Ile Tyr Tyr Cys Leu Gln Ser Arg Lys Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(105/235) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:105 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:235"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Tyr Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Phe Cys Thr Arg Gly Ile Thr Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Ser Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(34/314) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:34 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:314"
https://patents.google.com/patent/WO2021213520A1/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys Gly Glu Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Tyr Gly Ser Arg Gly Tyr Phe Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Phe Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Thr Tyr Met Phe Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Arg Leu Leu Ile Tyr Asp Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Asn Ser Tyr Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys ,  Mus musculus  ,  Mus musculus  ,"(181/349) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:181 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:349"
https://patents.google.com/patent/WO2021213520A1/en, Glu Val Gln Pro Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Arg Gly Leu Ser Tyr Thr Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Ala Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Ala Asp Phe Thr Leu Thr Ile Ser Ala Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ,  Mus musculus  ,  Mus musculus  ,"(122/269) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:122 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:269"
https://patents.google.com/patent/KR101828794B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Ser Tyr Ser Met Ile Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Pro Ile Asp Ala Val Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Asn Ile Ser Cys Ser Gly Ser Ser Ser Asn Val Gly Ser Asn Ala Val Thr Trp Tyr Gln Gln Val Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asn Asn Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Glu Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly , Heavy chain variable region, Light chain variable region,"(7/8)  in one embodiment of the invention, the antibody comprises the heavy chain variable region of seq id no:7 and the light chain variable region of seq id no:8."
https://patents.google.com/patent/CN112250763B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Glu Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Asp Thr Ala Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Pro Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu His Thr Val Ala Pro Val Tyr Gly Phe Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Artificial sequence, Artificial sequence,(3/4)  a heavy chain variable region comprising the amino acid sequence set forth in seq id no:3; and the variable region of the light chain of the amino acid sequence shown as seq id no:4;
https://patents.google.com/patent/CN112250763B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Tyr Ser Ser Ser Trp Leu Leu Gln Ser Phe Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asn Ile Gln Leu Thr Gln Ser Pro Val Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Leu Thr Cys Arg Ala Ser Gln Gly Ile Gly Tyr Ser Leu Val Trp Tyr Gln Lys Lys Pro Gly Thr Ala Pro Lys Leu Leu Ile Phe Asp Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Ser Ala Thr Tyr Tyr Cys Gln Gln Val Ile His Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Artificial sequence, Artificial sequence,(11/12)  a heavy chain variable region comprising the amino acid sequence set forth in seq id no:11; and the variable region of the light chain of the amino acid sequence shown as seq id no:12.
https://patents.google.com/patent/CN112625136B/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Arg Phe Gly Ser Tyr Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Ala Pro Glu Trp Val Ser Asp Ile Asn Thr Arg Gly Glu Thr Thr Arg Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Val Ala Ala Ser Pro Ala Thr Phe Glu Gly Arg Ser Asp Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,"(5) in some embodiments, the single domain antibody or vhh fragment thereof comprises or consists of the sequence: a vhh amino acid sequence as set forth in seq id no:5,6 or 7 or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto."
https://patents.google.com/patent/CN112625136B/en, Gln Met Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Gly Ala Phe Tyr Tyr Gly Ser Gly Ser Tyr Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asp Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ala Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(22/23) the polypeptide complex of claim 7 wherein the first epitope-binding portion comprises a heavy chain comprising the heavy chain variable region and a light chain comprising the light chain variable region, and wherein the heavy chain comprises the sequence set forth in seq id no:22 or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto; and/or the light chain comprises the sequence shown as seq id no:23 or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto."
https://patents.google.com/patent/CN112625136B/en, Gln Met Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Gly Ala Phe Tyr Tyr Gly Ser Gly Ser Tyr Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Arg Phe Gly Ser Tyr Val Met Ser Trp Phe Arg Gln Ala Pro Gly Lys Ala Pro Glu Trp Val Ser Asp Ile Asn Thr Arg Gly Ile Val Thr Arg Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Val Ala Ala Ser Gly Asp Thr Phe Glu Gly Arg Ser Asp Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asp Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ala Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(29/23) in some embodiments, the polypeptide complex is a bispecific antibody complex consisting of 2 heavy chains consisting of the amino acid sequence set forth in seq id no:29, 30, or 31 and 2 light chains consisting of the amino acid sequence set forth in seq id no:23."
https://patents.google.com/patent/KR20220012792A/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr His Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No.139 HC variable region , No.139 LC variable region ,"(2018/2017)  in one embodiment of the present invention, the binding molecule comprises a light chain variable region of the polypeptide sequence of seq id no:2017; and a heavy chain variable region of the polypeptide sequence of seq id no:2018."
https://patents.google.com/patent/CN114106162A/en, gaggtgatcc tgtccgaatc cggcggaggc tctgtgaagc ccggcggcag cctgagactg tcctgtgccg cctccggctt taccttcagt agctacgcta tgtcctggat ccgccaggcc cctggcaaga gactagagtg gggatctacc atcaacagcg gcggcaactt catctactat cctgattccg tgaaaggacg gttcaccatc tctcgggata acgccaagaa ctctctgtac ctgcagatga actccctgag ggctgaggac acagccgtgt acttctgcgg cagacactcc ggaaactacg tggactcggc catggactat tggggccagg gcaccaccgt gaccgtctcc tccgcaagca ccaagggacc ttctgtgttt cctctggccc catgtagtcg ctcaacttcc gagagcaccg cagcactggg atgcctggtg aaggattact tcccagaacc cgtcacagtg tcttggaaca gtggggccct gacaagcggt gtccacactt ttccagctgt gctgcagtca tccggactgt actctctgag ctctgtggtc actgtgccca gttcaaattt cgggacccag acatatactt gtaacgtgga ccataagcct tccaatacca aggtcgataa aacagtggtg gaatgtccac cttgcccagc tccaccagtc gcaggaccta gcgtgttcct gtttcctcca aagcccaaag acacactgat gatctcacgc acacctgagg tcacttgcgt ggtcgtggac gtgtcccacg aggaccctga agtccagttt aactggtacg tggatggcgt cgaagtgcat aatgccaaga ccaaaccaag agaggaacag ttcaactcca catttcgcgt cgtgagcgtg ctgactgtcg tgcaccagga ctggctgaac ggcaaggagt ataagtgtaa agtgagcaat aagggcctgc ctgctccaat cgagaaaacc atttctaaga caaaaggcca gcccagagaa cctcaggtgt acacactgcc cccttcccgc gaggaaatga ctaagaacca ggtcagcctg acctgcctgg tgaaaggttt ttatcccagt gacatcgccg tggagtggga atcaaatggc cagcctgaga acaattacaa gactacccca cccatgctgg actcagatgg ttccttcttt ctgtattcaa agctgaccgt ggataaatcc aggtggcagc agggcaacgt cttctcttgt agtgtgatgc atgaggctct gcacaatcat tacacacaga agtcactgtc cctgagccca ggcaag , gagatcgtgt tgacacagtc cccagctacc ctgtctgtct ctcctggcga gcgggccacc ctgtcctgtt ctgccagctc ctctgtgtcc gacatgcatt ggtaccagca gaagcctgga aagtccccca agctgctgat ctactccacc tctaatctgg cctctggcgt gccctccaga tttagcggct ctggctccgg caccgagtac accctgacca tctcctccct gcaacccgag gacgtggcta cctactactg tcatcagtgg tccacctgga cctttggcgg tggtaccaag gtggaaatca agcgtactgt cgctgcacca agcgtgttca tttttcctcc atctgacgaa cagctgaagt ctggaaccgc tagtgtcgtg tgcctgctga acaattttta ccccagggag gcaaaggtcc agtggaaagt ggataacgcc ctgcagagcg gcaattctca ggagagtgtg accgaacagg actcaaagga ttccacatat agcctgtcat ccactctgac cctgagcaaa gctgactacg agaagcacaa agtctatgca tgcgaagtga cccatcaggg actgagctct cctgtgacaa agtctttcaa ccggggggag tgc , humanized antibody hS1B-82-5 heavy chain nucleic acid sequence (), light chain nucleic acid sequence of humanized antibody hS1B-82-5 (),"(24/25) in a preferred embodiment of the invention, the dna molecule encoding the heavy chain of the above antibody has the amino acid sequence shown in seq id no:24; and/or, the dna molecule encoding the light chain of the antibody has the amino acid sequence shown in seq id no:25."
https://patents.google.com/patent/WO2022022666A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg His Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ala Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Pro Tyr Cys Ser Ser Thr Ser Cys His Arg Asp Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp Ser Asp Asp Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Arg Ile Glu Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Asp Ile Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Ser ,  人工序列(Artificial Sequence)  ,  人工序列(Artificial Sequence)  ,"(6/8)  further preferably, the bispecific antibody bs-mab-2, which the amino acid sequence of the light chain is as shown in seq id no:8 or the amino acid sequence of the protein with the same function obtained by the replacement, deletion or insertion of one or more amino acids, and the amino acid sequence of the heavy chain is as shown in seq id no:6. the amino acid sequence of a protein with the same function obtained by substitution, deletion or insertion of one or more amino acids."
https://patents.google.com/patent/WO2022022666A1/en, caggttcagt tagttcagag tggagcagaa gtgaagaagc ccggtgcctc tgtgaaagtg tcatgcaaag catcaggata cacatttaca ggatactaca tgcactgggt taggcaggcg cccggtcaag gcctggagtg gatgggcaga atcaacccta actctggcgg gacgaattat gcacagaagt tccagggaag agtgacaatg acaagagata catcaatctc aacagcatac atggaacttt caagacttag atcagatgac actgctgtct actactgcgc acgagtcccg tactgctcat caacatcatg ccacagagat tggtactttg atctttgggg gagaggtaca cttgtgacag tctcatcggg tggaggcgga tcagggggtg gtggctccga agtccagctc gtcgagagtg gtggaggact ggttcaacct ggaggatcac ttagactttc atgcgcagca tcaggattta tcgtgtcatc aaactacatg tcatgggtac gccaggctcc cgggaagggt ctggagtggg tctcggtgat ctactcagga ggatcaacat actacgcaga ttcagtgaaa ggaagattta caatctcaag acacaactca aagaatactc tttaccttca aatgaactca cttagagcag aagacactgc ggtttactac tgcgcaagag aagcgtacgg aatggatgtg tggggccagg gtacaacagt tactgtttcg tctgcgtcca ctaaaggccc ttccgtcttc ccgctggcac cttcatcaaa gtctacttct ggtggaacgg cggctcttgg atgtctggtt aaggactatt tcccggagcc tgtaactgta tcgtggaact caggagcact tacatcagga gtgcacacat ttcctgcagt gcttcaatca tcaggacttt actcactttc atcagtggtg acagtgcctt catcatcact tggaacacaa acatacatct gcaacgtgaa ccacaaacct tcaaacacaa aggttgacaa gaaggtcgag cctaaatcat gcgataagac tcatacatgc cctccttgcc ctgcacctga acttcttgga ggcccgtcgg tgtttttatt cccgccaaaa ccgaaggata cacttatgat ctcaagaaca cctgaagtga catgcgtggt ggtggatgtg tcacacgaag atcctgaagt gaaatttaac tggtacgtgg atggagtgga agtgcacaac gcaaagacta agcctagaga agaacaatac aactcaacat acagagtggt gtcagtgctt acagtgcttc accaagattg gcttaacgga aaggagtata aatgcaaagt gtcaaacaaa gcacttcctg cacctatcga gaagactata tcaaaagcaa aaggacaacc tagagaacct caagtgtaca cacttcctcc ttcaagagat gaacttacaa agaatcaggt gtcacttaca tgtttagtaa agggcttcta cccatctgac atcgcagtgg aatgggaatc aaacggacaa cctgagaata attataagac cactcctcct gtacttgatt cagatggatc attcttcctc tattcaaagt taaccgtgga taaatcaaga tggcaacaag gaaacgtgtt ctcctgttca gtgatgcacg aagcacttca caaccactac acacagaaga gtctatcact ttcacctgga tga , gatatccaaa tgacccagag cccattgagc cttcctgtga cacctggaga acctgcatca atctcatgca gatcatcaca atcacttctt gattcagatg atggaaacac ataccttgat tggtaccttc agaagcccgg tcagtctcct cagctactaa tttatactct atcatacaga gcatcgggcg taccggaccg cttctccgga tcagggtcag ggactgattt caccctaaag atatccagag tggaagcaga agatgtggga gtgtactact gcatgcaaag aatcgaattt cctcttacat ttggaggagg aacaaaggta gagatcaaag gtggaggagg atccggagga ggtggatccg atatcgtgat gacgcagagc cctagctttc tttctgctag tgtaggcgac agagtgacaa tcacatgcag agcatcacaa ggaatctcat cataccttgc atggtaccaa cagaagccgg gaaaggcgcc caagctgctc atatatgctg cctcaactct gcagagtggc gtgccgtctc gcttcagcgg tagcggatcg ggaacagagt ttacacttac aatctcatca cttcaacctg aagatttcgc cacgtactac tgccaacaac ttaactcata ccctccttac acatttggac aaggaacaaa gttagagatc aagcgaaccg tggcagcacc ttcagtgttt atctttcctc cttcagatga acaacttaaa tcaggaactg cgtctgtagt ttgtcttctt aacaacttct atccaagaga agcaaaggta cagtggaaag tggataacgc cctgcagtct ggtaatagcc aagaatcagt gacagaacaa gattcaaagg acagtacata ctcactttca tcaacactta cactttcaaa ggcggactac gagaagcata aggtgtacgc atgcgaagtg acacaccaag gactttcatc acctgtgaca aagtccttca acagaggaga atgctga ,  人工序列(Artificial Sequence)  ,  人工序列(Artificial Sequence)  ,"(1/3)  the light chain and heavy chain dna sequences (shown in seq id no:3 and seq id no:1, respectivel"
https://patents.google.com/patent/WO2022022666A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg His Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ala Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  人工序列(Artificial Sequence)  ,  人工序列(Artificial Sequence)  ,"(32/33)  preferably, the amino acid sequence of the variable region of the heavy chain of the monoclonal antibody b38 is shown in seq id no:32, and the amino acid sequence of the variable region of the light chain of the monoclonal antibody b38 is shown in seq id no:33"
https://patents.google.com/patent/WO2022022666A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Pro Tyr Cys Ser Ser Thr Ser Cys His Arg Asp Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp Ser Asp Asp Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Arg Ile Glu Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  人工序列(Artificial Sequence)  ,  人工序列(Artificial Sequence)  ,"(34/35)  the amino acid sequence of the heavy chain variable region of anti-h4 is shown in seq id no:34, and the amino acid sequence of the light chain variable region of monoclonal antibody h4 is shown in seq id no:35."
https://patents.google.com/patent/WO2022022666A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Pro Tyr Cys Ser Ser Thr Ser Cys His Arg Asp Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg His Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ala Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly , Asp Ile Gln Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp Ser Asp Asp Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Arg Ile Glu Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  人工序列(Artificial Sequence)  ,  人工序列(Artificial Sequence)  ,"(2/4)  preferably, the bispecific antibody bs-mab-1, the amino acid sequence of its light chain is as shown in seq id no:4 or a protein with the same function obtained by one or more amino acid substitutions, deletions or insertions amino acid sequence, the amino acid sequence of its heavy chain is shown in seq id no:2 or the amino acid sequence of a protein with the same function obtained by one or more amino acid substitutions, deletions or insertions."
https://patents.google.com/patent/WO2022022666A1/en, gaggtccagc tcgttgagtc cggtggggga ttggtgcaac ctggaggatc acttagactt tcatgcgcag catcaggatt tatcgtgtca tcaaactaca tgtcatgggt acggcaggcg ccagggaaag gcctagagtg ggtttcggtg atctactcag gaggatcaac atactacgca gattcagtga aaggaagatt tacaatctca agacacaact caaagaatac tctttacctt caaatgaact cacttagagc agaagacact gcggtgtact actgcgcacg ggaggcgtac ggaatggatg tgtgggggca gggaacaaca gtcacggtct ctagcgccag caccaaaggc ccgtctgtct ttccactcgc accttcatca aagagcacgt cgggagggac ggctgcgctt ggatgtttag ttaaggacta tttcccagag ccggtcacag ttagctggaa ctcaggagca cttacctcgg gcgttcacac ctttcctgca gtgcttcaat catcaggact ttactcactt tcatcagtgg tgacagtgcc ttcatcatca cttggaacac aaacatacat ctgcaacgtg aaccacaaac cttcaaacac aaaggtagac aagcgagtag aacctaaatc atgcgataag acccatacat gccctccttg ccctgcacct gaacttcttg gaggtccatc ggtattctta tttccgccaa agccgaagga tacacttatg atctcaagaa cacctgaagt gacatgcgtg gtggtggatg tgtcacacga agatcctgaa gtgaaattta actggtacgt ggatggagtg gaagtgcaca acgcaaagac gaagcctaga gaagaacaat acaactcaac atacagagtg gtgtcagtgc ttacagtgct tcaccaagat tggcttaacg gaaaggagta taaatgcaaa gtgtcaaaca aagcacttcc tgcacctatc gagaagacga tatcaaaagc aaaaggacaa cctagagaac ctcaagtgta cacacttcct ccttcaagag atgaacttac aaagaatcag gtgtcactta catgtttagt caagggcttc tacccttcag atatcgcagt ggaatgggaa tcaaacggac aacctgagaa taattataag actacaccac cggtgttgga cagtgacggg agcttcttcc tgtattcaaa gctcactgtg gataaatcaa gatggcaaca aggaaacgtg ttctcgtgtt cagtgatgca cgaagcactt cacaaccact acacacagaa gtcgctgtca ctttcacctg gtggtggaag tcaagttcag ttggtacaga gcggagcaga agtgaagaag cccggtgcga gtgtgaaagt gtcatgcaaa gcatcaggat acacatttac aggatactac atgcactggg tacgacaggc tccgggtcaa ggtttagagt ggatgggcag aatcaaccct aactctggag gcaccaacta cgcacagaag ttccagggaa gagtgacaat gacaagagat acatcaatct caacagcata catggaactt tcaagactta gatcagatga cactgcggtc tattattgtg cacgggtacc ttactgctca tcaacatcat gccacagaga ttggtacttt gatctttggg gaagaggaac acttgtcact gtgtcgtcag gaggcggagg atcagggggt gggggcagcg gcggtggcgg ttctggtgga ggtggcagcg acatccaaat gacacaatca cctctttcac ttcctgtgac acctggagaa cctgcatcaa tctcatgcag atcatcacaa tcacttctgg actcggacga cggcaacaca taccttgatt ggtaccttca gaagccgggt caatcacctc aacttcttat ctacacactt tcatacagag cgtccggagt cccggacaga ttcagcggtt caggatcagg aacagatttc acgttgaaga tttctagagt ggaagcagaa gatgtgggag tgtactactg catgcaaaga atcgaatttc ctcttacatt tggaggtggc acgaaagtgg agatcaaatg a , gacatcgtga tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc atcacttgcc gggccagtca gggcattagc agttatttag cctggtatca gcaaaaacca gggaaagccc ctaagctcct gatctatgct gcatccactt tgcaaagtgg ggtcccatca aggttcagcg gcagtggatc tgggacagag ttcactctca caatcagcag cctgcagcct gaagattttg caacttatta ctgtcaacag cttaatagtt accctccgta cacttttggc caggggacca agctggagat caaacgaact gtggctgcac caagcgtgtt tatcttccct cccagcgacg agcagctgaa gagcggcacc gccagcgtgg tctgtctcct gaacaacttc tatcccaggg aggccaaggt ccagtggaaa gtggacaacg ccctgcaaag cggcaatagc caggagtccg tcacagagca ggacagcaag gacagcacct acagcctgtc cagcaccctg accctcagca aggccgacta cgagaagcac aaggtgtacg cttgcgaggt gacccatcag ggcctgtcca gccccgtgac caagtccttc aacaggggcg aatgcagc ,  人工序列(Artificial Sequence)  ,  人工序列(Artificial Sequence)  ,"(5/7)  the light chain and heavy chain dna sequences (shown in seq id no:7 and seq id no:5, respectivel"
https://patents.google.com/patent/KR20220010410A/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr His Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No.139 HC variable region , No.139 LC variable region ,"(2018/2017)  according to claim 1, the antibody or antigen-binding fragment thereof light chain variable region of the polypeptide sequence of seq id no:2017; and heavy chain variable region of the polypeptide sequence of seq id no:2018 a method comprising "
https://patents.google.com/patent/CN112521494B/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Ile Thr Val Ser Ser Asn Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Met Glu Val Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Leu Pro Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Val Glu Asn Asp Asn Val Asn Trp Phe Gln Gln Gln Val Pro Gly Ser Thr Pro Lys Leu Val Ile Tyr Asn Asp Arg Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Tyr Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Val Ala Trp Asp Ala Ser Leu Gln Ser Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , Artificial sequence, Artificial sequence,"(7/8) specifically, the sequences of the light chain variable region and the heavy chain variable region are respectively the same as seq id no:8 and seq id no:7."
https://patents.google.com/patent/US11021531B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Arg Phe Ser Asp AlaAla Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Arg Ser Tyr Gly Ile Asp Tyr Trp Gly Gln Gly Thr LeuVal Thr Val Ser Ser ,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro LeuThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,72117PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 72,84108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 84,"(72/84) in further embodiments, the 2ghw-derived antibody or antigen-binding fragment comprises a vl having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to any one of seq id no:84-95, and a vh having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to any one of seq id no:72-83"
https://patents.google.com/patent/US11021531B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asn TyrAla Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly LeuGlu Trp ValSer Thr Met Ser Asn Ile Gly Gly Asp Thr Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Arg Arg Val Tyr Leu Asp Tyr Trp Gly Gln Gly Thr LeuVal Thr Val Ser Ser ,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln SerGlu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro LeuThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,76117PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 76,88108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 88,"(76/88) in one instance, a 2ghw-derived antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise an vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:76 an vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:88."
https://patents.google.com/patent/US11021531B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser AsnTyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Val Ile Tyr Pro Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val LysGly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr LeuGln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys AlaArg Asp Arg Ser Tyr Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu ValThr Val Ser Ser ,Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro GlyGlu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser SerTyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu LeuIle Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe SerGly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu GlnSer Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ala Ser Ser Thr ProLeu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,82116PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 82,94109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 94,"(82/94) in one instance, a 2ghw-derived antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise an vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:82 an vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:94."
https://patents.google.com/patent/US11021531B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp TyrAla Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValAla Ile Ile Tyr Glu Gly Gly Ser Pro His Tyr Ala Asp Ser Val LysGly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr LeuGln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys AlaArg Asp Arg Ser Gly Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu ValThr Val Ser Ser ,Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro GlyGlu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn AsnLeu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu IleTyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser GlySer Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln SerGlu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro ProThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,81116PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 81,93108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 93,"(81/93) an antibody or an antigen-binding fragment that selectively binds to a sars-cov-2, that comprises a vh having an amino acid sequence of seq id no:81 and a vl having an amino acid sequence of seq id no:93."
https://patents.google.com/patent/US11021531B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala Ser HisAla Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Gly Ile Ser Ser Asp Gly Ser Ile Thr Thr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Arg Gly Trp Tyr Leu Asp Tyr Trp Gly Gln Gly Thr LeuVal Thr Val Ser Ser ,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro LeuThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,75117PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 75,87108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 87,"(75/87) in one instance, a 2ghw-derived antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise an vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:75 an vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:87."
https://patents.google.com/patent/US11021531B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser TyrGly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Met Asn Arg Asp Gly Ser Tyr Ile Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Arg Ser Tyr Tyr Val Gly Tyr Trp Gly Gln Gly Thr LeuVal Thr Val Ser Ser ,Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro GlyGlu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser AsnLeu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu IleTyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser GlySer Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln SerGlu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Asn Asn Trp Pro ProThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,83117PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 83,95Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg 100 10595108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 95,"(83/95) in one instance, a 2ghw-derived antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise an vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:83 an vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:95."
https://patents.google.com/patent/US11021531B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser TyrGly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Met Asn Arg Asp Gly Ser Tyr Ile Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Arg Ser Tyr Tyr Val Gly Tyr Trp Gly Gln Gly Thr LeuVal Thr Val Ser Ser ,Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro GlyGlu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Arg Ser AsnLeu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu IleTyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser GlySer Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln SerGlu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Asn Asn Trp Pro ProThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,79117PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 79,91108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 91,"(79/91) in one instance, a 2ghw-derived antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise an vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:79 an vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:91."
https://patents.google.com/patent/US11021531B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser AsnTyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Val Val Tyr Pro Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val LysGly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr LeuGln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys AlaArg Asp Arg Ser Tyr Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu ValThr Val Ser Ser ,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro LeuThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,73116PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 73,85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg 100 10585108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 85,"(73/85) in one instance, a 2ghw-derived antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise an vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:73 an vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:85."
https://patents.google.com/patent/US11021531B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp HisTyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Ile Ser Thr Ser Gly Asp Ser Thr Phe Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Arg Ser Tyr Tyr Leu Asp Tyr Trp Gly Gln Gly Thr LeuVal Thr Val Ser Ser ,Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro GlyGlu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Arg Ser AsnLeu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu IleTyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser GlySer Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln SerGlu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Gly Thr Ser Pro ProGly Leu Ser Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,80117PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 80,92110PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 92,"(80/92) in one instance, a 2ghw-derived antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise an vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:80 an vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:92."
https://patents.google.com/patent/US11021531B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn HisTyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Arg Ser Tyr Tyr Leu Asp Tyr Trp Gly Gln Gly Thr LeuVal Thr Val Ser Ser ,Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro GlyGlu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr TyrLeu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu IleTyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser GlySer Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln SerGlu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Leu Ser Leu Pro ValThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,77117PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 77,89108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 89,"(77/89) in one instance, a 2ghw-derived antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise an vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:77 an vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:89."
https://patents.google.com/patent/US11021531B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn SerAsp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Ala Ile Ser Gly Thr Gly Asp Thr Thr Glu Tyr Ala Asp Ser ValLys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu TyrLeu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Arg Ser Leu Met Leu Asp Tyr Trp Gly Gln Gly Thr LeuVal Thr Val Ser Ser ,Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro GlyGlu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Arg Ser AsnLeu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu IleTyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser GlySer Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln SerGlu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Asn Asn Trp Pro ProThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,78117PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 78,90 95Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg 100 10590108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 90,"(78/90) in one instance, a 2ghw-derived antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise an vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:78 an vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:90."
https://patents.google.com/patent/US11021531B1/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ser Val Thr Ser AsnTyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValSer Val Ile Tyr Pro Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val LysGly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr LeuGln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys AlaArg Asp Arg Ser Tyr Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu ValThr Val Ser Ser ,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro LeuThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,74116PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 74,86108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 86,"(74/86) in one instance, a 2ghw-derived antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise an vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:74 an vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:86."
https://patents.google.com/patent/KR20220012826A/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr His Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No.139 HC variable region , No.139 LC variable region ,"(2018/2017) the method according to any one of claims 1 to 6, the binding molecule is light chain variable region of the polypeptide sequence of seq id no:2017; and seq id no:2018 heavy chain variable region of the polypeptide sequence a binding molecule comprising a."
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Ser Gly Ser Gly Gly Ser Thr Ser Asn Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Val Tyr Cys Gly Asp Asp Cys Tyr Pro Val Val Gly Thr Pro Gly Asp Ala Phe Asp Ile Trp Gly Gly Gly Thr Met Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Glu Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp His Trp Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No. 38 HC variable region , No. 38 LC variable region ,(1216/1215)  a) a light chain variable region of seq id no:1215; and b) a binding molecule comprising the heavy chain variable region of seq id no:1216; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Phe Tyr Ala Ile Ser Trp Met Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Leu Phe Gly Thr Ala Lys Tyr Ala Gln Arg Phe Gln Asp Arg Val Thr Phe Ile Ala Asp Asp Thr Ser Thr Ala Tyr Met Glu Leu Asn Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Trp Ile Tyr Arg Gly Asn Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Gly Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 26 HC variable region , No. 26 LC variable region ,(1192/1191)  a) a light chain variable region of seq id no:1191; and b) a binding molecule comprising a heavy chain variable region of seq id no:1192; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser Ser Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Gly Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ile Ala Leu Asn Asn Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , No. 63 HC variable region , No. 63 LC variable region ,(1266/1265)  a) a light chain variable region of seq id no:1265; and b) a binding molecule comprising a heavy chain variable region of seq id no:1266; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Gly Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Gln Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , No. 40 HC variable region , No. 40 LC variable region ,(1220/1219)  a) a light chain variable region of seq id no:1219; and b) a binding molecule comprising the heavy chain variable region of seq id no:1220; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Ile Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Asp Thr Asn Tyr Ala His Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Ser Tyr Tyr Asn Val Met Tyr Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Leu Tyr Ala Ala Ser Arg Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , No. 178 HC variable region , No. 178 LC variable region ,(1496/1495)  a) a light chain variable region of seq id no:1495; and b) a binding molecule comprising a heavy chain variable region of seq id no:1496; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Ile Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Asp Thr Asn Tyr Ala His Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Ser Tyr Tyr Asn Val Met Tyr Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Arg Ser Asp Ile Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Thr Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Val Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Thr Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , No. 47 HC variable region , No. 47 LC variable region ,(1234/1233)  a) a light chain variable region of seq id no:1233; and b) a binding molecule comprising a heavy chain variable region of seq id no:1234; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser Ser Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ile Ala Leu Asn Asn Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Ala Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys , No. 67 HC variable region , No. 67 LC variable region ,(1274/1273)  a) a light chain variable region of seq id no:1273; and b) a binding molecule comprising a heavy chain variable region of seq id no:1274; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Pro Asn Ile Tyr Asn Trp Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asn Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 83 HC variable region , No. 83 LC variable region ,(1306/1305)  a) a light chain variable region of seq id no:1305; and b) a binding molecule comprising the heavy chain variable region of seq id no:1306; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Arg Tyr Tyr Ser Ser Trp Tyr Gly Pro Arg Thr Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , No. 125 HC variable region , No. 125 LC variable region ,(1390/1389)  a) a light chain variable region of seq id no:1389; and b) a binding molecule comprising the heavy chain variable region of seq id no:1390; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Glu Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ile Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Asn Pro Phe Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , No. 98 HC variable region , No. 98 LC variable region ,(1336/1335)  a) a light chain variable region of seq id no:1335; and b) a binding molecule comprising a heavy chain variable region of seq id no:1336; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ile Trp Val Arg Gln Thr Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Met Tyr Thr Phe Gly Gin Gly Thr Lys Leu Glu Ile Lys , No. 99 HC variable region , No. 99 LC variable region ,(1338/1337)  a) a light chain variable region of seq id no:1337; and b) a binding molecule comprising the heavy chain variable region of seq id no:1338; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Thr Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 122 HC variable region , No. 122 LC variable region ,(1384/1383)  a) a light chain variable region of seq id no:1383; and b) a binding molecule comprising the heavy chain variable region of seq id no:1384; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Ala Ser Leu Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 16 HC variable region , No.16 LC variable region ,(1172/1171)  a) a light chain variable region of seq id no:1171; and b) a binding molecule comprising a heavy chain variable region of seq id no:1172; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Gly Ile Ser Trp Met Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Ala Thr Thr Lys Phe Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Thr Tyr Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Trp Gly Leu Arg Leu Phe Gly Glu Phe Ser Val Trp Phe Asp Pro Trp Gly Leu Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Val Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 76 HC variable region , No. 76 LC variable region ,(1292/1291)  a) a light chain variable region of seq id no:1291; and b) a binding molecule comprising the heavy chain variable region of seq id no:1292; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Phe Phe Gly Thr Ser Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Val Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gln Phe Ser Asp Ser Ser Gly Tyr Gln His Pro Tyr Tyr Asp Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Pro Asn Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 186 HC variable region , No. 186 LC variable region ,(1512/1511)  a) a light chain variable region of seq id no:1511; and b) a binding molecule comprising a heavy chain variable region of seq id no:1512; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Gly Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Gln Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , No. 166 HC variable region , No. 166 LC variable region ,(1472/1471)  a) a light chain variable region of seq id no:1471; and b) a binding molecule comprising the heavy chain variable region of seq id no:1472; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Pro Gly Gly Ser Thr Phe Phe Ala Asp Ser Val Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Tyr Asp Phe Leu Thr Asp Tyr Thr Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Leu Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Gln , No. 48 HC variable region , No. 48 LC variable region ,(1236/1235)  a) a light chain variable region of seq id no:1235; and b) a binding molecule comprising a heavy chain variable region of seq id no:1236; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ser Asn His Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Tyr Asp Ser Asp Thr Lys Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Val Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Asn Pro Thr Val Thr Asn Trp Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Val Gly Ser Asn Ile Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asn Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Ala Trp Val Phe Gly Gly Gly Thr Lys Val Asp Ile Lys , No. 185 HC variable region , No. 185 LC variable region ,(1510/1509)  a) a light chain variable region of seq id no:1509; and b) a binding molecule comprising a heavy chain variable region of seq id no:1510; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Gln Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Thr Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 120 HC variable region , No. 120 LC variable region ,(1380/1379)  a) a light chain variable region of seq id no:1379; and b) a binding molecule comprising a heavy chain variable region of seq id no:1380; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Phe Leu Ala Trp Tyr Gln His Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Ala Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 108 HC variable region , No. 108 LC variable region ,(1356/1355)  a) a light chain variable region of seq id no:1355; and b) a binding molecule comprising the heavy chain variable region of seq id no:1356; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser Ser Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ile Ala Leu Asn Asn Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys , No. 65 HC variable region , No. 65 LC variable region ,(1270/1269)  a) a light chain variable region of seq id no:1269; and b) a binding molecule comprising a heavy chain variable region of seq id no:1270; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Gly Ile Ser Trp Met Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Ala Thr Thr Lys Phe Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Thr Tyr Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Trp Gly Leu Arg Leu Phe Gly Glu Phe Ser Val Trp Phe Asp Pro Trp Gly Leu Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Ala Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Ser Tyr Arg Pro Ser Gly Val Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Arg Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ala Leu Arg Gly Pro Leu Phe Gly Gly Gly Thr Lys Val Asp Ile Lys , No. 72 HC variable region , No. 72 LC variable region ,(1284/1283)  a) a light chain variable region of seq id no:1283; and b) a binding molecule comprising a heavy chain variable region of seq id no:1284; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Ile Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Asp Thr Asn Tyr Ala His Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Ser Tyr Tyr Asn Val Met Tyr Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , No. 57 HC variable region , No. 57 LC variable region ,(1254/1253)  a) a light chain variable region of seq id no:1253; and b) a binding molecule comprising the heavy chain variable region of seq id no:1254; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Arg Gly Tyr Ser Gly Tyr Gly Ser Asn Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 107 HC variable region , No. 107 LC variable region ,(1354/1353)  a) a light chain variable region of seq id no:1353; and b) a binding molecule comprising the heavy chain variable region of seq id no:1354; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Asn Asn Tyr Val Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Phe Ile Pro Val Phe Gly Ile Ala Asp Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Gly Leu Phe Asp Trp Leu Leu Pro Arg Ser Arg His Arg Asp Tyr Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 145 HC variable region , No. 145 LC variable region ,(1430/1429)  a) a light chain variable region of seq id no:1429; and b) a binding molecule comprising the heavy chain variable region of seq id no:1430; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Arg Ser Asn Ile Gly Ile Asn Ser Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Leu Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Glu Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu , No. 100 HC variable region , No. 100 LC variable region ,(1340/1339)  a) a light chain variable region of seq id no:1339; and b) a binding molecule comprising a heavy chain variable region of seq id no:1340; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Ser Arg Gly Asp Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Ala Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Ala Tyr Tyr Cys Ala Arg His Gly Thr Ser Gly Tyr Tyr Tyr Pro Asn Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 15 HC variable region , No.15 LC variable region ,(1170/1169)  a) a light chain variable region of seq id no:1169; and b) a binding molecule comprising the heavy chain variable region of seq id no:1170; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Thr Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Tyr Ala Leu Asn Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 110 HC variable region , No. 110 LC variable region ,(1360/1359)  a) a light chain variable region of seq id no:1359; and b) a binding molecule comprising the heavy chain variable region of seq id no:1360; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr Ala Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Val Arg Tyr Tyr Asp Phe Trp Ser Gly Trp Asp Val Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 117 HC variable region , No. 117 LC variable region ,(1374/1373)  a) a light chain variable region of seq id no:1373; and b) a binding molecule comprising the heavy chain variable region of seq id no:1374; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Asp Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg Asp Ser Gly Leu Tyr Gly Ser Gly Trp Ser Thr Tyr Gln Tyr Tyr Ala Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp His Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 33 HC variable region , No. 33 LC variable region ,(1206/1205)  a) a light chain variable region of seq id no:1205; and b) a binding molecule comprising the heavy chain variable region of seq id no:1206; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Phe Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Glu Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 2 HC variable region , No.2 LC variable region ,(1144/1143)  a) a light chain variable region of seq id no:1143; and b) a binding molecule comprising the heavy chain variable region of seq id no:1144; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ile Ser Tyr Trp Ile Val Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Thr Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Pro Asn Ile Tyr Asn Trp Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Leu Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu , No. 31 HC variable region , No. 31 LC variable region ,(1202/1201)  a) a light chain variable region of seq id no:1201; and b) a binding molecule comprising a heavy chain variable region of seq id no:1202; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser Ser Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ile Ala Leu Asn Asn Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Asn Arg Ser Asp Ile Gly Gly Tyr Asn Ser Leu Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Ile Ile Tyr Asp Val Asn Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Ala Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Thr Ser Lys Asn Thr Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 64 HC variable region , No. 64 LC variable region ,(1268/1267)  a) a light chain variable region of seq id no:1267; and b) a binding molecule comprising a heavy chain variable region of seq id no:1268; 
https://patents.google.com/patent/KR20220013344A/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 20 HC variable region , No.20 LC variable region ,(1180/1179)  a) a light chain variable region of seq id no:1179; and b) a binding molecule comprising the heavy chain variable region of seq id no:1180; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Ile Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Asp Thr Asn Tyr Ala His Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Ser Tyr Tyr Asn Val Met Tyr Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , No. 177 HC variable region , No. 177 LC variable region ,(1494/1493)  a) a light chain variable region of seq id no:1493; and b) a binding molecule comprising a heavy chain variable region of seq id no:1494; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Val Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 30 HC variable region , No. 30 LC variable region ,(1200/1199)  a) a light chain variable region of seq id no:1199; and b) a binding molecule comprising the heavy chain variable region of seq id no:1200; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Pro Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ile Ser Pro Ala Ile Ile Arg Val Asp Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Asp Ser Ile Thr Ile Ser Cys Thr Gly Thr Arg Gly Asp Ile Gly Ala Tyr Asp Gly Val Ser Trp Tyr Gln Gln Leu Pro Gly Lys Ala Pro Lys Leu Ile Ile Tyr Ala Val Thr Gln Arg Pro Ser Gly Ile Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Ser Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 133 HC variable region , No. 133 LC variable region ,(1406/1405)  a) a light chain variable region of seq id no:1405; and b) a binding molecule comprising a heavy chain variable region of seq id no:1406; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 4 HC variable region , No.4 LC variable region ,(1148/1147)  a) a light chain variable region of seq id no:1147; and b) a binding molecule comprising a heavy chain variable region of seq id no:1148; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 140 HC variable region , No. 140 LC variable region ,(1420/1419)  a) a light chain variable region of seq id no:1419; and b) a binding molecule comprising the heavy chain variable region of seq id no:1420; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , No. 51 HC variable region , No. 51 LC variable region ,(1242/1241)  a) a light chain variable region of seq id no:1241; and b) a binding molecule comprising a heavy chain variable region of seq id no:1242; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Phe Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Gln Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 81 HC variable region , No. 81 LC variable region ,(1302/1301)  a) a light chain variable region of seq id no:1301; and b) a binding molecule comprising a heavy chain variable region of seq id no:1302; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Leu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Ser Cys Ser Gly Gly Ser Cys Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Ser Ser Ser Thr Gly Ala Val Thr Arg Gly His Phe Pro Asn Trp Leu Gln Gln Lys Pro Gly Gln Thr Pro Arg Ala Leu Ile His Ser Thr Ser Asn Lys His Ser Trp Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Asp Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Leu Leu Tyr Asp Ala Gly Ala Pro Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 75 HC variable region , No. 75 LC variable region ,(1290/1289)  a) a light chain variable region of seq id no:1289; and b) a binding molecule comprising a heavy chain variable region of seq id no:1290; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Asp Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Val Arg Tyr Tyr Asp Phe Trp Ser Gly Trp Asp Val Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 3 HC variable region , No.3 LC variable region ,(1146/1145)  a) a light chain variable region of seq id no:1145; and b) a binding molecule comprising a heavy chain variable region of seq id no:1146; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Gly Gly Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys , No. 159 HC variable region , No. 159 LC variable region ,(1458/1457)  a) a light chain variable region of seq id no:1457; and b) a binding molecule comprising a heavy chain variable region of seq id no:1458; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Asn Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Thr Tyr Gly Ser Gly Ser Tyr Ser Asp Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Ser Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 179 HC variable region , No. 179 LC variable region ,(1498/1497)  a) a light chain variable region of seq id no:1497; and b) a binding molecule comprising the heavy chain variable region of seq id no:1498; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Thr Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 142 HC variable region , No. 142 LC variable region ,(1424/1423)  a) a light chain variable region of seq id no:1423; and b) a binding molecule comprising a heavy chain variable region of seq id no:1424; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Arg Val Ser Cys Lys Ala Ser Gly Asp Thr Phe Ile Arg Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Pro Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Lys Val Asn Tyr Ala Gln Lys Phe Gln Asp Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Val Asn Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Gly Ser Thr Trp Tyr Gly Gly Asn Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Pro Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 11 HC variable region , No.11 LC variable region ,(1162/1161)  a) a light chain variable region of seq id no:1161; and b) a binding molecule comprising the heavy chain variable region of seq id no:1162; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Arg Ala Ser Gly Tyr Ala Phe Thr Arg Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Lys Tyr Ala Gln Lys Leu Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Leu Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Leu Gly Ile Ala Val Ala Gly Thr Pro Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Pro , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 46 HC variable region , No. 46 LC variable region ,(1232/1231)  a) a light chain variable region of seq id no:1231; and b) a binding molecule comprising a heavy chain variable region of seq id no:1232; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Asp Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ala Thr Tyr Asp Ser Ser Gly Arg Pro Thr Gly Asp Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Arg Ile Thr Cys Ser Gly Asp Val Leu Ala Lys Lys Tyr Ala Arg Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Ala Gln Val Glu Asp Glu Ala Asp Tyr Tyr Cys Tyr Ser Ala Ala Asp Asn Asn Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 12 HC variable region , No.12 LC variable region ,(1164/1163)  a) a light chain variable region of seq id no:1163; and b) a binding molecule comprising the heavy chain variable region of seq id no:1164; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu Pro Ile His Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Arg Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Asn Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Asp Leu Thr Thr Val Thr Asn Pro Leu Asn Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Arg Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 148 HC variable region , No. 148 LC variable region ,(1436/1435)  a) a light chain variable region of seq id no:1435; and b) a binding molecule comprising the heavy chain variable region of seq id no:1436; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Ala Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Gly Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys , No. 36 HC variable region , No. 36 LC variable region ,(1212/1211)  a) a light chain variable region of seq id no:1211; and b) a binding molecule comprising a heavy chain variable region of seq id no:1212; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Glu Asn Asn Tyr Val Ser Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Asn Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 62 HC variable region , No. 62 LC variable region ,(1264/1263)  a) a light chain variable region of seq id no:1263; and b) a binding molecule comprising a heavy chain variable region of seq id no:1264; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Asp Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Thr Lys Val Arg Tyr Tyr Asp Phe Trp Ser Gly Trp Asp Val Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 150 HC variable region , No. 150 LC variable region ,(1440/1439)  a) a light chain variable region of seq id no:1439; and b) a binding molecule comprising a heavy chain variable region of seq id no:1440; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Ser Arg Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 113 HC variable region , No. 113 LC variable region ,(1366/1365)  a) a light chain variable region of seq id no:1365; and b) a binding molecule comprising a heavy chain variable region of seq id no:1366; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn Tyr Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Tyr Pro Gly Tyr Tyr Asp Ile Leu Thr Gly Gln Ile Gly Thr Gly Glu Arg Asn Ala Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asp Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 188 HC variable region , No. 188 LC variable region ,(1516/1515)  a) a light chain variable region of seq id no:1515; and b) a binding molecule comprising a heavy chain variable region of seq id no:1516; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Ala Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 6 HC variable region , No.6 LC variable region ,(1152/1151)  a) a light chain variable region of seq id no:1151; and b) a binding molecule comprising a heavy chain variable region of seq id no:1152; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Pro Gly Gly Ser Thr Phe Phe Ala Asp Ser Val Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Tyr Asp Phe Leu Thr Asp Tyr Thr Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 56 HC variable region , No. 56 LC variable region ,(1252/1251)  a) a light chain variable region of seq id no:1251; and b) a binding molecule comprising the heavy chain variable region of seq id no:1252; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Glu Tyr Gly Ser Ser Pro Arg Arg Val Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys , No. 21 HC variable region , No. 21 LC variable region ,(1182/1181)  a) a light chain variable region of seq id no:1181; and b) a binding molecule comprising a heavy chain variable region of seq id no:1182; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Arg Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , No. 86 HC variable region , No. 86 LC variable region ,(1312/1311)  a) a light chain variable region of seq id no:1311; and b) a binding molecule comprising a heavy chain variable region of seq id no:1312; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Thr Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Asn Asn Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ser Ser His Asn Gly Asn Thr Lys Tyr Ala Gln Lys Leu Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Tyr Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Arg Phe Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Leu Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 27 HC variable region , No. 27 LC variable region ,(1194/1193)  a) a light chain variable region of seq id no:1193; and b) a binding molecule comprising a heavy chain variable region of seq id no:1194; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Arg Asp Asp Ser Leu Asn Gly Ala Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 19 HC variable region , No.19 LC variable region ,(1178/1177)  a) a light chain variable region of seq id no:1177; and b) a binding molecule comprising a heavy chain variable region of seq id no:1178; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Ser Tyr Ser Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr His Thr Ser Pro Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , No. 161 HC variable region , No. 161 LC variable region ,(1462/1461)  a) a light chain variable region of seq id no:1461; and b) a binding molecule comprising a heavy chain variable region of seq id no:1462; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Asn Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Thr Tyr Gly Ser Gly Ser Tyr Ser Asp Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 180 HC variable region , No. 180 LC variable region ,(1500/1499)  a) a light chain variable region of seq id no:1499; and b) a binding molecule comprising a heavy chain variable region of seq id no:1500; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ile Trp Val Arg Gln Thr Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 156 HC variable region , No. 156 LC variable region ,(1452/1451)  a) a light chain variable region of seq id no:1451; and b) a binding molecule comprising the heavy chain variable region of seq id no:1452; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Arg Leu Ser Cys Lys Ala Ser Gly Gly Pro Phe Glu Arg Lys Val Ile Ala Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val Gly Gly His Ala Pro Phe Val Arg Lys Pro Thr Tyr Ala Arg Lys Phe Gln Gly Arg Val Thr Leu Thr Ala Asp Asp Ser Thr Ser Thr Ala Phe Met Glu Phe Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Phe Cys Ala Thr Lys Ala Val Thr Thr Tyr Ser Gly Phe Asp Asn Trp Gly Gln Gly Thr Leu Val Phe Val Ser Ala , Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 68 HC variable region , No. 68 LC variable region ,(1276/1275)  a) a light chain variable region of seq id no:1275; and b) a binding molecule comprising a heavy chain variable region of seq id no:1276; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Gly Ser Tyr Gly Ile Ser Trp Met Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Ala Thr Thr Lys Phe Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Thr Tyr Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Trp Gly Leu Arg Leu Phe Gly Glu Phe Ser Val Trp Phe Asp Pro Trp Gly Leu Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Asp Val Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 73 HC variable region , No. 73 LC variable region ,(1286/1285)  a) a light chain variable region of seq id no:1285; and b) a binding molecule comprising a heavy chain variable region of seq id no:1286; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Met Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Pro Asp Asp Ser Ser Gly Tyr Tyr Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Leu Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 131 HC variable region , No. 131 LC variable region ,(1402/1401)  a) a light chain variable region of seq id no:1401; and b) a binding molecule comprising a heavy chain variable region of seq id no:1402; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ser Asn Tyr Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Tyr Asp Ser Asp Thr Arg Lys Ser Pro Ser Phe Gln Gly Gln Val Thr Met Ser Ala Asp Lys Ser Ile Thr Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Thr Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gln Asp Ser Gly Thr Tyr Gly Trp Ile Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Met Gln Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 183 HC variable region , No. 183 LC variable region ,(1506/1505)  a) a light chain variable region of seq id no:1505; and b) a binding molecule comprising a heavy chain variable region of seq id no:1506; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ile Ser Tyr Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Val Asp Lys Ser Ile Thr Thr Ala Tyr Leu Gln Trp Ser Ser Leu Glu Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Pro Asn Leu Tyr Asn Trp Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly His Val Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 175 HC variable region , No. 175 LC variable region ,(1490/1489)  a) a light chain variable region of seq id no:1489; and b) a binding molecule comprising a heavy chain variable region of seq id no:1490; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Pro Gly Gly Ser Thr Phe Phe Ala Asp Ser Val Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Tyr Asp Phe Leu Thr Asp Tyr Thr Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , No. 53 HC variable region , No. 53 LC variable region ,(1246/1245)  a) a light chain variable region of seq id no:1245; and b) a binding molecule comprising a heavy chain variable region of seq id no:1246; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr His Cys Val Arg Val Gly Thr Tyr Asp Ser Ser Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Ser Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , No. 127 HC variable region , No. 127 LC variable region ,(1394/1393)  a) a light chain variable region of seq id no:1393; and b) a binding molecule comprising the heavy chain variable region of seq id no:1394; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Arg Gly Gly Ser Tyr Leu Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , No. 97 HC variable region , No. 97 LC variable region ,(1334/1333)  a) a light chain variable region of seq id no:1333; and b) a binding molecule comprising the heavy chain variable region of seq id no:1334; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Phe Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Phe Cys Ala Arg Gln Glu Trp Leu Arg Gly Gly Phe Asp Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 184 HC variable region , No. 184 LC variable region ,(1508/1507)  a) a light chain variable region of seq id no:1507; and b) a binding molecule comprising a heavy chain variable region of seq id no:1508; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser Ser Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ile Ala Leu Asn Asn Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys , No. 153 HC variable region , No. 153 LC variable region ,(1446/1445)  a) a light chain variable region of seq id no:1445; and b) a binding molecule comprising a heavy chain variable region of seq id no:1446; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys His Gln Tyr Gly Thr Ser Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , No. 158 HC variable region , No. 158 LC variable region ,(1456/1455)  a) a light chain variable region of seq id no:1455; and b) a binding molecule comprising the heavy chain variable region of seq id no:1456; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu , No. 112 HC variable region , No. 112 LC variable region ,(1364/1363)  a) a light chain variable region of seq id no:1363; and b) a binding molecule comprising the heavy chain variable region of seq id no:1364; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Arg Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 114 HC variable region , No. 114 LC variable region ,(1368/1367)  a) a light chain variable region of seq id no:1367; and b) a binding molecule comprising a heavy chain variable region of seq id no:1368; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Arg Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Gly Asn Tyr Val His Trp Tyr Gln Gln Leu Pro Gly Ala Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Arg Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 43 HC variable region , No. 43 LC variable region ,(1226/1225)  a) a light chain variable region of seq id no:1225; and b) a binding molecule comprising a heavy chain variable region of seq id no:1226; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Glu Ala Trp Asp Ser Ser Leu Ser Ala Val Leu Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 141 HC variable region , No. 141 LC variable region ,(1422/1421)  a) a light chain variable region of seq id no:1421; and b) a binding molecule comprising the heavy chain variable region of seq id no:1422; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Val Ile Ser Trp Val Arg Gln Ala Pro Gly Gin Gly Leu Glu Trp Val Gly Arg Ile Ile Pro Ile Phe Gly Thr Val Lys Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Pro Gly Asp Ser Arg Asp Gly Tyr Asn Tyr Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Leu , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 80 HC variable region , No. 80 LC variable region ,(1300/1299)  a) a light chain variable region of seq id no:1299; and b) a binding molecule comprising the heavy chain variable region of seq id no:1300; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Asp His Gly Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Arg Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Arg Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 121 HC variable region , No. 121 LC variable region ,(1382/1381)  a) a light chain variable region of seq id no:1381; and b) a binding molecule comprising a heavy chain variable region of seq id no:1382; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Leu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Ser Cys Ser Gly Gly Ser Cys Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Phe Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Ala Trp Asp Ser Ser Leu Ser Thr Pro Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 77 HC variable region , No. 77 LC variable region ,(1294/1293)  a) a light chain variable region of seq id no:1293; and b) a binding molecule comprising a heavy chain variable region of seq id no:1294; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Thr Ser Ser Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Val Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Phe Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Asp His Ile Val Ser Pro Leu Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , No. 55 HC variable region , No. 55 LC variable region ,(1250/1249)  a) a light chain variable region of seq id no:1249; and b) a binding molecule comprising a heavy chain variable region of seq id no:1250; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Asp Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 143 HC variable region , No. 143 LC variable region ,(1426/1425)  a) a light chain variable region of seq id no:1425; and b) a binding molecule comprising a heavy chain variable region of seq id no:1426; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Asp Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ala Thr Tyr Asp Ser Ser Gly Arg Pro Thr Gly Asp Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Arg Ile Thr Cys Ser Gly Asp Val Leu Ala Lys Lys Tyr Ala Arg Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Ala Gln Val Glu Asp Glu Ala Asp Tyr Tyr Cys Tyr Ser Ala Ala Asp Asn Asn Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 123 HC variable region , No. 123 LC variable region ,(1386/1385)  a) a light chain variable region of seq id no:1385; and b) a binding molecule comprising the heavy chain variable region of seq id no:1386; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Asp Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Gly Leu Tyr Gly Ser Gly Trp Ser Thr Tyr Gln Tyr Tyr Ala Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Gly Gln Thr Gln Gln Leu Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 85 HC variable region , No. 85 LC variable region ,(1310/1309)  a) a light chain variable region of seq id no:1309; and b) a binding molecule comprising the heavy chain variable region of seq id no:1310; 
https://patents.google.com/patent/KR20220013344A/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Gly Arg Asn Tyr Leu Ala Trp Tyr Gln His Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Thr Arg Ala Thr Asp Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , No. 157 HC variable region , No. 157 LC variable region ,(1454/1453)  a) a light chain variable region of seq id no:1453; and b) a binding molecule comprising the heavy chain variable region of seq id no:1454; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Asp Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 95 HC variable region , No. 95 LC variable region ,(1330/1329)  a) a light chain variable region of seq id no:1329; and b) a binding molecule comprising the heavy chain variable region of seq id no:1330; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Thr Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 164 HC variable region , No. 164 LC variable region ,(1468/1467)  a) a light chain variable region of seq id no:1467; and b) a binding molecule comprising a heavy chain variable region of seq id no:1468; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Gly Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Gly Ser Ser Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , No. 168 HC variable region , No. 168 LC variable region ,(1476/1475)  a) a light chain variable region of seq id no:1475; and b) a binding molecule comprising a heavy chain variable region of seq id no:1476; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Arg Gly Ser Gly Tyr Ser Phe Thr Ser His Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Ser Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Gly Pro Asn Leu Tyr Asn Trp Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 176 HC variable region , No. 176 LC variable region ,(1492/1491)  a) a light chain variable region of seq id no:1491; and b) a binding molecule comprising a heavy chain variable region of seq id no:1492; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser His Lys Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Asn Cys Gly Gly Asp Cys Gly Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Lys Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Pro Trp Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No. 136 HC variable region , No. 136 LC variable region ,(1412/1411)  a) a light chain variable region of seq id no:1411; and b) a binding molecule comprising a heavy chain variable region of seq id no:1412; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Ser Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , No. 44 HC variable region , No. 44 LC variable region ,(1228/1227)  a) a light chain variable region of seq id no:1227; and b) a binding molecule comprising a heavy chain variable region of seq id no:1228; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Ser Gly Thr Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Arg Ser Leu Lys Pro Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Glu Glu Leu Gly Pro Tyr Ser Asn Arg Trp Tyr Ser Ser Ser Ser Asp Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 54 HC variable region , No. 54 LC variable region ,(1248/1247)  a) a light chain variable region of seq id no:1247; and b) a binding molecule comprising a heavy chain variable region of seq id no:1248; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Ala Met Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Thr Gly Trp Tyr Ser Gly Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Val Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Pro Ile Thr Phe Gly Gin Gly Thr Lys Val Glu Ile Lys , No. 130 HC variable region , No. 130 LC variable region ,(1400/1399)  a) a light chain variable region of seq id no:1399; and b) a binding molecule comprising a heavy chain variable region of seq id no:1400; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Ser Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ala Pro Ser Asp Leu Ser Phe Ile Trp Thr Gly Tyr Tyr Ser Glu Tyr Tyr Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Ala Leu Asn Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala His Lys Leu Met Met Tyr Asp Val Ser Asn Arg Pro Ser Gly Ala Tyr Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Ala Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Ser His Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 14 HC variable region , No.14 LC variable region ,(1168/1167)  a) a light chain variable region of seq id no:1167; and b) a binding molecule comprising a heavy chain variable region of seq id no:1168; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ile Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Met Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Thr Ser Arg Ser Thr Tyr Tyr Tyr Tyr Ser Gly Ser Tyr Tyr Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Gly Ser Asn Ile Gly Ser Asn Tyr Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Ser Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No. 147 HC variable region , No. 147 LC variable region ,(1434/1433)  a) a light chain variable region of seq id no:1433; and b) a binding molecule comprising the heavy chain variable region of seq id no:1434; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Arg Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Pro , Glu Leu Thr Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Lys Tyr Thr Phe Gly Gin Gly Thr Lys Val Glu Ile Lys , No. 88 HC variable region , No. 88 LC variable region ,(1316/1315)  a) a light chain variable region of seq id no:1315; and b) a binding molecule comprising a heavy chain variable region of seq id no:1316; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Ser Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 116 HC variable region , No. 116 LC variable region ,(1372/1371)  a) a light chain variable region of seq id no:1371; and b) a binding molecule comprising a heavy chain variable region of seq id no:1372; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Pro Glu Val Ala Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Gly Pro Val Leu Gly Leu Ser Lys Trp Leu Glu Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Thr Asp Ile Gly Arg Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Tyr Ala Phe Gly Thr Gly Thr Lys Val Asp Ile Lys , No. 138 HC variable region , No. 138 LC variable region ,(1416/1415)  a) a light chain variable region of seq id no:1415; and b) a binding molecule comprising a heavy chain variable region of seq id no:1416; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Ser Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 91 HC variable region , No. 91 LC variable region ,(1322/1321)  a) a light chain variable region of seq id no:1321; and b) a binding molecule comprising a heavy chain variable region of seq id no:1322; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Gly Thr Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Val Ile Ser Tyr Asp Gly Phe Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Ile Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Ala Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Gly Asp Tyr Phe Cys Ser Ser Tyr Thr Ser Ser Ser Gly Thr Leu Asn Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , No. 101 HC variable region , No. 101 LC variable region ,(1342/1341)  a) a light chain variable region of seq id no:1341; and b) a binding molecule comprising a heavy chain variable region of seq id no:1342; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ile Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Phe Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , No. 87 HC variable region , No. 87 LC variable region ,(1314/1313)  a) a light chain variable region of seq id no:1313; and b) a binding molecule comprising a heavy chain variable region of seq id no:1314; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Leu Lys Lys Pro Gly Ser Ser Val Arg Leu Ser Cys Lys Ala Ser Gly Gly Pro Phe Glu Arg Lys Val Ile Ala Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val Gly Gly His Ala Pro Phe Val Arg Lys Pro Thr Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Ala Asp Asp Ser Thr Ala Thr Ala Phe Met Glu Leu Ser Ser Leu Gly Tyr Gly Asp Thr Gly Val Tyr Tyr Cys Ala Thr Lys Ala Val Thr Thr Tyr Ser Gly Phe Asp Asn Trp Gly Gln Gly Thr Leu Val Phe Val Ser Thr , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 7 HC variable region , No.7 LC variable region ,(1154/1153)  a) a light chain variable region of seq id no:1153; and b) a binding molecule comprising the heavy chain variable region of seq id no:1154; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Lys Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No. 169 HC variable region , No. 169 LC variable region ,(1478/1477)  a) a light chain variable region of seq id no:1477; and b) a binding molecule comprising the heavy chain variable region of seq id no:1478; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Phe Ile Val Ser Ser Asn Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ile Ile Tyr Pro Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Arg Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Pro Leu Thr Gly Thr Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 32 HC variable region , No. 32 LC variable region ,(1204/1203)  a) a light chain variable region of seq id no:1203; and b) a binding molecule comprising the heavy chain variable region of seq id no:1204; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Ser Ser Gly Tyr Ser Phe Ile Ser Tyr Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Val Asp Lys Ser Ile Thr Thr Ala Tyr Leu Gln Trp Ser Ser Leu Glu Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Pro Asn Leu Tyr Asn Trp Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Ser Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 174 HC variable region , No. 174 LC variable region ,(1488/1487)  a) a light chain variable region of seq id no:1487; and b) a binding molecule comprising a heavy chain variable region of seq id no:1488; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 5 HC variable region , No.5 LC variable region ,(1150/1149)  a) a light chain variable region of seq id no:1149; and b) a binding molecule comprising a heavy chain variable region of seq id no:1150; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ala Pro Ser Asp Leu Ser Phe Ile Trp Thr Gly Tyr Tyr Ser Glu Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Ser Pro Gly Gln Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser Asn Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 28 HC variable region , No. 28 LC variable region ,(1196/1195)  a) a light chain variable region of seq id no:1195; and b) a binding molecule comprising the heavy chain variable region of seq id no:1196; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Arg Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 82 HC variable region , No. 82 LC variable region ,(1304/1303)  a) a light chain variable region of seq id no:1303; and b) a binding molecule comprising the heavy chain variable region of seq id no:1304; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ile Trp Val Arg Gln Thr Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Ala Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 60 HC variable region , No. 60 LC variable region ,(1260/1259)  a) a light chain variable region of seq id no:1259; and b) a binding molecule comprising a heavy chain variable region of seq id no:1260; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Ser Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Arg Gly Gly Ser Tyr Leu Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , No. 89 HC variable region , No. 89 LC variable region ,(1318/1317)  a) a light chain variable region of seq id no:1317; and b) a binding molecule comprising the heavy chain variable region of seq id no:1318; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Thr Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Met Tyr Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , No. 105 HC variable region , No. 105 LC variable region ,(1350/1349)  a) a light chain variable region of seq id no:1349; and b) a binding molecule comprising the heavy chain variable region of seq id no:1350; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Arg Leu Ser Cys Lys Ala Ser Gly Gly Pro Phe Glu Arg Lys Val Ile Ala Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val Gly Gly His Ala Pro Phe Val Arg Lys Pro Thr Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Ala Asp Asp Ser Thr Ser Thr Ala Phe Met Glu Leu Ser Thr Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Thr Lys Ala Val Thr Thr Tyr Ser Gly Phe Asp Thr Trp Gly Gln Gly Thr Leu Val Leu Val Ser Ala , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 9 HC variable region , No.9 LC variable region ,(1158/1157)  a) a light chain variable region of seq id no:1157; and b) a binding molecule comprising the heavy chain variable region of seq id no:1158; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Gly Thr Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Val Ile Ser Tyr Asp Gly Phe Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 94 HC variable region , No. 94 LC variable region ,(1328/1327)  a) a light chain variable region of seq id no:1327; and b) a binding molecule comprising a heavy chain variable region of seq id no:1328; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu Ser Gly Arg Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 170 HC variable region , No. 170 LC variable region ,(1480/1479)  a) a light chain variable region of seq id no:1479; and b) a binding molecule comprising the heavy chain variable region of seq id no:1480; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Met Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Tyr Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 115 HC variable region , No. 115 LC variable region ,(1370/1369)  a) a light chain variable region of seq id no:1369; and b) a binding molecule comprising a heavy chain variable region of seq id no:1370; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Arg Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Gly Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Leu Tyr Tyr Tyr Asp Arg Ser Gly Tyr Pro Ile Ser Glu Asp Tyr Phe Asp Tyr Trp Gly Gly Gly Thr Leu Val Thr Val Ser Ala , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 35 HC variable region , No. 35 LC variable region ,(1210/1209)  a) a light chain variable region of seq id no:1209; and b) a binding molecule comprising the heavy chain variable region of seq id no:1210; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Arg Gly Gly Asn Tyr Arg Gly Ala Leu Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asp Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asn Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Asp Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Ala Pro Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 129 HC variable region , No. 129 LC variable region ,(1398/1397)  a) a light chain variable region of seq id no:1397; and b) a binding molecule comprising a heavy chain variable region of seq id no:1398; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Gln Tyr Leu His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Tyr Gly Gly Ser Thr Thr Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Pro Ser Gly Tyr Tyr Gly Asp Tyr Glu Gly Asp Ala Phe Asp Ile Trp Gly Gin Gly Thr Met Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Ala Ser Lys Asp Ala Ala Ser Ala Tyr Leu Thr Ile Thr Gly Leu Gln Ala Glu Asp Glu Gly Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Arg Leu Arg Ala Val Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 79 HC variable region , No. 79 LC variable region ,(1298/1297)  a) a light chain variable region of seq id no:1297; and b) a binding molecule comprising a heavy chain variable region of seq id no:1298; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Pro Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Ser His Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Ile Leu Tyr Glu Val Ser Asp Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Thr Ser Ser Ser Thr Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 58 HC variable region , No. 58 LC variable region ,(1256/1255)  a) a light chain variable region of seq id no:1255; and b) a binding molecule comprising a heavy chain variable region of seq id no:1256; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Ser Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Ser Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Trp Asp Asp Arg Leu Ser Ala Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 1 HC variable region , No.1 LC variable region ,(1142/1141)  a) a light chain variable region of seq id no:1141; and b) a binding molecule comprising a heavy chain variable region of seq id no:1142; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Pro Glu Val Ala Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Gly Pro Val Leu Gly Leu Ser Lys Trp Leu Glu Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ala Tyr Asn Tyr Val Ser Trp Tyr Gln His His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Thr Ser Ser Ser Thr Trp Val Phe Gly Gly Gly Thr Lys Val Asp Ile Lys , No. 139 HC variable region , No. 139 LC variable region ,(1418/1417)  a) a light chain variable region of seq id no:1417; and b) a binding molecule comprising a heavy chain variable region of seq id no:1418; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser His Lys Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Asn Cys Gly Gly Asp Cys Gly Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Arg Thr Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 71 HC variable region , No. 71 LC variable region ,(1282/1281)  a) a light chain variable region of seq id no:1281; and b) a binding molecule comprising the heavy chain variable region of seq id no:1282; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Arg Gly Ser Gly Tyr Ser Phe Thr Ser His Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Ser Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Gly Pro Asn Leu Tyr Asn Trp Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Thr Asn Asn Arg Arg Pro Ser Gly Ala Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Leu Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 37 HC variable region , No. 37 LC variable region ,(1214/1213)  a) a light chain variable region of seq id no:1213; and b) a binding molecule comprising a heavy chain variable region of seq id no:1214; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Glu Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asn Ala Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Arg Ile Lys Thr Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Thr Phe Ser Thr Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Leu Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Ala Ala Val Tyr Tyr Cys Leu Gln Tyr Phe Thr Ile Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , No. 10 HC variable region , No.10 LC variable region ,(1160/1159)  a) a light chain variable region of seq id no:1159; and b) a binding molecule comprising the heavy chain variable region of seq id no:1160; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Thr Tyr Tyr Tyr Asp Ser Ser Gly Pro Leu Asn Trp Phe Asp Pro Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 151 HC variable region , No. 151 LC variable region ,(1442/1441)  a) a light chain variable region of seq id no:1441; and b) a binding molecule comprising a heavy chain variable region of seq id no:1442; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Ala Ile Trp His Asp Gly Tyr Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Lys Ala Ala Asp Tyr Trp Gly Gln Gly Thr Leu Val Ile Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Arg Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Lys Thr Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , No. 103 HC variable region , No. 103 LC variable region ,(1346/1345)  a) a light chain variable region of seq id no:1345; and b) a binding molecule comprising the heavy chain variable region of seq id no:1346; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Asn Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Phe Leu Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Arg Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Thr Gly Lys Pro Tyr Tyr Cys Thr Gly Ser Thr Cys Tyr Gln Pro Leu Gly Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Ser Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Gly Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , No. 152 HC variable region , No. 152 LC variable region ,(1444/1443)  a) a light chain variable region of seq id no:1443; and b) a binding molecule comprising the heavy chain variable region of seq id no:1444; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asn Val Gly Asp Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Thr Asn Arg Pro Ser Gly Val Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Gly Ser Thr Pro Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 163 HC variable region , No. 163 LC variable region ,(1466/1465)  a) a light chain variable region of seq id no:1465; and b) a binding molecule comprising a heavy chain variable region of seq id no:1466; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Ser Gly Tyr Asp Ser Ser Gly Tyr Tyr Ser Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Leu Gln Arg Ser Asn Trp Pro Pro Ala Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 126 HC variable region , No. 126 LC variable region ,(1392/1391)  a) a light chain variable region of seq id no:1391; and b) a binding molecule comprising a heavy chain variable region of seq id no:1392; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 18 HC variable region , No.18 LC variable region ,(1176/1175)  a) a light chain variable region of seq id no:1175; and b) a binding molecule comprising the heavy chain variable region of seq id no:1176; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Thr His Ala Leu Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Pro Ala Asp Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Leu Ser Leu Gly Phe Cys Ser Ala Gly Ser Cys Tyr Asp Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 187 HC variable region , No. 187 LC variable region ,(1514/1513)  a) a light chain variable region of seq id no:1513; and b) a binding molecule comprising a heavy chain variable region of seq id no:1514; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Glu Gly Tyr Asp Ser Ser Gly Tyr Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Arg Asn Trp Pro Pro Val Leu Thr Phe Gly Gin Gly Thr Lys Val Glu Ile Lys , No. 84 HC variable region , No. 84 LC variable region ,(1308/1307)  a) a light chain variable region of seq id no:1307; and b) a binding molecule comprising a heavy chain variable region of seq id no:1308; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Ser Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 118 HC variable region , No. 118 LC variable region ,(1376/1375)  a) a light chain variable region of seq id no:1375; and b) a binding molecule comprising the heavy chain variable region of seq id no:1376; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Pro Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu Ala Leu Ile Ser Tyr Asp Gly Asn Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Thr Tyr Gly Ser Tyr Tyr Tyr Gly Met Asp Ala Trp Gly Leu Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr Thr Gln Asn Ile Asn Thr Tyr Leu Asn Trp Tyr Gln Gln Gln Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Thr Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Ser Val Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Arg Ser Tyr Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , No. 109 HC variable region , No. 109 LC variable region ,(1358/1357)  a) a light chain variable region of seq id no:1357; and b) a binding molecule comprising a heavy chain variable region of seq id no:1358; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ala Pro Ser Asp Leu Ser Phe Ile Trp Thr Gly Tyr Tyr Ser Glu Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 29 HC variable region , No. 29 LC variable region ,(1198/1197)  a) a light chain variable region of seq id no:1197; and b) a binding molecule comprising a heavy chain variable region of seq id no:1198; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser , Glu Leu Val Val Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Arg Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 144 HC variable region , No. 144 LC variable region ,(1428/1427)  a) a light chain variable region of seq id no:1427; and b) a binding molecule comprising the heavy chain variable region of seq id no:1428; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , No. 162 HC variable region , No. 162 LC variable region ,(1464/1463)  a) a light chain variable region of seq id no:1463; and b) a binding molecule comprising the heavy chain variable region of seq id no:1464; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Arg Gly Ser Gly Tyr Ser Phe Thr Ser His Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Ser Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Gly Pro Asn Leu Tyr Asn Trp Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 173 HC variable region , No. 173 LC variable region ,(1486/1485)  a) a light chain variable region of seq id no:1485; and b) a binding molecule comprising a heavy chain variable region of seq id no:1486; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Asp Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Pro Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Gly Val Thr Ile Ser Cys Ser Gly Leu Thr Ser Asn Ile Gly Ser Asn Phe Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Asn Glu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Gly Glu Tyr Phe Cys Ala Ala Trp Asp Asp Thr Leu Val Gly Arg Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 171 HC variable region , No. 171 LC variable region ,(1482/1481)  a) a light chain variable region of seq id no:1481; and b) a binding molecule comprising the heavy chain variable region of seq id no:1482; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 111 HC variable region , No. 111 LC variable region ,(1362/1361)  a) a light chain variable region of seq id no:1361; and b) a binding molecule comprising the heavy chain variable region of seq id no:1362; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gly Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Gly Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Arg Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Met Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 167 HC variable region , No. 167 LC variable region ,(1474/1473)  a) a light chain variable region of seq id no:1473; and b) a binding molecule comprising a heavy chain variable region of seq id no:1474; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 52 HC variable region , No. 52 LC variable region ,(1244/1243)  a) a light chain variable region of seq id no:1243; and b) a binding molecule comprising a heavy chain variable region of seq id no:1244; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 160 HC variable region , No. 160 LC variable region ,(1460/1459)  a) a light chain variable region of seq id no:1459; and b) a binding molecule comprising a heavy chain variable region of seq id no:1460; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Arg Phe Ser Ser Asn Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Asn Ser Pro Ser Phe Gln Gly Gln Val Thr Met Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Ser Ala Met Tyr Tyr Cys Ala Arg Leu Ala Tyr Phe His Pro Gln Arg Asn Gly Gly Tyr Glu Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Pro , Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 78 HC variable region , No. 78 LC variable region ,(1296/1295)  a) a light chain variable region of seq id no:1295; and b) a binding molecule comprising the heavy chain variable region of seq id no:1296; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ile Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Met Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Thr Ser Arg Ser Thr Tyr Tyr Tyr Tyr Ser Gly Ser Tyr Tyr Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Gly Gln Thr Gln Gln Leu Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 146 HC variable region , No. 146 LC variable region ,(1432/1431)  a) a light chain variable region of seq id no:1431; and b) a binding molecule comprising a heavy chain variable region of seq id no:1432; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Leu Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Val Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Arg Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Thr Ser Leu Ser Ser Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 119 HC variable region , No. 119 LC variable region ,(1378/1377)  a) a light chain variable region of seq id no:1377; and b) a binding molecule comprising a heavy chain variable region of seq id no:1378; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Gly Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Pro Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Gly Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln His Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 59 HC variable region , No. 59 LC variable region ,(1258/1257)  a) a light chain variable region of seq id no:1257; and b) a binding molecule comprising a heavy chain variable region of seq id no:1258; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Asn Ile Lys Glu Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Tyr Ser Gly Asn Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Asn Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Phe Cys Ala Thr Trp Asp Asp Ser Leu Asn Gly Gln Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 155 HC variable region , No. 155 LC variable region ,(1450/1449)  a) a light chain variable region of seq id no:1449; and b) a binding molecule comprising the heavy chain variable region of seq id no:1450; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Asp Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Gly Leu Tyr Gly Ser Gly Trp Ser Thr Tyr Gln Tyr Tyr Ala Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Gly Gln Thr Gln Gln Leu Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 23 HC variable region , No. 23 LC variable region ,(1186/1185)  a) a light chain variable region of seq id no:1185; and b) a binding molecule comprising a heavy chain variable region of seq id no:1186; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Asp Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Gly Ile Pro Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Arg Gly Tyr Ser Gly Tyr Gly Ala Asn Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Glu Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 45 HC variable region , No. 45 LC variable region ,(1230/1229)  a) a light chain variable region of seq id no:1229; and b) a binding molecule comprising a heavy chain variable region of seq id no:1230; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu Ser Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Ala Glu Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ser Pro Ala Val Thr Thr Ala Gly Trp Phe Asp Pro Cys Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Lys Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Thr Ser Ser Thr Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 132 HC variable region , No. 132 LC variable region ,(1404/1403)  a) a light chain variable region of seq id no:1403; and b) a binding molecule comprising the heavy chain variable region of seq id no:1404; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Asp Ser Ile Thr Ile Ser Cys Thr Gly Thr Arg Gly Asp Ile Gly Ala Tyr Asp Gly Val Ser Trp Tyr Gln Gln Leu Pro Gly Lys Ala Pro Lys Leu Ile Ile Tyr Ala Val Thr Gln Arg Pro Ser Gly Ile Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Ser Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 134 HC variable region , No. 134 LC variable region ,(1408/1407)  a) a light chain variable region of seq id no:1407; and b) a binding molecule comprising a heavy chain variable region of seq id no:1408; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Val Thr Phe Ser Arg Tyr Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Leu Leu Gly Thr Ala Asp Tyr Pro Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Thr Asp Glu Ser Thr Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Leu Tyr Tyr Tyr Asp Arg Ser Gly Asn Ala Arg Thr Asp Asp Tyr Phe Asp His Trp Ala Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Pro Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 50 HC variable region , No. 50 LC variable region ,(1240/1239)  a) a light chain variable region of seq id no:1239; and b) a binding molecule comprising a heavy chain variable region of seq id no:1240; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Arg Gly Ser Gly Tyr Ser Phe Thr Ser His Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Ser Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Gly Pro Asn Leu Tyr Asn Trp Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Glu Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Pro Val Phe Gly Gly Thr Gln Leu Thr Val Leu , No. 172 HC variable region , No. 172 LC variable region ,(1484/1483)  a) a light chain variable region of seq id no:1483; and b) a binding molecule comprising a heavy chain variable region of seq id no:1484; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Thr Ser Gly Gly Thr Phe Ser Asn Tyr Pro Leu Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Gly Ile Ile Pro Ile Ile Gly Ala Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Phe Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Arg Gly Tyr Ser Gly Tyr Gly Ala Ala Tyr Tyr Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 189 HC variable region , No. 189 LC variable region ,(1518/1517)  a) a light chain variable region of seq id no:1517; and b) a binding molecule comprising a heavy chain variable region of seq id no:1518; and 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Ser Gly Ser Gly Gly Ser Thr Ser Asn Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Val Tyr Cys Gly Asp Asp Cys Tyr Pro Val Val Gly Thr Pro Gly Asp Ala Phe Asp Ile Trp Gly Gly Gly Thr Met Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Arg Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 181 HC variable region , No. 181 LC variable region ,(1502/1501)  a) a light chain variable region of seq id no:1501; and b) a binding molecule comprising the heavy chain variable region of seq id no:1502; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Ser Gly Ser Gly Gly Ser Thr Ser Asn Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Val Tyr Cys Gly Asp Asp Cys Tyr Pro Val Val Gly Thr Pro Gly Asp Ala Phe Asp Ile Trp Gly Gly Gly Thr Met Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 182 HC variable region , No. 182 LC variable region ,(1504/1503)  a) a light chain variable region of seq id no:1503; and b) a binding molecule comprising the heavy chain variable region of seq id no:1504; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Asp Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Ser Tyr Gly Thr Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Gly Tyr Asn Glu Asn Ser Thr His Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Thr Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ala Leu Arg Tyr Asp Ile Leu Thr Gly Phe Thr Gly Phe Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Val Gly Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Ser Gln Arg Pro Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Val Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Met Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 149 HC variable region , No. 149 LC variable region ,(1438/1437)  a) a light chain variable region of seq id no:1437; and b) a binding molecule comprising a heavy chain variable region of seq id no:1438; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Ser Ser Ser Ser Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ile Ala Leu Asn Asn Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 66 HC variable region , No. 66 LC variable region ,(1272/1271)  a) a light chain variable region of seq id no:1271; and b) a binding molecule comprising a heavy chain variable region of seq id no:1272; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr Ala Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 128 HC variable region , No. 128 LC variable region ,(1396/1395)  a) a light chain variable region of seq id no:1395; and b) a binding molecule comprising a heavy chain variable region of seq id no:1396; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Phe Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser His Lys Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Asn Cys Gly Gly Asp Cys Gly Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Asn Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln His His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Thr Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 137 HC variable region , No. 137 LC variable region ,(1414/1413)  a) a light chain variable region of seq id no:1413; and b) a binding molecule comprising the heavy chain variable region of seq id no:1414; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ile Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Met Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Thr Ser Arg Ser Thr Tyr Tyr Tyr Tyr Ser Gly Ser Tyr Tyr Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Asn Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Pro Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 69 HC variable region , No. 69 LC variable region ,(1278/1277)  a) a light chain variable region of seq id no:1277; and b) a binding molecule comprising a heavy chain variable region of seq id no:1278; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Gly Thr Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Val Ile Ser Tyr Asp Gly Phe Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Gly Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 92 HC variable region , No. 92 LC variable region ,(1324/1323)  a) a light chain variable region of seq id no:1323; and b) a binding molecule comprising the heavy chain variable region of seq id no:1324; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Glu Gly Tyr Asp Ser Ser Gly Tyr Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Arg Asn Trp Pro Pro Arg Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , No. 90 HC variable region , No. 90 LC variable region ,(1320/1319)  a) a light chain variable region of seq id no:1319; and b) a binding molecule comprising the heavy chain variable region of seq id no:1320; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Phe Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Phe Cys Ala Arg Gln Glu Trp Leu Arg Gly Gly Phe Asp Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 42 HC variable region , No. 42 LC variable region ,(1224/1223)  a) a light chain variable region of seq id no:1223; and b) a binding molecule comprising a heavy chain variable region of seq id no:1224; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Ala Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 165 HC variable region , No. 165 LC variable region ,(1470/1469)  a) a light chain variable region of seq id no:1469; and b) a binding molecule comprising a heavy chain variable region of seq id no:1470; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Gly Val Val Thr Ala Asp Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Ala Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Pro Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 49 HC variable region , No. 49 LC variable region ,(1238/1237)  a) a light chain variable region of seq id no:1237; and b) a binding molecule comprising a heavy chain variable region of seq id no:1238; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Met Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Pro Asp Asp Ser Ser Gly Tyr Tyr Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Thr Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Ser Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 70 HC variable region , No. 70 LC variable region ,(1280/1279)  a) a light chain variable region of seq id no:1279; and b) a binding molecule comprising a heavy chain variable region of seq id no:1280; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 13 HC variable region , No.13 LC variable region ,(1166/1165)  a) a light chain variable region of seq id no:1165; and b) a binding molecule comprising the heavy chain variable region of seq id no:1166; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser His Lys Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Asn Cys Gly Gly Asp Cys Gly Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Trp Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No. 74 HC variable region , No. 74 LC variable region ,(1288/1287)  a) a light chain variable region of seq id no:1287; and b) a binding molecule comprising a heavy chain variable region of seq id no:1288; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Gly Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Gln Val Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , No. 22 HC variable region , No. 22 LC variable region ,(1184/1183)  a) a light chain variable region of seq id no:1183; and b) a binding molecule comprising the heavy chain variable region of seq id no:1184; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser His Lys Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Asn Cys Gly Gly Asp Cys Gly Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Ser Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Trp Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No. 135 HC variable region , No. 135 LC variable region ,(1410/1409)  a) a light chain variable region of seq id no:1409; and b) a binding molecule comprising the heavy chain variable region of seq id no:1410; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Asp Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Gly Leu Tyr Gly Ser Gly Trp Ser Thr Tyr Gln Tyr Tyr Ala Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Gly Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 39 HC variable region , No. 39 LC variable region ,(1218/1217)  a) a light chain variable region of seq id no:1217; and b) a binding molecule comprising a heavy chain variable region of seq id no:1218; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Thr Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Thr Asp Asn Arg Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu , No. 17 HC variable region , No.17 LC variable region ,(1174/1173)  a) a light chain variable region of seq id no:1173; and b) a binding molecule comprising the heavy chain variable region of seq id no:1174; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Arg Tyr Tyr Ser Ser Trp Tyr Gly Pro Arg Thr Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , No. 41 HC variable region , No. 41 LC variable region ,(1222/1221)  a) a light chain variable region of seq id no:1221; and b) a binding molecule comprising a heavy chain variable region of seq id no:1222; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Gly Thr Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Val Ile Ser Tyr Asp Gly Phe Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 104 HC variable region , No. 104 LC variable region ,(1348/1347)  a) a light chain variable region of seq id no:1347; and b) a binding molecule comprising a heavy chain variable region of seq id no:1348; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Arg Ile Lys Thr Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asn Asp Ser Lys Asn Met Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Thr His Ser Arg Pro Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Leu Tyr Ala Ala Ser Arg Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , No. 8 HC variable region , No.8 LC variable region ,(1156/1155)  a) a light chain variable region of seq id no:1155; and b) a binding molecule comprising the heavy chain variable region of seq id no:1156; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Phe Ile Asn Pro Ser Asp Val Thr Thr Tyr Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Phe Cys Ala Arg Ser Arg Ile Ala Pro Thr Glu Asp Phe Phe Asp Tyr Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp His Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 190 HC variable region , No. 190 LC variable region ,(1520/1519)  a) a light chain variable region of seq id no:1519; and b) a binding molecule comprising the heavy chain variable region of seq id no:1520. 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu Ser Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Ala Glu Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ser Pro Ala Val Thr Thr Ala Gly Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln His His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu , No. 24 HC variable region , No. 24 LC variable region ,(1188/1187)  a) a light chain variable region of seq id no:1187; and b) a binding molecule comprising a heavy chain variable region of seq id no:1188; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Ser Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Lys Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , No. 93 HC variable region , No. 93 LC variable region ,(1326/1325)  a) a light chain variable region of seq id no:1325; and b) a binding molecule comprising the heavy chain variable region of seq id no:1326; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Thr Asn Thr Val Asn Trp Tyr Gln His Leu Pro Gly Met Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Leu Leu Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 25 HC variable region , No. 25 LC variable region ,(1190/1189)  a) a light chain variable region of seq id no:1189; and b) a binding molecule comprising the heavy chain variable region of seq id no:1190; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Thr Ser Gly Gly Thr Phe Ser Asn Tyr Pro Leu Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Gly Ile Ile Pro Ile Ile Gly Ala Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Phe Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Arg Gly Tyr Ser Gly Tyr Gly Ala Ala Tyr Tyr Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 34 HC variable region , No. 34 LC variable region ,(1208/1207)  a) a light chain variable region of seq id no:1207; and b) a binding molecule comprising a heavy chain variable region of seq id no:1208; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile Gly Asn Asn Phe Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Val Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Thr Ser Leu Ser Ser Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 102 HC variable region , No. 102 LC variable region ,(1344/1343)  a) a light chain variable region of seq id no:1343; and b) a binding molecule comprising a heavy chain variable region of seq id no:1344; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Glu Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ile Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , No. 96 HC variable region , No. 96 LC variable region ,(1332/1331)  a) a light chain variable region of seq id no:1331; and b) a binding molecule comprising a heavy chain variable region of seq id no:1332; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Ala Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Gly Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Thr Thr Trp Asn Ser Gly Thr Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Glu Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Ile Gly Ser Gly Asp Arg Pro Asp Ala Phe His Leu Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp Arg Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 61 HC variable region , No. 61 LC variable region ,(1262/1261)  a) a light chain variable region of seq id no:1261; and b) a binding molecule comprising the heavy chain variable region of seq id no:1262; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Thr Gly Tyr Asp Gly Ser Gly Tyr Tyr Gln Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Arg Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , No. 124 HC variable region , No. 124 LC variable region ,(1388/1387)  a) a light chain variable region of seq id no:1387; and b) a binding molecule comprising a heavy chain variable region of seq id no:1388; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Pro Glu Leu Ser Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asn Gly Glu Thr Ile His Ala Gln Arg Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ser Thr Pro Met Ile Arg Ala Ser Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Asn Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Asp Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Gly Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 154 HC variable region , No. 154 LC variable region ,(1448/1447)  a) a light chain variable region of seq id no:1447; and b) a binding molecule comprising the heavy chain variable region of seq id no:1448; 
https://patents.google.com/patent/KR20220013344A/en, Gln Ile Thr Leu Lys Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Gly Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ala Pro Ser Asp Leu Ser Phe Ile Trp Thr Gly Tyr Tyr Ser Glu Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Arg Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , No. 106 HC variable region , No. 106 LC variable region ,(1352/1351)  a) a light chain variable region of seq id no:1351; and b) a binding molecule comprising a heavy chain variable region of seq id no:1352; 
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Ser Ser Gly Arg Asn Lys Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Ser Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(278/334) [0163] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:278 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:334"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Ser Ser Phe Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Asp Ser Gly Asp Ala Thr Gln Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Pro Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu His Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(235/289) [0116] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:235 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:289"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Thr Ser Ala Val Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Gln Arg Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Tyr Ser Asp Gly Asp Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Ile Arg Ala Pro Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Leu Glu Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(256/311) [0138] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:256 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:311"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Arg Phe Asn Thr Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Ser Ser Gly Arg Asn Lys Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser His Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Leu Pro His Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(265/320) [0148] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:265 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:320"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Gln Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Tyr Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Ala Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(247/301) [0128] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:247 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:301"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Ser Tyr Ala Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Arg Asn Gly Tyr Asn Tyr Val Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Arg Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Arg Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(279/336) [0165] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:279 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:336"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Val Ser Ala Ser Gly Asp Arg Thr His Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Ala Ala Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(240/319) [0147] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:240 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:319"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Arg Ser Gly Asp Ser Ala Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Leu Gln Thr Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(267/322) [0150] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:267 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:322"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Phe Asn Asn Tyr Ala Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Gln Arg Asp Asn Pro Val Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Tyr Ser Asp Gly Asp Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Ile Arg Ala Pro Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(275/331) [0159] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:275 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:331"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Val Ser Ser Ser Gly Gly Ser Pro Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asp Asn Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Ser Gly Ser Tyr Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Thr His Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(242/296) [0123] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:242 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:296"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Val Ser Ala Ser Gly Asp Arg Thr His Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Arg Leu Ala Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Tyr Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Ser Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(240/294) [0121] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:240 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:294"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Ser Ser Gly Arg Asn Lys Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(241/295) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:241 and a vl having an amino acid sequence of seq id no:295
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Gly Ala Gly Gly Gly Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Thr Leu Gln Thr Pro Arg Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(238/292) [0119] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:238 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:292"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Thr Ile Ser Gly Asn Gly Val Ser Thr Ser Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser Asp Gly Tyr Thr Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Gln Val Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Ala Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(248/303) [0130] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:248 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:303"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Glu Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ile Gln Ala Leu Gln Thr Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(236/333) [0161] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:236 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:333"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Arg Phe Ser Asp His Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Thr Gly Ser Gly Arg Asn Lys Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Arg Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Thr Gln Ser Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(231/285) [0112] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:231 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:285"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Thr Asn Tyr Ala Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr His Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Val Leu Gln Thr Pro Phe Ser Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(246/300) [0127] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:246 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:300"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Thr Gly Asp Gly Arg Asn Lys Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Ala Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(268/323) [0151] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:268 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:323"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Asn Tyr Gln Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Ile Gln Asn Arg Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(245/299) [0126] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:245 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:299"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Arg Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Ala Asp Gly Gly Thr Ala Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Gln Ser Asn Gly Asp Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Leu His Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(261/315) [0143] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:261 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:315"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Val Ser Ala Ser Gly Gly Gly Pro Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Phe Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Thr Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Ala Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(264/318) [0146] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:264 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:318"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Ser Gly Gly Ser Gly Thr His Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Gln Gly Ser Asn Arg Asp Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(263/317) [0145] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:263 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:317"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Phe Ser Leu Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Thr Ser Asp Gly Arg Ser Lys Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Ser Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Leu Gln Ser Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(276/332) [0160] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:276 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:332"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Lys Phe Asn Thr Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Ile Thr Gly Gly Asn Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Ala Tyr Ser Phe Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(273/329) [0157] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:273 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:329"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Val Ser Ala Ser Gly Asp Arg Thr His Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Leu Gly Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(240/324) [0009] the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:240 and a vl having an amino acid sequence of seq id no:324
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser His Thr Ile Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu Ser His Ile Ser Ser Ser Gly Ser Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Gln Arg Asp Asn Ser Arg Asp Met Ser Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp Ser Asn Gly Phe Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Ser Arg Ala Pro Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Ser Tyr Asn Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(250/305) [0132] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:250 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:305"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Arg Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Ser Asp Gly Arg Asn Lys Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Phe Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Asp Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Arg Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(271/327) [0155] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:271 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:327"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Val Ser Thr Thr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asp Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Thr Leu His Thr Pro Gly Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(234/288) [0115] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:234 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:288"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Asp Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Gly Gly Ser Asn Gly Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(236/290) [0117] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:236 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:290"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Gly Ala Gly Gly Gly Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Tyr Ser Asp Gly Asp Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(229/283) [0110] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:229 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:283"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ser Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Arg Ile Asn Gly Asp Gly Ser Thr Thr Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Thr Gly Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Asp Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Ile Arg Ala Pro Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Ser Tyr Ile Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(251/306) [0133] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:251 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:306"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Val Ser Ala Ser Gly Asp Arg Thr His Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Tyr Thr Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Val Gly Ser Tyr Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Ser Gln Trp Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(240/302) . [0129] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:240 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:302 (covid19_p08_g"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp His Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Ala Ile Gly Ala Ser Gly Glu Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Gln Arg Asp Asn Ser Arg Asp Tyr Phe Pro Leu Trp Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Tyr Ser Asp Gly Asp Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Ile Arg Ala Pro Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ser Ile Gln Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(249/304) [0131] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:249 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:304"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Ile Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ser Gln Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(270/326) [0154] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:270 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:326"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Val Ser Trp Asn Gly Ser Arg Thr His Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Tyr Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Arg Thr Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(280/337) [0166] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:280 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:337"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Ala Ser Ser Ala Gly Ala Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Asn Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Gly Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Ser Tyr Thr Pro Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(252/307) [0134] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:252 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:307"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ser Asp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Gly Gly Gly Ala Gly Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Tyr Arg Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asp Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Ile Arg Ala Pro Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(259/309) [0141] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:259 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:309"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser His Asp Ala Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Met Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Thr Leu Gln Met Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(232/286) [0113] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:232 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:286"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Ala Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Val Ser Trp Asn Gly Ser Arg Thr His Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(228/282) [0109] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:228 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:282"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Thr Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Pro Lys Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(266/321) [0149] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:266 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:321"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Val Gly Asp Ser Gly Arg Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(237/291) the antibody or antigen-binding fragment of 1 or 5, that comprises a vh having an amino acid sequence of seq id no:237 and a vl having an amino acid sequence of seq id no:291"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Ala Ile Ser Gly Ser Gly Gly Ser Thr His Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ile Asn Gly Tyr Asn Tyr Leu Asp Trp Phe Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Asn Pro Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(253/308) [0135] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:253 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:308"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Val Ser Arg Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Gln Arg Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asp Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Ile Arg Ala Pro Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(254/309) [0136] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:254 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:309"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Gly Ser Gly Asp Arg Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ser Met Gln Arg Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Tyr Ser Asp Gly Asp Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Ile Arg Ala Pro Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ser Val Gln Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(258/313) [0140] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:258 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:313"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Val Ser Ala Ser Gly Gly Gly Pro Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Thr Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(272/328) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:272 and a vl having an amino acid sequence of seq id no:328
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Tyr Ser Gly Ser Gly Gly Tyr Thr Tyr Phe Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu His Ile Asn Gly Phe Asn Tyr Leu Asp Trp Phe Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Pro Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Ser Leu Gln Asn Pro Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(255/310) [0137] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:255 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:310"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Ser Ala Ser Gly Gly Asn Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Arg Ser Leu Leu His Thr Asn Gly Leu Asn Tyr Ile Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Thr Gln Ala Leu Gln Thr Pro Ile Ser Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(281/338) [0167] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:281 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:338"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Val His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser His Asp Gly Lys Lys Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Val Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Arg Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(260/314) [0142] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:260 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:314"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Ser Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Gly Ser Gly Gly Gly Ala Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Gln Ser Asn Gly Tyr Asn Tyr Met Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Thr Ser Asn Arg Ala Ala Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Ser Tyr Gly Pro Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(244/298) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:244 and a vl having an amino acid sequence of seq id no:298
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Asn Tyr Ala Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Val Ser Trp Asn Gly Ser Arg Thr His Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Leu Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Ser Ser Arg Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Val Gln Ala Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(243/297) [0124] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:243 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:297"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Asn Tyr Gly Met His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Asp Gly Ser Gly Gly Thr Ala His Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asp Arg Ala Pro Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Gly Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(262/335) [0164] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:262 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:335"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asn Asp Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Asn Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Leu Gln Thr Pro Gly Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(269/325) [0153] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:269 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:325"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Asn Tyr Gly Met His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Asp Gly Ser Gly Gly Thr Ala His Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Gln Gln Thr Pro Ile Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(262/316) [0144] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:262 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:316"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Asp Asn Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Leu Gly Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(277/324) [0162] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:277 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:324"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Ser Gly Ser Gly Arg Asn Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Pro Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Ala His Trp Pro Ile Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(230/284) [0111] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:230 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:284"
https://patents.google.com/patent/WO2021194985A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Gly Thr Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Asn Met Asp Asn Ser Arg Asp Tyr Phe Pro His Tyr Phe His Asp Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Ile Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Val Leu Arg Thr Pro Ile Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,"(233/287) [0114] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:233 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:287"
https://patents.google.com/patent/CN111690058A/en,Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Ala Thr Leu Met Asn Asn Lys Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , antibody P17-A11 VH sequence, antibody P17-A11 VL sequence,"(3/4)  a heavy chain variable region comprising the sequence of seq id no:3 or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto, and a light chain variable region comprising the sequence of seq id no:4 or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto."
https://patents.google.com/patent/CN111690058A/en,Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Tyr Ser Ser Ser Trp Leu Leu Gln Ser Phe Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,Asn Ile Gln Leu Thr Gln Ser Pro Val Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Leu Thr Cys Arg Ala Ser Gln Gly Ile Gly Tyr Ser Leu Val Trp Tyr Gln Lys Lys Pro Gly Thr Ala Pro Lys Leu Leu Ile Phe Asp Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Ser Ala Thr Tyr Tyr Cys Gln Gln Val Ile His Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys, antibody P16-A3 VH sequence, antibody P16-A3 VL sequence,"(1/2) (a) a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the sequence of seq id no:1 or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto, and the light chain variable region comprises the sequence of seq id no:2 or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto"
https://patents.google.com/patent/CN112979793B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/CN112979793B/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Arg Gly Pro Thr Gly Trp Thr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Asn Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ser Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Arg Ser Asn Trp Lys Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) the antibody of claim 1, wherein said antibody comprises the heavy chain variable region of seq id no:4 and the light chain variable region of seq id no:8."
https://patents.google.com/patent/WO2021170090A1/en, Gln Met Gln Leu Val Gln Ser Gly Thr Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Ile Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Leu Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  CR3022  ,  CR3022  ,"(6/7) in some embodiments, the heavy chain of the first antibody is shown in seq id no:6, and the light chain is shown in seq id no:7"
https://patents.google.com/patent/WO2021170090A1/en, Gln Met Gln Leu Val Gln Ser Gly Thr Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Ile Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Leu Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  CR3022  ,  CR3022˵ɱ  ,(6/5)  the sequence of the cr3022 antibody light chain variable region is shown in seq id no:5. the cr3022 antibody heavy chain sequence is shown in seq id no:6
https://patents.google.com/patent/WO2021170090A1/en, Gln Met Gln Leu Val Gln Ser Gly Thr Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Ile Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val , Asp Ile Gln Leu Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  CR3022ɱ  ,  CR3022˵ɱ  ,"(4/5) in some embodiments, the variable region of the antibody heavy chain is shown in seq id no:4, and the variable region of the antibody light chain is shown in seq id no:5."
https://patents.google.com/patent/CN112979790A/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/WO2021237534A1/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  人工序列(Artificial Sequence)  ,  人工序列(Artificial Sequence)  ,"(60/64)  furthermore, a monoclonal antibody or an antigen binding portion thereof in the combination comprises a heavy chain variable region shown in seq id no:60 and a light chain variable region shown in seq id no:64."
https://patents.google.com/patent/KR20220003405A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Gly Gly Gly Tyr Gly Gly Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Tyr Gly Gly Ser Ala Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Tyr Tyr Arg Tyr Asn Arg Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly , Heavy c hain variable region of R3 , light chain variable region of R3 ,"(23/24)  in one embodiment of the present invention, the heavy chain variable region of (b) comprises the amino acid sequence of seq id no:23, and the light chain variable region of (b) comprises the amino acid sequence of seq id no:24."
https://patents.google.com/patent/KR20220003405A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Ser Gly Tyr Tyr Tyr Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Tyr Ser Tyr Asp Tyr Ser Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Ser Ala Asn Asp Tyr Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly , Heavy chain variable region of R15 , light chain variable region of R15 ,"(71/72)  in one embodiment of the present invention, the heavy chain variable region of (e) includes the amino acid sequence of seq id no:71, and the light chain variable region of (e) includes the amino acid sequence of seq id no:72."
https://patents.google.com/patent/KR20220003405A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr Ser Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Ser Ser Tyr Tyr Tyr Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Tyr Gly Tyr Ser Gly Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Ser Pro Ala Tyr Tyr Tyr Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly , Heavy chain variable region of R1 , light chain variable region of R1 ,"(7/8)  in one embodiment of the present invention, the heavy chain variable region of (a) comprises the amino acid sequence of seq id no:7, and the light chain variable region of (a) comprises the amino acid sequence of seq id no:8."
https://patents.google.com/patent/KR20220003405A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Ser Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Ser Gly His Tyr Gly Tyr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Tyr Ser Tyr Ser Asn Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg A sn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Ser Gly Asn Tyr Arg Ser Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly , Heavy chain variable region of R17 , light chain variable region of R17 ,"(87/88)  in one embodiment of the present invention, the heavy chain variable region of (f) comprises the amino acid sequence of seq id no:87, and the light chain variable region of (f) comprises the amino acid sequence of seq id no:88."
https://patents.google.com/patent/KR20220003405A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Tyr Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Ser Ser Tyr Tyr Ser Tyr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Tyr Gly Gly Ser Tyr Pro Tyr Asp Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg As n Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Ala Pro Asp Tyr Ala Ser Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly , Heavy chain variable regi on of R9 , light chain variable region of R9 ,"(55/56)  in one embodiment of the present invention, the heavy chain variable region of (d) comprises the amino acid sequence of seq id no:55, and the light chain variable region of (d) comprises the amino acid sequence of seq id no:56."
https://patents.google.com/patent/CN112574299A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Val Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Val Ser Leu Ile Tyr Pro Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Ser Glu Lys Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial Sequence, Artificial Sequence,"(15/17)  vh comprises the amino acid sequence as set forth in seq id no:15, and vl comprises the amino acid sequence set forth in seq id no:17;"
https://patents.google.com/patent/CN112574299A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Val Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Val Ser Leu Ile Tyr Pro Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Ser Glu Lys Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Val Thr Leu Ser Cys Arg Thr Ser Gln Ser Val Ser Arg Phe Phe Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile His Thr Ala Ser Thr Arg Ala Thr Asp Ile Pro Asp Arg Phe Ser Ala Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Ser Ala Met Tyr Tyr Cys Gln His Tyr Gly Ala Ser Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys , Artificial Sequence, Artificial Sequence,"(23/25)  vh comprises the amino acid sequence as set forth in seq id no:23, and vl comprises the amino acid sequence set forth in seq id no:25;"
https://patents.google.com/patent/CN112574299A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Val Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Val Ser Leu Ile Tyr Pro Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Ser Glu Lys Gly Gly Met Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ser Val Leu Pro Leu Phe Pro Gly Glu Ser Gly Ser Leu Ser Cys Arg Ala Ser Gln Asn Val Gly Asp Phe Leu Ala Trp Tyr Gln His Lys Pro Gly Gln Ala Pro Lys Leu Leu Ile Tyr Gly Ala Thr Asn Arg Pro Thr Gly Ile Pro Asp Arg Phe Ser Gly Thr Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Met Glu Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Tyr Gly Thr Ser Pro Pro Ile Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Artificial Sequence, Artificial Sequence,"(19/21)  vh comprises the amino acid sequence as set forth in seq id no:19, and vl comprises the amino acid sequence set forth in seq id no:21;"
https://patents.google.com/patent/CN112574299A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Val Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Val Ser Leu Ile Tyr Pro Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Ser Glu Lys Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Gly Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys , Artificial Sequence, Artificial Sequence,"(27/29)  vh comprises the amino acid sequence as set forth in seq id no:27, and vl comprises the amino acid sequence set forth in seq id no:29;"
https://patents.google.com/patent/CN112574299A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Val Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Val Ser Leu Ile Tyr Pro Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Ser Glu Lys Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Arg Phe Gly Pro Gly Thr Lys Val Glu Ile Lys , Artificial Sequence, Artificial Sequence,"(31/33)  vh comprises the amino acid sequence as set forth in seq id no:31, and vl comprises the amino acid sequence set forth in seq id no:33;"
https://patents.google.com/patent/CN112574299A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Val Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Val Ser Leu Ile Tyr Pro Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Ser Glu Lys Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ala Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn His Ile Gly Ser Lys Ser Val Asn Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Val Leu Val Ile Tyr Ser Asp Ser Asp Arg Pro Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Asn Arg Ser Asp His Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , Artificial Sequence, Artificial Sequence,"(35/37)  vh comprises the amino acid sequence as set forth in seq id no:35, and vl comprises the amino acid sequence set forth in seq id no:37;"
https://patents.google.com/patent/CN111732655A/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Thr Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu His Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Asp Tyr Gly Asp Tyr Val Leu Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Thr Tyr Lys Phe Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Gly Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Cys Ser Tyr Ala Gly Ser Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,Homo sapiens,Homo sapiens,"(1/5) in a preferred embodiment, the amino acid sequence of the heavy chain variable region of the antibody is shown in seq id no:1, and the amino acid sequence of the light chain variable region is shown in seq id no:5."
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Asn Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Pro Thr Trp Phe Gly Glu Leu Pro Ser Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5343/5344)  a heavy chain comprising seq id no:5343 and a light chain comprising seq id no:5344; or (
https://patents.google.com/patent/WO2021183195A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Gly Asp Gln Leu Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5353/5354)  a heavy chain comprising seq id no:5353 and a light chain comprising seq id no:5354; or (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Leu Ser Gly Ser Tyr Arg Ser Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1267/1268)  a vh set forth as seq id no:1267 and a vl set forth as seq id no:1268; or (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Pro Asp Tyr Tyr Asp Phe Trp Ser Gly Tyr Phe Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5325/5326)  a heavy chain comprising seq id no:5325 and a light chain comprising seq id no:5326; or (
https://patents.google.com/patent/WO2021183195A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Pro Tyr Gly Gly Asn Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1121/1122)  the vh set forth as seq id no:1121 and the vl set forth as seq id no:1122; (
https://patents.google.com/patent/WO2021183195A1/en, Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ser Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr His Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Gly Leu Arg Val Val Ile Thr Phe Gly Gly Val Ile Pro Lys Gly Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(761/762)  a vh set forth as seq id no:761 and a vl set forth as seq id no:762; (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Tyr Tyr Glu Ala Arg His Tyr Tyr Tyr Tyr Tyr Ala Met Asp Val Trp Gly Gln Gly Thr Ala Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1255/1256)  (23) the vh set forth as seq id no:1255 and the vl set forth as seq id no:1256
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Tyr Ala Ala Thr Phe Gly Val Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ser Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Ala Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5361/5362)  a heavy chain comprising seq id no:5361 and a light chain comprising seq id no:5362; or (
https://patents.google.com/patent/WO2021183195A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gln Gly Gly Gly Gly Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5319/5320)  a heavy chain comprising seq id no:5319 and a light chain comprising seq id no:5320; or (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Pro Asp Tyr Tyr Asp Phe Trp Ser Gly Tyr Phe Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(891/892)  the vh set forth as seq id no:891 and the vl set forth as seq id no:892; (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Ser Ser Gly Gly Tyr Gln Gly Pro Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Leu Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(1269/1270)  the vh set forth as seq id no:1269 and the vl set forth as seq id no:1270. 9. an antibody selected from the group consisting of: (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Ser Gly Gly Ser Tyr Phe Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(727/728)  a vh set forth as seq id no:727 and a vl set forth as seq id no:728; (
https://patents.google.com/patent/WO2021183195A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly His Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Arg Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1225/1226)  the vh set forth as seq id no:1225 and the vl set forth as seq id no:1226; (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Ala Asp Thr Pro His Tyr Ser Gly Tyr Asp Phe Leu Ser Val Gly Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Phe Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ala Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5329/5330)  a heavy chain comprising seq id no:5329 and a light chain comprising seq id no:5330; or (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Val Gly Gly Tyr Ser Tyr Leu Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1071/1072)  a heavy chain variable region set forth as seq id no:1071 and a light chain variable region set forth as seq id no:1072; or (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Ser Ser Gly Gly Tyr Gln Gly Pro Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Leu Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Homo sapiens  ,  Homo sapiens  ,(5365/5366)  a heavy chain comprising seq id no:5365 and a light chain comprising seq id no:5366. 
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Tyr Tyr Glu Ala Arg His Tyr Tyr Tyr Tyr Tyr Ala Met Asp Val Trp Gly Gln Gly Thr Ala Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5363/5364)  a heavy chain comprising seq id no:5363 and a light chain comprising seq id no:5364; or (
https://patents.google.com/patent/WO2021183195A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Lys Ser Ser Gly Ser Gly Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1039/1040)  the vh set forth as seq id no:1039 and the vl set forth as seq id no:1040; (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr Ala Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Arg Gly Gly Tyr Arg Ser Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Asn Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(921/922)  the vh set forth as seq id no:921 and the vl set forth as seq id no:922; (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Pro Gly Arg Asp Phe Trp Ser Gly Tyr Tyr Phe Gly Ala Pro Asp Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Lys Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(973/974)  the vh set forth as seq id no:973 and the vl set forth as seq id no:974; (
https://patents.google.com/patent/WO2021183195A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Pro Tyr Gly Gly Asn Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5351/5352)  a heavy chain comprising seq id no:5351 and a light chain comprising seq id no:5352; or (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val His Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Ala Ala Ser Gly Tyr Thr Phe Asn Asn Tyr Gly Val Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Ala Ser Asn Gly Asn Thr Lys Tyr Ala Gln Asn Leu Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Gly Pro Thr Ala Pro Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Ala Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Ser Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ala Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Leu Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(725/726)  a heavy chain variable region set forth as seq id no:725 and a light chain variable region set forth as seq id no:726; or (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Ser Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Lys Gly Gly Ser Tyr Ser Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Gln Ser Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5337/5338)  a heavy chain comprising seq id no:5337 and a light chain comprising seq id no:5338; or (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr Ala Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Arg Gly Gly Tyr Arg Ser Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Asn Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5327/5328)  a heavy chain comprising seq id no:5327 and a light chain comprising seq id no:5328; or (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Trp Thr Gln Ser Ser Gly Tyr Asp Tyr Tyr Tyr Gly Leu Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Arg Ile Thr Cys Ser Gly Asp Ala Leu Pro Lys Gln Tyr Ala Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Val Val Ile Tyr Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Val Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Ala Asp Ser Ser Gly Thr Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(983/984)  the vh set forth as seq id no:983 and the vl set forth as seq id no:984; (
https://patents.google.com/patent/WO2021183195A1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Ser Pro Ser Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala His His Ser Leu Ser Ser Ile Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Asp Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Homo sapiens  ,  Homo sapiens  ,(5355/5356)  a heavy chain comprising seq id no:5355 and a light chain comprising seq id no:5356; or (
https://patents.google.com/patent/WO2021183195A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Gly Asp Gln Leu Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1133/1134)  the vh set forth as seq id no:1133 and the vl set forth as seq id no:1134; (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Thr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Ala Gly Tyr Gly Ser Ile Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Arg Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(661/662)  a heavy chain variable region set forth as seq id no:661 and a light chain variable region set forth as seq id no:662; or (
https://patents.google.com/patent/WO2021183195A1/en, Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Gly Asp Tyr Ala Met Ser Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Phe Ile Arg Ser Lys Ala Tyr Gly Gly Thr Thr Glu Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Phe Gly Ile Asp Tyr Asp Tyr Ile Trp Gly Ser Tyr Arg Tyr Thr Thr Leu Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys ,  Homo sapiens  ,  Homo sapiens  ,"(5322/5323) in some embodiments, provided herein is an antibody comprising a heavy chain comprising seq id no:5322 and a light chain comprising seq id no:5323"
https://patents.google.com/patent/WO2021183195A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Ser Ser Ser Ser Ser Thr Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gly Ala Arg Thr Pro Trp Asp Ile Val Val Val Pro Ala Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Arg Ser Pro Asn Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5345/5346)  a heavy chain comprising seq id no:5345 and a light chain comprising seq id no:5346; or (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Ser Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Lys Gly Gly Ser Tyr Ser Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Gln Ser Phe Gly Pro Gly Thr Lys Val Asp Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1029/1030)  the vh set forth as seq id no:1029 and the vl set forth as seq id no:1030; (
https://patents.google.com/patent/WO2021183195A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Ser Ser Ser Ser Ser Thr Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gly Ala Arg Thr Pro Trp Asp Ile Val Val Val Pro Ala Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Arg Ser Pro Asn Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1103/1104)  the vh set forth as seq id no:1103 and the vl set forth as seq id no:1104; (
https://patents.google.com/patent/WO2021183195A1/en, Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Ser Glu Lys Val Asp Phe Trp Ser Gly Gly Pro Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ile Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(1167/1168)  a vh set forth as seq id no:1167 and a vl set forth as seq id no:1168; (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Gly Ser Gly Asn Tyr Tyr Asn Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Thr Val Ser Ser Asn Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1123/1124)  a vh set forth as seq id no:1123 and a vl set forth as seq id no:1124; (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly Gly Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Thr Thr Met Val Arg Gly Val Ile Arg Leu Asp His Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Leu Phe Gly Thr Gly Thr Lys Val Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(867/868)  a vh set forth as seq id no:867 and a vl set forth as seq id no:868; (
https://patents.google.com/patent/WO2021183195A1/en, Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Pro Ile Met Ile Thr Phe Gly Gly Val Thr Gly His Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(979/980)  the vh set forth as seq id no:979 and the vl set forth as seq id no:980; (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Trp Thr Gln Ser Ser Gly Tyr Asp Tyr Tyr Tyr Gly Leu Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Arg Ile Thr Cys Ser Gly Asp Ala Leu Pro Lys Gln Tyr Ala Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Val Val Ile Tyr Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Val Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Ala Asp Ser Ser Gly Thr Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Homo sapiens  ,  Homo sapiens  ,(5335/5336)  a heavy chain comprising seq id no:5335 and a light chain comprising seq id no:5336; or (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Tyr Ser Gly Ser Tyr Gln Ser Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5321/5322)  a heavy chain comprising seq id no:5321 and a light chain comprising seq id no:5322; or (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Pro Glu Glu Lys Ser Ser Glu Ile Gly Glu Leu Val Gly Trp Gly Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Ser Ile Ile Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala Cys Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(1111/1112)  the vh set forth as seq id no:1111 and the vl set forth as seq id no:1112; (
https://patents.google.com/patent/WO2021183195A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly His Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Glu Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Arg Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5357/5358)  a heavy chain comprising seq id no:5357 and a light chain comprising seq id no:5358; or (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Thr Glu Val Gly Ala Thr Ser Glu Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Arg Ile Thr Cys Ser Gly Asp Ala Leu Pro Lys Gln Tyr Ala Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Val Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Ala Asp Ser Ser Gly Thr Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Homo sapiens  ,  Homo sapiens  ,(5339/5340)  a heavy chain comprising seq id no:5339 and a light chain comprising seq id no:5340; or (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Ser Pro Ala Ala Ala Gly Thr Ser Gln Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Thr Pro Leu Ser Ser Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Thr Gln Phe Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(779/780)  the vh set forth as seq id no:779 and the vl set forth as seq id no:780; (
https://patents.google.com/patent/WO2021183195A1/en, Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Pro Ile Met Ile Thr Phe Gly Gly Val Thr Gly His Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5333/5334)  a heavy chain comprising seq id no:5333 and a light chain comprising seq id no:5334; or (
https://patents.google.com/patent/WO2021183195A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Gly Asp Tyr Ala Met Ser Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Phe Ile Arg Ser Lys Ala Tyr Gly Gly Thr Thr Glu Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Phe Gly Ile Asp Tyr Asp Tyr Ile Trp Gly Ser Tyr Arg Tyr Thr Thr Leu Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(873/874)  the vh set forth as seq id no:873 and the vl set forth as seq id no:874; (
https://patents.google.com/patent/WO2021183195A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Pro Tyr Gly Gly Asn Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Gln Thr Ile Tyr Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Phe Leu Ile Tyr Ala Ala Ser Ser Phe Gln Asn Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5359/5360)  a heavy chain comprising seq id no:5359 and a light chain comprising seq id no:5360; or (
https://patents.google.com/patent/WO2021183195A1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Ser Pro Ser Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala His His Ser Leu Ser Ser Ile Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Asp Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(1157/1158)  the vh set forth as seq id no:1157 and the vl set forth as seq id no:1158; (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Ala Asp Thr Pro His Tyr Ser Gly Tyr Asp Phe Leu Ser Val Gly Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Phe Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ala Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(961/962)  the vh set forth as seq id no:961 and the vl set forth as seq id no:962; (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Thr Glu Val Gly Ala Thr Ser Glu Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Arg Ile Thr Cys Ser Gly Asp Ala Leu Pro Lys Gln Tyr Ala Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Val Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Ala Asp Ser Ser Gly Thr Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(1035/1036)  the vh set forth as seq id no:1035 and the vl set forth as seq id no:1036; (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Tyr Ser Gly Ser Tyr Gln Ser Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(763/764)  the vh set forth as seq id no:763 and the vl set forth as seq id no:764; (
https://patents.google.com/patent/WO2021183195A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Pro Ala Gly Ile Val Val Gly Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Phe Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr His Ser Ser Asn Pro His Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens  ,  Homo sapiens  ,(1143/1144)  the vh set forth as seq id no:1143 and the vl set forth as seq id no:1144; (x
https://patents.google.com/patent/WO2021183195A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Lys Ser Ser Gly Ser Gly Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5341/5342)  a heavy chain comprising seq id no:5341 and a light chain comprising seq id no:5342; or (
https://patents.google.com/patent/WO2021183195A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gln Gly Gly Gly Gly Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(729/730)  the vh set forth as seq id no:729 and the vl set forth as seq id no:730; (
https://patents.google.com/patent/WO2021183195A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Val Ala Gly Thr Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Gly Gly Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1107/1108)  the vh set forth as seq id no:1107 and the vl set forth as seq id no:1108; (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Asn Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Pro Thr Trp Phe Gly Glu Leu Pro Ser Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1069/1070)  the vh set forth as seq id no:1069 and the vl set forth as seq id no:1070; (
https://patents.google.com/patent/WO2021183195A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Pro Tyr Gly Gly Asn Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Gln Thr Ile Tyr Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Phe Leu Ile Tyr Ala Ala Ser Ser Phe Gln Asn Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1243/1244)  the vh set forth as seq id no:1243 and the vl set forth as seq id no:1244; (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Pro Glu Glu Lys Ser Ser Glu Ile Gly Glu Leu Val Gly Trp Gly Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Ser Ile Ile Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala Cys Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  Homo sapiens  ,  Homo sapiens  ,(5349/5350)  (q) a heavy chain comprising seq id no:5349 and a light chain comprising seq id no:5350
https://patents.google.com/patent/WO2021183195A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Gly Asp Tyr Ala Met Ser Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Phe Ile Arg Ser Lys Ala Tyr Gly Gly Thr Thr Glu Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Phe Gly Ile Asp Tyr Asp Tyr Ile Trp Gly Ser Tyr Arg Tyr Thr Thr Leu Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5323/5324)  a heavy chain comprising seq id no:5323 and a light chain comprising seq id no:5324; or (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Tyr Ala Ala Thr Phe Gly Val Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ser Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Ala Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys ,  Homo sapiens  ,  Homo sapiens  ,(1251/1252)  the vh set forth as seq id no:1251 and the vl set forth as seq id no:1252; (
https://patents.google.com/patent/WO2021183195A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Pro Gly Arg Asp Phe Trp Ser Gly Tyr Tyr Phe Gly Ala Pro Asp Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Lys Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5331/5332)  a heavy chain comprising seq id no:5331 and a light chain comprising seq id no:5332; or (
https://patents.google.com/patent/WO2021183195A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Val Ala Gly Thr Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Gly Gly Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens  ,  Homo sapiens  ,(5347/5348)  a heavy chain comprising seq id no:5347 and a light chain comprising seq id no:5348; (
https://patents.google.com/patent/CN112062839A/en, Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro Arg Gly Ser His Met Ala Ser Met Ser Asp Ser Glu Val Asn Gln Glu Ala Lys Pro Glu Val Lys Pro Glu Val Lys Pro Glu Thr His Ile Asn Leu Lys Val Ser Asp Gly Ser Ser Glu Ile Phe Phe Lys Ile Lys Lys Thr Thr Pro Leu Arg Arg Leu Met Glu Ala Phe Ala Lys Arg Gln Gly Lys Glu Met Asp Ser Leu Arg Phe Leu Tyr Asp Gly Ile Arg Ile Gln Ala Asp Gln Thr Pro Glu Asp Leu Asp Met Glu Asp Asn Asp Ile Ile Glu Ala His Arg Glu Gln Ile Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Asn Ser Arg Tyr Tyr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Ala Ile Gly Arg Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Asp Ser Ser Leu Ala Gly Leu Arg Gly Arg Leu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Ala Ala Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Gly Ser,, Artificial Sequence (Artificial Sequence),,"(2) a nanobody based on the s protein s1 subunit of a novel coronavirus, which is characterized in that: the amino acid sequence of the expression cassette sequence of the nano antibody is shown in seq id no:2."
https://patents.google.com/patent/CN112062839A/en, atgggcagca gccatcatca tcatcatcac agcagcggcc tggtgccgcg cggcagccat atggctagca tgtcggactc agaagtcaat caagaagcta agccagaggt caagccagaa gtcaagcctg agactcacat caatttaaag gtgtccgatg gatcttcaga gatcttcttc aagatcaaaa agaccactcc tttaagaagg ctgatggaag cgttcgctaa aagacagggt aaggaaatgg actccttaag attcttgtac gacggtatta gaatccaagc tgatcagacc cctgaagatt tggacatgga ggataacgat attattgagg ctcacagaga acagattggt ggatcccagg tgcagctgca ggagtctgga ggaggcttgg tgcaggctgg agggtctctg agactctctt gtgccgccag cggatacacc aacagtcgct actacatggg ctggttccgc caggctccag ggaaggagcg tgagttcgta gcagcgattt ctgctattgg tcgcacatac tatgcagact ccgtgaaggg ccgattcacc atctccagag acaacgccaa gaacacggtg tatcttcaaa tgaacagcct gaaacctgag gacacggccg tttattactg tgcagccgac tcttctctgg ctggtctgcg tggtcgtctg tacgactact ggggtcaggg tactcaggtc accgtctcct cagcggccgc atacccgtac gacgttccgg actacggttc ctgactcgag ,, Artificial Sequence (Artificial Sequence),,"(1) the nanobody of claim 1, based on the s1 subunit of the s protein of a novel coronavirus, characterized in that: the nucleotide sequence of the expression cassette sequence of the nano antibody is shown in seq id no:1."
https://patents.google.com/patent/CN113045647A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Tyr Ser Ser Tyr Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Ser Ile Ser Pro Ser Tyr Ser Tyr Thr Ser Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Tyr Ser Tyr Tyr Gly Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Val Ser Ser Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Ser Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Pro Pro Trp His Gly Leu Ile Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(18/22) in some embodiments, the antibody is a fab, wherein the vl amino acid sequence of the fab is set forth in seq id no:22, and the vh amino acid sequence of the fab is set forth in seq id no:18."
https://patents.google.com/patent/CN112979794A/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/CN112979794A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Ser Gly Ser Tyr Tyr Trp Gly Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Asn Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) preferably, the antibody comprises the heavy chain variable region shown in seq id no:4 and the light chain variable region shown in seq id no:8."
https://patents.google.com/patent/CN114106164A/en, Val Lys Leu Gln Glu Ser Gly Ala Glu Leu Val Arg Pro Gly Thr Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr Leu Ile Glu Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Val Ile Asn Pro Gly Ser Gly Gly Thr Asn Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Phe Cys Ala Arg Gly Arg Ala Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser, Asp Ile Leu Met Thr Gln Ser Pro Ser Ser Met Ser Val Ser Leu Gly Asp Thr Val Ser Ile Thr Cys His Ala Ser Gln Gly Phe Ser Ser Asn Ile Gly Trp Leu Gln Gln Lys Pro Gly Lys Ser Phe Lys Gly Leu Ile Tyr His Gly Thr Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Ala Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser Glu Asp Phe Ala Asp Tyr Tyr Cys Val Gln Tyr Ala Gln Phe Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(7/8) the amino acid sequence of the heavy chain variable region is shown as seq id no:7, and the amino acid sequence of the light chain variable region is shown as seq id no:8."
https://patents.google.com/patent/CN113999301A/en, Met Tyr Leu Gly Leu Asn Tyr Val Phe Ile Val Phe Leu Leu Asn Gly Val Gln Ser Glu Val Lys Phe Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Pro Tyr Asp Tyr Ala Tyr Pro Trp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Met Gln Ile Ile Ser Leu Leu Leu Ile Ser Val Thr Val Ile Val Ser Asn Gly Glu Ile Val Leu Thr Gln Ser Pro Thr Thr Met Ala Ala Ser Pro Gly Glu Lys Ile Thr Ile Thr Cys Ser Ala Ser Ser Ser Ile Ser Ser His Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Phe Ser Pro Lys Leu Leu Ile Tyr Arg Ser Tyr Ser Leu Ala Ser Gly Phe Pro Gly Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Phe Ser Leu Ser Ile Gly Thr Met Glu Ala Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Gly Ser Ser Arg Ile Thr Pro Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , mouse (Mus musculus), mouse (Mus musculus),(7/8) seq id no:7 and seq id no:8 are the amino acid sequences of the heavy chain variable region and the light chain variable region of the anti-sars-cov-2 (covid-
https://patents.google.com/patent/KR102007161B1/en, Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Glu Asp Thr Phe Arg Arg Phe Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Ala Phe Phe Gly Ser Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Val Tyr Met Glu Leu Gly Ser Leu Arg Phe Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Gly Phe Gly Val Val Thr Pro Pro Asn Ile Tyr Ser Tyr Gly Leu Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser, Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Thr Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Thr Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Gly Ser Ser Pro Gln Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys arg , MERS-CoV Spike S1 KNIH-95, Mers-cov spike S1 KNIH-95,(49/56)  and  an antibody comprising a heavy chain variable region having the amino acid sequence represented by seq id no:49 and a light chain variable region having the amino acid sequence represented by seq id no:56  an antibody or antigen-binding fragment thereof selected from the group consisting of:  
https://patents.google.com/patent/KR102007161B1/en, Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Thr Ser Val Lys Val Ser Cys Arg Ala Ser Gly Gly Thr Val Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Leu Phe Gly Thr Val Asn Tyr Thr Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Ala Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Thr Ser Gly Trp Tyr Gly Gly Arg Asn Trp Leu Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Asp Ile Val Met Thr Gln Ser Pro Phe Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ala Ile Tyr Asn Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Leu Tyr Gly Ala Ser Gly Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr His Ser Thr Pro Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg , MERS-CoV Spike S1 KNIH-90, Mers-cov spike S1 KNIH-90,(48/55)   an antibody comprising a heavy chain variable region having an amino acid sequence represented by seq id no:48 and a light chain variable region having an amino acid sequence represented by seq id no:55
https://patents.google.com/patent/KR102007161B1/en, Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ala Phe Asn Thr Tyr Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Leu Phe Arg Ser Ser Ser Tyr Ala Gln Arg Phe Gln Gly Arg Val Thr Phe Thr Ala Asp Glu Ser Thr Asn Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Arg Gly Asp Gly Ser Gly Arg Leu Gly Tyr Ile His Tyr Asp Thr Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser, Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Gln Pro Val Leu Thr Gln Leu Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Gly Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Ala Gly Ala Ala Pro Lys Leu Leu Ile Tyr Lys Asn Asn Glu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Asp Asp Glu Gly Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Leu , MERS-CoV Spike S1 KNIH-68, MERS-CoV Spike S1 KNIH-68,(44/51)   an antibody comprising a heavy chain variable region having an amino acid sequence represented by seq id no:44 and a light chain variable region having an amino acid sequence represented by seq id no:51
https://patents.google.com/patent/KR102007161B1/en, Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Met Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Ser Gly Ile Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Phe Phe Gly Thr Thr Thr Tyr Ala Gln Arg Phe Gln Gly Arg Phe Thr Ile Thr Ala Asp Lys Ser Thr Asn Thr Ala Tyr Met Glu Leu Asn Asn Leu Arg Phe Glu Asp Thr Ala Ile Tyr Phe Cys Ala Arg Asp Gly Gly Ile Pro Ser Ala Arg Leu Asn Asn His Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser, Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Cys Thr Ile Cys Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Ser Gly Ala Ser Ser Arg Ala Ala Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ile Ile Asp Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Gly Ser Ala Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg , MERS-CoV Spike S1 KNIH-78, Mers-cov spike S1 KNIH-78,(46/53)   an antibody comprising a heavy chain variable region having an amino acid sequence represented by seq id no:46 and a light chain variable region having an amino acid sequence represented by seq id no:53
https://patents.google.com/patent/KR102007161B1/en, Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ile Asp Tyr Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ala Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Tyr Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Asp Tyr Leu Ala Ala Gly Gly Leu Trp Gly Gln Gly Ala Leu Val Thr Val Ser Ser , Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Val Pro Glu Leu Leu Ile Tyr Gly Ala Ser Asn Leu Lys Pro Gly Val Pro Ser Arg Phe Ser Gly Ser Ala Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Met Gln Pro Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asp Ser Ala Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg , MERS-CoV Spike S1 KNIH-88, Mers-cov spike S1 KNIH-88,(47/54)   an antibody comprising a heavy chain variable region having an amino acid sequence represented by seq id no:47 and a light chain variable region having an amino acid sequence represented by seq id no:54
https://patents.google.com/patent/KR102007161B1/en, Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Phe Ser Thr Tyr Glu Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Leu Gly Trp Met Asn Pro Lys Ser Gly Ile Thr Gly Tyr Ala Pro Lys Phe Gln Gly Arg Val Thr Met Thr Gly Asn Thr Ser Ile Asn Thr Thr Tyr Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Phe Leu Gly Ala Asp Tyr Tyr Gly Leu Asp Val Trp Gly Gln Gly Thr Thr Val Thr Arg Leu Leu Gln Leu , Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Glu Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Arg Val Ile Ser Thr Tyr Leu Asn Trp Tyr Gln Gln Ser Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Arg Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Gly Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Asn Thr Pro Gln Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg , MERS-CoV Spike S1 KNIH-72, MERS-CoV Spike S1 KNIH-72,(45/52)   an antibody comprising a heavy chain variable region having an amino acid sequence represented by seq id no:45 and a light chain variable region having an amino acid sequence represented by seq id no:52
https://patents.google.com/patent/KR102007161B1/en, Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Leu Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Lys Ile Ser Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val Gly Gly Ile Ile Pro Ile Phe Gly Thr Pro His Tyr Ala Gln Lys Leu Gln Gly Arg Val Thr Ile Thr Ala Asp Asp Ser Thr Ala Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Asp Leu Gly Gly Thr Thr Gly Phe Trp Gln Leu Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Ser Tyr Glu Leu Thr Gln Pro Leu Ser Val Ser Val Ala Leu Gly Gln Thr Ala Thr Leu Thr Cys Gly Gly Asp Asn Ile Gly Ser Lys Asn Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Ile Asn Asp Asn Arg Pro Ser Ala Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Arg Arg Ala Gln Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Leu Trp Asp Gly Ser Thr Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu Leu , MERS-CoV Spike S1 KNIH-58, MERS-CoV Spike S1 KNIH-58,(43/50)  an antibody comprising a heavy chain variable region having an amino acid sequence represented by seq id no:43 and a light chain variable region having an amino acid sequence represented by seq id no:50
https://patents.google.com/patent/US11028167B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu AsnGlu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysThr Arg Glu Gly Ile Pro Trp Trp Leu Arg Thr Leu Asp Tyr Trp GlyGln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Thr Thr Pro GluTrp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,154121PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 154,178109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 178,"(154/178) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:154 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:178."
https://patents.google.com/patent/US11028167B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu AsnGlu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Val Ile Asn Pro Ser Gly Gly Tyr Thr Ser Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysThr Arg Glu Gly Ile Pro Gln Leu Leu Arg His Leu Asp Tyr Trp GlyGln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Gly TyrLeu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Trp Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro LeuThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,161121PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 161,185108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 185,"(161/185) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:161 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:185."
https://patents.google.com/patent/US11028167B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu AsnGlu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asn Thr Ser Gly Gly Tyr Thr Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysThr Arg Glu Gly Ile Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp GlyGln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser TrpLeu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Asn Pro TyrThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,160121PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 160,184108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 184,"(160/184) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:160 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:184."
https://patents.google.com/patent/US11028167B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Gly Asn TyrAla Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ala Ile Tyr Pro Gly Asn Ser Asp Thr Thr Tyr Asn Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysAla Arg Asp Thr Val Met Gly Gly Met Asp Val Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Glu Ile Ser Gly TyrLeu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Val Ser Tyr Pro TrpThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,153118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 153,177108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 177,"(153/177) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:153 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:177."
https://patents.google.com/patent/US11028167B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser TyrTyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asn Pro Arg Gly Gly Ser Thr Ser Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysThr Arg Glu Ala Lys Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp GlyGln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Asp Thr TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Asn Ser Leu Gln ProGlu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro LeuThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,208121PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 208,209108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 209,"(208/209) a vh having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to seq id no:208 and a vl having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to seq id no:209"
https://patents.google.com/patent/US11028167B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser TyrGlu Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asn Pro Ser Gly Gly Tyr Thr Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysThr Arg Glu Gly Ile Pro Gln Val Leu Arg Thr Leu Asp Tyr Trp GlyGln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser TrpLeu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Asn Pro TyrThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,162121PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 162,186108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 186,"(162/186) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:162 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:186."
https://patents.google.com/patent/US11028167B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu AsnGlu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Met Ile Asn Pro Ser Gly Gly Tyr Thr Asn Tyr Ala Gln Glu PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysThr Arg Glu Gly Ile Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp GlyGln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Tyr Arg TrpLeu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Gly Asn Pro TyrThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,159121PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 159,183108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 183,"(159/183) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:159 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:183."
https://patents.google.com/patent/US11028167B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser TyrSer Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ala Ile Tyr Pro Gly Asn Ser Asp Thr Thr Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysThr Leu Asp Gly Ile Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp GlyGln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Gly Val Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr Val Ser Tyr Pro TrpThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,155121PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 155,179108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 179,"(155/179) an antibody or an antigen-binding fragment that selectively binds to a sars-cov-2, that comprises a vh chain having an amino acid sequence of seq id no:155 and a vl chain having an amino acid sequence of seq id no:179."
https://patents.google.com/patent/US11028167B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Asp TyrTyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asp Pro Ser Gly Gly Ser Ala Ser Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysThr Arg Glu Gly Ile Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp GlyGln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Val Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Leu AlaVal Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,163121PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 163,187109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 187,"(163/187) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:163 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:187."
https://patents.google.com/patent/US11028167B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ala Ser TyrAsp Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asn Pro Arg Ser Gly Asp Ala Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysThr Arg Glu Arg His Pro Gln Leu Leu Met Pro Leu Asp Tyr Trp GlyGln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Arg Leu Glu Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro ArgThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,156121PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 156,180108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 180,"(156/180) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:156 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:180."
https://patents.google.com/patent/US11028167B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu AsnGlu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asn Pro Asp Gly Gly Ser Thr Ser Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysThr Arg Glu Gly Ile Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp GlyGln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Arg TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro GlnTyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,158121PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 158,182109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 182,"(158/182) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:158 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:182."
https://patents.google.com/patent/US11028167B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Arg Phe Thr Ser TyrGlu Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysThr Arg Glu Gly Ile Pro Gln Leu Leu Trp Ala Leu Asp Tyr Trp GlyGln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro LeuThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,152121PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 152,176108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 176,"(152/176) in one instance, an antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:152 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:176."
https://patents.google.com/patent/US11028167B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu AsnGlu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asn Pro Asn Gly Gly Gly Thr Tyr Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysThr Arg Glu Gly Ile Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp GlyGln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn AspLeu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Ser Ala Pro TyrThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,168121PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 168,192108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 192,"(168/192) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:168 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:192."
https://patents.google.com/patent/US11028167B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Asp Ile Trp Arg Leu HisTrp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp MetAsn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe Gln Gly ArgVal Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu LeuSer Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg GluGly Ile Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp Gly Gln Gly ThrLeu Val Thr Val Ser Ser ,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Glu Ile Ser Ser TyrLeu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Ser Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro LeuThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,149118PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 149,173108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 173,"(149/173) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:149 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:173."
https://patents.google.com/patent/US11028167B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Asn Thr Phe Thr Gly TyrTyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ala Ile Tyr Pro Gly Gly Ser Asp Thr Ser Tyr Asn Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysThr Arg Glu Gly Ile Pro Gln Leu Ala Trp Thr Leu Asp Tyr Trp GlyGln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Met Ser Ser TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Phe Gly Ser Phe Gly GlyGly Thr Lys Val Glu Ile Lys Arg ,148121PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 148,172104PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 172,"(148/172) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:148 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:172."
https://patents.google.com/patent/US11028167B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu AsnGlu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asn Pro Ser Ala Gly Ser Thr Ser Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysThr Arg Glu Gly Ile Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp GlyGln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro SerTyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,150121PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 150,174109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 174,"(150/174) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:150 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:174."
https://patents.google.com/patent/US11028167B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu TyrGlu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asn Pro Ser Gly Gly Tyr Thr Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysThr Arg Glu Gly Ile Pro Gln Val Leu Arg Thr Leu Asp Tyr Trp GlyGln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser TrpLeu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Asn Pro TyrThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,165121PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 165,189108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 189,"(165/189) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:165 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:189."
https://patents.google.com/patent/US11028167B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Asp Phe Ile Asn TyrTyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asp Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysThr Arg Glu Gly Ile Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp GlyGln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asp SerLeu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Arg Leu AlaTrp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,157121PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 157,181109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 181,"(157/181) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:157 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:181."
https://patents.google.com/patent/US11028167B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser TyrGlu Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Val Ile Asn Pro Ser Gly Gly His Thr Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysThr Arg Glu Gly Ile Pro Gln Leu Ala Gly Thr Leu Asp Tyr Trp GlyGln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Gly TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Thr Thr Pro ArgThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,145121PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 145,169108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 169,"(145/169) in further embodiments, the 3bgf-derived antibody or antigen-binding fragment comprises a vl having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to any one of seq id no:169-192, and a vh having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to any one of seq id no:145-168"
https://patents.google.com/patent/US11028167B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser TyrAsp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Met Val Asp Pro Asn Ser Gly Asn Thr Tyr Tyr Ala Gln Lys PheGln Gly Arg Phe Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysThr Arg Glu Gly Ile Pro Gln Leu Leu Gly Thr Leu Asp Tyr Trp GlyGln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Thr Thr Pro ArgThr Phe Gly Gly Gly Thr Lys Gly Gly Asp Gln Thr,164121PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 164,188108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 188,"(164/188) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:164 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:188."
https://patents.google.com/patent/US11028167B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu AsnGlu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysThr Arg Glu Gly Pro Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp GlyGln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr His Thr Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Phe Pro AlaThr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,166121PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 166,190109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 190,"(166/190) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:166 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:190."
https://patents.google.com/patent/US11028167B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu AsnGlu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysThr Arg Glu Gly Ile Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp GlyGln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Arg Thr TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro SerTyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,151121PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 151,175109PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 175,"(151/175) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:151 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:175."
https://patents.google.com/patent/US11028167B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser HisAsp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Met Ile Asn Pro Ser Gly Gly Tyr Thr Ser Tyr Ala Gln Asn PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysThr Arg Glu Gly Ile Pro Ala Leu Leu Arg Thr Leu Asp Tyr Trp GlyGln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn AspLeu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Thr Thr Pro TyrThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,146121PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 146,170108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 170,"(146/170) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:146 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:170."
https://patents.google.com/patent/US11028167B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu AsnGlu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Val Val Asn Pro Ser Gly Gly Tyr Thr Ser Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysThr Arg Glu Gly Ile Pro Gln Leu Leu Arg Ser Gln Asp Tyr Trp GlyGln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser TyrLeu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro LeuThr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,147121PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 147,171108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 171,"(147/171) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:147 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:171."
https://patents.google.com/patent/US11028167B1/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly AlaSer Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu AsnGlu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp MetGly Ile Ile Asn Thr Ser Gly Gly Tyr Thr Asn Tyr Ala Gln Lys PheGln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val TyrMet Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr CysThr Arg Glu Gly Ile Pro Gln Leu Leu Arg Thr Leu Asp Tyr Trp GlyGln Gly Thr Leu Val Thr Val Ser Ser,Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val GlyAsp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser TrpLeu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu IleTyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser GlySer Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln ProGlu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Asn Pro LeuHis Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg,167121PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 167,191108PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 191,"(167/191) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:167 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:191."
https://patents.google.com/patent/US8106170B2/en,Met Ala Gln Met Gln Leu Val Gln Ser Gly Thr Glu Val Lys Lys ProGly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Gly Phe IleThr Tyr Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu GluTrp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser ProSer Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Asn ThrAla Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Ile TyrTyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp GlyGln Gly Thr Thr Val Thr Val Ser Ser,Asp Ile Gln Leu Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu GlyGlu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr SerSer Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly GlnPro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly ValPro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu ThrIle Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln GlnTyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu IleLys Arg Ala Ala ,63Gln Gly Thr Thr Val Thr Val Ser Ser 115 1206121PRTArtificial sequenceVariable heavy chain of SC03-022 6,100 105 110aaa cgt gcg gcc 348Lys Arg Ala Ala 11510116PRTArtificial sequenceVariable light chain of SC03-022 10,"(6/10) 9. a powder composition for reconstitution, the composition comprising two immunoglobulin molecules that are capable of specifically binding to s protein of sars-cov, wherein the immunoglobulin molecule comprising a heavy chain variable region comprising the amino acid sequence of seq id no:6 and a light chain variable region comprising the amino acid sequence of seq id no:10"
https://patents.google.com/patent/US8106170B2/en,Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln ProGly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe SerAsp His Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu GluTrp Val Gly Arg Thr Arg Asn Lys Ala Asn Ser Tyr Thr Thr Glu TyrAla Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser LysAsn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr AlaVal Tyr Tyr Cys Ala Arg Gly Ile Ser Pro Phe Tyr Phe Asp Tyr TrpGly Gln Gly Thr Leu Val Thr Val Ser Ser,Glu Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp ArgVal Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu AsnTrp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr AlaAla Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser GlySer Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu AspPhe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro Thr PheGly Gln Gly Thr Lys Val Glu Ile Lys Arg,4122PRTArtificial sequenceVariable heavy chain of SC03-014 4,85 90 95ggc caa ggg acc aag gtg gag atc aaa cgt 318Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 100 1058106PRTArtificial sequenceVariable light chain of SC03-014 8,"(4/8)  and the second immunoglobulin molecule comprising a heavy chain variable region comprising the amino acid sequence of seq id no:4, and a light chain variable region comprising the amino acid sequence of seq id no:8."
https://patents.google.com/patent/WO2021226560A1/en, Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Thr Ser Val Arg Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Ser Ser Ala Val Gln Trp Val Arg Gln Ala Arg Gly Gln Arg Leu Glu Trp Val Gly Trp Ile Val Val Gly Ser Gly Asn Thr Asn Tyr Ala Gln Lys Phe His Glu Arg Val Thr Ile Thr Arg Asp Met Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Pro Tyr Cys Ser Gly Gly Ser Cys Ser Asp Gly Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Thr Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Val Gly Leu Thr Gly Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Synthetic sequence SARS-CoV-2 S2E12-v1 mAb VH  , Synthetic sequence Antibody 409_11_4_v4 VL(VK)  ,"(399/746) , wherein the vh comprises or consists of the amino acid sequence set forth in any one of seq id no:399, 748, 749, 750, 752, 754, 756, 758, 759, and 761, the vl comprises or consists of the amino acid sequence set forth in seq id no:746, wherein the antibody or antigen-binding fragment is capable of binding to a surface glycoprotein of sars-cov-2 expressed on a cell surface of a host cell and/or on a virion. "
https://patents.google.com/patent/WO2021226560A1/en, Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Thr Ser Val Arg Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Ser Ser Ala Val Gln Trp Val Arg Gln Ala Arg Gly Gln Arg Leu Glu Trp Val Gly Trp Ile Val Val Gly Ser Gly Asn Thr Asn Tyr Ala Gln Lys Phe His Glu Arg Val Thr Ile Thr Arg Asp Met Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Pro Tyr Cys Ser Gly Gly Ser Cys Ser Asp Gly Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Thr Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Ala Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Val Gly Leu Thr Gly Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Synthetic sequence SARS-CoV-2 S2E12-v1 mAb VH  , Synthetic sequence Antibody 409_11_4_v2 VL(VK)  ,"(399/738) , wherein the vh comprises or consists of the amino acid sequence set forth in seq id no:399 and the vl comprises or consists of the amino acid sequence set forth in seq id no:738, wherein the antibody or antigen-binding fragment is capable of binding to a surface glycoprotein of sars-cov-2 expressed on a cell surface of a host cell and/or on a virion. "
https://patents.google.com/patent/WO2021226560A1/en, Asp Ile Val Leu Thr Gln Thr Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Ala Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Val Gly Leu Thr Gly Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Thr Ser Val Arg Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Ser Ser Ala Val Gln Trp Val Arg Gln Ala Arg Gly Gln Arg Leu Glu Trp Val Gly Trp Ile Val Val Gly Ser Gly Asn Thr Asn Tyr Ala Gln Lys Phe His Glu Arg Val Thr Ile Thr Arg Asp Met Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Pro Tyr Cys Ser Gly Gly Ser Cys Ser Asp Gly Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Synthetic sequence Antibody 409_11_4_v2 VL(VK)  , Synthetic sequence SARS-CoV-2 S2E12-v1 mAb VH  ,"(738/399) , wherein the vh comprises or consists of the amino acid sequence set forth in any one of seq id no:399, 748, 749, 750, 752, 754, 756, 758, 759, and 761, the vl comprises or consists of the amino acid sequence set forth in seq id no:738, wherein the antibody or antigen-binding fragment is capable of binding to a surface glycoprotein of sars-cov-2 expressed on a cell surface of a host cell and/or on a virion.  embodiment 24. an antibody, or an antigen-binding fragment thereof, comprising a heavy chain variable domain (v"
https://patents.google.com/patent/WO2021226560A1/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Phe Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Ala Thr Ser Phe Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Ser Ser Gly Tyr Leu Gly Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Val Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro His Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Synthetic sequence SARS-CoV-2 S2H58-v1 mAb VH  , Synthetic sequence SARS-CoV-2 S2H58-v2 mAb VL(VK)  ,(228/238) s2h58-v2 comprises the vh amino acid sequence set forth in seq id no:228 and the vl amino acid sequence (kappa light chain) set forth in seq id no:238
https://patents.google.com/patent/WO2021226560A1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Pro Phe Thr Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Thr Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Gly Tyr Met Glu Leu Arg Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Tyr Thr Arg Gly Ala Trp Phe Gly Glu Ser Leu Ile Gly Gly Phe Asp Asn Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Thr Val Ser Ser Thr Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Asp Thr Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic sequence SARS-CoV-2 S309 mAb VH  , Synthetic sequence SARS-CoV-2 S309 mAb VL(VK)  ,"(139/143)  a second antibody or antigen-binding fragment comprising, a vh comprising or consisting of the amino acid sequence as set forth in seq id no:139 and a vl comprising of consisting of the amino acid sequence as set forth in seq id no:143. "
https://patents.google.com/patent/WO2021226560A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Leu Ser Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Ser Pro Leu Val Gly Phe Gly Asp Asn Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Arg Ile Thr Cys Ser Gly Asp Ala Leu Pro Lys Lys Tyr Ala Tyr Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Val Leu Val Ile Tyr Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Ser Ser Gly Thr Met Ala Thr Leu Thr Ile Ser Gly Ala Gln Val Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Thr Asp Ser Ser Gly Asn Gln Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Synthetic sequence SARS-CoV-2 S2X28-v1 mAb VH  , Synthetic sequence SARS-CoV-2 S2X28-v1 mAb VL  ,"(32/36) , wherein the vh comprises or consists of the amino acid sequence as set forth in seq id no:32 and the vl comprises or consists of the amino acid sequence as set forth in seq id no:36. "
https://patents.google.com/patent/WO2021226560A1/en, Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Arg Ile Thr Cys Ser Gly Asp Ala Leu Pro Lys Lys Tyr Ala Tyr Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Val Leu Val Ile Tyr Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Ser Ser Gly Thr Met Ala Thr Leu Thr Ile Ser Gly Ala Gln Val Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Thr Asp Ser Ser Gly Asn Gln Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Leu Ser Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Ser Pro Leu Val Gly Phe Gly Asp Asn Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Synthetic sequence SARS-CoV-2 S2X28-v1 mAb VL  , Synthetic sequence SARS-CoV-2 S2X28-v1 mAb VH  ,"(36/32) , wherein the vh comprises or consists of the amino acid sequence as set forth in seq id no:32 and the vl comprises or consists of the amino acid sequence as set forth in seq id no:36.  embodiment 31. an antibody, or an antigen-binding fragment thereof, comprising a heavy chain variable domain (v"
https://patents.google.com/patent/WO2021226560A1/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Ile Ser Ser Gly Thr Ser Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Ser Asp Thr Ser Ile Thr Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Ala Pro Phe Tyr Asp Phe Trp Ser Gly Tyr Ser Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Met Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Ala Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Synthetic sequence SARS-CoV-2 S2M11-v1 mAb VH  , Synthetic sequence SARS-CoV-2 S2M11-v1 mAb VL(VK)  ,"(524/528) , wherein the vh comprises or consists of the amino acid sequence set forth in seq id no:524 and the vl comprises or consists of the amino acid sequence set forth in seq id no:528, wherein the antibody or antigen-binding fragment is capable of binding to a surface glycoprotein of sars-cov-2 expressed on a cell surface of a host cell and/or on a virion. "
https://patents.google.com/patent/WO2021226560A1/en, Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Thr Ser Val Arg Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Ser Ser Ala Val Gln Trp Val Arg Gln Ala Arg Gly Gln Arg Leu Glu Trp Val Gly Trp Ile Val Val Gly Ser Gly Asn Thr Asn Tyr Ala Gln Lys Phe His Glu Arg Val Thr Ile Thr Arg Asp Met Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Pro Tyr Cys Ser Gly Gly Ser Cys Ser Asp Gly Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Thr Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Val Gly Leu Thr Gly Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Synthetic sequence SARS-CoV-2 S2E12-v1 mAb VH  , Synthetic sequence SARS-CoV-2 S2E12-v1 mAb VL(VK)  ,"(399/403)  a second antibody or antigen-binding fragment comprising a vh comprising or consisting of the amino acid sequence as set forth in seq id no:399, 748, 749, 750, 752, 754, 756, 758, 759, or 761, and a vl comprising or consisting of the amino acid sequence as set forth in seq id no:403, 744, or 746. "
https://patents.google.com/patent/WO2021226560A1/en, Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Thr Ser Val Arg Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Ser Ser Ala Val Gln Trp Val Arg Gln Ala Arg Gly Gln Arg Leu Glu Trp Val Gly Trp Ile Val Val Gly Ser Gly Asn Thr Asn Tyr Ala Gln Lys Phe His Glu Arg Val Thr Ile Thr Arg Asp Met Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Pro Tyr Cys Ser Gly Gly Ser Cys Ser Asp Gly Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Thr Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Val Gly Leu Thr Gly Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Synthetic sequence SARS-CoV-2 S2E12-v1 mAb VH  , Synthetic sequence Antibody 409_11_4_v3 VL(VK)  ,"(399/744) , wherein the vh comprises or consists of the amino acid sequence set forth in any one of seq id no:399, 748, 749, 750, 752, 754, 756, 758, 759, and 761, the vl comprises or consists of the amino acid sequence set forth in seq id no:744, wherein the antibody or antigen-binding fragment is capable of binding to a surface glycoprotein of sars-cov-2 expressed on a cell surface of a host cell and/or on a virion. "
https://patents.google.com/patent/WO2021169932A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Met Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Leu Pro Met Tyr Gly Asp Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Arg Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro Glu Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Ser ,  人工序列(artificial sequence)  ,  人工序列(artificial sequence)  ,"(22/23)  (i) the heavy chain whose amino acid sequence is shown in seq id no:22, and the light chain whose amino acid sequence is shown in seq id no:23"
https://patents.google.com/patent/WO2021169932A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Ala Gly Trp Val Arg Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Leu Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser ,  人工序列(artificial sequence)  ,  人工序列(artificial sequence)  ,"(33/34)  the amino acid sequence of the heavy chain is shown in seq id no:33, and the amino acid sequence of the light chain is shown in seq id no:34."
https://patents.google.com/patent/WO2021169932A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Met Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Leu Pro Met Tyr Gly Asp Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Arg Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro Glu Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val ,  人工序列(artificial sequence)  ,  人工序列(artificial sequence)  ,(7/8)  the heavy chain variable region whose amino acid sequence is shown in seq id no:7 and the light chain variable region whose amino acid sequence is shown in seq id no:8;
https://patents.google.com/patent/WO2021169932A1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Ala Gly Trp Val Arg Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Leu Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys ,  人工序列(artificial sequence)  ,  人工序列(artificial sequence)  ,(31/32)  the amino acid sequence of the heavy chain variable region shown in seq id no:31 and the amino acid sequence of the light chain variable region shown in seq id no:32.
https://patents.google.com/patent/WO2022015668A1/en, Met Ala Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Lys Asn Ala Asp Met Asn Trp Tyr Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val Thr Ser Ile Tyr Ser Asp Gly Ser Thr Val Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Pro Lys Ser Thr Val Ser Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Gly Val Tyr Tyr Cys Met Ala Gly Ser Lys Ser Gly His Glu Leu Asp His Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Met Ala Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Lys Asn Ala Asp Met Asn Trp Tyr Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val Thr Ser Ile Tyr Ser Asp Gly Ser Thr Val Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Pro Lys Ser Thr Val Ser Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Gly Val Tyr His Gly Met Ala Gly Ser Lys Ser Gly Gln Glu Leu Asp His Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Description of Artificial Sequence: Synthetic       polypeptide  , Description of Artificial Sequence: Synthetic       polypeptide  ,(10/6) diavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealh nhytqkslslspgk (seq id no:6); and (c) maqvqlvesggglvqpggslrlscaasgftfknadmnwyrqapgqgl ewvtsiysdgstvyadsvkgrftvsrdnpkstvslqmnslkpedtgvyycmagsksgh eldhwgqgtqvtvssepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevt cvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlng keykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfyps diavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealh nhytqkslslspgk (seq id no:10)
https://patents.google.com/patent/WO2022015668A1/en, Met Ala Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Lys Asn Ala Asp Met Asn Trp Tyr Arg Gln Val Pro Gly Gln Gly Leu Glu Trp Val Thr Ser Ile Tyr Ser Asp Gly Arg Thr Val Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Pro Lys Ser Thr Val Ser Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Gly Val Tyr Tyr Cys Met Ala Gly Ser Lys Ser Gly His Glu Leu Asp His Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Description of Artificial Sequence: Synthetic       polypeptide  ,,"(11) the isolated anti-sars-cov-2 nanobody of claim 1, comprising seq id no:11"
https://patents.google.com/patent/WO2022015668A1/en, Met Ala Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Lys Asn Ala Asp Met Asn Trp Tyr Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val Thr Ser Ile Tyr Ser Asp Gly Ser Thr Val Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Pro Lys Ser Thr Val Ser Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Gly Val Tyr His Gly Met Ala Gly Ser Lys Ser Gly Gln Glu Leu Asp His Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Description of Artificial Sequence: Synthetic       polypeptide  ,,"(1) the isolated anti-sars-cov-2 nanobody of claim 1, comprising seq id no:1"
https://patents.google.com/patent/WO2022015668A1/en, Met Ala Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Lys Asn Ala Asp Met Asn Trp Tyr Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val Thr Ser Ile Tyr Ser Asp Gly Ser Thr Val Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Pro Lys Ser Thr Val Ser Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Gly Val Tyr Tyr Cys Met Ala Gly Ser Lys Ser Gly His Glu Leu Asp His Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Pro Gly Gly Gln His His His His His His Gly Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser ,, Description of Artificial Sequence: Synthetic       polypeptide  ,,"(9) the isolated anti-sars-cov-2 nanobody of claim 16, comprising an amino acid sequence selected from the group consisting of: (a) maqvqlvesggglvqpggslrlscaasgftfknadmnwyrqvpgqgl ewvtsiysdgrtvyadsvkgrftvsrdnpkstvslqmnslkpedtgvyycmagsksg heldhwgqgtqvtvssgpggqhhhhhhgaypydvpdyas (seq id no:13); (b) maqvqlvesggglvqpggslrlscaasgftfknadmnwyrqapgqgl ewvtsiysdgstvyadsvkgrftvsrdnpkstvslqmnslkpedtgvyhgmagsksgq eldhwgqgtqvtvssgpggqhhhhhhgaypydvpdyas (seq id no:5); and (c) maqvqlvesggglvqpggslrlscaasgftfknadmnwyrqapgqgl ewvtsiysdgstvyadsvkgrftvsrdnpkstvslqmnslkpedtgvyycmagsksgh eldhwgqgtqvtvssgpggqhhhhhhgaypydvpdyas (seq id no:9)"
https://patents.google.com/patent/WO2022015668A1/en, Met Ala Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Lys Asn Ala Asp Met Asn Trp Tyr Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val Thr Ser Ile Tyr Ser Asp Gly Ser Thr Val Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Pro Lys Ser Thr Val Ser Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Gly Val Tyr Tyr Cys Met Ala Gly Ser Lys Ser Gly His Glu Leu Asp His Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Description of Artificial Sequence: Synthetic       polypeptide  ,,"(7) the isolated anti-sars-cov-2 nanobody of claim 1, comprising seq id no:7"
https://patents.google.com/patent/WO2022015668A1/en, Met Ala Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Lys Asn Ala Asp Met Asn Trp Tyr Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val Thr Ser Ile Tyr Ser Asp Gly Ser Thr Val Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Pro Lys Ser Thr Val Ser Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Gly Val Tyr His Gly Met Ala Gly Ser Lys Ser Gly Gln Glu Leu Asp His Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Pro Gly Gly Gln His His His His His His Gly Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser ,, Description of Artificial Sequence: Synthetic       polypeptide  ,,"(5) in some embodiments, an anti-sars-cov-2 nanobody comprises an amino acid sequence of any one of seq id no:5, 9, and 13"
https://patents.google.com/patent/WO2022015668A1/en, Met Ala Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Lys Asn Ala Asp Met Asn Trp Tyr Arg Gln Val Pro Gly Gln Gly Leu Glu Trp Val Thr Ser Ile Tyr Ser Asp Gly Arg Thr Val Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Pro Lys Ser Thr Val Ser Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Gly Val Tyr Tyr Cys Met Ala Gly Ser Lys Ser Gly His Glu Leu Asp His Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Pro Gly Gly Gln His His His His His His Gly Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser ,, Description of Artificial Sequence: Synthetic       polypeptide  ,,"(13) 20. the isolated anti-sars-cov-2 nanobody of claim 16, comprising an amino acid sequence selected from the group consisting of: (a) maqvqlvesggglvqpggslrlscaasgftfknadmnwyrqvpgqgl ewvtsiysdgrtvyadsvkgrftvsrdnpkstvslqmnslkpedtgvyycmagsksg heldhwgqgtqvtvssgpggqhhhhhhgaypydvpdyas (seq id no:13)"
https://patents.google.com/patent/WO2022015668A1/en, atggctcagg tgcagctcgt ggagtctggg ggaggcttgg tgcagcctgg ggggtctctg agactctcct gtgcagcctc tggcttcacc ttcaaaaacg cggacatgaa ctggtatcgc caggcaccag gtcaggggct cgagtgggtg actagtattt atagtgacgg tagtacagtc tatgcagact ccgtgaaggg ccgattcacc gtctccagag acaaccccaa gagcacggtg tctctgcaaa tgaacagcct gaaacctgag gacacaggtg tctatcatgg tatggcaggt tcaaagtcgg gccaagagtt ggatcattgg ggccagggga cccaggtcac cgtctccagc ggcccgggag gccaacacca tcaccaccat catggcgcat atccgtatga tgtgccggac tatgcttct ,, Description of Artificial Sequence: Synthetic       polynucleotide  ,,"(23) in some embodiments, the nanobody polypeptide is encoded by a polynucleotide comprising a nucleic acid sequence that has at least about 80% (e.g., at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity to seq id no:23, 25, or 27"
https://patents.google.com/patent/CN112521496A/en, caggtccaac tgcagcagcc tggggctgag ctggtgaggc ctggaccttc agtgaagctg tcctgcaagg cttctggcta ttccttcacc agctactgga tgaactgggt gaagcagagg cctggacaag gccttgagtg gattggcatg attcatcctt ccgatagtga aactaggtta aatcagaagt tcaaggacaa ggccacattg actgtagaca aatcctccag cacagcctac atgcaactca gcagcccgac atctgaggac tctgcggtct attactgtgc aagatcggac ggctactatt ggtacttcga tgtctggggc gcagggacca cggtcaccgt ctcctcagcc , attgtgttga cccaatctcc agcttctttg gcggtgtctc tagggcagag ggccaccata tcctgcagag ccagtgaaag tgttgatagt tatggcaata gttttatgca ctggtaccag cagaaaccag gacagccacc caaactcctc atctatcttg catccaacct agaatctggg gtccctgcca ggttcagtgg cagtgggtct aggacagact tcaccctcac cattgatcct gtggaggctg ctgatgctgc aacctattac tgtcagcaag ataatgagga tccgtggacg ttcggtggag gcaccaagct ggaaatcaaa , Artificial Synthesis, Artificial Synthesis,"(6/5) the gene of the encoding monoclonal antibody, the gene sequence of the variable region of the light chain of the encoding sars-cov-2 spike rbd/2e10 is shown in seq id no:5; the gene sequence of the heavy chain variable region of coding sars-cov-2 spike rbd/2e10 is shown in seq id no:6."
https://patents.google.com/patent/CN112521496A/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Pro Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Ser Asp Gly Tyr Tyr Trp Tyr Phe Asp Val Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser Ala , Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp Pro Val Glu Ala Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Asp Asn Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Synthesis, Artificial Synthesis,"(2/1)  the amino acid sequence of the light chain variable region of the sars-cov-2 spike rbd/2e10 is shown in seq id no:1, and the amino acid sequence of the heavy chain variable region of the sars-cov-2 spike rbd/2e10 is shown in seq id no:2."
https://patents.google.com/patent/CN112521496A/en, Met Ala Val Val Thr Gly Val Asn Ser Glu Val Gln Val Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr Ile His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Arg Ile Asp Pro Thr Asn Asp Asp Ile Lys Tyr Asp Pro Lys Phe Gln Gly Lys Ala Ser Ile Thr Ala Asp Thr Ser Ser Asn Val Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Phe Tyr Cys Ala Ser Arg Tyr Asp Tyr Val Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Pro Val Tyr Pro Leu Ala Pro Gly Ser Leu Gly Ile Ser Arg Gly Ser Pro Gly Thr Glu Leu Glu Phe Val Ile Met Val Ile Ala Val Ser Cys Val Lys Leu Leu Ser Ala His Asn Ser Thr Gln His Thr Ser Arg Lys His Lys Val , Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro Gly Ser Thr Gly Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Tyr Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr Met His Trp Asn Gln Gln Lys Pro Gly Gln Pro Pro Arg Leu Leu Ile Tyr Leu Val Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ile Arg Glu Leu Thr Arg Ser Glu Gly Gly Pro Ser Trp Lys , Artificial Synthesis, Artificial Synthesis,"(4/3) the amino acid sequence of the light chain variable region of the sars-cov-2 spike rbd/6e2 is shown in seq id no:3, and the amino acid sequence of the heavy chain variable region of the sars-cov-2 spike rbd/6e2 is shown in seq id no:4"
